[{"path":"index.html","id":"about","chapter":"About","heading":"About","text":"Information intended assist preparation Clinical Blood Bank content ASCP BOC’s MLS, BB SBB certification exams Content Guidelines MLS, BB SBB certification examsYou recommend use information supplement “Reading List” cited ASCP BOC certificationMedical Laboratory Scientist, MLS(ASCP)Technologist Blood Bank, BB(ASCP)Specialist Blood Bank, SBB(ASCP)","code":""},{"path":"index.html","id":"certification-prerequisites","chapter":"About","heading":"Certification Prerequisites","text":"","code":""},{"path":"index.html","id":"mls-bb-certifications","chapter":"About","heading":"MLS & BB Certifications","text":"Concurrent enrollment , completion past 5 years , NAACLS accredited Medical Laboratory Scientist program","code":""},{"path":"index.html","id":"sbb-certification","chapter":"About","heading":"SBB Certification","text":"Route 1\nBaccalaureate degree accredited (regionally nationally)* college/university including biology chemistry courses,\nsuccessful completion CAAHEP accredited Specialist Blood Bank Technology program within last five years\nBaccalaureate degree accredited (regionally nationally)* college/university including biology chemistry courses,successful completion CAAHEP accredited Specialist Blood Bank Technology program within last five yearsRoute 2\nValid MLS(ASCP) BB(ASCP) certification,\nbaccalaureate degree accredited (regionally nationally)* college/university,\nthree years full time acceptable clinical** experience blood banking acceptable laboratory within last six years. three years experience must acquired post baccalaureate degree\nValid MLS(ASCP) BB(ASCP) certification,baccalaureate degree accredited (regionally nationally)* college/university,three years full time acceptable clinical** experience blood banking acceptable laboratory within last six years. three years experience must acquired post baccalaureate degreeRoute 3\nMaster’s degree accredited (regionally nationally)* college/university chemistry, biology, immunology, immunohematology, microbiology, allied health, medical laboratory science, appropriately related field,\nthree years full time acceptable clinical** experience blood banking acceptable laboratory within last six years. three years experience must acquired post baccalaureate degree\nMaster’s degree accredited (regionally nationally)* college/university chemistry, biology, immunology, immunohematology, microbiology, allied health, medical laboratory science, appropriately related field,three years full time acceptable clinical** experience blood banking acceptable laboratory within last six years. three years experience must acquired post baccalaureate degreeRoute 4\nDoctorate accredited (regionally nationally)* college/university chemistry, biology, immunology, immunohematology, microbiology, allied health, medical laboratory science, appropriately related field,\ntwo years post-doctoral fellowship*** clinical** blood banking U.S. Canada within last five years two years full time acceptable clinical** experience blood banking acceptable laboratory within last five years. two years experience must acquired post baccalaureate degree\nDoctorate accredited (regionally nationally)* college/university chemistry, biology, immunology, immunohematology, microbiology, allied health, medical laboratory science, appropriately related field,two years post-doctoral fellowship*** clinical** blood banking U.S. Canada within last five years two years full time acceptable clinical** experience blood banking acceptable laboratory within last five years. two years experience must acquired post baccalaureate degreeRoute 5\nValid MLS(ASCP) BB(ASCP) certification,\nbaccalaureate degree accredited (regionally nationally)* college/university,\nthree years full time acceptable experience academic educator clinical blood banking accredited (regionally nationally)* college/university acceptable laboratory** within last six years. three years experience must acquired post baccalaureate degree\nValid MLS(ASCP) BB(ASCP) certification,baccalaureate degree accredited (regionally nationally)* college/university,three years full time acceptable experience academic educator clinical blood banking accredited (regionally nationally)* college/university acceptable laboratory** within last six years. three years experience must acquired post baccalaureate degreeRoute 6\nMaster’s degree accredited (regionally nationally)* college/university chemistry, biology, immunology, immunohematology, microbiology, allied health, medical laboratory science, appropriately related field,\nthree years full time acceptable experience academic educator clinical blood banking accredited (regionally nationally)* college/university acceptable laboratory** within last six years. three years experience must acquired post baccalaureate degree\nMaster’s degree accredited (regionally nationally)* college/university chemistry, biology, immunology, immunohematology, microbiology, allied health, medical laboratory science, appropriately related field,three years full time acceptable experience academic educator clinical blood banking accredited (regionally nationally)* college/university acceptable laboratory** within last six years. three years experience must acquired post baccalaureate degreeRoute 7\nValid MLS(ASCP) BB(ASCP) certification,\nDoctorate accredited (regionally nationally)* college/university chemistry, biology, immunology, immunohematology, microbiology, allied health, medical laboratory science, appropriately related field,\none year full time acceptable clinical** experience blood banking acceptable laboratory within last five years one year full time acceptable research experience blood banking U.S. Canada within last five years. year experience must acquired post baccalaureate degree\nValid MLS(ASCP) BB(ASCP) certification,Doctorate accredited (regionally nationally)* college/university chemistry, biology, immunology, immunohematology, microbiology, allied health, medical laboratory science, appropriately related field,one year full time acceptable clinical** experience blood banking acceptable laboratory within last five years one year full time acceptable research experience blood banking U.S. Canada within last five years. year experience must acquired post baccalaureate degreeLaboratory Teaching Experience\nfulfill experience requirement Specialist Blood Banking examination, must laboratory teaching experience, within time frame required, following procedures: Serologic Testing, Molecular Testing, Routine Problem Solving, Quality Control/Assurance, Laboratory Operations, Donor Collection, Processing, Testing\nfulfill experience requirement Specialist Blood Banking examination, must laboratory teaching experience, within time frame required, following procedures: Serologic Testing, Molecular Testing, Routine Problem Solving, Quality Control/Assurance, Laboratory Operations, Donor Collection, Processing, Testing","code":""},{"path":"content-areas.html","id":"content-areas","chapter":"Content Areas","heading":"Content Areas","text":"Major content areas covered:","code":""},{"path":"content-areas.html","id":"blood-products","chapter":"Content Areas","heading":"Blood Products","text":"DonorsProcessingStorageBlood ComponentsBlood Component Quality Control","code":""},{"path":"content-areas.html","id":"blood-group-systems","chapter":"Content Areas","heading":"Blood Group Systems","text":"GeneticsBiochemistry/AntigensRole Blood Groups Transfusion","code":""},{"path":"content-areas.html","id":"immunology-and-physiology","chapter":"Content Areas","heading":"Immunology and Physiology","text":"ImmunologyPhysiology Pathophysiology","code":""},{"path":"content-areas.html","id":"serologic-and-molecular-testing","chapter":"Content Areas","heading":"Serologic and Molecular Testing","text":"Routine TestsReagentsSpecial Tests ReagentsQuality Assurance","code":""},{"path":"content-areas.html","id":"transfusion-practice","chapter":"Content Areas","heading":"Transfusion Practice","text":"Indications TransfusionComponent TherapyAdverse Effects TransfusionApheresis Extracorporeal CirculationBlood Administration Patient Blood Management","code":""},{"path":"content-areas.html","id":"last-updated","chapter":"Content Areas","heading":"Last Updated","text":"Last edit pushed site 2025-04-10","code":""},{"path":"author.html","id":"author","chapter":"Author","heading":"Author","text":"Author: Brett M. Rice, MLS(ASCP)SH,SCYMHe graduate Augusta University’s Clinical Laboratory Science program. worked Clinical Hematology bench Wellstar MCG Health’s Core Laboratory full time 2013-18. 2016, earned Specialist Hematology (ASCP). time, gained experience Bone Marrow Flow Cytometry bench successful Specialist Cytometry (ASCP) 2018Since September 2018, teaching full time Augusta University’s Clinical Laboratory Science (BS-CLS | MHS-CLS) program primary teaching focus Clinical Hematology. still practices Clinical Hematology, Bone Marrow, Flow Cytometry Laboratory one day week","code":""},{"path":"author.html","id":"disclaimer","chapter":"Author","heading":"Disclaimer","text":"AI used creation site. AI makes mistakes, double-check informationIf see mistakes omissions, please let know edits need made using “Edit page” feature displayed right column (desktop view). hoping time can build project reliable resource . Along line, considering project perpetual state “-progress”","code":""},{"path":"author.html","id":"license","chapter":"Author","heading":"License","text":"work licensed CC -NC-SA 4.0","code":""},{"path":"author.html","id":"contribute","chapter":"Author","heading":"Contribute","text":"author appreciates help maintain reference material. use resource, please consider using “Edit page” feature right side page (desktop view) suggest changes content. Another way can contribute keep author caffeinated!","code":""},{"path":"ascp-boc.html","id":"ascp-boc","chapter":"ASCP BOC","heading":"ASCP BOC","text":"ASCP BOC’s Content Guideline Technologist Blood Bank, BB(ASCP), Specialist Blood Bank, SBB(ASCP), certification exams consists five major content areas. information last revised ASCP’s website Octoboer 2023","code":""},{"path":"ascp-boc.html","id":"blood-products-1","chapter":"ASCP BOC","heading":"Blood Products","text":"Exam Percentage BB(ASCP): 15% - 20% | SBB(ASCP): 10% - 15%Description Donors, processing, storage, types blood components, blood component quality contro","code":""},{"path":"ascp-boc.html","id":"blood-group-systems-1","chapter":"ASCP BOC","heading":"Blood Group Systems","text":"Exam Percentage BB(ASCP): 15% - 20% | SBB(ASCP): 15% - 20%Description Genetics, biochemistry/antigens, role blood groups transfusion","code":""},{"path":"ascp-boc.html","id":"immunology-and-physiology-1","chapter":"ASCP BOC","heading":"Immunology and Physiology","text":"Exam Percentage BB(ASCP): 10% - 20% | SBB(ASCP): 15% - 20%Description Immune response, immunoglobulins, antigen-antibody interactions, complement, physiology blood, hemostasis coagulation, HDFN, cytopenias, transplantation","code":""},{"path":"ascp-boc.html","id":"serologic-and-molecular-testing-1","chapter":"ASCP BOC","heading":"Serologic and Molecular Testing","text":"Exam Percentage BB(ASCP): 20% - 25% | SBB(ASCP): 20% - 25%Description Routine tests, reagents, application special tests reagents, quality assurance","code":""},{"path":"ascp-boc.html","id":"transfusion-practice-1","chapter":"ASCP BOC","heading":"Transfusion Practice","text":"Exam Percentage BB(ASCP): 15% - 20% | SBB(ASCP): 15% - 20%Description Indications transfusion, component therapy, adverse effects transfusion, apheresis extracorporeal circulation, blood administration patient blood management","code":""},{"path":"reading-list.html","id":"reading-list","chapter":"Reading List","heading":"Reading List","text":"ASCP makes clear suggested reading/reference list Technologist Blood Bank, BB(ASCP), Specialist Blood Bank, SBB(ASCP), certification exams “intended partial reference source”. suggested reading/reference list last revised ASCP’s website January 2025","code":""},{"path":"reading-list.html","id":"journals","chapter":"Reading List","heading":"Journals","text":"Immunohematology. Published SciendoJournal Clinical Apheresis. Published John Wiley & Sons, LtdTransfusion. Published John Wiley & Sons, LtdTransfusion Medicine. Published John Wiley & Sons, LtdTransfusion Medicine Reviews. Published ScienceDirectVox Sanguinis. Published John Wiley & Sons, LtdConnelly-Smith, L., et al. (2023). Guidelines Use Therapeutic Apheresis Clinical Practice – Evidence-Based Approach Writing Committee American Society Apheresis: Ninth Special Issue. Journal Clinical Apheresis, 38(2), 77-278. https://doi.org/10.1002/jca.22043","code":""},{"path":"reading-list.html","id":"texts","chapter":"Reading List","heading":"Texts","text":"","code":""},{"path":"reading-list.html","id":"regulations","chapter":"Reading List","heading":"Regulations","text":"AABB. (2024). Standards Blood Banks Transfusion Services (34 th ed.). Bethesda, MD: AABB PressAABB. (2024). Standards Immunohematology Reference Laboratories (13 th ed.). Bethesda, MD: AABB Press","code":""},{"path":"reading-list.html","id":"code-of-federal-regulations-cfr","chapter":"Reading List","heading":"Code of Federal Regulations (CFR)","text":"Code Federal Regulations, Title 21, Food Drugs, Parts 600, 601,606, 607, 610, 660, 680. Washington D.C.: U.S. Government Publishing OfficeCode Federal Regulations, Title 42.493.Public Health—Laboratory Requirements. Washington D.C.: U.S. Government Publishing OfficeCode Federal Regulations, Title 29, Section 1910.1450 Occupational Safety Health Standards Subpart Z - Toxic Hazardous Substances, Occupational exposure hazardous chemicals laboratories. Washington D.C.: U.S. Government Publishing OfficeCode Federal Regulations, Title 29, Section 1910.1030. Occupational Safety Health Standards Subpart Z - Toxic Hazardous Substances, Bloodborne pathogens. Washington D.C.: U.S. Government Publishing Office","code":""},{"path":"reading-list.html","id":"general-immunohematology","chapter":"Reading List","heading":"General Immunohematology","text":"Cohn, C.S., et al. (Eds.). (2023). Technical Manual (21 st ed.). Bethesda, MD: AABB PressDaniels, G. (2013). Human Blood Groups (3 rd ed.). Oxford, UK: Wiley-Blackwell, IncDoucette, L.J. (2021). Mathematics Clinical Laboratory (4 th ed.) St. Louis: ElsevierHamilton, J.R, Johnson, S.T., & Rudmann, S.V. (2013). Antibody Identification: Art Science? Case Study Approach (1 st ed.). Bethesda, MD: AABB PressHamilton, J.R., Johnson, S.T., & Rudmann, S.V. (2016). Investigating Positive DAT Results: Case Study Approach. Bethesda, MD: AABB Press. (appropriate SBB level)Harmening, D.M. (2018). Modern Blood Banking Transfusion Practices (7 th ed.). Philadelphia: F.. Davis CompanyReid, M.E., Lomas-Francis, C., & Olsson, M.L. (2012). Blood Group Antigen Facts Book (3 rd ed.). San Diego, CA: Elsevier, Academic PressVege, S., Gannett, M., & Delaney, M. (2020). Introduction Molecular Immunohematology. Bethesda, MD: AABB Press","code":""},{"path":"reading-list.html","id":"for-current-blood-group-antigen-nomenclature-refer-to-this-website","chapter":"Reading List","heading":"For current blood group antigen nomenclature, refer to this website","text":"International Society Blood Transfusion","code":""},{"path":"reading-list.html","id":"hematology-hemostasis-hla-and-immunology","chapter":"Reading List","heading":"Hematology, Hemostasis, HLA, and Immunology","text":"Eisenbrey, .B. (2021). HLA Benchtop Bedside (1 st ed.). San Diego, CA: Elsevier, Academic PressKeohane, E.M., et al. (2024). Rodak’s Hematology: Clinical Principles & Applications (7 th ed.). St. Louis, MO: ElsevierMiller, L.E. & Stevens, C.D. (2021). Clinical Immunology Serology: Laboratory Perspective (5 th ed.). Philadelphia: F.. Davis Company","code":""},{"path":"reading-list.html","id":"transfusion-practice-2","chapter":"Reading List","heading":"Transfusion Practice","text":"Marquez, M., Schwartz, J., & Wu, Y. (Eds.). (2019). Transfusion Therapy: Clinical Principles Practice (4 th ed.). Bethesda, MD: AABB PressSchmidt, . & Sullivan, H.C. (Eds.). (2023). Transfusion Medicine Self-Assessment Review (4 th ed.). Bethesda, MD: AABB Press. (appropriate SBB level)Simon, T.S. et al. (Eds.). (2022). Rossi’s Principles Transfusion Medicine (6 th ed.). West Sussex, UK: John Wiley & Sons, Ltd","code":""},{"path":"reading-list.html","id":"management","chapter":"Reading List","heading":"Management","text":"Cohn, C.S., et al. (Eds.). (2023). Technical Manual (21 st ed.). Bethesda, MD: AABB PressGarcia, L.S., et al. (Eds.). (2024). Clinical Laboratory Management (3 rd ed.). Washington D.C.: ASM PressHarmening, D.M. (2020). Laboratory Management: Principles Processes (4 th ed.). St. Petersburg: D.H. Pub. & Consulting, Inc","code":""},{"path":"reading-list.html","id":"online","chapter":"Reading List","heading":"Online","text":"AABB ResourcesBlood Bank Guy – Transfusion Medicine EducationCAP Accreditation ChecklistsInternational Society Blood TransfusionTransfusion Medicine Questions","code":""},{"path":"donors.html","id":"donors","chapter":"Donors","heading":"Donors","text":"entire donor process, initial screening collection managing reactions, meticulously designed ensure integrity safety blood supply, starting well-suitability volunteer donor. type donation serves purpose, guided specific regulations best practices","code":""},{"path":"donors.html","id":"donor-qualification","chapter":"Donors","heading":"Donor Qualification","text":"Goal: Protect donor’s health recipient’s safetyProcess: Involves thorough screening based FDA regulations AABB standards. Includes:\nRegistration/ID: Linking donor history unit\nEducation: Informing donors risks importance honesty\nDonor Health History Questionnaire (DHQ): Detailed questions health, travel, medications, risk behaviors\nMini-Physical: Checking Hgb/Hct, blood pressure, pulse, temperature, weight, arms\nInformed Consent: Formal agreement donate\nRegistration/ID: Linking donor history unitEducation: Informing donors risks importance honestyDonor Health History Questionnaire (DHQ): Detailed questions health, travel, medications, risk behaviorsMini-Physical: Checking Hgb/Hct, blood pressure, pulse, temperature, weight, armsInformed Consent: Formal agreement donateOutcome: Donor either accepted deferred (temporarily, indefinitely, permanently) based eligibility criteria","code":""},{"path":"donors.html","id":"collection-methods","chapter":"Donors","heading":"Collection Methods","text":"Whole Blood Donation: standard method; collecting ~500 mL blood bag anticoagulant-preservative. unit later processed components (RBCs, plasma, sometimes platelets). Requires strict aseptic technique venipunctureApheresis (Hemapheresis): Uses machine draw blood, separate specific component (platelets, plasma, double red cells, granulocytes, stem cells), return remaining parts donor. Allows larger yields specific components one donor. Uses citrate anticoagulant, returned donor","code":""},{"path":"donors.html","id":"adverse-reactions","chapter":"Donors","heading":"Adverse Reactions","text":"Generally Safe: donations occur without incidentCommon Reactions\nVasovagal: Fainting/near-fainting (common), due nerve response, blood loss volume. Managed positioning (legs ), cool compresses, reassurance\nHematoma: Bruising needle site. Managed pressure cold packs\nVasovagal: Fainting/near-fainting (common), due nerve response, blood loss volume. Managed positioning (legs ), cool compresses, reassuranceHematoma: Bruising needle site. Managed pressure cold packsLess Common Reactions: Nerve irritation (sharp pain), arterial puncture (rare), allergic reactions (disinfectant, etc.)Apheresis-Specific: Citrate reaction (tingling, chills due temporary low calcium). Managed slowing return giving calciumKey Management: Recognize symptoms early, act quickly following protocol, prioritize donor safety, document everything","code":""},{"path":"donors.html","id":"special-donations","chapter":"Donors","heading":"Special Donations","text":"Autologous: Donating blood one’s future use (e.g., surgery). Safer donor-recipient regarding disease/alloimmunization specific criteria (lower Hgb allowed) strict labeling (“Autologous Use ”)Directed (Designated): Donating specific, named recipient. Donor must meet standard allogeneic criteria. proven safety benefit regular donations. Requires irradiation blood relativeApheresis: described , often considered ‘special’ due targeted component collectionHematopoietic Progenitor Cells (HPCs): Stem cell collection (marrow, peripheral blood via apheresis, cord blood) transplantation. Requires extensive screening HLA matchingTherapeutic Phlebotomy: Blood removal medical treatment donor (e.g., hemochromatosis, polycythemia). Blood might usable transfusion donor meets allogeneic criteria, otherwise discarded","code":""},{"path":"qualification.html","id":"qualification","chapter":"Qualification","heading":"Qualification","text":"section discusses Blood Product Donors looking donor Qualification. Think essential first step guaranteeing safety effectiveness blood transfusions. ’s carefully designed process two primary goals: protecting health potential recipient ensuring donated blood safe, safeguarding well-donor throughout donation process. screening guided strict regulations FDA standards set organizations like AABB, involving detailed health history review mini-physical exam anyone can donate. goal twofold:Protect recipient need make sure blood donated safe won’t transmit diseases cause harmProtect donor need ensure donation process safe person giving blood won’t negatively impact healthEligibility determined multi-step process:","code":""},{"path":"qualification.html","id":"registration-identification","chapter":"Qualification","heading":"Registration & Identification","text":"seems basic, ’s vital! need positively identify donor link donation history collected unitWe collect demographic information check ’ve donated existing deferrals. Photo ID usually required","code":""},{"path":"qualification.html","id":"educational-materials","chapter":"Qualification","heading":"Educational Materials","text":"nitty-gritty questions, donors receive information explaining donation process, potential risks (like bruising fainting), eligibility requirements, importantly, information diseases transmitted blood, like HIV/AIDS hepatitisThis material emphasizes importance honesty provides donors opportunity self-defer realize might risk going whole screening","code":""},{"path":"qualification.html","id":"donor-health-history-questionnaire-dhq","chapter":"Qualification","heading":"Donor Health History Questionnaire (DHQ)","text":"core screening! ’s standardized set questions designed identify potential risks. exact wording might vary slightly centers, intent scope consistent. Key areas covered include:\nGeneral Health: feeling healthy well today? colds, flu, sore throats?\nMedical Conditions: History cancer, heart lung disease, bleeding disorders, unexplained weight loss, certain infections (HIV, hepatitis B/C, syphilis, babesiosis, Chagas disease, etc.)\nMedications: Use certain drugs can grounds deferral, either drug harm recipient (like Accutane, Propecia, Soriatane) underlying condition treats makes donation unsafe (like anticoagulants, bovine insulin). Antibiotic use might indicate active infection\nTravel History: Recent travel areas endemic certain diseases, especially malaria, vCJD (variant Creutzfeldt-Jakob disease - associated travel/residence parts Europe), Zika, Ebola, may result temporary indefinite deferral\nRisk Behaviors Associated Bloodborne Pathogens: Questions intravenous drug use (even !), history payment sex, specific sexual contact scenarios (e.g., men sex men - MSM guidelines evolved recently based individual risk assessment rather blanket deferral regions, specific questions remain), contact individuals known HIV hepatitis\nVaccinations: Waiting periods apply receiving certain live-attenuated vaccines (e.g., MMR, chickenpox). deferral inactivated mRNA vaccines (like flu shots COVID-19 vaccines)\nPrevious Transfusions/Donations: received blood, components, grafts? last donation? issues previous donations?\nSurgery, Tattoos, Piercings: Recent procedures might require waiting period due potential infection risk\nGeneral Health: feeling healthy well today? colds, flu, sore throats?Medical Conditions: History cancer, heart lung disease, bleeding disorders, unexplained weight loss, certain infections (HIV, hepatitis B/C, syphilis, babesiosis, Chagas disease, etc.)Medications: Use certain drugs can grounds deferral, either drug harm recipient (like Accutane, Propecia, Soriatane) underlying condition treats makes donation unsafe (like anticoagulants, bovine insulin). Antibiotic use might indicate active infectionTravel History: Recent travel areas endemic certain diseases, especially malaria, vCJD (variant Creutzfeldt-Jakob disease - associated travel/residence parts Europe), Zika, Ebola, may result temporary indefinite deferralRisk Behaviors Associated Bloodborne Pathogens: Questions intravenous drug use (even !), history payment sex, specific sexual contact scenarios (e.g., men sex men - MSM guidelines evolved recently based individual risk assessment rather blanket deferral regions, specific questions remain), contact individuals known HIV hepatitisVaccinations: Waiting periods apply receiving certain live-attenuated vaccines (e.g., MMR, chickenpox). deferral inactivated mRNA vaccines (like flu shots COVID-19 vaccines)Previous Transfusions/Donations: received blood, components, grafts? last donation? issues previous donations?Surgery, Tattoos, Piercings: Recent procedures might require waiting period due potential infection risk","code":""},{"path":"qualification.html","id":"physical-examination-mini-physical","chapter":"Qualification","heading":"Physical Examination (“Mini-Physical”)","text":"quick check donor’s vital signs physical state time donation\nHemoglobin/Hematocrit: Must meet minimum level ensure donor doesn’t become anemic donating. (Commonly: Allogeneic Hgb ≥ 12.5 g/dL females, ≥ 13.0 g/dL males)\nBlood Pressure: Must within acceptable range (e.g., Systolic ≤ 180 mmHg, Diastolic ≤ 100 mmHg). High BP might indicate risk donor\nPulse: Needs regular within range (e.g., 50-100 beats per minute). high low rates might need evaluation\nTemperature: Must normal (e.g., ≤ 37.5°C 99.5°F) rule fever/active infection\nWeight: Minimum weight required (usually ≥ 110 lbs 50 kg) ensure safe volume blood can drawn relative total blood volume\nArm Check: Examination antecubital area (needle goes) check rashes, lesions, signs IV drug use (“track marks”)\nHemoglobin/Hematocrit: Must meet minimum level ensure donor doesn’t become anemic donating. (Commonly: Allogeneic Hgb ≥ 12.5 g/dL females, ≥ 13.0 g/dL males)Blood Pressure: Must within acceptable range (e.g., Systolic ≤ 180 mmHg, Diastolic ≤ 100 mmHg). High BP might indicate risk donorPulse: Needs regular within range (e.g., 50-100 beats per minute). high low rates might need evaluationTemperature: Must normal (e.g., ≤ 37.5°C 99.5°F) rule fever/active infectionWeight: Minimum weight required (usually ≥ 110 lbs 50 kg) ensure safe volume blood can drawn relative total blood volumeArm Check: Examination antecubital area (needle goes) check rashes, lesions, signs IV drug use (“track marks”)","code":""},{"path":"qualification.html","id":"informed-consent","chapter":"Qualification","heading":"Informed Consent","text":"going information screening steps, donor must formally consent donation. confirms understand process, risks, blood tested infectious diseases. also consent use blood transfusion","code":""},{"path":"qualification.html","id":"deferrals","chapter":"Qualification","heading":"Deferrals","text":"donor doesn’t meet criteria stage, deferred. Deferrals can :\nTemporary: Requires waiting specific period (e.g., taking certain medications, travel malaria zone, recent tattoo, low hemoglobin)\nIndefinite: set end date, often due high-risk factors (e.g., history IV drug use, certain medical conditions like leukemia). donor might become eligible later criteria change\nPermanent: donor never eligible (e.g., confirmed positive test HIV, viral hepatitis B/C certain dates, history Chagas disease, vCJD risk)\nTemporary: Requires waiting specific period (e.g., taking certain medications, travel malaria zone, recent tattoo, low hemoglobin)Indefinite: set end date, often due high-risk factors (e.g., history IV drug use, certain medical conditions like leukemia). donor might become eligible later criteria changePermanent: donor never eligible (e.g., confirmed positive test HIV, viral hepatitis B/C certain dates, history Chagas disease, vCJD risk)","code":""},{"path":"qualification.html","id":"key-takeaway","chapter":"Qualification","heading":"Key Takeaway","text":"Donor qualification rigorous essential process. relies heavily donor honesty adherence established regulatory standards. Every step designed maximize safety blood product eventual recipient also ensuring well-generous individual donating","code":""},{"path":"qualification.html","id":"key-terms","chapter":"Qualification","heading":"Key Terms","text":"Allogeneic Donation: Blood donated individual transfusion another person (general blood supply). common type donation strict qualification criteriaAutologous Donation: Blood donated individual specifically future use, typically scheduled surgery. Qualification criteria might slightly modified medical director, basic safety checks still applyDonor Health History Questionnaire (DHQ): standardized set questions required regulatory agencies (like FDA) used screen potential donors risk factors related health, medications, travel, behaviors affect donation safety donor recipientDeferral: decision accept individual blood donation based failure meet eligibility criteria. Deferrals protect donor potential recipientsTemporary Deferral: deferral prevents donation specific, limited period. Examples include recent travel malaria-endemic area, taking certain medications, low hemoglobin level day donationIndefinite Deferral: deferral without defined end date, often due higher-risk factors (e.g., certain past behaviors medical conditions). donor might become eligible future screening criteria changePermanent Deferral: deferral indicating donor never eligible donate blood according current regulations (e.g., confirmed positive test HIV, Hepatitis C, history IV drug use)Informed Consent: process potential donor, received understood information donation process, associated risks, required testing, potential uses blood, formally agrees donateAABB (Association Advancement Blood & Biotherapies): key professional organization sets standards practice provides accreditation blood banks transfusion services, often influencing exceeding regulatory requirements donor qualificationHemoglobin (Hgb) / Hematocrit (Hct) Check: mandatory part donor mini-physical exam measure oxygen-carrying capacity blood. Donors must meet minimum level (e.g., Hgb ≥ 12.5 g/dL females, ≥ 13.0 g/dL males allogeneic donation) ensure donation won’t make anemic","code":""},{"path":"processing.html","id":"processing","chapter":"Processing","heading":"Processing","text":"section discusses blood actually collected. obviously critical step, methods used depend specific blood components needed donor’s eligibilityThink collection methods falling two main categories: traditional Whole Blood donation targeted Apheresis procedures. require meticulous technique ensure donor safety product quality","code":""},{"path":"processing.html","id":"whole-blood-collection","chapter":"Processing","heading":"Whole Blood Collection","text":"classic method people picture think donating bloodConcept: standard, fixed volume blood (typically 450-500 mL) collected directly donor’s vein sterile bag containing anticoagulant-preservative solutionProcedure\nSite Selection Usually large, prominent vein antecubital area (crook elbow)\nAseptic Preparation crucial prevent bacterial contamination blood product! site vigorously scrubbed using FDA-approved disinfectant (often iodine compound like povidone-iodine , donors sensitive iodine, chlorhexidine gluconate isopropyl alcohol). aim remove surface bacteria kill microbes deeper skin follicles. prepared area must touched venipuncture\nVenipuncture sterile, single-use needle (typically 16-17 gauge) attached collection bag tubing inserted smoothly vein\nCollection Blood flows gravity primary collection bag. bag contains specific amount anticoagulant (like CPD, CPDA-1, CPD additive solution like -1, -3, -5, -7 satellite bag)\nMixing bag must mixed gently frequently (either manually using automated mixer/scale) collection ensure blood immediately combines anticoagulant, preventing clots\nVolume Monitoring collection stopped target volume reached (often monitored weight using scale). Scales also clamp tubing automatically\nSample Collection removing main needle, tubes filled blood samples diversion pouch collection line mandatory infectious disease testing blood typing. diversion pouch collection bag collects first mL blood (containing skin plug potentially contaminated venipuncture) diverts away main unit, reducing contamination risk\nNeedle Removal & Post-Care needle withdrawn, pressure applied site, sterile bandage applied. donor rests given refreshments\nSite Selection Usually large, prominent vein antecubital area (crook elbow)Aseptic Preparation crucial prevent bacterial contamination blood product! site vigorously scrubbed using FDA-approved disinfectant (often iodine compound like povidone-iodine , donors sensitive iodine, chlorhexidine gluconate isopropyl alcohol). aim remove surface bacteria kill microbes deeper skin follicles. prepared area must touched venipunctureVenipuncture sterile, single-use needle (typically 16-17 gauge) attached collection bag tubing inserted smoothly veinCollection Blood flows gravity primary collection bag. bag contains specific amount anticoagulant (like CPD, CPDA-1, CPD additive solution like -1, -3, -5, -7 satellite bag)Mixing bag must mixed gently frequently (either manually using automated mixer/scale) collection ensure blood immediately combines anticoagulant, preventing clotsVolume Monitoring collection stopped target volume reached (often monitored weight using scale). Scales also clamp tubing automaticallySample Collection removing main needle, tubes filled blood samples diversion pouch collection line mandatory infectious disease testing blood typing. diversion pouch collection bag collects first mL blood (containing skin plug potentially contaminated venipuncture) diverts away main unit, reducing contamination riskNeedle Removal & Post-Care needle withdrawn, pressure applied site, sterile bandage applied. donor rests given refreshmentsAnticoagulant/Preservative Solutions: solutions (like CPD, CPDA-1, -1) prevent clotting provide nutrients keep red cells viable storage. type solution dictates shelf-life red blood cells (e.g., 21 days CPD, 35 days CPDA-1, 42 days solutions)Outcome: unit Whole Blood, typically processed lab components: Red Blood Cells (RBCs), Plasma (usually Fresh Frozen Plasma - FFP), sometimes Platelets (though platelet concentrates whole blood less common now due popularity apheresis platelets)Donation Frequency: Typically, donors must wait least 56 days (8 weeks) whole blood donations","code":""},{"path":"processing.html","id":"apheresis-collection-hemapheresis","chapter":"Processing","heading":"Apheresis Collection (Hemapheresis)","text":"Apheresis (Greek, meaning “take away” “separate”) specialized collection method whole blood drawn, specific component separated collected using machine, remaining components returned donor procedureConcept: Allows collection larger volume specific component (like platelets, plasma, red cells) single donor compared can separated one unit whole bloodGeneral Procedure\nSimilar donor qualification rigorous site preparation whole blood\nVenipuncture performed, often arms (one draw, one return) sometimes using single, larger needle capable alternating draw/return cycles\nBlood drawn sterile, closed system connected apheresis machine\nAnticoagulation anticoagulant, typically citrate, added blood enters machine. Citrate prevents clotting binding calcium\nSeparation machine uses centrifugation separate whole blood components based density (RBCs heaviest, WBCs, platelets, plasma lightest)\nCollection & Return desired component diverted collection bag, components (e.g., red cells, plasma) returned donor return line\nMonitoring donor continuously monitored throughout procedure (takes longer whole blood donation, often 1-2 hours) adverse reactions, particularly related citrate\nSimilar donor qualification rigorous site preparation whole bloodVenipuncture performed, often arms (one draw, one return) sometimes using single, larger needle capable alternating draw/return cyclesBlood drawn sterile, closed system connected apheresis machineAnticoagulation anticoagulant, typically citrate, added blood enters machine. Citrate prevents clotting binding calciumSeparation machine uses centrifugation separate whole blood components based density (RBCs heaviest, WBCs, platelets, plasma lightest)Collection & Return desired component diverted collection bag, components (e.g., red cells, plasma) returned donor return lineMonitoring donor continuously monitored throughout procedure (takes longer whole blood donation, often 1-2 hours) adverse reactions, particularly related citrateTypes Apheresis Procedures\nPlateletpheresis (Platelets): Collects concentrated platelets. single apheresis platelet unit equivalent platelets derived 5-6 whole blood donations. Frequency: Donors can often donate platelets frequently whole blood (e.g., every 7 days, 24 times per year, regulations vary)\nPlasmapheresis (Plasma): Collects plasma (FFP Source Plasma manufacturing). Frequency: Can done relatively frequently (e.g., every 4 weeks FFP, even often Source Plasma specific programs)\nRed Cell Apheresis (Double Red Cell / “Power Reds”): Collects two units’ worth red blood cells. Donors need higher hemoglobin/hematocrit levels meet weight/height requirements. Frequency: Less frequent whole blood (e.g., every 112 days / 16 weeks) RBCs removed\nGranulocyte Apheresis: Collects granulocytes (neutrophils). Less common, usually specific patients severe infections unresponsive antibiotics. Often requires donor pre-treatment medications (like G-CSF /corticosteroids) boost granulocyte count\nMulticomponent Apheresis: Collects two components simultaneously (e.g., platelets plasma, platelets red cells). Efficient use single donation\nPlateletpheresis (Platelets): Collects concentrated platelets. single apheresis platelet unit equivalent platelets derived 5-6 whole blood donations. Frequency: Donors can often donate platelets frequently whole blood (e.g., every 7 days, 24 times per year, regulations vary)Plasmapheresis (Plasma): Collects plasma (FFP Source Plasma manufacturing). Frequency: Can done relatively frequently (e.g., every 4 weeks FFP, even often Source Plasma specific programs)Red Cell Apheresis (Double Red Cell / “Power Reds”): Collects two units’ worth red blood cells. Donors need higher hemoglobin/hematocrit levels meet weight/height requirements. Frequency: Less frequent whole blood (e.g., every 112 days / 16 weeks) RBCs removedGranulocyte Apheresis: Collects granulocytes (neutrophils). Less common, usually specific patients severe infections unresponsive antibiotics. Often requires donor pre-treatment medications (like G-CSF /corticosteroids) boost granulocyte countMulticomponent Apheresis: Collects two components simultaneously (e.g., platelets plasma, platelets red cells). Efficient use single donationAdvantages Apheresis\nHigher yield targeted component one donor\nReduces recipient exposure multiple donors (e.g., one apheresis platelet unit vs. pool 5-6 whole blood-derived platelets)\nAllows donors give specific needed components frequently (platelets, plasma)\nHigher yield targeted component one donorReduces recipient exposure multiple donors (e.g., one apheresis platelet unit vs. pool 5-6 whole blood-derived platelets)Allows donors give specific needed components frequently (platelets, plasma)Donor Considerations\nLonger procedure time\nCitrate Reaction: citrate anticoagulant returned donor (unlike whole blood donation stays bag), donors can experience symptoms temporary hypocalcemia (low calcium) like tingling around lips fingers, chills, rarely, muscle cramps. managed slowing return rate giving calcium supplements (like Tums)\nLonger procedure timeCitrate Reaction: citrate anticoagulant returned donor (unlike whole blood donation stays bag), donors can experience symptoms temporary hypocalcemia (low calcium) like tingling around lips fingers, chills, rarely, muscle cramps. managed slowing return rate giving calcium supplements (like Tums)","code":""},{"path":"processing.html","id":"key-elements-common-to-all-methods","chapter":"Processing","heading":"Key Elements Common to All Methods","text":"Donor Safety & Comfort: Constant monitoring, managing reactions promptlyAseptic Technique: Paramount prevent bacterial contaminationAccurate Labeling: Ensuring unit correctly labeled linked donor record test samplesQuality Control: Regular checks equipment (scales, apheresis machines, sealers, etc.)","code":""},{"path":"processing.html","id":"key-terms-1","chapter":"Processing","heading":"Key Terms","text":"Whole Blood Donation: Collection standard unit (approx. 450-500 mL) blood bag containing anticoagulant-preservative solution. unit later separated componentsApheresis (Hemapheresis): procedure whole blood drawn donor, specific component (like platelets, plasma, red cells) separated collected using machine, remaining components returned donorAnticoagulant-Preservative Solution: Solutions like CPD, CPDA-1, containing Additive Solutions () used whole blood collection bags prevent clotting maintain red cell viability storageCitrate: anticoagulant typically used apheresis procedures. works chelating (binding) calcium, necessary coagulation. Can cause temporary hypocalcemia symptoms donorAseptic Technique: Procedures used prevent microbial contamination, critically important skin preparation venipuncture blood collectionDiversion Pouch: small pouch integral blood collection bag tubing collects initial mL blood drawn, diverting skin plug potential surface bacteria away main collection bagVenipuncture: act puncturing vein needle purpose drawing bloodPlateletpheresis: apheresis procedure specifically designed collect plateletsPlasmapheresis: apheresis procedure specifically designed collect plasmaRed Cell Apheresis (Double Red Cell Donation): apheresis procedure designed collect two doses red blood cellsCitrate Reaction/Toxicity: Symptoms experienced apheresis donors due temporary reduction ionized calcium caused return citrated blood. Symptoms often include tingling sensations (paresthesia)","code":""},{"path":"adverse-reactions-1.html","id":"adverse-reactions-1","chapter":"Adverse Reactions","heading":"Adverse Reactions","text":"blood donation incredibly safe people, sometimes donors can experience side effects reactions shortly donation. ’s crucial us recognize reactions, know respond appropriately, understand minimize occurrence. Adverse reactions can range mild common , rarely, serious events","code":""},{"path":"adverse-reactions-1.html","id":"common-reactions-mostly-mild-manageable","chapter":"Adverse Reactions","heading":"Common Reactions (Mostly Mild & Manageable)","text":"","code":""},{"path":"adverse-reactions-1.html","id":"vasovagal-reactions-faintingnear-fainting","chapter":"Adverse Reactions","heading":"Vasovagal Reactions (Fainting/Near Fainting)","text":": common type reaction! ’s directly caused blood loss volume , rather body’s reaction stress donation (needle insertion, sight blood, anxiety). vagus nerve gets stimulated, causing sudden drop heart rate blood pressure, reducing blood flow brainSymptoms\nMild/Moderate: Feeling lightheaded, dizzy, nauseous, sweaty (diaphoretic), pale (pallor), weak, blurred vision, hyperventilation\nSevere (Syncope): Actual loss consciousness (fainting). May brief, sometimes accompanied brief seizure-like muscle contractions (convulsive syncope - usually benign due lack oxygen brain, true seizure disorder)\nMild/Moderate: Feeling lightheaded, dizzy, nauseous, sweaty (diaphoretic), pale (pallor), weak, blurred vision, hyperventilationSevere (Syncope): Actual loss consciousness (fainting). May brief, sometimes accompanied brief seizure-like muscle contractions (convulsive syncope - usually benign due lack oxygen brain, true seizure disorder)Management\nRecognize early signs! Ask donor ’re feeling\nsymptoms start: Stop pause donation immediately\ndonor lie flat elevate legs heart level (Trendelenburg position, modified). helps blood flow back brain\nApply cool compresses forehead back neck\nOffer sips water feel better\nReassure donor calmly\nMonitor vital signs (pulse, blood pressure)\nsyncope occurs, protect donor injury faint. Ensure airway clear\nRecognize early signs! Ask donor ’re feelingIf symptoms start: Stop pause donation immediatelyHave donor lie flat elevate legs heart level (Trendelenburg position, modified). helps blood flow back brainApply cool compresses forehead back neckOffer sips water feel betterReassure donor calmlyMonitor vital signs (pulse, blood pressure)syncope occurs, protect donor injury faint. Ensure airway clearPrevention: Ensure donor well-hydrated eaten beforehand, create calm environment, use distraction techniques (conversation, music), identify support anxious donors, instruct donors tense muscles (like crossing legs tensing thighs) feel faint","code":""},{"path":"adverse-reactions-1.html","id":"needle-site-complications","chapter":"Adverse Reactions","heading":"Needle Site Complications","text":"Hematoma (Bruise)\n: Blood leaks punctured vein surrounding tissues\nCause: Needle going vein, inadequate pressure needle removal, fragile veins\nSymptoms: Swelling, tenderness, pain, discoloration (bruising) venipuncture site\nManagement: forming donation, stop immediately. Remove needle, apply firm, direct pressure least 5-10 minutes. Apply cold compress later reduce swelling pain\nPrevention: Skilled venipuncture technique, selecting good vein, ensuring adequate pressure post-donation, instructing donor proper arm care\n: Blood leaks punctured vein surrounding tissuesCause: Needle going vein, inadequate pressure needle removal, fragile veinsSymptoms: Swelling, tenderness, pain, discoloration (bruising) venipuncture siteManagement: forming donation, stop immediately. Remove needle, apply firm, direct pressure least 5-10 minutes. Apply cold compress later reduce swelling painPrevention: Skilled venipuncture technique, selecting good vein, ensuring adequate pressure post-donation, instructing donor proper arm careInfiltration (Apheresis Return)\n: return needle (apheresis) slips vein, fluids (blood components, saline, citrate) infuse tissue instead bloodstream\nSymptoms: Swelling, pain, coolness site\nManagement: Stop return immediately, remove needle, elevate arm, apply compresses (often cold initially)\nPrevention: Secure needle placement, careful monitoring return site apheresis\n: return needle (apheresis) slips vein, fluids (blood components, saline, citrate) infuse tissue instead bloodstreamSymptoms: Swelling, pain, coolness siteManagement: Stop return immediately, remove needle, elevate arm, apply compresses (often cold initially)Prevention: Secure needle placement, careful monitoring return site apheresis","code":""},{"path":"adverse-reactions-1.html","id":"less-common-potentially-more-serious-reactions","chapter":"Adverse Reactions","heading":"Less Common, Potentially More Serious Reactions","text":"","code":""},{"path":"adverse-reactions-1.html","id":"nerve-irritationinjury","chapter":"Adverse Reactions","heading":"Nerve Irritation/Injury","text":": needle comes close touches nerve insertion manipulationSymptoms: Sharp, tingling, shooting, radiating pain arm hand/fingers; numbnessManagement: Stop donation immediately. Carefully reposition remove needle. Document event thoroughly. symptoms resolve quickly, persistent symptoms require medical evaluationPrevention: Careful vein selection (avoiding areas major nerves close surface), smooth venipuncture technique, avoiding excessive needle probing. Listen donor! report sharp, radiating pain, act immediately","code":""},{"path":"adverse-reactions-1.html","id":"arterial-puncture","chapter":"Adverse Reactions","heading":"Arterial Puncture","text":": needle accidentally punctures artery instead veinSymptoms: Bright red blood, rapid filling bag (may pulsatile), pain siteManagement: Stop donation immediately. Remove needle apply firm, direct pressure longer duration (least 10-15 minutes, sometimes ) arterial pressure higher. Check hematoma formation. Notify supervisor/medical directorPrevention: Careful palpation distinguish veins (bouncier) arteries (firmer pulse). Avoid venipuncture near known arterial locations","code":""},{"path":"adverse-reactions-1.html","id":"citrate-toxicity-apheresis-specific","chapter":"Adverse Reactions","heading":"Citrate Toxicity (Apheresis Specific)","text":": Occurs apheresis citrate anticoagulant (binds calcium) returned donor’s circulation. temporarily lowers amount ionized calcium bloodSymptoms: Tingling numbness, especially around lips (circumoral paresthesia) fingers/toes; chills; shivering; muscle cramps; feeling vibration; rarely, severe muscle spasms (tetany) cardiac rhythm changes (rare)Management: Slow rate blood return. Give oral calcium supplements (like Tums calcium carbonate tablets) donor chew. Reassure donor. Symptoms usually resolve quicklyPrevention: Prophylactic oral calcium procedure susceptible donors, careful monitoring infusion rates, adjusting citrate concentration based donor tolerance","code":""},{"path":"adverse-reactions-1.html","id":"allergic-reactions","chapter":"Adverse Reactions","heading":"Allergic Reactions","text":": Reaction substances used donationCause: commonly, sensitivity skin disinfectants (iodine, chlorhexidine), latex (gloves wraps), tape adhesive. Extremely rarely, reaction something returned apheresisSymptoms: Itching (pruritus), rash, hives (urticaria) site widespread. Rarely, respiratory symptoms (wheezing) anaphylaxis (severe, life-threatening reaction)Management: Stop donation/return. Assess severity. mild skin reactions, remove offending agent, apply cool compress, consider oral antihistamine. severe reactions (anaphylaxis), immediate emergency medical intervention (epinephrine, airway support) neededPrevention: Screen donors known allergies (iodine, latex, chlorhexidine). Use alternative supplies available (e.g., non-latex wraps, chlorhexidine scrub iodine allergy)","code":""},{"path":"adverse-reactions-1.html","id":"severe-systemic-reactions-very-rare","chapter":"Adverse Reactions","heading":"Severe Systemic Reactions (Very Rare)","text":"Bacterial Contamination/Sepsis: Extremely rare donor become septic donation process , theoretically possible grossly inadequate site disinfection, especially immunocompromised donor. Much greater risk recipientHemolytic Reaction: Essentially impossible standard allogeneic donation. theoretical risk specific apheresis autologous scenarios ’s catastrophic misidentification error return/reinfusion","code":""},{"path":"adverse-reactions-1.html","id":"delayed-reactions","chapter":"Adverse Reactions","heading":"Delayed Reactions","text":"Delayed Fainting/Syncope: Fainting leaving donation center (usually within 24 hours)Hematoma: Bruising may appear worsen hours donationIron Deficiency: acute reaction, potential long-term consequence, especially frequent whole blood double red cell donors. Managed education iron supplementation advice","code":""},{"path":"adverse-reactions-1.html","id":"general-management-prevention-principles","chapter":"Adverse Reactions","heading":"General Management & Prevention Principles","text":"Observe: Keep close eye donors immediately donationListen: Pay attention donor tells feelAct Quickly: Respond promptly signs symptoms reactionFollow Protocol: Know institution’s procedures managing adverse eventsDocument: Record reactions, interventions, outcomes accuratelyEducate: Provide clear post-donation instructions, including warning signs delayed reactions contactPrevent: Focus good technique, donor comfort, pre-donation screening, hydration/nutrition advice","code":""},{"path":"adverse-reactions-1.html","id":"key-takeaway-1","chapter":"Adverse Reactions","heading":"Key Takeaway","text":"need prepared adverse reactions, vast majority donations go smoothly. knowledgeable, vigilant, responsive, ensure donation process remains safe positive volunteer donors!","code":""},{"path":"adverse-reactions-1.html","id":"key-terms-2","chapter":"Adverse Reactions","heading":"Key Terms","text":"Vasovagal Reaction: common reaction triggered stress/anxiety leading drop blood pressure heart rate, potentially causing dizziness fainting (syncope)Syncope: Fainting temporary loss consciousnessHematoma: collection blood outside blood vessels, commonly called bruise, often occurring venipuncture siteCitrate Toxicity: Symptoms caused temporary low ionized calcium levels due citrate anticoagulant infusion apheresis (e.g., tingling, muscle cramps)Paresthesia: abnormal sensation, typically tingling, numbness, “pins needles,” often experienced around mouth extremities citrate reactionsDiaphoresis: Excessive sweating, often symptom accompanying vasovagal reactionsPallor: Paleness skin, another common sign vasovagal reactionsTrendelenburg Position: Placing patient flat back feet elevated higher head, used manage vasovagal reactionsInfiltration: Leakage intravenous fluids (like saline blood components returned apheresis) tissue surrounding veinUrticaria: Hives; raised, itchy welts skin, often indicating allergic reaction","code":""},{"path":"special-donations-1.html","id":"special-donations-1","chapter":"Special Donations","heading":"Special Donations","text":"standard allogeneic donation (giving blood general population) backbone blood supply, specific situations different types donations needed preferred. “special” donations cater unique circumstances, often involving specific donors recipients, might slightly different criteria procedures","code":""},{"path":"special-donations-1.html","id":"autologous-donation","chapter":"Special Donations","heading":"Autologous Donation","text":"Concept: person donates blood use later . Think self-storage blood!Purpose/Indications: Primarily done scheduled surgery blood loss anticipated. goal eliminate risks associated allogeneic transfusion, :\nTransfusion-transmitted diseases (viral, bacterial)\nAlloimmunization (developing antibodies foreign red cell, platelet, HLA antigens)\nAllergic febrile transfusion reactions\nTransfusion-transmitted diseases (viral, bacterial)Alloimmunization (developing antibodies foreign red cell, platelet, HLA antigens)Allergic febrile transfusion reactionsDonor Criteria\nRequires prescription order patient’s physician\nDonor must healthy enough undergo donation planned surgery\nHemoglobin/Hematocrit: Requirements might slightly lower allogeneic donation (e.g., Hgb ≥ 11.0 g/dL Hct ≥ 33%), determined blood center’s medical director prescribing physician. key ensuring donation doesn’t make patient dangerously anemic surgery\nFrequency: Can donate frequently allogeneic donors, often every days 72 hours surgery, allowing collection multiple units needed. Iron supplementation usually recommended\nAge/Weight: Standard minimum weight usually applies (≥110 lbs). ’s often upper age limit patient otherwise fit\nInfectious Disease Markers: Testing still performed. unit tests positive (e.g., Hepatitis B), specific labeling handling procedures apply, use requires careful consideration notification\nRequires prescription order patient’s physicianDonor must healthy enough undergo donation planned surgeryHemoglobin/Hematocrit: Requirements might slightly lower allogeneic donation (e.g., Hgb ≥ 11.0 g/dL Hct ≥ 33%), determined blood center’s medical director prescribing physician. key ensuring donation doesn’t make patient dangerously anemic surgeryFrequency: Can donate frequently allogeneic donors, often every days 72 hours surgery, allowing collection multiple units needed. Iron supplementation usually recommendedAge/Weight: Standard minimum weight usually applies (≥110 lbs). ’s often upper age limit patient otherwise fitInfectious Disease Markers: Testing still performed. unit tests positive (e.g., Hepatitis B), specific labeling handling procedures apply, use requires careful consideration notificationCollection Process: Usually collected standard Whole Blood unitsLabeling & Handling: CRITICAL! Autologous units must clearly labeled “Autologous Use ” segregated general inventory. Rigorous identification checks needed collection transfusion ensure unit goes back correct patient-donorAdvantages: safest option donor-recipient regarding disease transmission alloimmunizationDisadvantages\nRisk pre-operative anemia donor-patient\nHigher administrative logistical effort\nUnits often discarded surgery cancelled less blood needed collected (wastage)\n: typically “crossed ” general inventory unused, due potentially different donor criteria testing implications\neliminate risk bacterial contamination collection storage errors\nRisk pre-operative anemia donor-patientHigher administrative logistical effortUnits often discarded surgery cancelled less blood needed collected (wastage): typically “crossed ” general inventory unused, due potentially different donor criteria testing implicationsDoes eliminate risk bacterial contamination collection storage errors","code":""},{"path":"special-donations-1.html","id":"directed-or-designated-donation","chapter":"Special Donations","heading":"Directed (or Designated) Donation","text":"Concept: donor gives blood specifically transfusion named, intended recipient (donor )Purpose/Indications: Often requested patient family, usually emotional reasons belief (often medically unsupported) blood family/friends safer. rare cases, might medically indicated find antigen-negative blood family members patients complex antibodies. ’s also necessary transfusion first-degree relatives prevent Graft-versus-Host Disease (GVHD) requiring irradiation cellular componentsDonor Criteria: directed donor must meet standard allogeneic donor eligibility criteria. exceptions relaxed standards allowed. undergo screening testing regular volunteer donorsCollection Process: Standard Whole Blood Apheresis collectionLabeling & Handling: Units must labeled clearly identify intended recipient. held specifically patientAdvantages: Provides psychological comfort patient family. Can sometimes useful finding rare compatible blood within family. Ensures necessary irradiation related donorsDisadvantages\nproven safety advantage: standard allogeneic donations volunteer donors (screened identically). studies suggest potential disadvantages (e.g., donors feeling pressured donate despite risk factors)\nLogistical complexity coordinating donation ensuring ’s available needed\nused intended recipient, unit typically discarded requires specific procedures/consent moved general inventory (meets criteria)\nIrradiation mandatory: cellular products blood relatives prevent TA-GVHD (Transfusion-Associated Graft-versus-Host Disease)\nproven safety advantage: standard allogeneic donations volunteer donors (screened identically). studies suggest potential disadvantages (e.g., donors feeling pressured donate despite risk factors)Logistical complexity coordinating donation ensuring ’s available neededIf used intended recipient, unit typically discarded requires specific procedures/consent moved general inventory (meets criteria)Irradiation mandatory: cellular products blood relatives prevent TA-GVHD (Transfusion-Associated Graft-versus-Host Disease)","code":""},{"path":"special-donations-1.html","id":"apheresis-donation","chapter":"Special Donations","heading":"Apheresis Donation","text":"Concept: Collecting specific blood components (platelets, plasma, red cells, granulocytes, stem cells) using apheresis machine, returning remaining components donorPurpose/Indications: Allows collection larger dose specific component single donor, reducing recipient exposure. Essential collecting components like granulocytes double units red cellsDonor Criteria: Generally must meet allogeneic criteria, specific requirements may apply:\nPlateletpheresis: May specific platelet count requirements. Can donate frequently (e.g., every 7 days, 24 times/year)\nDouble Red Cell Apheresis: Requires higher Hgb/Hct levels meeting specific height/weight criteria ensure adequate blood volume. Donation interval longer (e.g., 112 days/16 weeks)\nGranulocyte Apheresis: Often requires donor pre-treatment medications (G-CSF, corticosteroids) increase granulocyte count. Specific consent regarding medications needed\nPlateletpheresis: May specific platelet count requirements. Can donate frequently (e.g., every 7 days, 24 times/year)Double Red Cell Apheresis: Requires higher Hgb/Hct levels meeting specific height/weight criteria ensure adequate blood volume. Donation interval longer (e.g., 112 days/16 weeks)Granulocyte Apheresis: Often requires donor pre-treatment medications (G-CSF, corticosteroids) increase granulocyte count. Specific consent regarding medications neededCollection Process: Involves apheresis machine, often requires venous access arms, takes longer (1-2 hours), uses citrate anticoagulant (potential citrate reaction). Covered detail Collection MethodsLabeling & Handling: Labeled according specific component collected (e.g., Platelets Pheresis, RBC Pheresis)Advantages: High yield specific component, reduced donor exposure recipient, allows frequent donation certain componentsDisadvantages: Longer procedure time, potential citrate reactions, requires specialized equipment trained staff","code":""},{"path":"special-donations-1.html","id":"hematopoietic-progenitor-cell-hpc-donation","chapter":"Special Donations","heading":"Hematopoietic Progenitor Cell (HPC) Donation","text":"Concept: Collection stem cells, can differentiate various blood cells, transplantationPurpose/Indications: Used treat cancers (leukemia, lymphoma, myeloma), bone marrow failure syndromes, certain genetic disordersSources\nBone Marrow (HPC-M): Collected surgically donor’s hip bones anesthesia\nPeripheral Blood Stem Cells (PBSC / HPC-): Collected via apheresis donor receives injections mobilizing agents (like G-CSF) several days push stem cells marrow bloodstream. common method now\nCord Blood (HPC-C): Collected umbilical cord placenta birth\nBone Marrow (HPC-M): Collected surgically donor’s hip bones anesthesiaPeripheral Blood Stem Cells (PBSC / HPC-): Collected via apheresis donor receives injections mobilizing agents (like G-CSF) several days push stem cells marrow bloodstream. common method nowCord Blood (HPC-C): Collected umbilical cord placenta birthDonor Criteria: Involves extensive medical screening, infectious disease testing (often extensive standard donation), crucial HLA (Human Leukocyte Antigen) matching donor recipient (unless ’s autologous HPC transplant). Donor registries (like NMDP/Match) facilitate finding unrelated donors. Separate regulatory standards apply (e.g., FACT)Collection Process: Either surgery (marrow) apheresis (PBSC)Labeling & Handling: Extremely strict labeling (ISBT 128 format), handling, cryopreservation protocolsAdvantages: Can curative life-threatening diseasesDisadvantages: Complex process, potential side effects donor (bone pain G-CSF, risks anesthesia marrow harvest), requires specialized collection transplant centers","code":""},{"path":"special-donations-1.html","id":"therapeutic-phlebotomy","chapter":"Special Donations","heading":"Therapeutic Phlebotomy","text":"Concept: Blood withdrawn individual medical reasons related health, primarily transfusion othersPurpose/Indications: treat conditions characterized excess red blood cells iron, :\nPolycythemia Vera (excess RBC production)\nHereditary Hemochromatosis (iron overload)\nPorphyria Cutanea Tarda\nPolycythemia Vera (excess RBC production)Hereditary Hemochromatosis (iron overload)Porphyria Cutanea TardaDonor Criteria: Requires physician’s order specifying diagnosis, amount blood removed, frequency. primary reason treatment, donationCollection Process: Similar standard whole blood donation, volume removed based prescriptionLabeling & Handling\npatient-donor also meets allogeneic donor eligibility criteria (sometimes case, e.g., hemochromatosis donors), blood may eligible transfusion use (“qualified therapeutic collection”). must labeled accordingly\npatient-donor meet allogeneic criteria (e.g., due underlying condition like polycythemia vera, standard deferrals), unit must labeled Therapeutic Phlebotomy discarded (used transfusion)\npatient-donor also meets allogeneic donor eligibility criteria (sometimes case, e.g., hemochromatosis donors), blood may eligible transfusion use (“qualified therapeutic collection”). must labeled accordinglyIf patient-donor meet allogeneic criteria (e.g., due underlying condition like polycythemia vera, standard deferrals), unit must labeled Therapeutic Phlebotomy discarded (used transfusion)Advantages: Effectively treats patient’s medical condition. Potential contribute blood supply criteria metDisadvantages: blood often discarded. Requires careful coordination blood center treating physician","code":""},{"path":"special-donations-1.html","id":"key-takeaway-2","chapter":"Special Donations","heading":"Key Takeaway","text":"Special donations address specific clinical needs beyond scope standard allogeneic donation. require careful attention unique donor criteria, collection procedures, especially labeling handling protocols ensure safety efficacy either donor-patient (autologous, therapeutic) intended recipient (directed, HPC). Medical director oversight often crucial managing special cases","code":""},{"path":"special-donations-1.html","id":"key-terms-3","chapter":"Special Donations","heading":"Key Terms","text":"Autologous Donation: Donation blood individual future useDirected (Designated) Donation: Donation blood individual specific, named recipient themselvesApheresis: Procedure collect specific blood components using automated equipmentHematopoietic Progenitor Cells (HPCs): Stem cells capable developing blood cells, collected transplantation (bone marrow, peripheral blood, cord blood)Therapeutic Phlebotomy: Removal blood medical treatment person undergoing phlebotomyAlloimmunization: development antibodies response foreign antigens (e.g., blood transfusion pregnancy)Graft-versus-Host Disease (GVHD): complication immune cells donated tissue (graft, e.g., blood transfusion, HPC transplant) attack recipient’s tissues (host). Prevented relevant transfusions irradiationIrradiation: Treatment cellular blood components gamma rays X-rays inactivate donor lymphocytes prevent TA-GVHD. Mandatory directed donations blood relativesHLA (Human Leukocyte Antigen): Proteins surface cells key immune system recognition; critical matching HPC transplantation sometimes relevant platelet transfusionG-CSF (Granulocyte Colony-Stimulating Factor): medication used increase production release granulocytes stem cells bone marrow bloodstream, often used PBSC granulocyte apheresis donation","code":""},{"path":"processing-1.html","id":"processing-1","chapter":"Processing","heading":"Processing","text":"Blood processing highly regulated controlled sequence. starts adhering FDA/AABB rules every action taken. incorporates rigorous testing screen infectious agents determine compatibility. Finally, culminates precise labeling clearly communicates identity characteristics finished component. step builds upon last, ensuring final blood product reaching hospital shelf safe effective possible patient care. Think whole phase crucial transformation step collected unit blood becomes safe, identifiable, ready--use component transfusion. ’s governed strict rules, involves critical testing, culminates precise labelingProcessing encompasses everything happens unit blood collection ’s placed inventory potential transfusion. ’s meticulously controlled ensure safety, quality, efficacy","code":""},{"path":"processing-1.html","id":"fda-aabb-requirements-the-rulebook","chapter":"Processing","heading":"FDA & AABB Requirements (The Rulebook)","text":"Foundation: Processing operates strict framework set FDA (Food Drug Administration) federal regulations (like cGMP - Current Good Manufacturing Practices 21 CFR 606) AABB (Association Advancement Blood & Biotherapies) detailed StandardsGoal: ensure safety, purity, potency, identity blood componentsKey Elements: requirements mandate:\nRobust Quality Management Systems\nQualified trained personnel\nValidated maintained equipment suitable facilities\nDetailed Standard Operating Procedures (SOPs) every step\nMeticulous record-keeping ensuring traceability (“vein--vein”)\nRobust Quality Management SystemsQualified trained personnelValidated maintained equipment suitable facilitiesDetailed Standard Operating Procedures (SOPs) every stepMeticulous record-keeping ensuring traceability (“vein--vein”)Focus: Consistency, control, documentation paramount throughout processing activities, centrifugation component preparation specialized modifications like leukoreduction irradiation","code":""},{"path":"processing-1.html","id":"testing-the-safety-check","chapter":"Processing","heading":"Testing (The Safety Check)","text":"Purpose: prevent disease transmission ensure immunological compatibility. non-negotiable step every donationInfectious Disease Markers (TTIs)\nUses FDA-licensed kits screen viruses bacteria (HIV, HCV, HBV, HTLV, Syphilis, WNV, Zika, Chagas, Babesia)\nEmploys serology (detecting antibodies/antigens) highly sensitive Nucleic Acid Testing (NAT) (detecting viral genetic material, crucial “window period”)\nOutcome: reactive screening result leads unit quarantine discard, donor notification, deferral\nUses FDA-licensed kits screen viruses bacteria (HIV, HCV, HBV, HTLV, Syphilis, WNV, Zika, Chagas, Babesia)Employs serology (detecting antibodies/antigens) highly sensitive Nucleic Acid Testing (NAT) (detecting viral genetic material, crucial “window period”)Outcome: reactive screening result leads unit quarantine discard, donor notification, deferralImmunohematology (Blood Typing)\nDetermines ABO group (forward reverse typing must match) Rh type (including Weak D testing apparent Rh negatives)\nOften includes antibody screen detect unexpected red cell antibodies\nOutcome: Confirms blood type labeling identifies antibodies might require special considerations plasma components unit labeling\nDetermines ABO group (forward reverse typing must match) Rh type (including Weak D testing apparent Rh negatives)Often includes antibody screen detect unexpected red cell antibodiesOutcome: Confirms blood type labeling identifies antibodies might require special considerations plasma components unit labelingQuarantine: Units remain quarantine, unavailable use, required testing complete results acceptable","code":""},{"path":"processing-1.html","id":"labeling-the-final-id","chapter":"Processing","heading":"Labeling (The Final ID)","text":"Purpose: accurately uniquely identify component, providing critical information needed safe storage, selection, transfusionCritical Timing: final transfusion-ready label applied testing complete, reviewed, acceptable, unit released quarantineKey Information (often using ISBT 128 standard)\nUnique Donation ID number\nComponent Name (Product Code)\nABO/Rh Type\nExpiration Date/Time\nVolume, Anticoagulant/Additive\nStorage Temperature\nFacility Information\nSpecial Attributes (e.g., Irradiated, Leukocytes Reduced, CMV Neg, Antigen Neg, Autologous Use )\nUnique Donation ID numberComponent Name (Product Code)ABO/Rh TypeExpiration Date/TimeVolume, Anticoagulant/AdditiveStorage TemperatureFacility InformationSpecial Attributes (e.g., Irradiated, Leukocytes Reduced, CMV Neg, Antigen Neg, Autologous Use )Accuracy Paramount: Labeling errors (e.g., wrong blood type) extremely dangerous. Systems (like validated computer systems) procedures focus heavily preventing errors. ISBT 128 barcoding helps reduce manual transcription mistakes","code":""},{"path":"fda-aabb-requirements.html","id":"fda-aabb-requirements","chapter":"FDA, AABB Requirements","heading":"FDA, AABB Requirements","text":"section covers crucial regulatory accreditation framework governs blood processed lab. Think FDA (Food Drug Administration) AABB (Association Advancement Blood & Biotherapies) two main pillars ensuring safety, purity, potency blood products. work together, distinct roles:FDA: US government’s regulatory agency. requirements, primarily found Code Federal Regulations (CFR) Title 21, Parts 600-680 (specifically 606 GMPs, 610 testing, 640 product standards), law. Compliance mandatory facility collecting processing blood. focus setting minimum standards safety efficacyAABB: international, non-profit accrediting organization. publish Standards Blood Banks Transfusion Services. standards often incorporate sometimes exceed FDA requirements, representing industry best practices. AABB accreditation technically voluntary, ’s widely recognized hallmark quality often required hospital operations reimbursementBoth FDA regulations AABB standards aim ensure every unit blood safe transfusion. ’s breakdown key requirements processing phase (collection, storage/distribution):","code":""},{"path":"fda-aabb-requirements.html","id":"overarching-requirements-apply-throughout-processing","chapter":"FDA, AABB Requirements","heading":"Overarching Requirements (Apply throughout Processing)","text":"Quality Management System (QMS)\nFDA (Current Good Manufacturing Practices - cGMPs - 21 CFR 606): Mandates comprehensive quality systems covering personnel, facilities, equipment, procedures, records, error management, etc\nAABB (Quality System Essentials - QSEs): Provides detailed framework quality management, often used model implementing cGMPs. Covers areas like process control, documents & records, assessments, non-conformance management, personnel training\nKey Idea: robust systems place ensure quality built every step, just tested end\nFDA (Current Good Manufacturing Practices - cGMPs - 21 CFR 606): Mandates comprehensive quality systems covering personnel, facilities, equipment, procedures, records, error management, etcAABB (Quality System Essentials - QSEs): Provides detailed framework quality management, often used model implementing cGMPs. Covers areas like process control, documents & records, assessments, non-conformance management, personnel trainingKey Idea: robust systems place ensure quality built every step, just tested endPersonnel & Training\nFDA & AABB: Require adequate number qualified personnel defined responsibilities. Staff must receive initial ongoing training relevant tasks. Competency must assessed documented regularly\nFDA & AABB: Require adequate number qualified personnel defined responsibilities. Staff must receive initial ongoing training relevant tasks. Competency must assessed documented regularlyFacilities & Equipment\nFDA & AABB: Facilities must clean, orderly, suitable size construction. Critical equipment (centrifuges, refrigerators, freezers, irradiators, sterile connection devices, testing instruments) must qualified, calibrated, maintained, monitored according established schedules. Procedures must place equipment malfunction\nFDA & AABB: Facilities must clean, orderly, suitable size construction. Critical equipment (centrifuges, refrigerators, freezers, irradiators, sterile connection devices, testing instruments) must qualified, calibrated, maintained, monitored according established schedules. Procedures must place equipment malfunctionStandard Operating Procedures (SOPs)\nFDA & AABB: Written, detailed procedures must exist significant steps processing. SOPs must readily available, followed precisely staff, reviewed/updated regularly. deviations must documented\nFDA & AABB: Written, detailed procedures must exist significant steps processing. SOPs must readily available, followed precisely staff, reviewed/updated regularly. deviations must documentedRecord Keeping & Traceability\nFDA & AABB: Meticulous records essential! Must allow tracking unit donor processing steps final disposition (transfusion, shipment, discard) – often called “vein--vein” traceability. Records must legible, accurate, contemporaneous, retained specified periods (often 10+ years). Computer systems used must validated\nFDA & AABB: Meticulous records essential! Must allow tracking unit donor processing steps final disposition (transfusion, shipment, discard) – often called “vein--vein” traceability. Records must legible, accurate, contemporaneous, retained specified periods (often 10+ years). Computer systems used must validated","code":""},{"path":"fda-aabb-requirements.html","id":"specific-processing-step-requirements","chapter":"FDA, AABB Requirements","heading":"Specific Processing Step Requirements","text":"Component Preparation\nFDA & AABB: Procedures separating whole blood components (RBCs, Plasma, Platelets, Cryoprecipitate) must validated consistently produce products meeting specific quality criteria (e.g., volume, cell count, residual plasma/RBCs). Centrifugation speeds, times, temperatures critical parameters. Maintaining closed system whenever possible crucial prevent contamination\nFDA & AABB: Procedures separating whole blood components (RBCs, Plasma, Platelets, Cryoprecipitate) must validated consistently produce products meeting specific quality criteria (e.g., volume, cell count, residual plasma/RBCs). Centrifugation speeds, times, temperatures critical parameters. Maintaining closed system whenever possible crucial prevent contaminationTesting (Donor Units)\nFDA (21 CFR 610): Mandates testing every donation using FDA-licensed test kits specific transfusion-transmitted infections (TTIs). Current required tests include:\nHIV-1/2 (antibody NAT - Nucleic Acid Testing)\nHepatitis C (HCV) (antibody NAT)\nHepatitis B (HBV) (HBsAg, anti-HBc, NAT)\nHTLV-/II (Human T-lymphotropic virus) (antibody)\nSyphilis (serological test)\nWest Nile Virus (WNV) (NAT)\nZika Virus (NAT - specific guidance)\nTrypanosoma cruzi (Chagas disease) (antibody - usually per donor)\nBabesia microti (NAT antibody - required certain states, recommended elsewhere)\n\nAABB: Standards align FDA requirements TTI testing. May additional recommendations requirements based emerging risks\nImmunohematology Testing\nFDA & AABB: ABO group Rh type (including weak D testing based policy) required donations. Antibody screen required donors history transfusion pregnancy. Results must compared historical records available\n\nFDA (21 CFR 610): Mandates testing every donation using FDA-licensed test kits specific transfusion-transmitted infections (TTIs). Current required tests include:\nHIV-1/2 (antibody NAT - Nucleic Acid Testing)\nHepatitis C (HCV) (antibody NAT)\nHepatitis B (HBV) (HBsAg, anti-HBc, NAT)\nHTLV-/II (Human T-lymphotropic virus) (antibody)\nSyphilis (serological test)\nWest Nile Virus (WNV) (NAT)\nZika Virus (NAT - specific guidance)\nTrypanosoma cruzi (Chagas disease) (antibody - usually per donor)\nBabesia microti (NAT antibody - required certain states, recommended elsewhere)\nHIV-1/2 (antibody NAT - Nucleic Acid Testing)Hepatitis C (HCV) (antibody NAT)Hepatitis B (HBV) (HBsAg, anti-HBc, NAT)HTLV-/II (Human T-lymphotropic virus) (antibody)Syphilis (serological test)West Nile Virus (WNV) (NAT)Zika Virus (NAT - specific guidance)Trypanosoma cruzi (Chagas disease) (antibody - usually per donor)Babesia microti (NAT antibody - required certain states, recommended elsewhere)AABB: Standards align FDA requirements TTI testing. May additional recommendations requirements based emerging risksImmunohematology Testing\nFDA & AABB: ABO group Rh type (including weak D testing based policy) required donations. Antibody screen required donors history transfusion pregnancy. Results must compared historical records available\nFDA & AABB: ABO group Rh type (including weak D testing based policy) required donations. Antibody screen required donors history transfusion pregnancy. Results must compared historical records availableLabeling\nFDA (21 CFR 606 Subpart G): Specifies mandatory information container labels. Labels must accurate, clear, indelible. system must place prevent labeling errors\nAABB: Strongly advocates requires use ISBT 128 international labeling standard uniformity enhanced safety (barcodes, standardized product codes, ABO/Rh representation)\nCritical Step: Final component labels confirming suitability (e.g., ABO/Rh, expiration date, negative infectious disease results) can applied required testing completed, reviewed, found acceptable. Units must remain quarantine final labeling occurs\nLabel Content: Includes unique donation ID, component name, ABO/Rh, volume, anticoagulant/additive, storage temp, expiration date/time, facility info, donor status (volunteer/autologous), special attributes (Irradiated, Leukoreduced, CMV Seronegative, Antigen Negative, etc.)\nFDA (21 CFR 606 Subpart G): Specifies mandatory information container labels. Labels must accurate, clear, indelible. system must place prevent labeling errorsAABB: Strongly advocates requires use ISBT 128 international labeling standard uniformity enhanced safety (barcodes, standardized product codes, ABO/Rh representation)Critical Step: Final component labels confirming suitability (e.g., ABO/Rh, expiration date, negative infectious disease results) can applied required testing completed, reviewed, found acceptable. Units must remain quarantine final labeling occursLabel Content: Includes unique donation ID, component name, ABO/Rh, volume, anticoagulant/additive, storage temp, expiration date/time, facility info, donor status (volunteer/autologous), special attributes (Irradiated, Leukoreduced, CMV Seronegative, Antigen Negative, etc.)Modifications (Leukoreduction, Irradiation, Washing, etc.)\nFDA & AABB: components modified, process must validated, performed according SOPs, documented\nLeukoreduction: Must meet specific standards residual white blood cell count (e.g., < 5 x 10⁶ WBCs per unit US). QC testing required\nIrradiation: Requires validated process delivering specific dose range (typically 25-50 Gy) prevent TA-GVHD. irradiation indicator label usually applied\nWashing/Volume Reducing: Procedures must minimize residual plasma additive solution maintaining component quality. Affects expiration time\nFreezing/Deglycerolizing (RBCs): Requires specific glycerolization, freezing, thawing, deglycerolization protocols. Post-thaw/deglycerolization expiration short (usually 24 hours open system)\n\nFDA & AABB: components modified, process must validated, performed according SOPs, documented\nLeukoreduction: Must meet specific standards residual white blood cell count (e.g., < 5 x 10⁶ WBCs per unit US). QC testing required\nIrradiation: Requires validated process delivering specific dose range (typically 25-50 Gy) prevent TA-GVHD. irradiation indicator label usually applied\nWashing/Volume Reducing: Procedures must minimize residual plasma additive solution maintaining component quality. Affects expiration time\nFreezing/Deglycerolizing (RBCs): Requires specific glycerolization, freezing, thawing, deglycerolization protocols. Post-thaw/deglycerolization expiration short (usually 24 hours open system)\nLeukoreduction: Must meet specific standards residual white blood cell count (e.g., < 5 x 10⁶ WBCs per unit US). QC testing requiredIrradiation: Requires validated process delivering specific dose range (typically 25-50 Gy) prevent TA-GVHD. irradiation indicator label usually appliedWashing/Volume Reducing: Procedures must minimize residual plasma additive solution maintaining component quality. Affects expiration timeFreezing/Deglycerolizing (RBCs): Requires specific glycerolization, freezing, thawing, deglycerolization protocols. Post-thaw/deglycerolization expiration short (usually 24 hours open system)Quarantine & Release\nFDA & AABB: Units must held designated quarantine area mandatory testing, component preparation, record review complete acceptable. can units labeled appropriately released inventory storage distribution. Procedures must prevent inadvertent release unsuitable units\nFDA & AABB: Units must held designated quarantine area mandatory testing, component preparation, record review complete acceptable. can units labeled appropriately released inventory storage distribution. Procedures must prevent inadvertent release unsuitable units","code":""},{"path":"fda-aabb-requirements.html","id":"key-takeaway-3","chapter":"FDA, AABB Requirements","heading":"Key Takeaway","text":"FDA regulations (law) AABB standards (best practices/accreditation) provide comprehensive framework blood processing. Adherence isn’t optional; ’s fundamental ensuring every blood component prepared lab safe, pure, potent, correctly labeled ever reaches patient. requires meticulous attention detail, robust quality systems, well-trained staff following validated procedures","code":""},{"path":"fda-aabb-requirements.html","id":"key-terms-4","chapter":"FDA, AABB Requirements","heading":"Key Terms","text":"FDA (Food Drug Administration): US federal agency responsible regulating blood products biological drugsAABB (Association Advancement Blood & Biotherapies): Professional organization setting standards providing accreditation blood banks transfusion servicesCFR (Code Federal Regulations): FDA regulations published (Title 21 Food Drugs)cGMP (Current Good Manufacturing Practices): FDA regulations (21 CFR 606) outlining minimum requirements methods, facilities, controls used manufacturing (including blood collection/processing)AABB Standards: detailed requirements published AABB accredited facilitiesISBT 128: international standard terminology, coding, labeling medical products human origin (blood, cells, tissues). Uses standardized barcodes product codesQuality Management System (QMS): organizational structure, procedures, processes, resources needed implement quality managementValidation: Documented evidence providing high degree assurance specific process consistently produce product meeting predetermined specifications quality attributesTraceability: ability track blood unit donor source steps processing testing final disposition (including recipient)Leukoreduction: process removing white blood cells (leukocytes) blood componentIrradiation: Treating blood components gamma rays X-rays inactivate T-lymphocytes prevent Transfusion-Associated Graft-versus-Host Disease (TA-GVHD)NAT (Nucleic Acid Testing): Highly sensitive molecular tests detect genetic material (RNA DNA) viruses, allowing earlier detection infections compared antibody tests","code":""},{"path":"testing.html","id":"testing","chapter":"Testing","heading":"Testing","text":"arguably one critical parts ensuring blood safety, acting multi-layered shield protect recipients. blood collected, can labeled released transfusion, samples every single donation undergo battery tests mandated FDA upheld AABB standardsThink testing two main categories:Infectious Disease Marker Testing: prevent transmitting diseasesImmunohematology Testing: ensure blood type compatibility","code":""},{"path":"testing.html","id":"infectious-disease-marker-testing-transfusion-transmitted-infections---ttis","chapter":"Testing","heading":"Infectious Disease Marker Testing (Transfusion-Transmitted Infections - TTIs)","text":"Goal: detect presence specific viruses bacteria donated blood harm recipientMandate: Required FDA (21 CFR 610 Subpart E) every donation. AABB standards mirror requirementsMethodology: Uses FDA-licensed screening test kits. Two main technologies employed:\nSerological Tests: Detect either antibodies produced donor’s immune system response infection, antigens, proteins directly infectious agent (like Hepatitis B surface antigen - HBsAg)\nNucleic Acid Testing (NAT): highly sensitive molecular method detects genetic material (RNA DNA) virus. NAT crucial can detect infections much earlier antibody tests, “window period” someone infected hasn’t yet produced detectable antibodies. significantly enhances safety. NAT often performed pooled samples first; pool tests positive, individual units within pool tested\nSerological Tests: Detect either antibodies produced donor’s immune system response infection, antigens, proteins directly infectious agent (like Hepatitis B surface antigen - HBsAg)Nucleic Acid Testing (NAT): highly sensitive molecular method detects genetic material (RNA DNA) virus. NAT crucial can detect infections much earlier antibody tests, “window period” someone infected hasn’t yet produced detectable antibodies. significantly enhances safety. NAT often performed pooled samples first; pool tests positive, individual units within pool testedRequired Tests (Current US FDA Requirements)\nHIV (Human Immunodeficiency Virus)\nHIV-1/2 Antibody (detects antibodies major types)\nHIV-1 NAT (detects viral RNA)\n\nHCV (Hepatitis C Virus)\nHCV Antibody (detects antibodies)\nHCV NAT (detects viral RNA)\n\nHBV (Hepatitis B Virus)\nHBsAg (Hepatitis B Surface Antigen - detects part virus )\nAnti-HBc (Antibody Hepatitis B Core antigen - indicates current past infection)\nHBV NAT (detects viral DNA)\n\nHTLV (Human T-lymphotropic Virus)\nHTLV-/II Antibody (detects antibodies)\n\nSyphilis\nSerological test (detects antibodies Treponema pallidum)\n\nWNV (West Nile Virus)\nWNV NAT (detects viral RNA; crucial WNV often causes asymptomatic infection)\n\nZika Virus\nZika Virus NAT (detects viral RNA; requirement often based FDA guidance risk)\n\nTrypanosoma cruzi (Chagas Disease)\nAntibody test (required least per donor; detects antibodies parasite)\n\nBabesia microti:\nNAT Antibody test (required states designated FDA endemic, recommended elsewhere; detects parasite common tick-borne infections)\n\nHIV (Human Immunodeficiency Virus)\nHIV-1/2 Antibody (detects antibodies major types)\nHIV-1 NAT (detects viral RNA)\nHIV-1/2 Antibody (detects antibodies major types)HIV-1 NAT (detects viral RNA)HCV (Hepatitis C Virus)\nHCV Antibody (detects antibodies)\nHCV NAT (detects viral RNA)\nHCV Antibody (detects antibodies)HCV NAT (detects viral RNA)HBV (Hepatitis B Virus)\nHBsAg (Hepatitis B Surface Antigen - detects part virus )\nAnti-HBc (Antibody Hepatitis B Core antigen - indicates current past infection)\nHBV NAT (detects viral DNA)\nHBsAg (Hepatitis B Surface Antigen - detects part virus )Anti-HBc (Antibody Hepatitis B Core antigen - indicates current past infection)HBV NAT (detects viral DNA)HTLV (Human T-lymphotropic Virus)\nHTLV-/II Antibody (detects antibodies)\nHTLV-/II Antibody (detects antibodies)Syphilis\nSerological test (detects antibodies Treponema pallidum)\nSerological test (detects antibodies Treponema pallidum)WNV (West Nile Virus)\nWNV NAT (detects viral RNA; crucial WNV often causes asymptomatic infection)\nWNV NAT (detects viral RNA; crucial WNV often causes asymptomatic infection)Zika Virus\nZika Virus NAT (detects viral RNA; requirement often based FDA guidance risk)\nZika Virus NAT (detects viral RNA; requirement often based FDA guidance risk)Trypanosoma cruzi (Chagas Disease)\nAntibody test (required least per donor; detects antibodies parasite)\nAntibody test (required least per donor; detects antibodies parasite)Babesia microti:\nNAT Antibody test (required states designated FDA endemic, recommended elsewhere; detects parasite common tick-borne infections)\nNAT Antibody test (required states designated FDA endemic, recommended elsewhere; detects parasite common tick-borne infections)Interpretation & Action\nscreening test reactive (positive), unit blood quarantined discarded. used transfusion\nConfirmatory testing usually performed reactive units verify result\ndonor notified confirmed positive results placed appropriate deferral list (often permanent HIV, HCV, HBV)\n“Lookback” procedures may initiated identify recipients previous donations donor applicable\nscreening test reactive (positive), unit blood quarantined discarded. used transfusionConfirmatory testing usually performed reactive units verify resultThe donor notified confirmed positive results placed appropriate deferral list (often permanent HIV, HCV, HBV)“Lookback” procedures may initiated identify recipients previous donations donor applicable","code":""},{"path":"testing.html","id":"immunohematology-testing-blood-group-serology","chapter":"Testing","heading":"Immunohematology Testing (Blood Group Serology)","text":"Goal: determine donor’s blood type (ABO Rh) screen unexpected red cell antibodies ensure compatibility potential recipients prevent hemolytic transfusion reactionsMandate: Required FDA (21 CFR 640) AABB standardsRequired Tests\nABO Grouping\nForward Type: Tests donor’s red cells known anti-anti-B reagents detect /B antigens\nReverse Type: Tests donor’s plasma/serum known A1 B red cells detect anti-/anti-B antibodies\nCrucial Step: forward reverse type results must agree ABO group validly assigned. discrepancy requires investigation\n\nRh Typing\nTests donor’s red cells anti-D reagent determine D antigen (primary Rh antigen) present (Rh positive) absent (Rh negative)\nWeak D Testing: Required AABB standards (implicitly FDA outcomes) donors initially test Rh negative standard anti-D. weak D test positive, unit labeled Rh Positive. negative, ’s labeled Rh Negative. prevents Rh-negative recipients exposed D antigen\n\nABO Grouping\nForward Type: Tests donor’s red cells known anti-anti-B reagents detect /B antigens\nReverse Type: Tests donor’s plasma/serum known A1 B red cells detect anti-/anti-B antibodies\nCrucial Step: forward reverse type results must agree ABO group validly assigned. discrepancy requires investigation\nForward Type: Tests donor’s red cells known anti-anti-B reagents detect /B antigensReverse Type: Tests donor’s plasma/serum known A1 B red cells detect anti-/anti-B antibodiesCrucial Step: forward reverse type results must agree ABO group validly assigned. discrepancy requires investigationRh Typing\nTests donor’s red cells anti-D reagent determine D antigen (primary Rh antigen) present (Rh positive) absent (Rh negative)\nWeak D Testing: Required AABB standards (implicitly FDA outcomes) donors initially test Rh negative standard anti-D. weak D test positive, unit labeled Rh Positive. negative, ’s labeled Rh Negative. prevents Rh-negative recipients exposed D antigen\nTests donor’s red cells anti-D reagent determine D antigen (primary Rh antigen) present (Rh positive) absent (Rh negative)Weak D Testing: Required AABB standards (implicitly FDA outcomes) donors initially test Rh negative standard anti-D. weak D test positive, unit labeled Rh Positive. negative, ’s labeled Rh Negative. prevents Rh-negative recipients exposed D antigenAdditional Immunohematology Testing\nAntibody Screen (Detection Unexpected Red Cell Antibodies)\nTests donor’s plasma/serum screening cells (group O cells known antigen profiles) detect clinically significant IgG antibodies (expected anti-anti-B)\nRequired AABB donors history pregnancy transfusion. Many centers perform donors\n?: unexpected antibodies present:\nPlasma-containing components (FFP, Platelets) ideally given recipients whose red cells corresponding antigen\nRed Blood Cell units generally safe (plasma removed), information valuable. unit must labeled containing antibody\ndonors may recruited reagent red cell manufacturing\n\n\nRed Cell Antigen Phenotyping\nroutinely required donors, may performed identify donors negative common antigens (like Kell, Duffy, Kidd, S, s) build inventory patients specific antibodies\n\nAntibody Screen (Detection Unexpected Red Cell Antibodies)\nTests donor’s plasma/serum screening cells (group O cells known antigen profiles) detect clinically significant IgG antibodies (expected anti-anti-B)\nRequired AABB donors history pregnancy transfusion. Many centers perform donors\n?: unexpected antibodies present:\nPlasma-containing components (FFP, Platelets) ideally given recipients whose red cells corresponding antigen\nRed Blood Cell units generally safe (plasma removed), information valuable. unit must labeled containing antibody\ndonors may recruited reagent red cell manufacturing\n\nTests donor’s plasma/serum screening cells (group O cells known antigen profiles) detect clinically significant IgG antibodies (expected anti-anti-B)Required AABB donors history pregnancy transfusion. Many centers perform donorsWhy?: unexpected antibodies present:\nPlasma-containing components (FFP, Platelets) ideally given recipients whose red cells corresponding antigen\nRed Blood Cell units generally safe (plasma removed), information valuable. unit must labeled containing antibody\ndonors may recruited reagent red cell manufacturing\nPlasma-containing components (FFP, Platelets) ideally given recipients whose red cells corresponding antigenRed Blood Cell units generally safe (plasma removed), information valuable. unit must labeled containing antibodyThese donors may recruited reagent red cell manufacturingRed Cell Antigen Phenotyping\nroutinely required donors, may performed identify donors negative common antigens (like Kell, Duffy, Kidd, S, s) build inventory patients specific antibodies\nroutinely required donors, may performed identify donors negative common antigens (like Kell, Duffy, Kidd, S, s) build inventory patients specific antibodiesInterpretation & Action\nABO Rh type results critical correct unit labeling\nPositive antibody screen requires antibody identification. Units labeled accordingly\nHistorical records repeat donors checked ensure consistency ABO/Rh typing\nABO Rh type results critical correct unit labelingPositive antibody screen requires antibody identification. Units labeled accordinglyHistorical records repeat donors checked ensure consistency ABO/Rh typing","code":""},{"path":"testing.html","id":"quality-control-testing-of-components","chapter":"Testing","heading":"Quality Control Testing of Components","text":"donor testing per se, ’s part processing. Blood centers perform QC tests subset components preparation ensure meet standards (e.g., platelet count pH platelets, residual WBCs leukoreduced units, hematocrit RBCs)","code":""},{"path":"testing.html","id":"key-takeaway-4","chapter":"Testing","heading":"Key Takeaway","text":"Testing non-negotiable, highly regulated part blood processing. combines sensitive infectious disease screening (especially using NAT) precise immunohematology testing. rigorous process essential ensuring blood components released blood center safe possible compatible intended recipients. unit gets labeled released required tests completed acceptable","code":""},{"path":"testing.html","id":"key-terms-5","chapter":"Testing","heading":"Key Terms","text":"Transfusion-Transmitted Infection (TTI): infection acquired blood transfusionSerological Testing: Testing blood serum/plasma presence antibodies antigensNucleic Acid Testing (NAT): Molecular testing detects DNA RNA infectious agents like virusesWindow Period: time infection test (usually antibody-based) can detect evidence infection. NAT significantly shortens periodAntigen: substance (often protein) surface cell pathogen can trigger immune responseAntibody: protein produced immune system response antigenABO Grouping: Determining blood type based presence absence B antigens red cells anti-anti-B antibodies plasmaRh Typing: Determining presence absence D antigen red cellsWeak D: Red cells express D antigen weakly, requiring special testing methods detection. Donors positive weak D considered Rh PositiveAntibody Screen: test detect unexpected clinically significant red cell antibodies plasma/serumLookback: process identifying recipients blood donor later tested positive relevant TTI, notify test recipientsQuarantine: Holding blood units designated area, unavailable issue, required testing processing steps completed reviewed","code":""},{"path":"labeling.html","id":"labeling","chapter":"Labeling","heading":"Labeling","text":"Think final, critical communication step bridges testing processing work directly physical unit blood. Accurate labeling absolutely paramount patient safety – errors can devastating consequences. ’s governed strict FDA regulations AABB standards","code":""},{"path":"labeling.html","id":"purpose-and-importance","chapter":"Labeling","heading":"Purpose and Importance","text":"primary goals blood product labeling :Uniquely Identify unit must unique identifier linking back donor associated records (testing, processing history)Accurately Describe Clearly state component , blood type, special characteristicsProvide Essential Information Give transfusion staff critical details needed safe storage administration (expiration date, volume, etc.)Ensure Traceability Facilitate tracking donor final dispositionComply Regulations Meet legal accreditation requirements","code":""},{"path":"labeling.html","id":"regulatory-framework","chapter":"Labeling","heading":"Regulatory Framework","text":"FDA (21 CFR 606, Subpart G - Container Labeling): Sets mandatory requirements information must appear blood component labels. Non-compliance can lead regulatory actionAABB Standards: Incorporate FDA requirements often include additional best practices. AABB strongly promotes use ISBT 128 standardISBT 128: isn’t regulatory body, international standard terminology, identification, coding, labeling medical products human origin (including blood). uses standardized:\nBarcodes: machine readability, reducing transcription errors\nProduct Codes: Uniform codes specific components attributes\nData Structures: Consistent format information like ABO/Rh, expiration date, donation ID\n’s important: Promotes global uniformity, enhances safety automation, improves traceability. US blood centers transfusion services now use ISBT 128\nBarcodes: machine readability, reducing transcription errorsProduct Codes: Uniform codes specific components attributesData Structures: Consistent format information like ABO/Rh, expiration date, donation IDWhy ’s important: Promotes global uniformity, enhances safety automation, improves traceability. US blood centers transfusion services now use ISBT 128","code":""},{"path":"labeling.html","id":"timing-the-critical-link-to-testing-release","chapter":"Labeling","heading":"Timing: The Critical Link to Testing & Release","text":"crucial: final container label, indicating unit suitable transfusion, applied untilAll mandatory testing (infectious disease markers, ABO/Rh) completedAll test results reviewed found acceptable (negative/non-reactive diseases, ABO/Rh confirmed)processing steps complete records reviewedThe unit officially released quarantineBefore point, units might temporary labels held quarantine labels indicating status (e.g., “Untested,” “Quarantine”). Applying final label act signifies unit ready inventory potential transfusion","code":""},{"path":"labeling.html","id":"essential-information-on-the-final-container-label-per-fdaaabbisbt-128","chapter":"Labeling","heading":"Essential Information on the Final Container Label (Per FDA/AABB/ISBT 128)","text":"exact layout follows ISBT 128 structure, key information includes:Unique Donation Identification Number (DIN) primary identifier linking unit donor records (often barcoded)Component Name Standardized name (e.g., “Red Blood Cells Leukocytes Reduced,” “Platelets Pheresis,” “Plasma Frozen within 24 hours - PF24”). ISBT 128 uses specific product codesABO Group Rh Type Clearly stated (e.g., “O POS,” “NEG”). ISBT 128 specific coded representationsExpiration Date Time (applicable) Critical ensuring potency safetyVolume Weight Approximate amount componentAnticoagulant/Additive Solution Type volume usedStorage Temperature Required range (e.g., “1-6 C,” “-18 C colder”)Collecting Facility Information Name address license/registration numberDonor Status Indication “Volunteer Donor,” “Autologous Use ,” “Directed Donor”Required Statements “Rx ,” “Properly Identify Intended Recipient,” “See Circular Information…” etcBiohazard Legend Standard symbol indicating biological material","code":""},{"path":"labeling.html","id":"special-attribute-labeling","chapter":"Labeling","heading":"Special Attribute Labeling","text":"component undergone modification specific characteristics, must clearly indicated label, often using specific ISBT 128 codes eye-readable text:Irradiated: Indicates unit irradiated prevent TA-GVHDLeukocytes Reduced: Indicates unit meets standards leukocyte reductionCMV Seronegative: Indicates donor tested negative CMV antibodiesAntigen Negative: Specifies red cell antigens unit lacks (e.g., “Kell Negative,” “Fy(-b-)”)Washed: Indicates component washed remove plasmaFrozen/Thawed/Deglycerolized: applicable RBC productsAutologous Use : Mandatory autologous unitsDirected Donor Information: Including intended recipient’s name/ID (applicable)","code":""},{"path":"labeling.html","id":"the-labeling-process-ensuring-accuracy","chapter":"Labeling","heading":"The Labeling Process: Ensuring Accuracy","text":"Systems Approach: Labeling usually integrated Blood Establishment Computer System (BECS). system verifies test results component information allowing label generated appliedVerification: Procedures must place ensure correct label applied correct unit. might involve barcode scanning comparisons visual checks recordsLabel Quality: Labels must legible, indelible (permanent ink, resistant smudging/fading), adhere securely container storage conditionsError Prevention: Preventing labeling errors major focus quality systems. Mislabeled units (e.g., wrong ABO/Rh) significant transfusion risk","code":""},{"path":"labeling.html","id":"key-takeaway-5","chapter":"Labeling","heading":"Key Takeaway","text":"Labeling final checkpoint blood processing, translating complex testing preparation clear, standardized information unit . requires meticulous accuracy, adherence strict regulatory formatting standards (like ISBT 128), robust systems prevent errors. Getting label right absolutely essential ensuring correct safe transfusion patient","code":""},{"path":"labeling.html","id":"key-terms-6","chapter":"Labeling","heading":"Key Terms","text":"ISBT 128: International standard terminology, coding, labeling blood, cell, tissue productsDonation Identification Number (DIN): unique number assigned specific blood donation, linking unit, donor, recordsComponent Name (Product Code): Standardized name/code identifying specific blood product (e.g., RBCs, Platelets Pheresis)Expiration Date: date (sometimes time) component transfusedQuarantine: status blood unit held pending completion review testing processingTraceability: ability track blood unit donor final dispositionCircular Information: document providing detailed information blood components, indications, contraindications, dosage, administration, potential adverse effects, required FDA available transfusion servicesAttribute: specific characteristic blood unit (e.g., Irradiated, CMV Negative, Antigen Negative) indicated label","code":""},{"path":"storage.html","id":"storage","chapter":"Storage","heading":"Storage","text":"Proper storage dynamic process requiring right solutions, strict temperature control (static transport), awareness inevitable product changes time, strict adherence expiration dates, especially manipulation, ensure patient safety transfusion efficacy. Think proper storage maintaining carefully controlled environment preserves safety effectiveness life-saving components moment processed reach patientStorage encompasses solutions used, critical temperatures maintained, products moved, changes undergo, ultimate limits use (expiration)","code":""},{"path":"storage.html","id":"anticoagulantsadditives-the-preservation-formula","chapter":"Storage","heading":"Anticoagulants/Additives (The Preservation Formula)","text":"Purpose: Prevent clotting (using citrate bind calcium) maintain cell viability (using dextrose energy, adenine ATP synthesis, phosphate buffer)Impact: specific formulation dictates RBC shelf life. Early solutions (CPD) allowed 21 days; adding adenine (CPDA-1) extended 35 days. Modern Additive Solutions (), added RBCs plasma removal, contain saline, dextrose, adenine (+/- mannitol) allow 42-day storage providing lower hematocrit component","code":""},{"path":"storage.html","id":"temperature-requirements-the-climate-control","chapter":"Storage","heading":"Temperature Requirements (The Climate Control)","text":"Critical: Essential preventing bacterial growth maintaining component functionSpecific Ranges\nRBCs (Liquid): 1°C 6°C (Slows metabolism, prevents freezing/hemolysis)\nPlatelets: 20°C 24°C continuous agitation (Prevents cold activation, allows gas exchange)\nPlasma / Cryoprecipitate (Frozen): ≤ -18°C (Preserves coagulation factors)\nGranulocytes: 20°C 24°C (agitation, short storage)\nRBCs (Liquid): 1°C 6°C (Slows metabolism, prevents freezing/hemolysis)Platelets: 20°C 24°C continuous agitation (Prevents cold activation, allows gas exchange)Plasma / Cryoprecipitate (Frozen): ≤ -18°C (Preserves coagulation factors)Granulocytes: 20°C 24°C (agitation, short storage)Monitoring: Requires calibrated thermometers, alarms, regular checks","code":""},{"path":"storage.html","id":"transportation-storage-on-the-move","chapter":"Storage","heading":"Transportation (Storage on the Move)","text":"Goal: Maintain required temperature range outside monitored storage unitsMethod: Use validated containers appropriate packing:\nRBCs (1-10°C transport range): Wet ice cool packs (avoid direct contact)\nPlatelets (20-24°C): Insulated container, coolant\nFrozen Products (Solidly frozen): Dry ice validated ultra-low temp shippers\nRBCs (1-10°C transport range): Wet ice cool packs (avoid direct contact)Platelets (20-24°C): Insulated container, coolantFrozen Products (Solidly frozen): Dry ice validated ultra-low temp shippersKey: Validation, secure packing, minimizing transit time, documentation (chain custody) crucial","code":""},{"path":"storage.html","id":"properties-of-stored-products-what-happens-over-time","chapter":"Storage","heading":"Properties of Stored Products (What Happens Over Time)","text":"RBC “Storage Lesion”: 1-6°C storage, RBCs experience decreased ATP & 2,3-DPG (affecting energy/O₂ release), pH drop, potassium (K+) leakage , shape changes (less deformable), hemolysis (free hemoglobin supernatant)Platelets: 20-24°C, risk bacterial growth significant. pH drops due metabolism; viability/function can decrease 5-7 day shelf lifePlasma/Cryo: Frozen state preserves factors well, labile factors (V, VIII) degrade slowly (defining 1 yr expiry) rapidly upon thawing","code":""},{"path":"storage.html","id":"expiration-the-use-by-date","chapter":"Storage","heading":"Expiration (The Use-By Date)","text":"Basis: Set regulators based loss viability/function safety risks (e.g., bacteria)Standard Dates: Depend component anticoagulant/additive (e.g., RBCs = 42 days; Platelets = 5-7 days; FFP/Cryo = 1 year frozen)Modifications Shorten Expiry\nOpen Systems: (washing, pooling): Expiry often becomes 4 hours (platelets, pooled cryo) 24 hours (washed RBCs)\nThawing: Plasma expires 24 hrs (5 days “Thawed Plasma”) 1-6°C; Cryo expires 4-6 hrs room temp\nIrradiation: RBC expiry becomes original outdate 28 days post-irradiation, whichever sooner\nOpen Systems: (washing, pooling): Expiry often becomes 4 hours (platelets, pooled cryo) 24 hours (washed RBCs)Thawing: Plasma expires 24 hrs (5 days “Thawed Plasma”) 1-6°C; Cryo expires 4-6 hrs room tempIrradiation: RBC expiry becomes original outdate 28 days post-irradiation, whichever sooner","code":""},{"path":"anticoagulantsadditives.html","id":"anticoagulantsadditives","chapter":"Anticoagulants/Additives","heading":"Anticoagulants/Additives","text":"Anticoagulant-preservative additive solutions essential cocktails designed prevent clotting provide necessary fuel environment red blood cells survive storage. evolution simple citrate solutions complex Additive Solutions like -1 -3 dramatically increased shelf life RBCs (21 42 days), improving blood inventory management availability. Understanding role ingredient helps appreciate solutions critical transfusion medicineWithout anticoagulants additives, whole blood clot almost immediately, red blood cells wouldn’t survive long enough outside body useful transfusion. solutions carefully formulated liquids present blood collection bags. primary goals twofold:Prevent Clotting (Anticoagulation) stop coagulation cascade activating moment blood leaves veinMaintain Cell Viability Function (Preservation/Addition) provide nutrients suitable chemical environment red blood cells, particular, remain alive functional storage","code":""},{"path":"anticoagulantsadditives.html","id":"key-components-and-their-roles","chapter":"Anticoagulants/Additives","heading":"Key Components and Their Roles","text":"Let’s break common ingredients found solutions included:Citrate (Sodium Citrate / Citric Acid)\nFunction: primary anticoagulant\nMechanism: works chelating (binding) ionized calcium (Ca++). Calcium essential multiple steps coagulation cascade. binding , citrate effectively stops clotting can start within collection bag. Citric acid also helps lower initial pH\nFunction: primary anticoagulantMechanism: works chelating (binding) ionized calcium (Ca++). Calcium essential multiple steps coagulation cascade. binding , citrate effectively stops clotting can start within collection bag. Citric acid also helps lower initial pHDextrose (Glucose)\nFunction: primary energy source red blood cells\nMechanism: RBCs rely anaerobic glycolysis produce ATP (adenosine triphosphate), energy currency need maintain membrane integrity, ion pumps, shape. Dextrose fuels process throughout storage\nFunction: primary energy source red blood cellsMechanism: RBCs rely anaerobic glycolysis produce ATP (adenosine triphosphate), energy currency need maintain membrane integrity, ion pumps, shape. Dextrose fuels process throughout storageAdenine\n* Function: substrate ATP synthesis\n* Mechanism: RBCs consume ATP storage, adenine provides necessary building block cells synthesize new ATP, helping maintain energy levels longer periods. key addition significantly extended RBC shelf lifePhosphate (Sodium Biphosphate / Monobasic Sodium Phosphate)\nFunction: Acts buffer supports ATP/2,3-DPG levels\nMechanism: Helps maintain optimal pH within stored unit acidic metabolic byproducts accumulate. Phosphate also crucial glycolysis synthesis 2,3-diphosphoglycerate (2,3-DPG), molecule important oxygen release hemoglobin (though 2,3-DPG levels inevitably fall storage)\nFunction: Acts buffer supports ATP/2,3-DPG levelsMechanism: Helps maintain optimal pH within stored unit acidic metabolic byproducts accumulate. Phosphate also crucial glycolysis synthesis 2,3-diphosphoglycerate (2,3-DPG), molecule important oxygen release hemoglobin (though 2,3-DPG levels inevitably fall storage)Mannitol (Found Additive Solutions, e.g., -1, -5)\nFunction: Protects storage-related hemolysis\nMechanism: Thought act osmotic stabilizer, helping strengthen red blood cell membrane reduce amount cell lysis (bursting) occurs storage\nFunction: Protects storage-related hemolysisMechanism: Thought act osmotic stabilizer, helping strengthen red blood cell membrane reduce amount cell lysis (bursting) occurs storageSaline (Sodium Chloride - Found Additive Solutions)\nFunction: Provides volume appropriate osmolarity additive solution\nFunction: Provides volume appropriate osmolarity additive solution","code":""},{"path":"anticoagulantsadditives.html","id":"common-formulations-and-their-impact-on-storage","chapter":"Anticoagulants/Additives","heading":"Common Formulations and Their Impact on Storage","text":"specific combination concentration ingredients determine approved storage duration (shelf life) Red Blood Cells. ’s evolution:ACD (Acid-Citrate-Dextrose)\nolder formulation\nComponents: Citrate, Citric Acid, Dextrose\nRBC Shelf Life: 21 days 1-6°C\nolder formulationComponents: Citrate, Citric Acid, DextroseRBC Shelf Life: 21 days 1-6°CCPD (Citrate-Phosphate-Dextrose)\nImprovement ACD adding Phosphate\nComponents: Citrate, Citric Acid, Dextrose, Monobasic Sodium Phosphate\nRBC Shelf Life: 21 days 1-6°C. (Better maintenance 2,3-DPG initially compared ACD)\nImprovement ACD adding PhosphateComponents: Citrate, Citric Acid, Dextrose, Monobasic Sodium PhosphateRBC Shelf Life: 21 days 1-6°C. (Better maintenance 2,3-DPG initially compared ACD)CP2D (Citrate-Phosphate-Double Dextrose)\nCPD twice dextrose\nComponents: Citrate, Citric Acid, Dextrose, Monobasic Sodium Phosphate\nRBC Shelf Life: 21 days 1-6°C. (Provides fuel, doesn’t extend maximum storage time)\nCPD twice dextroseComponents: Citrate, Citric Acid, Dextrose, Monobasic Sodium PhosphateRBC Shelf Life: 21 days 1-6°C. (Provides fuel, doesn’t extend maximum storage time)CPDA-1 (Citrate-Phosphate-Dextrose-Adenine)\nmajor breakthrough adding Adenine\nComponents: Citrate, Citric Acid, Dextrose, Monobasic Sodium Phosphate, Adenine\nRBC Shelf Life: 35 days 1-6°C. (adenine allows better ATP regeneration, significantly extending viability)\nmajor breakthrough adding AdenineComponents: Citrate, Citric Acid, Dextrose, Monobasic Sodium Phosphate, AdenineRBC Shelf Life: 35 days 1-6°C. (adenine allows better ATP regeneration, significantly extending viability)Additive Solutions () - e.g., -1 (Adsol), -3 (Nutricel), -5 (Optisol), -7 (SOLX)\nConcept: current standard Red Blood Cell units. Whole blood collected primary bag containing minimal amount anticoagulant-preservative (usually CPD). Soon collection, plasma expressed (make FFP plasma components), ~100-110 mL Additive Solution attached satellite bag added directly packed red cells\nComponents: Typically contain Saline, Adenine, Dextrose, sometimes Mannitol (-1, -5) extra Citrate Phosphate (-3)\nRBC Shelf Life: 42 days 1-6°C\nAdvantages\nExtends shelf life 6 weeks\nResults RBCs lower viscosity (hematocrit usually 55-65%) may improve transfusion flow\nAllows harvesting plasma original whole blood donation\n\nConcept: current standard Red Blood Cell units. Whole blood collected primary bag containing minimal amount anticoagulant-preservative (usually CPD). Soon collection, plasma expressed (make FFP plasma components), ~100-110 mL Additive Solution attached satellite bag added directly packed red cellsAS Components: Typically contain Saline, Adenine, Dextrose, sometimes Mannitol (-1, -5) extra Citrate Phosphate (-3)RBC Shelf Life: 42 days 1-6°CAdvantages\nExtends shelf life 6 weeks\nResults RBCs lower viscosity (hematocrit usually 55-65%) may improve transfusion flow\nAllows harvesting plasma original whole blood donation\nExtends shelf life 6 weeksResults RBCs lower viscosity (hematocrit usually 55-65%) may improve transfusion flowAllows harvesting plasma original whole blood donation","code":""},{"path":"anticoagulantsadditives.html","id":"impact-on-stored-components","chapter":"Anticoagulants/Additives","heading":"Impact on Stored Components","text":"Red Blood Cells: primary focus solutions. aim minimize “storage lesion” – collection biochemical morphological changes occurring storage (decreased ATP & 2,3-DPG, pH drop, potassium leakage, cell shape changes). Additives slow changes don’t eliminate themPlatelets: Collected citrate anticoagulants (usually ACD CPD). Platelet storage requires different conditions (room temperature agitation) specific Platelet Additive Solutions (PAS) now often used replace portion plasma storage, initial anticoagulant still citrate-basedPlasma (FFP, PF24, etc.): anticoagulant (CPD, CPDA-1, ACD) collected whole blood remains plasma component. primary storage method freezing, halts biochemical degradation preserves coagulation factor activity","code":""},{"path":"anticoagulantsadditives.html","id":"key-terms-7","chapter":"Anticoagulants/Additives","heading":"Key Terms","text":"Anticoagulant: substance prevents blood clotting (e.g., Citrate)Preservative: substance helps maintain viability function cells storage (e.g., Dextrose, Adenine, Phosphate)Additive Solution (): solution added packed red blood cells plasma removal, designed optimize RBC survival 42-day storage (contains Saline, Adenine, Dextrose +/- Mannitol)Citrate: primary anticoagulant used blood collection, works binding calciumDextrose: Glucose; main energy source stored RBCsAdenine: component necessary RBCs synthesize ATP, extending storage lifePhosphate: buffer helps maintain pH supports ATP/2,3-DPG levelsMannitol: additive solutions helps protect RBC membranesShelf Life: maximum allowable time blood component can stored expiration (e.g., 42 days -preserved RBCs 1-6°C)Storage Lesion: sum biochemical morphological changes occur red blood cells storage","code":""},{"path":"temperature-requirements.html","id":"temperature-requirements","chapter":"Temperature Requirements","heading":"Temperature Requirements","text":"One critical aspects maintaining blood product quality. Getting right absolutely non-negotiable, deviations can quickly render life-saving product useless even harmfulThink way: blood component like specific type produce. need refrigeration, need freezing, need stay room temperature – need specific environment stay “fresh” safe","code":""},{"path":"temperature-requirements.html","id":"why-is-temperature-so-critical","chapter":"Temperature Requirements","heading":"Why is Temperature So Critical?","text":"Preventing Bacterial Growth: major safety concern. blood collected aseptically, contamination can occur. Incorrect temperatures, especially storing refrigerated products warm room-temp products without proper care, can allow bacteria proliferate dangerous levels, potentially causing sepsis recipientMaintaining Cell Viability & Function\nRed Blood Cells (RBCs): Need stay metabolically active enough survive slow enough last storage period. warm, burn energy fast (accelerating “storage lesion”). cold (freezing), cells lyse (hemolysis)\nPlatelets: sensitive. Cold temperatures cause irreversible activation shape changes, destroying ability function clotting\nRed Blood Cells (RBCs): Need stay metabolically active enough survive slow enough last storage period. warm, burn energy fast (accelerating “storage lesion”). cold (freezing), cells lyse (hemolysis)Platelets: sensitive. Cold temperatures cause irreversible activation shape changes, destroying ability function clottingPreserving Protein Function\nPlasma (Coagulation Factors): Freezing essential halt degradation delicate proteins, especially labile coagulation factors (Factor V Factor VIII) needed clotting\nPlasma (Coagulation Factors): Freezing essential halt degradation delicate proteins, especially labile coagulation factors (Factor V Factor VIII) needed clottingEnsuring Product Potency & Efficacy: stored incorrectly, component simply won’t work intended transfused","code":""},{"path":"temperature-requirements.html","id":"specific-temperature-requirements-for-major-components","chapter":"Temperature Requirements","heading":"Specific Temperature Requirements for Major Components","text":"ranges mandated FDA AABB standards:Red Blood Cells (RBCs) - Liquid State\nTemperature: 1°C 6°C\nRationale: narrow range optimal slowing RBC metabolism (preserving ATP 2,3-DPG) without causing freezing significant hemolysis. also inhibits growth bacteria\nStorage Device: Monitored blood bank refrigerator\nTemperature: 1°C 6°CRationale: narrow range optimal slowing RBC metabolism (preserving ATP 2,3-DPG) without causing freezing significant hemolysis. also inhibits growth bacteriaStorage Device: Monitored blood bank refrigeratorPlatelets (Apheresis Whole Blood Derived)\nTemperature: 20°C 24°C (Controlled Room Temperature)\nCritical Addition: Requires continuous gentle agitation (specialized rotators/flatbed agitators)\nRationale: Prevents cold-induced activation/aggregation. Agitation facilitates gas exchange (O₂ , CO₂ ) prevents clumping. temperature allow bacterial growth, making screening/detection crucial limiting shelf life (typically 5-7 days)\nStorage Device: Monitored platelet incubator/agitator\nTemperature: 20°C 24°C (Controlled Room Temperature)Critical Addition: Requires continuous gentle agitation (specialized rotators/flatbed agitators)Rationale: Prevents cold-induced activation/aggregation. Agitation facilitates gas exchange (O₂ , CO₂ ) prevents clumping. temperature allow bacterial growth, making screening/detection crucial limiting shelf life (typically 5-7 days)Storage Device: Monitored platelet incubator/agitatorPlasma Components (Frozen State)\nIncludes: Fresh Frozen Plasma (FFP), Plasma Frozen within 24 hours (PF24), Cryoprecipitate-Reduced Plasma\nTemperature: ≤ -18°C (FDA minimum requirement)\nOften Stored : ≤ -30°C (Many centers prefer colder temps better long-term preservation labile factors)\nRationale: Freezing effectively stops enzymatic degradation, preserving coagulation factor activity extended periods (typically 1 year longer depending specific product storage temp)\nStorage Device: Monitored laboratory freezer (manual auto-defrost protocols must carefully managed)\nIncludes: Fresh Frozen Plasma (FFP), Plasma Frozen within 24 hours (PF24), Cryoprecipitate-Reduced PlasmaTemperature: ≤ -18°C (FDA minimum requirement)Often Stored : ≤ -30°C (Many centers prefer colder temps better long-term preservation labile factors)Rationale: Freezing effectively stops enzymatic degradation, preserving coagulation factor activity extended periods (typically 1 year longer depending specific product storage temp)Storage Device: Monitored laboratory freezer (manual auto-defrost protocols must carefully managed)Cryoprecipitated AHF (Antihemophilic Factor) - Frozen State\nTemperature: ≤ -18°C\nRationale: Derived FFP, concentrate Factor VIII, fibrinogen, Factor XIII, von Willebrand factor requires freezing maintain potency specific proteins\nStorage Device: Monitored laboratory freezer\nTemperature: ≤ -18°CRationale: Derived FFP, concentrate Factor VIII, fibrinogen, Factor XIII, von Willebrand factor requires freezing maintain potency specific proteinsStorage Device: Monitored laboratory freezerGranulocytes\nTemperature: 20°C 24°C (Controlled Room Temperature)\nCritical Note: agitate. Store undisturbed\nRationale: Like platelets, granulocyte function impaired cold. Storage short-term (typically 24 hours) due rapid loss function high risk bacterial growth\nStorage Device: Designated room temperature storage area (special device needed beyond temperature control)\nTemperature: 20°C 24°C (Controlled Room Temperature)Critical Note: agitate. Store undisturbedRationale: Like platelets, granulocyte function impaired cold. Storage short-term (typically 24 hours) due rapid loss function high risk bacterial growthStorage Device: Designated room temperature storage area (special device needed beyond temperature control)Frozen Red Blood Cells (Glycerolized)\nTemperature: ≤ -65°C (Often stored specialized ultra-low temperature freezers)\nRationale: Requires low temperatures due cryoprotectant (glycerol) used. Allows long-term storage (10 years ) rare units special circumstances\nStorage Device: Monitored ultra-low temperature freezer\nTemperature: ≤ -65°C (Often stored specialized ultra-low temperature freezers)Rationale: Requires low temperatures due cryoprotectant (glycerol) used. Allows long-term storage (10 years ) rare units special circumstancesStorage Device: Monitored ultra-low temperature freezer","code":""},{"path":"temperature-requirements.html","id":"thawed-component-storage","chapter":"Temperature Requirements","heading":"Thawed Component Storage","text":"frozen products thawed, storage requirements expiration times change drastically:Thawed Plasma (FFP, PF24, etc.)\nTemperature: 1°C 6°C\nExpiration: Typically 24 hours thawing. Can relabeled “Thawed Plasma” stored 5 days, labile factors (V, VIII) decrease significantly\nTemperature: 1°C 6°CExpiration: Typically 24 hours thawing. Can relabeled “Thawed Plasma” stored 5 days, labile factors (V, VIII) decrease significantlyThawed Cryoprecipitate\nTemperature: 20°C 24°C (Room Temperature)\nExpiration: short!\nUnpooled: 6 hours thawing\nPooled (Open System): 4 hours pooling/thawing\n\nTemperature: 20°C 24°C (Room Temperature)Expiration: short!\nUnpooled: 6 hours thawing\nPooled (Open System): 4 hours pooling/thawing\nUnpooled: 6 hours thawingPooled (Open System): 4 hours pooling/thawing","code":""},{"path":"temperature-requirements.html","id":"monitoring-and-alarms-the-safety-net","chapter":"Temperature Requirements","heading":"Monitoring and Alarms: The Safety Net","text":"Ensuring temperatures maintained isn’t passive. requires:Calibrated Thermometers: Continuously monitoring internal temperature storage unitsRecording Devices: Chart recorders , commonly now, electronic data logging systems provide continuous record temperaturesAlarm Systems: Audible visual alarms trigger immediately temperature goes outside acceptable range (high low)Regular Checks: Staff visually checking manually recording temperatures defined intervals (e.g., every 4-8 hours)Emergency Procedures: Backup power critical units, action plans equipment failures, criteria determining product suitability temperature deviation","code":""},{"path":"temperature-requirements.html","id":"temperature-deviations","chapter":"Temperature Requirements","heading":"Temperature Deviations","text":"time component exposed temperatures outside required range, ’s deviationClear policies must define long unit can temperature extremes acceptable/unacceptableInvestigation required: long ? temperature reach?Outcome: Often results unit discarded ensure patient safety. Consultation medical director may needed","code":""},{"path":"temperature-requirements.html","id":"key-terms-8","chapter":"Temperature Requirements","heading":"Key Terms","text":"Storage Lesion: sum biochemical morphological changes occurring stored Red Blood Cells (affected temperature)Hemolysis: rupture destruction red blood cellsLabile Factors: Coagulation factors degrade relatively quickly warmer temperatures storage (esp. Factors V VIII)Agitation: Continuous gentle mixing required platelet storageCryoprotectant: substance (like glycerol) used protect cells damage freezing thawingValidation: Documented process confirming equipment (like refrigerators, freezers, incubators) consistently operates within specified limitsCalibration: Process adjusting measuring devices (like thermometers) ensure accuracy known standard","code":""},{"path":"transportation.html","id":"transportation","chapter":"Transportation","heading":"Transportation","text":"Transportation essentially extension storage, added challenge maintaining required conditions outside controlled refrigerator, freezer, incubator. Proper transport critical failure maintain correct environment, even relatively short periods, can compromise safety efficacy blood product","code":""},{"path":"transportation.html","id":"why-is-controlled-transport-essential","chapter":"Transportation","heading":"Why is Controlled Transport Essential?","text":"reasons temperature control vital static storage apply transport:Preventing Bacterial Growth: Temperature excursions, especially allowing refrigerated room-temperature products get warm, can promote dangerous bacterial proliferationMaintaining Cell Viability/Function\nRBCs: Must stay cool (freeze!) preserve energy stores membrane integrity\nPlatelets: Must stay room temperature avoid cold shock renders useless\nRBCs: Must stay cool (freeze!) preserve energy stores membrane integrityPlatelets: Must stay room temperature avoid cold shock renders uselessPreserving Protein Function: Frozen products must remain frozen solid protect labile coagulation factorsEnsuring Product Integrity: Physical damage (dropping, crushing) must also avoided","code":""},{"path":"transportation.html","id":"core-principles-of-blood-product-transportation","chapter":"Transportation","heading":"Core Principles of Blood Product Transportation","text":"Regardless specific component, several key principles apply:Maintain Temperature: Use appropriate, validated containers packing materials designed keep component within required temperature range expected duration transportUse Validated Containers: Transport systems (coolers, boxes, bags) must validated – meaning ’s documented proof can consistently maintain required temperature range defined period expected conditionsSecure Handling: Components must packed securely prevent shifting physical damageMinimize Transit Time: Transport efficient, minimizing time products spend outside continuously monitored storage unitsAccurate Documentation: Records must kept detailing transported, left, arrived, condition upon arrival, handled (chain custody)Regulatory Compliance: Transport procedures must meet FDA AABB requirements","code":""},{"path":"transportation.html","id":"transport-requirements-for-specific-components","chapter":"Transportation","heading":"Transport Requirements for Specific Components","text":"pack transport depends heavily ’re moving:Red Blood Cells (RBCs) & Thawed Plasma (1°C 6°C Storage)\nTransport Goal: Maintain temperature 1°C 10°C. (Note: AABB allows slightly wider range transport compared static storage)\nContainer: Validated coolers insulated containers\nCoolant: Use wet ice (contained waterproof bags prevent direct contact waterlogging labels) validated coolant packs/gel packs\nCritical Point: Never place RBCs directly frozen packs dry ice! can cause localized freezing hemolysis. barrier (cardboard, bubble wrap) often used. Pack ensure units stay cool don’t freeze\nTransport Goal: Maintain temperature 1°C 10°C. (Note: AABB allows slightly wider range transport compared static storage)Container: Validated coolers insulated containersCoolant: Use wet ice (contained waterproof bags prevent direct contact waterlogging labels) validated coolant packs/gel packsCritical Point: Never place RBCs directly frozen packs dry ice! can cause localized freezing hemolysis. barrier (cardboard, bubble wrap) often used. Pack ensure units stay cool don’t freezePlatelets & Granulocytes (20°C 24°C Storage)\nTransport Goal: Maintain temperature 20°C 24°C. Protect excessive heat cold\nContainer: Validated transport containers designed maintain room temperature (may use phase-change materials simply insulation, depending validation)\nCoolant: None! use ice cold packs\nProtection: Must protected cold drafts (e.g., sitting near /C vent) excessive heat (e.g., direct sunlight, near heaters)\nAgitation: Platelets need agitated transport short periods, placed agitator upon arrival transfused immediately\nTransport Goal: Maintain temperature 20°C 24°C. Protect excessive heat coldContainer: Validated transport containers designed maintain room temperature (may use phase-change materials simply insulation, depending validation)Coolant: None! use ice cold packsProtection: Must protected cold drafts (e.g., sitting near /C vent) excessive heat (e.g., direct sunlight, near heaters)Agitation: Platelets need agitated transport short periods, placed agitator upon arrival transfused immediatelyFrozen Components (FFP, Cryoprecipitate, Frozen RBCs) (≤ -18°C ≤ -65°C Storage)\nTransport Goal: Maintain solidly frozen state\nContainer: Well-insulated containers (e.g., thick styrofoam validated hard-shell coolers)\nCoolant: Dry Ice (Solid Carbon Dioxide) typically required, especially longer transport times. Ensure enough dry ice used expected duration. Handle dry ice safely (gloves, ventilation)\nAlternative: Validated shippers using special phase-change materials capable maintaining ultra-low temperatures might used\nCritical Point: Product must remain frozen solid; signs thawing usually mean product refrozen may need discarded used within short timeframe appropriate (e.g., thawed plasma)\nTransport Goal: Maintain solidly frozen stateContainer: Well-insulated containers (e.g., thick styrofoam validated hard-shell coolers)Coolant: Dry Ice (Solid Carbon Dioxide) typically required, especially longer transport times. Ensure enough dry ice used expected duration. Handle dry ice safely (gloves, ventilation)Alternative: Validated shippers using special phase-change materials capable maintaining ultra-low temperatures might usedCritical Point: Product must remain frozen solid; signs thawing usually mean product refrozen may need discarded used within short timeframe appropriate (e.g., thawed plasma)Thawed Cryoprecipitate (Pooled Unpooled) (20°C 24°C Post-Thaw Storage)\nTransport Goal: Maintain 20°C 24°C\nHandling: Transport similar platelets (validated room-temperature container, coolant)\nUrgency: Due short expiration thawing/pooling (4-6 hours), transport must rapid coordinated time use\nTransport Goal: Maintain 20°C 24°CHandling: Transport similar platelets (validated room-temperature container, coolant)Urgency: Due short expiration thawing/pooling (4-6 hours), transport must rapid coordinated time use","code":""},{"path":"transportation.html","id":"validation-of-transport-systems","chapter":"Transportation","heading":"Validation of Transport Systems","text":"Blood banks transfusion services must validate transport containers packing configurationsThis involves studies demonstrating system can maintain required temperature maximum expected transport time worst-case ambient conditions (e.g., simulating transport hot summer day cold winter day)Validation data must documented available inspection","code":""},{"path":"transportation.html","id":"monitoring-during-transport","chapter":"Transportation","heading":"Monitoring During Transport","text":"critical shipments longer distances, temperature monitoring devices might included:\nMin/Max thermometers\nChemical temperature indicators (show threshold breached)\nElectronic temperature data loggers\nMin/Max thermometersChemical temperature indicators (show threshold breached)Electronic temperature data loggersVisual inspection upon arrival always necessary (e.g., frozen products still solid? hemolysis RBCs?)","code":""},{"path":"transportation.html","id":"documentation-and-chain-of-custody","chapter":"Transportation","heading":"Documentation and Chain of Custody","text":"Detailed records essential:\nUnique ID units transported\nTime unit(s) removed storage\nTransport container ID\nMethod packing/coolant used\nPersonnel releasing units\nIntended destination/recipient\nTime arrival/receipt\nCondition upon receipt (temperature check, visual inspection)\nPersonnel receiving units\nUnique ID units transportedTime unit(s) removed storageTransport container IDMethod packing/coolant usedPersonnel releasing unitsIntended destination/recipientTime arrival/receiptCondition upon receipt (temperature check, visual inspection)Personnel receiving units","code":""},{"path":"transportation.html","id":"receiving-transported-products","chapter":"Transportation","heading":"Receiving Transported Products","text":"Personnel receiving blood products must inspect immediatelyVerify product, check signs damage tamperingAssess temperature (visual check frozen items, potentially using surface temperature probes checking included indicators)Document receipt conditionPlace product appropriate monitored storage immediately imminent transfusion","code":""},{"path":"transportation.html","id":"key-terms-9","chapter":"Transportation","heading":"Key Terms","text":"Validated Container: transport box, bag, cooler proven documented studies maintain specific temperature range defined timeCoolant: Material used maintain cold temperatures (e.g., wet ice, gel packs)Dry Ice: Solid carbon dioxide (-78.5°C / -109.3°F), used transporting frozen productsTemperature Indicator/Monitor: device included shipment show temperature stayed within limits (can simple chemical strips electronic data loggers)Temperature Excursion: event product’s temperature goes outside required storage transport rangeChain Custody: chronological documentation showing handling, transfer, control product departure arrivalPhase-Change Material: Substances used validated shippers absorb release heat specific temperatures help maintain stable environment (e.g., keeping platelets room temp)","code":""},{"path":"stored-products.html","id":"stored-products","chapter":"Stored Products","heading":"Stored Products","text":"section covers actually happens blood components sitting storage required conditions (temperature, anticoagulant/additive). changes, often collectively referred “storage lesion” (especially Red Blood Cells), reason components expiration dates. Understanding properties key appreciating storage conditions strict unit might function upon transfusion","code":""},{"path":"stored-products.html","id":"red-blood-cells-rbcs---stored-at-1-6c","chapter":"Stored Products","heading":"Red Blood Cells (RBCs) - Stored at 1-6°C","text":"RBCs undergo significant well-studied changes liquid storage. goal anticoagulant-preservative additive solutions slow changes, stop entirelyMetabolic Changes\nDecreased ATP (Adenosine Triphosphate): RBCs need ATP energy, primarily maintain ion pumps (like Na+/K+ pump) preserve shape flexibility. ATP levels fall storage, functions decline. Additives like adenine help RBCs regenerate ATP, extending shelf life\nDecreased 2,3-Diphosphoglycerate (2,3-DPG): molecule crucial hemoglobin’s ability release oxygen tissues. 2,3-DPG levels drop significantly within first 1-2 weeks storage\nImplication: Immediately transfusion older stored RBCs, cells may higher oxygen affinity (hold onto O₂ tightly) recipient’s body helps restore 2,3-DPG levels (usually within 24 hours). generally considered clinically significant except possibly massive transfusions specific patient populations (e.g., neonates)\n\nDecreased pH: Anaerobic glycolysis (RBCs make ATP) produces lactic acid, causing pH inside unit gradually decrease (become acidic). lower pH inhibits glycolysis affects cell function. Buffers (like phosphate) help mitigate \nDecreased ATP (Adenosine Triphosphate): RBCs need ATP energy, primarily maintain ion pumps (like Na+/K+ pump) preserve shape flexibility. ATP levels fall storage, functions decline. Additives like adenine help RBCs regenerate ATP, extending shelf lifeDecreased 2,3-Diphosphoglycerate (2,3-DPG): molecule crucial hemoglobin’s ability release oxygen tissues. 2,3-DPG levels drop significantly within first 1-2 weeks storage\nImplication: Immediately transfusion older stored RBCs, cells may higher oxygen affinity (hold onto O₂ tightly) recipient’s body helps restore 2,3-DPG levels (usually within 24 hours). generally considered clinically significant except possibly massive transfusions specific patient populations (e.g., neonates)\nImplication: Immediately transfusion older stored RBCs, cells may higher oxygen affinity (hold onto O₂ tightly) recipient’s body helps restore 2,3-DPG levels (usually within 24 hours). generally considered clinically significant except possibly massive transfusions specific patient populations (e.g., neonates)Decreased pH: Anaerobic glycolysis (RBCs make ATP) produces lactic acid, causing pH inside unit gradually decrease (become acidic). lower pH inhibits glycolysis affects cell function. Buffers (like phosphate) help mitigate thisBiochemical Changes (Membrane Integrity & Environment)\nIncreased Extracellular Potassium (K+): ATP-dependent Na+/K+ pump fails, potassium leaks RBCs surrounding plasma/additive solution. Sodium leaks \nImplication: supernatant (liquid portion) older RBC units can high potassium levels. concern primarily rapid, large-volume transfusions (especially neonates patients renal impairment) recipient might experience hyperkalemia. Washing RBCs can remove excess potassium\n\nIncreased Free Hemoglobin: RBCs lyse (break open) storage due membrane damage. releases free hemoglobin supernatant. Visible hemolysis (pink/red supernatant) sign unacceptable damage, unit transfused. Standards set limits acceptable hemolysis levels expiration\nIncreased Extracellular Potassium (K+): ATP-dependent Na+/K+ pump fails, potassium leaks RBCs surrounding plasma/additive solution. Sodium leaks \nImplication: supernatant (liquid portion) older RBC units can high potassium levels. concern primarily rapid, large-volume transfusions (especially neonates patients renal impairment) recipient might experience hyperkalemia. Washing RBCs can remove excess potassium\nImplication: supernatant (liquid portion) older RBC units can high potassium levels. concern primarily rapid, large-volume transfusions (especially neonates patients renal impairment) recipient might experience hyperkalemia. Washing RBCs can remove excess potassiumIncreased Free Hemoglobin: RBCs lyse (break open) storage due membrane damage. releases free hemoglobin supernatant. Visible hemolysis (pink/red supernatant) sign unacceptable damage, unit transfused. Standards set limits acceptable hemolysis levels expirationMorphological Changes (Shape & Flexibility)\nShape Transformation: RBCs progressively lose normal biconcave disc shape, becoming echinocytes (spiculated) eventually spherocytes (smaller, denser spheres)\nDecreased Deformability: shape changes, along membrane alterations, make RBCs rigid less able squeeze tiny capillaries\nImplication: Less deformable cells cleared rapidly recipient’s circulation transfusion. Expiration dates set ensure least 75% transfused RBCs still circulating 24 hours post-transfusion (measure viability)\n\nShape Transformation: RBCs progressively lose normal biconcave disc shape, becoming echinocytes (spiculated) eventually spherocytes (smaller, denser spheres)Decreased Deformability: shape changes, along membrane alterations, make RBCs rigid less able squeeze tiny capillaries\nImplication: Less deformable cells cleared rapidly recipient’s circulation transfusion. Expiration dates set ensure least 75% transfused RBCs still circulating 24 hours post-transfusion (measure viability)\nImplication: Less deformable cells cleared rapidly recipient’s circulation transfusion. Expiration dates set ensure least 75% transfused RBCs still circulating 24 hours post-transfusion (measure viability)Changes\nFormation Microparticles/Microvesicles: Small fragments bud RBC membrane storage. clinical significance still investigation may relate inflammation thrombosis\nOxidative Damage: RBCs experience oxidative stress storage, can damage lipids proteins\nFormation Microparticles/Microvesicles: Small fragments bud RBC membrane storage. clinical significance still investigation may relate inflammation thrombosisOxidative Damage: RBCs experience oxidative stress storage, can damage lipids proteins","code":""},{"path":"stored-products.html","id":"platelets---stored-at-20-24c-with-agitation","chapter":"Stored Products","heading":"Platelets - Stored at 20-24°C with Agitation","text":"Platelet storage presents different challenges due room temperature requirementMetabolic Activity & pH: Platelets metabolically active room temperature. consume glucose produce lactic acid, causing pH drop. pH falls low (e.g., 6.2), platelet viability function irreversibly lost\nImplication: Agitation crucial gas exchange (allowing CO₂ , O₂ ) helps buffer pH. Plasma Platelet Additive Solutions (PAS) provide buffering capacity. Shelf life (typically 5-7 days) limited partly ability maintain adequate pH\nImplication: Agitation crucial gas exchange (allowing CO₂ , O₂ ) helps buffer pH. Plasma Platelet Additive Solutions (PAS) provide buffering capacity. Shelf life (typically 5-7 days) limited partly ability maintain adequate pHActivation & Function: degree platelet activation occurs storage. remain functional, effectiveness may decrease storage period. Loss characteristic “swirling” phenomenon (light-scattering effect seen viable, discoid platelets) indicates potential loss qualityBacterial Growth Risk: significant risk associated platelet storage. Room temperature allows bacteria potentially introduced collection processing multiply\nImplication: Strict aseptic collection, diversion pouches, often bacterial detection testing (culture rapid tests) employed minimize septic transfusion reactions. limited shelf life also helps mitigate risk\nImplication: Strict aseptic collection, diversion pouches, often bacterial detection testing (culture rapid tests) employed minimize septic transfusion reactions. limited shelf life also helps mitigate risk","code":""},{"path":"stored-products.html","id":"plasma-ffp-pf24-etc.---stored-frozen--18c","chapter":"Stored Products","heading":"Plasma (FFP, PF24, etc.) - Stored Frozen (≤ -18°C)","text":"Freezing dramatically slows biochemical processesCoagulation Factor Stability: primary goal preserve activity coagulation factors\nFrozen: Factor levels generally stable, especially colder temperatures (≤ -30°C preferred long-term storage labile factors). However, even -18°C, slow decline, particularly labile factors V VIII. decline dictates typical 1-year expiration date\nThawing: thawed stored 1-6°C, Factors V VIII degrade much rapidly. thawed plasma must transfused within 24 hours (relabeled “Thawed Plasma” 5-day expiry, acknowledging lower labile factor levels)\nFrozen: Factor levels generally stable, especially colder temperatures (≤ -30°C preferred long-term storage labile factors). However, even -18°C, slow decline, particularly labile factors V VIII. decline dictates typical 1-year expiration dateAfter Thawing: thawed stored 1-6°C, Factors V VIII degrade much rapidly. thawed plasma must transfused within 24 hours (relabeled “Thawed Plasma” 5-day expiry, acknowledging lower labile factor levels)Components: plasma proteins (albumin, immunoglobulins, coagulation factors) generally stable frozen","code":""},{"path":"stored-products.html","id":"cryoprecipitated-ahf---stored-frozen--18c","chapter":"Stored Products","heading":"Cryoprecipitated AHF - Stored Frozen (≤ -18°C)","text":"concentrate derived FFP, properties relate specific factors containsFactor Stability: Contains concentrated Factor VIII, fibrinogen, Factor XIII, von Willebrand factor, fibronectin\nFrozen: Stability similar FFP, Factor VIII sensitive labile factor. 1-year expiration applies\nThawing: Factor VIII activity declines rapidly, especially stored room temperature (20-24°C). Fibrinogen stable. short post-thaw expiration (6 hours unpooled, 4 hours pooled open system) reflects need maintain Factor VIII potency\nFrozen: Stability similar FFP, Factor VIII sensitive labile factor. 1-year expiration appliesAfter Thawing: Factor VIII activity declines rapidly, especially stored room temperature (20-24°C). Fibrinogen stable. short post-thaw expiration (6 hours unpooled, 4 hours pooled open system) reflects need maintain Factor VIII potency","code":""},{"path":"stored-products.html","id":"key-terms-10","chapter":"Stored Products","heading":"Key Terms","text":"Storage Lesion: collection biochemical morphological changes occurring Red Blood Cells refrigerated storageATP (Adenosine Triphosphate): main energy currency cells2,3-DPG (2,3-Diphosphoglycerate): molecule RBCs facilitates oxygen release hemoglobinViability: ability transfused cells (especially RBCs) survive recipient’s circulation. Often measured % recovery 24 hours post-transfusionHemolysis: breakdown red blood cells release hemoglobinLabile Factors: Coagulation factors degrade relatively easily storage (esp. Factors V VIII)Swirling: characteristic shimmering, swirling appearance viable, discoid platelets gently agitated, caused light scattering. Loss swirl indicates potential quality issuesSupernatant: liquid portion bathing cells blood component unit (plasma /additive solution)","code":""},{"path":"expiration.html","id":"expiration","chapter":"Expiration","heading":"Expiration","text":"Expiration dates critical safety efficacy limits. depend component, preparation, storage conditions, subsequent manipulations. Understanding modifications like thawing, washing, pooling, irradiating affect expiration date crucial safe transfusion practice. Always check label correct expiration date time!section focuses expiration dates assigned blood products. dates aren’t arbitrary; represent end period product considered safe effective transfusion, based expected decline viability/function potential safety risks (like bacterial growth) defined storage conditions","code":""},{"path":"expiration.html","id":"why-do-blood-products-expire","chapter":"Expiration","heading":"Why Do Blood Products Expire?","text":"Expiration dates determined regulatory agencies (like FDA) standards organizations (like AABB) based scientific evidence addressing:Loss Viability/Function: discussed “Properties Stored Products,” cells proteins degrade time. expiration date ensures minimum level effectiveness remains (e.g., RBCs, ≥75% survival 24 hours post-transfusion; adequate levels coagulation factors plasma)Risk Bacterial Contamination: components stored room temperature (Platelets, Granulocytes, thawed Cryo), risk bacterial growth increases significantly time. expiration limits riskAccumulation Storage Lesion Byproducts: RBCs, accumulation potassium, free hemoglobin, metabolic byproducts supernatant increases time","code":""},{"path":"expiration.html","id":"factors-determining-expiration-date","chapter":"Expiration","heading":"Factors Determining Expiration Date","text":"assigned expiration date depends primarily :Component Type: Different components vastly different stability (e.g., RBCs vs. Platelets vs. Plasma)Anticoagulant/Preservative/Additive Solution: Especially crucial RBCs (e.g., CPD vs. CPDA-1 vs. Additive Solutions)Storage Temperature: Must maintained within required rangeInitial Processing Method: component preparedSubsequent Modifications: Actions like washing, pooling, thawing, irradiating can significantly shorten original expiration date, especially “closed system” compromised","code":""},{"path":"expiration.html","id":"standard-expiration-dates-under-normal-storage","chapter":"Expiration","heading":"Standard Expiration Dates (Under Normal Storage)","text":"typical maximum storage times date collection (unless otherwise noted):Red Blood Cells (RBCs) - Liquid State (1-6°C)\nACD / CPD / CP2D: 21 days\nCPDA-1: 35 days\nAdditive Solutions (-1, -3, -5, -7): 42 days\nACD / CPD / CP2D: 21 daysCPDA-1: 35 daysAdditive Solutions (-1, -3, -5, -7): 42 daysPlatelets (20-24°C continuous agitation)\nTypically 5 days. Can sometimes extended 7 days specific FDA-approved bacterial detection methods pathogen reduction technologies used\nTypically 5 days. Can sometimes extended 7 days specific FDA-approved bacterial detection methods pathogen reduction technologies usedPlasma (Frozen State, ≤ -18°C)\nFFP, PF24, Cryo-Reduced Plasma: 1 year\nFFP, PF24, Cryo-Reduced Plasma: 1 yearCryoprecipitated AHF (Frozen State, ≤ -18°C)\n1 year\n1 yearGranulocytes (20-24°C, without agitation)\n24 hours: (due rapid loss function bacterial risk)\n24 hours: (due rapid loss function bacterial risk)Frozen Red Blood Cells (Glycerolized, ≤ -65°C)\n10 years\n10 years","code":""},{"path":"expiration.html","id":"expiration-dates-after-modification-or-thawing","chapter":"Expiration","heading":"Expiration Dates After Modification or Thawing","text":"things change significantly, often due entering “open system” (potentially exposing component ambient air/microbes) due inherent instability product thawed alteredThawed Plasma (FFP, PF24, etc.)\nStored 1-6°C: Expires 24 hours thawing\nRelabeled “Thawed Plasma”: Can stored 1-6°C 5 days thawing (note: Factor V VIII levels significantly reduced compared FFP/PF24)\nStored 1-6°C: Expires 24 hours thawingRelabeled “Thawed Plasma”: Can stored 1-6°C 5 days thawing (note: Factor V VIII levels significantly reduced compared FFP/PF24)Thawed Cryoprecipitate\nStored 20-24°C:\nSingle units (unpooled): Expire 6 hours thawing\nPooled (open system): Expire 4 hours pooling/entry\n\nStored 20-24°C:\nSingle units (unpooled): Expire 6 hours thawing\nPooled (open system): Expire 4 hours pooling/entry\nSingle units (unpooled): Expire 6 hours thawingPooled (open system): Expire 4 hours pooling/entryWashed Volume-Reduced RBCs/Platelets (Open System)\nRBCs stored 1-6°C: Expire 24 hours washing\nPlatelets stored 20-24°C: Expire 4 hours washing\nRBCs stored 1-6°C: Expire 24 hours washingPlatelets stored 20-24°C: Expire 4 hours washingIrradiated RBCs\nStored 1-6°C: Expires original outdate 28 days date irradiation, whichever comes first\nRationale: Irradiation damages RBC membrane, increasing potassium leak potentially reducing viability time\nStored 1-6°C: Expires original outdate 28 days date irradiation, whichever comes firstRationale: Irradiation damages RBC membrane, increasing potassium leak potentially reducing viability timePooled Platelets (Open System)\nStored 20-24°C: Expire 4 hours pooling\nStored 20-24°C: Expire 4 hours poolingDeglycerolized RBCs (Post-Thaw)\nStored 1-6°C:\ndeglycerolized using open system: Expire 24 hours deglycerolization\ndeglycerolized using validated closed system: Can longer expiration (e.g., 14 days, depending system/validation)\n\nStored 1-6°C:\ndeglycerolized using open system: Expire 24 hours deglycerolization\ndeglycerolized using validated closed system: Can longer expiration (e.g., 14 days, depending system/validation)\ndeglycerolized using open system: Expire 24 hours deglycerolizationIf deglycerolized using validated closed system: Can longer expiration (e.g., 14 days, depending system/validation)Leukoreduced Components (Closed System)\nleukoreduction performed using sterile, closed system (e.g., -line filter collection sterile connecting devices), original expiration date component maintained\nleukoreduction performed using sterile, closed system (e.g., -line filter collection sterile connecting devices), original expiration date component maintained","code":""},{"path":"expiration.html","id":"handling-of-expired-units","chapter":"Expiration","heading":"Handling of Expired Units","text":"Expired units must transfusedThey must clearly identified removed transfusion service inventoryDiscarded according institutional policy biohazardous waste","code":""},{"path":"expiration.html","id":"key-terms-11","chapter":"Expiration","heading":"Key Terms","text":"Expiration Date: last day (sometimes time) blood component considered suitable transfusion specified storage conditionsShelf Life: total allowable storage time blood component collection expirationOpen System: system procedure sterility component potentially compromised exposure environment (e.g., pooling units using needles/syringes, washing cells). Results significantly shortened expiration time (usually 4 24 hours)Closed System: system component remains sterile throughout processing (e.g., using sterile connecting devices, -line filters). Maintains original expiration datePooling: Combining contents multiple units component (e.g., platelets, cryoprecipitate) single container transfusionWashing: process plasma supernatant removed cellular components adding removing saline, usually open systemIrradiation: Treatment gamma rays X-rays inactivate T-lymphocytes; affects RBC membrane shortens expiration 28 days post-irradiation original outdate, whichever soonerDeglycerolization: process removing glycerol previously frozen RBCs transfusion","code":""},{"path":"blood-components.html","id":"blood-components","chapter":"Blood Components","heading":"Blood Components","text":"section covers components derived whole blood apheresis","code":""},{"path":"blood-components.html","id":"core-components","chapter":"Blood Components","heading":"Core Components","text":"Red Blood Cells (RBCs)\n: Concentrated red cells (carry oxygen via hemoglobin) suspended plasma/additive solution\nUse: Treat symptomatic anemia, acute blood loss\nKey: Stored 1-6°C; expiry 21-42 days depending solution\n: Concentrated red cells (carry oxygen via hemoglobin) suspended plasma/additive solutionUse: Treat symptomatic anemia, acute blood lossKey: Stored 1-6°C; expiry 21-42 days depending solutionPlatelets\n: Cell fragments essential forming blood clots (primary hemostasis). Collected via apheresis (SDP) whole blood (WBD, requires pooling)\nUse: Prevent/treat bleeding due low platelet count (thrombocytopenia) dysfunction\nKey: Stored 20-24°C agitation; short expiry (5-7 days) due bacterial risk\n: Cell fragments essential forming blood clots (primary hemostasis). Collected via apheresis (SDP) whole blood (WBD, requires pooling)Use: Prevent/treat bleeding due low platelet count (thrombocytopenia) dysfunctionKey: Stored 20-24°C agitation; short expiry (5-7 days) due bacterial riskPlasma\n: Liquid portion blood containing water, proteins, coagulation factors. Prepared FFP (frozen <8hrs), PF24 (frozen <24hrs), etc\nUse: Replace multiple coagulation factors (e.g., liver disease, DIC, massive transfusion, warfarin reversal)\nKey: Stored frozen (≤ -18°C) 1 year; must ABO compatible\n: Liquid portion blood containing water, proteins, coagulation factors. Prepared FFP (frozen <8hrs), PF24 (frozen <24hrs), etcUse: Replace multiple coagulation factors (e.g., liver disease, DIC, massive transfusion, warfarin reversal)Key: Stored frozen (≤ -18°C) 1 year; must ABO compatibleCryoprecipitated AHF (Cryo)\n: Concentrate precipitated thawed FFP, rich Fibrinogen, Factor VIII, vWF, Factor XIII\nUse: Primarily replace fibrinogen; secondary Factors VIII, XIII, vWD concentrates unavailable\nKey: Stored frozen (≤ -18°C); thawed units stored room temp, expire 4-6 hours. Requires pooling adult dose\n: Concentrate precipitated thawed FFP, rich Fibrinogen, Factor VIII, vWF, Factor XIIIUse: Primarily replace fibrinogen; secondary Factors VIII, XIII, vWD concentrates unavailableKey: Stored frozen (≤ -18°C); thawed units stored room temp, expire 4-6 hours. Requires pooling adult doseGranulocytes\n: Concentrate neutrophils collected apheresis (donor requires stimulation)\nUse: Rare indication severe neutropenia documented infection unresponsive antimicrobials\nKey: Stored 20-24°C without agitation; 24-hr expiry; MUST irradiated crossmatched. High reaction rate\n: Concentrate neutrophils collected apheresis (donor requires stimulation)Use: Rare indication severe neutropenia documented infection unresponsive antimicrobialsKey: Stored 20-24°C without agitation; 24-hr expiry; MUST irradiated crossmatched. High reaction rateWhole Blood\n: Unseparated blood containing RBCs, plasma, platelets, WBCs\nUse: Largely replaced component therapy; niche use massive hemorrhage (trauma/military) resource-limited settings\nKey: Stored 1-6°C; platelets/labile factors degrade quickly. Requires ABO identical transfusion\n: Unseparated blood containing RBCs, plasma, platelets, WBCsUse: Largely replaced component therapy; niche use massive hemorrhage (trauma/military) resource-limited settingsKey: Stored 1-6°C; platelets/labile factors degrade quickly. Requires ABO identical transfusion","code":""},{"path":"blood-components.html","id":"modifications-specialized-components","chapter":"Blood Components","heading":"Modifications & Specialized Components","text":"Leukocyte-Reduced Components\n: RBCs Platelets processed (usually filtration) remove WBCs\nPurpose: Reduce febrile reactions (FNHTRs), HLA alloimmunization, CMV transmission. Standard practice many regions (Universal Leukoreduction)\nKey: change expiry done via closed system\n: RBCs Platelets processed (usually filtration) remove WBCsPurpose: Reduce febrile reactions (FNHTRs), HLA alloimmunization, CMV transmission. Standard practice many regions (Universal Leukoreduction)Key: change expiry done via closed systemIrradiated Components\n: Cellular components (RBCs, Platelets, Granulocytes) exposed radiation\nPurpose: Inactivate donor T-lymphocytes prevent Transfusion-Associated Graft-vs-Host Disease (TA-GVHD) -risk recipients\nKey: Mandatory granulocytes, directed donations relatives, immunocompromised pts. Shortens RBC expiry (original 28 days post-irradiation, whichever first); change platelet expiry\n: Cellular components (RBCs, Platelets, Granulocytes) exposed radiationPurpose: Inactivate donor T-lymphocytes prevent Transfusion-Associated Graft-vs-Host Disease (TA-GVHD) -risk recipientsKey: Mandatory granulocytes, directed donations relatives, immunocompromised pts. Shortens RBC expiry (original 28 days post-irradiation, whichever first); change platelet expiryWashed Red Blood Cells / Platelets\n: Cellular components washed saline remove plasma proteins\nPurpose: Prevent severe allergic reactions (esp. IgA deficiency w/ anti-IgA); reduce supernatant potassium RBCs neonates/renal patients\nKey: Open system process shortens expiry 24 hrs (RBCs) 4 hrs (Platelets)\n: Cellular components washed saline remove plasma proteinsPurpose: Prevent severe allergic reactions (esp. IgA deficiency w/ anti-IgA); reduce supernatant potassium RBCs neonates/renal patientsKey: Open system process shortens expiry 24 hrs (RBCs) 4 hrs (Platelets)Frozen/Deglycerolized Red Blood Cells\n: RBCs treated glycerol (cryoprotectant), frozen (≤ -65°C) long-term storage (10 yrs), thawed washed (deglycerolized) use\nPurpose: Store rare units, autologous units, strategic reserves\nKey: Deglycerolization (washing) required prevent hemolysis; post-wash expiry 24 hrs (open system) longer (closed system)\n: RBCs treated glycerol (cryoprotectant), frozen (≤ -65°C) long-term storage (10 yrs), thawed washed (deglycerolized) usePurpose: Store rare units, autologous units, strategic reservesKey: Deglycerolization (washing) required prevent hemolysis; post-wash expiry 24 hrs (open system) longer (closed system)Rejuvenated Red Blood Cells\n: Stored RBCs treated vitro solutions (PIPA) restore ATP 2,3-DPG levels\nPurpose: Salvage near-expiry units; potentially improve O₂ delivery (debated); enhance quality freezing\nKey: Requires extensive washing rejuvenation; 24-hr post-wash expiry (open system). routine\n: Stored RBCs treated vitro solutions (PIPA) restore ATP 2,3-DPG levelsPurpose: Salvage near-expiry units; potentially improve O₂ delivery (debated); enhance quality freezingKey: Requires extensive washing rejuvenation; 24-hr post-wash expiry (open system). routineApheresis Products\n: Components collected using apheresis machine (Platelets, Plasma, Double RBCs, Granulocytes, Stem Cells)\nPurpose: Obtain larger dose specific component single donor, reducing recipient exposure\nKey: Donor may experience citrate reaction. Enables frequent donation certain components (e.g., platelets)\n: Components collected using apheresis machine (Platelets, Plasma, Double RBCs, Granulocytes, Stem Cells)Purpose: Obtain larger dose specific component single donor, reducing recipient exposureKey: Donor may experience citrate reaction. Enables frequent donation certain components (e.g., platelets)Hematopoietic Progenitors (HPCs / Stem Cells)\n: Stem cells capable generating blood cells; collected bone marrow (HPC-M), peripheral blood mobilization (PBSC / HPC-), umbilical cord blood (HPC-C)\nPurpose: Used transplantation restore hematopoietic function high-dose chemo/radiation marrow failure states\nKey: Requires HLA matching allogeneic transplant; often cryopreserved using DMSO; specialized processing infusion protocols apply\n: Stem cells capable generating blood cells; collected bone marrow (HPC-M), peripheral blood mobilization (PBSC / HPC-), umbilical cord blood (HPC-C)Purpose: Used transplantation restore hematopoietic function high-dose chemo/radiation marrow failure statesKey: Requires HLA matching allogeneic transplant; often cryopreserved using DMSO; specialized processing infusion protocols applyFractionation Products\n: Highly purified plasma proteins derived large pools plasma via industrial manufacturing (e.g., Albumin, IVIG, Factor VIII/IX concentrates, PCCs, Fibrinogen concentrate)\nPurpose: Provide specific protein replacement therapy enhanced viral safety standardized dosing\nKey: Regulated pharmaceuticals, often stored room temp/refrigerated long shelf lives. Distinct blood bank components\n: Highly purified plasma proteins derived large pools plasma via industrial manufacturing (e.g., Albumin, IVIG, Factor VIII/IX concentrates, PCCs, Fibrinogen concentrate)Purpose: Provide specific protein replacement therapy enhanced viral safety standardized dosingKey: Regulated pharmaceuticals, often stored room temp/refrigerated long shelf lives. Distinct blood bank components","code":""},{"path":"red-blood-cells.html","id":"red-blood-cells","chapter":"Red Blood Cells","heading":"Red Blood Cells","text":"Red Blood Cells (sometimes just called “packed cells”) vital component treating symptomatic anemia acute blood loss improving oxygen-carrying capacity. preparation, storage, modification carefully controlled ensure safety efficacy. Understanding specific properties potential modifications RBC units allows us provide best possible product patient’s unique needs","code":""},{"path":"red-blood-cells.html","id":"what-are-red-blood-cells","chapter":"Red Blood Cells","heading":"What Are Red Blood Cells?","text":"Definition: Red Blood Cells (erythrocytes) component obtained removing plasma whole blood. primary function transport oxygen lungs body’s tissues carry carbon dioxide back lungs, thanks hemoglobin packed inside themComposition: standard unit packed RBCs consists mainly red cells suspended small amount residual plasma, plus anticoagulant-preservative additive solution. hematocrit (percentage volume occupied red cells) typically ranges 55-80%, depending collection/additive solution used (units additive solutions generally lower hematocrit, around 55-65%)","code":""},{"path":"red-blood-cells.html","id":"preparation-methods","chapter":"Red Blood Cells","heading":"Preparation Methods","text":"RBCs primarily prepared two ways:Whole Blood Donation\nstandard unit whole blood (~500 mL) collected bag containing anticoagulant (e.g., CPD) potentially satellite bags additive solutions (e.g., -1, -3)\nunit undergoes centrifugation (“hard spin”) separate components density\nmajority plasma expressed satellite bag (make plasma components)\nadditive solution system used, solution (~100-110 mL) added back concentrated red cells\nfinal RBC component usually volume around 250-350 mL\nstandard unit whole blood (~500 mL) collected bag containing anticoagulant (e.g., CPD) potentially satellite bags additive solutions (e.g., -1, -3)unit undergoes centrifugation (“hard spin”) separate components densityThe majority plasma expressed satellite bag (make plasma components)additive solution system used, solution (~100-110 mL) added back concentrated red cellsThe final RBC component usually volume around 250-350 mLBy Apheresis (Red Cell Apheresis / Double Red Cell Donation)\napheresis machine selectively collects red blood cells donor returning plasma platelets\nmethod allows collection two standard doses RBCs single donor one session (“double unit”). Requires donors meet higher hemoglobin/hematocrit weight criteria\nUnits collected way often already leukoreduced apheresis process \napheresis machine selectively collects red blood cells donor returning plasma plateletsThis method allows collection two standard doses RBCs single donor one session (“double unit”). Requires donors meet higher hemoglobin/hematocrit weight criteriaUnits collected way often already leukoreduced apheresis process ","code":""},{"path":"red-blood-cells.html","id":"indications-for-transfusion","chapter":"Red Blood Cells","heading":"Indications for Transfusion","text":"primary goal RBC transfusion increase oxygen-carrying capacity blood. Indications include:Symptomatic Anemia: Transfusion indicated anemia (low RBC count/hemoglobin) causes symptoms like shortness breath (dyspnea), weakness, fatigue, chest pain (angina), dizziness manageable means. Important Transfusion decisions based solely hemoglobin number (“transfusion trigger”) patient’s overall clinical picture, symptoms, underlying conditionAcute Blood Loss: Significant hemorrhage (e.g., trauma surgery) requires RBC transfusion restore blood volume oxygen-carrying capacityChronic Anemias: Patients conditions like sickle cell disease, thalassemia, kidney failure, myelodysplastic syndromes may require chronic transfusion supportPerioperative Anemia: support oxygen delivery major surgery","code":""},{"path":"red-blood-cells.html","id":"storage-and-expiration","chapter":"Red Blood Cells","heading":"Storage and Expiration","text":"(’ve covered detail previously!)Storage Temperature: 1°C 6°C monitored blood bank refrigeratorsExpiration: Depends anticoagulant/additive solution used:\nACD/CPD/CP2D: 21 days\nCPDA-1: 35 days\nAdditive Solutions (-1, -3, -5, -7): 42 days (common now)\nACD/CPD/CP2D: 21 daysCPDA-1: 35 daysAdditive Solutions (-1, -3, -5, -7): 42 days (common now)Storage Lesion: Remember stored RBCs undergo changes (↓ATP, ↓2,3-DPG, ↑K+ leak, shape changes) impact function survival post-transfusion","code":""},{"path":"red-blood-cells.html","id":"quality-control-specifications","chapter":"Red Blood Cells","heading":"Quality Control / Specifications","text":"Volume: Varies typically 250-350 mLHematocrit: Usually 55-80% (lower end additive solutions)Hemolysis: Must minimal (<1% total RBC mass expiration FDA standards)Viability: ≥75% transfused cells must remain recipient’s circulation 24 hours post-transfusion","code":""},{"path":"red-blood-cells.html","id":"modifications-to-red-blood-cell-units","chapter":"Red Blood Cells","heading":"Modifications to Red Blood Cell Units","text":"Standard RBC units can modified meet specific patient needs:Leukoreduced RBCs\n: reduce number white blood cells (WBCs). minimizes risk febrile non-hemolytic transfusion reactions (FNHTRs), transmission cell-associated viruses like CMV, HLA alloimmunization\n: Filtration (either pre-storage bedside, though pre-storage preferred)\nStandard: Must contain < 5 x 10⁶ residual WBCs per unit (US standard). standard practice almost RBCs many countries now\n: reduce number white blood cells (WBCs). minimizes risk febrile non-hemolytic transfusion reactions (FNHTRs), transmission cell-associated viruses like CMV, HLA alloimmunizationHow: Filtration (either pre-storage bedside, though pre-storage preferred)Standard: Must contain < 5 x 10⁶ residual WBCs per unit (US standard). standard practice almost RBCs many countries nowWashed RBCs\n: remove plasma proteins. Indicated patients history severe allergic reactions (anaphylaxis) plasma components, especially IgA deficiency anti-IgA antibodies. Can also used reduce accumulated potassium older units neonatal transfusions\n: Washing RBCs multiple times sterile saline using automated cell processors\nImpact: open system procedure, expiration date shortened 24 hours stored 1-6°C. Washing also causes loss RBCs\n: remove plasma proteins. Indicated patients history severe allergic reactions (anaphylaxis) plasma components, especially IgA deficiency anti-IgA antibodies. Can also used reduce accumulated potassium older units neonatal transfusionsHow: Washing RBCs multiple times sterile saline using automated cell processorsImpact: open system procedure, expiration date shortened 24 hours stored 1-6°C. Washing also causes loss RBCsIrradiated RBCs\n: prevent Transfusion-Associated Graft-versus-Host Disease (TA-GVHD) inactivating donor T-lymphocytes. TA-GVHD rare often fatal\nIndications: Immunocompromised patients (e.g., congenital immunodeficiencies, stem cell transplant recipients, patients certain immunosuppressive drugs), recipients directed donations blood relatives, intrauterine transfusions, sometimes premature neonates\n: Exposing unit specific dose gamma irradiation X-rays (typically 25-50 Gy)\nImpact: Irradiation damages RBC membrane slightly, increasing potassium leakage. expiration date becomes original outdate 28 days date irradiation, whichever sooner\n: prevent Transfusion-Associated Graft-versus-Host Disease (TA-GVHD) inactivating donor T-lymphocytes. TA-GVHD rare often fatalIndications: Immunocompromised patients (e.g., congenital immunodeficiencies, stem cell transplant recipients, patients certain immunosuppressive drugs), recipients directed donations blood relatives, intrauterine transfusions, sometimes premature neonatesHow: Exposing unit specific dose gamma irradiation X-rays (typically 25-50 Gy)Impact: Irradiation damages RBC membrane slightly, increasing potassium leakage. expiration date becomes original outdate 28 days date irradiation, whichever soonerVolume-Reduced RBCs\n: reduce total volume infused, important patients risk circulatory overload (TACO), especially infants small children\n: Removing portion supernatant (plasma/additive solution) gentle centrifugation\nImpact: Often performed open system, shortening expiration 24 hours 1-6°C unless sterile docking device used\n: reduce total volume infused, important patients risk circulatory overload (TACO), especially infants small childrenHow: Removing portion supernatant (plasma/additive solution) gentle centrifugationImpact: Often performed open system, shortening expiration 24 hours 1-6°C unless sterile docking device usedFrozen / Deglycerolized RBCs\n: long-term storage (10 years) rare blood types, autologous units, special inventories\n: Adding cryoprotective agent (glycerol), freezing ultra-low temperatures (≤ -65°C). transfusion, unit must thawed glycerol removed washing process (deglycerolization)\nImpact: Expiration thawing/deglycerolization typically 24 hours performed open system, can longer (14 days) validated closed systems. process complex results RBC loss\n: long-term storage (10 years) rare blood types, autologous units, special inventoriesHow: Adding cryoprotective agent (glycerol), freezing ultra-low temperatures (≤ -65°C). transfusion, unit must thawed glycerol removed washing process (deglycerolization)Impact: Expiration thawing/deglycerolization typically 24 hours performed open system, can longer (14 days) validated closed systems. process complex results RBC lossAntigen-Negative RBCs\n: patients developed clinically significant red cell alloantibodies (antibodies antigens lack) prevent alloimmunization chronically transfused patients (e.g., sickle cell disease)\n: Selecting units donors phenotyped known lack specific antigen(s) required patient (e.g., Kell negative, Fy() negative, Jk(b) negative)\n: patients developed clinically significant red cell alloantibodies (antibodies antigens lack) prevent alloimmunization chronically transfused patients (e.g., sickle cell disease): Selecting units donors phenotyped known lack specific antigen(s) required patient (e.g., Kell negative, Fy() negative, Jk(b) negative)","code":""},{"path":"red-blood-cells.html","id":"administration","chapter":"Red Blood Cells","heading":"Administration","text":"Compatibility: MUST ABO Rh compatible recipient. crossmatch required transfusionFiltration: Administered standard blood filter (170-260 microns) remove clots debrisInfusion Time: Typically infused 1.5 2 hours, must completed within 4 hours removal controlled storage minimize bacterial risk room temperatureMonitoring: Patients must monitored closely signs transfusion reactions, especially first 15 minutes","code":""},{"path":"red-blood-cells.html","id":"potential-risks-adverse-reactions","chapter":"Red Blood Cells","heading":"Potential Risks / Adverse Reactions","text":"Transfusion generally safe carries potential risks:Hemolytic Transfusion Reactions (Acute Delayed)Febrile Non-Hemolytic Transfusion Reactions (FNHTRs)Allergic Reactions (Mild Urticaria Anaphylaxis)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Septic Reactions (Bacterial Contamination)Iron Overload (chronic transfusion)Alloimmunization (development antibodies RBC antigens)Disease Transmission (extremely low risk now due rigorous testing)","code":""},{"path":"red-blood-cells.html","id":"key-terms-12","chapter":"Red Blood Cells","heading":"Key Terms","text":"Hemoglobin (Hgb): protein within RBCs binds transports oxygenHematocrit (Hct): proportion blood volume occupied red blood cells, expressed percentageAdditive Solution (): Solution added packed RBCs plasma removal extend shelf life 42 daysLeukoreduction: Removal white blood cells prevent adverse reactionsIrradiation: Treatment radiation inactivate T-lymphocytes prevent TA-GVHDWashing: Removal plasma proteins using saline washes prevent severe allergic reactionsStorage Lesion: collection biochemical morphological changes occurring RBCs storageAntigen-Negative: RBC units lacking specific red cell antigens, selected patients corresponding antibodiesTA-GVHD (Transfusion-Associated Graft-versus-Host Disease): rare serious complication donor lymphocytes attack recipient tissuesDeglycerolization: process removing glycerol thawed frozen RBCs transfusion","code":""},{"path":"cryoprecipitated-ahf.html","id":"cryoprecipitated-ahf","chapter":"Cryoprecipitated AHF","heading":"Cryoprecipitated AHF","text":"Cryoprecipitated Antihemophilic Factor (AHF), often simply called “Cryo.” sounds complex, think highly concentrated “super-glue” kit derived plasma, packed specific clotting factors","code":""},{"path":"cryoprecipitated-ahf.html","id":"what-is-cryoprecipitated-ahf","chapter":"Cryoprecipitated AHF","heading":"What is Cryoprecipitated AHF?","text":"Definition: Cryoprecipitated AHF cold-insoluble protein fraction precipitates unit Fresh Frozen Plasma (FFP) thawed slowly controlled refrigerated conditions (1°C 6°C)Composition: ’s concentrate, whole plasma. small unit (typically 10-20 mL) contains significant portion specific coagulation factors derived original ~250 mL unit FFP. key components concentrated Cryo :\nFibrinogen (Factor ): Essential forming fibrin meshwork blood clot. important component primary reason Cryo used today.\nFactor VIII (Antihemophilic Factor): key factor intrinsic coagulation cascade. Deficiency causes Hemophilia \nvon Willebrand Factor (vWF): Important platelet adhesion injured vessel walls acts carrier protein Factor VIII\nFactor XIII: Stabilizes fibrin clot cross-linking fibrin strands\nFibronectin: Involved cell adhesion wound healing\nFibrinogen (Factor ): Essential forming fibrin meshwork blood clot. important component primary reason Cryo used today.Factor VIII (Antihemophilic Factor): key factor intrinsic coagulation cascade. Deficiency causes Hemophilia Avon Willebrand Factor (vWF): Important platelet adhesion injured vessel walls acts carrier protein Factor VIIIFactor XIII: Stabilizes fibrin clot cross-linking fibrin strandsFibronectin: Involved cell adhesion wound healing","code":""},{"path":"cryoprecipitated-ahf.html","id":"preparation-method","chapter":"Cryoprecipitated AHF","heading":"Preparation Method","text":"process quite specific:Start unit Fresh Frozen Plasma (FFP)Thaw FFP slowly controlled refrigerator (1°C 6°C) several hoursAs thaws, white, gelatinous precipitate forms (cryoprecipitate)thawing complete precipitate remains, unit (now containing slushy plasma precipitate) centrifuged heavily (“hard spin”)supernatant plasma (now called Cryoprecipitate-Reduced Plasma) expressed another bag, leaving behind concentrated precipitate small volume (10-20 mL) residual plasmaThis remaining concentrate Cryoprecipitated AHF, refrozen rapidly ≤ -18°C storage","code":""},{"path":"cryoprecipitated-ahf.html","id":"indications-for-transfusion-1","chapter":"Cryoprecipitated AHF","heading":"Indications for Transfusion","text":"Cryo used primarily replace specific factors contains, particularly fibrinogen:Primary Indication: Treatment bleeding associated low fibrinogen levels (hypofibrinogenemia) functionally abnormal fibrinogen (dysfibrinogenemia). common situations like:\nDisseminated Intravascular Coagulation (DIC)\nSevere liver disease\nMassive transfusion protocols (fibrinogen consumed diluted)\nCongenital fibrinogen deficiency\nDisseminated Intravascular Coagulation (DIC)Severe liver diseaseMassive transfusion protocols (fibrinogen consumed diluted)Congenital fibrinogen deficiencySecondary Indications (Less Common Now due specific factor concentrates)\nHemophilia (Factor VIII deficiency): Factor VIII concentrates unavailable\nvon Willebrand Disease (vWD): vWF-containing concentrates unavailable\nFactor XIII deficiency: (Rare)\nHemophilia (Factor VIII deficiency): Factor VIII concentrates unavailablevon Willebrand Disease (vWD): vWF-containing concentrates unavailableFactor XIII deficiency: (Rare)Use: source Fibrin Sealant (often prepared pharmacy used commercially) topical application control surgical bleedingImportant Note Cryo indicated general volume replacement source coagulation factors listed (e.g., ’s poor source Factor V, Factor II, etc., compared FFP)","code":""},{"path":"cryoprecipitated-ahf.html","id":"storage-and-expiration-1","chapter":"Cryoprecipitated AHF","heading":"Storage and Expiration","text":"Frozen State\nStorage Temperature: ≤ -18°C\nExpiration: 1 year date original whole blood collection\nStorage Temperature: ≤ -18°CExpiration: 1 year date original whole blood collectionThawed State\nThawing: Done rapidly 30-37°C water bath approved thawing device\nStorage Temperature: 20°C 24°C (Room Temperature) - refrigerate thawing!\nExpiration (Critical):\nSingle Units: Expire 6 hours thawing\nPooled Units (Open System): multiple units pooled together using needles/syringes (open system), pool expires 4 hours pooling begins\n\nThawing: Done rapidly 30-37°C water bath approved thawing deviceStorage Temperature: 20°C 24°C (Room Temperature) - refrigerate thawing!Expiration (Critical):\nSingle Units: Expire 6 hours thawing\nPooled Units (Open System): multiple units pooled together using needles/syringes (open system), pool expires 4 hours pooling begins\nSingle Units: Expire 6 hours thawingPooled Units (Open System): multiple units pooled together using needles/syringes (open system), pool expires 4 hours pooling begins","code":""},{"path":"cryoprecipitated-ahf.html","id":"quality-control-specifications-1","chapter":"Cryoprecipitated AHF","heading":"Quality Control / Specifications","text":"Regulatory requirements (e.g., AABB Standards) mandate minimum levels key factors QC testing manufactured units:Fibrinogen: ≥ 150 mg per individual unitFactor VIII: ≥ 80 International Units (IU) per individual unit","code":""},{"path":"cryoprecipitated-ahf.html","id":"administration-1","chapter":"Cryoprecipitated AHF","heading":"Administration","text":"Pooling: single unit contains relatively small amount factors, multiple units (often 5-10, sometimes ) typically pooled together one bag provide therapeutic dose adult. number units pooled depends clinical indication patient sizeCompatibility: ABO compatibility preferred strictly required due small volume plasma antibodies. Hospital policies often require ABO-compatible Cryo. Rh type generally considered relevant Cryo transfusionFiltration: Must administered standard blood filter (170-260 microns)Infusion: Usually infused rapidly, quickly patient can tolerate, often 10-30 minutes. Must completed 4-hour (pooled) 6-hour (single unit) expiration timeDosage: Calculated based patient’s weight, clinical situation, desired increase factor levels (especially fibrinogen)","code":""},{"path":"cryoprecipitated-ahf.html","id":"potential-risks-adverse-reactions-1","chapter":"Cryoprecipitated AHF","heading":"Potential Risks / Adverse Reactions","text":"Risks similar associated plasma components, although small volume per unit reduces risks unless large numbers pooled transfused:Febrile Non-Hemolytic ReactionsAllergic Reactions (Urticaria Anaphylaxis)Transfusion-Transmitted Infections (TTIs) - low riskTransfusion-Related Acute Lung Injury (TRALI) - risk associated plasmaCirculatory Overload (less common unless many units given rapidly)","code":""},{"path":"cryoprecipitated-ahf.html","id":"key-terms-13","chapter":"Cryoprecipitated AHF","heading":"Key Terms","text":"Cryoprecipitate (Cryo): cold-insoluble protein fraction precipitated thawed FFPFibrinogen (Factor ): primary protein Cryo, essential clot formation; common reason transfusionFactor VIII (AHF): Antihemophilic Factor, concentrated Cryo; deficiency causes Hemophilia Avon Willebrand Factor (vWF): Aids platelet adhesion, carries Factor VIII; concentrated CryoFactor XIII: Stabilizes fibrin clots; concentrated CryoPooling: Combining multiple single units Cryo one container transfusionHypofibrinogenemia: Low level fibrinogen bloodLabile Factors: Coagulation factors (like V VIII) degrade relatively quickly, especially frozenFibrin Sealant: topical hemostatic agent made fibrinogen (often Cryo) thrombin","code":""},{"path":"platelets.html","id":"platelets","chapter":"Platelets","heading":"Platelets","text":"Platelets (Thrombocytes) tiny cell fragments unsung heroes hemostasis, rushing scene vessel injury form initial plug stops bleeding. Providing functional platelets crucial patients can’t make enough whose platelets aren’t working correctly","code":""},{"path":"platelets.html","id":"what-are-platelets","chapter":"Platelets","heading":"What Are Platelets?","text":"Definition: Platelets small, irregular-shaped, anucleated (nucleus) cell fragments derived megakaryocytes bone marrowFunction: primary role primary hemostasis – adhering injured blood vessel walls, aggregating together form platelet plug, releasing substances promote platelet recruitment initiate coagulation cascade (secondary hemostasis)","code":""},{"path":"platelets.html","id":"preparation-methods-1","chapter":"Platelets","heading":"Preparation Methods","text":"Platelets transfusion prepared two main ways, resulting slightly different products:Whole Blood Derived Platelets (WBD) / Platelet Concentrates\nProcess\nunit whole blood centrifuged low speed (“light spin”) separate Platelet-Rich Plasma (PRP) red cells\nPRP expressed satellite bag\nPRP centrifuged high speed (“hard spin”) pellet platelets\nsupernatant plasma (Platelet-Poor Plasma) expressed , leaving platelets suspended small volume (approx. 50-70 mL) residual plasma\n\nKey Feature: single WBD unit contain enough platelets therapeutic dose adult. Therefore, multiple units (typically 4-6) must pooled together transfusion\nPooling: increases recipient’s exposure multiple donors\nProcess\nunit whole blood centrifuged low speed (“light spin”) separate Platelet-Rich Plasma (PRP) red cells\nPRP expressed satellite bag\nPRP centrifuged high speed (“hard spin”) pellet platelets\nsupernatant plasma (Platelet-Poor Plasma) expressed , leaving platelets suspended small volume (approx. 50-70 mL) residual plasma\nunit whole blood centrifuged low speed (“light spin”) separate Platelet-Rich Plasma (PRP) red cellsThe PRP expressed satellite bagThe PRP centrifuged high speed (“hard spin”) pellet plateletsMost supernatant plasma (Platelet-Poor Plasma) expressed , leaving platelets suspended small volume (approx. 50-70 mL) residual plasmaKey Feature: single WBD unit contain enough platelets therapeutic dose adult. Therefore, multiple units (typically 4-6) must pooled together transfusionPooling: increases recipient’s exposure multiple donorsApheresis Platelets (Single Donor Platelets - SDP)\nProcess: apheresis machine draws whole blood donor, selectively separates collects platelets using centrifugation, returns remaining components (red cells, plasma) donor\nKey Feature: single apheresis procedure collects full therapeutic dose platelets one donor. preferred method many institutions\nAdvantages: Reduces donor exposure recipient, potentially lowering risks alloimmunization disease transmission. Units often leukoreduced collection process\nProcess: apheresis machine draws whole blood donor, selectively separates collects platelets using centrifugation, returns remaining components (red cells, plasma) donorKey Feature: single apheresis procedure collects full therapeutic dose platelets one donor. preferred method many institutionsAdvantages: Reduces donor exposure recipient, potentially lowering risks alloimmunization disease transmission. Units often leukoreduced collection process","code":""},{"path":"platelets.html","id":"indications-for-transfusion-2","chapter":"Platelets","heading":"Indications for Transfusion","text":"Platelet transfusions given prevent treat bleeding due :Thrombocytopenia (Low Platelet Count)\nProphylactic Transfusion: Given prevent spontaneous bleeding counts low, typically <10,000/µL (<20,000/µL cases, like fever/infection) patients bone marrow failure (e.g., due chemotherapy, leukemia, aplastic anemia)\nPre-Procedure: Given raise count invasive procedures surgery (target count depends procedure’s bleeding risk, e.g., >50,000/µL many surgeries, >80,000-100,000/µL neurosurgery)\nTherapeutic Transfusion: Given actively bleeding patients thrombocytopenia\nProphylactic Transfusion: Given prevent spontaneous bleeding counts low, typically <10,000/µL (<20,000/µL cases, like fever/infection) patients bone marrow failure (e.g., due chemotherapy, leukemia, aplastic anemia)Pre-Procedure: Given raise count invasive procedures surgery (target count depends procedure’s bleeding risk, e.g., >50,000/µL many surgeries, >80,000-100,000/µL neurosurgery)Therapeutic Transfusion: Given actively bleeding patients thrombocytopeniaPlatelet Dysfunction (Thrombocytopathia)\nPatients whose platelets don’t function normally (due inherited disorders like Glanzmann’s thrombasthenia Bernard-Soulier syndrome, acquired dysfunction like post-cardiopulmonary bypass due certain medications like aspirin/clopidogrel) may require transfusion actively bleeding undergoing high-risk surgery\nPatients whose platelets don’t function normally (due inherited disorders like Glanzmann’s thrombasthenia Bernard-Soulier syndrome, acquired dysfunction like post-cardiopulmonary bypass due certain medications like aspirin/clopidogrel) may require transfusion actively bleeding undergoing high-risk surgeryMassive Transfusion Protocols: Included along RBCs plasma address dilutional consumptive coagulopathy seen massive hemorrhageImportant Note Platelet transfusions generally contraindicated used extreme caution conditions like Thrombotic Thrombocytopenic Purpura (TTP) Heparin-Induced Thrombocytopenia (HIT), transfused platelets can worsen thrombotic process","code":""},{"path":"platelets.html","id":"storage-and-expiration-2","chapter":"Platelets","heading":"Storage and Expiration","text":"unique critical platelets:Storage Temperature: 20°C 24°C (Controlled Room Temperature)\nRationale: Cold temperatures cause irreversible activation shape change, destroying platelet function\nRationale: Cold temperatures cause irreversible activation shape change, destroying platelet functionAgitation: Requires continuous, gentle agitation (specialized rotators flatbed agitators)\nRationale: Prevents platelets clumping together facilitates gas exchange (O₂ , CO₂ ) across bag, crucial maintaining pH\nRationale: Prevents platelets clumping together facilitates gas exchange (O₂ , CO₂ ) across bag, crucial maintaining pHExpiration: Typically 5 days collection\nRationale: room temperature storage significantly increases risk bacterial proliferation. primary limiting factor shelf life\nExtension: Can sometimes extended 7 days specific FDA-approved bacterial detection systems pathogen reduction technology (PRT) used\nRationale: room temperature storage significantly increases risk bacterial proliferation. primary limiting factor shelf lifeExtension: Can sometimes extended 7 days specific FDA-approved bacterial detection systems pathogen reduction technology (PRT) used","code":""},{"path":"platelets.html","id":"quality-control-specifications-2","chapter":"Platelets","heading":"Quality Control / Specifications","text":"Units must meet specific quality standards:Volume: ~50-70 mL single WBD units; ~200-400 mL apheresis unitsPlatelet Content\nWBD units: ≥ 5.5 x 10¹⁰ platelets per unit (average expected pooling)\nApheresis units: ≥ 3.0 x 10¹¹ platelets per unit (equivalent 4-6 WBD units)\nWBD units: ≥ 5.5 x 10¹⁰ platelets per unit (average expected pooling)Apheresis units: ≥ 3.0 x 10¹¹ platelets per unit (equivalent 4-6 WBD units)pH: Must ≥ 6.2 end storage period (critical viability)Residual WBCs (Leukoreduced): < 8.3 x 10⁵ (pooled WBD) < 5 x 10⁶ (apheresis) per AABB standards – ensures reduction WBC-related risksBacterial Testing: Increasingly common/required due storage conditions. Methods include culture systems rapid tests","code":""},{"path":"platelets.html","id":"modifications-to-platelet-units","chapter":"Platelets","heading":"Modifications to Platelet Units","text":"Leukoreduced Platelets: Standard apheresis units, often performed filtration WBD pools. Reduces risk FNHTRs, CMV transmission, HLA alloimmunizationIrradiated Platelets: Prevents TA-GVHD. Indicated patient populations irradiated RBCs. change 5-day (7-day) expirationWashed Platelets: Removes plasma proteins patients history severe allergic reactions (e.g., anti-IgA). Open system shortens expiration 4 hoursVolume-Reduced Platelets: Reduces plasma volume patients risk TACO. Often open system, shortening expiration 4 hoursPlatelet Additive Solutions (PAS): Solutions designed replace large portion (~60-70%) plasma used platelet storage. Reduces plasma exposure allergic reactions. May affect ABO compatibility considerations","code":""},{"path":"platelets.html","id":"administration-2","chapter":"Platelets","heading":"Administration","text":"Compatibility\nABO: ABO antigens present platelets, compatibility less critical RBCs due lower antigen density small plasma volume (WBD pools). However, ABO-identical compatible platelets preferred, especially apheresis units PAS platelets may contain residual plasma containing anti-/anti-B. Transfusing ABO-incompatible platelets can sometimes lead mild hemolysis (due incompatible plasma) slightly lower platelet recovery\nRh: Platelets don’t express Rh antigens, platelet products can contain small numbers contaminating RBCs (~0.01-0.1 mL). Therefore, Rh-negative females childbearing potential ideally receive Rh-negative platelets (available) prevent sensitization D antigen. Rh-positive platelets must given, Rh Immune Globulin (RhIG) administration considered. Leukoreduction significantly minimizes number contaminating RBCs\nABO: ABO antigens present platelets, compatibility less critical RBCs due lower antigen density small plasma volume (WBD pools). However, ABO-identical compatible platelets preferred, especially apheresis units PAS platelets may contain residual plasma containing anti-/anti-B. Transfusing ABO-incompatible platelets can sometimes lead mild hemolysis (due incompatible plasma) slightly lower platelet recoveryRh: Platelets don’t express Rh antigens, platelet products can contain small numbers contaminating RBCs (~0.01-0.1 mL). Therefore, Rh-negative females childbearing potential ideally receive Rh-negative platelets (available) prevent sensitization D antigen. Rh-positive platelets must given, Rh Immune Globulin (RhIG) administration considered. Leukoreduction significantly minimizes number contaminating RBCsPooling: Required WBD units (4-6 units pooled one bag adult dose)Filtration: Must administered standard blood filter (170-260 microns) specific platelet filterInfusion Time: Typically infused rapidly, often 30-60 minutes per therapeutic dose. Must completed within 4 hours pooling spiking bagExpected Outcome: therapeutic dose increase platelet count average adult ~30,000-60,000/µL (measured 1 hour post-transfusion). Poor increments may indicate platelet refractoriness (often due HLA platelet-specific antibodies)","code":""},{"path":"platelets.html","id":"potential-risks-adverse-reactions-2","chapter":"Platelets","heading":"Potential Risks / Adverse Reactions","text":"Bacterial Contamination / Sepsis: significant infectious risk associated platelet transfusion due room temperature storageFebrile Non-Hemolytic Transfusion Reactions (FNHTRs)Allergic Reactions (Mild Urticaria Anaphylaxis)Transfusion-Related Acute Lung Injury (TRALI) (associated plasma)Transfusion-Associated Circulatory Overload (TACO)Alloimmunization (HLA platelet-specific antigens), potentially leading platelet refractoriness","code":""},{"path":"platelets.html","id":"key-terms-14","chapter":"Platelets","heading":"Key Terms","text":"Thrombocytopenia: Low platelet countThrombocytopathia: Abnormal platelet functionHemostasis: process stopping bleedingApheresis Platelets (SDP): Platelets collected single donor using apheresis machine (provides full therapeutic dose)Whole Blood Derived Platelets (WBD): Platelets prepared centrifuging whole blood (requires pooling therapeutic dose)Pooling: Combining multiple WBD platelet units one containerPlatelet Additive Solution (PAS): solution used replace plasma platelet storagePlatelet Refractoriness: Failure achieve expected increase platelet count transfusion, often due antibodiesCorrected Count Increment (CCI): calculation used assess effectiveness platelet transfusion, accounting patient size doseSwirling: visible light-scattering phenomenon viable, discoid platelets agitation","code":""},{"path":"plasma.html","id":"plasma","chapter":"Plasma","heading":"Plasma","text":"liquid matrix blood. might look like just yellowish fluid, ’s packed essential proteins crucial coagulation, immunity, maintaining osmotic pressure. transfusion purposes, ’re primarily interested coagulation factors","code":""},{"path":"plasma.html","id":"what-is-plasma","chapter":"Plasma","heading":"What is Plasma?","text":"Definition: Plasma largest component blood (~55% volume), primarily composed water (~92%) containing vital dissolved substances:\nProteins: Albumin (maintains osmotic pressure), Globulins (including immunoglobulins/antibodies), Fibrinogen, Coagulation Factors (Factors II, V, VII, VIII, IX, X, XI, XII, XIII, etc.)\nSolutes: Electrolytes (sodium, potassium, chloride, etc.), nutrients (glucose, amino acids, lipids), hormones, waste products (urea, CO₂)\nProteins: Albumin (maintains osmotic pressure), Globulins (including immunoglobulins/antibodies), Fibrinogen, Coagulation Factors (Factors II, V, VII, VIII, IX, X, XI, XII, XIII, etc.)Solutes: Electrolytes (sodium, potassium, chloride, etc.), nutrients (glucose, amino acids, lipids), hormones, waste products (urea, CO₂)Function Transfusion: primary goal transfusing plasma replenish deficient coagulation factors treat prevent bleeding","code":""},{"path":"plasma.html","id":"types-of-plasma-components-for-transfusion","chapter":"Plasma","heading":"Types of Plasma Components for Transfusion","text":"key difference plasma products lies quickly frozen collection, impacts preservation labile coagulation factors (Factors V VIII sensitive degradation):Fresh Frozen Plasma (FFP)\nPreparation: Plasma separated whole blood frozen solid ≤ -18°C (colder) within 8 hours collection (collected CPD, CPDA-1) within 6 hours (collected ACD). Can also collected apheresis\nKey Feature: Considered “gold standard” rapid freezing best preserves coagulation factors, including labile Factors V VIII\nVolume: Typically ~200-275 mL per unit\nPreparation: Plasma separated whole blood frozen solid ≤ -18°C (colder) within 8 hours collection (collected CPD, CPDA-1) within 6 hours (collected ACD). Can also collected apheresisKey Feature: Considered “gold standard” rapid freezing best preserves coagulation factors, including labile Factors V VIIIVolume: Typically ~200-275 mL per unitPlasma Frozen within 24 hours (PF24)\nPreparation: Plasma separated whole blood frozen solid ≤ -18°C within 8 24 hours collection\nKey Feature: Contains clinically effective levels coagulation factors, may slightly lower levels Factor V Factor VIII compared FFP. clinical situations requiring factor replacement, PF24 considered equivalent FFP\nVolume: Similar FFP (~200-275 mL)\nPreparation: Plasma separated whole blood frozen solid ≤ -18°C within 8 24 hours collectionKey Feature: Contains clinically effective levels coagulation factors, may slightly lower levels Factor V Factor VIII compared FFP. clinical situations requiring factor replacement, PF24 considered equivalent FFPVolume: Similar FFP (~200-275 mL)Plasma Frozen within 24 hours held Room Temperature (PF24RT24)\nPreparation: Plasma separated whole blood held room temperature (20-24°C) 24 hours, frozen solid ≤ -18°C within 24 hours collection\nKey Feature: Logistical advantage processing. Factor levels comparable PF24 (slightly lower Factor V/VIII FFP)\nVolume: Similar FFP/PF24\nPreparation: Plasma separated whole blood held room temperature (20-24°C) 24 hours, frozen solid ≤ -18°C within 24 hours collectionKey Feature: Logistical advantage processing. Factor levels comparable PF24 (slightly lower Factor V/VIII FFP)Volume: Similar FFP/PF24Thawed Plasma\nPreparation: frozen plasma products (FFP, PF24, PF24RT24) thawed\nStorage: Stored 1°C 6°C thawing\nKey Feature: Factor V VIII levels decline significantly refrigerated storage thawing. Can used 5 days, ideal specific replacement labile factors critical first 24 hours\nPreparation: frozen plasma products (FFP, PF24, PF24RT24) thawedStorage: Stored 1°C 6°C thawingKey Feature: Factor V VIII levels decline significantly refrigerated storage thawing. Can used 5 days, ideal specific replacement labile factors critical first 24 hoursLiquid Plasma\nPreparation: Plasma separated whole blood never frozen\nStorage: Stored 1°C 6°C\nKey Feature: low levels labile Factors V VIII. Limited use, primarily patients needing plasma exchange don’t require labile factors. Shelf life tied original whole blood expiry + 5 days\nPreparation: Plasma separated whole blood never frozenStorage: Stored 1°C 6°CKey Feature: low levels labile Factors V VIII. Limited use, primarily patients needing plasma exchange don’t require labile factors. Shelf life tied original whole blood expiry + 5 daysCryoprecipitate-Reduced Plasma\nPreparation: supernatant plasma remaining Cryoprecipitated AHF removed thawed FFP\nKey Feature: Deficient Fibrinogen, Factor VIII, Factor XIII, von Willebrand Factor. main use plasma exchange patients Thrombotic Thrombocytopenic Purpura (TTP), lacks large vWF multimers implicated TTP pathogenesis\nPreparation: supernatant plasma remaining Cryoprecipitated AHF removed thawed FFPKey Feature: Deficient Fibrinogen, Factor VIII, Factor XIII, von Willebrand Factor. main use plasma exchange patients Thrombotic Thrombocytopenic Purpura (TTP), lacks large vWF multimers implicated TTP pathogenesisSource Plasma\nPreparation: Collected plasmapheresis specifically manufacturing plasma derivatives (like Albumin, IVIG, Factor Concentrates). typically intended direct transfusion\nPreparation: Collected plasmapheresis specifically manufacturing plasma derivatives (like Albumin, IVIG, Factor Concentrates). typically intended direct transfusion","code":""},{"path":"plasma.html","id":"indications-for-transfusion-3","chapter":"Plasma","heading":"Indications for Transfusion","text":"Plasma transfusion indicated :Replacement Multiple Coagulation Factor Deficiencies: patients actively bleeding high risk bleeding due :\nSevere Liver Disease (impaired factor synthesis)\nDisseminated Intravascular Coagulation (DIC) (factor consumption)\nMassive Transfusion (dilution consumption factors)\nSevere Liver Disease (impaired factor synthesis)Disseminated Intravascular Coagulation (DIC) (factor consumption)Massive Transfusion (dilution consumption factors)Urgent Reversal Warfarin (Coumadin): Vitamin K slow Prothrombin Complex Concentrates (PCCs) unavailable contraindicatedPlasma Exchange Procedures: conditions like TTP, Guillain-Barré syndrome, Myasthenia GravisRare Specific Factor Deficiencies: specific factor concentrates unavailable (e.g., Factor V deficiency)Contraindications Plasma used :Volume expansion alone (use crystalloids albumin)Nutritional supportWhen specific factor concentrates Vitamin K appropriate available","code":""},{"path":"plasma.html","id":"storage-and-expiration-3","chapter":"Plasma","heading":"Storage and Expiration","text":"Frozen State (FFP, PF24, PF24RT24, Cryo-Reduced Plasma)\nStorage Temperature: ≤ -18°C (≤ -30°C preferred better long-term stability)\nExpiration: 1 year date original collection\nStorage Temperature: ≤ -18°C (≤ -30°C preferred better long-term stability)Expiration: 1 year date original collectionThawed State\nStorage Temperature: 1°C 6°C\nExpiration:\n“Thawed FFP/PF24”: 24 hours thawing\nRelabeled “Thawed Plasma”: 5 days thawing (acknowledging lower labile factor levels)\n\nStorage Temperature: 1°C 6°CExpiration:\n“Thawed FFP/PF24”: 24 hours thawing\nRelabeled “Thawed Plasma”: 5 days thawing (acknowledging lower labile factor levels)\n“Thawed FFP/PF24”: 24 hours thawingRelabeled “Thawed Plasma”: 5 days thawing (acknowledging lower labile factor levels)Liquid Plasma\nStorage Temperature: 1°C 6°C\nExpiration: 5 days past original whole blood expiration date\nStorage Temperature: 1°C 6°CExpiration: 5 days past original whole blood expiration date","code":""},{"path":"plasma.html","id":"administration-3","chapter":"Plasma","heading":"Administration","text":"Thawing: Rapidly 30-37°C monitored water bath FDA-approved microwave/thawing device. Overwrapping crucial water baths prevent port contaminationCompatibility: Plasma units MUST ABO compatible recipient’s RED BLOOD CELLS. means:\nGroup O recipient can receive O, , B, AB plasma\nGroup recipient can receive , AB plasma\nGroup B recipient can receive B, AB plasma\nGroup AB recipient can receive AB plasma (Universal plasma donor)\nRationale: antibodies (anti-, anti-B) donor plasma must react recipient’s red cell antigens\nRh Type: Generally considered critical plasma transfusion , plasma contains negligible RBCs. However, hospital policies may prefer Rh-compatible plasma\nGroup O recipient can receive O, , B, AB plasmaGroup recipient can receive , AB plasmaGroup B recipient can receive B, AB plasmaGroup AB recipient can receive AB plasma (Universal plasma donor)Rationale: antibodies (anti-, anti-B) donor plasma must react recipient’s red cell antigensRh Type: Generally considered critical plasma transfusion , plasma contains negligible RBCs. However, hospital policies may prefer Rh-compatible plasmaDosage: Typically 10-20 mL/kg body weight, adjusted based clinical situation coagulation results (e.g., INR, PTT)Filtration: Administered standard blood filter (170-260 microns)Infusion Time: Usually infused 30-60 minutes, must completed within 4 hours thawing (spiking bag)","code":""},{"path":"plasma.html","id":"potential-risks-adverse-reactions-3","chapter":"Plasma","heading":"Potential Risks / Adverse Reactions","text":"Transfusion-Related Acute Lung Injury (TRALI): leading cause transfusion-related mortality. Often associated antibodies (anti-HLA anti-neutrophil) donor plasma reacting recipient WBCs. Risk mitigated using plasma predominantly male donors, female donors tested negative HLA antibodiesTransfusion-Associated Circulatory Overload (TACO): Risk due volume infused, especially susceptible patients (elderly, cardiac/renal impairment)Allergic Reactions: Range mild urticaria (hives) severe anaphylaxisFebrile Non-Hemolytic Reactions (FNHTRs)Transfusion-Transmitted Infections (TTIs): low risk due donor screening testingCitrate Toxicity: Possible rapid, large-volume infusions (especially patients liver impairment) due citrate anticoagulant binding calcium","code":""},{"path":"plasma.html","id":"key-terms-15","chapter":"Plasma","heading":"Key Terms","text":"Coagulation Factors: Proteins plasma essential blood clot formationLabile Factors: Factors V VIII, degrade relatively quickly frozen promptlyFFP (Fresh Frozen Plasma): Plasma frozen within 8 hours collectionPF24 (Plasma Frozen within 24 hours): Plasma frozen within 8-24 hours collectionThawed Plasma: Previously frozen plasma stored 1-6°C, expires 24 hours 5 daysTRALI (Transfusion-Related Acute Lung Injury): Serious pulmonary complication potentially linked donor antibodiesTACO (Transfusion-Associated Circulatory Overload): Pulmonary edema due excessive volume infusionABO Compatibility (Plasma): Donor plasma antibodies must compatible recipient red cell antigens (e.g., Group recipient needs AB plasma)","code":""},{"path":"granulocytes.html","id":"granulocytes","chapter":"Granulocytes","heading":"Granulocytes","text":"Granulocyte transfusions among least common blood components used, reserved specific, life-threatening situations. represent concentrated dose white blood cells, primarily neutrophils, aimed helping patients fight severe infections neutrophil count dangerously low","code":""},{"path":"granulocytes.html","id":"what-are-granulocytes","chapter":"Granulocytes","heading":"What Are Granulocytes?","text":"Definition: Granulocytes category white blood cells characterized presence granules cytoplasm. category includes Neutrophils, Eosinophils, Basophils. transfusion purposes, focus almost entirely Neutrophils, primary phagocytic cells responsible engulfing destroying bacteria fungiFunction: goal granulocyte transfusion provide temporary boost functional neutrophils patients unable mount adequate response severe infection","code":""},{"path":"granulocytes.html","id":"preparation-method-1","chapter":"Granulocytes","heading":"Preparation Method","text":"Granulocytes effectively prepared standard whole blood donations due low numbers present. Collection requires Apheresis, involves several specialized steps:Donor Stimulation (Mobilization) Donors typically receive agents beforehand significantly increase number circulating neutrophils:\nG-CSF (Granulocyte Colony-Stimulating Factor): cytokine administered injection several days hours donation, stimulating bone marrow produce release neutrophils\nCorticosteroids (e.g., Dexamethasone): Often given orally hours donation. cause neutrophils marginated along blood vessel walls enter circulation prevent egress, boosting circulating count\nDonor Consideration: Requires specific informed consent regarding side effects medications (e.g., bone pain, headache G-CSF; usual steroid effects)\nG-CSF (Granulocyte Colony-Stimulating Factor): cytokine administered injection several days hours donation, stimulating bone marrow produce release neutrophilsCorticosteroids (e.g., Dexamethasone): Often given orally hours donation. cause neutrophils marginated along blood vessel walls enter circulation prevent egress, boosting circulating countDonor Consideration: Requires specific informed consent regarding side effects medications (e.g., bone pain, headache G-CSF; usual steroid effects)Apheresis Collection Whole blood drawn apheresis machine. Often, sedimenting agent (like Hydroxyethyl Starch - HES, though use decreasing due safety concerns) added enhance separation WBCs RBCs causing RBC rouleaux formationSeparation & Collection machine uses centrifugation separate collect granulocyte layer (often appearing “buffy coat”)Resulting Product granulocyte concentrate typically volume 200-300 mL contains:\nhigh number granulocytes (mostly neutrophils) - target dose often >1.0 x 10¹⁰ per unit\nSignificant numbers lymphocytes (requiring irradiation - see )\nVariable numbers platelets\nSignificant numbers Red Blood Cells (often >20-30 mL, requiring crossmatch compatibility)\nPlasma anticoagulant (usually citrate)\nhigh number granulocytes (mostly neutrophils) - target dose often >1.0 x 10¹⁰ per unitSignificant numbers lymphocytes (requiring irradiation - see )Variable numbers plateletsSignificant numbers Red Blood Cells (often >20-30 mL, requiring crossmatch compatibility)Plasma anticoagulant (usually citrate)","code":""},{"path":"granulocytes.html","id":"indications-for-transfusion-4","chapter":"Granulocytes","heading":"Indications for Transfusion","text":"Granulocyte transfusion rarely indicated considered supportive therapy last resort. Stringent criteria usually apply:Severe Neutropenia: Absolute Neutrophil Count (ANC) typically < 500/µLDocumented Infection: Evidence severe bacterial fungal infection (e.g., positive cultures, imaging)Lack Response: Infection progressing despite appropriate, high-dose antimicrobial therapyPotential Marrow Recovery: reasonable expectation patient’s bone marrow function eventually recover (granulocytes temporary bridge, cure)Specific Situations\nNeonatal sepsis neutropenia\nPatients chronic granulomatous disease (CGD) experiencing severe infections\nNeonatal sepsis neutropeniaPatients chronic granulomatous disease (CGD) experiencing severe infectionsContraindications Generally useful marrow recovery anticipated infection well-controlled antibiotics alone","code":""},{"path":"granulocytes.html","id":"storage-and-expiration-4","chapter":"Granulocytes","heading":"Storage and Expiration","text":"Storage conditions critical differ components:Storage Temperature: 20°C 24°C (Controlled Room Temperature)\nRationale: Neutrophil function (phagocytosis, chemotaxis) significantly impaired refrigeration\nRationale: Neutrophil function (phagocytosis, chemotaxis) significantly impaired refrigerationAgitation: AGITATE. Store undisturbed\nRationale: Agitation can damage fragile neutrophils\nRationale: Agitation can damage fragile neutrophilsExpiration: Extremely short - 24 hours end collection\nRationale: Rapid loss neutrophil function vitro high risk bacterial proliferation room temperature\nRationale: Rapid loss neutrophil function vitro high risk bacterial proliferation room temperature","code":""},{"path":"granulocytes.html","id":"quality-control-specifications-3","chapter":"Granulocytes","heading":"Quality Control / Specifications","text":"Granulocyte Content: Target dose usually > 1.0 x 10¹⁰ per adult unit (actual content varies)Volume: Typically 200-300 mLRBC Content: Usually significant enough require crossmatchingBacterial Testing: Standard protocols apply due room temperature storage","code":""},{"path":"granulocytes.html","id":"administration-4","chapter":"Granulocytes","heading":"Administration","text":"Administration requires careful planning monitoring due high reaction rates specific requirements:Irradiation: MANDATORY. Granulocyte concentrates contain viable T-lymphocytes must irradiated (25-50 Gy) shortly infusion prevent TA-GVHD. Irradiation change 24-hour expiration timeCompatibility\nABO: Plasma must ABO compatible recipient red cells\nRh: Must Rh compatible due significant RBC content. Rh-negative recipients receive Rh-negative granulocytes possible. Consider RhIG Rh-negative females childbearing age receiving Rh-positive units\nCrossmatch: RBC crossmatch required due volume contaminating RBCs\nHLA: HLA matching desirable (especially patient alloimmunized expected receive multiple transfusions) often feasible due urgency short shelf life. HLA antibodies recipient can cause reactions neutralize transfused granulocytes. Antibodies donor plasma can contribute TRALI\nABO: Plasma must ABO compatible recipient red cellsRh: Must Rh compatible due significant RBC content. Rh-negative recipients receive Rh-negative granulocytes possible. Consider RhIG Rh-negative females childbearing age receiving Rh-positive unitsCrossmatch: RBC crossmatch required due volume contaminating RBCsHLA: HLA matching desirable (especially patient alloimmunized expected receive multiple transfusions) often feasible due urgency short shelf life. HLA antibodies recipient can cause reactions neutralize transfused granulocytes. Antibodies donor plasma can contribute TRALIFiltration: Use standard blood filter (170-260 microns). use leukocyte-reduction filter – remove therapeutic granulocytes!Infusion Time: Infuse slowly, typically 2-4 hours, minimize reactionsPre-medication: Often recommended (e.g., antihistamines, acetaminophen, corticosteroids) due high frequency transfusion reactionsTiming Amphotericin B: Controversial. older data suggested increased pulmonary reactions given concurrently. Many institutions separate administration times several hours precaution","code":""},{"path":"granulocytes.html","id":"potential-risks-adverse-reactions-4","chapter":"Granulocytes","heading":"Potential Risks / Adverse Reactions","text":"Granulocyte transfusions higher rate adverse reactions compared components:Febrile Non-Hemolytic Reactions (FNHTRs): common due cytokines alloantigensPulmonary Reactions: significant concern. Can range mild dyspnea hypoxia severe TRALI-like reactions. May related neutrophil activation, sequestration lungs, underlying infection/inflammationAlloimmunization: HLA neutrophil-specific antigens, potentially hindering effectiveness future transfusionsCMV Transmission: Risk donor CMV positive recipient negative/risk. Finding CMV-seronegative granulocyte donors can challengingTA-GVHD: Prevented mandatory irradiationAllergic ReactionsSeptic Reactions (Bacterial Contamination): Risk due room temperature storageHemolytic Transfusion Reactions: Possible RBC incompatibility occurs","code":""},{"path":"granulocytes.html","id":"key-terms-16","chapter":"Granulocytes","heading":"Key Terms","text":"Granulocyte: Type WBC including neutrophils, eosinophils, basophils. Transfusions primarily provide neutrophilsNeutrophil: Primary phagocytic cell fighting bacterial/fungal infectionsApheresis: Method used collect granulocytes donorG-CSF (Granulocyte Colony-Stimulating Factor): Medication stimulate neutrophil productionCorticosteroids: Medications used mobilize neutrophils circulationNeutropenia: Low neutrophil count (ANC < 500/µL severe)Irradiation: Mandatory treatment prevent TA-GVHDTA-GVHD (Transfusion-Associated Graft-versus-Host Disease): Complication donor lymphocytes attack recipient tissuesCrossmatch: Required due significant RBC content granulocyte concentratesAlloimmunization: Development antibodies foreign antigens (e.g., HLA, neutrophil antigens)","code":""},{"path":"wbc-reduced-components.html","id":"wbc-reduced-components","chapter":"WBC-Reduced Components","heading":"WBC-Reduced Components","text":"section focuses crucial modification applied cellular blood components: Leukocyte Reduction. process involves removing vast majority white blood cells (WBCs leukocytes) Red Blood Cell (RBC) Platelet units transfusion. become standard practice many parts world due significant benefits reducing certain transfusion-related complications","code":""},{"path":"wbc-reduced-components.html","id":"what-are-leukocyte-reduced-components","chapter":"WBC-Reduced Components","heading":"What are Leukocyte-Reduced Components?","text":"Definition: Blood components (primarily RBCs Platelets) undergone process significantly decrease number contaminating leukocytes (WBCs) present final productGoal: minimize adverse effects associated transfusing donor WBCs along intended therapeutic cells (RBCs platelets)","code":""},{"path":"wbc-reduced-components.html","id":"why-leukoreduce-rationale-benefits","chapter":"WBC-Reduced Components","heading":"Why Leukoreduce? (Rationale & Benefits)","text":"Transfusing donor leukocytes can lead several undesirable outcomes. Leukoreduction aims mitigate risks:****Reduce Febrile Non-Hemolytic Transfusion Reactions (FNHTRs):** one common transfusion reactions. ’s often caused :\nCytokines (like IL-1, IL-6, TNF-α) released WBCs accumulating storage\nRecipient antibodies reacting donor HLA antigens antigens present transfused WBCs\nBenefit: Removing WBCs significantly reduces cytokine load antigenic stimulus, thus lowering incidence FNHTRs\nCytokines (like IL-1, IL-6, TNF-α) released WBCs accumulating storageRecipient antibodies reacting donor HLA antigens antigens present transfused WBCsBenefit: Removing WBCs significantly reduces cytokine load antigenic stimulus, thus lowering incidence FNHTRs****Reduce/Prevent HLA Alloimmunization:** Exposure foreign HLA antigens present donor leukocytes can cause recipient develop HLA antibodies. particularly problematic :\nPatients requiring long-term platelet support (can lead platelet refractoriness)\nPatients awaiting organ hematopoietic progenitor cell (HPC) transplantation (can complicate matching increase rejection risk)\nBenefit: Reducing number transfused WBCs decreases recipient’s exposure foreign HLA antigens, lowering risk developing HLA antibodies\nPatients requiring long-term platelet support (can lead platelet refractoriness)Patients awaiting organ hematopoietic progenitor cell (HPC) transplantation (can complicate matching increase rejection risk)Benefit: Reducing number transfused WBCs decreases recipient’s exposure foreign HLA antigens, lowering risk developing HLA antibodies****Reduce Risk Transmitting Cell-Associated Viruses:** Certain viruses, notably Cytomegalovirus (CMV), primarily reside within leukocytes\nBenefit: Removing WBCs significantly reduces amount transmissible CMV. Leukoreduction considered largely equivalent providing CMV-seronegative blood (“CMV safe”) preventing transfusion-transmitted CMV infection, especially RBCs. (Note: highest-risk patients like CMV-negative transplant recipients receiving cells CMV-positive donor, CMV-seronegative units might still preferred clinicians available.)\nBenefit: Removing WBCs significantly reduces amount transmissible CMV. Leukoreduction considered largely equivalent providing CMV-seronegative blood (“CMV safe”) preventing transfusion-transmitted CMV infection, especially RBCs. (Note: highest-risk patients like CMV-negative transplant recipients receiving cells CMV-positive donor, CMV-seronegative units might still preferred clinicians available.)****Potential Benefits (Less definitively proven primary indications)**\nMay reduce transfusion-associated immunomodulation (TRIM) - subtle immunosuppressive effects sometimes attributed transfusion\nMay reduce transmission certain bacteria can carried WBCs\nMay reduce transfusion-associated immunomodulation (TRIM) - subtle immunosuppressive effects sometimes attributed transfusionMay reduce transmission certain bacteria can carried WBCs","code":""},{"path":"wbc-reduced-components.html","id":"how-is-leukoreduction-achieved-methods","chapter":"WBC-Reduced Components","heading":"How is Leukoreduction Achieved? (Methods)","text":"Filtration: common method\nPre-storage Leukoreduction (Preferred Method): Filtration occurs blood collection center shortly collection, component stored. typically done using specialized filters integrated blood collection set attached via sterile connection devices\nAdvantages: Removes WBCs significant cytokine accumulation occurs; allows better quality control blood center\n\nPost-storage / Laboratory Leukoreduction: Filtration occurs hospital transfusion service laboratory just unit issued. Less common now routine LR\nBedside Leukoreduction: Filtration occurs transfusion using specific leukoreduction filter patient’s bedside\nDisadvantages: Less effective preventing FNHTRs caused pre-formed cytokines; quality control variable; requires specific bedside filters distinct standard blood filters\n\nPre-storage Leukoreduction (Preferred Method): Filtration occurs blood collection center shortly collection, component stored. typically done using specialized filters integrated blood collection set attached via sterile connection devices\nAdvantages: Removes WBCs significant cytokine accumulation occurs; allows better quality control blood center\nAdvantages: Removes WBCs significant cytokine accumulation occurs; allows better quality control blood centerPost-storage / Laboratory Leukoreduction: Filtration occurs hospital transfusion service laboratory just unit issued. Less common now routine LRBedside Leukoreduction: Filtration occurs transfusion using specific leukoreduction filter patient’s bedside\nDisadvantages: Less effective preventing FNHTRs caused pre-formed cytokines; quality control variable; requires specific bedside filters distinct standard blood filters\nDisadvantages: Less effective preventing FNHTRs caused pre-formed cytokines; quality control variable; requires specific bedside filters distinct standard blood filters****Apheresis Collection:** Many modern apheresis instruments designed collect platelet products (sometimes RBCs) already significantly leukocyte-reduced part automated collection process****Buffy Coat Removal (Less Common North America):** processing method used regions WBC-rich buffy coat layer physically removed component preparation","code":""},{"path":"wbc-reduced-components.html","id":"standards-and-quality-control","chapter":"WBC-Reduced Components","heading":"Standards and Quality Control","text":"labeled “Leukocytes Reduced,” component must meet defined standards residual WBC content:AABB / US Standard: Residual WBC count must < 5 x 10⁶ per final component (RBCs apheresis platelets)Council Europe Standard: Often stricter, requiring < 1 x 10⁶ residual WBCs per final componentQuality Control: Blood centers must perform regular QC testing sample units ensure leukoreduction processes consistently meet standards","code":""},{"path":"wbc-reduced-components.html","id":"which-components-are-leukoreduced","chapter":"WBC-Reduced Components","heading":"Which Components are Leukoreduced?","text":"Red Blood Cells (RBCs)Platelets: (Apheresis/SDP pooled WBD units)Note Plasma Cryoprecipitate essentially leukocyte-free due centrifugation processes used preparation, leukoreduction applicable. Granulocytes never leukoreduced, leukocytes intended therapeutic component","code":""},{"path":"wbc-reduced-components.html","id":"usage-universal-vs.-indicated-leukoreduction","chapter":"WBC-Reduced Components","heading":"Usage: Universal vs. Indicated Leukoreduction","text":"Universal Leukoreduction (ULR): standard practice many developed countries (including US, Canada, UK, etc.). Nearly cellular components (RBCs, Platelets) leukoreduced patients. approach simplifies inventory management ensures benefits provided broadly without needing specific physician orders LRIndicated Leukoreduction: regions without ULR, leukoreduction might specifically ordered patients known indications (e.g., history FNHTRs, transplant candidates, chronically transfused patients)","code":""},{"path":"wbc-reduced-components.html","id":"impact-on-product","chapter":"WBC-Reduced Components","heading":"Impact on Product","text":"Expiration Date: performed using closed system (e.g., pre-storage filtration, sterile connection), leukoreduction change original expiration date componentCell Loss: minimal loss RBCs platelets filtration process, ’s generally considered clinically significantCost: Leukoreduction adds small incremental cost blood component due filter processing","code":""},{"path":"wbc-reduced-components.html","id":"key-terms-17","chapter":"WBC-Reduced Components","heading":"Key Terms","text":"Leukocyte (WBC): White blood cellLeukoreduction (LR): process removing leukocytes cellular blood componentsFebrile Non-Hemolytic Transfusion Reaction (FNHTR): common reaction characterized fever, chills, sometimes rigors, caused red cell destructionHLA Alloimmunization: Development antibodies Human Leukocyte Antigens non-self source (like transfusion)Platelet Refractoriness: Poor platelet count increment transfusion, often due HLA antibodiesCytokines: Signaling proteins released cells (including WBCs) mediate inflammation immune responsesCMV (Cytomegalovirus): virus commonly transmitted via leukocytesPre-storage Leukoreduction: Removal WBCs blood center storage (preferred method)Bedside Leukoreduction: Removal WBCs transfusion using bedside filter (least preferred method)Universal Leukoreduction (ULR): Policy providing leukoreduced components essentially patients","code":""},{"path":"frozendeglycerolized-rbcs.html","id":"frozendeglycerolized-rbcs","chapter":"Frozen/Deglycerolized RBCs","heading":"Frozen/Deglycerolized RBCs","text":"section delves Frozen Deglycerolized Red Blood Cells, specialized component involving cryopreservation extended storage. used routinely transfusions, ’s vital tool managing inventories rare blood types, autologous units, strategic reserves","code":""},{"path":"frozendeglycerolized-rbcs.html","id":"what-are-frozendeglycerolized-rbcs","chapter":"Frozen/Deglycerolized RBCs","heading":"What Are Frozen/Deglycerolized RBCs?","text":"Definition: Red Blood Cells treated cryoprotective agent (glycerol), frozen solid ultra-low temperatures long-term storage, thawed washed (deglycerolized) remove glycerol transfusionConcept: Freezing allows RBCs stored years instead weeks, requires special processing freezing thawing","code":""},{"path":"frozendeglycerolized-rbcs.html","id":"purpose-indications-why-freeze-rbcs","chapter":"Frozen/Deglycerolized RBCs","heading":"Purpose / Indications (Why Freeze RBCs?)","text":"primary reason long-term storage (10 years potentially longer). particularly useful :Rare Blood Units: Maintaining inventory RBC units rare antigen phenotypes (e.g., negative high-frequency antigens, specific combinations needed patients multiple antibodies)Autologous Units: Storing patient’s blood extended periods planned surgeries (less common now due shorter maximum liquid storage times improved surgical techniques, still option)Military / Strategic Reserves: Stockpiling blood deployment emergency preparedness remote locationsPatients Multiple Alloantibodies: Ensuring availability compatible units finding liquid-stored compatible blood difficult","code":""},{"path":"frozendeglycerolized-rbcs.html","id":"the-process-freezing-and-thawingdeglycerolizing","chapter":"Frozen/Deglycerolized RBCs","heading":"The Process: Freezing and Thawing/Deglycerolizing","text":"multi-step process requiring specialized equipment reagents:Selection RBC Unit Usually, relatively fresh RBCs (often < 6 days old) selected freezing ensure optimal post-thaw qualityGlycerolization (Adding Cryoprotectant)\nGlycerol? Glycerol acts cryoprotective agent. penetrates RBC membrane reduces amount intracellular water, preventing formation large, damaging ice crystals freezing. Without , freezing destroy cells\nMethods: concentrated glycerol solution added slowly packed RBCs mixing intracellular equilibrium reached. Two main methods exist based final glycerol concentration:\nHigh Glycerol (40% weight/volume): common method. Allows slower, uncontrolled freezing rates storage mechanical freezers -65°C -80°C\nLow Glycerol (20% weight/volume): Requires rapid, controlled-rate freezing much colder storage temperatures (-120°C colder, often using liquid nitrogen vapor phase -196°C). Less common due complex storage needs\n\nGlycerol? Glycerol acts cryoprotective agent. penetrates RBC membrane reduces amount intracellular water, preventing formation large, damaging ice crystals freezing. Without , freezing destroy cellsMethods: concentrated glycerol solution added slowly packed RBCs mixing intracellular equilibrium reached. Two main methods exist based final glycerol concentration:\nHigh Glycerol (40% weight/volume): common method. Allows slower, uncontrolled freezing rates storage mechanical freezers -65°C -80°C\nLow Glycerol (20% weight/volume): Requires rapid, controlled-rate freezing much colder storage temperatures (-120°C colder, often using liquid nitrogen vapor phase -196°C). Less common due complex storage needs\nHigh Glycerol (40% weight/volume): common method. Allows slower, uncontrolled freezing rates storage mechanical freezers -65°C -80°CLow Glycerol (20% weight/volume): Requires rapid, controlled-rate freezing much colder storage temperatures (-120°C colder, often using liquid nitrogen vapor phase -196°C). Less common due complex storage needsFreezing Storage (Frozen State)\nglycerolized RBC unit placed protective overwrap frozen\nStorage Temperature: ≤ -65°C (high glycerol method)\nExpiration (Frozen): 10 years (FDA standard; may longer specific protocols)\nglycerolized RBC unit placed protective overwrap frozenStorage Temperature: ≤ -65°C (high glycerol method)Expiration (Frozen): 10 years (FDA standard; may longer specific protocols)Thawing\nneeded, frozen unit removed freezer\nThawed rapidly monitored water bath approved thawing device 30-37°C ice melted\nneeded, frozen unit removed freezerThawed rapidly monitored water bath approved thawing device 30-37°C ice meltedDeglycerolization (Removing Cryoprotectant - CRITICAL STEP)\nDeglycerolize? Glycerol hypertonic. glycerolized RBCs infused directly, high intracellular glycerol concentration compared patient’s plasma cause water rush cells, leading massive osmotic lysis (hemolysis)\n: essentially washing process performed using automated cell washers. thawed unit undergoes sequential washes solutions decreasing tonicity (decreasing salt concentration) gradually remove glycerol RBCs without lysing . Typical wash solutions might include 12% NaCl, 1.6% NaCl, finally isotonic 0.9% NaCl (often added dextrose)\nfinal product RBCs suspended isotonic saline/dextrose solution\nDeglycerolize? Glycerol hypertonic. glycerolized RBCs infused directly, high intracellular glycerol concentration compared patient’s plasma cause water rush cells, leading massive osmotic lysis (hemolysis): essentially washing process performed using automated cell washers. thawed unit undergoes sequential washes solutions decreasing tonicity (decreasing salt concentration) gradually remove glycerol RBCs without lysing . Typical wash solutions might include 12% NaCl, 1.6% NaCl, finally isotonic 0.9% NaCl (often added dextrose)final product RBCs suspended isotonic saline/dextrose solution","code":""},{"path":"frozendeglycerolized-rbcs.html","id":"properties-of-deglycerolized-rbcs","chapter":"Frozen/Deglycerolized RBCs","heading":"Properties of Deglycerolized RBCs","text":"final product thawing washing different standard liquid-stored RBCs:Composition: Primarily RBCs suspended saline/dextrose solutionReduced Plasma: Virtually plasma proteins removed washing processReduced Leukocytes: washing process significantly reduces number WBCs (similar effect leukoreduction filtration)Reduced Platelets: Platelets removed washingReduced Potassium & Additives: Accumulated potassium byproducts initial liquid storage period (freezing) additive solutions washed awayCell Recovery: RBC loss occurs freeze-thaw-wash cycle. Acceptable recovery typically ≥ 80% original RBCs","code":""},{"path":"frozendeglycerolized-rbcs.html","id":"storage-and-expiration-post-deglycerolization","chapter":"Frozen/Deglycerolized RBCs","heading":"Storage and Expiration (Post-Deglycerolization)","text":"key limitation:Storage Temperature: 1°C 6°C (like standard RBCs)Expiration: Highly dependent whether deglycerolization process performed open closed system:\nOpen System: process potentially exposed unit ambient air (traditional methods), expiration 24 hours due risk bacterial contamination\nClosed System: performed using FDA-approved sterile connecting devices closed washing systems, expiration can extended, often 14 days, depending specific system’s validation labeling. significantly improves logistics\nOpen System: process potentially exposed unit ambient air (traditional methods), expiration 24 hours due risk bacterial contaminationClosed System: performed using FDA-approved sterile connecting devices closed washing systems, expiration can extended, often 14 days, depending specific system’s validation labeling. significantly improves logistics","code":""},{"path":"frozendeglycerolized-rbcs.html","id":"quality-control","chapter":"Frozen/Deglycerolized RBCs","heading":"Quality Control","text":"QC measures may include:Adequate RBC recoveryAcceptable levels residual glycerol (measured indirectly osmolality directly)Acceptable levels free hemoglobin (hemolysis)Sterility testing (especially longer post-thaw storage)","code":""},{"path":"frozendeglycerolized-rbcs.html","id":"administration-5","chapter":"Frozen/Deglycerolized RBCs","heading":"Administration","text":"Compatibility: Standard ABO/Rh typing crossmatch procedures requiredFiltration: Administer standard blood filter (170-260 microns)Infusion Time: Must completed within 4 hours spiking bag removal controlled 1-6°C storage","code":""},{"path":"frozendeglycerolized-rbcs.html","id":"advantages","chapter":"Frozen/Deglycerolized RBCs","heading":"Advantages","text":"Extended Storage (10+ years): Primary benefit, crucial rare units strategic reservesReduced Plasma Proteins: Beneficial patients severe allergic reactions (similar washed RBCs)Leukocyte Reduced: Reduces risk FNHTRs, HLA alloimmunization, CMV transmissionLower Potassium Load: Removes accumulated potassium supernatant","code":""},{"path":"frozendeglycerolized-rbcs.html","id":"disadvantages","chapter":"Frozen/Deglycerolized RBCs","heading":"Disadvantages","text":"Complex Time-Consuming Process: Requires specialized equipment, trained personnel, significant processing time (provided “demand” quickly)Costly: Higher cost due equipment, reagents, labor involvedRBC Loss: Inevitable loss RBCs processingShort Post-Thaw Shelf Life: Especially open systems (24 hours), limiting flexibilityLogistics: Requires careful inventory management planning thawing/deglycerolization","code":""},{"path":"frozendeglycerolized-rbcs.html","id":"key-terms-18","chapter":"Frozen/Deglycerolized RBCs","heading":"Key Terms","text":"Cryoprotective Agent: substance (like glycerol) protects cells damage freezingGlycerolization: process adding glycerol RBCs freezingDeglycerolization: washing process used thawing remove glycerol RBCsOsmotic Lysis: Rupture cells due rapid water influx caused osmotic imbalancesOpen System: processing method sterility component may compromised (limits post-process expiration)Closed System: processing method maintaining sterility throughout (allows longer post-process expiration)High/Low Glycerol Method: Refers final concentration glycerol used, impacting freezing rate storage temperature requirements","code":""},{"path":"apheresis-products.html","id":"apheresis-products","chapter":"Apheresis Products","heading":"Apheresis Products","text":"Apheresis Products represent components collected using specialized technology allows selective removal one specific blood components donor, returning remaining constituents circulation. contrasts whole blood donation, components collected initially separated later laboratory","code":""},{"path":"apheresis-products.html","id":"what-is-apheresis-hemapheresis","chapter":"Apheresis Products","heading":"What is Apheresis (Hemapheresis)?","text":"Definition: Derived Greek word meaning “take away” “separate,” apheresis automated process :\nWhole blood withdrawn donor (patient, therapeutic apheresis)\nblood anticoagulated, usually citrate\nenters sterile, disposable tubing set within apheresis machine\nmachine uses centrifugation (sometimes filtration) separate blood different components based density (RBCs heaviest, granulocytes, lymphocytes, platelets, plasma lightest)\ndesired component(s) selectively diverted collection bag\nremaining components recombined returned donor/patient different venous access point\nWhole blood withdrawn donor (patient, therapeutic apheresis)blood anticoagulated, usually citrateIt enters sterile, disposable tubing set within apheresis machineThe machine uses centrifugation (sometimes filtration) separate blood different components based density (RBCs heaviest, granulocytes, lymphocytes, platelets, plasma lightest)desired component(s) selectively diverted collection bagThe remaining components recombined returned donor/patient different venous access pointKey Feature: Allows collection larger quantity specific component single individual compared can derived one unit whole blood donation","code":""},{"path":"apheresis-products.html","id":"common-apheresis-products-for-transfusion","chapter":"Apheresis Products","heading":"Common Apheresis Products for Transfusion","text":"Platelets (Plateletpheresis / Single Donor Platelets - SDP)\n’s Collected: concentrated dose platelets, suspended small amount plasma mixture plasma Platelet Additive Solution (PAS)\nKey Advantage: One apheresis platelet unit contains full therapeutic dose adult (typically ≥ 3.0 x 10¹¹ platelets), equivalent pooling 4-6 units Whole Blood Derived (WBD) platelets. reduces recipient exposure multiple donors, minimizing risks alloimmunization disease transmission\nDonor Considerations: Donors can typically donate platelets frequently whole blood (e.g., every 7 days, 24 times/year)\nStorage: Standard platelet storage (20-24°C continuous agitation, 5-7 day expiration)\nLeukoreduction: Usually inherently leukoreduced collection process\n’s Collected: concentrated dose platelets, suspended small amount plasma mixture plasma Platelet Additive Solution (PAS)Key Advantage: One apheresis platelet unit contains full therapeutic dose adult (typically ≥ 3.0 x 10¹¹ platelets), equivalent pooling 4-6 units Whole Blood Derived (WBD) platelets. reduces recipient exposure multiple donors, minimizing risks alloimmunization disease transmissionDonor Considerations: Donors can typically donate platelets frequently whole blood (e.g., every 7 days, 24 times/year)Storage: Standard platelet storage (20-24°C continuous agitation, 5-7 day expiration)Leukoreduction: Usually inherently leukoreduced collection processPlasma (Plasmapheresis)\n’s Collected: Plasma, intended either transfusion (FFP, PF24) manufacturing (“Source Plasma”) plasma derivatives (Albumin, IVIG, factor concentrates)\nKey Advantage: Collects larger volume plasma (~500-880 mL, depending donor weight procedure) can obtained single whole blood donation. Efficient way collect plasma specific needs\nDonor Considerations: Frequency depends product type (less frequent FFP, frequent Source Plasma specific programs)\nStorage (Transfusion Plasma): Standard frozen storage (≤ -18°C, 1 year expiration)\n’s Collected: Plasma, intended either transfusion (FFP, PF24) manufacturing (“Source Plasma”) plasma derivatives (Albumin, IVIG, factor concentrates)Key Advantage: Collects larger volume plasma (~500-880 mL, depending donor weight procedure) can obtained single whole blood donation. Efficient way collect plasma specific needsDonor Considerations: Frequency depends product type (less frequent FFP, frequent Source Plasma specific programs)Storage (Transfusion Plasma): Standard frozen storage (≤ -18°C, 1 year expiration)Red Blood Cells (Erythrocytapheresis / Red Cell Apheresis)\n’s Collected: Primarily Red Blood Cells. commonly performed “Double Red Cell” (2RBC) donation\nKey Advantage: Collects two standard doses RBCs single donor one session. Efficient donors helps manage inventory\nDonor Considerations: Requires donors meet higher hemoglobin/hematocrit levels often height/weight criteria ensure sufficient blood volume. Donation interval longer whole blood (typically 112 days / 16 weeks)\nStorage: Standard RBC storage (1-6°C, 42 days additive solution)\nLeukoreduction: Often inherently leukoreduced\n’s Collected: Primarily Red Blood Cells. commonly performed “Double Red Cell” (2RBC) donationKey Advantage: Collects two standard doses RBCs single donor one session. Efficient donors helps manage inventoryDonor Considerations: Requires donors meet higher hemoglobin/hematocrit levels often height/weight criteria ensure sufficient blood volume. Donation interval longer whole blood (typically 112 days / 16 weeks)Storage: Standard RBC storage (1-6°C, 42 days additive solution)Leukoreduction: Often inherently leukoreducedGranulocytes (Granulocytapheresis)\n’s Collected: concentrate rich neutrophils\nKey Advantage: Apheresis essentially practical way collect therapeutic dose granulocytes\nDonor Considerations: Requires donor stimulation G-CSF /corticosteroids boost neutrophil counts. Donation infrequent targeted specific patient needs\nStorage: Unique (20-24°C, agitation, 24-hour expiration). Must irradiated crossmatched\n’s Collected: concentrate rich neutrophilsKey Advantage: Apheresis essentially practical way collect therapeutic dose granulocytesDonor Considerations: Requires donor stimulation G-CSF /corticosteroids boost neutrophil counts. Donation infrequent targeted specific patient needsStorage: Unique (20-24°C, agitation, 24-hour expiration). Must irradiated crossmatchedHematopoietic Progenitor Cells (HPCs) / Stem Cells (Leukapheresis)\n’s Collected: Mononuclear cells containing hematopoietic stem cells, used transplantation\nKey Advantage: Apheresis collection Peripheral Blood Stem Cells (PBSCs) now common method HPC donation (vs. bone marrow harvest)\nDonor Considerations: Requires donor mobilization G-CSF several days prior collection push stem cells marrow peripheral blood. Requires careful HLA matching donor recipient (unless autologous)\nStorage: Often cryopreserved later use\n’s Collected: Mononuclear cells containing hematopoietic stem cells, used transplantationKey Advantage: Apheresis collection Peripheral Blood Stem Cells (PBSCs) now common method HPC donation (vs. bone marrow harvest)Donor Considerations: Requires donor mobilization G-CSF several days prior collection push stem cells marrow peripheral blood. Requires careful HLA matching donor recipient (unless autologous)Storage: Often cryopreserved later useMulticomponent Collection\n’s Collected: Two different components single apheresis procedure (e.g., platelets plasma; platelets red cells; plasma red cells)\nKey Advantage: Maximizes yield single donor visit venipuncture\n’s Collected: Two different components single apheresis procedure (e.g., platelets plasma; platelets red cells; plasma red cells)Key Advantage: Maximizes yield single donor visit venipuncture","code":""},{"path":"apheresis-products.html","id":"advantages-of-apheresis-collection-general","chapter":"Apheresis Products","heading":"Advantages of Apheresis Collection (General)","text":"Reduced Donor Exposure: Fewer donors needed achieve therapeutic dose (especially platelets), reducing risks recipientHigher Yield: Larger volume/dose target component collectedComponent Specificity: Collects needed component(s)Donation Frequency: Allows donors give certain components (platelets, plasma) often whole bloodLeukoreduction: Many apheresis procedures inherently produce leukoreduced components","code":""},{"path":"apheresis-products.html","id":"disadvantages-considerations-of-apheresis","chapter":"Apheresis Products","heading":"Disadvantages / Considerations of Apheresis","text":"Donor Time Commitment: Procedures take longer whole blood donation (typically 1-2 hours)Citrate Reaction: anticoagulant (citrate) returned donor, potentially causing temporary hypocalcemia symptoms (tingling, chills). Requires careful monitoring management (e.g., oral calcium)Venous Access: Often requires good veins, sometimes armsCost: Apheresis machines disposable kits expensive whole blood collection suppliesTrained Personnel: Requires staff specifically trained operating apheresis equipment managing donors","code":""},{"path":"apheresis-products.html","id":"regulatory-and-quality-aspects","chapter":"Apheresis Products","heading":"Regulatory and Quality Aspects","text":"Apheresis devices regulated FDAProcedures must validatedCollected components must meet specific quality control standards (e.g., platelet count, volume, residual WBCs, pH)","code":""},{"path":"apheresis-products.html","id":"key-terms-19","chapter":"Apheresis Products","heading":"Key Terms","text":"Apheresis (Hemapheresis): Automated process separate collect specific blood components returning others donorCitrate: Anticoagulant used apheresis; binds calciumCitrate Reaction: Symptoms (tingling, chills) due temporary low ionized calcium returned citratePlateletpheresis: Apheresis collection platelets (yields Single Donor Platelets - SDP)Plasmapheresis: Apheresis collection plasmaErythrocytapheresis: Apheresis collection red blood cells (often Double Red Cell - 2RBC)Granulocytapheresis: Apheresis collection granulocytesLeukapheresis: Apheresis collection leukocytes (often referring HPC/stem cell collection)Mobilization/Stimulation: Use agents like G-CSF steroids increase count specific cells (neutrophils, stem cells) donor’s blood apheresis","code":""},{"path":"fractionation-products.html","id":"fractionation-products","chapter":"Fractionation Products","heading":"Fractionation Products","text":"section moves beyond blood components prepared directly hospital blood bank (like RBCs, platelets, FFP, Cryo) delves highly purified protein products derived large pools human plasma industrial manufacturing processes. essentially plasma-derived pharmaceuticals","code":""},{"path":"fractionation-products.html","id":"what-are-fractionation-products","chapter":"Fractionation Products","heading":"What are Fractionation Products?","text":"Definition: Therapeutic protein concentrates obtained large-scale industrial process called plasma fractionation. process separates purifies specific proteins large pools human plasma collected primarily Source Plasma (via plasmapheresis) sometimes Recovered Plasma (plasma whole blood donations used direct transfusion)Process (Simplified): Involves sophisticated biochemical biophysical techniques, traditionally starting Cohn fractionation method (using cold ethanol precipitation) now often incorporating advanced methods like chromatography (ion exchange, affinity), filtration, ultrafiltration. critical part manufacturing process includes rigorous steps specifically designed inactivate remove viruses (e.g., solvent/detergent treatment, pasteurization, nanofiltration), providing high margin viral safety compared single-donor plasma components","code":""},{"path":"fractionation-products.html","id":"key-differences-from-standard-blood-components-ffp-cryo","chapter":"Fractionation Products","heading":"Key Differences from Standard Blood Components (FFP, Cryo)","text":"","code":""},{"path":"fractionation-products.html","id":"major-plasma-fractionation-products","chapter":"Fractionation Products","heading":"Major Plasma Fractionation Products","text":"important therapeutic products derived plasma fractionation:Albumin\nFunction: Maintains plasma oncotic pressure (keeps fluid blood vessels), transports various substances\nConcentrations: Available typically 5% (iso-oncotic) 25% (hyper-oncotic) solutions\nIndications: Volume expansion (especially 5%), treatment edema hypoalbuminemia (e.g., liver disease, nephrotic syndrome), burns, support plasma exchange\nFunction: Maintains plasma oncotic pressure (keeps fluid blood vessels), transports various substancesConcentrations: Available typically 5% (iso-oncotic) 25% (hyper-oncotic) solutionsIndications: Volume expansion (especially 5%), treatment edema hypoalbuminemia (e.g., liver disease, nephrotic syndrome), burns, support plasma exchangeIntravenous Immunoglobulin (IVIG)\nFunction: Provides passive immunity (contains broad spectrum IgG antibodies), also complex immunomodulatory effects\nIndications: Primary immunodeficiency diseases (PIDs), autoimmune disorders (e.g., Immune Thrombocytopenic Purpura - ITP, Guillain-Barré Syndrome - GBS, Chronic Inflammatory Demyelinating Polyneuropathy - CIDP), Kawasaki disease, prevention/treatment infections immunocompromised hosts. (Subcutaneous preparations - SCIG - also available)\nFunction: Provides passive immunity (contains broad spectrum IgG antibodies), also complex immunomodulatory effectsIndications: Primary immunodeficiency diseases (PIDs), autoimmune disorders (e.g., Immune Thrombocytopenic Purpura - ITP, Guillain-Barré Syndrome - GBS, Chronic Inflammatory Demyelinating Polyneuropathy - CIDP), Kawasaki disease, prevention/treatment infections immunocompromised hosts. (Subcutaneous preparations - SCIG - also available)Factor VIII Concentrate\nFunction: Essential coagulation factor intrinsic pathway\nIndications: Treatment prevention bleeding Hemophilia (Factor VIII deficiency). Largely replaced Cryoprecipitate/FFP indication due purity, standardized dosing, enhanced viral safety. (Recombinant Factor VIII also widely used)\nFunction: Essential coagulation factor intrinsic pathwayIndications: Treatment prevention bleeding Hemophilia (Factor VIII deficiency). Largely replaced Cryoprecipitate/FFP indication due purity, standardized dosing, enhanced viral safety. (Recombinant Factor VIII also widely used)Factor IX Concentrate\nFunction: Essential coagulation factor intrinsic pathway\nIndications: Treatment prevention bleeding Hemophilia B (Factor IX deficiency). (Recombinant Factor IX also widely used)\nFunction: Essential coagulation factor intrinsic pathwayIndications: Treatment prevention bleeding Hemophilia B (Factor IX deficiency). (Recombinant Factor IX also widely used)Prothrombin Complex Concentrates (PCCs)\nFunction: Contains varying combinations Vitamin K-dependent coagulation factors: Factor II (Prothrombin), Factor VII, Factor IX, Factor X. May also contain anticoagulant proteins C S\nTypes: 3-Factor PCCs (low Factor VII) 4-Factor PCCs\nIndications: Urgent reversal Warfarin (Coumadin) anticoagulation, treatment bleeding due deficiency one Vitamin K-dependent factors (e.g., liver disease, specific factor deficiencies single concentrates unavailable)\nFunction: Contains varying combinations Vitamin K-dependent coagulation factors: Factor II (Prothrombin), Factor VII, Factor IX, Factor X. May also contain anticoagulant proteins C STypes: 3-Factor PCCs (low Factor VII) 4-Factor PCCsIndications: Urgent reversal Warfarin (Coumadin) anticoagulation, treatment bleeding due deficiency one Vitamin K-dependent factors (e.g., liver disease, specific factor deficiencies single concentrates unavailable)Fibrinogen Concentrate (Factor Concentrate)\nFunction: Precursor fibrin, essential clot structure\nIndications: Treatment bleeding congenital afibrinogenemia/hypofibrinogenemia acquired hypofibrinogenemia (e.g., DIC, massive transfusion) Cryoprecipitate unavailable large volumes required\nFunction: Precursor fibrin, essential clot structureIndications: Treatment bleeding congenital afibrinogenemia/hypofibrinogenemia acquired hypofibrinogenemia (e.g., DIC, massive transfusion) Cryoprecipitate unavailable large volumes requiredAlpha-1 Antitrypsin (AAT)\nFunction: Inhibits proteases (like neutrophil elastase) lungs\nIndications: Augmentation therapy patients congenital AAT deficiency leading emphysema\nFunction: Inhibits proteases (like neutrophil elastase) lungsIndications: Augmentation therapy patients congenital AAT deficiency leading emphysemaAntithrombin () Concentrate (Formerly ATIII)\nFunction: Major inhibitor thrombin coagulation proteases (natural anticoagulant)\nIndications: Treatment hereditary deficiency, especially surgery pregnancy/delivery\nFunction: Major inhibitor thrombin coagulation proteases (natural anticoagulant)Indications: Treatment hereditary deficiency, especially surgery pregnancy/deliveryC1 Esterase Inhibitor (C1-INH) Concentrate\nFunction: Regulates activation complement contact (kallikrein-kinin) systems\nIndications: Treatment prevention attacks patients Hereditary Angioedema (HAE)\nFunction: Regulates activation complement contact (kallikrein-kinin) systemsIndications: Treatment prevention attacks patients Hereditary Angioedema (HAE)","code":""},{"path":"fractionation-products.html","id":"advantages-of-fractionation-products","chapter":"Fractionation Products","heading":"Advantages of Fractionation Products","text":"Targeted Therapy: Allows replacement specific deficient proteinEnhanced Viral Safety: Multiple viral inactivation/removal steps significantly reduce risk transmitting known virusesStandardized Dosing: Products defined concentrations activity levels (often International Units - IU), allowing precise dosingConvenience: Many lyophilized (freeze-dried powder), allowing room temperature refrigerated storage easier transport/reconstitution compared frozen plasma productsReduced Volume: Provides therapeutic dose much smaller volume plasma cryoprecipitate, reducing risk circulatory overload","code":""},{"path":"fractionation-products.html","id":"disadvantages-considerations","chapter":"Fractionation Products","heading":"Disadvantages / Considerations","text":"Cost: Often significantly expensive standard plasma componentsSource Material: Reliant consistent supply human plasma donationsPotential Reactions: Although highly purified, allergic anaphylactic reactions can still occurThrombotic Risk: Particularly associated PCCs due concentration procoagulant factorsTransmission Novel Pathogens: current methods effective known viruses, theoretical risk transmitting new prion agents (like vCJD) pooled plasma, although extremely low, completely eliminated","code":""},{"path":"fractionation-products.html","id":"key-terms-20","chapter":"Fractionation Products","heading":"Key Terms","text":"Plasma Fractionation: Industrial process separate purify proteins large pools plasmaSource Plasma: Plasma collected via apheresis specifically manufacturing derivativesRecovered Plasma: Plasma separated whole blood donations, sometimes used fractionationCohn Fractionation: Classic method using cold ethanol precipitationChromatography: Purification technique based differential binding proteins stationary phaseViral Inactivation/Removal: Mandatory steps manufacturing (e.g., solvent/detergent, pasteurization, nanofiltration) enhance safetyLyophilized: Freeze-dried powder stability reconstitutionInternational Unit (IU): Standardized measure biological activity many coagulation factors proteinsOncotic Pressure: Pressure exerted proteins (especially albumin) plasma helps hold fluid within blood vessels","code":""},{"path":"whole-blood.html","id":"whole-blood","chapter":"Whole Blood","heading":"Whole Blood","text":"Whole Blood (WB) original product used transfusion, use direct infusion become relatively uncommon developed countries, largely replaced component therapy. However, understanding Whole Blood essential historical context remains starting material blood components still niche applications, particularly massive hemorrhage situations","code":""},{"path":"whole-blood.html","id":"what-is-whole-blood","chapter":"Whole Blood","heading":"What is Whole Blood?","text":"Definition: Whole Blood essentially blood collected donor, containing primary constituents: Red Blood Cells (RBCs), Plasma, Platelets, White Blood Cells (WBCs), suspended anticoagulant-preservative solutionComposition: standard unit contains approximately:\n~450-500 mL donor blood\n~63-70 mL anticoagulant-preservative solution (e.g., CPD, CPDA-1)\nTotal Volume: ~513-570 mL\n~450-500 mL donor blood~63-70 mL anticoagulant-preservative solution (e.g., CPD, CPDA-1)Total Volume: ~513-570 mLKey Point: contains components roughly physiological proportions time collection","code":""},{"path":"whole-blood.html","id":"historical-context-the-shift-to-component-therapy","chapter":"Whole Blood","heading":"Historical Context & The Shift to Component Therapy","text":"Historically, WB transfusion option availableThe development plastic bags satellite containers advances centrifugation techniques allowed separation WB constituent parts (RBCs, Platelets, Plasma, Cryoprecipitate)Reasons Shift\nTargeted Therapy: Allows clinicians transfuse specific component patient needs, avoiding unnecessary volume constituents\nOptimal Storage: Different components require different storage conditions maximum viability function (e.g., RBCs 1-6°C, Platelets 20-24°C, Plasma frozen)\nReduced Wastage: Prevents discarding functional components one part WB unit needed\nConcentration: Allows concentrated doses (e.g., apheresis platelets, cryoprecipitate)\nReduced Adverse Reactions: Giving fewer unnecessary plasma proteins WBCs can reduce allergic febrile reactions\nTargeted Therapy: Allows clinicians transfuse specific component patient needs, avoiding unnecessary volume constituentsOptimal Storage: Different components require different storage conditions maximum viability function (e.g., RBCs 1-6°C, Platelets 20-24°C, Plasma frozen)Reduced Wastage: Prevents discarding functional components one part WB unit neededConcentration: Allows concentrated doses (e.g., apheresis platelets, cryoprecipitate)Reduced Adverse Reactions: Giving fewer unnecessary plasma proteins WBCs can reduce allergic febrile reactions","code":""},{"path":"whole-blood.html","id":"preparation-collection","chapter":"Whole Blood","heading":"Preparation (Collection)","text":"Collected via standard venipuncture primary collection bag containing anticoagulant-preservative solution (CPD, CPDA-1)Crucial Distinction: blood donations start Whole Blood collection, vast majority processed components within hours. Units intended transfusion Whole Blood specifically designated stored ","code":""},{"path":"whole-blood.html","id":"indications-for-transfusion-5","chapter":"Whole Blood","heading":"Indications for Transfusion","text":"use Whole Blood direct transfusion now limited primarily :Massive Hemorrhage / Trauma Resuscitation: Especially military settings trauma centers adopting “balanced resuscitation” strategies. rationale replace lost blood product containing oxygen-carrying capacity (RBCs), volume clotting factors (plasma), platelets, potentially closer physiological ratios combining separate components. Often, “fresh” whole blood (collected <24 hours prior) desired settings maximize platelet factor function, though presents significant logistical challengesNeonatal Exchange Transfusion: Sometimes used, though often reconstituted WB (RBCs + FFP) RBCs alone usedResource-Limited Settings: May used commonly capacity component preparation limited","code":""},{"path":"whole-blood.html","id":"storage-and-expiration-5","chapter":"Whole Blood","heading":"Storage and Expiration","text":"key limitation Whole Blood:Storage Temperature: 1°C 6°C (RBCs)Expiration: Determined anticoagulant-preservative solution:\nCPD CP2D: 21 days\nCPDA-1: 35 days\nCPD CP2D: 21 daysCPDA-1: 35 daysCritical Limitations due Storage Temperature\nPlatelet Function: Platelets rapidly lose viability function stored 1-6°C. 24-48 hours, stored WB contains functional platelets\nLabile Coagulation Factors: Factors V VIII degrade significantly refrigerated temperatures time. Stored WB poor source factors compared FFP\nWBC Viability: Leukocytes also lose function, though presence contributes risks like alloimmunization FNHTRs\nPlatelet Function: Platelets rapidly lose viability function stored 1-6°C. 24-48 hours, stored WB contains functional plateletsLabile Coagulation Factors: Factors V VIII degrade significantly refrigerated temperatures time. Stored WB poor source factors compared FFPWBC Viability: Leukocytes also lose function, though presence contributes risks like alloimmunization FNHTRs","code":""},{"path":"whole-blood.html","id":"advantages-in-specific-contexts","chapter":"Whole Blood","heading":"Advantages (in Specific Contexts)","text":"Balanced Resuscitation: massive hemorrhage, potentially provides physiologically balanced replacement fluid compared crystalloids just RBCs initiallyLogistical Simplicity: One product store transfuse instead coordinating three (RBCs, plasma, platelets) – relevant emergencies remote settingsReduced Donor Exposure (Potentially): Receiving one WB unit exposes recipient one donor, whereas receiving individual components might involve multiple donors (though apheresis components mitigate )","code":""},{"path":"whole-blood.html","id":"disadvantages-why-component-therapy-is-preferred","chapter":"Whole Blood","heading":"Disadvantages (Why Component Therapy is Preferred)","text":"Suboptimal Component Viability: Platelets labile factors (V, VIII) poorly preserved 1-6°CComponent Wastage: Transfusing unnecessary components (e.g., giving plasma non-functional platelets patient needs RBCs)Circulatory Overload Risk: Larger infusion volume compared packed RBCs, potentially problematic patients sensitive volume (e.g., cardiac renal patients)Increased Risk Certain Reactions: Contains plasma proteins (higher risk allergic reactions) non-functional leukocytes (higher risk FNHTRs, alloimmunization, CMV transmission) compared leukoreduced, plasma-reduced componentsStorage Incompatibility: single temperature optimally preserves components simultaneously","code":""},{"path":"whole-blood.html","id":"modifications","chapter":"Whole Blood","heading":"Modifications","text":"Leukoreduction: Whole Blood can leukoreduced using appropriate filters, though less common LR componentsIrradiation: Can irradiated indications RBCs/Platelets (preventing TA-GVHD). Irradiation imposes expiration constraint (original outdate 28 days post-irradiation, whichever sooner)","code":""},{"path":"whole-blood.html","id":"administration-6","chapter":"Whole Blood","heading":"Administration","text":"Compatibility: MUST ABO identical recipient. means donor’s red cells must compatible recipient’s plasma, donor’s plasma must compatible recipient’s red cells. Rh compatibility also requiredCrossmatch: crossmatch required transfusionFiltration: Administered standard blood filter (170-260 microns)Infusion Time: Must completed within 4 hours removal controlled storage","code":""},{"path":"whole-blood.html","id":"potential-risks-adverse-reactions-5","chapter":"Whole Blood","heading":"Potential Risks / Adverse Reactions","text":"Includes risks associated components:Hemolytic Transfusion Reactions (Acute Delayed)Febrile Non-Hemolytic Transfusion Reactions (FNHTRs)Allergic Reactions (Mild Anaphylaxis)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Septic Reactions (Bacterial Contamination)Alloimmunization (RBC, HLA, Platelet antigens)Disease TransmissionTA-GVHD (irradiated indicated)","code":""},{"path":"whole-blood.html","id":"key-terms-21","chapter":"Whole Blood","heading":"Key Terms","text":"Component Therapy: practice transfusing specific blood components (RBCs, Platelets, Plasma) rather Whole BloodAnticoagulant-Preservative Solution: Solutions like CPD, CPDA-1 used collection bagsMassive Hemorrhage: Acute, severe blood loss requiring large-volume transfusionBalanced Resuscitation: Transfusion strategy aiming replace lost blood components (WB) ratio approximating physiological levelsLabile Factors: Coagulation Factors V VIII, degrade relatively quickly refrigerated temperaturesABO Identical: Donor recipient ABO group (required WB transfusion)","code":""},{"path":"washed-rbcs.html","id":"washed-rbcs","chapter":"Washed RBCs","heading":"Washed RBCs","text":"Washed Red Blood Cells, modification performed standard RBC units remove majority plasma constituents","code":""},{"path":"washed-rbcs.html","id":"what-are-washed-red-blood-cells","chapter":"Washed RBCs","heading":"What Are Washed Red Blood Cells?","text":"Definition: Washed Red Blood Cells RBC units undergone procedure involving sequential additions sterile isotonic saline (0.9% NaCl) followed centrifugation removal supernatant saline/plasma mixture. final product consists red blood cells suspended primarily salineGoal: remove much original plasma (/additive solution) possible RBC unit","code":""},{"path":"washed-rbcs.html","id":"preparation-method-the-washing-process","chapter":"Washed RBCs","heading":"Preparation Method (The Washing Process)","text":"unit standard Red Blood Cells (usually Leukoreduced) selectedUsing automated cell washer manual methods (less common), sterile 0.9% saline added unitThe unit mixed centrifugedThe supernatant fluid (saline mixed original plasma/additive solution) expressed discardedSteps 2-4 repeated multiple times (typically 2-3 wash cycles) achieve significant removal original supernatantAfter final wash, RBCs resuspended small volume sterile 0.9% salineCritical Point process typically involves connecting bags tubing, often creating “open system” breaches original sterility unit","code":""},{"path":"washed-rbcs.html","id":"indications-for-use-why-wash-rbcs","chapter":"Washed RBCs","heading":"Indications for Use (Why Wash RBCs?)","text":"Washing performed specific clinical situations plasma component RBC unit problematic recipient:Prevention Severe Allergic Transfusion Reactions: primary indication\nPatients history recurrent, severe allergic reactions (e.g., anaphylaxis, severe urticaria, bronchospasm) attributed plasma proteins transfused blood\nSpecifically indicated patients IgA deficiency clinically significant anti-IgA antibodies. Transfusing plasma containing IgA patients can trigger severe anaphylactic reactions. Washing removes vast majority IgA unit\nPatients history recurrent, severe allergic reactions (e.g., anaphylaxis, severe urticaria, bronchospasm) attributed plasma proteins transfused bloodSpecifically indicated patients IgA deficiency clinically significant anti-IgA antibodies. Transfusing plasma containing IgA patients can trigger severe anaphylactic reactions. Washing removes vast majority IgA unitPrevention Hyperkalemic Complications Transfusion\nStored RBCs leak potassium (K+) supernatant. Older units can high supernatant K+ levels\nWashing removes high-potassium supernatant\nIndicated patients high risk adverse effects potassium load, :\nNeonates (especially premature infants receiving large-volume exchange transfusions)\nPatients pre-existing hyperkalemia severe renal impairment undergoing large-volume rapid transfusions\n\nNote: Using fresh RBCs (e.g., <7-10 days old) often alternative strategy minimize potassium load\nStored RBCs leak potassium (K+) supernatant. Older units can high supernatant K+ levelsWashing removes high-potassium supernatantIndicated patients high risk adverse effects potassium load, :\nNeonates (especially premature infants receiving large-volume exchange transfusions)\nPatients pre-existing hyperkalemia severe renal impairment undergoing large-volume rapid transfusions\nNeonates (especially premature infants receiving large-volume exchange transfusions)Patients pre-existing hyperkalemia severe renal impairment undergoing large-volume rapid transfusionsNote: Using fresh RBCs (e.g., <7-10 days old) often alternative strategy minimize potassium load","code":""},{"path":"washed-rbcs.html","id":"storage-and-expiration-6","chapter":"Washed RBCs","heading":"Storage and Expiration","text":"major limitation washed RBCs:Storage Temperature: 1°C 6°C (standard RBCs)Expiration: Due washing process typically performed open system, risk bacterial contamination increased. Therefore, expiration date significantly shortened:\n24 hours: time washing procedure completed (stored 1-6°C)\n24 hours: time washing procedure completed (stored 1-6°C)","code":""},{"path":"washed-rbcs.html","id":"properties-of-washed-rbcs","chapter":"Washed RBCs","heading":"Properties of Washed RBCs","text":"Compared standard RBC units, washed RBCs :Minimal Plasma: plasma proteins (including IgA, antibodies, cytokines) removedMinimal Additive Solution: solution also washed awayReduced Potassium: Accumulated extracellular potassium removedReduced Leukocytes & Platelets: washing process also removes residual WBCs platelets (though pre-storage leukoreduction usually performed initially anyway)Slight RBC Loss: washing process inevitably causes loss red blood cells (typically around 10-20%)","code":""},{"path":"washed-rbcs.html","id":"administration-7","chapter":"Washed RBCs","heading":"Administration","text":"Compatibility: Standard ABO/Rh typing crossmatch procedures requiredFiltration: Administer standard blood filter (170-260 microns)Infusion Time: Must completed within 4 hours spiking bag removal controlled 1-6°C storage (well within 24-hour post-wash expiration)","code":""},{"path":"washed-rbcs.html","id":"advantages-1","chapter":"Washed RBCs","heading":"Advantages","text":"Prevents Severe Allergic Reactions: Effectively removes plasma proteins responsible anaphylaxis (especially IgA)Reduces Potassium Load: Removes accumulated potassium, safer susceptible patients receiving large/rapid transfusionsRemoves Plasma Constituents: Can remove donor antibodies cytokines (though leukoreduction targeted cytokine removal)","code":""},{"path":"washed-rbcs.html","id":"disadvantages-1","chapter":"Washed RBCs","heading":"Disadvantages","text":"Short Expiration (24 hours): Major logistical challenge, requires washing close time anticipated transfusion, increases wastage usedOpen System Risk: Potential bacterial contamination processingTime-Consuming & Labor-Intensive: Requires specialized equipment staff time (approx. 30-60 minutes per unit)Costly: Adds significant cost compared standard RBC unitsRBC Loss: Reduces effective dose RBCs delivered","code":""},{"path":"washed-rbcs.html","id":"alternatives","chapter":"Washed RBCs","heading":"Alternatives","text":"preventing allergic reactions IgA deficient patients anti-IgA: Using blood products IgA deficient donors (rare difficult source)reducing potassium load: Using fresh RBC units (<7-10 days old)","code":""},{"path":"washed-rbcs.html","id":"key-terms-22","chapter":"Washed RBCs","heading":"Key Terms","text":"Washing: Process removing plasma/supernatant cellular components using saline exchangeSupernatant: liquid portion surrounding cells blood component unitIgA Deficiency: Condition individual lacks Immunoglobulin AAnti-IgA: Antibodies IgA, found IgA-deficient individuals, capable causing anaphylaxis upon exposure IgAHyperkalemia: High levels potassium bloodOpen System: Processing method sterility component may compromised, leading shortened expirationAutomated Cell Washer: Equipment used perform washing procedure efficiently","code":""},{"path":"rejuvenated-rbcs.html","id":"rejuvenated-rbcs","chapter":"Rejuvenated RBCs","heading":"Rejuvenated RBCs","text":"fascinating, though commonly used, process aimed turning back metabolic clock stored red cells, least partially! Think like giving older RBCs energy drink head transfusion","code":""},{"path":"rejuvenated-rbcs.html","id":"what-are-rejuvenated-red-blood-cells","chapter":"Rejuvenated RBCs","heading":"What Are Rejuvenated Red Blood Cells?","text":"Definition: Rejuvenated RBCs units stored Red Blood Cells treated vitro (lab) special chemical solution designed restore intracellular levels ATP (adenosine triphosphate) 2,3-Diphosphoglycerate (2,3-DPG), normally decline storageGoal: reverse key aspects RBC “storage lesion,” specifically metabolic decline, potentially improving function viability cells, especially nearing expiration date","code":""},{"path":"rejuvenated-rbcs.html","id":"the-rejuvenation-process","chapter":"Rejuvenated RBCs","heading":"The Rejuvenation Process","text":"isn’t just adding drop something; ’s specific laboratory procedure:Selection RBC Unit Often, units nearing original expiration date (e.g., > 30 days old) chosen, although fresher units can also rejuvenated, particularly intended freezingAddition Rejuvenation Solution sterile, FDA-approved rejuvenation solution added RBC unit. solutions typically contain substrates fuel RBC metabolic pathways:\nPyruvate\nInosine: (precursor ATP synthesis via alternative pathways)\nPhosphate\nAdenine\n(Often referred collectively acronym PIPA)\nPyruvateInosine: (precursor ATP synthesis via alternative pathways)PhosphateAdenine(Often referred collectively acronym PIPA)Incubation mixture RBCs rejuvenation solution incubated, usually water bath 37°C, specific period (often around 1 hour) allow metabolic restoration occurPost-Incubation Processing (CRITICAL STEP)\nrejuvenation solution contains substances (like inosine) safe direct intravenous infusion process creates hypertonic environment\nTherefore, incubation, rejuvenated RBCs MUST processed :\nWashing: common next step extensively wash RBCs using automated cell washer sterile saline. removes rejuvenation solution chemicals accumulated metabolic byproducts. washing step makes unit OPEN SYSTEM.\nGlycerolization Freezing: Alternatively, rejuvenated RBCs can glycerolized frozen immediately rejuvenation (following standard freezing protocols). preserves restored ATP/2,3-DPG levels long-term storage. units require thawing deglycerolization (washing) transfusion\n\nrejuvenation solution contains substances (like inosine) safe direct intravenous infusion process creates hypertonic environmentTherefore, incubation, rejuvenated RBCs MUST processed :\nWashing: common next step extensively wash RBCs using automated cell washer sterile saline. removes rejuvenation solution chemicals accumulated metabolic byproducts. washing step makes unit OPEN SYSTEM.\nGlycerolization Freezing: Alternatively, rejuvenated RBCs can glycerolized frozen immediately rejuvenation (following standard freezing protocols). preserves restored ATP/2,3-DPG levels long-term storage. units require thawing deglycerolization (washing) transfusion\nWashing: common next step extensively wash RBCs using automated cell washer sterile saline. removes rejuvenation solution chemicals accumulated metabolic byproducts. washing step makes unit OPEN SYSTEM.Glycerolization Freezing: Alternatively, rejuvenated RBCs can glycerolized frozen immediately rejuvenation (following standard freezing protocols). preserves restored ATP/2,3-DPG levels long-term storage. units require thawing deglycerolization (washing) transfusion","code":""},{"path":"rejuvenated-rbcs.html","id":"indications-for-use-purpose","chapter":"Rejuvenated RBCs","heading":"Indications for Use / Purpose","text":"Rejuvenation routine procedure. use limited specific situations:Salvaging Near-Expiry RBC Units: primary historical use “rescue” valuable RBC units (especially rare phenotypes) close outdate restoring metabolic function, allowing used frozenImproving Oxygen Delivery Characteristics (Restoring 2,3-DPG): Restoring 2,3-DPG levels lowers hemoglobin’s oxygen affinity, theoretically improving oxygen release tissues immediately transfusion. might considered specific patient populations immediate oxygen offloading critical (e.g., massive transfusion, certain cardiac surgeries, neonatal exchange transfusions), although clinical benefit using fresh, non-rejuvenated units debated definitively proven scenariosEnhancing Quality Cryopreservation (Freezing): Rejuvenating RBCs freezing can improve post-thaw viability quality","code":""},{"path":"rejuvenated-rbcs.html","id":"properties-of-rejuvenated-and-washed-rbcs","chapter":"Rejuvenated RBCs","heading":"Properties of Rejuvenated (and Washed) RBCs","text":"Restored ATP/2,3-DPG: Levels typically restored , even exceed, found fresh bloodImproved Oxygen Release: Lower oxygen affinity due restored 2,3-DPGStorage Lesion Effects Remain: Rejuvenation primarily addresses ATP/2,3-DPG; fully reverse storage-related changes like membrane loss, shape changes, oxidative damageWashed Product: final transfusable product (unless frozen) RBCs suspended saline, essentially free plasma, additive solution, rejuvenation chemicals. also leukocyte-reduced (original unit ) low potassium levels","code":""},{"path":"rejuvenated-rbcs.html","id":"storage-and-expiration-7","chapter":"Rejuvenated RBCs","heading":"Storage and Expiration","text":"dictated mandatory post-rejuvenation processing:Rejuvenation Washing (Open System)\nStorage Temperature: 1°C 6°C\nExpiration: 24 hours time washing (due open system bacterial risk)\nStorage Temperature: 1°C 6°CExpiration: 24 hours time washing (due open system bacterial risk)Rejuvenation, Freezing, Thawing, Deglycerolization (Open System)\nFrozen Storage: 10 years ≤ -65°C\nPost-Thaw/Deglycerolization Storage: 24 hours 1-6°C\nFrozen Storage: 10 years ≤ -65°CPost-Thaw/Deglycerolization Storage: 24 hours 1-6°C","code":""},{"path":"rejuvenated-rbcs.html","id":"administration-8","chapter":"Rejuvenated RBCs","heading":"Administration","text":"Compatibility: Standard ABO/Rh typing crossmatch procedures requiredFiltration: Administer standard blood filter (170-260 microns)Infusion Time: Must completed within 4 hours spiking bag removal controlled 1-6°C storage (within 24-hour post-wash expiration)","code":""},{"path":"rejuvenated-rbcs.html","id":"advantages-2","chapter":"Rejuvenated RBCs","heading":"Advantages","text":"Restores Key Metabolites: Effectively increases ATP 2,3-DPG levelsPotential Improved Oxygen Delivery: Theoretically beneficial specific high-need situationsSalvages Near-Expiry Units: Reduces wastage valuable unitsImproves Quality Freezing: Leads better post-thaw recovery","code":""},{"path":"rejuvenated-rbcs.html","id":"disadvantages-limitations","chapter":"Rejuvenated RBCs","heading":"Disadvantages / Limitations","text":"Complex Costly Process: Requires special solutions, incubation equipment, mandatory extensive washing (similar deglycerolization)Time-Consuming: suitable urgent transfusion needsOpen System Risk: Washing step increases potential bacterial contaminationShort Post-Wash Shelf Life (24 hours): Significant logistical constraint, requires careful coordinationLimited Proven Clinical Benefit: Widespread use supported strong evidence demonstrating superior outcomes compared standard transfusion practices patientsAvailability: Rejuvenation solutions protocols implemented blood centers transfusion services","code":""},{"path":"rejuvenated-rbcs.html","id":"key-terms-23","chapter":"Rejuvenated RBCs","heading":"Key Terms","text":"Rejuvenation: vitro process restoring ATP 2,3-DPG levels stored RBCsStorage Lesion: sum biochemical morphological changes occurring stored RBCsATP (Adenosine Triphosphate): main energy currency cells2,3-DPG (2,3-Diphosphoglycerate): Molecule regulates hemoglobin’s oxygen affinityRejuvenation Solution (PIPA): Solution containing Pyruvate, Inosine, Phosphate, Adenine used restore RBC metabolismWashing: Mandatory post-rejuvenation step remove solution chemicals, typically creating open systemCryopreservation: Freezing cells long-term storage (often follows rejuvenation)Open System: Processing method potentially compromising sterility, leading shortened expiration","code":""},{"path":"irradiated-components.html","id":"irradiated-components","chapter":"Irradiated Components","heading":"Irradiated Components","text":"section covers Irradiated Blood Components, critical modification performed prevent rare devastating complication transfusion: Transfusion-Associated Graft-versus-Host Disease (TA-GVHD)","code":""},{"path":"irradiated-components.html","id":"what-is-irradiation-of-blood-components","chapter":"Irradiated Components","heading":"What is Irradiation of Blood Components?","text":"Definition: process exposing cellular blood components (Red Blood Cells, Platelets, Granulocytes, Whole Blood) measured dose ionizing radiation (gamma rays X-rays) transfusionMechanism: radiation damages DNA donor T-lymphocytes present within blood component. renders lymphocytes incapable proliferating (dividing multiplying) transfused recipientGoal: prevent viable donor T-lymphocytes engrafting recipient, multiplying, attacking recipient’s tissues (TA-GVHD)Important Distinction: Irradiation sterilize blood product; kill bacteria, viruses, parasites. sole purpose inactivate donor T-lymphocytes","code":""},{"path":"irradiated-components.html","id":"why-irradiate-the-threat-of-ta-gvhd","chapter":"Irradiated Components","heading":"Why Irradiate? The Threat of TA-GVHD","text":"Transfusion-Associated Graft-versus-Host Disease (TA-GVHD): rare usually fatal complication transfusion\nPathophysiology: occurs viable donor T-lymphocytes transfused recipient recognize eliminate . donor lymphocytes engraft, proliferate, mount immune attack recipient’s “foreign” tissues (skin, liver, gut, bone marrow)\nRisk Factors: TA-GVHD likely :\nrecipient significantly immunocompromised (e.g., congenital immunodeficiencies, hematopoietic stem cell transplant recipients, patients receiving intense chemotherapy/immunosuppression)\ndonor recipient share HLA haplotypes (genetic markers immune system), making harder recipient’s immune system recognize donor lymphocytes foreign. particularly relevant directed donations blood relatives (parents, siblings, children)\n\nPathophysiology: occurs viable donor T-lymphocytes transfused recipient recognize eliminate . donor lymphocytes engraft, proliferate, mount immune attack recipient’s “foreign” tissues (skin, liver, gut, bone marrow)Risk Factors: TA-GVHD likely :\nrecipient significantly immunocompromised (e.g., congenital immunodeficiencies, hematopoietic stem cell transplant recipients, patients receiving intense chemotherapy/immunosuppression)\ndonor recipient share HLA haplotypes (genetic markers immune system), making harder recipient’s immune system recognize donor lymphocytes foreign. particularly relevant directed donations blood relatives (parents, siblings, children)\nrecipient significantly immunocompromised (e.g., congenital immunodeficiencies, hematopoietic stem cell transplant recipients, patients receiving intense chemotherapy/immunosuppression)donor recipient share HLA haplotypes (genetic markers immune system), making harder recipient’s immune system recognize donor lymphocytes foreign. particularly relevant directed donations blood relatives (parents, siblings, children)Prevention: Since TA-GVHD difficult treat often fatal, prevention irradiation cellular components -risk recipients standard care","code":""},{"path":"irradiated-components.html","id":"indications-for-irradiation-who-needs-irradiated-blood","chapter":"Irradiated Components","heading":"Indications for Irradiation (Who Needs Irradiated Blood?)","text":"Irradiation indicated patients whose immune systems may unable eliminate transfused donor lymphocytes ’s increased risk shared HLA types:Severely Immunocompromised Patients\nCongenital immunodeficiency syndromes (e.g., SCID)\nHematopoietic Progenitor Cell (HPC) / Stem Cell Transplant recipients (autologous allogeneic)\nPatients receiving intense immunosuppressive therapy (e.g., certain chemotherapy regimens, anti-thymocyte globulin)\nPatients Hodgkin lymphoma\nCongenital immunodeficiency syndromes (e.g., SCID)Hematopoietic Progenitor Cell (HPC) / Stem Cell Transplant recipients (autologous allogeneic)Patients receiving intense immunosuppressive therapy (e.g., certain chemotherapy regimens, anti-thymocyte globulin)Patients Hodgkin lymphomaFetal Neonatal Transfusions\nIntrauterine transfusions\nNeonatal exchange transfusions\nPremature infants (especially low birth weight) - policies vary, often irradiated\nIntrauterine transfusionsNeonatal exchange transfusionsPremature infants (especially low birth weight) - policies vary, often irradiatedDirected Donations Blood Relatives: Mandatory first- second-degree relatives due increased likelihood shared HLA haplotypesHLA-Matched Components: components (especially platelets) specifically selected HLA-matched recipient, irradiation required recipient’s immune system may recognize donor lymphocytes foreignGranulocyte Transfusions: Mandatory due high number viable lymphocytes presentNote Policies may vary slightly institutions, represent core indications","code":""},{"path":"irradiated-components.html","id":"the-irradiation-process","chapter":"Irradiated Components","heading":"The Irradiation Process","text":"Equipment: Performed using dedicated blood irradiator. devices contain either:\nradioactive source (commonly Cesium-137 Cobalt-60) emitting gamma rays\nX-ray generating system\nradioactive source (commonly Cesium-137 Cobalt-60) emitting gamma raysAn X-ray generating systemDose: standard required dose :\n25 Gray (Gy): delivered central portion unit\nminimum dose 15 Gy delivered part unit\n25 Gray (Gy): delivered central portion unitA minimum dose 15 Gy delivered part unitVerification: irradiation indicator label usually affixed unit irradiation. label undergoes visible color change upon exposure required radiation dose, providing visual confirmation process performed","code":""},{"path":"irradiated-components.html","id":"which-components-are-irradiated","chapter":"Irradiated Components","heading":"Which Components Are Irradiated?","text":"Irradiation necessary components containing significant numbers viable T-lymphocytes:Red Blood Cells (RBCs)Platelets: (Whole Blood Derived Apheresis)Granulocytes: (Mandatory units)Whole BloodComponents Requiring IrradiationThese components essentially acellular contain non-viable lymphocytes:Fresh Frozen Plasma (FFP)Plasma Frozen within 24 hours (PF24)Cryoprecipitated AHFCryoprecipitate-Reduced PlasmaPlasma Fractionation Products (Albumin, IVIG, Factor Concentrates)","code":""},{"path":"irradiated-components.html","id":"impact-of-irradiation-on-components-especially-rbcs","chapter":"Irradiated Components","heading":"Impact of Irradiation on Components (Especially RBCs)","text":"necessary safety, irradiation effects, particularly Red Blood Cells:RBC Membrane Damage: radiation causes damage RBC membraneIncreased Potassium Leakage: membrane damage leads accelerated rate potassium (K+) leaking RBCs supernatant plasma/additive solutionPotentially Reduced Viability: May slightly decrease 24-hour post-transfusion survival RBCs, though usually still well acceptable minimumImpact Expiration Date (CRITICAL): Due increased potassium leak potential impact viability, expiration date irradiated Red Blood Cells changed:\nunit expires original expiration date 28 days date irradiation, WHICHEVER COMES FIRST\nExample 1: RBC unit 42-day original expiry irradiated Day 10. new expiry date Day 10 + 28 days = Day 38 (sooner original Day 42)\nExample 2: RBC unit 42-day original expiry irradiated Day 30. new expiry date Day 30 + 28 days = Day 58, original expiry Day 42. , unit expires Day 42 (whichever sooner)\nunit expires original expiration date 28 days date irradiation, WHICHEVER COMES FIRSTExample 1: RBC unit 42-day original expiry irradiated Day 10. new expiry date Day 10 + 28 days = Day 38 (sooner original Day 42)Example 2: RBC unit 42-day original expiry irradiated Day 30. new expiry date Day 30 + 28 days = Day 58, original expiry Day 42. , unit expires Day 42 (whichever sooner)Platelets: Irradiation minimal impact platelet function storage. original 5-day (7-day) expiration date retained irradiated platelets","code":""},{"path":"irradiated-components.html","id":"storage-and-expiration-post-irradiation","chapter":"Irradiated Components","heading":"Storage and Expiration (Post-Irradiation)","text":"RBCs: Store 1-6°C. Expiry original date 28 days post-irradiation, whichever sooner. Must check label carefully!Platelets: Store 20-24°C agitation. Original 5- 7-day expiry appliesGranulocytes: Store 20-24°C without agitation. Original 24-hour expiry applies","code":""},{"path":"irradiated-components.html","id":"administration-9","chapter":"Irradiated Components","heading":"Administration","text":"special administration procedures required specifically unit irradiatedStandard procedures apply: ABO/Rh compatibility, crossmatch (RBCs/Granulocytes), standard blood filter, infusion within 4 hours","code":""},{"path":"irradiated-components.html","id":"key-terms-24","chapter":"Irradiated Components","heading":"Key Terms","text":"Irradiation: Treatment ionizing radiation (gamma X-rays)TA-GVHD (Transfusion-Associated Graft-versus-Host Disease): Complication donor T-lymphocytes attack recipient tissuesT-Lymphocyte: Type white blood cell responsible cell-mediated immunity; inactivated irradiationImmunocompromised: weakened immune systemHLA (Human Leukocyte Antigen): Immune system markers cells; shared haplotypes increase TA-GVHD risk related donorsGray (Gy): Unit absorbed radiation doseBlood Irradiator: Device used irradiate blood componentsIrradiation Indicator: Label changes color visually confirm irradiation","code":""},{"path":"hematopoietic-progenitors.html","id":"hematopoietic-progenitors","chapter":"Hematopoietic Progenitors","heading":"Hematopoietic Progenitors","text":"section covers Hematopoietic Progenitor Cells (HPCs), also commonly referred stem cells. infusion technically form cellular therapy transplantation rather traditional transfusion, HPCs collected, processed, stored, often managed protocols closely related blood banking transfusion medicine. represent source blood cells","code":""},{"path":"hematopoietic-progenitors.html","id":"what-are-hematopoietic-progenitor-cells-hpcs","chapter":"Hematopoietic Progenitors","heading":"What Are Hematopoietic Progenitor Cells (HPCs)?","text":"Definition: HPCs multipotent stem cells found primarily bone marrow (smaller numbers peripheral blood umbilical cord blood) remarkable ability :\nSelf-renew: Make copies \nDifferentiate: Develop types mature blood immune cells (red blood cells, white blood cells including lymphocytes granulocytes, platelets)\nSelf-renew: Make copies themselvesDifferentiate: Develop types mature blood immune cells (red blood cells, white blood cells including lymphocytes granulocytes, platelets)Function Therapy: goal HPC transplantation replace patient’s diseased damaged bone marrow healthy stem cells, allowing restoration normal hematopoiesis (blood cell production) immune function","code":""},{"path":"hematopoietic-progenitors.html","id":"sources-of-hpcs","chapter":"Hematopoietic Progenitors","heading":"Sources of HPCs","text":"HPCs transplantation can obtained three primary sources:Bone Marrow (HPC-M)\nCollection Method: Traditionally collected via bone marrow harvest, surgical procedure performed general spinal anesthesia. Multiple aspirations taken donor’s posterior iliac crests (hip bones)\nCharacteristics: Rich source HPCs marrow stromal cells. Requires anesthesia donor\nCollection Method: Traditionally collected via bone marrow harvest, surgical procedure performed general spinal anesthesia. Multiple aspirations taken donor’s posterior iliac crests (hip bones)Characteristics: Rich source HPCs marrow stromal cells. Requires anesthesia donorPeripheral Blood (PBSC / HPC-)\nCollection Method: Collected via apheresis (leukapheresis) donor undergone mobilization. Mobilization involves administering injections Granulocyte Colony-Stimulating Factor (G-CSF), sometimes Plerixafor, several days. G-CSF stimulates bone marrow produce large numbers HPCs release peripheral bloodstream\nCharacteristics: Now common source adult allogeneic autologous transplants. Yields high numbers HPCs. Donor avoids anesthesia experiences side effects G-CSF (bone pain, flu-like symptoms). Faster neutrophil platelet engraftment post-transplant compared marrow, potentially higher rates chronic Graft-versus-Host Disease (GVHD) allogeneic settings\nCollection Method: Collected via apheresis (leukapheresis) donor undergone mobilization. Mobilization involves administering injections Granulocyte Colony-Stimulating Factor (G-CSF), sometimes Plerixafor, several days. G-CSF stimulates bone marrow produce large numbers HPCs release peripheral bloodstreamCharacteristics: Now common source adult allogeneic autologous transplants. Yields high numbers HPCs. Donor avoids anesthesia experiences side effects G-CSF (bone pain, flu-like symptoms). Faster neutrophil platelet engraftment post-transplant compared marrow, potentially higher rates chronic Graft-versus-Host Disease (GVHD) allogeneic settingsUmbilical Cord Blood (UCB / HPC-C)\nCollection Method: Collected umbilical cord placenta birth baby. blood remaining cord vessels drained collection bag containing anticoagulant\nCharacteristics: Rich primitive HPCs. Collected non-invasively. Lower risk transmitting infections like CMV. Less stringent HLA matching may acceptable. Lower risk/severity GVHD. Main limitations smaller cell dose (often insufficient larger adults unless using double cord units) slower engraftment time (longer period neutropenia post-transplant)\nCollection Method: Collected umbilical cord placenta birth baby. blood remaining cord vessels drained collection bag containing anticoagulantCharacteristics: Rich primitive HPCs. Collected non-invasively. Lower risk transmitting infections like CMV. Less stringent HLA matching may acceptable. Lower risk/severity GVHD. Main limitations smaller cell dose (often insufficient larger adults unless using double cord units) slower engraftment time (longer period neutropenia post-transplant)","code":""},{"path":"hematopoietic-progenitors.html","id":"indications-for-hpc-transplantation","chapter":"Hematopoietic Progenitors","heading":"Indications for HPC Transplantation","text":"HPC transplantation potentially curative therapy range malignant non-malignant conditions:Malignant Diseases: Acute chronic leukemias, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), multiple myeloma, lymphomas (Hodgkin non-Hodgkin), neuroblastomaNon-Malignant Diseases: Aplastic anemia, Fanconi anemia, Sickle cell disease, Thalassemia, severe combined immunodeficiency (SCID) inherited immune disorders, inherited metabolic disorders","code":""},{"path":"hematopoietic-progenitors.html","id":"types-of-hpc-transplants","chapter":"Hematopoietic Progenitors","heading":"Types of HPC Transplants","text":"Allogeneic: HPCs collected donor (related unrelated) infused recipient (patient)Autologous: HPCs collected patient earlier treatment (e.g., remission), stored (usually cryopreserved), re-infused patient receives high-dose chemotherapy/radiotherapy intended eradicate underlying diseaseSyngeneic: HPCs collected identical twin donor","code":""},{"path":"hematopoietic-progenitors.html","id":"donor-selection-matching-allogeneic","chapter":"Hematopoietic Progenitors","heading":"Donor Selection & Matching (Allogeneic)","text":"HLA Matching: CRITICAL allogeneic transplantation. Human Leukocyte Antigens (HLA) proteins cell surfaces immune system uses recognize “self” vs. “non-self.” Close matching donor recipient key HLA loci (HLA-, -B, -C, -DRB1 important) essential minimize risk :\nGraft Rejection: Recipient’s immune system attacking donor cells\nGraft-versus-Host Disease (GVHD): Donor immune cells (T-lymphocytes) attacking recipient’s tissues\nGraft Rejection: Recipient’s immune system attacking donor cellsGraft-versus-Host Disease (GVHD): Donor immune cells (T-lymphocytes) attacking recipient’s tissuesDonor Sources: Matched related donor (MRD - sibling), matched unrelated donor (MUD - found registries like NMDP/Match), mismatched related/unrelated donor, haploidentical donor (usually parent/child, half-matched), umbilical cord blood","code":""},{"path":"hematopoietic-progenitors.html","id":"processing-storage-and-expiration","chapter":"Hematopoietic Progenitors","heading":"Processing, Storage, and Expiration","text":"HPC products undergo specialized processing storage:Processing: May include:\nVolume reduction: Removing excess plasma saline\nRed Blood Cell depletion: Especially important major ABO incompatibility donor recipient (prevent acute hemolysis upon infusion)\nPlasma reduction: minor ABO incompatibility\nCell selection/depletion (less common): E.g., CD34+ selection (enrich stem cells), T-cell depletion (reduce GVHD risk, may increase relapse/infection risk)\nQuality Control: Includes cell counts (Total Nucleated Cells - TNC, CD34+ cell count - key measure stem cell dose), viability testing, sterility cultures\nVolume reduction: Removing excess plasma salineRed Blood Cell depletion: Especially important major ABO incompatibility donor recipient (prevent acute hemolysis upon infusion)Plasma reduction: minor ABO incompatibilityCell selection/depletion (less common): E.g., CD34+ selection (enrich stem cells), T-cell depletion (reduce GVHD risk, may increase relapse/infection risk)Quality Control: Includes cell counts (Total Nucleated Cells - TNC, CD34+ cell count - key measure stem cell dose), viability testing, sterility culturesCryopreservation: HPC products (especially autologous cord blood, often PBSC/marrow intended later use transport) cryopreserved using cryoprotectant agent, commonly Dimethyl Sulfoxide (DMSO), sometimes added agents like albumin dextran. DMSO prevents intracellular ice crystal formation distinct odor can cause side effects infusionStorage\nFrozen: Stored ultra-low temperatures, typically vapor phase liquid nitrogen (≤ -135°C, often closer -196°C)\nFresh: cryopreserved (e.g., marrow harvests, PBSC immediate infusion), stored controlled conditions (often 4°C, varies) limited time (usually 24-72 hours)\nFrozen: Stored ultra-low temperatures, typically vapor phase liquid nitrogen (≤ -135°C, often closer -196°C)Fresh: cryopreserved (e.g., marrow harvests, PBSC immediate infusion), stored controlled conditions (often 4°C, varies) limited time (usually 24-72 hours)Expiration\nFrozen: long-term stability (years) stored correctly liquid nitrogen. Practical expiration often guided institutional policy stability studies\nFresh: short, typically 24-72 hours, due rapid loss viability non-frozen temperatures\nFrozen: long-term stability (years) stored correctly liquid nitrogen. Practical expiration often guided institutional policy stability studiesFresh: short, typically 24-72 hours, due rapid loss viability non-frozen temperatures","code":""},{"path":"hematopoietic-progenitors.html","id":"administration-infusion","chapter":"Hematopoietic Progenitors","heading":"Administration (Infusion)","text":"Thawing (frozen): Rapidly thawed bedside lab using 37°C water bath immediately infusionInfusion: Administered intravenously, similar blood transfusion, often slowly. Specific infusion protocols varyFiltration: Usually infused tubing without standard leukocyte-reduction filter (trap HPCs). standard blood filter (170-260 micron) may may used, depending institutional policy visible clots/debrisCompatibility (ABO/Rh)\nABO/Rh matching required engraftment, incompatibility can cause complications:\nMajor ABO Mismatch: (e.g., Group donor cells Group O recipient). Requires RBC depletion HPC product infusion prevent severe hemolysis\nMinor ABO Mismatch: (e.g., Group O donor cells Group recipient). Donor plasma contains anti-/B can hemolyze recipient RBCs. May require plasma reduction product monitoring post-infusion\nRh incompatibility managed based RBC content recipient Rh status (consider RhIG needed)\n\nABO/Rh matching required engraftment, incompatibility can cause complications:\nMajor ABO Mismatch: (e.g., Group donor cells Group O recipient). Requires RBC depletion HPC product infusion prevent severe hemolysis\nMinor ABO Mismatch: (e.g., Group O donor cells Group recipient). Donor plasma contains anti-/B can hemolyze recipient RBCs. May require plasma reduction product monitoring post-infusion\nRh incompatibility managed based RBC content recipient Rh status (consider RhIG needed)\nMajor ABO Mismatch: (e.g., Group donor cells Group O recipient). Requires RBC depletion HPC product infusion prevent severe hemolysisMinor ABO Mismatch: (e.g., Group O donor cells Group recipient). Donor plasma contains anti-/B can hemolyze recipient RBCs. May require plasma reduction product monitoring post-infusionRh incompatibility managed based RBC content recipient Rh status (consider RhIG needed)Monitoring: Close monitoring infusion reactions (see )","code":""},{"path":"hematopoietic-progenitors.html","id":"potential-risks-adverse-events","chapter":"Hematopoietic Progenitors","heading":"Potential Risks / Adverse Events","text":"Donor Risks: Related collection method (anesthesia marrow harvest; G-CSF side effects apheresis reactions PBSC)Recipient Infusion Reactions\nVolume overload\nAllergic reactions\nFebrile reactions\nDMSO Toxicity: Nausea, vomiting, abdominal cramps, flushing, hypertension/hypotension, dyspnea, characteristic garlic-like odor/taste\nHemolytic reactions (ABO incompatible product adequately processed)\nVolume overloadAllergic reactionsFebrile reactionsDMSO Toxicity: Nausea, vomiting, abdominal cramps, flushing, hypertension/hypotension, dyspnea, characteristic garlic-like odor/tasteHemolytic reactions (ABO incompatible product adequately processed)Recipient Post-Transplant Complications\nGraft Failure: HPCs fail engraft produce blood cells\nGraft-versus-Host Disease (GVHD): Major complication allogeneic transplant donor T-cells attack recipient tissues (acute chronic)\nInfections: High risk period neutropenia engraftment\nOrgan Toxicity: pre-transplant conditioning regimen (chemo/radiotherapy)\nDisease Relapse\nGraft Failure: HPCs fail engraft produce blood cellsGraft-versus-Host Disease (GVHD): Major complication allogeneic transplant donor T-cells attack recipient tissues (acute chronic)Infections: High risk period neutropenia engraftmentOrgan Toxicity: pre-transplant conditioning regimen (chemo/radiotherapy)Disease Relapse","code":""},{"path":"hematopoietic-progenitors.html","id":"key-terms-25","chapter":"Hematopoietic Progenitors","heading":"Key Terms","text":"HPC (Hematopoietic Progenitor Cell): Stem cell gives rise blood cellsStem Cell: Undifferentiated cell capable self-renewal differentiationMobilization: Process stimulating HPCs move bone marrow peripheral blood (using G-CSF)G-CSF (Granulocyte Colony-Stimulating Factor): Cytokine used mobilizationApheresis (Leukapheresis): Procedure used collect PBSCsHLA (Human Leukocyte Antigen): Key immune markers matching donors recipientsGVHD (Graft-versus-Host Disease): Complication donor immune cells attack recipientEngraftment: Process transfused HPCs migrate marrow, begin dividing, produce new blood cellsCryopreservation: Freezing cells cryoprotectant long-term storageDMSO (Dimethyl Sulfoxide): Common cryoprotectant HPCsConditioning Regimen: High-dose chemotherapy /radiation given transplant eliminate underlying disease suppress recipient’s immune systemAllogeneic: donorAutologous: patient themselvesSyngeneic: identical twin","code":""},{"path":"blood-component-qc.html","id":"blood-component-qc","chapter":"Blood Component QC","heading":"Blood Component QC","text":"Blood component QC systematic process checks tests serves final verification product quality release. ensures components meet established specifications volume, cellular content, purity (e.g., low residual WBCs), potency (e.g., factor levels, pH), appearance, ultimately safeguarding patient safety ensuring effectiveness transfusion therapyThis section focuses Quality Control (QC) applies specifically final Blood Components prepared blood center transfusion service. QC critical part overall Quality Management System, ensuring components produced consistently meet established standards safety, purity, potency, identity released transfusion","code":""},{"path":"blood-component-qc.html","id":"what-is-blood-component-quality-control","chapter":"Blood Component QC","heading":"What is Blood Component Quality Control?","text":"Definition: program specific tests checks performed representative sample blood components verify collection, processing, storage, modification procedures consistently yield products meeting predefined specificationsGoal: ensure every component released transfusion likely safe provide intended therapeutic benefitDistinction Donor Testing: QC focuses characteristics final component, whereas donor testing focuses screening donor infectious diseases determining blood type","code":""},{"path":"blood-component-qc.html","id":"why-is-component-qc-essential","chapter":"Blood Component QC","heading":"Why is Component QC Essential?","text":"Patient Safety: Verifies components free unacceptable characteristics (e.g., excessive hemolysis, bacterial contamination, incorrect volume) harm patientProduct Efficacy: Confirms component contains expected amount therapeutic element (e.g., adequate platelet count, sufficient fibrinogen Cryo, acceptable Hct RBCs)Regulatory Compliance: Required regulatory agencies (FDA - cGMP) accrediting bodies (AABB Standards)Process Monitoring: Provides ongoing verification manufacturing processes (e.g., centrifugation speeds/times, leukoreduction filtration, storage conditions) operating correctly consistentlyConsistency: Ensures uniformity different units component type","code":""},{"path":"blood-component-qc.html","id":"regulatory-framework-1","chapter":"Blood Component QC","heading":"Regulatory Framework","text":"FDA (21 CFR 606 - cGMP): Requires procedures assuring quality blood products, including testing representative samplesAABB Standards: Provide detailed requirements QC testing frequencies, sample sizes, specific parameters blood component","code":""},{"path":"blood-component-qc.html","id":"general-qc-principles-applied-to-components","chapter":"Blood Component QC","heading":"General QC Principles Applied to Components","text":"QC checks apply broadly:Visual Inspection: Every unit visually inspected issue :\nAbnormal color (e.g., excessive hemolysis RBCs, unusual plasma color)\nPresence clots\nContainer integrity (leaks, damage)\nPresence turbidity unusual particulates (esp. platelets, plasma)\nCorrect labeling (matches records, legible, appropriate format like ISBT 128)\nAppearance appropriate component (e.g., “swirling” viable platelets)\nAbnormal color (e.g., excessive hemolysis RBCs, unusual plasma color)Presence clotsContainer integrity (leaks, damage)Presence turbidity unusual particulates (esp. platelets, plasma)Correct labeling (matches records, legible, appropriate format like ISBT 128)Appearance appropriate component (e.g., “swirling” viable platelets)Volume/Weight Checks: Ensuring volume weight within expected range component typeRecord Review: Confirmation required processing testing steps completed acceptable release","code":""},{"path":"blood-component-qc.html","id":"specific-qc-tests-for-major-components","chapter":"Blood Component QC","heading":"Specific QC Tests for Major Components","text":"AABB Standards typically require QC testing specified number percentage units produced month (e.g., 1% units 4 units per month, whichever greater, many parameters)Red Blood Cells (RBCs)\nHematocrit (Hct) Hemoglobin (Hgb): Must meet minimum/maximum levels depending preparation method (e.g., Hct typically ≤ 80% non-additive units; variable units often measured)\nVolume: Checked ensure consistency\nHemolysis: Measured end storage period (outdate) ensure doesn’t exceed acceptable limits (typically <1% RBC mass)\nResidual Leukocytes (Leukoreduced): Must verify process consistently produces units meeting standard (e.g., < 5 x 10⁶ WBCs/unit)\nHematocrit (Hct) Hemoglobin (Hgb): Must meet minimum/maximum levels depending preparation method (e.g., Hct typically ≤ 80% non-additive units; variable units often measured)Volume: Checked ensure consistencyHemolysis: Measured end storage period (outdate) ensure doesn’t exceed acceptable limits (typically <1% RBC mass)Residual Leukocytes (Leukoreduced): Must verify process consistently produces units meeting standard (e.g., < 5 x 10⁶ WBCs/unit)Platelets (Apheresis Pooled WBD)\nPlatelet Count: Must contain minimum required number platelets (e.g., ≥ 3.0 x 10¹¹ apheresis; ≥ 5.5 x 10¹⁰ per individual WBD unit pooling, checks final pool counts)\nVolume: Checked consistency\npH: CRITICAL. Must ≥ 6.2 end allowable storage period (tested 20-24°C). Low pH indicates poor viability\nResidual Leukocytes (Leukoreduced): Must verify process meets standards\nBacterial Detection: Increasingly performed routinely (e.g., culture sampling, rapid tests) due room temperature storage risk. Must show detectable bacterial contamination per validated methods\nVisual Inspection: Check aggregates, abnormal appearance, presence swirling\nPlatelet Count: Must contain minimum required number platelets (e.g., ≥ 3.0 x 10¹¹ apheresis; ≥ 5.5 x 10¹⁰ per individual WBD unit pooling, checks final pool counts)Volume: Checked consistencypH: CRITICAL. Must ≥ 6.2 end allowable storage period (tested 20-24°C). Low pH indicates poor viabilityResidual Leukocytes (Leukoreduced): Must verify process meets standardsBacterial Detection: Increasingly performed routinely (e.g., culture sampling, rapid tests) due room temperature storage risk. Must show detectable bacterial contamination per validated methodsVisual Inspection: Check aggregates, abnormal appearance, presence swirlingPlasma (FFP, PF24, etc.)\nVolume: Checked consistency\nVisual Inspection: Checked thawing unusual color, clots, particulates; container integrity\nResidual Cells: Limits contaminating RBCs/WBCs/Platelets may checked, especially initial process validation\nFactor Assays (Less Common Routine QC): Factor VIII Fibrinogen levels might checked periodically validation ensure freezing/storage preserves activity, typically done routine monthly basis like platelet counts\nVolume: Checked consistencyVisual Inspection: Checked thawing unusual color, clots, particulates; container integrityResidual Cells: Limits contaminating RBCs/WBCs/Platelets may checked, especially initial process validationFactor Assays (Less Common Routine QC): Factor VIII Fibrinogen levels might checked periodically validation ensure freezing/storage preserves activity, typically done routine monthly basis like platelet countsCryoprecipitated AHF (Cryo)\nVolume: Checked (small, 10-20 mL)\nFibrinogen Content: REQUIRED QC. Must contain ≥ 150 mg per unit\nFactor VIII Content: REQUIRED QC. Must contain ≥ 80 IU per unit\nVolume: Checked (small, 10-20 mL)Fibrinogen Content: REQUIRED QC. Must contain ≥ 150 mg per unitFactor VIII Content: REQUIRED QC. Must contain ≥ 80 IU per unitGranulocytes\nVolume: Checked\nGranulocyte Count: Measured ensure target dose (often > 1.0 x 10¹⁰ per unit), though actual yield varies significantly\nRed Cell Content: Often assessed confirm need crossmatch\nSterility: May performed due open processing steps room temperature storage\nVolume: CheckedGranulocyte Count: Measured ensure target dose (often > 1.0 x 10¹⁰ per unit), though actual yield varies significantlyRed Cell Content: Often assessed confirm need crossmatchSterility: May performed due open processing steps room temperature storage","code":""},{"path":"blood-component-qc.html","id":"frequency-and-sampling","chapter":"Blood Component QC","heading":"Frequency and Sampling","text":"QC typically performed statistical sampling basis tests requiring entry unit (e.g., cell counts, pH)Frequencies defined AABB Standards internal SOPs (e.g., monthly)Visual inspection label checks performed 100% units issueEquipment QC (refrigerator/freezer temps, centrifuge speeds, irradiator dose) also critical performed regular schedule","code":""},{"path":"blood-component-qc.html","id":"documentation-and-corrective-action","chapter":"Blood Component QC","heading":"Documentation and Corrective Action","text":"QC results must meticulously documented, reviewed, signed qualified personnelOut--specification (OOS) results: require investigation determine causeCorrective actions: must implemented documented prevent recurrenceIf QC failure indicates potential problem multiple units, units may need quarantined recalled","code":""},{"path":"blood-component-qc.html","id":"key-terms-26","chapter":"Blood Component QC","heading":"Key Terms","text":"Quality Control (QC): Testing performed products verify meet predefined specificationsSpecification: predefined requirement standard product must meetSampling Plan: statistically based method selecting subset units testingHemolysis: Percentage red blood cells lysed (broken open)pH: Measure acidity/alkalinity; critical platelet viabilityResidual Leukocytes: Number white blood cells remaining leukoreductionBacterial Detection: Testing methods (e.g., culture, rapid tests) screen bacterial contamination, especially plateletsOut--Specification (OOS): QC result meet predefined acceptance criteriaCorrective Action: Steps taken eliminate cause detected nonconformity undesirable situation","code":""},{"path":"genetics.html","id":"genetics","chapter":"Genetics","heading":"Genetics","text":"Basic genetics tells us inherit (alleles) rules expression (dominance/codominance). Molecular genetics explains tiny differences DNA create different alleles antigens. Inheritance patterns describe alleles transmitted generations, often influenced whether genes linked together chromosomes. Together, principles form foundation understanding blood group diversity critical implications transfusion medicineThink blood group genetics like building LEGOs® following specific instructions:","code":""},{"path":"genetics.html","id":"the-instructions-basic-genetics","chapter":"Genetics","heading":"The Instructions (Basic Genetics)","text":"traits, like blood type, determined genes, specific sections DNA blueprint found particular addresses called loci chromosomesGenes come different versions called alleles (e.g., , B, O alleles ABO gene). inherit one allele parentOur specific inherited pair alleles genotype (e.g., AO). actually detect red cells lab phenotype (e.g., Group )Alleles can interact: Codominant ones (like B) show inherited together (AB phenotype). dominant allele (like D Rh) shows even paired recessive one (d), shows trait two copies present (dd)","code":""},{"path":"genetics.html","id":"decoding-the-instructions-molecular-genetics","chapter":"Genetics","heading":"Decoding the Instructions (Molecular Genetics)","text":"difference alleles lies specific DNA sequence (order , T, C, G bases)Variations like Single Nucleotide Polymorphisms (SNPs) – change just one DNA base – common. variations include insertions/deletions (indels)DNA changes can alter protein gene codes . protein might antigen (like Rh Kell proteins) might enzyme (like ABO glycosyltransferases) builds carbohydrate antigenExample: specific SNPs differentiate B alleles, changing enzyme produce, turn adds different sugar make B antigen. deletion causing frameshift often leads non-functional enzyme, resulting O alleleMolecular techniques (like PCR-based methods) allow us directly read DNA sequence (genotyping) predict phenotype, invaluable complex cases, recently transfused patients, fetal testing","code":""},{"path":"genetics.html","id":"passing-down-the-instructions-inheritance","chapter":"Genetics","heading":"Passing Down the Instructions (Inheritance)","text":"inherit alleles according Mendel’s Laws:\nSegregation: parent passes one two alleles gene offspring\nIndependent Assortment: Genes different traits different chromosomes inherited independently (e.g., ABO type doesn’t influence Rh type)\nSegregation: parent passes one two alleles gene offspringIndependent Assortment: Genes different traits different chromosomes inherited independently (e.g., ABO type doesn’t influence Rh type)Exception - Linkage: Genes located close together chromosome (like RHD RHCE, GYPA GYPB MNS) often inherited block, called haplotype (e.g., DCe, Ns)Punnett squares: help predict probability offspring inheriting specific genotypes phenotypes based parental genotypesUnderstanding inheritance helps explain family patterns, predict risk Hemolytic Disease Fetus Newborn (HDFN), understand certain antibodies might formed","code":""},{"path":"basic.html","id":"basic","chapter":"Basic","heading":"Basic","text":"blood type determined genes, specific instructions DNA found particular locations called loci. inherit different versions genes, called alleles (like , B, O D, d), getting one parent. specific combination inherited alleles genotype (e.g., AO, Dd). actually detect red blood cells lab phenotype (e.g., Group , Rh Pos). alleles interact matters: codominant alleles (like B) show , dominant alleles (like D) show even paired recessive one, recessive alleles (like O d) show two copies inherited. Understanding fundamental genetic principles crucial predicting inheritance, explaining people make certain blood group antibodies, interpreting lab tests accurately","code":""},{"path":"basic.html","id":"the-blueprint-genes-alleles-and-loci","chapter":"Basic","heading":"The Blueprint: Genes, Alleles, and Loci","text":"Gene: Imagine gene specific instruction DNA blueprint. blood groups, instructions often tell body make specific protein enzyme results blood group antigen red blood cellsLocus (plural: Loci): specific address location gene chromosome. Think like street address specific instruction. example, ABO gene specific locus chromosome 9Allele: Genes can come different versions, like different flavors instruction. different versions called alleles. example, ABO locus, can allele, B allele, O allele. inherit one allele parent genes","code":""},{"path":"basic.html","id":"your-genetic-makeup-genotype-vs.-phenotype","chapter":"Basic","heading":"Your Genetic Makeup: Genotype vs. Phenotype","text":"Genotype: actual pair alleles person inherited specific gene (one parent). ’s genetic code. Examples: AA, AO, BO, AB, OO ABO system; DD, Dd, dd RhD systemPhenotype: observable trait – actually detect lab! ’s physical expression genotype. blood groups, phenotype collection antigens find red blood cells serological testing\nExample: person genotype AO phenotype , antigen expressed, O generally considered “silent” amorphous basic terms. person genotype AB phenotype AB B antigens expressed\nExample: person genotype AO phenotype , antigen expressed, O generally considered “silent” amorphous basic terms. person genotype AB phenotype AB B antigens expressed","code":""},{"path":"basic.html","id":"inheritance-patterns-how-genes-are-passed-down","chapter":"Basic","heading":"Inheritance Patterns: How Genes are Passed Down","text":"Blood group genes follow basic Mendelian inheritance patterns:Mendel’s First Law (Law Segregation): sperm egg cells formed, two alleles locus separate (segregate) gamete (sperm egg) receives one alleles. pass one ABO alleles child, bothMendel’s Second Law (Law Independent Assortment): Alleles different traits (genes located different chromosomes far apart chromosome) inherited independently . example, inheriting allele ABO system doesn’t influence whether inherit D allele Rh system (different chromosomes). Caveat: Genes located close together chromosome (linked genes) tend inherited together often – see systems like MNS Rh","code":""},{"path":"basic.html","id":"expressing-yourself-dominant-recessive-and-codominant-alleles","chapter":"Basic","heading":"Expressing Yourself: Dominant, Recessive, and Codominant Alleles","text":"alleles interact determines phenotype:Dominant Allele: allele expresses trait even one copy present (heterozygous state). Rh system (simplified), D allele dominant. Genotypes DD (homozygous) Dd (heterozygous) result RhD-positive phenotypeRecessive Allele: allele expresses trait two copies present (homozygous state). d allele (representing absence D antigen) recessive. genotype dd results RhD-negative phenotype. O allele ABO system generally considered recessive BCodominant Alleles: alleles expressed equally heterozygous state. B alleles ABO system classic examples. inherit one parent B , genotype AB, phenotype AB – B antigens present red cells. M N alleles MNS system another great example (MN genotype leads MN phenotype)","code":""},{"path":"basic.html","id":"homozygous-vs.-heterozygous","chapter":"Basic","heading":"Homozygous vs. Heterozygous","text":"terms describe pair alleles specific locus:Homozygous: two identical alleles trait (e.g., AA, OO, dd, MM)Heterozygous: two different alleles trait (e.g., AO, BO, AB, Dd, MN)\nmatters: Sometimes, individuals homozygous antigen allele (like MM) might stronger expression antigen cells compared heterozygous (MN). can occasionally affect reactivity strength lab, concept known “dosage.”\nmatters: Sometimes, individuals homozygous antigen allele (like MM) might stronger expression antigen cells compared heterozygous (MN). can occasionally affect reactivity strength lab, concept known “dosage.”","code":""},{"path":"basic.html","id":"why-is-this-basic-genetics-stuff-important-in-blood-bank","chapter":"Basic","heading":"Why is this Basic Genetics Stuff Important in Blood Bank?","text":"Predicting Offspring Phenotypes: Helps understanding potential blood types children based parents’ types (useful clinical scenarios)Understanding Antibody Formation: group O person make anti-anti-B? don’t B genes/antigens!Resolving Discrepancies: Sometimes lab results don’t make sense. Understanding inheritance patterns can help figure (e.g., presence rare allele, weak subgroup)Paternity Testing (Historically): Blood groups early tools used parentage testing, though DNA methods now standardPopulation Studies: Frequencies different alleles vary different populations, impacting availability certain blood types likelihood encountering specific antibodies","code":""},{"path":"basic.html","id":"key-terms-27","chapter":"Basic","heading":"Key Terms","text":"Gene: fundamental unit heredity; segment DNA carries instructions producing specific protein enzyme, ultimately determining blood group antigen characteristicAllele: alternative form version gene found specific locusLocus (plural: Loci): specific physical location gene chromosomeGenotype: specific combination alleles individual inherited particular locus (loci). represents genetic makeupPhenotype: observable physical biochemical characteristics individual, determined genotype environmental factors. blood banking, ’s detect serologically (antigens present red cells)Homozygous: two identical alleles specific gene given locusHeterozygous: two different alleles specific gene given locusDominant Allele: allele whose trait expressed phenotype even one copy present (heterozygous state)Recessive Allele: allele whose trait expressed phenotype two copies present (homozygous state). masked dominant allele heterozygous stateCodominant Alleles: Two different alleles locus fully expressed phenotype heterozygote","code":""},{"path":"molecular.html","id":"molecular","chapter":"Molecular","heading":"Molecular","text":"Molecular genetics provides underlying explanation blood group polymorphisms observe serologically. analyzing DNA, can directly determine individual’s genetic potential express specific antigens, overcoming many limitations traditional serology allowing precise comprehensive blood group analysis, ultimately contributing safer transfusionsAt core, molecular genetics blood banking focuses sequence nucleotides (, T, C, G) DNA dictates blood group antigens expressed cells","code":""},{"path":"molecular.html","id":"the-central-dogma-revisited","chapter":"Molecular","heading":"The Central Dogma Revisited","text":"DNA: Contains genetic code, organized genesTranscription: DNA sequence gene copied messenger RNA (mRNA)Translation: mRNA sequence read ribosomes, assemble amino acids specific proteinProtein/Enzyme Function: resulting protein might blood group antigen , might enzyme (like glycosyltransferase) modifies precursor substance cell surface create antigen","code":""},{"path":"molecular.html","id":"from-dna-sequence-to-antigen","chapter":"Molecular","heading":"From DNA Sequence to Antigen","text":"Codons: mRNA sequence read groups three bases called codons. codon specifies particular amino acid (stop signal)Amino Acid Sequence: sequence codons dictates sequence amino acids proteinProtein Structure & Function: amino acid sequence determines protein folds 3D shape, critical function (e.g., enzymatic activity, structural integrity, acting antigen recognized antibodies)","code":""},{"path":"molecular.html","id":"genetic-variations-the-source-of-blood-group-polymorphism","chapter":"Molecular","heading":"Genetic Variations: The Source of Blood Group Polymorphism","text":"differences blood group alleles (like vs. B, K vs. k) arise variations DNA sequence corresponding genes. Common types include:Single Nucleotide Polymorphisms (SNPs): common type. change single DNA base pair specific locus (e.g., G changes )\nImpact: Can change codon, leading different amino acid protein (missense mutation), potentially altering antigen structure enzyme activity. Can create stop codon (nonsense mutation), leading shortened, often non-functional protein. Can occur non-coding regions (promoters, introns) affect much protein made mRNA processed\nImpact: Can change codon, leading different amino acid protein (missense mutation), potentially altering antigen structure enzyme activity. Can create stop codon (nonsense mutation), leading shortened, often non-functional protein. Can occur non-coding regions (promoters, introns) affect much protein made mRNA processedInsertions/Deletions (Indels): Addition removal one DNA base pairs\nImpact: number bases inserted/deleted multiple three, causes frameshift mutation. changes entire downstream codon reading frame, usually leading completely different often non-functional protein, frequently ending prematurely stop codon. Small -frame indels (multiples 3) might add remove amino acids preserve rest protein sequence. Large deletions can remove entire exons even whole gene\nImpact: number bases inserted/deleted multiple three, causes frameshift mutation. changes entire downstream codon reading frame, usually leading completely different often non-functional protein, frequently ending prematurely stop codon. Small -frame indels (multiples 3) might add remove amino acids preserve rest protein sequence. Large deletions can remove entire exons even whole geneGene Rearrangements/Fusions: complex changes parts different genes might swap places (recombination) fuse together\nImpact: Can create hybrid genes encoding novel proteins altered antigenic properties. Important systems like MNS (creating variant glycophorins) Rh (creating partial D antigens)\nImpact: Can create hybrid genes encoding novel proteins altered antigenic properties. Important systems like MNS (creating variant glycophorins) Rh (creating partial D antigens)","code":""},{"path":"molecular.html","id":"how-genes-produce-antigens---two-main-routes","chapter":"Molecular","heading":"How Genes Produce Antigens - Two Main Routes","text":"Route 1: Direct Gene Product Antigen: gene directly codes protein , part , blood group antigen embedded red cell membrane. Changes (like SNPs) gene directly alter antigen’s structure\nExamples: Rh (RhD RhCE proteins), MNS (Glycophorin B proteins), Kell (Kell protein), Duffy (Duffy protein/DARC), Kidd (Kidd urea transporter protein)\nExamples: Rh (RhD RhCE proteins), MNS (Glycophorin B proteins), Kell (Kell protein), Duffy (Duffy protein/DARC), Kidd (Kidd urea transporter protein)Route 2: Gene Product Enzyme (Glycosyltransferase): gene codes enzyme, typically glycosyltransferase. enzyme adds specific sugar molecules onto precursor carbohydrate chains already present red cell surface (glycoproteins/glycolipids). resulting sugar structure antigen\nExamples: ABO, H, Lewis, P1PK, . difference B antigens isn’t protein backbone, specific sugar added B transferase enzyme. O allele often results frameshift deletion producing non-functional enzyme, extra sugar added H antigen precursor\nExamples: ABO, H, Lewis, P1PK, . difference B antigens isn’t protein backbone, specific sugar added B transferase enzyme. O allele often results frameshift deletion producing non-functional enzyme, extra sugar added H antigen precursor","code":""},{"path":"molecular.html","id":"molecular-basis-examples","chapter":"Molecular","heading":"Molecular Basis Examples","text":"ABO System\nABO gene encodes glycosyltransferase\nallele B allele differ key SNPs, resulting enzymes add different sugars (N-acetylgalactosamine , D-galactose B) H antigen precursor\ncommon O allele (O01) single base deletion near start, causing frameshift non-functional enzyme. O alleles exist different mutations\nSubgroups like A2 result SNPs make -transferase slightly less efficient A1 enzyme\nABO gene encodes glycosyltransferaseThe allele B allele differ key SNPs, resulting enzymes add different sugars (N-acetylgalactosamine , D-galactose B) H antigen precursorThe common O allele (O01) single base deletion near start, causing frameshift non-functional enzyme. O alleles exist different mutationsSubgroups like A2 result SNPs make -transferase slightly less efficient A1 enzymeRh System\nTwo highly homologous (similar) closely linked genes: RHD RHCE\nRhD Positive: functional RHD gene\nRhD Negative: commonly caused complete deletion RHD gene (common Caucasians). mechanisms include inactivating mutations rearrangements within RHD (common individuals African Asian descent)\nC/c E/e Antigens: Determined SNPs within RHCE gene. example, single SNP determines C vs c expression (encoding serine vs proline position 103), another SNP largely determines E vs e (proline vs alanine position 226)\nWeak D/Partial D: Result various RHD gene alterations: missense mutations (SNPs) changing amino acids (often affecting antigen density - Weak D, antigen structure - Partial D), gene rearrangements creating hybrid RHD-RHCE genes\nTwo highly homologous (similar) closely linked genes: RHD RHCERhD Positive: functional RHD geneRhD Negative: commonly caused complete deletion RHD gene (common Caucasians). mechanisms include inactivating mutations rearrangements within RHD (common individuals African Asian descent)C/c E/e Antigens: Determined SNPs within RHCE gene. example, single SNP determines C vs c expression (encoding serine vs proline position 103), another SNP largely determines E vs e (proline vs alanine position 226)Weak D/Partial D: Result various RHD gene alterations: missense mutations (SNPs) changing amino acids (often affecting antigen density - Weak D, antigen structure - Partial D), gene rearrangements creating hybrid RHD-RHCE genesKell System\nKEL gene encodes Kell glycoprotein\nmajor K (K1) vs. k (K2, Cellano) polymorphism due single SNP (C T) changing one amino acid (Threonine Methionine)\nKEL gene encodes Kell glycoproteinThe major K (K1) vs. k (K2, Cellano) polymorphism due single SNP (C T) changing one amino acid (Threonine Methionine)Duffy System\nDARC gene encodes Duffy Antigen Receptor Chemokines (DARC protein), carries Fya Fyb antigens\nFya vs. Fyb determined single SNP changing amino acid\ncommon Fy(-b-) phenotype individuals African descent usually caused SNP promoter region (GATA box) DARC gene. SNP prevents transcription (making mRNA) red blood cell precursors, Duffy protein isn’t made RBCs, still present tissues\nDARC gene encodes Duffy Antigen Receptor Chemokines (DARC protein), carries Fya Fyb antigensFya vs. Fyb determined single SNP changing amino acidThe common Fy(-b-) phenotype individuals African descent usually caused SNP promoter region (GATA box) DARC gene. SNP prevents transcription (making mRNA) red blood cell precursors, Duffy protein isn’t made RBCs, still present tissuesMNS System\nTwo linked genes, GYPA GYPB, encoding Glycophorin (GPA) Glycophorin B (GPB) respectively\nM/N antigens: Located GPA. Determined SNPs GYPA causing amino acid changes positions 1 5\nS/s antigens: Located GPB. Determined single SNP GYPB causing amino acid change position 29\nU antigen: High-prevalence antigen associated GPB. U-negative individuals often deletions rearrangements involving GYPB gene\nTwo linked genes, GYPA GYPB, encoding Glycophorin (GPA) Glycophorin B (GPB) respectivelyM/N antigens: Located GPA. Determined SNPs GYPA causing amino acid changes positions 1 5S/s antigens: Located GPB. Determined single SNP GYPB causing amino acid change position 29U antigen: High-prevalence antigen associated GPB. U-negative individuals often deletions rearrangements involving GYPB gene","code":""},{"path":"molecular.html","id":"molecular-techniques-in-the-reference-lab","chapter":"Molecular","heading":"Molecular Techniques in the Reference Lab","text":"Understanding molecular basis allows DNA-based testing (genotyping):PCR (Polymerase Chain Reaction): Amplifies specific DNA regions interestMethods based PCR\nSSP (Sequence-Specific Priming): Uses primers designed bind amplify specific alleles\nRFLP (Restriction Fragment Length Polymorphism): Uses restriction enzymes cut DNA specific sequences; different alleles may different cutting patterns mutation affects restriction site\nSequencing: Directly determines exact nucleotide sequence gene segment\nBead Chip Arrays/Microarrays: Simultaneously test numerous SNPs across multiple blood group genes using probes attached beads chip\nSSP (Sequence-Specific Priming): Uses primers designed bind amplify specific allelesRFLP (Restriction Fragment Length Polymorphism): Uses restriction enzymes cut DNA specific sequences; different alleles may different cutting patterns mutation affects restriction siteSequencing: Directly determines exact nucleotide sequence gene segmentBead Chip Arrays/Microarrays: Simultaneously test numerous SNPs across multiple blood group genes using probes attached beads chip","code":""},{"path":"molecular.html","id":"why-is-molecular-genetics-important-in-blood-bank","chapter":"Molecular","heading":"Why is Molecular Genetics Important in Blood Bank?","text":"Resolving Serologic Problems: routine antibody-antigen tests give unclear, weak, conflicting resultsTesting Recently Transfused Patients: Serology detects antigens patient donor cells. Genotyping looks patient’s DNA, unaffected transfusionTesting DAT Positive Patients: Strong positive DAT can interfere serological typing, especially weaker antigens. Genotyping unaffectedPredicting Antigen Phenotype Antisera Unavailable: Especially rare antigens commercial antisera weak/limitedFetal Genotyping: Can determine fetal RhD type (antigens) maternal plasma (using cell-free fetal DNA) amniotic fluid assess risk Hemolytic Disease Fetus Newborn (HDFN)Screening Donors: Identifying donors negative multiple antigens rare blood types needed specific patientsUnderstanding Weak/Variant Phenotypes: Differentiating weak D types can safely receive D+ blood vs. partial D types receive D- blood","code":""},{"path":"molecular.html","id":"key-terms-28","chapter":"Molecular","heading":"Key Terms","text":"Single Nucleotide Polymorphism (SNP): variation single position DNA sequence among individuals. example, specific base position, people might ‘G’, minority might ‘’. SNPs common type genetic variation responsible many blood group antigen polymorphisms (e.g., K vs. k, C vs. c)Codon: sequence three consecutive nucleotides DNA RNA molecule specifies particular amino acid signals termination translation (stop codon). sequence codons determines amino acid sequence proteinMissense Mutation: type SNP change single nucleotide results codon codes different amino acid original codon. change amino acid sequence can alter structure function resulting protein, potentially changing antigenic properties (e.g., creating different blood group antigen)Frameshift Mutation: genetic mutation caused insertion deletion (indel) number nucleotides DNA sequence divisible three. shifts grouping bases codons, changing entire amino acid sequence downstream mutation site often leading premature stop codon truncated, non-functional protein (e.g., common O allele ABO system)Glycosyltransferase: enzyme catalyzes transfer sugar molecules (glycosyl groups) activated donor molecule onto acceptor molecule, typically carbohydrate, protein, lipid. Genes encoding enzymes responsible creating carbohydrate-based blood group antigens like ABO, H, LewisPolymerase Chain Reaction (PCR): laboratory technique used amplify (make many copies ) specific segment DNA. ’s fundamental tool molecular diagnostics, allowing detection analysis genes associated blood groups even small DNA samplesGenotyping: process determining specific allele composition (genotype) individual particular DNA loci. blood banking, refers DNA-based methods used predict blood group phenotypes, especially serological testing difficult inconclusiveAllele: molecular level, allele represents one several different DNA sequence variations possible particular gene locus. sequence differences (like SNPs indels) lead different versions blood group genes (e.g., , B, O alleles ABO gene)Promoter: region DNA located upstream (near start) gene initiates transcription particular gene. Mutations within promoter region can affect much, , tissues gene expressed, without altering coding sequence (e.g., GATA box mutation associated Fy(-b-) phenotype)Gene Deletion: type mutation segment DNA, ranging single base pair entire gene chromosome region, lost. Complete gene deletions common cause null phenotypes, antigen product made (e.g., common cause RhD-negative phenotype Caucasians deletion RHD gene)","code":""},{"path":"blood-group-inheritance.html","id":"blood-group-inheritance","chapter":"Blood Group Inheritance","heading":"Blood Group Inheritance","text":"Let’s tie together basic genetics molecular concepts see blood groups actually passed families. Understanding inheritance patterns fundamental predicting phenotypes, resolving discrepancies, understanding population frequencies","code":""},{"path":"blood-group-inheritance.html","id":"inheritance-of-blood-groups-passing-the-torch","chapter":"Blood Group Inheritance","heading":"Inheritance of Blood Groups: Passing the Torch","text":"Inheritance blood group systems follows fundamental principles established Gregor Mendel. inherit one set chromosomes (thus, one allele gene locus) mother via egg, one set father via sperm","code":""},{"path":"blood-group-inheritance.html","id":"mendels-first-law-law-of-segregation","chapter":"Blood Group Inheritance","heading":"Mendel’s First Law: Law of Segregation","text":"Concept: gamete formation (sperm egg production), two alleles trait separate (segregate) , gamete carries one allele traitBlood Bank Relevance: parent genotype AO, don’t pass AO child. pass either allele O allele sperm egg. parent . combination determines child’s genotype","code":""},{"path":"blood-group-inheritance.html","id":"mendels-second-law-law-of-independent-assortment","chapter":"Blood Group Inheritance","heading":"Mendel’s Second Law: Law of Independent Assortment","text":"Concept: Alleles different traits (genes located different chromosomes far apart chromosome) inherited independently one anotherBlood Bank Relevance: inheritance ABO type (gene chromosome 9) independent RhD type (gene chromosome 1). Getting allele doesn’t make less likely get D alleleImportant Exception - Linkage: law doesn’t strictly apply genes located close together chromosome. called linked genes","code":""},{"path":"blood-group-inheritance.html","id":"linked-genes-and-haplotypes","chapter":"Blood Group Inheritance","heading":"Linked Genes and Haplotypes","text":"Concept: Genes physically close together chromosome tend inherited together block chance crossover (recombination) event happening meiosis lowHaplotype: set linked alleles inherited together chromosomeBlood Bank Relevance\nRh System: RHD RHCE genes tightly linked chromosome 1. inherit block Rh alleles parent. example, common haplotype Caucasians DCe. Someone might inherit DCe one parent dce . genotype often written DCe/dce. pass either DCe combination dce combination children\nMNS System: GYPA (coding M/N antigens) GYPB (coding S/s antigens) genes closely linked chromosome 4. Common haplotypes include MS, Ms, NS, Ns. Someone genotype MS/Ns inherited MS one parent Ns \nRh System: RHD RHCE genes tightly linked chromosome 1. inherit block Rh alleles parent. example, common haplotype Caucasians DCe. Someone might inherit DCe one parent dce . genotype often written DCe/dce. pass either DCe combination dce combination childrenMNS System: GYPA (coding M/N antigens) GYPB (coding S/s antigens) genes closely linked chromosome 4. Common haplotypes include MS, Ms, NS, Ns. Someone genotype MS/Ns inherited MS one parent Ns ","code":""},{"path":"blood-group-inheritance.html","id":"predicting-inheritance-the-punnett-square","chapter":"Blood Group Inheritance","heading":"Predicting Inheritance: The Punnett Square","text":"Punnett square simple grid used predict possible genotypes offspring based genotypes parentsHow works\nDetermine possible alleles parent can contribute gametes (based genotype Law Segregation)\nList one parent’s possible gametes along top square parent’s along side\nFill boxes combining alleles corresponding row column. box represents possible genotype offspring, typically, box equal probability (e.g., 25% 4 boxes)\nDetermine possible alleles parent can contribute gametes (based genotype Law Segregation)List one parent’s possible gametes along top square parent’s along sideFill boxes combining alleles corresponding row column. box represents possible genotype offspring, typically, box equal probability (e.g., 25% 4 boxes)Example 1: ABO Inheritance\nParent 1: Genotype AO (Phenotype ) -> Possible gametes: O\nParent 2: Genotype BO (Phenotype B) -> Possible gametes: B O\n\nB\nO\n\nAB\nAO\nO\nBO\nOO\nPredicted Offspring Genotypes: 25% AB, 25% AO, 25% BO, 25% OO\nPredicted Offspring Phenotypes: 25% AB, 25% , 25% B, 25% O\nParent 1: Genotype AO (Phenotype ) -> Possible gametes: OParent 2: Genotype BO (Phenotype B) -> Possible gametes: B OPredicted Offspring Genotypes: 25% AB, 25% AO, 25% BO, 25% OOPredicted Offspring Phenotypes: 25% AB, 25% , 25% B, 25% OExample 2: RhD Inheritance (Simplified)\nParent 1: Genotype Dd (Phenotype RhD Positive) -> Possible gametes: D d\nParent 2: Genotype Dd (Phenotype RhD Positive) -> Possible gametes: D d\n\nD\nd\nD\nDD\nDd\nd\nDd\ndd\nPredicted Offspring Genotypes: 25% DD, 50% Dd, 25% dd\nPredicted Offspring Phenotypes: 75% RhD Positive (DD Dd), 25% RhD Negative (dd)\nParent 1: Genotype Dd (Phenotype RhD Positive) -> Possible gametes: D dParent 2: Genotype Dd (Phenotype RhD Positive) -> Possible gametes: D dPredicted Offspring Genotypes: 25% DD, 50% Dd, 25% ddPredicted Offspring Phenotypes: 75% RhD Positive (DD Dd), 25% RhD Negative (dd)Example 3: MNS Inheritance (M/N simplicity)\nParent 1: Genotype MM (Phenotype M) -> Possible gametes: M \nParent 2: Genotype MN (Phenotype MN) -> Possible gametes: M N\n\nM\nN\nM\nMM\nMN\nM\nMM\nMN\nPredicted Offspring Genotypes: 50% MM, 50% MN\nPredicted Offspring Phenotypes: 50% M, 50% MN\nParent 1: Genotype MM (Phenotype M) -> Possible gametes: M onlyParent 2: Genotype MN (Phenotype MN) -> Possible gametes: M NPredicted Offspring Genotypes: 50% MM, 50% MNPredicted Offspring Phenotypes: 50% M, 50% MN","code":""},{"path":"blood-group-inheritance.html","id":"dominance-recessiveness-and-codominance-in-inheritance","chapter":"Blood Group Inheritance","heading":"Dominance, Recessiveness, and Codominance in Inheritance","text":"alleles interact (discussed Basic Genetics) determines resulting phenotype inherited genotypeCodominance (e.g., B, M N): alleles like B inherited (AB genotype), expressed (AB phenotype)Dominance/Recessiveness (e.g., RhD, ABO O): dominant allele (D) inherited recessive one (d), dominant phenotype (RhD Pos) expressed (Dd genotype). recessive phenotype (RhD Neg) appears two recessive alleles inherited (dd genotype). O allele recessive B","code":""},{"path":"blood-group-inheritance.html","id":"why-understanding-inheritance-matters-in-blood-bank","chapter":"Blood Group Inheritance","heading":"Why Understanding Inheritance Matters in Blood Bank","text":"Family Studies: Helps resolve complex antibody problems identify compatible family members transfusion, especially patients multiple antibodies antibodies high-prevalence antigensPredicting HDFN Risk: Knowing parental genotypes (especially RhD, Kell, etc.) helps predict likelihood fetus inheriting antigen mother lacks, potentially leading HDFN. Fetal genotyping directly assesses thisUnderstanding Antibody Likelihood: person generally make antibodies antigens lack. Inheritance patterns dictate antigens present absent. example, O person inherited O parents thus lacks B antigens, making capable forming anti-anti-BPopulation Frequencies: Allele frequencies vary among different ethnic populations. affects probability finding antigen-negative blood specific patients likelihood encountering certain antibodies within populationResolving Discrepancies: Apparent contradictions typing results family history (e.g., Group O child AB parent) might indicate sample mix-ups, misidentification, rare genetic events (like Bombay phenotype chimerism)essence, inheritance patterns dictated basic Mendelian genetics, combined understanding dominance/codominance linkage, provide framework understanding blood group diversity arises maintained within families populations","code":""},{"path":"blood-group-inheritance.html","id":"key-terms-29","chapter":"Blood Group Inheritance","heading":"Key Terms","text":"Law Segregation: Mendel’s first law, stating two alleles trait separate gamete formation, gamete receives one alleleLaw Independent Assortment: Mendel’s second law, stating alleles different traits (different chromosomes far apart chromosome) inherited independently otherLinked Genes: Genes located close together chromosome tend inherited together crossing infrequentHaplotype: set specific alleles located close together single chromosome inherited unit (e.g., DCe Rh system, Ms MNS system)Punnett Square: diagram used predict probability offspring inheriting particular genotypes based genotypes parentsPedigree: chart shows presence absence trait within family across generations, used track inheritance patterns","code":""},{"path":"biochemistryantigens.html","id":"biochemistryantigens","chapter":"Biochemistry/Antigens","heading":"Biochemistry/Antigens","text":"surfaces red blood cells, white blood cells, platelets decorated vast array molecules, primarily proteins carbohydrates. Variations molecules, determined genes, create different antigens. antigens define various blood group systems cellular markers crucial transfusion medicine immunology. Understanding basic biochemistry characteristics fundamental predicting immune responses, ensuring compatibility, diagnosing related disordersHere’s overview key players:","code":""},{"path":"biochemistryantigens.html","id":"abo-system-isbt-001","chapter":"Biochemistry/Antigens","heading":"ABO System (ISBT 001)","text":"Biochemistry: Carbohydrate antigens (, B, H). Built upon common precursor substance glycoproteins glycolipids. Genes code glycosyltransferase enzymes (-transferase, B-transferase) add specific sugars H antigen (built H-transferase, FUT1). O allele usually codes non-functional enzymeKey Antigens: , B, H. (Presence/absence defines groups , B, AB, O). Subgroups exist (e.g., A1, A2)","code":""},{"path":"biochemistryantigens.html","id":"lewis-system-isbt-007","chapter":"Biochemistry/Antigens","heading":"Lewis System (ISBT 007)","text":"Biochemistry: Carbohydrate antigens (Lea, Leb) synthesized tissues, present soluble antigens plasma, adsorb onto red cell surface. Synthesis depends Lewis (FUT3) Secretor (FUT2) enzymes acting precursor chains similar ABO/HKey Antigens: Lea, Leb. Phenotype depends interaction Le Se genes","code":""},{"path":"biochemistryantigens.html","id":"rh-system-isbt-004","chapter":"Biochemistry/Antigens","heading":"Rh System (ISBT 004)","text":"Biochemistry: Proteins (RhD RhCE) non-glycosylated, transmembrane proteins forming complex Rh-associated glycoprotein (RhAG). Integral components RBC membrane. Encoded highly homologous RHD RHCE genesKey Antigens: D, C, c, E, e. (Presence/absence D determines Rh Positive/Negative status). Numerous variants exist (Weak D, Partial D)","code":""},{"path":"biochemistryantigens.html","id":"mns-system-isbt-002","chapter":"Biochemistry/Antigens","heading":"MNS System (ISBT 002)","text":"Biochemistry: Located Glycophorins (GPA) B (GPB), major sialic acid-rich glycoproteins RBC membrane. Encoded linked genes GYPA GYPBKey Antigens: M, N (GPA); S, s, U (GPB). Many variants exist due gene rearrangements","code":""},{"path":"biochemistryantigens.html","id":"p1pk-globoside-systems-isbt-003-isbt-028","chapter":"Biochemistry/Antigens","heading":"P1PK / Globoside Systems (ISBT 003 / ISBT 028)","text":"Biochemistry: Carbohydrate antigens synthesized sequentially glycolipid precursors RBC membraneKey Antigens: P1 (P1PK system); P, Pk (Globoside system). rare ‘p’ phenotype lacks antigens","code":""},{"path":"biochemistryantigens.html","id":"ii-system-isbt-027","chapter":"Biochemistry/Antigens","heading":"Ii System (ISBT 027)","text":"Biochemistry: Carbohydrate antigens (= branched, = linear chains) present precursor chains used ABO/H synthesis. Found glycoproteins glycolipidsKey Antigens: , . Expression changes age (infants high , adults high )","code":""},{"path":"biochemistryantigens.html","id":"kell-system-isbt-006","chapter":"Biochemistry/Antigens","heading":"Kell System (ISBT 006)","text":"Biochemistry: Located transmembrane glycoprotein (Kell protein) linked single disulfide bond XK protein. Involved membrane integrityKey Antigens: K (low prevalence), k (high prevalence). Also Kpa/Kpb, Jsa/Jsb. 30 antigens system. K0 (Kell null) phenotype lacks Kell antigens","code":""},{"path":"biochemistryantigens.html","id":"kidd-system-isbt-009","chapter":"Biochemistry/Antigens","heading":"Kidd System (ISBT 009)","text":"Biochemistry: Located multi-pass transmembrane protein functions urea transporter (HUT11/SLC14A1)Key Antigens: Jka, Jkb. Jk(-b-) null phenotype","code":""},{"path":"biochemistryantigens.html","id":"duffy-system-isbt-008","chapter":"Biochemistry/Antigens","heading":"Duffy System (ISBT 008)","text":"Biochemistry: Located Duffy Antigen Receptor Chemokines (DARC), multi-pass transmembrane glycoprotein binds various inflammatory chemokinesKey Antigens: Fya, Fyb. Fy(-b-) phenotype common African ancestry (associated malaria resistance)","code":""},{"path":"biochemistryantigens.html","id":"lutheran-lu","chapter":"Biochemistry/Antigens","heading":"Lutheran (LU)","text":"Biochemistry: Antigens (Lua, Lub) glycoprotein (Basal Cell Adhesion Molecule - BCAM)Significance: Anti-Lua often IgM/mixed, often naturally occurring, usually causes mild reactions. Anti-Lub (rare Ab high-prevalence Ag) usually IgG, causes mild-moderate HTR/HDFN. Often associated mixed-field agglutination","code":""},{"path":"biochemistryantigens.html","id":"other-blood-group-systems","chapter":"Biochemistry/Antigens","heading":"Other Blood Group Systems","text":"Biochemistry: Diverse. Includes antigens proteins (e.g., Diego Band 3/AE1; Colton Aquaporin-1), GPI-anchored proteins (e.g., Cartwright Acetylcholinesterase; Dombrock), etcKey Antigens: Numerous systems (Lutheran, Diego, Yt, Xg, Scianna, Dombrock, Colton, Landsteiner-Wiener, Gerbich, Vel, etc.) set antigens","code":""},{"path":"biochemistryantigens.html","id":"antigens-of-high-prevalence-public","chapter":"Biochemistry/Antigens","heading":"Antigens of High Prevalence (“Public”)","text":"Biochemistry: Variable - can protein carbohydrate, part many different systemsKey Feature: Present RBCs >99% population (e.g., k, Kpb, Jsb, Lub, U, Vel, Emm, Ge3, Yta). Antibodies rare cause significant compatibility problems","code":""},{"path":"biochemistryantigens.html","id":"antigens-of-low-prevalence-private","chapter":"Biochemistry/Antigens","heading":"Antigens of Low Prevalence (“Private”)","text":"Biochemistry: Variable - often antithetical partner high-prevalence antigenKey Feature: Present RBCs <1-10% population (e.g., K, Kpa, Jsa, Lua, Wra, Dia). Antibodies often detected via incompatible crossmatch, compatible blood usually easy find","code":""},{"path":"biochemistryantigens.html","id":"hla-human-leukocyte-antigens","chapter":"Biochemistry/Antigens","heading":"HLA (Human Leukocyte Antigens)","text":"Biochemistry: Glycoproteins encoded Major Histocompatibility Complex (MHC) chromosome 6. Class (HLA-, -B, -C) nucleated cells platelets. Class II (HLA-DR, -DQ, -DP) primarily antigen-presenting cells. Absent mature RBCs.Key Feature: Extremely polymorphic. Critical immune recognition, transplantation, implicated platelet refractoriness, FNHTR, TRALI","code":""},{"path":"biochemistryantigens.html","id":"platelet-specific-antigens-hpa---human-platelet-antigens","chapter":"Biochemistry/Antigens","heading":"Platelet-Specific Antigens (HPA - Human Platelet Antigens)","text":"Biochemistry: Located platelet membrane glycoproteins, primarily GPIIb/IIIa, GPIb/IX/V, GPIa/IIa. Arise SNPs genes encoding proteinsKey Antigens: HPA-1a/1b, HPA-2a/2b, HPA-3a/3b, HPA-5a/5b common clinically. Implicated NAIT, PTP, platelet refractoriness","code":""},{"path":"biochemistryantigens.html","id":"granulocyte-specific-antigens-hna---human-neutrophil-antigens","chapter":"Biochemistry/Antigens","heading":"Granulocyte-Specific Antigens (HNA - Human Neutrophil Antigens)","text":"Biochemistry: Located various neutrophil membrane glycoproteins, including FcγRIIIb (CD16b), CD177, CTL2, etcKey Antigens: HNA-1, HNA-2, HNA-3 systems studied. Antibodies primarily implicated TRALI, neonatal alloimmune neutropenia (NAN), autoimmune neutropenia (AIN)","code":""},{"path":"abo.html","id":"abo","chapter":"ABO","heading":"ABO","text":"ABO blood group system (ISBT 001) arguably critical system transfusion medicine due presence potent, naturally occurring antibodies. Unlike many systems involve protein structures, ABO antigens carbohydrates, specifically sugars added sequentially onto precursor chains found red blood cell surface. specific sugar added determined inherited enzymes called glycosyltransferases, ultimately resulting familiar , B, H antigens define person’s ABO type","code":""},{"path":"abo.html","id":"the-foundation-precursor-substances","chapter":"ABO","heading":"The Foundation: Precursor Substances","text":"Everything starts basic carbohydrate chains attached proteins lipids sticking red blood cell membrane (glycoproteins glycolipids). precursor chains come two main flavors relevant ABO:Type 1 Chains: Found primarily plasma/secretions body cells. terminal galactose (Gal) linked N-acetylglucosamine (GlcNAc) beta 1->3 linkage. (Galβ1->3GlcNAc-R)Type 2 Chains: Found predominantly red blood cell surface. terminal galactose (Gal) linked N-acetylglucosamine (GlcNAc) beta 1->4 linkage. (Galβ1->4GlcNAc-R)\nThink Type 2 chains primary building site RBCs ABO antigens\nThink Type 2 chains primary building site RBCs ABO antigens","code":""},{"path":"abo.html","id":"step-1-building-the-h-antigen---the-essential-intermediate","chapter":"ABO","heading":"Step 1: Building the “H” Antigen - The Essential Intermediate","text":"B antigens can made, another antigen, H antigen, must formed precursor substanceGene: FUT1 (also known H gene), located chromosome 19Enzyme: gene codes enzyme called α-2-L-fucosyltransferaseAction: enzyme transfers sugar L-fucose donor molecule (GDP-fucose) onto terminal galactose Type 2 precursor chain red blood cell surfaceResult: H antigen formed. (Fucα1->2Galβ1->4GlcNAc-R)Significance: H antigen mandatory substrate (building block) B enzymes. H antigen = B antigen expression RBCs (leads Bombay phenotype, ’ll discuss)Alleles: common functional allele H (FUT1). common non-functional allele h, produces inactive enzyme. people HH Hh make H antigen. hh genotype results Bombay phenotype","code":""},{"path":"abo.html","id":"step-2-adding-the-a-and-b-antigens---the-defining-step","chapter":"ABO","heading":"Step 2: Adding the “A” and “B” Antigens - The Defining Step","text":"ABO gene, located chromosome 9, determines () additional sugar added H antigenGene: ABO geneAlleles: Three main alleles: , B, OEnzymes (Glycosyltransferases)\nallele codes α-3-N-acetylgalactosaminyltransferase. enzyme transfers N-acetyl-D-galactosamine (GalNAc) onto galactose H antigen. creates antigen. (GalNAcα1->3[Fucα1->2]Galβ1->4GlcNAc-R)\nB allele codes α-3-D-galactosyltransferase. enzyme transfers D-galactose (Gal) onto galactose H antigen. creates B antigen. (Galα1->3[Fucα1->2]Galβ1->4GlcNAc-R)\nO allele typically results mutation (often frameshift deletion) leads non-functional enzyme. sugar added H antigen. Therefore, Group O individuals red cells rich unmodified H antigen\nallele codes α-3-N-acetylgalactosaminyltransferase. enzyme transfers N-acetyl-D-galactosamine (GalNAc) onto galactose H antigen. creates antigen. (GalNAcα1->3[Fucα1->2]Galβ1->4GlcNAc-R)B allele codes α-3-D-galactosyltransferase. enzyme transfers D-galactose (Gal) onto galactose H antigen. creates B antigen. (Galα1->3[Fucα1->2]Galβ1->4GlcNAc-R)O allele typically results mutation (often frameshift deletion) leads non-functional enzyme. sugar added H antigen. Therefore, Group O individuals red cells rich unmodified H antigenImmunodominant Sugars: final sugar added determines antigen’s specificity:\nantigen: N-acetyl-D-galactosamine (GalNAc)\nB antigen: D-galactose (Gal)\nH antigen: L-fucose (present , B, O phenotypes, abundant O)\nantigen: N-acetyl-D-galactosamine (GalNAc)B antigen: D-galactose (Gal)H antigen: L-fucose (present , B, O phenotypes, abundant O)","code":""},{"path":"abo.html","id":"genotype-to-phenotype---putting-it-together","chapter":"ABO","heading":"Genotype to Phenotype - Putting it Together","text":"","code":""},{"path":"abo.html","id":"abo-subgroups-a1-and-a2","chapter":"ABO","heading":"ABO Subgroups: A1 and A2","text":"phenotype uniform; major subgroups A1 A2A1: Represents 80% Group (AB) individuals\nA1 transferase highly efficient produces large number antigen sites, branched structures (complex)\nA1 transferase highly efficient produces large number antigen sites, branched structures (complex)A2: Represents 20% Group (AB) individuals\nA2 transferase results slightly different allele SNPs less efficient. produces fewer antigen sites per RBC, primarily linear (less complex) structures\nA2 cells unconverted H antigen A1 cells\nA2 transferase results slightly different allele SNPs less efficient. produces fewer antigen sites per RBC, primarily linear (less complex) structuresA2 cells unconverted H antigen A1 cellsClinical Relevance: A2 (especially A2B) individuals (~1-8% A2, ~22-35% A2B) may produce anti-A1 antibody. antibody reacts A1 cells A2 cells. ’s usually cold-reacting IgM clinically significant reactive 37°C (rare). lectin Dolichos biflorus specifically agglutinates A1 cells, helping differentiate A1 A2","code":""},{"path":"abo.html","id":"location-of-abo-antigens","chapter":"ABO","heading":"Location of ABO Antigens","text":"ABO antigens aren’t just red blood cells!Red Blood Cells: Synthesized Type 2 precursor chainsOther Cells: Widely expressed surface endothelial cells (lining blood vessels) many epithelial cells throughout body. Also present platelets (adsorbed plasma) lymphocytesSecretions (Soluble Antigens): ABO antigens can also found soluble glycoproteins body fluids like plasma, saliva, tears, sweat, etc. depends inheriting Secretor gene (FUT2)\nSecretor Gene (FUT2): Also chromosome 19, codes another α-2-L-fucosyltransferase acts primarily Type 1 chains secretory tissues\nIndividuals SeSe Sese (80% population) express soluble H antigen secretions. also B genes, secrete soluble B antigens, respectively\nIndividuals sese secrete H, , B antigens, regardless ABO type\nNote: FUT1 gene controls H RBCs; FUT2 gene controls H (thus /B) secretions\nSecretor Gene (FUT2): Also chromosome 19, codes another α-2-L-fucosyltransferase acts primarily Type 1 chains secretory tissuesIndividuals SeSe Sese (80% population) express soluble H antigen secretions. also B genes, secrete soluble B antigens, respectivelyIndividuals sese secrete H, , B antigens, regardless ABO typeNote: FUT1 gene controls H RBCs; FUT2 gene controls H (thus /B) secretions","code":""},{"path":"abo.html","id":"the-bombay-phenotype-oh","chapter":"ABO","heading":"The Bombay Phenotype (Oh)","text":"rare phenotype critical understand:Genotype: Homozygous recessive H locus (hh) ABO genotypeBiochemistry: Lack functional FUT1 enzyme. produce H antigen red cellsConsequence: Since H substrate B enzymes, individuals make B antigens RBCs, even B genesSerology: Types Group O routine forward typing (reaction anti-anti-B)Antibodies: Crucially, Bombay individuals produce potent, wide-thermal range anti-H antibody (addition anti-anti-B, unless B genes might prevent ). anti-H reacts strongly red cells except Bombay cells (non-Bombay cells H antigen, Group O )Transfusion: Can receive blood Bombay donors","code":""},{"path":"abo.html","id":"abo-antibodies","chapter":"ABO","heading":"ABO Antibodies","text":"unique feature ABO system predictable presence antibodies plasma/serum directed antigen(s) absent individual’s red cells“Naturally Occurring”: Usually appear first 3-6 months life, likely stimulated environmental exposure -like B-like antigens bacteria, pollen, etc. typically present birthReciprocal Relationship (Landsteiner’s Rule)\nGroup individuals Anti-B\nGroup B individuals Anti-\nGroup O individuals Anti-, Anti-B, Anti-,B\nGroup AB individuals ABO antibodies\nBombay individuals Anti-, Anti-B, Anti-,B, Anti-H\nGroup individuals Anti-BGroup B individuals Anti-AGroup O individuals Anti-, Anti-B, Anti-,BGroup AB individuals ABO antibodiesBombay individuals Anti-, Anti-B, Anti-,B, Anti-HImmunoglobulin Class: Primarily IgM, large molecules, excellent agglutination (visible clumping) potent activators classical complement pathway. leads rapid intravascular hemolysis incompatible blood transfusedIgG Component: Group O individuals often significant IgG component anti-anti-B, addition IgM. IgG anti-,B can cross placenta common cause ABO Hemolytic Disease Fetus Newborn (HDFN). Group B individuals typically mostly IgM antibodiesClinical Significance: ABO antibodies clinically significant blood group antibodies, capable causing acute, severe, potentially fatal hemolytic transfusion reactions (HTRs)","code":""},{"path":"abo.html","id":"key-terms-30","chapter":"ABO","heading":"Key Terms","text":"Glycosyltransferase: enzyme transfers sugar molecule donor acceptor molecule (e.g., -transferase, B-transferase, H-transferase)Immunodominant Sugar: terminal sugar molecule antigen defines specificity primarily recognized antibody (GalNAc , Gal B, Fucose H)Precursor Substance: basic carbohydrate chain (Type 1 Type 2) upon H, , B antigens builtH Antigen: antigen formed adding fucose precursor chain; substrate B antigen synthesis red cells. Controlled FUT1 (H gene)Antigen: Antigen formed adding N-acetylgalactosamine (GalNAc) H antigenB Antigen: Antigen formed adding D-galactose (Gal) H antigenAmorph: gene produce detectable product (e.g., O allele produces non-functional enzyme)Bombay Phenotype (Oh): Rare phenotype resulting hh genotype; individuals lack H, , B antigens red cells produce anti-HSecretor (Se) Gene (FUT2): Gene controlling expression H antigen (thus /B antigens) body secretions via action Type 1 chainsLectin: protein, usually plant origin, binds specifically carbohydrates (e.g., Dolichos biflorus lectin binds A1 antigen)Naturally Occurring Antibody: Antibody present serum/plasma without known prior exposure corresponding red cell antigen (typically IgM, like anti-anti-B)Landsteiner’s Rule: Healthy individuals possess ABO antibodies serum/plasma directed ABO antigen(s) absent red cells","code":""},{"path":"lewis.html","id":"lewis","chapter":"Lewis","heading":"Lewis","text":"Lewis blood group system (ISBT 007) fascinating , unlike ABO Rh, Lewis antigens aren’t manufactured red blood cell . Instead, soluble carbohydrate antigens found plasma secretions passively adsorb onto red cell membrane. system intricately linked Secretor system (FUT2 gene) ABO genetics, interplay Lewis (FUT3) Secretor (FUT2) fucosyltransferase enzymes determining whether Lea Leb antigens formed Type 1 precursor chains","code":""},{"path":"lewis.html","id":"genetics-two-key-players-fut3-and-fut2","chapter":"Lewis","heading":"Genetics: Two Key Players (FUT3 and FUT2)","text":"expression Lewis antigens depends interplay two genes, located chromosome 19:Lewis Gene (FUT3 Le)\nCodes enzyme called α-1,4-L-fucosyltransferase (sometimes written Fucosyltransferase 3 FucT-III)\nFunction: Adds fucose sugar N-acetylglucosamine (GlcNAc) residue Type 1 precursor chains\nAlleles\nLe: Functional allele, produces enzyme\nle: Amorph (non-functional) allele, common mutation results active enzyme. le recessive Le\n\nCodes enzyme called α-1,4-L-fucosyltransferase (sometimes written Fucosyltransferase 3 FucT-III)Function: Adds fucose sugar N-acetylglucosamine (GlcNAc) residue Type 1 precursor chainsAlleles\nLe: Functional allele, produces enzyme\nle: Amorph (non-functional) allele, common mutation results active enzyme. le recessive Le\nLe: Functional allele, produces enzymele: Amorph (non-functional) allele, common mutation results active enzyme. le recessive LeSecretor Gene (FUT2 Se): (discussed ABO secretions)\nCodes enzyme called α-1,2-L-fucosyltransferase (Fucosyltransferase 2 FucT-II)\nFunction: Adds fucose sugar terminal galactose (Gal) residue Type 1 precursor chains (primarily secretory tissues) also Type 2 chains (relevant H RBCs via FUT1)\nAlleles\nSe: Functional allele, produces enzyme active secretory tissues\nse: Amorph allele, results active enzyme secretory tissues. se recessive Se\n\nCodes enzyme called α-1,2-L-fucosyltransferase (Fucosyltransferase 2 FucT-II)Function: Adds fucose sugar terminal galactose (Gal) residue Type 1 precursor chains (primarily secretory tissues) also Type 2 chains (relevant H RBCs via FUT1)Alleles\nSe: Functional allele, produces enzyme active secretory tissues\nse: Amorph allele, results active enzyme secretory tissues. se recessive Se\nSe: Functional allele, produces enzyme active secretory tissuesse: Amorph allele, results active enzyme secretory tissues. se recessive Se","code":""},{"path":"lewis.html","id":"biochemistry-building-the-lewis-antigens-on-type-1-chains","chapter":"Lewis","heading":"Biochemistry: Building the Lewis Antigens (on Type 1 Chains)","text":"Lewis antigens built Type 1 precursor chains (Galβ1->3GlcNAc-R), primarily found secretions plasma glycolipids glycoproteinsStep 1: Formation Lea Antigen\nindividual least one functional Le gene (FUT3), α-1,4-L-fucosyltransferase adds fucose GlcNAc Type 1 chain\nResult: Lea antigen formed\nStructure: Galβ1->3[Fucα1->4]GlcNAc-R\nRequires Le enzyme\nindividual least one functional Le gene (FUT3), α-1,4-L-fucosyltransferase adds fucose GlcNAc Type 1 chainResult: Lea antigen formedStructure: Galβ1->3[Fucα1->4]GlcNAc-RRequires Le enzymeStep 2: Formation H Antigen (Type 1)\nindividual least one functional Se gene (FUT2), α-1,2-L-fucosyltransferase adds fucose terminal Galactose Type 1 chain (secretory tissue)\nResult: H antigen (Type 1) formed\nStructure: Fucα1->2Galβ1->3GlcNAc-R\nRequires Se enzyme\nindividual least one functional Se gene (FUT2), α-1,2-L-fucosyltransferase adds fucose terminal Galactose Type 1 chain (secretory tissue)Result: H antigen (Type 1) formedStructure: Fucα1->2Galβ1->3GlcNAc-RRequires Se enzymeStep 3: Formation Leb Antigen - Interaction!\nindividual functional Le gene functional Se gene, enzymes present\nSe gene enzyme adds fucose Galactose (creating H Type 1)\nLe gene enzyme adds fucose GlcNAc chain\nResult: Leb antigen formed, containing two fucose molecules adjacent sugars\nStructure: Fucα1->2Galβ1->3[Fucα1->4]GlcNAc-R\nRequires Le Se enzymes acting Type 1 chain\nCompetition: Se gene enzyme (FucT-II) acts preferentially Type 1 chain. H formed, Le enzyme (FucT-III) readily adds second fucose create Leb. efficient process means individuals Le Se genes, precursor chains converted Leb, leaving little Lea available\nindividual functional Le gene functional Se gene, enzymes presentThe Se gene enzyme adds fucose Galactose (creating H Type 1)Le gene enzyme adds fucose GlcNAc chainResult: Leb antigen formed, containing two fucose molecules adjacent sugarsStructure: Fucα1->2Galβ1->3[Fucα1->4]GlcNAc-RRequires Le Se enzymes acting Type 1 chainCompetition: Se gene enzyme (FucT-II) acts preferentially Type 1 chain. H formed, Le enzyme (FucT-III) readily adds second fucose create Leb. efficient process means individuals Le Se genes, precursor chains converted Leb, leaving little Lea available","code":""},{"path":"lewis.html","id":"lewis-antigens-on-red-blood-cells-adsorption","chapter":"Lewis","heading":"Lewis Antigens on Red Blood Cells: Adsorption","text":"Lewis antigens synthesized primarily epithelial cells mucous tissues present glycolipids plasmaThese plasma Lewis glycolipids passively adsorb onto red blood cell membrane, intercalating lipid bilayerThe amount type Lewis antigen RBCs directly reflect present individual’s plasmaBecause adsorbed, Lewis antigen expression can decrease pregnancy certain diseases, donor Lewis antigens can elute transfused red cells time","code":""},{"path":"lewis.html","id":"common-lewis-phenotypes","chapter":"Lewis","heading":"Common Lewis Phenotypes","text":"RBC phenotype depends interaction Le Se genes:Le(+b-)\nGenotype: Le/ (LeLe Lele), sese\nEnzymes: functional Le enzyme, lacks functional Se enzyme\nAntigens Formed: Can make Lea antigen (adds fucose GlcNAc). make H Type 1 Leb secretions/plasma\nResult: Lea present plasma/saliva adsorbs onto RBCs\nGenotype: Le/ (LeLe Lele), seseEnzymes: functional Le enzyme, lacks functional Se enzymeAntigens Formed: Can make Lea antigen (adds fucose GlcNAc). make H Type 1 Leb secretions/plasmaResult: Lea present plasma/saliva adsorbs onto RBCsLe(-b+)\nGenotype: Le/ (LeLe Lele), Se/ (SeSe Sese)\nEnzymes: functional Le Se enzymes\nAntigens Formed: enzymes act Type 1 chains. Leb formed efficiently. little free Lea remains. H Type 1 also formed\nResult: Leb predominant antigen plasma/saliva adsorbs onto RBCs. RBCs type Le(-b+). (common phenotype many populations)\nGenotype: Le/ (LeLe Lele), Se/ (SeSe Sese)Enzymes: functional Le Se enzymesAntigens Formed: enzymes act Type 1 chains. Leb formed efficiently. little free Lea remains. H Type 1 also formedResult: Leb predominant antigen plasma/saliva adsorbs onto RBCs. RBCs type Le(-b+). (common phenotype many populations)Le(-b-)\nGenotype Possibility 1: lele, Se (SeSe, Sese, sese)\nEnzymes: Lacks functional Le enzyme. add fucose GlcNAc\nAntigens Formed: make Lea Leb. May make H Type 1 Se present, Lewis antigens\nResult: Lewis antigens plasma/saliva adsorb onto RBCs\n\nGenotype Possibility 2: Le/, sese Le/, Se/ (Transiently)\nExplanation: Newborns may initially type Le(-b-) Lewis glycolipid synthesis adsorption take time. Pregnant women often show temporary decrease loss Lewis antigens RBCs, typing Le(-b-)\n\nGenotype Possibility 1: lele, Se (SeSe, Sese, sese)\nEnzymes: Lacks functional Le enzyme. add fucose GlcNAc\nAntigens Formed: make Lea Leb. May make H Type 1 Se present, Lewis antigens\nResult: Lewis antigens plasma/saliva adsorb onto RBCs\nEnzymes: Lacks functional Le enzyme. add fucose GlcNAcAntigens Formed: make Lea Leb. May make H Type 1 Se present, Lewis antigensResult: Lewis antigens plasma/saliva adsorb onto RBCsGenotype Possibility 2: Le/, sese Le/, Se/ (Transiently)\nExplanation: Newborns may initially type Le(-b-) Lewis glycolipid synthesis adsorption take time. Pregnant women often show temporary decrease loss Lewis antigens RBCs, typing Le(-b-)\nExplanation: Newborns may initially type Le(-b-) Lewis glycolipid synthesis adsorption take time. Pregnant women often show temporary decrease loss Lewis antigens RBCs, typing Le(-b-)Le(+b+)\nOccurrence: rare adults, common infants/young children\nExplanation: May represent transitional stage Lea Leb glycolipids present plasma adsorb. Possibly due less efficient conversion Leb initially variations enzyme activity. adults, ’s extremely uncommon conversion Leb usually efficient Le/Se individuals\nOccurrence: rare adults, common infants/young childrenExplanation: May represent transitional stage Lea Leb glycolipids present plasma adsorb. Possibly due less efficient conversion Leb initially variations enzyme activity. adults, ’s extremely uncommon conversion Leb usually efficient Le/Se individuals","code":""},{"path":"lewis.html","id":"lewis-antibodies-anti-lea-anti-leb","chapter":"Lewis","heading":"Lewis Antibodies (Anti-Lea, Anti-Leb)","text":"Formation: Often “naturally occurring,” meaning appear without known red cell stimulus (transfusion pregnancy). Usually found individuals Le(-b-) phenotype. Le(+b-) individuals make anti-LebImmunoglobulin Class: Primarily IgMReactivity: Typically react best room temperature saline (immediate spin). May sometimes detected 37°C /AHG phase, especially enzyme-treated cellsClinical Significance\nGenerally considered clinically insignificant react 37°C. usually cause hemolytic transfusion reactions (HTRs) Hemolytic Disease Fetus Newborn (HDFN)\nusually significant?\nOften IgM, doesn’t cross placenta (HDFN)\nAntigens poorly developed fetal/newborn RBCs (HDFN)\nAntibodies often neutralized soluble Lewis antigens present donor plasma transfused RBCs\nLewis antigens can elute transfused Le+ cells Le- recipient\nOptimal reactivity usually body temperature\n\nException: RARELY, Lewis antibody (especially anti-Lea) may show reactivity 37°C cause complement activation, potentially leading hemolysis vitro , infrequently, vivo. Antibodies reacting 37°C/AHG phase require careful consideration provision antigen-negative units\nGenerally considered clinically insignificant react 37°C. usually cause hemolytic transfusion reactions (HTRs) Hemolytic Disease Fetus Newborn (HDFN)usually significant?\nOften IgM, doesn’t cross placenta (HDFN)\nAntigens poorly developed fetal/newborn RBCs (HDFN)\nAntibodies often neutralized soluble Lewis antigens present donor plasma transfused RBCs\nLewis antigens can elute transfused Le+ cells Le- recipient\nOptimal reactivity usually body temperature\nOften IgM, doesn’t cross placenta (HDFN)Antigens poorly developed fetal/newborn RBCs (HDFN)Antibodies often neutralized soluble Lewis antigens present donor plasma transfused RBCsLewis antigens can elute transfused Le+ cells Le- recipientOptimal reactivity usually body temperatureException: RARELY, Lewis antibody (especially anti-Lea) may show reactivity 37°C cause complement activation, potentially leading hemolysis vitro , infrequently, vivo. Antibodies reacting 37°C/AHG phase require careful consideration provision antigen-negative unitsNeutralization: Lewis antibodies can often neutralized incubating patient’s plasma commercial Lewis substance sometimes even pooled plasma/saliva (contain soluble Lewis antigens), preventing reactivity test cells. can useful identification technique","code":""},{"path":"lewis.html","id":"summary-table-lewis-system-genetics-and-phenotypes","chapter":"Lewis","heading":"Summary Table: Lewis System Genetics and Phenotypes","text":"","code":""},{"path":"lewis.html","id":"key-terms-31","chapter":"Lewis","heading":"Key Terms","text":"Adsorption: process soluble substances (like Lewis glycolipids) plasma attach surface red blood cellsType 1 Precursor Chain: carbohydrate chain (Galβ1->3GlcNAc-R) found primarily secretions plasma, serving substrate Lewis Secretor enzymesFUT3 (Lewis Gene): Gene encoding α-1,4-L-fucosyltransferase, responsible adding fucose GlcNAc create Lea antigenFUT2 (Secretor Gene): Gene encoding α-1,2-L-fucosyltransferase, responsible adding fucose Galactose create H Type 1 antigen (secretions) influencing Leb formationLea Antigen: Lewis antigen formed action Le gene enzyme onlyLeb Antigen: Lewis antigen formed sequential combined action Le Se gene enzymes Type 1 chainGlycolipid: lipid molecule attached carbohydrate chains (Lewis antigens exist plasma)Neutralization: technique used antibody identification soluble antigen added plasma inhibit antibody reactivity test cells","code":""},{"path":"rh.html","id":"rh","chapter":"Rh","heading":"Rh","text":"Rh blood group system (ISBT 004) stands second ABO clinical importance, largely due high immunogenicity D antigen role severe Hemolytic Disease Fetus Newborn (HDFN) transfusion reactions. Unlike carbohydrate-based systems, Rh antigens (D, C, c, E, e significant) integral parts complex transmembrane proteins encoded closely linked RHD RHCE genes chromosome 1. Understanding biochemistry proteins variants crucial safe transfusion practice","code":""},{"path":"rh.html","id":"genetics-recap-the-foundation","chapter":"Rh","heading":"Genetics Recap: The Foundation","text":"Remember two highly similar (homologous) closely linked genes chromosome 1?RHD Gene: Codes RhD protein. Determines RhD positive negative statusRHCE Gene: Codes RhCE protein. Polymorphisms (variations) gene determine expression C vs c E vs e antigensLinkage: close, inherit together haplotype (e.g., DCe, dce, DcE). get one haplotype parentRHAG Gene (Rh-Associated Glycoprotein): Located chromosome 6. gene crucial! codes “coexpressor” “support” protein (RhAG) essential trafficking integrating RhD RhCE proteins red blood cell membrane. functional RhAG = RhD/RhCE expression (one cause Rhnull phenotype)","code":""},{"path":"rh.html","id":"biochemistry-the-rh-proteins","chapter":"Rh","heading":"Biochemistry: The Rh Proteins","text":"Unlike ABO Lewis antigens carbohydrates built enzymes, Rh antigens integral parts proteins span red blood cell membraneRhD RhCE Proteins\nHighly similar structure (92% identical amino acid sequence)\nLarge, transmembrane proteins loop RBC membrane 12 times\nglycosylated (sugar chains attached), unusual many red cell surface proteins\nFunction isn’t fully confirmed, thought involved membrane integrity potentially act transporters (perhaps ammonia CO2), though still debated\nexist membrane part protein complex, primarily associated RhAG. proteins like LW, Glycophorin B, CD47, Band 3 might also part complex, likely helps maintain RBC shape structure\nHighly similar structure (92% identical amino acid sequence)Large, transmembrane proteins loop RBC membrane 12 timesThey glycosylated (sugar chains attached), unusual many red cell surface proteinsFunction isn’t fully confirmed, thought involved membrane integrity potentially act transporters (perhaps ammonia CO2), though still debatedThey exist membrane part protein complex, primarily associated RhAG. proteins like LW, Glycophorin B, CD47, Band 3 might also part complex, likely helps maintain RBC shape structureRh-Associated Glycoprotein (RhAG)\nAlso transmembrane protein 12 loops, structurally similar RhD/RhCE coded different gene (RHAG) different chromosome\nglycosylated\nEssential expression RhD RhCE proteins cell surface. acts like scaffold escort service get properly inserted membrane\nAlso transmembrane protein 12 loops, structurally similar RhD/RhCE coded different gene (RHAG) different chromosomeIt glycosylatedEssential expression RhD RhCE proteins cell surface. acts like scaffold escort service get properly inserted membrane","code":""},{"path":"rh.html","id":"the-major-rh-antigens-d-c-c-e-e","chapter":"Rh","heading":"The Major Rh Antigens: D, C, c, E, e","text":"five antigens important serologically. presence absence determined specific RhD RhCE proteins expressedD Antigen\nimmunogenic Rh antigen\nPresence absence determines Rh positive (D+) Rh negative (D-) status\nLocated RhD protein. RHD gene present functional, RhD protein made, person D+\nRHD gene absent (like common deletion Caucasians) non-functional (due mutations), RhD protein made, person D-\n“d” antigen.: lowercase “d” simply indicates absence D antigen\nimmunogenic Rh antigenPresence absence determines Rh positive (D+) Rh negative (D-) statusLocated RhD protein. RHD gene present functional, RhD protein made, person D+RHD gene absent (like common deletion Caucasians) non-functional (due mutations), RhD protein made, person D-“d” antigen.: lowercase “d” simply indicates absence D antigenC/c Antigens\nAntithetical pair (coded different alleles genetic locus within RHCE)\nLocated RhCE protein\nDiffer single amino acid change, determined SNPs RHCE gene. Specifically, Serine position 103 corresponds C, Proline position 103 corresponds c\nindividual can homozygous (CC cc) heterozygous (Cc)\nAntithetical pair (coded different alleles genetic locus within RHCE)Located RhCE proteinDiffer single amino acid change, determined SNPs RHCE gene. Specifically, Serine position 103 corresponds C, Proline position 103 corresponds cAn individual can homozygous (CC cc) heterozygous (Cc)E/e Antigens\nAnother antithetical pair\nAlso located RhCE protein\nDiffer single amino acid change different location protein, determined SNPs RHCE gene. Specifically, Proline position 226 corresponds E, Alanine position 226 corresponds e\nindividual can homozygous (EE ee) heterozygous (Ee)\nAnother antithetical pairAlso located RhCE proteinDiffer single amino acid change different location protein, determined SNPs RHCE gene. Specifically, Proline position 226 corresponds E, Alanine position 226 corresponds eAn individual can homozygous (EE ee) heterozygous (Ee)Combined Expression: RhCE protein expresses either C c either E e molecule, depending inherited RHCE allele (haplotype). example:\nDCe haplotype codes RhD protein RhCE protein expressing C e\nDcE haplotype codes RhD protein RhCE protein expressing c E\ndce haplotype codes RhD protein RhCE protein expressing c e\nDCe haplotype codes RhD protein RhCE protein expressing C eThe DcE haplotype codes RhD protein RhCE protein expressing c EThe dce haplotype codes RhD protein RhCE protein expressing c e","code":""},{"path":"rh.html","id":"nomenclature-snippet","chapter":"Rh","heading":"Nomenclature Snippet","text":"Fisher-Race (DCE): Describes antigens (D, C/c, E/e). Genotypes written based haplotypes (e.g., DCe/dce)Wiener (Rh-hr): Postulated single gene multiple alleles. Uses shorthand (e.g., R1 = DCe, r = dce, R2 = DcE, R0 = Dce). Less intuitive biochemically still widely used notationISBT Numerical: Standardized system (Rh 004). D=RH1, C=RH2, E=RH3, c=RH4, e=RH5","code":""},{"path":"rh.html","id":"variations-in-d-antigen-expression-weak-d-and-partial-d","chapter":"Rh","heading":"Variations in D Antigen Expression: Weak D and Partial D","text":"Rh gets particularly interesting clinically critical! D+ individuals express D antigen equally strongly completelyWeak D (Formerly Du)\nBiochemistry/Genetics: Usually caused missense mutations (SNPs) RHD gene change single amino acids. changes often occur transmembrane intracellular regions RhD protein\nResult: Leads fewer D antigen sites RBC surface (quantitative difference). D antigens present generally structurally normal\nSerology: React weakly non-reactive anti-D reagents direct agglutination tests (), usually react (sometimes weakly) AHG phase\nClinical Significance\nRecipients: Weak D individuals (especially Types 1, 2, 3 common) make anti-D exposed D+ blood. safety, often managed D-negative transfusion\nDonors: Weak D blood units considered D-positive can immunize D-negative recipients\n\nMolecular testing often needed confirm Weak D type\nBiochemistry/Genetics: Usually caused missense mutations (SNPs) RHD gene change single amino acids. changes often occur transmembrane intracellular regions RhD proteinResult: Leads fewer D antigen sites RBC surface (quantitative difference). D antigens present generally structurally normalSerology: React weakly non-reactive anti-D reagents direct agglutination tests (), usually react (sometimes weakly) AHG phaseClinical Significance\nRecipients: Weak D individuals (especially Types 1, 2, 3 common) make anti-D exposed D+ blood. safety, often managed D-negative transfusion\nDonors: Weak D blood units considered D-positive can immunize D-negative recipients\nRecipients: Weak D individuals (especially Types 1, 2, 3 common) make anti-D exposed D+ blood. safety, often managed D-negative transfusionAs Donors: Weak D blood units considered D-positive can immunize D-negative recipientsMolecular testing often needed confirm Weak D typePartial D\nBiochemistry/Genetics: Often caused gene rearrangements parts RHD gene replaced corresponding parts RHCE gene (creating hybrid genes), mutations causing significant changes external loops RhD protein\nResult: RhD protein altered, meaning D epitopes (parts antigen recognized antibodies) missing (qualitative difference). number antigen sites might normal reduced\nSerology: Reactivity anti-D reagents can vary strong positive weak negative, depending epitopes missing clones used anti-D reagent\nClinical Significance\nHIGH RISK: Partial D individuals can make allo-anti-D epitope(s) missing exposed D+ blood (containing complete D antigen)\nManagement: Partial D individuals must identified transfused D-negative blood. Pregnant Partial D women carrying D+ fetus may need Rh Immune Globulin (RhIG)\n\nDistinguishing Weak D Partial D crucial often requires molecular genotyping\nBiochemistry/Genetics: Often caused gene rearrangements parts RHD gene replaced corresponding parts RHCE gene (creating hybrid genes), mutations causing significant changes external loops RhD proteinResult: RhD protein altered, meaning D epitopes (parts antigen recognized antibodies) missing (qualitative difference). number antigen sites might normal reducedSerology: Reactivity anti-D reagents can vary strong positive weak negative, depending epitopes missing clones used anti-D reagentClinical Significance\nHIGH RISK: Partial D individuals can make allo-anti-D epitope(s) missing exposed D+ blood (containing complete D antigen)\nManagement: Partial D individuals must identified transfused D-negative blood. Pregnant Partial D women carrying D+ fetus may need Rh Immune Globulin (RhIG)\nHIGH RISK: Partial D individuals can make allo-anti-D epitope(s) missing exposed D+ blood (containing complete D antigen)Management: Partial D individuals must identified transfused D-negative blood. Pregnant Partial D women carrying D+ fetus may need Rh Immune Globulin (RhIG)Distinguishing Weak D Partial D crucial often requires molecular genotyping","code":""},{"path":"rh.html","id":"other-important-rh-antigens","chapter":"Rh","heading":"Other Important Rh Antigens","text":"D, C, c, E, e main players, others exist:G Antigen: Almost always present cells either D C antigen (). Anti-G reacts like combination anti-D + anti-C. Important obstetric settingsf Antigen (ce): Expressed c e present RhCE protein molecule (.e., inherited cis, haplotype, like dce)Cw Antigen: alternative allele C/c C/c locus. Low prevalenceV (RH10) VS (RH20): Low prevalence Caucasians higher prevalence individuals African descent. Associated specific RHCE gene variants","code":""},{"path":"rh.html","id":"rhnull-syndrome","chapter":"Rh","heading":"Rhnull Syndrome","text":"rare condition individuals lack Rh antigens (D, C, c, E, e, etc.) RBCsGenetics\nRegulator Type: Mutations RHAG gene. functional RhAG means RhD/RhCE proteins get membrane, even RHD/RHCE genes normal\nAmorphic Type: deletion RHD gene plus mutations inherited RHCE alleles, along normal RHAG gene\nRegulator Type: Mutations RHAG gene. functional RhAG means RhD/RhCE proteins get membrane, even RHD/RHCE genes normalAmorphic Type: deletion RHD gene plus mutations inherited RHCE alleles, along normal RHAG geneBiochemistry: Absence Rh protein complex (RhD, RhCE, RhAG)Clinical Features: Associated red blood cell membrane abnormalities (e.g., stomatocytosis, increased osmotic fragility) leading mild--moderate chronic hemolytic anemiaTransfusion: Extremely difficult. individuals can make antibodies high-prevalence antigens related Rh complex (like anti-Rh29 - total Rh). need blood Rhnull donors, exceptionally rare","code":""},{"path":"rh.html","id":"key-terms-32","chapter":"Rh","heading":"Key Terms","text":"RHD Gene: Codes protein carrying D antigenRHCE Gene: Codes protein carrying C/c E/e antigensRHAG Gene: Codes essential Rh-associated glycoprotein needed Rh protein expressionRhD/RhCE Proteins: Non-glycosylated, 12-pass transmembrane proteins forming structural basis Rh antigensRhAG Protein: Glycosylated transmembrane protein essential RhD/RhCE membrane integrationAntithetical Antigens: Antigens coded alleles locus (e.g., C c, E e)Haplotype: set linked genes inherited together one chromosome (e.g., DCe)Weak D: Quantitative reduction D antigen expression, usually due mutations affecting protein transport stability. Cells fewer D sitesPartial D: Qualitative alteration D antigen, missing epitopes, often due hybrid genes mutations external loops. Individuals can make allo-anti-DEpitope: specific part antigen molecule recognized antibodyRhnull: Absence Rh antigens due defects RHAG (regulator) RHD/RHCE (amorphic). Associated hemolytic anemiaImmunogenicity: ability antigen provoke immune response (antibody production). D highly immunogenic","code":""},{"path":"mns.html","id":"mns","chapter":"MNS","heading":"MNS","text":"MNS blood group system (ISBT 002) complex system characterized antigens located two major red blood cell sialoglycoproteins: Glycophorin (GPA) Glycophorin B (GPB). Unlike ABO Lewis antigens carbohydrates, MNS antigens like antithetical pairs M/N (GPA) S/s (GPB) defined specific amino acid variations proteins, encoded closely linked GYPA GYPB genes. system also includes high-prevalence U antigen, also GPB, numerous variants arising genetic mutations rearrangements, antibodies like anti-S, anti-s, anti-U holding significant clinical importance","code":""},{"path":"mns.html","id":"the-players-glycophorin-a-gpa-and-glycophorin-b-gpb","chapter":"MNS","heading":"The Players: Glycophorin A (GPA) and Glycophorin B (GPB)","text":"MNS antigens located two important sialoglycoproteins (proteins lots sialic acid-containing sugar chains attached) span red blood cell membrane:Glycophorin (GPA)\nmajor sialoglycoprotein RBC surface (1 million copies per cell)\nEncoded GYPA gene chromosome 4\nCarries M N antigens\nHeavily glycosylated, contributing significantly RBC’s negative surface charge (due sialic acid). charge helps keep RBCs sticking together\nMay serve receptors certain pathogens (like Plasmodium falciparum) cytokines\nmajor sialoglycoprotein RBC surface (1 million copies per cell)Encoded GYPA gene chromosome 4Carries M N antigensHeavily glycosylated, contributing significantly RBC’s negative surface charge (due sialic acid). charge helps keep RBCs sticking togetherMay serve receptors certain pathogens (like Plasmodium falciparum) cytokinesGlycophorin B (GPB)\nStructurally similar N-terminal portion GPA present fewer copies (200,000 per cell)\nEncoded GYPB gene, located close GYPA chromosome 4 (linkage important inheritance)\nCarries S, s, U antigens\nAlso glycosylated contributes negative surface charge\nStructurally similar N-terminal portion GPA present fewer copies (200,000 per cell)Encoded GYPB gene, located close GYPA chromosome 4 (linkage important inheritance)Carries S, s, U antigensAlso glycosylated contributes negative surface charge","code":""},{"path":"mns.html","id":"genetics-recap-linked-genes","chapter":"MNS","heading":"Genetics Recap: Linked Genes","text":"GYPA GYPB tightly linked chromosome 4This means usually inherited together haplotype (e.g., MS, Ms, NS, Ns)","code":""},{"path":"mns.html","id":"biochemistry-of-antigen-specificity","chapter":"MNS","heading":"Biochemistry of Antigen Specificity","text":"differences M/N S/s antigens determined variations amino acid sequences GPA GPB, caused single nucleotide polymorphisms (SNPs) GYPA GYPB genesM N Antigens (GPA)\ndifference M N lies positions 1 5 GPA protein sequence (N-terminus, sticking cell)\nM Antigen: Serine position 1 Glycine position 5\nN Antigen: Leucine position 1 Glutamic Acid position 5\nantithetical antigens – individual inherits genetic information produce either M N GPA chromosome 4. Genotypes can MM, MN, NN\ndifference M N lies positions 1 5 GPA protein sequence (N-terminus, sticking cell)M Antigen: Serine position 1 Glycine position 5N Antigen: Leucine position 1 Glutamic Acid position 5These antithetical antigens – individual inherits genetic information produce either M N GPA chromosome 4. Genotypes can MM, MN, NNS s Antigens (GPB)\ndifference S s lies position 29 GPB protein sequence\nS Antigen: Methionine position 29\ns Antigen: Threonine position 29\nalso antithetical antigens. Genotypes can SS, Ss, ss\ndifference S s lies position 29 GPB protein sequenceS Antigen: Methionine position 29s Antigen: Threonine position 29These also antithetical antigens. Genotypes can SS, Ss, ss","code":""},{"path":"mns.html","id":"the-u-antigen-on-gpb","chapter":"MNS","heading":"The U Antigen (on GPB)","text":"Location: Located GPB, closer red cell membrane S/s antigens. requires presence significant portion GPB protein structurePrevalence: high-prevalence antigen, present RBCs 99.9% individuals populationsU-Negative Phenotype\nIndividuals lack U antigen. phenotype rare, found almost exclusively individuals African descent (1% prevalence population)\nUsually results deletion mutations GYPB gene, leading absence severe truncation GPB\nS s also GPB, U-negative individuals almost always S-s- well\nClinical Significance: U-negative individuals can form anti-U, clinically significant antibody capable causing severe HTRs HDFN. Finding U-negative blood transfusion extremely challenging\nIndividuals lack U antigen. phenotype rare, found almost exclusively individuals African descent (1% prevalence population)Usually results deletion mutations GYPB gene, leading absence severe truncation GPBBecause S s also GPB, U-negative individuals almost always S-s- wellClinical Significance: U-negative individuals can form anti-U, clinically significant antibody capable causing severe HTRs HDFN. Finding U-negative blood transfusion extremely challenging","code":""},{"path":"mns.html","id":"common-haplotypes-and-phenotypes","chapter":"MNS","heading":"Common Haplotypes and Phenotypes","text":"Due linkage GYPA GYPB, certain combinations antigens inherited together:Common Haplotypes: MS, Ms, NS, NsResulting Genotypes: individual inherits one haplotype parent (e.g., MS/Ms, MS/NS, Ns/Ns)Phenotype: combination antigens detected cells (e.g., M+N+S+s+)","code":""},{"path":"mns.html","id":"effect-of-proteolytic-enzymes-ficin-papain","chapter":"MNS","heading":"Effect of Proteolytic Enzymes (Ficin, Papain)","text":"Enzyme treatment key tool antibody identification involving MNS system:M N Antigens: Located outer portion GPA, easily cleaved enzymes like ficin papain. Therefore, M N antigens DESTROYED enzyme treatmentS s Antigens: Located GPB. susceptibility enzymes VARIABLE. S often sensitive s, can weakened sometimes resistant depending specific enzyme conditions. generally considered resistant M NU Antigen: closer membrane GPB, U antigen generally RESISTANT enzyme treatment","code":""},{"path":"mns.html","id":"dosage-effect","chapter":"MNS","heading":"Dosage Effect","text":"Antibodies MNS system (especially anti-M, -N, -S, -s) often show dosage. means react strongly red cells homozygous corresponding antigen compared heterozygous cellsExample: Anti-M may react 3+ M+N- cells (genotype MM) 1+ M+N+ cells (genotype MN)","code":""},{"path":"mns.html","id":"mns-antibodies-a-quick-overview","chapter":"MNS","heading":"MNS Antibodies: A Quick Overview","text":"Anti-M\nCommonly encountered “naturally occurring” antibody\nOften IgM, reactive room temperature (phase)\nUsually clinically insignificant unless reactive 37°C/AHG\nFrequently shows dosage\npH dependent (enhanced reactivity pH 6.5)\nCommonly encountered “naturally occurring” antibodyOften IgM, reactive room temperature (phase)Usually clinically insignificant unless reactive 37°C/AHGFrequently shows dosagepH dependent (enhanced reactivity pH 6.5)Anti-N\nLess common anti-M\nUsually IgM, cold-reactive, clinically insignificant\nOften shows dosage\nrare “dialysis-associated” anti-N form can seen (reacts formaldehyde-treated N+ cells)\nLess common anti-MUsually IgM, cold-reactive, clinically insignificantOften shows dosageA rare “dialysis-associated” anti-N form can seen (reacts formaldehyde-treated N+ cells)Anti-S\nUsually IgG, reactive 37°C /AHG phase\nClinically significant: Can cause HTRs HDFN\nCan show dosage\nUsually IgG, reactive 37°C /AHG phaseClinically significant: Can cause HTRs HDFNCan show dosageAnti-s\nUsually IgG, reactive 37°C /AHG phase\nClinically significant: Can cause HTRs HDFN\nCan show dosage\nUsually IgG, reactive 37°C /AHG phaseClinically significant: Can cause HTRs HDFNCan show dosageAnti-U\nRare antibody found U-negative (S-s-) individuals\nUsually IgG, reactive 37°C/AHG\nClinically significant: Associated severe HTRs HDFN. Requires rare U-negative blood transfusion\nRare antibody found U-negative (S-s-) individualsUsually IgG, reactive 37°C/AHGClinically significant: Associated severe HTRs HDFN. Requires rare U-negative blood transfusion","code":""},{"path":"mns.html","id":"other-mns-variants","chapter":"MNS","heading":"Other MNS Variants","text":"Numerous antigens exist within MNS system (40!), often resulting :Mutations GYPA GYPBGene rearrangements unequal crossing-events GYPA GYPB, leading hybrid glycophorin molecules (e.g., Miltenberger subsystem antigens)Null phenotypes (e.g., MkMk genotype results lack GPA GPB)","code":""},{"path":"mns.html","id":"key-terms-33","chapter":"MNS","heading":"Key Terms","text":"Glycophorin (GPA): Major RBC sialoglycoprotein carrying M N antigensGlycophorin B (GPB): Minor RBC sialoglycoprotein carrying S, s, U antigensGYPA & GYPB: Genes encoding GPA GPB, respectively, located chromosome 4Sialoglycoprotein: protein attached sialic acid-containing carbohydrate chainsAntithetical Antigens: Antigens encoded alleles locus (M/N, S/s)Haplotype: set linked genes inherited together (e.g., Ms)U Antigen: High-prevalence antigen GPB; absence (U-negative) rare associated lack GPBDosage Effect: Stronger serological reaction cells homozygous antigen compared heterozygous cellsEnzyme Treatment: Use proteolytic enzymes (ficin, papain) modify antigen expression; M/N destroyed, S/s/U generally resistant","code":""},{"path":"p1pkglobosidep.html","id":"p1pkglobosidep","chapter":"P1PK/Globoside(P)","heading":"P1PK/Globoside(P)","text":"P1PK (ISBT 003) Globoside (ISBT 028) blood group systems involve carbohydrate antigens synthesized sequentially glycosphingolipid precursors found red blood cell surface. Specific glycosyltransferase enzymes add sugars, creating Pk antigen (precursor P), P antigen (Globoside ), independently synthesized P1 antigen. presence absence antigens, determined functionality encoding enzymes, defines various phenotypes within biochemically linked systems","code":""},{"path":"p1pkglobosidep.html","id":"the-foundation-glycosphingolipids","chapter":"P1PK/Globoside(P)","heading":"The Foundation: Glycosphingolipids","text":"Unlike protein-based antigens (like Rh) antigens primarily glycoproteins (like MNS), antigens systems primarily glycosphingolipids. molecules consist :Ceramide: lipid molecule embedded red cell membraneCarbohydrate Chain: Attached ceramide baseThe basic precursor relevant lactosylceramide (LacCer: Galβ1→4Glcβ1→Cer)","code":""},{"path":"p1pkglobosidep.html","id":"the-biosynthetic-pathway-step-by-step-antigen-construction","chapter":"P1PK/Globoside(P)","heading":"The Biosynthetic Pathway: Step-by-Step Antigen Construction","text":"synthesis involves specific enzymes called glycosyltransferases adding sugar molecules one oneStep 1: Synthesis Pk Antigen (Ceramide Trihexoside, CTH)\nEnzyme: α1,4-galactosyltransferase\nGene: A4GALT (located chromosome 22)\nAction: enzyme transfers galactose (Gal) molecule UDP-Galactose onto lactosylceramide α1→4 linkage\nResulting Structure (Pk): Galα1→4Galβ1→4Glcβ1→Cer\nSignificance: Pk essential precursor P antigen also antigen within P1PK system\nEnzyme: α1,4-galactosyltransferaseGene: A4GALT (located chromosome 22)Action: enzyme transfers galactose (Gal) molecule UDP-Galactose onto lactosylceramide α1→4 linkageResulting Structure (Pk): Galα1→4Galβ1→4Glcβ1→CerSignificance: Pk essential precursor P antigen also antigen within P1PK systemStep 2: Synthesis P Antigen (Globoside, Gb4)\nEnzyme: β1,3-N-acetylgalactosaminyltransferase 1\nGene: B3GALNT1 (located chromosome 3)\nAction: enzyme transfers N-acetylgalactosamine (GalNAc) molecule UDP-GalNAc onto Pk antigen β1→3 linkage\nResulting Structure (P / Globoside): GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→Cer\nSignificance: P antigen defining antigen Globoside system. synthesis requires prior synthesis Pk\nEnzyme: β1,3-N-acetylgalactosaminyltransferase 1Gene: B3GALNT1 (located chromosome 3)Action: enzyme transfers N-acetylgalactosamine (GalNAc) molecule UDP-GalNAc onto Pk antigen β1→3 linkageResulting Structure (P / Globoside): GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→CerSignificance: P antigen defining antigen Globoside system. synthesis requires prior synthesis PkStep 3: Synthesis P1 Antigen\nEnzyme: α1,4-galactosyltransferase (functionally distinct Pk synthase, often called “P1 synthase”)\nGene: specific gene responsible P1 synthesis (P1 gene) yet definitively cloned identified, although existence inferred genetic phenotypic data. thought distinct A4GALT\nAction: enzyme transfers galactose (Gal) molecule onto different precursor called paragloboside (nLc4Cer: Galβ1→4GlcNAcβ1→3Galβ1→4Glcβ1→Cer) α1→4 linkage\nResulting Structure (P1): Galα1→4Galβ1→4GlcNAcβ1→3Galβ1→4Glcβ1→Cer\nSignificance: P1 antigen synthesis independent Pk P synthesis uses related precursor structure. presence defines P1 phenotype\nEnzyme: α1,4-galactosyltransferase (functionally distinct Pk synthase, often called “P1 synthase”)Gene: specific gene responsible P1 synthesis (P1 gene) yet definitively cloned identified, although existence inferred genetic phenotypic data. thought distinct A4GALTAction: enzyme transfers galactose (Gal) molecule onto different precursor called paragloboside (nLc4Cer: Galβ1→4GlcNAcβ1→3Galβ1→4Glcβ1→Cer) α1→4 linkageResulting Structure (P1): Galα1→4Galβ1→4GlcNAcβ1→3Galβ1→4Glcβ1→CerSignificance: P1 antigen synthesis independent Pk P synthesis uses related precursor structure. presence defines P1 phenotype","code":""},{"path":"p1pkglobosidep.html","id":"the-blood-group-systems-collection","chapter":"P1PK/Globoside(P)","heading":"The Blood Group Systems & Collection","text":"classification can seem bit confusing antigens biochemically linked defined different genes/synthetic steps:P1PK System (ISBT 003): Includes P1 Pk antigens. Defined activity A4GALT gene (Pk) presumed P1 geneGloboside System (ISBT 028): Includes P antigen (Globoside). Defined activity B3GALNT1 geneGloboside Collection (ISBT 209): Groups antigens biochemically related via globoside pathway don’t fit neatly single system based current genetic knowledge. collection currently includes Pk, P, rare LKE antigen","code":""},{"path":"p1pkglobosidep.html","id":"phenotypes-resulting-from-enzyme-presenceabsence","chapter":"P1PK/Globoside(P)","heading":"Phenotypes: Resulting from Enzyme Presence/Absence","text":"common rare phenotypes arise inheritance functional non-functional alleles key enzyme genes:P1 Phenotype: (Approx. 75% Caucasians, >90% Black individuals)\nAntigens Present: P1, P, Pk\nPresumed Genetics: Functional A4GALT, B3GALNT1, P1 genes\nBiochemistry: Can perform three synthetic steps described \nAntigens Present: P1, P, PkPresumed Genetics: Functional A4GALT, B3GALNT1, P1 genesBiochemistry: Can perform three synthetic steps described aboveP2 Phenotype: (Approx. 25% Caucasians, <10% Black individuals)\nAntigens Present: P, Pk (P1)\nPresumed Genetics: Functional A4GALT B3GALNT1, non-functional P1 gene (regulatory mechanism preventing P1 synthesis)\nBiochemistry: Can make Pk convert P, synthesize P1 paragloboside\nAntigens Present: P, Pk (P1)Presumed Genetics: Functional A4GALT B3GALNT1, non-functional P1 gene (regulatory mechanism preventing P1 synthesis)Biochemistry: Can make Pk convert P, synthesize P1 paraglobosidep Phenotype (Null Phenotype): (Rare)\nAntigens Present: None (Lack P1, P, Pk)\nGenetics: Non-functional A4GALT gene (homozygous null alleles)\nBiochemistry: perform Step 1 (Pk synthesis). Without Pk precursor, P antigen made (Step 2 fails). P1 antigen also absent (mechanism unclear - perhaps related precursor issues linked gene regulation). Red cells precursors like lactosylceramide paragloboside\nAntigens Present: None (Lack P1, P, Pk)Genetics: Non-functional A4GALT gene (homozygous null alleles)Biochemistry: perform Step 1 (Pk synthesis). Without Pk precursor, P antigen made (Step 2 fails). P1 antigen also absent (mechanism unclear - perhaps related precursor issues linked gene regulation). Red cells precursors like lactosylceramide paraglobosideP1k Phenotype: (Rare)\nAntigens Present: P1, Pk (P)\nGenetics: Functional A4GALT P1 genes, non-functional B3GALNT1 gene\nBiochemistry: Can make Pk (Step 1) P1 (Step 3), convert Pk P (Step 2 fails). Pk antigen accumulates\nAntigens Present: P1, Pk (P)Genetics: Functional A4GALT P1 genes, non-functional B3GALNT1 geneBiochemistry: Can make Pk (Step 1) P1 (Step 3), convert Pk P (Step 2 fails). Pk antigen accumulatesP2k Phenotype: (Rare)\nAntigens Present: Pk (Lack P1 P)\nGenetics: Functional A4GALT, non-functional B3GALNT1 P1 genes\nBiochemistry: Can perform Step 1 (Pk synthesis). convert Pk P (Step 2 fails) make P1 (Step 3 fails)\nAntigens Present: Pk (Lack P1 P)Genetics: Functional A4GALT, non-functional B3GALNT1 P1 genesBiochemistry: Can perform Step 1 (Pk synthesis). convert Pk P (Step 2 fails) make P1 (Step 3 fails)","code":""},{"path":"p1pkglobosidep.html","id":"location-and-expression","chapter":"P1PK/Globoside(P)","heading":"Location and Expression","text":"antigens found red blood cells, lymphocytes, platelets, fibroblastsP1 antigen expression strength can vary considerably individuals may weaken upon storageThey exist primarily glycosphingolipids can also found glycoproteins","code":""},{"path":"p1pkglobosidep.html","id":"associated-antibodies-briefly","chapter":"P1PK/Globoside(P)","heading":"Associated Antibodies (Briefly)","text":"Anti-P1: Common, naturally occurring IgM found P2 individuals. Usually reacts best cold typically clinically insignificant. Can neutralized P1 substance (found hydatid cyst fluid, pigeon droppings)Anti-PP1Pk (formerly Anti-Tja): Found individuals rare p phenotype. Reacts P, Pk, P1 antigens. potent mixture IgM IgG, clinically significant, causing HTRs HDFN, strongly associated recurrent spontaneous abortionsAnti-P: Found individuals P1k P2k phenotypes. Reacts P antigen. Clinically significantAlloanti-Pk: Theoretically possible individuals lacking Pk (p phenotype), anti-PP1Pk characteristic antibodyAutoanti-P (Donath-Landsteiner Antibody): antibody responsible Paroxysmal Cold Hemoglobinuria (PCH). ’s biphasic IgG hemolysin – binds P-positive RBCs cold (extremities) causes complement-mediated lysis cells warm (central circulation)","code":""},{"path":"p1pkglobosidep.html","id":"key-terms-34","chapter":"P1PK/Globoside(P)","heading":"Key Terms","text":"Glycosphingolipid: lipid molecule (ceramide) linked carbohydrate chain, forming structural basis P1PK Globoside antigens RBCsGlycosyltransferase: enzyme catalyzes addition specific sugar molecules onto substrate (e.g., α1,4-galactosyltransferase)A4GALT: Gene encoding enzyme synthesizes Pk antigenB3GALNT1: Gene encoding enzyme synthesizes P antigen (Globoside) Pk precursorPk Antigen: Galα1→4Galβ1→4Glcβ1→Cer; precursor P antigenP Antigen (Globoside): GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→CerP1 Antigen: Galα1→4Galβ1→4GlcNAcβ1→3Galβ1→4Glcβ1→Cer; synthesized paraglobosideParagloboside: precursor structure (nLc4Cer) onto P1 antigen builtp Phenotype: Rare null phenotype lacking P1, P, Pk antigens due non-functional A4GALTPCH (Paroxysmal Cold Hemoglobinuria): Autoimmune hemolytic anemia associated biphasic IgG autoanti-P (Donath-Landsteiner antibody)","code":""},{"path":"ii.html","id":"ii","chapter":"Ii","heading":"Ii","text":"Ii blood group system (ISBT 027) unique antigens, , represent different structural arrangements – linear versus branched – repeating N-acetyllactosamine carbohydrate chains. system characterized significant developmental shift, fetal/newborn red cells expressing predominantly linear antigen, transitions branched antigen adult red cells due increasing activity specific branching enzyme. /structures also serve crucial carbohydrate backbone synthesis important blood group antigens like ABO H","code":""},{"path":"ii.html","id":"the-building-blocks-linear-vs.-branched-chains","chapter":"Ii","heading":"The Building Blocks: Linear vs. Branched Chains","text":"Unlike systems defined single amino acid changes (like MNS, Rh C/c) single sugar additions (like ABO), antigens represent different arrangements basic repeating sugar unit: N-acetyllactosamine (LacNAc), Galactose linked N-acetylglucosamine (Galβ1→4GlcNAc)Antigen: Characterized LINEAR, repeating chains N-acetyllactosamine units (Galβ1→4GlcNAcβ1→3Galβ1→4GlcNAc…)\nThink like simple, straight chain beads\nlinear structure predominant form found fetal newborn red blood cells\nThink like simple, straight chain beadsThis linear structure predominant form found fetal newborn red blood cellsI Antigen: Characterized BRANCHED N-acetyllactosamine chains\nbranching occurs additional N-acetyllactosamine unit added via β1→6 linkage internal galactose residue within linear chain\nImagine branches coming main trunk chain\nbranched structure becomes predominant form adult red blood cells\nbranching occurs additional N-acetyllactosamine unit added via β1→6 linkage internal galactose residue within linear chainImagine branches coming main trunk chainThis branched structure becomes predominant form adult red blood cells","code":""},{"path":"ii.html","id":"the-biochemistry-the-branching-enzyme","chapter":"Ii","heading":"The Biochemistry: The Branching Enzyme","text":"transition linear ‘’ structure branched ‘’ structure controlled specific enzyme:Enzyme: β-1,6-N-acetylglucosaminyltransferase (-branching enzyme)Gene: GCNT2Action: enzyme creates crucial β1→6 linkage adds “branch” onto linear -active chainsDevelopmental Control: activity enzyme low fetuses newborns increases significantly first 18-24 months life. enzymatic change drives conversion antigen antigen red cell surface","code":""},{"path":"ii.html","id":"developmental-expression-the-big-switch","chapter":"Ii","heading":"Developmental Expression: The Big Switch","text":"change antigen expression birth adulthood hallmark Ii system:Newborn RBCs: Rich antigen (linear chains), poor antigen (branched chains). Cord blood cells excellent source + cells testingAdult RBCs: Rich antigen (branched chains), small amounts residual antigenTransition Period: Takes place gradually first ~2 years life branching enzyme activity ramps ","code":""},{"path":"ii.html","id":"foundation-for-other-blood-groups","chapter":"Ii","heading":"Foundation for Other Blood Groups","text":"Crucially, carbohydrate structures just antigens right; form backbone upon important carbohydrate blood group antigens built:ABO Antigens: H antigen (precursor B) formed adding fucose terminal galactose /chains (specifically Type 2 chains RBCs). B transferases add specific sugars onto H structureLewis Antigens: Lewis antigens built Type 1 chains, also underlying /structures, primarily secretions plasmaSo, complexity /branching pattern underlies structure ABO/H antigens added","code":""},{"path":"ii.html","id":"location-of-ii-antigens","chapter":"Ii","heading":"Location of Ii Antigens","text":"Ii antigens widely distributed:Red Blood Cells: integral parts glycoproteins glycolipidsOther Cells: Leukocytes, plateletsBody Fluids: Present soluble glycoproteins plasma, saliva, milk, amniotic fluid, etc","code":""},{"path":"ii.html","id":"ii-system-antibodies","chapter":"Ii","heading":"Ii System Antibodies","text":"Antibodies system relatively common, particularly autoantibodiesAnti-\nType: Often naturally occurring autoantibody, usually IgM\nReactivity: Typically cold agglutinin, reacting best 4°C. Agglutination weakens disappears temperature increases towards 37°C. Reactivity often enhanced enzyme treatment test cells\nClinical Significance\nBenign Autoanti-: common. Can interfere vitro testing room temperature (e.g., ABO reverse grouping, immediate spin crossmatch, antibody screening) usually harmless vivo doesn’t react body temperature. Prewarming techniques used bypass interference\nPathologic Autoanti-: Less common, significant. antibodies high thermal amplitude (reactivity extends 30°C higher) /high titer. can cause Cold Agglutinin Syndrome (CAS), type autoimmune hemolytic anemia antibody binds cooler extremities activates complement, leading hemolysis upon warming central circulation\n\nAssociation: Potent, transient autoanti-production strongly associated infections Mycoplasma pneumoniae\nAlloanti-: rare, found individuals “adult ” phenotype (see )\nType: Often naturally occurring autoantibody, usually IgMReactivity: Typically cold agglutinin, reacting best 4°C. Agglutination weakens disappears temperature increases towards 37°C. Reactivity often enhanced enzyme treatment test cellsClinical Significance\nBenign Autoanti-: common. Can interfere vitro testing room temperature (e.g., ABO reverse grouping, immediate spin crossmatch, antibody screening) usually harmless vivo doesn’t react body temperature. Prewarming techniques used bypass interference\nPathologic Autoanti-: Less common, significant. antibodies high thermal amplitude (reactivity extends 30°C higher) /high titer. can cause Cold Agglutinin Syndrome (CAS), type autoimmune hemolytic anemia antibody binds cooler extremities activates complement, leading hemolysis upon warming central circulation\nBenign Autoanti-: common. Can interfere vitro testing room temperature (e.g., ABO reverse grouping, immediate spin crossmatch, antibody screening) usually harmless vivo doesn’t react body temperature. Prewarming techniques used bypass interferencePathologic Autoanti-: Less common, significant. antibodies high thermal amplitude (reactivity extends 30°C higher) /high titer. can cause Cold Agglutinin Syndrome (CAS), type autoimmune hemolytic anemia antibody binds cooler extremities activates complement, leading hemolysis upon warming central circulationAssociation: Potent, transient autoanti-production strongly associated infections Mycoplasma pneumoniaeAlloanti-: rare, found individuals “adult ” phenotype (see )Anti-\nType: Usually autoantibody, typically IgM, cold-reacting\nReactivity: Reacts preferentially cord blood cells (rich ) weakly adult cells (rich )\nClinical Significance: Mostly benign, potent examples high thermal amplitude can occasionally cause hemolysis\nAssociation: Strongly associated Infectious Mononucleosis (IM) caused Epstein-Barr virus (EBV). Also seen lymphoproliferative disorders\nAlloanti-: Extremely rare\nType: Usually autoantibody, typically IgM, cold-reactingReactivity: Reacts preferentially cord blood cells (rich ) weakly adult cells (rich )Clinical Significance: Mostly benign, potent examples high thermal amplitude can occasionally cause hemolysisAssociation: Strongly associated Infectious Mononucleosis (IM) caused Epstein-Barr virus (EBV). Also seen lymphoproliferative disordersAlloanti-: Extremely rare","code":""},{"path":"ii.html","id":"the-adult-i-phenotype","chapter":"Ii","heading":"The Adult i Phenotype","text":"rare phenotype individuals fail develop strong antigen expression adulthood. red cells remain rich antigen, similar newborn cells (+-)Cause: Usually due inheriting two non-functional alleles GCNT2 gene (encoding branching enzyme)Antibodies: individuals capable forming clinically significant alloanti-transfused normal adult (+) red blood cells. Finding compatible blood (adult donors) difficult","code":""},{"path":"ii.html","id":"summary-table-i-vs.-i","chapter":"Ii","heading":"Summary Table: I vs. i","text":"","code":""},{"path":"ii.html","id":"key-terms-35","chapter":"Ii","heading":"Key Terms","text":"N-acetyllactosamine (LacNAc): basic repeating disaccharide unit (Galβ1→4GlcNAc) Ii antigensLinear Chain: Characteristic structure antigenBranched Chain: Characteristic structure antigen, formed β1→6 linkagesBranching Enzyme: β-1,6-N-acetylglucosaminyltransferase (GCNT2 gene product) responsible creating iDevelopmental Antigen: antigen whose expression level changes significantly fetal life adulthood (like )Cold Agglutinin: antibody reacts optimally temperatures 37°C, often IgMThermal Amplitude: temperature range antibody reactive. Clinically significant cold antibodies wide thermal amplitude (react near body temperature)Cold Agglutinin Syndrome (CAS): Autoimmune hemolytic anemia caused pathologic cold agglutinin (often anti-)Adult Phenotype: Rare condition adult RBCs retain fetal -rich, -poor phenotype","code":""},{"path":"kell.html","id":"kell","chapter":"Kell","heading":"Kell","text":"Clinically, Kell blood group system (ISBT 006) major player, right behind ABO Rh, primarily K antigen (KEL1) highly immunogenic resulting anti-K relatively common can cause significant transfusion reactions Hemolytic Disease Fetus Newborn (HDFN). Unlike systems like ABO Lewis, Kell antigens located specific transmembrane protein (zinc endopeptidase) encoded KEL gene. presence absence key amino acids protein defines various Kell antigens, notably antithetical K (KEL1) k (Cellano, KEL2) pair. Proper expression Kell antigens also relies structural link another protein, Kx, implications absent (McLeod phenotype)","code":""},{"path":"kell.html","id":"genetics-the-kel-gene","chapter":"Kell","heading":"Genetics: The KEL Gene","text":"Kell system antigens encoded KEL gene, located chromosome 7This single gene responsible main Kell protein carries common Kell antigens","code":""},{"path":"kell.html","id":"biochemistry-the-kell-protein","chapter":"Kell","heading":"Biochemistry: The Kell Protein","text":"Unlike ABO, Lewis, P1PK, Ii involve carbohydrates, Kell antigens located proteinStructure: KEL gene codes Type II transmembrane glycoprotein (approx. 93 kDa). passes red cell membrane , short N-terminal end inside cell large C-terminal end (carrying antigenic sites) outside cellFunction: Kell protein zinc-dependent endopeptidase (metalloprotease). ’s known cleave substance called endothelin-3, suggesting role vasoactive peptide metabolism, although exact physiological role RBCs isn’t fully establishedCrucial Linkage: Kell protein covalently linked via disulfide bond another integral membrane protein called Kx (XK protein). linkage vital proper expression stability Kell antigens membrane","code":""},{"path":"kell.html","id":"major-kell-antigens-k-and-k-kell-and-cellano","chapter":"Kell","heading":"Major Kell Antigens: K and k (Kell and Cellano)","text":"commonly encountered antithetical pair Kell system:K Antigen (KEL1)\nBiochemistry: Defined presence Threonine amino acid position 193 Kell protein\nPrevalence: Relatively low prevalence antigen, found 9% Caucasian population, even less frequent individuals African descent (around 2%)\nImmunogenicity: Highly immunogenic! ’s considered third potent antigen stimulating antibody production , B, D. anti-K one common non-ABO antibodies encountered\nBiochemistry: Defined presence Threonine amino acid position 193 Kell proteinPrevalence: Relatively low prevalence antigen, found 9% Caucasian population, even less frequent individuals African descent (around 2%)Immunogenicity: Highly immunogenic! ’s considered third potent antigen stimulating antibody production , B, D. anti-K one common non-ABO antibodies encounteredk Antigen (Cellano, KEL2)\nBiochemistry: Defined presence Methionine amino acid position 193 (single nucleotide polymorphism KEL gene causes Thr -> Met swap)\nPrevalence: high prevalence antigen, found 98% populations\nImmunogenicity: Rarely encountered antibody (anti-k) people possess k antigen won’t make antibodies \nBiochemistry: Defined presence Methionine amino acid position 193 (single nucleotide polymorphism KEL gene causes Thr -> Met swap)Prevalence: high prevalence antigen, found 98% populationsImmunogenicity: Rarely encountered antibody (anti-k) people possess k antigen won’t make antibodies itInheritance: individual can homozygous (KK - rare, kk - common) heterozygous (Kk)","code":""},{"path":"kell.html","id":"other-important-kell-antigen-pairs","chapter":"Kell","heading":"Other Important Kell Antigen Pairs","text":"30 antigens Kell system, two antithetical pairs particularly noteworthy:Kp Antigens\nKpa (KEL3) / Kpb (KEL4): Result amino acid change position 281 (Arg -> Trp)\nKpa: Low prevalence (~2% Caucasians)\nKpb: High prevalence (>99.9%)\nAnti-Kpa sometimes seen; anti-Kpb rare\nKpa (KEL3) / Kpb (KEL4): Result amino acid change position 281 (Arg -> Trp)Kpa: Low prevalence (~2% Caucasians)Kpb: High prevalence (>99.9%)Anti-Kpa sometimes seen; anti-Kpb rareJs Antigens\nJsa (KEL6) / Jsb (KEL7): Result amino acid change position 597 (Leu -> Pro)\nJsa: Low prevalence Caucasians (<0.1%) significantly higher prevalence individuals African descent (~20%)\nJsb: High prevalence (>99.9% Caucasians, ~99% African descent)\nAnti-Jsa sometimes seen, particularly Caucasian populations; anti-Jsb rare\nJsa (KEL6) / Jsb (KEL7): Result amino acid change position 597 (Leu -> Pro)Jsa: Low prevalence Caucasians (<0.1%) significantly higher prevalence individuals African descent (~20%)Jsb: High prevalence (>99.9% Caucasians, ~99% African descent)Anti-Jsa sometimes seen, particularly Caucasian populations; anti-Jsb rare","code":""},{"path":"kell.html","id":"the-kx-blood-group-system-isbt-019-and-its-link-to-kell","chapter":"Kell","heading":"The Kx Blood Group System (ISBT 019) and its Link to Kell","text":"Kx system intrinsically linked Kell expression:Kx Protein (XK protein): Encoded XK gene, located X chromosome (important inheritance pattern!)Structure: multi-pass transmembrane protein, distinct Kell proteinFunction: Precise function unknown, thought involved membrane transport structural integrityRelationship: mentioned, Kx disulfide-linked Kell protein. Proper Kx expression necessary normal Kell antigen expression. Absence reduction Kx protein leads reduced Kell antigen density","code":""},{"path":"kell.html","id":"kell-system-null-phenotypes","chapter":"Kell","heading":"Kell System Null Phenotypes","text":"K0 (Kell Null)\nPhenotype: Individuals lack expression Kell system antigens (K, k, Kpa, Kpb, Jsa, Jsb, etc.) RBCs\nGenetics: Usually due inheriting two rare, non-functional (amorph) KEL alleles\nKx Expression: individuals elevated levels Kx antigen RBCs (’s linked /masked Kell protein)\nAntibodies: exposed normal Kell-positive cells, K0 individuals can produce potent antibody called anti-Ku (KEL5), reacts “universal” Kell epitope present cells except K0 cells. Finding compatible (K0) blood extremely difficult\nPhenotype: Individuals lack expression Kell system antigens (K, k, Kpa, Kpb, Jsa, Jsb, etc.) RBCsGenetics: Usually due inheriting two rare, non-functional (amorph) KEL allelesKx Expression: individuals elevated levels Kx antigen RBCs (’s linked /masked Kell protein)Antibodies: exposed normal Kell-positive cells, K0 individuals can produce potent antibody called anti-Ku (KEL5), reacts “universal” Kell epitope present cells except K0 cells. Finding compatible (K0) blood extremely difficultMcLeod Phenotype\nGenetics: Caused mutations deletions XK gene X chromosome (X-linked recessive inheritance)\nBiochemistry: Results absent severely deficient Kx protein\nKell Expression: Leads marked depression (weakening) Kell system antigens, Kx needed proper Kell expression/stability\nRBC Morphology: Associated acanthocytosis (spiky red cells)\nClinical Syndrome (McLeod Syndrome): multi-system disorder primarily affecting males, characterized :\nLate-onset neurological problems (chorea, psychiatric issues)\nSkeletal myopathy (muscle weakness)\nCardiomyopathy\nCompensated hemolytic anemia (due acanthocytosis)\n\nAntibodies: McLeod individuals may produce anti-Kx /anti-Km (KEL20) (another high-prevalence Kell antigen). Transfusion requires rare McLeod phenotype K0 blood\nGenetics: Caused mutations deletions XK gene X chromosome (X-linked recessive inheritance)Biochemistry: Results absent severely deficient Kx proteinKell Expression: Leads marked depression (weakening) Kell system antigens, Kx needed proper Kell expression/stabilityRBC Morphology: Associated acanthocytosis (spiky red cells)Clinical Syndrome (McLeod Syndrome): multi-system disorder primarily affecting males, characterized :\nLate-onset neurological problems (chorea, psychiatric issues)\nSkeletal myopathy (muscle weakness)\nCardiomyopathy\nCompensated hemolytic anemia (due acanthocytosis)\nLate-onset neurological problems (chorea, psychiatric issues)Skeletal myopathy (muscle weakness)CardiomyopathyCompensated hemolytic anemia (due acanthocytosis)Antibodies: McLeod individuals may produce anti-Kx /anti-Km (KEL20) (another high-prevalence Kell antigen). Transfusion requires rare McLeod phenotype K0 blood","code":""},{"path":"kell.html","id":"effect-of-reagents-on-kell-antigens","chapter":"Kell","heading":"Effect of Reagents on Kell Antigens","text":"key feature used antibody identification!Sulfhydryl Reagents (DTT, 2-, AET): Reagents like Dithiothreitol (DTT), 2-mercaptoethanol (2-), ZZAP (contains DTT) DESTROY Kell system antigens. work breaking disulfide bonds critical maintaining structure Kell protein link KxProteolytic Enzymes (Ficin, Papain): Kell antigens generally RESISTANT treatment common enzymes like ficin papain","code":""},{"path":"kell.html","id":"kell-antibodies","chapter":"Kell","heading":"Kell Antibodies","text":"Type: Usually IgG (primarily IgG1), reacting best AHG (Coombs) phaseStimulation: Typically immune stimulated (require exposure transfusion pregnancy)Clinical Significance: Clinically significant! Capable causing:\nHemolytic Transfusion Reactions (HTRs): Often extravascular, can severe\nHemolytic Disease Fetus Newborn (HDFN): Anti-K notorious cause severe HDFN, sometimes suppression fetal erythropoiesis addition hemolysis\nHemolytic Transfusion Reactions (HTRs): Often extravascular, can severeHemolytic Disease Fetus Newborn (HDFN): Anti-K notorious cause severe HDFN, sometimes suppression fetal erythropoiesis addition hemolysisDosage: Kell antibodies generally show dosage (react similarly homozygous heterozygous cells)","code":""},{"path":"kell.html","id":"key-terms-36","chapter":"Kell","heading":"Key Terms","text":"KEL Gene: Gene chromosome 7 encoding Kell glycoproteinKell Protein: Transmembrane zinc endopeptidase carrying Kell antigensXK Gene: Gene X chromosome encoding Kx proteinKx Protein: Membrane protein linked Kell protein, essential normal Kell expressionK/k (KEL1/KEL2): Major antithetical Kell antigens resulting Thr193Met substitutionKpa/Kpb (KEL3/KEL4): Antithetical Kell antigens (Arg281Trp)Jsa/Jsb (KEL6/KEL7): Antithetical Kell antigens (Leu597Pro), Jsa common African descentK0 (Kell Null): Phenotype lacking Kell antigens increased KxMcLeod Phenotype/Syndrome: X-linked condition due XK defect, causing absent Kx, weakened Kell antigens, acanthocytosis, multi-system clinical featuresSulfhydryl Reagents (DTT, ZZAP): Chemicals destroy Kell antigens breaking disulfide bondsImmunogenicity: Ability provoke immune response (K antigen highly immunogenic)","code":""},{"path":"kidd.html","id":"kidd","chapter":"Kidd","heading":"Kidd","text":"Kidd blood group system (ISBT 009) immunogenic RhD Kell’s K antigen upon initial exposure, Kidd antigens (Jka Jkb) critical players transfusion medicine. antigens actually part urea transporter protein (UT-B) found red blood cells, encoded SLC14A1 gene. real clinical impact comes Kidd antibodies, infamous causing delayed hemolytic transfusion reactions (DHTRs) due tendency decline detectable levels reappear strongly upon re-exposure, often efficiently activating complement","code":""},{"path":"kidd.html","id":"genetics-the-slc14a1-gene","chapter":"Kidd","heading":"Genetics: The SLC14A1 Gene","text":"Kidd antigens encoded SLC14A1 gene (Solute Carrier family 14, member 1), located chromosome 18This gene codes protein responsible urea transport red blood cells kidney","code":""},{"path":"kidd.html","id":"biochemistry-the-kidd-glycoprotein-urea-transporter-b-ut-b","chapter":"Kidd","heading":"Biochemistry: The Kidd Glycoprotein (Urea Transporter B, UT-B)","text":"Unlike systems defined enzymes adding sugars (ABO, Lewis) large structural proteins (Rh, Kell), Kidd antigens reside specific functional protein:Structure: SLC14A1 gene codes Kidd glycoprotein, also known Urea Transporter B (UT-B). multi-pass transmembrane protein, meaning weaves back forth red blood cell membrane multiple times (likely 10 loops)Function: primary job facilitate rapid transport urea across red blood cell membrane. important maintaining osmotic stability RBCs pass high urea concentrations kidney medulla. also plays role kidney’s ability concentrate urineAntigen Location: Jka Jkb antigenic determinants part protein structure , exposed external loops protein","code":""},{"path":"kidd.html","id":"the-major-kidd-antigens-jka-and-jkb","chapter":"Kidd","heading":"The Major Kidd Antigens: Jka and Jkb","text":"two principal, antithetical antigens system:Biochemical Difference: difference Jka Jkb arises single nucleotide polymorphism (SNP) SLC14A1 gene. SNP results single amino acid substitution position 280 Kidd protein:\nJka (JK1): Aspartic Acid (Asp) position 280\nJkb (JK2): Asparagine (Asn) position 280\nJka (JK1): Aspartic Acid (Asp) position 280Jkb (JK2): Asparagine (Asn) position 280Inheritance: individual inherits one SLC14A1 allele parent, leading three possible genotypes:\nJK*/JK*(Homozygous Jka) → Phenotype: Jk(+b-)\nJK*B/JK*B (Homozygous Jkb) → Phenotype: Jk(-b+)\nJK*/JK*B (Heterozygous) → Phenotype: Jk(+b+)\nJK*/JK*(Homozygous Jka) → Phenotype: Jk(+b-)JK*B/JK*B (Homozygous Jkb) → Phenotype: Jk(-b+)JK*/JK*B (Heterozygous) → Phenotype: Jk(+b+)Prevalence: Jka Jkb common antigens, frequencies vary among ethnic populations:\nCaucasians: ~77% Jk(+), ~73% Jk(b+)\nBlack individuals: ~91% Jk(+), ~49% Jk(b+)\nAsians: ~73% Jk(+), ~76% Jk(b+)\nCaucasians: ~77% Jk(+), ~73% Jk(b+)Black individuals: ~91% Jk(+), ~49% Jk(b+)Asians: ~73% Jk(+), ~76% Jk(b+)","code":""},{"path":"kidd.html","id":"the-jk3-antigen","chapter":"Kidd","heading":"The Jk3 Antigen","text":"Description: Jk3 high-prevalence antigen present whenever either Jka Jkb antigens () expressed. Think associated common structure Kidd protein carries either Asp280 Asn280 residueAbsence: Jk3 absent red cells rare Jk(-b-) individuals","code":""},{"path":"kidd.html","id":"the-null-phenotype-jka-b-","chapter":"Kidd","heading":"The Null Phenotype: Jk(a-b-)","text":"Description: rare phenotype individuals lack expression Jka, Jkb, Jk3 antigens red blood cellsGenetics: Often caused inheriting two non-functional SLC14A1 alleles. common mechanism, especially individuals Polynesian, Filipino, Finnish descent, homozygosity specific splice site mutation SLC14A1 gene prevents proper protein formation. mutations can also cause null phenotypeBiochemistry/Physiology: Since Kidd protein (UT-B) absent non-functional, individuals’ red cells transport urea rapidly. generally healthy, exhibit defect maximal urinary concentrating abilityAntibodies: Jk(-b-) individuals, immunized, can produce anti-Jk3. antibody reacts cells positive Jka Jkb (essentially cells except Jk(-b-) cells). Finding compatible blood extremely difficult","code":""},{"path":"kidd.html","id":"effect-of-reagents-on-kidd-antigens","chapter":"Kidd","heading":"Effect of Reagents on Kidd Antigens","text":"Proteolytic Enzymes (Ficin, Papain, Bromelin): Reactivity Kidd antibodies often ENHANCED treating test cells enzymes. key characteristic used antibody identification! Enzymes likely remove surrounding structures, making Kidd antigens accessible antibodiesSulfhydryl Reagents (DTT, 2-): Kidd antigens generally RESISTANT treatment DTT 2-","code":""},{"path":"kidd.html","id":"kidd-antibodies-anti-jka-anti-jkb-anti-jk3","chapter":"Kidd","heading":"Kidd Antibodies (Anti-Jka, Anti-Jkb, Anti-Jk3)","text":"reason Kidd system demands respect blood bank!Type: Usually IgG (often IgG1 /IgG3), reacting best AHG (Coombs) phaseStimulation: Typically immune stimulated (require exposure transfusion pregnancy)Complement Activation: Kidd antibodies notorious ability bind complement effectively. contributes significantly ability cause hemolysis, vitro (visible hemolysis test tube) vivoDosage: Often show dosage, meaning react strongly cells individuals homozygous antigen (e.g., anti-Jka reacts stronger Jk(+b-) cells Jk(+b+) cells)Evanescence (Treacherous Part!): Kidd antibody titers can decline rapidly vivo initial stimulation, sometimes becoming undetectable routine antibody screening tests exposures. However, upon re-exposure (e.g., transfusion antigen-positive blood), rapid strong anamnestic response can occur, leading toClinical Significance: HIGHLY Clinically Significant!\nDelayed Hemolytic Transfusion Reactions (DHTRs): Kidd antibodies leading cause DHTRs. reaction typically occurs 3-14 days post-transfusion antibody level rapidly rises destroys transfused antigen-positive cells. Symptoms can range mild (unexplained drop hemoglobin, fever, jaundice) severe (shock, renal failure)\nAcute Hemolytic Transfusion Reactions: less common DHTRs, potent Kidd antibodies can cause immediate HTRs\nHemolytic Disease Fetus Newborn (HDFN): Can cause HDFN, usually mild moderate, severe cases reported\nDelayed Hemolytic Transfusion Reactions (DHTRs): Kidd antibodies leading cause DHTRs. reaction typically occurs 3-14 days post-transfusion antibody level rapidly rises destroys transfused antigen-positive cells. Symptoms can range mild (unexplained drop hemoglobin, fever, jaundice) severe (shock, renal failure)Acute Hemolytic Transfusion Reactions: less common DHTRs, potent Kidd antibodies can cause immediate HTRsHemolytic Disease Fetus Newborn (HDFN): Can cause HDFN, usually mild moderate, severe cases reported","code":""},{"path":"kidd.html","id":"key-terms-37","chapter":"Kidd","heading":"Key Terms","text":"SLC14A1: Gene encoding Kidd glycoprotein/urea transporterKidd Glycoprotein (UT-B): Urea Transporter B; protein carrying Kidd antigensJka/Jkb: Antithetical antigens differing Asp/Asn position 280Jk3: High-prevalence antigen associated Jka/Jkb expressionJk(-b-): Rare null phenotype lacking Kidd antigens, associated impaired urine concentrationDosage: Antibody reacts strongly homozygous cellsEvanescent: Antibody titer tends disappear weaken time vivoComplement Activation: Ability antibody initiate complement cascade, often leading hemolysisDelayed Hemolytic Transfusion Reaction (DHTR): Hemolysis occurring days weeks transfusion, commonly caused Kidd antibodies due anamnestic response","code":""},{"path":"duffy.html","id":"duffy","chapter":"Duffy","heading":"Duffy","text":"Duffy blood group system (ISBT 008) clinically significant due role transfusion reactions HDFN, holds unique biological interest primary antigens, Fya Fyb, reside protein acts receptor chemokines , crucially, used Plasmodium vivax malaria parasite invade red blood cells. antigens defined amino acid variations Duffy Antigen Receptor Chemokines (DARC) protein, encoded DARC gene. common Fy(-b-) phenotype, prevalent individuals African descent, provides strong resistance P. vivax malaria distinct molecular basis compared blood group null phenotypes","code":""},{"path":"duffy.html","id":"genetics-the-darc-gene","chapter":"Duffy","heading":"Genetics: The DARC Gene","text":"Duffy antigens encoded DARC gene (also historically known FY), located chromosome 1The main alleles determining Fya Fyb antigens FY*FY*B","code":""},{"path":"duffy.html","id":"biochemistry-the-darc-protein","chapter":"Duffy","heading":"Biochemistry: The DARC Protein","text":"Structure: DARC gene codes Duffy Antigen Receptor Chemokines (DARC) protein. glycosylated, multi-pass transmembrane protein (passing RBC membrane 7 times), typical many cell surface receptorsFunction: DARC two well-established functions:\nChemokine Receptor binds wide variety pro-inflammatory chemokines (small signaling proteins involved inflammation immune responses), particularly CC CXC families. ’s considered “silent” “scavenging” receptor, potentially regulating inflammation binding excess chemokines without initiating traditional signaling cascades. ’s expressed RBCs also endothelial cells lining blood vessels (especially post-capillary venules), Purkinje cells cerebellum, tissues\nMalaria Receptor serves essential receptor merozoite stage malaria parasite Plasmodium vivax (related monkey malaria parasite P. knowlesi) enter red blood cells\nChemokine Receptor binds wide variety pro-inflammatory chemokines (small signaling proteins involved inflammation immune responses), particularly CC CXC families. ’s considered “silent” “scavenging” receptor, potentially regulating inflammation binding excess chemokines without initiating traditional signaling cascades. ’s expressed RBCs also endothelial cells lining blood vessels (especially post-capillary venules), Purkinje cells cerebellum, tissuesMalaria Receptor serves essential receptor merozoite stage malaria parasite Plasmodium vivax (related monkey malaria parasite P. knowlesi) enter red blood cells","code":""},{"path":"duffy.html","id":"the-major-duffy-antigens-fya-and-fyb","chapter":"Duffy","heading":"The Major Duffy Antigens: Fya and Fyb","text":"two main, antithetical antigens system:Biochemical Difference: difference Fya Fyb arises single nucleotide polymorphism (SNP) exon 2 DARC gene. SNP results single amino acid substitution position 42 first extracellular loop DARC protein:\nFya (FY1): Glycine (Gly) position 42\nFyb (FY2): Aspartic Acid (Asp) position 42\nFya (FY1): Glycine (Gly) position 42Fyb (FY2): Aspartic Acid (Asp) position 42Inheritance: individual inherits one DARC allele parent, leading three common genotypes:\nFY*/FY*→ Phenotype: Fy(+b-)\nFY*B/FY*B → Phenotype: Fy(-b+)\nFY*/FY*B → Phenotype: Fy(+b+)\nFY*/FY*→ Phenotype: Fy(+b-)FY*B/FY*B → Phenotype: Fy(-b+)FY*/FY*B → Phenotype: Fy(+b+)Prevalence: Antigen frequencies vary significantly among ethnic populations:\nCaucasians: ~66% Fy(+), ~83% Fy(b+)\nBlack individuals: ~10% Fy(+), ~23% Fy(b+) (High prevalence Fy(-b-))\nAsians: >99% Fy(+), ~18% Fy(b+)\nCaucasians: ~66% Fy(+), ~83% Fy(b+)Black individuals: ~10% Fy(+), ~23% Fy(b+) (High prevalence Fy(-b-))Asians: >99% Fy(+), ~18% Fy(b+)","code":""},{"path":"duffy.html","id":"the-null-phenotype-fya-b-","chapter":"Duffy","heading":"The Null Phenotype: Fy(a-b-)","text":"phenotype, red cells lack Fya Fyb, particularly important fascinating molecular basis, especially African populations:Common Mechanism (African Ancestry)\nGenetics: Fy(-b-) individuals African descent possess FY*B allele additional SNP promoter region DARC gene, specifically position -33 (T>C). mutation occurs within binding site GATA-1 erythroid transcription factor\nBiochemistry/Expression: GATA-1 factor essential gene expression red blood cell precursors. -33C mutation disrupts GATA-1 binding, preventing transcription DARC gene erythroid cells. Therefore, DARC protein (carrying Fyb antigen) absent red blood cells\nCrucially: DARC expression affected tissues (like endothelial cells) gene expression controlled different transcription factors. individuals often designated FY*BES allele (Erythroid Silent)\nMalaria Resistance: RBC-specific absence DARC confers strong resistance invasion Plasmodium vivax\nGenetics: Fy(-b-) individuals African descent possess FY*B allele additional SNP promoter region DARC gene, specifically position -33 (T>C). mutation occurs within binding site GATA-1 erythroid transcription factorBiochemistry/Expression: GATA-1 factor essential gene expression red blood cell precursors. -33C mutation disrupts GATA-1 binding, preventing transcription DARC gene erythroid cells. Therefore, DARC protein (carrying Fyb antigen) absent red blood cellsCrucially: DARC expression affected tissues (like endothelial cells) gene expression controlled different transcription factors. individuals often designated FY*BES allele (Erythroid Silent)Malaria Resistance: RBC-specific absence DARC confers strong resistance invasion Plasmodium vivaxRare Mechanisms (Populations)\npopulations (e.g., Caucasians), rare Fy(-b-) phenotype usually results inheriting two non-functional DARC alleles mutations within coding sequence (nonsense frameshift mutations). individuals lack DARC expression tissues, just RBCs\npopulations (e.g., Caucasians), rare Fy(-b-) phenotype usually results inheriting two non-functional DARC alleles mutations within coding sequence (nonsense frameshift mutations). individuals lack DARC expression tissues, just RBCs","code":""},{"path":"duffy.html","id":"other-duffy-antigens","chapter":"Duffy","heading":"Other Duffy Antigens","text":"Fy3: high-prevalence antigen present cells expressing Fya Fyb. likely located different part DARC protein Fya/Fyb site. Fy3 absent RBCs individuals rare Fy(-b-) phenotype caused mutations coding region. However, Fy3 antigen present (though perhaps weakly) RBCs individuals common GATA-box Fy(-b-) phenotype, residual protein might expressed. Anti-Fy3 made rare “true null” individualsFy5: Another antigen whose expression seems depend interaction DARC protein Rh protein complex. Fy5 weakened absent Rhnull cellsFy6: epitope DARC protein appears actual binding site P. vivax merozoites. conformation-dependent sensitive enzyme treatment","code":""},{"path":"duffy.html","id":"effect-of-reagents-on-duffy-antigens","chapter":"Duffy","heading":"Effect of Reagents on Duffy Antigens","text":"defining characteristic used antibody identification:Proteolytic Enzymes (Ficin, Papain, Bromelin): Duffy antigens (Fya, Fyb, Fy6) DESTROYED common enzyme treatments. enzymes cleave DARC protein, removing antigenic sitesSulfhydryl Reagents (DTT, 2-): Duffy antigens RESISTANT treatment DTT 2-","code":""},{"path":"duffy.html","id":"duffy-antibodies-anti-fya-anti-fyb-anti-fy3","chapter":"Duffy","heading":"Duffy Antibodies (Anti-Fya, Anti-Fyb, Anti-Fy3)","text":"Type: Usually IgG (often IgG1), reacting best AHG (Coombs) phaseStimulation: Typically immune stimulated (require exposure transfusion pregnancy). Anti-Fya encountered commonly anti-Fyb, likely reflecting antigen prevalence perhaps slightly higher immunogenicityDosage: Often show dosage (react strongly homozygous cells)Complement Activation: Generally activate complement efficientlyClinical Significance: Clinically Significant!\nHemolytic Transfusion Reactions (HTRs): Can cause acute delayed HTRs, typically extravascular\nHemolytic Disease Fetus Newborn (HDFN): well-recognized cause HDFN, can range mild severe\nHemolytic Transfusion Reactions (HTRs): Can cause acute delayed HTRs, typically extravascularHemolytic Disease Fetus Newborn (HDFN): well-recognized cause HDFN, can range mild severeAnti-Fy3: Rare antibody made individuals “true” Fy(-b-) null phenotype (coding region mutations). Reacts almost cells except lacking DARC protein. Clinically significant","code":""},{"path":"duffy.html","id":"key-terms-38","chapter":"Duffy","heading":"Key Terms","text":"DARC Gene: Gene chromosome 1 encoding Duffy proteinDARC Protein: Duffy Antigen Receptor Chemokines; protein carrying Duffy antigensChemokine: Small signaling proteins involved inflammation immune cell traffickingFya/Fyb: Antithetical antigens differing Gly/Asp position 42Fy(-b-): Null phenotype lacking Fya Fyb RBCsGATA-1: Erythroid transcription factor essential gene expression RBC precursorsPromoter Mutation: Genetic change regulatory region upstream gene (e.g., -33 T>C mutation DARC causing common Fy(-b-) phenotype)Plasmodium vivax: Malaria parasite uses DARC invade red blood cellsEnzyme Treatment: Use proteolytic enzymes (ficin, papain) destroy Duffy antigens","code":""},{"path":"lutheran.html","id":"lutheran","chapter":"Lutheran","heading":"Lutheran","text":"Lutheran blood group system (ISBT 005)! always causing dramatic reactions seen ABO Rh, Lutheran unique biochemical features inheritance patterns make fascinating. main antigens, Lua Lub, carried protein involved cell adhesion, system known characteristic mixed-field agglutination antibody testing interesting rare null phenotypes","code":""},{"path":"lutheran.html","id":"genetics-the-bcam-gene","chapter":"Lutheran","heading":"Genetics: The BCAM Gene","text":"Lutheran antigens encoded BCAM gene (Basal Cell Adhesion Molecule), also historically referred LU geneLocation: gene resides chromosome 19, interestingly, region closely linked Secretor (FUT2) Lewis (FUT3) genes","code":""},{"path":"lutheran.html","id":"biochemistry-the-lutheran-glycoprotein-b-camlu","chapter":"Lutheran","heading":"Biochemistry: The Lutheran Glycoprotein (B-CAM/LU)","text":"Lutheran antigens located specific protein important biological functions:Structure: BCAM gene codes Lutheran glycoprotein (B-CAM/LU). Type transmembrane glycoprotein, meaning passes red cell membrane , N-terminus outside C-terminus inside cellFamily: B-CAM/LU belongs Immunoglobulin Superfamily (IgSF), large group cell surface proteins involved recognition, binding, adhesionFunction: B-CAM/LU functions adhesion molecule. primary known ligand (binding partner) laminin, major component extracellular matrix (“scaffolding” outside cells). interaction thought play role :\nRed blood cell development maturation\nMaintaining membrane integrity\nPathophysiology: Notably, B-CAM/LU mediates adhesion sickle red blood cells endothelium (lining blood vessels), contributing vaso-occlusive events characteristic sickle cell disease\nRed blood cell development maturationMaintaining membrane integrityPathophysiology: Notably, B-CAM/LU mediates adhesion sickle red blood cells endothelium (lining blood vessels), contributing vaso-occlusive events characteristic sickle cell disease","code":""},{"path":"lutheran.html","id":"the-major-lutheran-antigens-lua-and-lub","chapter":"Lutheran","heading":"The Major Lutheran Antigens: Lua and Lub","text":"two primary, antithetical antigens system:Biochemical Difference: difference Lua Lub arises single nucleotide polymorphism (SNP) BCAM gene. SNP results single amino acid substitution position 77 mature protein:\nLua (LU1): Histidine () position 77\nLub (LU2): Arginine (Arg) position 77\nLua (LU1): Histidine () position 77Lub (LU2): Arginine (Arg) position 77Prevalence: key difference!\nLua: Low prevalence antigen, found 8% Caucasians less frequently populations\nLub: High prevalence antigen, found 99% populations\nLua: Low prevalence antigen, found 8% Caucasians less frequently populationsLub: High prevalence antigen, found 99% populationsInheritance: individual inherits one BCAM allele parent, leading three possible genotypes:\nLU*/LU*(Homozygous Lua) → Phenotype: Lu(+b-) (Rare)\nLU*B/LU*B (Homozygous Lub) → Phenotype: Lu(-b+) (Common)\nLU*/LU*B (Heterozygous) → Phenotype: Lu(+b+) (Uncommon, ~8%)\nLU*/LU*(Homozygous Lua) → Phenotype: Lu(+b-) (Rare)LU*B/LU*B (Homozygous Lub) → Phenotype: Lu(-b+) (Common)LU*/LU*B (Heterozygous) → Phenotype: Lu(+b+) (Uncommon, ~8%)","code":""},{"path":"lutheran.html","id":"other-lutheran-antigens","chapter":"Lutheran","heading":"Other Lutheran Antigens","text":"20 antigens identified within Lutheran system. Another important one :Lu3: high-prevalence antigen present red cells express either Lua Lub (). absent cells individuals rare recessive Lu(-b-) null phenotype","code":""},{"path":"lutheran.html","id":"lutheran-null-phenotypes-lua-b-","chapter":"Lutheran","heading":"Lutheran Null Phenotypes: Lu(a-b-)","text":"Individuals lacking Lua Lub rare, phenotype can arise different genetic mechanisms:Recessive Type Lu(-b-)\nGenetics: Caused inheriting two rare, non-functional (amorph) BCAM alleles. BCAM gene defective\nBiochemistry: Results complete absence B-CAM/LU protein red cell membrane\nAntibodies: individuals can produce anti-Lu3 immunized. Anti-Lu3 reacts cells except recessive-type Lu(-b-) cells\nClinical: Usually clinically healthy, RBCs function normally\nGenetics: Caused inheriting two rare, non-functional (amorph) BCAM alleles. BCAM gene defectiveBiochemistry: Results complete absence B-CAM/LU protein red cell membraneAntibodies: individuals can produce anti-Lu3 immunized. Anti-Lu3 reacts cells except recessive-type Lu(-b-) cellsClinical: Usually clinically healthy, RBCs function normallyDominant Inhibitor Type Lu(-b-) ((Lu))\nGenetics: Caused inheriting dominant suppressor gene, unrelated BCAM locus. common inhibitor called (Lu), results mutations EKLF (KLF1) gene. EKLF codes erythroid transcription factor crucial expression many genes red cell development\nBiochemistry: BCAM gene usually normal, expression severely reduced (suppressed) faulty EKLF transcription factor. individuals trace amounts Lutheran protein affected antigens (like P1, , AnWj) RBCs\nAntibodies: trace amounts Lutheran protein, make anti-Lu3. generally non-responsive Lutheran antigens\nClinical: Usually healthy, may subtle RBC abnormalities\nGenetics: Caused inheriting dominant suppressor gene, unrelated BCAM locus. common inhibitor called (Lu), results mutations EKLF (KLF1) gene. EKLF codes erythroid transcription factor crucial expression many genes red cell developmentBiochemistry: BCAM gene usually normal, expression severely reduced (suppressed) faulty EKLF transcription factor. individuals trace amounts Lutheran protein affected antigens (like P1, , AnWj) RBCsAntibodies: trace amounts Lutheran protein, make anti-Lu3. generally non-responsive Lutheran antigensClinical: Usually healthy, may subtle RBC abnormalitiesX-linked Inhibitor Type Lu(-b-)\nGenetics: extremely rare mechanism involving inhibitor gene X chromosome (XS2 locus)\nBiochemistry: Suppresses Lutheran expression\nGenetics: extremely rare mechanism involving inhibitor gene X chromosome (XS2 locus)Biochemistry: Suppresses Lutheran expression","code":""},{"path":"lutheran.html","id":"antigen-expression","chapter":"Lutheran","heading":"Antigen Expression","text":"Lutheran antigens poorly developed birth, cord blood cells often showing weaker reactivity adult cellsExpression strength can vary among adults","code":""},{"path":"lutheran.html","id":"effect-of-reagents-on-lutheran-antigens","chapter":"Lutheran","heading":"Effect of Reagents on Lutheran Antigens","text":"Proteolytic Enzymes (Ficin, Papain): Lutheran antigens generally RESISTANT treatment common enzymesSulfhydryl Reagents (DTT, 2-): Lutheran antigens also generally RESISTANT DTT 2-","code":""},{"path":"lutheran.html","id":"lutheran-antibodies-anti-lua-anti-lub-anti-lu3","chapter":"Lutheran","heading":"Lutheran Antibodies (Anti-Lua, Anti-Lub, Anti-Lu3)","text":"Lutheran antibodies often display characteristic reactivity pattern:Mixed-Field Agglutination: hallmark! Lutheran antibodies often cause agglutination clumps cells mixed unagglutinated free cells test tube. appearance can subtle easily missedAnti-Lua\nType: Can IgM, IgG, IgA, mixture. Often “naturally occurring” can immune stimulated\nReactivity: Often reacts best room temperature () may persist 37°C AHG. Frequently shows mixed-field agglutination\nClinical Significance: Generally considered clinically significant mildly significant. Rarely causes mild HTRs HDFN\nType: Can IgM, IgG, IgA, mixture. Often “naturally occurring” can immune stimulatedReactivity: Often reacts best room temperature () may persist 37°C AHG. Frequently shows mixed-field agglutinationClinical Significance: Generally considered clinically significant mildly significant. Rarely causes mild HTRs HDFNAnti-Lub\nType: Usually IgG, immune stimulated\nReactivity: Reacts best AHG phase. Can show mixed-field agglutination\nClinical Significance: Clinically significant! Although rare (due high prevalence Lub antigen), anti-Lub can cause HTRs (usually mild moderate) mild HDFN\nType: Usually IgG, immune stimulatedReactivity: Reacts best AHG phase. Can show mixed-field agglutinationClinical Significance: Clinically significant! Although rare (due high prevalence Lub antigen), anti-Lub can cause HTRs (usually mild moderate) mild HDFNAnti-Lu3\nType: IgG, immune stimulated\nReactivity: Reacts AHG cells except recessive Lu(-b-) cells\nClinical Significance: Clinically significant. Requires rare Lu(-b-) blood transfusion\nType: IgG, immune stimulatedReactivity: Reacts AHG cells except recessive Lu(-b-) cellsClinical Significance: Clinically significant. Requires rare Lu(-b-) blood transfusion","code":""},{"path":"lutheran.html","id":"key-terms-39","chapter":"Lutheran","heading":"Key Terms","text":"BCAM Gene: Gene chromosome 19 encoding Lutheran glycoproteinB-CAM/LU: Lutheran glycoprotein; Basal Cell Adhesion MoleculeImmunoglobulin Superfamily (IgSF): Large family cell surface proteins involved adhesion recognitionLaminin: Extracellular matrix protein binds B-CAM/LULua/Lub: Major antithetical Lutheran antigens differing /Arg position 77Antithetical Antigens: Antigens coded alleles locusLu3: High-prevalence antigen absent recessive Lu(-b-) cellsLu(-b-) Null Phenotype: Absence Lua Lub; can recessive (due BCAM mutations) dominant (due (Lu)/ EKLF mutations)(Lu): Dominant inhibitor gene (usually mutation EKLF) suppressing Lutheran expressionEKLF (KLF1): Erythroid transcription factor gene; mutations cause (Lu) phenotypeMixed-Field Agglutination: Characteristic pattern agglutination clumps free cells, common Lutheran antibodies","code":""},{"path":"other-blood-groups.html","id":"other-blood-groups","chapter":"Other Blood Groups","heading":"Other Blood Groups","text":"Beyond commonly encountered ABO, Rh, Kell, Duffy, Kidd, MNS systems, red blood cell surface hosts vast array antigens belonging numerous blood group systems, currently numbering 45 human blood group systems recognized ISBT containing 360 different red cell antigensThese systems exhibit diverse biochemistry, antigens residing various membrane proteins, glycoproteins, even adsorbed plasma components. many less frequently involved routine testing, understanding characteristics potential clinical significance crucial resolving complex antibody investigations, managing transfusion reactions, addressing HDFN, sourcing compatible blood patients antibodies either common rare antigensIt unnessary cover detail, understanding exist, knowing key examples, recognizing general characteristics important. systems often come play :Resolving complex antibody identification problemsInvestigating transfusion reactions HDFN common antibodies ruled outDealing antibodies high-prevalence antigens (present almost everyone’s cells) finding blood patients antibodies low-prevalence antigens (present people’s cells)’s look representative “” systems, focusing biochemistry antigens:","code":""},{"path":"other-blood-groups.html","id":"diego-system-di---isbt-system-010","chapter":"Other Blood Groups","heading":"Diego System (DI) - ISBT System 010","text":"Biochemistry/Antigen Carrier: antigens part Band 3 protein (also known Anion Exchanger 1 AE1), major structural transport protein spans red cell membrane multiple timesKey Antigens: Primarily Dia / Dib. Also includes Wright (Wra / Wrb) several less common antigens now assigned system\nDia: Low prevalence populations significantly higher people Native American East Asian descent (36% )\nDib: High prevalence antigen (nearly 100% populations)\nWra: Low prevalence antigen\nWrb: High prevalence antigen (associated specific conformation Band 3 Glycophorin )\nDia: Low prevalence populations significantly higher people Native American East Asian descent (36% )Dib: High prevalence antigen (nearly 100% populations)Wra: Low prevalence antigenWrb: High prevalence antigen (associated specific conformation Band 3 Glycophorin )Antibodies: Usually IgG, reactive IAT phase. Can stimulated pregnancy transfusionClinical Significance: Anti-Dia, Anti-Dib, Anti-Wra CAN cause moderate severe Hemolytic Transfusion Reactions (HTR) Hemolytic Disease Fetus Newborn (HDFN). Anti-Wrb extremely rare Wrb high prevalence","code":""},{"path":"other-blood-groups.html","id":"cartwright-system-yt---isbt-system-011","chapter":"Other Blood Groups","heading":"Cartwright System (YT) - ISBT System 011","text":"Biochemistry/Antigen Carrier: antigens reside Acetylcholinesterase (AChE), enzyme found red cell surface anchored GPI-link (Glycosylphosphatidylinositol anchor)Key Antigens: Yta / Ytb\nYta: High prevalence antigen (>99% populations)\nYtb: Lower prevalence (around 8% Caucasians)\nYta: High prevalence antigen (>99% populations)Ytb: Lower prevalence (around 8% Caucasians)Antigen Characteristics: AChE (thus Yt antigens) can destroyed treatment DTT (dithiothreitol), cleaves GPI-linked proteinsAntibodies: Usually IgG, reactive IAT. Anti-Yta commonClinical Significance: Generally considered clinically insignificant causing mild, delayed HTRs. HDFN rare usually mild occurs. However, crossmatch compatible blood typically provided","code":""},{"path":"other-blood-groups.html","id":"xg-system-xg---isbt-system-012","chapter":"Other Blood Groups","heading":"Xg System (XG) - ISBT System 012","text":"Biochemistry/Antigen Carrier: Xga antigen located glycoprotein encoded XG gene X chromosome. related gene, MIC2, encodes CD99 antigenKey Antigens: one well-established antigen: Xga. antithetical “Xgb”. Individuals either Xg(+) Xg(-)Inheritance: Unique X-linked dominant inheritance pattern. Females (XX) can homozygous heterozygous; males (XY) hemizygous (either don’t). Frequencies differ sexes (higher females)Antigen Characteristics: Susceptible ficin papain enzyme treatmentAntibodies: Usually IgM, sometimes IgG. Often naturally occurring, reactive best room temperature colder, can react weakly IATClinical Significance: Anti-Xga considered clinically insignificant. clearly implicated HTR HDFN","code":""},{"path":"other-blood-groups.html","id":"scianna-system-sc---isbt-system-013","chapter":"Other Blood Groups","heading":"Scianna System (SC) - ISBT System 013","text":"Biochemistry/Antigen Carrier: Antigens located ERMAP (Erythroid Membrane-Associated Protein), transmembrane glycoproteinKey Antigens: Include Sc1 (high prevalence, >99%), Sc2 (low prevalence, ~1%), Sc3 (present cells except rare Sc:-1,-2 null phenotype)Antibodies: Usually IgG, reactive IATClinical Significance: Antibodies (especially anti-Sc1) CAN cause delayed HTR mild moderate HDFN. Sc null phenotype can make anti-Sc3, reacts almost cells","code":""},{"path":"other-blood-groups.html","id":"dombrock-system-do---isbt-system-014","chapter":"Other Blood Groups","heading":"Dombrock System (DO) - ISBT System 014","text":"Biochemistry/Antigen Carrier: Antigens carried GPI-anchored glycoprotein encoded ART4 geneKey Antigens: Includes Doa Dob (common, antithetical), plus high-prevalence antigens Gya, Hy, Joa. absence Dombrock antigens (Gy(-), Hy-, Jo(-)) defines (null) phenotypeAntigen Characteristics: Destroyed DTT treatment (due GPI anchor). Expression can weaken upon storageAntibodies: Usually IgG, reactive IAT, often weak difficult detect, may show dosage. Notorious appearing delayed reactionsClinical Significance: Antibodies (especially anti-Doa, anti-Dob, anti-Gya) CAN cause delayed HTRs, sometimes severe. Mild HDFN also reported. Finding compatible blood patients antibodies high-prevalence antigens (like Gya) challenging","code":""},{"path":"other-blood-groups.html","id":"colton-system-co---isbt-system-015","chapter":"Other Blood Groups","heading":"Colton System (CO) - ISBT System 015","text":"Biochemistry/Antigen Carrier: Antigens located Aquaporin-1 (AQP1), red cell water channel proteinKey Antigens: Coa (high prevalence, >99.7%) Cob (low prevalence, ~10%). Co3 present cells except rare Co(-b-) null phenotypeAntibodies: Usually IgG, reactive IATClinical Significance: Antibodies (especially anti-Coa anti-Cob) CAN cause significant acute delayed HTRs moderate severe HDFN. Anti-Co3 can made Co(-b-) individuals","code":""},{"path":"other-blood-groups.html","id":"chidorodgers-system-chrg---isbt-system-901-collection-214","chapter":"Other Blood Groups","heading":"Chido/Rodgers System (CH/RG) - ISBT System 901 (Collection 214)","text":"(Note: Technically “Collection” now, full System, antigens aren’t intrinsic RBC structures)Biochemistry/Antigen Carrier: intrinsic red cell antigens. determinants located C4 complement components (C4b C4d) plasma, adsorb onto red cell surface. Ch antigens associated C4B isotype, Rg antigens C4A isotypeKey Antigens: Multiple Ch Rg antigens (e.g., Ch1-6, Rg1-2). high prevalenceAntigen Characteristics: Presence/absence depends inherited C4 genes plasma levels. Can neutralized plasma containing C4. Often give weak, fuzzy, variable reactions IATAntibodies: Almost always IgG, usually weak, non-hemolytic, non-complement bindingClinical Significance: Clinically insignificant. Often called “nuisance antibodies” can mask presence significant underlying antibodies. Identifying correctly (e.g., via plasma neutralization) avoids unnecessary searches rare antigen-negative blood","code":""},{"path":"other-blood-groups.html","id":"gerbich-system-ge---isbt-system-020","chapter":"Other Blood Groups","heading":"Gerbich System (GE) - ISBT System 020","text":"Biochemistry/Antigen Carrier: Antigens located Glycophorin C (GPC) Glycophorin D (GPD), minor sialoglycoproteins involved maintaining RBC shape membrane integrity. interact Protein 4.1Key Antigens: Complex system including high-prevalence antigens Ge2, Ge3, Ge4 lower prevalence antigens (Wb, Lsa, Ana, Dha). several “null” phenotypes associated deletions GYPC gene (e.g., Yus type, Gerbich type, Leach type), often resulting elliptocytosis. Ge3 absent null typesAntigen Characteristics: Antigens can destroyed ficin/papainAntibodies: Usually IgG, reactive IATClinical Significance: Antibodies (especially anti-Ge2, anti-Ge3) CAN cause HTRs HDFN, sometimes severe. phenotypes (e.g., Leach null) associated specific populations (e.g., Melanesia)","code":""},{"path":"other-blood-groups.html","id":"general-themes-for-other-systems","chapter":"Other Blood Groups","heading":"General Themes for “Other” Systems","text":"Biochemical Diversity: Antigens can proteins, glycoproteins (transmembrane GPI-linked), even adsorbed plasma componentsClinical Variability: Significance ranges completely insignificant (Xga, Ch/Rg) potentially life-threatening (Diego, Colton, Dombrock). Never assume antibody insignificant without proper investigation consulting references.Prevalence Matters: Antibodies high-prevalence antigens (e.g., Yta, Coa, Ge3, Vel, J MH) pose significant challenge finding compatible blood. Antibodies low-prevalence antigens (e.g., Dia, Wra, Cob, Kpa, Jsa) less common usually easier find compatible blood (though antibody might potent)Role Reference Labs: Identifying antibodies outside common systems often requires specialized reagents (rare antisera, enzyme/chemical treated cells) expertise found immunohematology reference laboratories (IRLs)Molecular Methods: DNA-based genotyping increasingly valuable predicting phenotypes systems, especially antisera rare unavailable, dealing recently transfused patients","code":""},{"path":"other-blood-groups.html","id":"key-terms-40","chapter":"Other Blood Groups","heading":"Key Terms","text":"ISBT (International Society Blood Transfusion): organization responsible standardizing nomenclature classifying human blood group systemsHigh-Prevalence Antigen: antigen found red blood cells large percentage (typically >99%) given population. Antibodies antigens problematic finding compatible (antigen-negative) blood difficult. Examples include k, Kpb, Jsb, Lub, Vel, J MH, Yta, Ge3Low-Prevalence Antigen: antigen found red blood cells small percentage (often <1-10%) given population. Antibodies less common, compatible (antigen-negative) blood usually easy find. Examples include K, Kpa, Jsa, Lua, Dia, Wra, CobGPI Anchor (Glycosylphosphatidylinositol anchor): glycolipid structure attaches certain proteins (like Acetylcholinesterase [Yt antigens] Dombrock antigens) outer surface cell membrane. Proteins attached way can often cleaved treatment reagents like DTT specific enzymes (PI-PLC)Band 3 Protein (Anion Exchanger 1, AE1): major transmembrane protein red blood cells, crucial CO2 transport (bicarbonate) maintaining cell structure. carries antigens Diego (DI) blood group systemAquaporin-1 (AQP1): protein forming water channels red blood cell membrane, allowing rapid water movement. carries antigens Colton (CO) blood group systemGlycophorins (e.g., GPC, GPD): Sialoglycoproteins (proteins attached sialic acid-rich carbohydrates) red cell surface. GPC GPD carry Gerbich (GE) system antigens play roles membrane stability. (GPA GPB carry MNS system antigens)Clinically Significant (Antibody): antibody capable causing adverse reactions transfusion (Hemolytic Transfusion Reactions - HTR) causing Hemolytic Disease Fetus Newborn (HDFN). Significance can range mild severeNeutralization: technique used antibody identification, typically antibodies soluble antigens (like Lewis Chido/Rodgers). Incubating patient plasma substance containing soluble antigen can inhibit antibody’s reactivity test cells, helping confirm specificityDTT (Dithiothreitol): reducing agent used blood banking primarily denature IgM antibodies (breaking disulfide bonds) destroy certain red cell antigens, particularly proteins sensitive disulfide bond reduction attached via GPI-anchors (like Kell, Lutheran, Dombrock, Cartwright)","code":""},{"path":"high-prevalence-antigens.html","id":"high-prevalence-antigens","chapter":"High Prevalence Antigens","heading":"High Prevalence Antigens","text":"High-prevalence antigens, sometimes called “public” antigens, red cell markers found vast majority population, often exceeding 99% frequency. presence norm, significance transfusion medicine arises dramatically rare individual lacks one common antigens develops corresponding antibody. scenario poses critical challenge: finding compatible (antigen-negative) blood becomes exceptionally difficult, often requiring extensive screening coordination rare donor networks","code":""},{"path":"high-prevalence-antigens.html","id":"antigens-of-high-prevalence-the-common-denominators","chapter":"High Prevalence Antigens","heading":"Antigens of High Prevalence: The Common Denominators","text":"Definition: high-prevalence antigen (sometimes called public antigen) red blood cell surface antigen expressed almost everyone given population (across multiple populations)","code":""},{"path":"high-prevalence-antigens.html","id":"why-are-they-important-in-blood-bank","chapter":"High Prevalence Antigens","heading":"Why are they important in Blood Bank?","text":"Antibodies Rare: people antigen, usually won’t make antibody (due self-tolerance). Therefore, antibodies high-prevalence antigens infrequently encounteredThe Compatibility Crisis: someone form antibody high-prevalence antigen (one rare individuals lacking ), finding compatible (antigen-negative) blood becomes extremely difficult. Imagine needing blood negative antigen 99.9% donors !Clinical Significance: Many antibodies high-prevalence antigens clinically significant, capable causing Hemolytic Transfusion Reactions (HTR) /Hemolytic Disease Fetus Newborn (HDFN)Key Biochemical Carriers: antigens can reside various structures: glycoproteins (like Kell, Lutheran, Gerbich), proteins (like Band 3/Diego, Aquaporin-1/Colton), even carbohydrate structures (like , P)","code":""},{"path":"high-prevalence-antigens.html","id":"examples-of-important-high-prevalence-antigens","chapter":"High Prevalence Antigens","heading":"Examples of Important High-Prevalence Antigens","text":"Note: isn’t exhaustive, covers many clinically relevant examples","code":""},{"path":"high-prevalence-antigens.html","id":"k-cellano---kell-system-kel-isbt-006","chapter":"High Prevalence Antigens","heading":"k (Cellano) - Kell System (KEL, ISBT 006)","text":"Biochemistry: Kell glycoproteinPrevalence: >99% Caucasians, >99.9% Black populations. Antithetical K (Kpa)Antibody (Anti-k): IgG, clinically significant (HTR, HDFN). Finding k-negative (K+k-) blood difficultAntigen-Negative: K+k- individuals. Extremely rare K0 (Kell null) individuals lack Kell antigens","code":""},{"path":"high-prevalence-antigens.html","id":"kpb---kell-system-kel-isbt-006","chapter":"High Prevalence Antigens","heading":"Kpb - Kell System (KEL, ISBT 006)","text":"Biochemistry: Kell glycoproteinPrevalence: >99.9% populations. Antithetical KpaAntibody (Anti-Kpb): IgG, clinically significant (HTR, HDFN). Finding Kp(b-) blood difficultAntigen-Negative: Kp(+b-) Kp(-b-) (K0)","code":""},{"path":"high-prevalence-antigens.html","id":"jsb---kell-system-kel-isbt-006","chapter":"High Prevalence Antigens","heading":"Jsb - Kell System (KEL, ISBT 006)","text":"Biochemistry: Kell glycoproteinPrevalence: >99.9% Caucasians, ~80% Black populations (Jsa common Black populations). Antithetical JsaAntibody (Anti-Jsb): IgG, clinically significant (HTR, HDFN). Finding Js(b-) blood difficult, especially non-Black patientsAntigen-Negative: Js(+b-)","code":""},{"path":"high-prevalence-antigens.html","id":"lub---lutheran-system-lu-isbt-005","chapter":"High Prevalence Antigens","heading":"Lub - Lutheran System (LU, ISBT 005)","text":"Biochemistry: Lutheran glycoprotein (BCAM)Prevalence: >99% populations. Antithetical LuaAntibody (Anti-Lub): Usually IgG, sometimes IgM/mixed. Can cause mild-moderate HTR (often delayed) mild HDFNAntigen-Negative: Lu(+b-) rare Lu(-b-) null phenotypes. Finding Lu(b-) blood difficult","code":""},{"path":"high-prevalence-antigens.html","id":"u---mns-system-mns-isbt-002","chapter":"High Prevalence Antigens","heading":"U - MNS System (MNS, ISBT 002)","text":"Biochemistry: Associated Glycophorin B (GPB). Present either S s antigen expressed normallyPrevalence: >99.9% Caucasians, slightly lower still high Black populations (~99%)Antibody (Anti-U): IgG, highly clinically significant (severe HTR, severe HDFN)Antigen-Negative: U-negative individuals almost exclusively African descent lack GPB (usually S-s- phenotype). Finding U-negative blood extremely challenging requires screening donors African ancestry","code":""},{"path":"high-prevalence-antigens.html","id":"i---i-system-i-isbt-027","chapter":"High Prevalence Antigens","heading":"I - I System (I, ISBT 027)","text":"Biochemistry: Branched carbohydrate structure precursor chains (related ABO). ‘’ develops fetal ‘’ antigen first ~18 months lifePrevalence: Virtually 100% adults. (Fetal/newborn cells rich , poor )Antibody (Anti-): Usually benign, cold-reacting IgM autoantibody. Can cause issues cold temperatures (Cold Agglutinin Disease) interfere room temperature/immediate spin testing. Pathologic anti-can potent IgM hemolysins. Alloanti-extremely rare (seen adult phenotype individuals)Antigen-Negative: Rare adult phenotype individuals","code":""},{"path":"high-prevalence-antigens.html","id":"vel---vel-system-vel-isbt-035","chapter":"High Prevalence Antigens","heading":"Vel - Vel System (VEL, ISBT 035)","text":"Biochemistry: Carried protein SMIM1Prevalence: >99.9% populationsAntibody (Anti-Vel): Often mixed IgG/IgM, potent complement activator. Highly clinically significant (severe immediate HTR). Known difficult identify serologically (weak/variable reactions)Antigen-Negative: Vel-negative phenotype rare (<0.01%). Finding Vel-negative blood exceptionally difficult, relying heavily rare donor registries","code":""},{"path":"high-prevalence-antigens.html","id":"j-mh-john-milton-hagen---j-mh-system-j-mh-isbt-026","chapter":"High Prevalence Antigens","heading":"J MH (John Milton Hagen) - J MH System (J MH, ISBT 026)","text":"Biochemistry: Located Semaphorin 7A (CD108), GPI-linked proteinPrevalence: >99.9% populationsAntibody (Anti-J MH): Usually IgG, often weak, refractile, difficult work (“nebulous”). Generally considered clinically insignificant causing mild RBC destruction. Can mask significant antibodies. Antigen expression can weak variableAntigen-Negative: J MH-negative extremely rare","code":""},{"path":"high-prevalence-antigens.html","id":"dib---diego-system-di-isbt-010","chapter":"High Prevalence Antigens","heading":"Dib - Diego System (DI, ISBT 010)","text":"Biochemistry: Located Band 3 protein (Anion Exchanger 1)Prevalence: >99.9% non-Asian/Native American populations. Antithetical DiaAntibody (Anti-Dib): IgG, clinically significant (HTR, HDFN)Antigen-Negative: Di(+b-) individuals (common East Asian/Native American populations)","code":""},{"path":"high-prevalence-antigens.html","id":"wrb---diego-system-di-isbt-010","chapter":"High Prevalence Antigens","heading":"Wrb - Diego System (DI, ISBT 010)","text":"Biochemistry: Requires interaction Band 3 Glycophorin APrevalence: >99.9% populations. Antithetical WraAntibody (Anti-Wrb): Extremely rare (antigen high prevalence). Can IgG, potentially significant. common autoanti-Wrb Warm Autoimmune Hemolytic Anemia (WAIHA)Antigen-Negative: Wr(+b-) individuals","code":""},{"path":"high-prevalence-antigens.html","id":"coa---colton-system-co-isbt-015","chapter":"High Prevalence Antigens","heading":"Coa - Colton System (CO, ISBT 015)","text":"Biochemistry: Located Aquaporin-1 (water channel)Prevalence: >99.7% populations. Antithetical CobAntibody (Anti-Coa): IgG, clinically significant (HTR, HDFN)Antigen-Negative: Co(-b+) rare Co(-b-) null phenotype","code":""},{"path":"high-prevalence-antigens.html","id":"ge3---gerbich-system-ge-isbt-020","chapter":"High Prevalence Antigens","heading":"Ge3 - Gerbich System (GE, ISBT 020)","text":"Biochemistry: Located Glycophorin C (GPC) Glycophorin D (GPD)Prevalence: >99% populationsAntibody (Anti-Ge3): IgG, clinically significant (HTR, HDFN)Antigen-Negative: Individuals Gerbich null phenotypes (e.g., Ge:-2,-3,-4 Leach phenotype). Finding Ge3-negative blood difficult","code":""},{"path":"high-prevalence-antigens.html","id":"emm---emm-system-emm-isbt-044","chapter":"High Prevalence Antigens","heading":"Emm - EMM System (EMM, ISBT 044)","text":"Biochemistry: Unknown protein carrier (recent knowledge, may updated)Prevalence: >99.99% (extremely high)Antibody (Anti-Emm): IgG, potent complement activator. Highly clinically significant (severe HTR, HDFN)Antigen-Negative: Emm-negative phenotype exceedingly rare. Finding compatible blood requires extensive international collaboration","code":""},{"path":"high-prevalence-antigens.html","id":"challenges-and-management","chapter":"High Prevalence Antigens","heading":"Challenges and Management","text":"Identification: Confirming antibody specificity often requires testing panel rare antigen-negative cells, typically done Immunohematology Reference Laboratory (IRL)Finding Compatible Blood: major hurdle. Strategies include:\nScreening large numbers donors (thousands)\nUtilizing national international Rare Donor Programs\nTesting family members (siblings 1 4 chance rare phenotype)\nAutologous donation: (patient donating ) need anticipated patient eligible\nMolecular genotyping donors can sometimes help identify rare antigen-negative units efficiently\nScreening large numbers donors (thousands)Utilizing national international Rare Donor ProgramsTesting family members (siblings 1 4 chance rare phenotype)Autologous donation: (patient donating ) need anticipated patient eligibleMolecular genotyping donors can sometimes help identify rare antigen-negative units efficientlyClinical Decisions: Balancing risk transfusion reaction vs. risk delaying transfusion. Sometimes, “least incompatible” blood might considered emergencies truly antigen-negative blood unavailable, carries significant risk","code":""},{"path":"high-prevalence-antigens.html","id":"key-terms-41","chapter":"High Prevalence Antigens","heading":"Key Terms","text":"High-Prevalence Antigen: antigen found red blood cells large percentage (typically >99%) given populationNull Phenotype: rare phenotype individual lacks antigens within specific blood group system (e.g., K0, Rhnull, Lu(-b-)). individuals may produce complex antibodies reacting cells except null typeRare Donor Program: system registry (often national international) catalogs donors known rare blood types (lacking high-prevalence antigens possessing combinations uncommon antigens) facilitate finding compatible blood patients rare antibodiesReference Laboratory (Immunohematology Reference Laboratory - IRL): specialized laboratory equipped reagents (including rare antisera antigen-typed cells), techniques, expertise investigate resolve complex immunohematology problems, including identifying antibodies high- low-prevalence antigensClinically Significant (Antibody): antibody capable causing adverse reactions transfusion (Hemolytic Transfusion Reactions - HTR) causing Hemolytic Disease Fetus Newborn (HDFN). Many antibodies high-prevalence antigens fall categoryAntithetical Antigen: One pair antigens encoded alleles gene locus (e.g., K k, Fya Fyb). antigen high prevalence (like k), antithetical partner (K) often low prevalence","code":""},{"path":"low-prevalence-antigens.html","id":"low-prevalence-antigens","chapter":"Low Prevalence Antigens","heading":"Low Prevalence Antigens","text":"Low-prevalence antigens (LPA) rare counterparts common blood group markers. finding compatible blood patients antibodies LPAs generally straightforward, primary challenge lies initial detection identification often-elusive antibodies, frequently revealed incompatible crossmatch. clinical significance varies must evaluated individuallyWhile antibodies high-prevalence antigens create finding compatible blood crisis, antibodies low-prevalence antigens present different set challenges, primarily around initial detection confirmation","code":""},{"path":"low-prevalence-antigens.html","id":"antigens-of-low-prevalence-the-rarities","chapter":"Low Prevalence Antigens","heading":"Antigens of Low Prevalence: The Rarities","text":"Definition: low-prevalence antigen (LPA), sometimes called “private” antigen, red blood cell surface antigen expressed small percentage given population, typically ranging <0.1% maybe 10%, depending specific antigen populationBiochemical Basis: Like blood group antigens, LPAs arise genetic variations (often SNPs) alter structure proteins glycoproteins red cell surface, modify carbohydrate structures. Many LPAs antithetical partners high-prevalence antigens (e.g., K LPA partner high-prevalence k antigen)","code":""},{"path":"low-prevalence-antigens.html","id":"key-characteristics-and-implications","chapter":"Low Prevalence Antigens","heading":"Key Characteristics and Implications","text":"Antibody Frequency: antigen rare, exposure transfusion pregnancy uncommon. Therefore, antibodies LPAs also relatively infrequently encountered routine testingAntibody Detection Challenge: main issue. patient form antibody LPA:\nlikely non-reactive standard antibody screening cells, cells usually chosen represent common antigen profiles likely lack specific LPA\nmay react one cell larger identification panel, panel happens include cell positive rare antigen. single reaction can sometimes dismissed insignificant difficult interpret\nantibody might detected crossmatch phase selected donor unit happens positive specific LPA patient antibody . classic cause “unexpected incompatible crossmatch” negative antibody screen\nlikely non-reactive standard antibody screening cells, cells usually chosen represent common antigen profiles likely lack specific LPAIt may react one cell larger identification panel, panel happens include cell positive rare antigen. single reaction can sometimes dismissed insignificant difficult interpretThe antibody might detected crossmatch phase selected donor unit happens positive specific LPA patient antibody . classic cause “unexpected incompatible crossmatch” negative antibody screenFinding Compatible Blood: generally EASY. Since antigen rare, vast majority random donors antigen-negative therefore compatible (assuming antibody correctly identified)Clinical Significance: Varies widely! antibodies LPAs clinically significant capable causing HTR HDFN (e.g., anti-K, anti-Jsa, anti-Wra), others considered insignificant low clinical relevance. Significance must assessed specific antibody","code":""},{"path":"low-prevalence-antigens.html","id":"examples-of-important-low-prevalence-antigens","chapter":"Low Prevalence Antigens","heading":"Examples of Important Low-Prevalence Antigens","text":"Many LPAs less common partner antithetical pair within major blood group systems","code":""},{"path":"low-prevalence-antigens.html","id":"k-kell---kell-system-kel-isbt-006","chapter":"Low Prevalence Antigens","heading":"K (Kell) - Kell System (KEL, ISBT 006)","text":"Biochemistry: Kell glycoproteinPrevalence: ~9% Caucasians, ~2% Black populations. Antithetical k (high prevalence)Antibody (Anti-K): IgG, highly clinically significant (can cause severe HTR HDFN). One common clinically significant antibodies outside ABO/RhAntigen-Positive: K+k+ K+k- individuals","code":""},{"path":"low-prevalence-antigens.html","id":"kpa-penney---kell-system-kel-isbt-006","chapter":"Low Prevalence Antigens","heading":"Kpa (Penney) - Kell System (KEL, ISBT 006)","text":"Biochemistry: Kell glycoproteinPrevalence: ~2% Caucasians, rare Black populations. Antithetical Kpb (high prevalence)Antibody (Anti-Kpa): IgG, clinically significant (HTR, HDFN)Antigen-Positive: Kp(+b+) Kp(+b-) individuals","code":""},{"path":"low-prevalence-antigens.html","id":"jsa-sutter---kell-system-kel-isbt-006","chapter":"Low Prevalence Antigens","heading":"Jsa (Sutter) - Kell System (KEL, ISBT 006)","text":"Biochemistry: Kell glycoproteinPrevalence: ~20% Black populations, rare (<0.1%) Caucasians. Antithetical Jsb (high prevalence Caucasians)Antibody (Anti-Jsa): IgG, clinically significant (HTR, HDFN)Antigen-Positive: Js(+b+) Js(+b-) individuals","code":""},{"path":"low-prevalence-antigens.html","id":"lua---lutheran-system-lu-isbt-005","chapter":"Low Prevalence Antigens","heading":"Lua - Lutheran System (LU, ISBT 005)","text":"Biochemistry: Lutheran glycoprotein (BCAM)Prevalence: ~8% Caucasians, less common populations. Antithetical Lub (high prevalence)Antibody (Anti-Lua): Often IgM mixed IgM/IgG, often naturally occurring. Can cause mild HTR, HDFN usually mild absent. Known characteristic loose/mixed-field agglutinationAntigen-Positive: Lu(+b+) Lu(+b-) individuals","code":""},{"path":"low-prevalence-antigens.html","id":"dia---diego-system-di-isbt-010","chapter":"Low Prevalence Antigens","heading":"Dia - Diego System (DI, ISBT 010)","text":"Biochemistry: Located Band 3 protein (Anion Exchanger 1)Prevalence: Low prevalence Caucasians Black populations (<0.1%), significantly higher (36% ) Native American East Asian populations. Antithetical Dib (high prevalence)Antibody (Anti-Dia): IgG, clinically significant (HTR, HDFN). Importance varies geographicallyAntigen-Positive: Di(+b+) Di(+b-) individuals","code":""},{"path":"low-prevalence-antigens.html","id":"wra-wright---diego-system-di-isbt-010","chapter":"Low Prevalence Antigens","heading":"Wra (Wright) - Diego System (DI, ISBT 010)","text":"Biochemistry: Requires Band 3 proteinPrevalence: ~0.1% Caucasians. Antithetical Wrb (high prevalence)Antibody (Anti-Wra): Can IgM IgG, naturally occurring immune stimulated. Clinically significant (can cause severe HTR, HDFN). Sometimes seen autoantibodyAntigen-Positive: Wr(+b+) Wr(+b-) individuals","code":""},{"path":"low-prevalence-antigens.html","id":"cob---colton-system-co-isbt-015","chapter":"Low Prevalence Antigens","heading":"Cob - Colton System (CO, ISBT 015)","text":"Biochemistry: Located Aquaporin-1 (water channel)Prevalence: ~10% Caucasians. Antithetical Coa (high prevalence)Antibody (Anti-Cob): IgG, clinically significant (HTR, HDFN)Antigen-Positive: Co(+b+) Co(-b+) individuals","code":""},{"path":"low-prevalence-antigens.html","id":"other-examples","chapter":"Low Prevalence Antigens","heading":"Other Examples","text":"V (MNS System): Low prevalence overall, higher Black populations (~30%)Mg (MNS System): Low prevalence antigen associated specific GPA variants. Anti-Mg can significantVarious antigens within Miltenberger subsystem (MNS System): complex group LPAs resulting rearrangements GYPA, GYPB, GYPE genesSc2 (Scianna System): Low prevalence (~1%), antithetical Sc1 (high prevalence). Anti-Sc2 can cause HTR/HDFN","code":""},{"path":"low-prevalence-antigens.html","id":"challenges-and-management-1","chapter":"Low Prevalence Antigens","heading":"Challenges and Management","text":"Identification: Requires testing patient plasma/serum panel cells known positive various LPAs. often done reference laboratory setting. Testing family members can sometimes help antibody specificity suspected unconfirmedCrossmatching: serological crossmatch remains crucial. ’s final check likely place detect antibody LPA antibody screen negativeTransfusion: antibody LPA identified considered clinically significant, antigen-negative blood provided. noted, usually readily availableHDFN: pregnant person antibody LPA, father baby phenotyped (genotyped) antigen. positive, fetus risk inheriting antigen developing HDFN","code":""},{"path":"low-prevalence-antigens.html","id":"key-terms-42","chapter":"Low Prevalence Antigens","heading":"Key Terms","text":"Low-Prevalence Antigen (LPA): antigen found red blood cells small percentage (typically <10%, often much lower) given population. Also sometimes called “private” antigenAntithetical Antigen: One pair antigens encoded alleles gene locus (e.g., K k, Lua Lub). Often, one high prevalence, low prevalenceCrossmatch: laboratory test performed transfusion determine serological compatibility donor red blood cells patient plasma/serum. serves final check unexpected antibodies, including low-prevalence antigens potentially missed antibody screeningAntibody Screen (Antibody Detection Test): test using reagent red blood cells known, common antigen profiles detect presence unexpected antibodies patient plasma/serum. May miss antibodies low-prevalence antigens screening cells lack specific antigenReference Laboratory (Immunohematology Reference Laboratory - IRL): specialized laboratory resources (rare reagents, extensive panels, molecular capabilities) expertise identify complex antibodies, including directed low-prevalence antigensClinically Significant (Antibody): antibody capable causing adverse reactions transfusion (Hemolytic Transfusion Reactions - HTR) causing Hemolytic Disease Fetus Newborn (HDFN). Antibodies low-prevalence antigens (like K, Wra) significant, others may ","code":""},{"path":"hla.html","id":"hla","chapter":"HLA","heading":"HLA","text":"Consideration HLA broadens scope beyond red cell membrane . traditional “blood group” antigens located mature red blood cells, Human Leukocyte Antigens (HLA) critically important surface proteins found leukocytes, platelets, almost nucleated cells. Encoded highly polymorphic Major Histocompatibility Complex (MHC) genes chromosome 6, HLA molecules essential immune system’s ability distinguish ‘self’ ‘non-self’. extreme diversity presence transfused platelets contaminating white cells components make highly relevant transfusion medicine, particularly concerning platelet refractoriness, febrile reactions, transfusion-related acute lung injury (TRALI)","code":""},{"path":"hla.html","id":"hla-the-immune-systems-id-card","chapter":"HLA","heading":"HLA: The Immune System’s ID Card","text":"?: HLA antigens proteins found surface almost nucleated cells body. includes white blood cells (leukocytes) platelets. Critically, mature red blood cells generally lack HLA antigens, although platelets contaminating leukocytes RBC units themWhat’s job?: main biological role present peptide fragments (inside cell, like viral proteins, outside, like bacterial proteins) T-lymphocytes, initiating adaptive immune responses","code":""},{"path":"hla.html","id":"biochemistry-and-genetics-why-hla-is-so-complex","chapter":"HLA","heading":"Biochemistry and Genetics: Why HLA is SO Complex","text":"Major Histocompatibility Complex (MHC): HLA genes located within region Chromosome 6 called Major Histocompatibility Complex (MHC). one gene-dense regions human genomeTwo Main Classes\nHLA Class (HLA-, HLA-B, HLA-C): Found virtually nucleated cells platelets. primarily present peptides within cell (e.g., viral proteins, tumor antigens) CD8+ cytotoxic T-lymphocytes\nHLA Class II (HLA-DR, HLA-DQ, HLA-DP): Found primarily antigen-presenting cells (APCs) like B-lymphocytes, monocytes, macrophages, dendritic cells. present peptides derived outside cell (e.g., bacterial proteins) CD4+ helper T-lymphocytes\nHLA Class (HLA-, HLA-B, HLA-C): Found virtually nucleated cells platelets. primarily present peptides within cell (e.g., viral proteins, tumor antigens) CD8+ cytotoxic T-lymphocytesHLA Class II (HLA-DR, HLA-DQ, HLA-DP): Found primarily antigen-presenting cells (APCs) like B-lymphocytes, monocytes, macrophages, dendritic cells. present peptides derived outside cell (e.g., bacterial proteins) CD4+ helper T-lymphocytesInheritance: HLA genes inherited together block parent, called haplotype. get one haplotype mother one fatherEXTREME Polymorphism: absolute key feature! HLA system polymorphic genetic system known humans. thousands different known alleles (versions) major HLA genes (especially HLA-, -B, -DR). incredible diversity means ’s rare two unrelated individuals identical HLA types. diversity great species’ ability fight diverse pathogens makes finding compatible donors (transfusion transplantation) challenging","code":""},{"path":"hla.html","id":"hla-vs.-red-cell-antigens-key-differences","chapter":"HLA","heading":"HLA vs. Red Cell Antigens: Key Differences","text":"","code":""},{"path":"hla.html","id":"clinical-relevance-in-transfusion-medicine","chapter":"HLA","heading":"Clinical Relevance in Transfusion Medicine","text":"Even though mature RBCs lack HLA, presence HLA antigens platelets contaminating leukocytes blood components leads several critical issues:Platelet Refractoriness (Immune-Mediated)\n: patient doesn’t achieve expected increase platelet count platelet transfusion\nHLA Role: common immune cause presence recipient antibodies donor HLA Class antigens transfused platelets. antibodies destroy transfused platelets rapidly. (Antibodies Platelet-Specific Antigens, HPA, main immune cause)\nManagement: Requires providing HLA-matched compatible platelets, donor platelets lack HLA antigens patient antibodies . Platelet crossmatching can also help select compatible units\n: patient doesn’t achieve expected increase platelet count platelet transfusionHLA Role: common immune cause presence recipient antibodies donor HLA Class antigens transfused platelets. antibodies destroy transfused platelets rapidly. (Antibodies Platelet-Specific Antigens, HPA, main immune cause)Management: Requires providing HLA-matched compatible platelets, donor platelets lack HLA antigens patient antibodies . Platelet crossmatching can also help select compatible unitsFebrile Non-Hemolytic Transfusion Reactions (FNHTR)\n: Fever chills shortly transfusion, without red cell destruction\nHLA Role: Often caused recipient antibodies reacting HLA antigens donor leukocytes (WBCs) present component. interaction, presence cytokines released WBCs storage, triggers fever\nManagement: Largely prevented Leukoreduction (filtering WBCs) blood components\n: Fever chills shortly transfusion, without red cell destructionHLA Role: Often caused recipient antibodies reacting HLA antigens donor leukocytes (WBCs) present component. interaction, presence cytokines released WBCs storage, triggers feverManagement: Largely prevented Leukoreduction (filtering WBCs) blood componentsTransfusion-Related Acute Lung Injury (TRALI)\n: serious, potentially fatal complication characterized acute respiratory distress non-cardiogenic pulmonary edema occurring within 6 hours transfusion\nHLA Role: common mechanism involves donor antibodies (usually HLA Class Class II, HNA - Human Neutrophil Antigens) directed recipient leukocytes. antibodies activate neutrophils recipient’s lungs, leading capillary leakage lung injury\nManagement: Primarily involves risk mitigation strategies, using plasma predominantly male donors female donors never pregnant tested negative HLA antibodies (pregnancy major route HLA sensitization). Leukoreduction effective preventing antibody-mediated TRALI\n: serious, potentially fatal complication characterized acute respiratory distress non-cardiogenic pulmonary edema occurring within 6 hours transfusionHLA Role: common mechanism involves donor antibodies (usually HLA Class Class II, HNA - Human Neutrophil Antigens) directed recipient leukocytes. antibodies activate neutrophils recipient’s lungs, leading capillary leakage lung injuryManagement: Primarily involves risk mitigation strategies, using plasma predominantly male donors female donors never pregnant tested negative HLA antibodies (pregnancy major route HLA sensitization). Leukoreduction effective preventing antibody-mediated TRALITransfusion-Associated Graft-versus-Host Disease (TA-GVHD)\n: rare usually fatal complication viable donor T-lymphocytes transfused component engraft recipient attack recipient’s tissues\nHLA Role: Risk highest recipient immunocompromised donor homozygous HLA haplotype recipient heterozygous (making recipient appear “foreign” donor lymphocytes, donor lymphocytes aren’t seen foreign recipient initially)\nManagement: Prevented Gamma Irradiation cellular blood components -risk patients, inactivates donor T-lymphocytes\n: rare usually fatal complication viable donor T-lymphocytes transfused component engraft recipient attack recipient’s tissuesHLA Role: Risk highest recipient immunocompromised donor homozygous HLA haplotype recipient heterozygous (making recipient appear “foreign” donor lymphocytes, donor lymphocytes aren’t seen foreign recipient initially)Management: Prevented Gamma Irradiation cellular blood components -risk patients, inactivates donor T-lymphocytes","code":""},{"path":"hla.html","id":"hla-antibodies","chapter":"HLA","heading":"HLA Antibodies","text":"Formation: Individuals become sensitized (form antibodies) HLA antigens primarily :\nPregnancy: Exposure paternal HLA antigens fetal cells\nTransfusion: Exposure HLA antigens donor platelets WBCs\nTransplantation: Exposure donor organ/tissue HLA antigens\nPregnancy: Exposure paternal HLA antigens fetal cellsTransfusion: Exposure HLA antigens donor platelets WBCsTransplantation: Exposure donor organ/tissue HLA antigensType: Usually IgG","code":""},{"path":"hla.html","id":"hla-testing","chapter":"HLA","heading":"HLA Testing","text":"Performed specialized HLA Histocompatibility laboratories, typically routine blood bankMethods: Include serological methods (complement-dependent cytotoxicity - CDC) , commonly now, molecular (DNA-based) methods provide higher resolution typing. Antibody screening identification also performedPurpose: Primarily transplantation matching (donor-recipient), identifying antibodies causing platelet refractoriness TRALI, selecting HLA-compatible donors","code":""},{"path":"hla.html","id":"mitigation-strategies-in-blood-banking","chapter":"HLA","heading":"Mitigation Strategies in Blood Banking","text":"Universal Leukoreduction: Removing WBCs RBC platelet components significantly reduces FNHTR risk may reduce HLA alloimmunizationHLA-Selected Platelets: Providing HLA-matched antigen-negative platelets refractory patientsTRALI Risk Mitigation Strategies: Managing plasma inventory based donor history (sex, pregnancy)Irradiation: Preventing TA-GVHD susceptible patients","code":""},{"path":"hla.html","id":"key-terms-43","chapter":"HLA","heading":"Key Terms","text":"HLA (Human Leukocyte Antigen): Proteins found surface nucleated cells platelets, encoded genes Major Histocompatibility Complex (MHC), crucial immune recognition distinguishing self non-selfMHC (Major Histocompatibility Complex): large genetic region chromosome 6 containing genes code HLA proteinsPolymorphism: existence many different forms (alleles) gene within population. HLA system extremely polymorphicHaplotype: set closely linked genes (like HLA genes) chromosome typically inherited together single unitLeukoreduction: process filtering blood components (RBCs, platelets) remove vast majority white blood cells (leukocytes). Primarily used reduce risk FNHTR, CMV transmission, possibly HLA alloimmunizationPlatelet Refractoriness: failure achieve expected rise platelet count platelet transfusion, often due immune destruction transfused platelets recipient HLA HPA antibodiesFNHTR (Febrile Non-Hemolytic Transfusion Reaction): common transfusion reaction characterized fever chills without red cell hemolysis, often caused recipient antibodies donor leukocyte HLA antigens cytokines released leukocytes storageTRALI (Transfusion-Related Acute Lung Injury): serious transfusion reaction characterized acute respiratory distress, often caused donor antibodies (HLA HNA) reacting recipient leukocytes, leading pulmonary edemaAlloimmunization: development antibodies response foreign antigens (different individual species) encountered transfusion, transplantation, pregnancyHPA (Human Platelet Antigen): Antigens specific platelets, distinct HLA antigens. Antibodies HPAs another cause immune-mediated platelet refractoriness neonatal alloimmune thrombocytopenia (NAIT)","code":""},{"path":"platelet-specific.html","id":"platelet-specific","chapter":"Platelet-Specific","heading":"Platelet-Specific","text":"Moving beyond red cells broadly expressed HLA system, now focus specifically antigens primarily found platelet surface, known Human Platelet Antigens (HPA). antigens reside critical platelet glycoproteins involved adhesion aggregation. less numerous red cell antigens, polymorphisms within HPA systems lead formation platelet-specific antibodies implicated significant clinical conditions Neonatal Alloimmune Thrombocytopenia (NAIT), Post-Transfusion Purpura (PTP), instances platelet refractoriness, making understanding vital transfusion medicine","code":""},{"path":"platelet-specific.html","id":"hpa-antigens-unique-to-platelets","chapter":"Platelet-Specific","heading":"HPA: Antigens Unique to Platelets","text":"?: HPAs polymorphic (variable individuals) antigens expressed platelet surface glycoproteins. arise single nucleotide polymorphisms (SNPs) genes encoding glycoproteins, leading amino acid substitutions create different antigenic formsDistinction HLA: platelets express HLA Class antigens, HPAs different molecules located different glycoproteins specific platelet lineage. patient can antibodies HLA, HPA, bothDistinction RBC Antigens: antigens generally absent red blood cells","code":""},{"path":"platelet-specific.html","id":"biochemistry-the-platelet-glycoproteins","chapter":"Platelet-Specific","heading":"Biochemistry: The Platelet Glycoproteins","text":"clinically relevant HPAs located major platelet membrane glycoproteins, crucial platelet function (adhesion aggregation):GPIIb/IIIa Complex (Integrin αIIbβ3): abundant glycoprotein complex platelet surface acts receptor fibrinogen, von Willebrand factor (vWF), fibronectin, mediating platelet aggregation\nHPA-1: antigens (formerly PlA) located GPIIIa (β3)\nHPA-3: antigens (formerly Bak) located GPIIb (αIIb)\nHPA-4: antigens (formerly Pen/Yuk) located GPIIIa (β3)\nHPA-1: antigens (formerly PlA) located GPIIIa (β3)HPA-3: antigens (formerly Bak) located GPIIb (αIIb)HPA-4: antigens (formerly Pen/Yuk) located GPIIIa (β3)GPIb/IX/V Complex: complex acts primary receptor vWF, mediating platelet adhesion injured vessel walls high shear stress\nHPA-2: antigens (formerly Ko) located GPIbα\nHPA-2: antigens (formerly Ko) located GPIbαGPIa/IIa Complex (Integrin α2β1): complex acts major receptor collagen, mediating platelet adhesion activation sites vascular injury\nHPA-5: antigens (formerly Br) located GPIa (α2)\nHPA-5: antigens (formerly Br) located GPIa (α2)","code":""},{"path":"platelet-specific.html","id":"genetics-and-nomenclature","chapter":"Platelet-Specific","heading":"Genetics and Nomenclature","text":"Inheritance: HPAs inherited simple Mendelian codominant fashionNomenclature: official system uses “HPA” followed number representing system (locus) letter (“” “b”) representing specific allele/antigen. “” allele generally encodes higher frequency antigen, “b” lower frequency one\nExample: HPA-1a / HPA-1b. individual can homozygous HPA-1a/1a, homozygous HPA-1b/1b (rare), heterozygous HPA-1a/1b\nExample: HPA-1a / HPA-1b. individual can homozygous HPA-1a/1a, homozygous HPA-1b/1b (rare), heterozygous HPA-1a/1bPolymorphism: numerous HPA systems exist (HPA-1 HPA-39 currently recognized ISBT), frequently involved clinical problems, largely due frequency alleles population immunogenicity antigens","code":""},{"path":"platelet-specific.html","id":"major-clinically-significant-hpa-systems","chapter":"Platelet-Specific","heading":"Major Clinically Significant HPA Systems","text":"Note: Frequencies can vary significantly different ethnic populations","code":""},{"path":"platelet-specific.html","id":"clinical-significance-when-hpa-matters","chapter":"Platelet-Specific","heading":"Clinical Significance: When HPA Matters","text":"Antibodies HPA systems primarily implicated three conditions:Neonatal Alloimmune Thrombocytopenia (NAIT)\nMechanism: Analogous HDFN, involving platelets. mother (usually HPA-1a negative, .e., HPA-1b/1b) becomes alloimmunized platelet antigen (usually HPA-1a) inherited fetus father. Maternal IgG anti-HPA antibodies cross placenta destroy fetal platelets\nConsequences: Can cause severe thrombocytopenia (low platelet count) fetus/newborn, leading bleeding, including potentially devastating intracranial hemorrhage (ICH), even utero. Can occur first pregnancy\nManagement: Requires identification maternal antibody prediction/monitoring fetal status. Treatment may involve maternal IVIG pregnancy, early delivery, transfusion infant antigen-negative platelets (often washed maternal platelets HPA-selected donor platelets) /IVIG\nMechanism: Analogous HDFN, involving platelets. mother (usually HPA-1a negative, .e., HPA-1b/1b) becomes alloimmunized platelet antigen (usually HPA-1a) inherited fetus father. Maternal IgG anti-HPA antibodies cross placenta destroy fetal plateletsConsequences: Can cause severe thrombocytopenia (low platelet count) fetus/newborn, leading bleeding, including potentially devastating intracranial hemorrhage (ICH), even utero. Can occur first pregnancyManagement: Requires identification maternal antibody prediction/monitoring fetal status. Treatment may involve maternal IVIG pregnancy, early delivery, transfusion infant antigen-negative platelets (often washed maternal platelets HPA-selected donor platelets) /IVIGPost-Transfusion Purpura (PTP)\nMechanism: rare serious delayed transfusion reaction occurring ~5-12 days post-transfusion. Typically seen previously sensitized individuals (usually multiparous women) negative high-prevalence HPA (like HPA-1a negative). Upon re-exposure antigen via transfusion RBCs platelets containing residual platelet material, produce strong anamnestic antibody response. Paradoxically, response destroys transfused antigen-positive platelets patient’s antigen-negative platelets (mechanism fully understood may involve immune complexes)\nConsequences: Leads sudden, profound thrombocytopenia severe bleeding risk\nManagement: Primarily supportive care IVIG. Future transfusions must use antigen-negative cellular components\nMechanism: rare serious delayed transfusion reaction occurring ~5-12 days post-transfusion. Typically seen previously sensitized individuals (usually multiparous women) negative high-prevalence HPA (like HPA-1a negative). Upon re-exposure antigen via transfusion RBCs platelets containing residual platelet material, produce strong anamnestic antibody response. Paradoxically, response destroys transfused antigen-positive platelets patient’s antigen-negative platelets (mechanism fully understood may involve immune complexes)Consequences: Leads sudden, profound thrombocytopenia severe bleeding riskManagement: Primarily supportive care IVIG. Future transfusions must use antigen-negative cellular components*Platelet Refractoriness\nMechanism: less common HLA antibodies cause, HPA antibodies can also lead poor platelet count increments transfusion destroying transfused platelets carrying cognate HPA\nManagement: Requires identifying specific HPA antibody providing antigen-negative platelets. Platelet crossmatching may also helpful\nMechanism: less common HLA antibodies cause, HPA antibodies can also lead poor platelet count increments transfusion destroying transfused platelets carrying cognate HPAManagement: Requires identifying specific HPA antibody providing antigen-negative platelets. Platelet crossmatching may also helpful","code":""},{"path":"platelet-specific.html","id":"hpa-antibodies","chapter":"Platelet-Specific","heading":"HPA Antibodies","text":"Formation: Alloimmunization occurs pregnancy transfusionType: Primarily IgG","code":""},{"path":"platelet-specific.html","id":"hpa-testing","chapter":"Platelet-Specific","heading":"HPA Testing","text":"Performed specialized reference laboratories (Platelet Immunology labs, IRLs)Antigen Typing (Genotyping): Molecular (DNA-based) methods now standard determining patient’s donor’s HPA type. Crucial NAIT workups finding compatible donorsAntibody Detection/Identification: Serological techniques like ELISA (Enzyme-Linked Immunosorbent Assay) flow cytometry-based assays used detect identify specific HPA antibodies patient serum/plasmaPlatelet Crossmatching: Similar principle RBC crossmatching, patient serum tested donor platelets predict compatibility","code":""},{"path":"platelet-specific.html","id":"key-terms-44","chapter":"Platelet-Specific","heading":"Key Terms","text":"HPA (Human Platelet Antigen): Polymorphic antigens expressed specifically platelet surface glycoproteins, distinct HLA RBC antigensPlatelet Glycoproteins (e.g., GPIIb/IIIa, GPIb/IX/V): Membrane proteins crucial platelet function (adhesion, aggregation) carry HPA determinantsSNP (Single Nucleotide Polymorphism): variation single DNA base pair commonly underlies difference HPA alleles (e.g., HPA-1a vs. HPA-1b)NAIT (Neonatal Alloimmune Thrombocytopenia): condition maternal IgG antibodies fetal HPA (inherited father) cross placenta destroy fetal platelets, leading thrombocytopenia bleeding risk newbornPTP (Post-Transfusion Purpura): rare, delayed transfusion reaction causing severe thrombocytopenia due anamnestic HPA antibody response destroys transfused autologous plateletsPlatelet Refractoriness: Failure achieve expected increase platelet count transfusion, can caused HPA antibodies (though HLA antibodies common)Antigen-Negative Platelets: Platelets collected donors specifically selected lack HPA recipient formed antibody. Crucial managing NAIT, PTP, HPA-mediated refractorinessIVIG (Intravenous Immunoglobulin): treatment used NAIT PTP, thought work blocking antibody-mediated destruction modulating immune response","code":""},{"path":"granulocyte-specific.html","id":"granulocyte-specific","chapter":"Granulocyte-Specific","heading":"Granulocyte-Specific","text":"section focuss attention surface markers another critical blood cell: granulocyte, particularly neutrophil. Just red cells platelets unique antigen systems, neutrophils possess set polymorphic surface proteins known Human Neutrophil Antigens (HNA). Distinct HLA, HPA, traditional red cell antigens, HNAs play roles neutrophil function. routinely typed blood bank, understanding HNAs vital antibodies directed significant causes serious conditions like Transfusion-Related Acute Lung Injury (TRALI) immune-mediated neutropenias","code":""},{"path":"granulocyte-specific.html","id":"hna-markers-on-the-immune-systems-first-responders","chapter":"Granulocyte-Specific","heading":"HNA: Markers on the Immune System’s First Responders","text":"?: HNAs polymorphic (variable individuals) antigens expressed surface membranes neutrophils sometimes granulocytes (eosinophils, basophils) monocytesDistinction HLA/HPA/RBC Antigens: HNAs distinct molecular structures located different proteins compared HLA (found almost nucleated cells + platelets), HPA (platelets), RBC antigens. However, neutrophils also express HLA Class antigensPrimary Clinical Relevance: Antibodies HNAs primarily implicated :\nTransfusion-Related Acute Lung Injury (TRALI)\nNeonatal Alloimmune Neutropenia (NAN)\nAutoimmune Neutropenia (AIN)\nFebrile Non-Hemolytic Transfusion Reactions (FNHTR - less common now universal leukoreduction)\nImmune-mediated refractoriness granulocyte transfusions (rarely used)\nTransfusion-Related Acute Lung Injury (TRALI)Neonatal Alloimmune Neutropenia (NAN)Autoimmune Neutropenia (AIN)Febrile Non-Hemolytic Transfusion Reactions (FNHTR - less common now universal leukoreduction)Immune-mediated refractoriness granulocyte transfusions (rarely used)","code":""},{"path":"granulocyte-specific.html","id":"biochemistry-where-hnas-live","chapter":"Granulocyte-Specific","heading":"Biochemistry: Where HNAs Live","text":"HNA antigens located various neutrophil membrane glycoproteins, many involved immune function like adhesion, phagocytosis, signaling:Fcγ Receptor IIIb (FcγRIIIb CD16b): receptor binds Fc portion IgG antibodies, playing role antibody-dependent cell-mediated cytotoxicity (ADCC) phagocytosis. ’s attached membrane via GPI anchor\nCarries HNA-1 system antigens (HNA-1a, HNA-1b, HNA-1c)\nCarries HNA-1 system antigens (HNA-1a, HNA-1b, HNA-1c)CD177: GPI-anchored protein whose function fully elucidated seems involved neutrophil migration adhesion. Expression variable among individuals – people neutrophils lack CD177 entirely\nCarries HNA-2 system antigen (HNA-2a). Individuals lacking CD177 HNA-2 null\nCarries HNA-2 system antigen (HNA-2a). Individuals lacking CD177 HNA-2 nullCholine Transporter-Like Protein 2 (CTL2): transmembrane protein\nCarries HNA-3 system antigens (HNA-3a, HNA-3b). HNA-3a polymorphism causes significant structural change\nCarries HNA-3 system antigens (HNA-3a, HNA-3b). HNA-3a polymorphism causes significant structural changeOther Glycoproteins: HNA-4 HNA-5 systems located glycoproteins (integrin αM/CD11b HNA-4a, integrin αL/CD11a HNA-5a)","code":""},{"path":"granulocyte-specific.html","id":"genetics-and-nomenclature-1","chapter":"Granulocyte-Specific","heading":"Genetics and Nomenclature","text":"Nomenclature: Uses “HNA” followed number system/locus letter (, b, c) specific allele/antigen (e.g., HNA-1a, HNA-1b)Inheritance: Inherited Mendelian codominant traitsPolymorphism: Arise SNPs genes encoding carrier glycoproteins, leading amino acid changes","code":""},{"path":"granulocyte-specific.html","id":"major-clinically-significant-hna-systems","chapter":"Granulocyte-Specific","heading":"Major Clinically Significant HNA Systems","text":"Note: Frequencies vary significantly across ethnic groups. HNA-1c primarily found individuals African descent","code":""},{"path":"granulocyte-specific.html","id":"clinical-significance-the-impact-of-hna-antibodies","chapter":"Granulocyte-Specific","heading":"Clinical Significance: The Impact of HNA Antibodies","text":"","code":""},{"path":"granulocyte-specific.html","id":"trali-transfusion-related-acute-lung-injury","chapter":"Granulocyte-Specific","heading":"TRALI (Transfusion-Related Acute Lung Injury)","text":"Mechanism: HNAs biggest transfusion medicine impact today. Donor plasma containing high-titer HNA antibodies (HLA Class II antibodies) transfused recipient whose neutrophils express corresponding antigen. antibodies activate recipient’s neutrophils, particularly lung vasculature, leading capillary damage, fluid leakage alveoli, acute respiratory distress. Anti-HNA-3a particularly notorious causing severe TRALIMitigation: Identifying implicated donors deferring donating plasma-rich components. TRALI risk reduction strategies (e.g., using plasma males, never-pregnant females, tested females). Leukoreduction components prevent antibody-mediated TRALI","code":""},{"path":"granulocyte-specific.html","id":"neonatal-alloimmune-neutropenia-nan","chapter":"Granulocyte-Specific","heading":"Neonatal Alloimmune Neutropenia (NAN)","text":"Mechanism: Analogous HDFN NAIT. Mother lacks HNA antigen fetus inherits father. Maternal IgG anti-HNA antibodies cross placenta destroy fetal neutrophilsConsequences: Causes neutropenia (low neutrophil count) newborn, increasing susceptibility bacterial infections, often presenting delayed cord separation, skin infections, sepsis. Usually less severe NAITManagement: Supportive care, antibiotics infections. Sometimes G-CSF (Granulocyte Colony-Stimulating Factor) boost neutrophil production. Rarely requires granulocyte transfusion (need antigen-negative)","code":""},{"path":"granulocyte-specific.html","id":"autoimmune-neutropenia-ain","chapter":"Granulocyte-Specific","heading":"Autoimmune Neutropenia (AIN)","text":"Mechanism: Patients develop autoantibodies HNA antigens, leading neutrophil destruction. Can primary (idiopathic) secondary conditions (e.g., autoimmune diseases, infections, drugs)Consequences: Increased risk infectionsManagement: Often resolves spontaneously children (AIN infancy). May require antibiotics, G-CSF severe cases","code":""},{"path":"granulocyte-specific.html","id":"febrile-non-hemolytic-transfusion-reactions-fnhtr","chapter":"Granulocyte-Specific","heading":"Febrile Non-Hemolytic Transfusion Reactions (FNHTR)","text":"Mechanism: Recipient antibodies reacting HNA (HLA) antigens donor leukocytes transfused component, cytokines released leukocytes storageMitigation: Largely prevented universal leukoreduction blood components","code":""},{"path":"granulocyte-specific.html","id":"hna-antibodies","chapter":"Granulocyte-Specific","heading":"HNA Antibodies","text":"Formation: Alloimmunization occurs via pregnancy transfusion. Autoantibodies occur AINType: Primarily IgGDetection: Challenging! Requires specialized tests performed routine blood banks","code":""},{"path":"granulocyte-specific.html","id":"hna-testing","chapter":"Granulocyte-Specific","heading":"HNA Testing","text":"Performed specialized reference laboratories (e.g., Platelet & Neutrophil Immunology labs)Methods\nSerological: Granulocyte Agglutination Test (GAT), Granulocyte Immunofluorescence Test (GIFT) using flow cytometry. Requires viable neutrophils\nMolecular (Genotyping): DNA-based methods determine HNA types. Increasingly used due difficulty serology\nSerological: Granulocyte Agglutination Test (GAT), Granulocyte Immunofluorescence Test (GIFT) using flow cytometry. Requires viable neutrophilsMolecular (Genotyping): DNA-based methods determine HNA types. Increasingly used due difficulty serologyChallenges: Neutrophils fragile, assays can complex less standardized RBC platelet testing","code":""},{"path":"granulocyte-specific.html","id":"key-takeaways","chapter":"Granulocyte-Specific","heading":"Key Takeaways","text":"HNAs antigens primarily neutrophilsAntibodies HNAs key players TRALI (especially anti-HNA-3a), Neonatal Alloimmune Neutropenia (NAN), Autoimmune Neutropenia (AIN)Testing specialized complexUnderstanding HNAs helps explain specific transfusion reactions immune cytopenias attributable RBC, platelet, HLA antibodies alone","code":""},{"path":"granulocyte-specific.html","id":"key-terms-45","chapter":"Granulocyte-Specific","heading":"Key Terms","text":"HNA (Human Neutrophil Antigen): Polymorphic antigens located primarily surface neutrophils (granulocytes)Neutrophil: type granulocyte (white blood cell) primary component innate immune system, crucial fighting bacterial infectionsTRALI (Transfusion-Related Acute Lung Injury): serious transfusion reaction characterized acute respiratory distress, often caused donor antibodies (HNA HLA) activating recipient neutrophils lungsNAN (Neonatal Alloimmune Neutropenia): condition maternal IgG anti-HNA antibodies cross placenta destroy fetal neutrophils, leading neutropenia infection risk newbornAIN (Autoimmune Neutropenia): condition individual produces autoantibodies neutrophils, leading neutrophil destruction increased infection riskFcγ Receptor IIIb (FcγRIIIb / CD16b): IgG receptor neutrophils carries HNA-1 antigensCD177: neutrophil glycoprotein carries HNA-2a antigenCTL2 (Choline Transporter-Like Protein 2): transmembrane protein carrying HNA-3 antigensGPI Anchor (Glycosylphosphatidylinositol anchor): glycolipid structure attaching certain proteins (like FcγRIIIb CD177) cell membraneLeukoreduction: process removing white blood cells blood components, effective reducing FNHTR risk antibody-mediated TRALIG-CSF (Granulocyte Colony-Stimulating Factor): medication used stimulate bone marrow produce neutrophils, sometimes used treat NAN severe AIN","code":""},{"path":"role-of-blood-groups-in-transfusion.html","id":"role-of-blood-groups-in-transfusion","chapter":"Role of Blood Groups in Transfusion","heading":"Role of Blood Groups in Transfusion","text":"Immunogenicity Antigen Prevalence must considered understand certain antibodies (like anti-D, anti-K, anti-c) common clinically significant, others (like anti-k, anti-U) rare problematic occur, still others (like anti-Wra) might potent easier manage supply perspective. combined understanding guides transfusion strategies, donor screening, patient management ensure safest possible transfusionsImmunogenicity: tells us risk antibody formation exposedAntigen Prevalence: tells us likelihood exposure difficulty finding compatible blood antibody exists","code":""},{"path":"role-of-blood-groups-in-transfusion.html","id":"immunogenicity-the-power-to-provoke","chapter":"Role of Blood Groups in Transfusion","heading":"Immunogenicity: The Power to Provoke","text":": inherent ability specific blood group antigen stimulate antibody response (alloimmunization) introduced someone lacking itThink: “strong” “noticeable” antigen recipient’s immune system?Key Players\nHighly Immunogenic: D, K, c, E, C, e, Jka/Jkb, Fya/Fyb (Proteins generally immunogenic)\nLess Immunogenic: Many antigens provoke antibodies less frequently upon exposure\nHighly Immunogenic: D, K, c, E, C, e, Jka/Jkb, Fya/Fyb (Proteins generally immunogenic)Less Immunogenic: Many antigens provoke antibodies less frequently upon exposureImpact: Determines likelihood exposure incompatible antigen actually lead antibody formation. High immunogenicity = higher chance making antibody exposure","code":""},{"path":"role-of-blood-groups-in-transfusion.html","id":"antigen-prevalence-how-common-it-is","chapter":"Role of Blood Groups in Transfusion","heading":"Antigen Prevalence: How Common It Is","text":": frequency (% people) specific blood group antigen found given populationThink: likely random donor/recipient antigen?Key Categories\nHigh Prevalence (>99%): k, Kpb, Lub, U, Vel, etc\nLow Prevalence (<1-10%): K, Kpa, Lua, Wra, etc\nIntermediate/Variable Prevalence: ABO, Rh (D, C, c, E, e), Kidd, Duffy, MNS (M, N, S, s). Crucially, vary significantly different ethnic populations\nHigh Prevalence (>99%): k, Kpb, Lub, U, Vel, etcLow Prevalence (<1-10%): K, Kpa, Lua, Wra, etcIntermediate/Variable Prevalence: ABO, Rh (D, C, c, E, e), Kidd, Duffy, MNS (M, N, S, s). Crucially, vary significantly different ethnic populationsImpact\nDetermines likelihood exposure incompatible antigen random transfusion\nDetermines ease difficulty finding antigen-negative blood antibody formed\nDetermines likelihood exposure incompatible antigen random transfusionDetermines ease difficulty finding antigen-negative blood antibody formed","code":""},{"path":"role-of-blood-groups-in-transfusion.html","id":"the-interplay-why-both-matter-together","chapter":"Role of Blood Groups in Transfusion","heading":"## The Interplay: Why Both Matter Together","text":"Considering immunogenicity prevalence together allows us predict clinical challenges:High Immunogenicity + High Prevalence Antigen (e.g., k, U, Lub)\nImmunogenicity: High (exposed, likely make Ab)\nPrevalence: High (people )\nResult: Antibody formation rare (people lack antigen stimulated), antibody formed, finding compatible (antigen-negative) blood extremely difficult. prevalence dominates compatibility challenge\nImmunogenicity: High (exposed, likely make Ab)Prevalence: High (people )Result: Antibody formation rare (people lack antigen stimulated), antibody formed, finding compatible (antigen-negative) blood extremely difficult. prevalence dominates compatibility challengeHigh Immunogenicity + Low Prevalence Antigen (e.g., K, Wra)\nImmunogenicity: High (exposed, likely make Ab)\nPrevalence: Low (people )\nResult: Antibody formation relatively common among exposed (due high immunogenicity), finding compatible (antigen-negative) blood usually easy (donors lack antigen). immunogenicity drives risk upon exposure\nImmunogenicity: High (exposed, likely make Ab)Prevalence: Low (people )Result: Antibody formation relatively common among exposed (due high immunogenicity), finding compatible (antigen-negative) blood usually easy (donors lack antigen). immunogenicity drives risk upon exposureHigh Immunogenicity + Intermediate Prevalence Antigen (e.g., D, c, E, Jka, Fya)\nImmunogenicity: High/Moderate\nPrevalence: Intermediate/Variable\nResult: Antibodies frequently encountered transfusion services. Finding compatible blood ranges easy moderately difficult, depending specific antigen’s frequency relevant donor population. factors significantly impact clinical practice. matching D standard, matching Rh/K antigens common chronically transfused patients\nImmunogenicity: High/ModeratePrevalence: Intermediate/VariableResult: Antibodies frequently encountered transfusion services. Finding compatible blood ranges easy moderately difficult, depending specific antigen’s frequency relevant donor population. factors significantly impact clinical practice. matching D standard, matching Rh/K antigens common chronically transfused patientsLow Immunogenicity Antigen (Regardless Prevalence)\nImmunogenicity: Low\nPrevalence: Can high, low, intermediate\nResult: Antibody formation less common, even upon exposure. compatibility testing still required, antigens cause fewer clinical problems overall compared highly immunogenic ones\nImmunogenicity: LowPrevalence: Can high, low, intermediateResult: Antibody formation less common, even upon exposure. compatibility testing still required, antigens cause fewer clinical problems overall compared highly immunogenic ones","code":""},{"path":"immunogenicity.html","id":"immunogenicity","chapter":"Immunogenicity","heading":"Immunogenicity","text":"patient receives blood transfusion, immune system may encounter red cell antigens different . Immunogenicity refers likelihood particular foreign blood group antigen stimulate recipient produce antibody (process called alloimmunization). concept crucial antigens, like D antigen Rh system, highly immunogenic frequently cause antibody formation, others rarely . Understanding immunogenicity helps predict antigen differences likely lead clinically significant antibodies, impacting transfusion safety potential future compatibility issues","code":""},{"path":"immunogenicity.html","id":"immunogenicity-the-power-to-provoke-1","chapter":"Immunogenicity","heading":"Immunogenicity: The Power to Provoke","text":"Definition: Immunogenicity refers relative ability specific blood group antigen stimulate antibody response (alloantibody formation) introduced individual lacks antigenAlloimmunization: process forming antibodies foreign antigens species (e.g., human forming antibody human blood group antigen lack)","code":""},{"path":"immunogenicity.html","id":"what-makes-an-antigen-more-immunogenic","chapter":"Immunogenicity","heading":"What Makes an Antigen More Immunogenic?","text":"Several factors contribute, practical blood bank perspective, key drivers :Foreignness: antigen must recognized non-self. inherent blood group differences donor recipientChemical Nature & Complexity: Generally, proteins immunogenic carbohydrates can processed presented antigen-presenting cells T-helper cells, leading robust IgG antibody response. Large, complex molecules often better targetsStructure & Accessibility: antigen presented cell surface mattersDose & Exposure: amount antigen introduced (e.g., number RBCs transfused) frequency exposure can influence likelihood strength response","code":""},{"path":"immunogenicity.html","id":"the-immunogenicity-hit-parade-who-causes-the-most-trouble","chapter":"Immunogenicity","heading":"The Immunogenicity Hit Parade: Who Causes the Most Trouble?","text":"Based decades transfusion experience, know antigens much likely cause alloimmunization others. ’s general ranking clinically significant immunogens encountered RBC transfusion:D (Rh System) far immunogenic blood group antigen outside ABO system. Studies show ~80% D-negative individuals transfused single unit D-positive RBCs develop anti-D preventative measures (like RhIG) taken. preventing anti-D formation cornerstone transfusion practiceK (Kell System) Considered immunogenic D. K antigen lower prevalence (~9% Caucasians), exposure readily stimulates anti-K production K-negative individuals. Anti-K common cause delayed HTR HDFNOther Rh Antigens (c, E, C, e) protein antigens also significantly immunogenic, generally ranked approximately order likelihood stimulate antibody production: c > E > C > e. Matching antigens often considered chronically transfused patientsKidd Antigens (Jka, Jkb) Known immunogenic. Anti-Jka anti-Jkb notorious causing delayed hemolytic transfusion reactions, partly antibody levels can decline time (making hard detect pre-transfusion) reappear strongly re-exposure (anamnestic response)Duffy Antigens (Fya, Fyb) Moderately immunogenic. Anti-Fya common anti-Fyb can cause HTR HDFNMNS System Antigens (S, s) S s significantly immunogenic M N. Anti-S anti-s can cause HTR HDFN. (M N can stimulate antibodies, anti-M often naturally occurring IgM less often clinically significant post-transfusion compared anti-S/s)ABO?\nABO antigens (B) highly immunogenic carbohydrates. However, “antibodies” (isoagglutinins anti-anti-B) typically naturally occurring. develop early life presumably due exposure similar carbohydrate structures environment (bacteria, food). Therefore, primary concern ABO isn’t post-transfusion alloimmunization way D K, rather immediate, severe hemolytic reaction ABO-incompatible blood transfused due pre-existing, potent antibodies","code":""},{"path":"immunogenicity.html","id":"factors-influencing-the-recipients-response","chapter":"Immunogenicity","heading":"Factors Influencing the Recipient’s Response","text":"’s just antigen – recipient’s immune system plays role :Immune Status: Immunocompromised patients may less likely form antibodiesGenetic Predisposition: individuals seem “responders” prone making antibodies othersPrevious Sensitization: sensitized, subsequent exposure leads faster, stronger anamnestic response","code":""},{"path":"immunogenicity.html","id":"clinical-significance-why-we-care","chapter":"Immunogenicity","heading":"Clinical Significance: Why We Care","text":"Alloimmunization due immunogenic blood group antigens clinically important resulting antibodies (usually IgG) can:Cause Hemolytic Transfusion Reactions (HTR): Destruction transfused red blood cells, leading anemia, jaundice, fever, potentially life-threatening complications like shock renal failure. Can acute delayedCause Hemolytic Disease Fetus Newborn (HDFN): Maternal IgG antibodies crossing placenta destroying fetal red blood cells expressing corresponding antigen inherited fatherMake finding compatible blood difficult: Patients multiple antibodies antibodies high-prevalence antigens pose significant challenges","code":""},{"path":"immunogenicity.html","id":"managing-immunogenicity-in-transfusion-practice","chapter":"Immunogenicity","heading":"Managing Immunogenicity in Transfusion Practice","text":"ABO/RhD Typing: Standard practice prevent immediate hemolysis (ABO) primary anti-D immunizationAntibody Screening: Detecting pre-existing antibodies ensure antigen-negative blood providedRhIG (RhoGAM): Given D-negative mothers pregnancy delivery D-positive baby (sensitizing events) prevent formation anti-DProphylactic Antigen Matching: chronically transfused patients (e.g., sickle cell disease), often matched Rh (C, E) K antigens, sometimes Kidd/Duffy, prevent alloimmunization highly immunogenic antigensIn summary, immunogenicity dictates blood group differences likely cause problems following transfusion pregnancy. D antigen stands potent, followed K Rh antigens, highlighting importance careful donor selection preventative strategies","code":""},{"path":"immunogenicity.html","id":"key-terms-46","chapter":"Immunogenicity","heading":"Key Terms","text":"Immunogenicity: ability antigen provoke immune response (antibody formation)Alloimmunization: process forming antibodies antigens another individual speciesAlloantibody: antibody produced foreign antigen speciesAntigen: molecule (usually protein carbohydrate) recognized immune systemSeroconversion: development detectable antibodies blood serum result infection immunizationAnamnestic Response: rapid heightened immune response following re-exposure antigen individual previously sensitizedHemolytic Transfusion Reaction (HTR): Destruction transfused red blood cells recipient antibodiesHemolytic Disease Fetus Newborn (HDFN): Destruction fetal/newborn red blood cells maternal antibodies crossed placentaRhIG (Rh Immune Globulin): preparation concentrated anti-D antibodies given prevent D-negative individuals forming anti-D exposure D-positive red cells","code":""},{"path":"antigen-prevalence.html","id":"antigen-prevalence","chapter":"Antigen Prevalence","heading":"Antigen Prevalence","text":"prevalence blood group antigen refers frequently occurs within specific population. ’s essentially asking: “percentage people particular antigen red blood cells?” Understanding antigen prevalence absolutely critical transfusion medicine directly impacts several key areas: likelihood encountering specific antibodies, ease difficulty finding compatible blood, strategies managing patient transfusions, especially requiring long-term support","code":""},{"path":"antigen-prevalence.html","id":"antigen-prevalence-a-numbers-game","chapter":"Antigen Prevalence","heading":"Antigen Prevalence: A Numbers Game","text":"Prevalence usually expressed percentage. can broadly categorize antigens based prevalence:High-Prevalence Antigens (“Public” Antigens)\nDefinition: Found red blood cells vast majority people, typically >99% population\nExamples: k (Cellano), Kpb, Jsb, Lub, U, Vel, Emm, Ge3, Yta, , P\nTransfusion Implications\nAntibodies Rare: almost everyone antigen, people capable making antibody (see “self”)\nFinding Compatible Blood Extremely Difficult: patient develop antibody high-prevalence antigen (one rare individuals lacking ), sourcing antigen-negative blood major challenge. often requires screening thousands donors, accessing national/international Rare Donor Programs, testing family members\n\nDefinition: Found red blood cells vast majority people, typically >99% populationExamples: k (Cellano), Kpb, Jsb, Lub, U, Vel, Emm, Ge3, Yta, , PTransfusion Implications\nAntibodies Rare: almost everyone antigen, people capable making antibody (see “self”)\nFinding Compatible Blood Extremely Difficult: patient develop antibody high-prevalence antigen (one rare individuals lacking ), sourcing antigen-negative blood major challenge. often requires screening thousands donors, accessing national/international Rare Donor Programs, testing family members\nAntibodies Rare: almost everyone antigen, people capable making antibody (see “self”)Finding Compatible Blood Extremely Difficult: patient develop antibody high-prevalence antigen (one rare individuals lacking ), sourcing antigen-negative blood major challenge. often requires screening thousands donors, accessing national/international Rare Donor Programs, testing family membersLow-Prevalence Antigens (“Private” Antigens)\nDefinition: Found red blood cells small percentage population, often <1% maybe 10%\nExamples: K (Kell), Kpa, Jsa, Lua, Wra, Dia (non-Asian/Native American populations), Cw, V\nTransfusion Implications\nAntibodies Relatively Uncommon: Although antigens can immunogenic (like K), exposure transfusion pregnancy less frequent simply antigen isn’t common donor/paternal population\nFinding Compatible Blood Usually Easy: patient develops antibody low-prevalence antigen, vast majority random donors lack antigen thus compatible. main challenge often detecting identifying antibody first place, might missed routine screening cells appear incompatible crossmatch\n\nDefinition: Found red blood cells small percentage population, often <1% maybe 10%Examples: K (Kell), Kpa, Jsa, Lua, Wra, Dia (non-Asian/Native American populations), Cw, VTransfusion Implications\nAntibodies Relatively Uncommon: Although antigens can immunogenic (like K), exposure transfusion pregnancy less frequent simply antigen isn’t common donor/paternal population\nFinding Compatible Blood Usually Easy: patient develops antibody low-prevalence antigen, vast majority random donors lack antigen thus compatible. main challenge often detecting identifying antibody first place, might missed routine screening cells appear incompatible crossmatch\nAntibodies Relatively Uncommon: Although antigens can immunogenic (like K), exposure transfusion pregnancy less frequent simply antigen isn’t common donor/paternal populationFinding Compatible Blood Usually Easy: patient develops antibody low-prevalence antigen, vast majority random donors lack antigen thus compatible. main challenge often detecting identifying antibody first place, might missed routine screening cells appear incompatible crossmatchIntermediate Variable Prevalence Antigens\nDefinition: Antigens frequencies fall extremes, often varying significantly populations\nExamples: ABO antigens (, B), Rh antigens (D, C, c, E, e), Kidd antigens (Jka, Jkb), Duffy antigens (Fya, Fyb), MNS antigens (M, N, S, s)\nTransfusion Implications\nAntibodies Common: Antibodies antigens systems frequently encountered patient testing (either naturally occurring like anti-/B, immune-stimulated like anti-D, -K, -E, -c, -Fya, -Jka)\nFinding Compatible Blood Varies: ease finding compatible blood depends specific antigen patient/donor populations. example, finding D-negative blood straightforward Caucasian populations (~15% D-neg) much harder Asian populations (<1% D-neg). Finding blood negative common combinations (like R1R1 needing R2R2 blood) requires considering prevalence specific Rh phenotypes\n\nDefinition: Antigens frequencies fall extremes, often varying significantly populationsExamples: ABO antigens (, B), Rh antigens (D, C, c, E, e), Kidd antigens (Jka, Jkb), Duffy antigens (Fya, Fyb), MNS antigens (M, N, S, s)Transfusion Implications\nAntibodies Common: Antibodies antigens systems frequently encountered patient testing (either naturally occurring like anti-/B, immune-stimulated like anti-D, -K, -E, -c, -Fya, -Jka)\nFinding Compatible Blood Varies: ease finding compatible blood depends specific antigen patient/donor populations. example, finding D-negative blood straightforward Caucasian populations (~15% D-neg) much harder Asian populations (<1% D-neg). Finding blood negative common combinations (like R1R1 needing R2R2 blood) requires considering prevalence specific Rh phenotypes\nAntibodies Common: Antibodies antigens systems frequently encountered patient testing (either naturally occurring like anti-/B, immune-stimulated like anti-D, -K, -E, -c, -Fya, -Jka)Finding Compatible Blood Varies: ease finding compatible blood depends specific antigen patient/donor populations. example, finding D-negative blood straightforward Caucasian populations (~15% D-neg) much harder Asian populations (<1% D-neg). Finding blood negative common combinations (like R1R1 needing R2R2 blood) requires considering prevalence specific Rh phenotypes","code":""},{"path":"antigen-prevalence.html","id":"population-variation-a-critical-factor","chapter":"Antigen Prevalence","heading":"Population Variation: A Critical Factor","text":"absolutely essential remember antigen prevalence figures population-specific. antigen common one ethnic group may rare anotherRhD: D-negative phenotype ~15% Caucasians, ~5-8% individuals African descent, <1% AsiansDuffy: Fy(-b-) phenotype common (~70%) individuals African descent (conferring resistance Plasmodium vivax malaria) extremely rare Caucasians AsiansDiego: Dia rare Caucasians/Africans common (30%+) East Asians Native AmericansKell: Jsa common (~20%) individuals African descent rare (<0.1%) CaucasiansMNS: U-negative phenotype (lacking Glycophorin B) found almost exclusively individuals African descent (~1%)","code":""},{"path":"antigen-prevalence.html","id":"why-prevalence-matters-in-the-blood-bank","chapter":"Antigen Prevalence","heading":"Why Prevalence Matters in the Blood Bank","text":"Predicting Antibody Likelihood: Knowing prevalence helps estimate chance patient might particular antibody. patient negative high-prevalence antigen, chance encountering antigen (thus forming antibody) high transfused randomlyCompatibility Testing Strategy\nAntibody High-Prevalence Ag: Triggers search rare blood\nAntibody Low-Prevalence Ag: Focus shifts confirming ID; finding units usually easy\nAntibody Intermediate-Prevalence Ag: Requires selecting appropriately phenotyped units based standard inventory\nAntibody High-Prevalence Ag: Triggers search rare bloodAntibody Low-Prevalence Ag: Focus shifts confirming ID; finding units usually easyAntibody Intermediate-Prevalence Ag: Requires selecting appropriately phenotyped units based standard inventoryDonor Inventory Management: Blood centers need understand prevalence various antigens donor population ensure adequate supply commonly needed rarer phenotypesManaging Chronically Transfused Patients: Patients conditions like sickle cell disease often develop multiple antibodies. Knowing antigen prevalence within ethnic group vital providing extended phenotype-matched blood prevent alloimmunizationInterpreting Antibody Screens/Panels: frequency reactions panel can give clues. antibody reacting almost cells suggests antibody high-prevalence antigen. antibody reacting one cell might indicate antibody low-prevalence antigen","code":""},{"path":"antigen-prevalence.html","id":"key-terms-47","chapter":"Antigen Prevalence","heading":"Key Terms","text":"Prevalence: proportion percentage individuals defined population express specific antigenHigh-Prevalence Antigen: antigen present red cells >99% populationLow-Prevalence Antigen: antigen present red cells <1-10% populationPopulation Variation: Significant differences antigen frequencies observed different ethnic geographic groupsRare Donor Program: registry system identifying accessing blood donors rare phenotypes (e.g., lacking high-prevalence antigens)Antithetical Antigen: One pair antigens encoded alleles gene locus. Often, one high prevalence, partner low prevalence (e.g., k vs. K)","code":""},{"path":"immunology.html","id":"immunology","chapter":"Immunology","heading":"Immunology","text":"section explores body mounts immune response encounters foreign antigens, focusing key cells like B cells, T cells, macrophages, difference first-time (primary) subsequent (secondary) encounter. ’ll look closely specific weapons produced – immunoglobulins (antibodies) – examining different classes, structures, unique properties. Understanding antibodies precisely bind antigens (antigen-antibody interactions) principles governing crucial testing. Finally, ’ll unravel powerful complement system, cascade proteins amplifies immune response, often working alongside antibodies destroy target cells, process vital understanding transfusion reactions compatibility","code":""},{"path":"immunology.html","id":"the-immune-systems-response-to-foreign-antigens","chapter":"Immunology","heading":"The Immune System’s Response to Foreign Antigens","text":"First Encounter & Recognition (Primary Immune Response)\nforeign antigen (like non-self red blood cell antigen transfusion fetus) enters body first time, Macrophages (acting Antigen Presenting Cells - APCs) engulf show pieces T Helper Cells. recognition relies body’s ability distinguish “self” “non-self,” largely governed HLA system (genetically determined)\nT helper cells activate specific B Cells whose surface receptors (thanks V(D)J gene rearrangement providing immense diversity) happen recognize foreign antigen\n’s lag phase, B cells differentiate plasma cells\nforeign antigen (like non-self red blood cell antigen transfusion fetus) enters body first time, Macrophages (acting Antigen Presenting Cells - APCs) engulf show pieces T Helper Cells. recognition relies body’s ability distinguish “self” “non-self,” largely governed HLA system (genetically determined)T helper cells activate specific B Cells whose surface receptors (thanks V(D)J gene rearrangement providing immense diversity) happen recognize foreign antigenThere’s lag phase, B cells differentiate plasma cellsProducing Weapons (Immunoglobulins - Primary Response)\nfirst antibody produced mainly IgM. ’s large pentameric molecule, excellent activating complement causing agglutination, generally doesn’t cross placenta shorter lifespan. Think ABO antibodies\nMemory cells: (B T) also created, remembering specific antigen\nfirst antibody produced mainly IgM. ’s large pentameric molecule, excellent activating complement causing agglutination, generally doesn’t cross placenta shorter lifespan. Think ABO antibodiesMemory cells: (B T) also created, remembering specific antigenAntibodies Find Target (Antigen-Antibody Interactions)\nAntibodies bind high specificity corresponding antigen epitope (“lock key”)\nbinding uses weak non-covalent forces reversible. Strength described affinity (single site) avidity (overall strength, high multivalent IgM)\nTesting: detect interactions using methods like:\nDirect Agglutination: Works well IgM\nAntiglobulin Test (IAT/DAT): Essential detecting non-agglutinating IgG complement coating red cells, using Anti-Human Globulin (AHG)\nSolid Phase & Gel: Modern, sensitive methods\n\nAntibodies bind high specificity corresponding antigen epitope (“lock key”)binding uses weak non-covalent forces reversible. Strength described affinity (single site) avidity (overall strength, high multivalent IgM)Testing: detect interactions using methods like:\nDirect Agglutination: Works well IgM\nAntiglobulin Test (IAT/DAT): Essential detecting non-agglutinating IgG complement coating red cells, using Anti-Human Globulin (AHG)\nSolid Phase & Gel: Modern, sensitive methods\nDirect Agglutination: Works well IgMAntiglobulin Test (IAT/DAT): Essential detecting non-agglutinating IgG complement coating red cells, using Anti-Human Globulin (AHG)Solid Phase & Gel: Modern, sensitive methodsAmplifying Attack (Complement System)\nbinding IgM certain IgG subclasses (IgG3>IgG1) antigens cell surface can trigger Classical Complement Pathway\nAlternative Pathway can activated spontaneously amplify classical pathway\npathways lead :\nOpsonization: Coating cell C3b, marking destruction macrophages (Extravascular Hemolysis). Detected C3d DAT\nInflammation: Release Anaphylatoxins (C3a, C5a), causing inflammatory symptoms\nLysis: Formation Membrane Attack Complex (MAC, C5b-9), punching holes cell -> Intravascular Hemolysis\n\nbinding IgM certain IgG subclasses (IgG3>IgG1) antigens cell surface can trigger Classical Complement PathwayThe Alternative Pathway can activated spontaneously amplify classical pathwayBoth pathways lead :\nOpsonization: Coating cell C3b, marking destruction macrophages (Extravascular Hemolysis). Detected C3d DAT\nInflammation: Release Anaphylatoxins (C3a, C5a), causing inflammatory symptoms\nLysis: Formation Membrane Attack Complex (MAC, C5b-9), punching holes cell -> Intravascular Hemolysis\nOpsonization: Coating cell C3b, marking destruction macrophages (Extravascular Hemolysis). Detected C3d DATInflammation: Release Anaphylatoxins (C3a, C5a), causing inflammatory symptomsLysis: Formation Membrane Attack Complex (MAC, C5b-9), punching holes cell -> Intravascular HemolysisThe Second Encounter (Secondary Immune Response)\nantigen encountered , memory cells respond much faster strongly\npredominant antibody produced IgG. ’s monomer, generally crosses placenta, key opsonin, subclasses activate complement (less efficiently IgM). IgG often requires Antiglobulin Test detection\nrapid, high-titer IgG response responsible Delayed Hemolytic Transfusion Reactions (DHTR) Hemolytic Disease Fetus Newborn (HDFN)\nantigen encountered , memory cells respond much faster stronglyThe predominant antibody produced IgG. ’s monomer, generally crosses placenta, key opsonin, subclasses activate complement (less efficiently IgM). IgG often requires Antiglobulin Test detectionThis rapid, high-titer IgG response responsible Delayed Hemolytic Transfusion Reactions (DHTR) Hemolytic Disease Fetus Newborn (HDFN)","code":""},{"path":"immunology.html","id":"why-this-matters-in-blood-banking","chapter":"Immunology","heading":"Why This Matters in Blood Banking","text":"Understanding sequence – initial antigen recognition types antibodies produced (IgM vs. IgG distinct properties), interact antigens activate complement, leading different types red cell destruction – fundamental :Performing accurate blood typing compatibility testingDetecting identifying: clinically significant antibodiesUnderstanding mechanisms behind transfusion reactions HDFNSelecting appropriate blood components patients","code":""},{"path":"immune-response.html","id":"immune-response","chapter":"Immune response","heading":"Immune response","text":"interaction macrophages, T cells, B cells, distinct nature primary vs. secondary responses, underlying genetic control receptors (V(D)J), antigen presentation (HLA), antigens (blood group genes) interconnected pieces explaining immune events happen transfusion transplantation medicine!","code":""},{"path":"immune-response.html","id":"overview-the-adaptive-immune-response-in-blood-banking","chapter":"Immune response","heading":"Overview: The Adaptive Immune Response in Blood Banking","text":"Think adaptive immune response body’s highly specific, targeted defense system learns experience. involves key cells, distinct phases upon encountering antigen, built upon genetic blueprintThe Spark: Antigen Encounter & Presentation\noften starts Macrophages (Antigen Presenting Cells - APCs) encounter something foreign – like transfused red blood cell carrying antigen patient lacks (e.g., K antigen)\nmacrophage engulfs processes antigen. Crucially, displays fragments antigen surface using special molecules coded HLA genes (specifically MHC Class II). presentation like waving flag alert immune system’s commanders\noften starts Macrophages (Antigen Presenting Cells - APCs) encounter something foreign – like transfused red blood cell carrying antigen patient lacks (e.g., K antigen)macrophage engulfs processes antigen. Crucially, displays fragments antigen surface using special molecules coded HLA genes (specifically MHC Class II). presentation like waving flag alert immune system’s commandersThe Commanders & Soldiers: T Cells B Cells\nT Helper Cells (CD4+): cells orchestrators. recognize antigen presented macrophages (MHC Class II). activated, provide essential help signals (cytokines direct contact)\nB Cells: potential antibody factories. B cell unique B Cell Receptor (BCR) surface (thanks V(D)J gene rearrangement: development, creating vast receptor diversity). B cell whose BCR happens match foreign antigen binds \nCytotoxic T Cells (CD8+): less directly involved typical red cell antibody production, critical recognizing antigens presented MHC Class (found cells) killing cells seen foreign infected (vital graft rejection/GVHD)\nT Helper Cells (CD4+): cells orchestrators. recognize antigen presented macrophages (MHC Class II). activated, provide essential help signals (cytokines direct contact)B Cells: potential antibody factories. B cell unique B Cell Receptor (BCR) surface (thanks V(D)J gene rearrangement: development, creating vast receptor diversity). B cell whose BCR happens match foreign antigen binds itCytotoxic T Cells (CD8+): less directly involved typical red cell antibody production, critical recognizing antigens presented MHC Class (found cells) killing cells seen foreign infected (vital graft rejection/GVHD)First Fight: Primary Immune Response\nB cell become fully activated (especially make high-quality IgG), usually needs help activated T helper cell\n’s lag phase (days/weeks) B cells multiply differentiate\nfirst antibody produced mainly IgM. ’s decent first responder usually doesn’t cross placenta might persist long\nImportantly, Memory B cells Memory T cells specific antigen generated stored away\nB cell become fully activated (especially make high-quality IgG), usually needs help activated T helper cellThere’s lag phase (days/weeks) B cells multiply differentiateThe first antibody produced mainly IgM. ’s decent first responder usually doesn’t cross placenta might persist longImportantly, Memory B cells Memory T cells specific antigen generated stored awayThe Rematch: Secondary (Anamnestic) Immune Response\nantigen enters body (e.g., another transfusion K-positive blood), memory cells swing action\nresponse faster (shorter lag phase), stronger (much higher antibody levels), dominant antibody produced IgG (due class switching)\nIgG antibodies often higher affinity (bind better) due refinement processes (somatic hypermutation) occurred earlier. IgG can cross placenta often efficient causing red cell destruction\nantigen enters body (e.g., another transfusion K-positive blood), memory cells swing actionThe response faster (shorter lag phase), stronger (much higher antibody levels), dominant antibody produced IgG (due class switching)IgG antibodies often higher affinity (bind better) due refinement processes (somatic hypermutation) occurred earlier. IgG can cross placenta often efficient causing red cell destructionThe Genetic Blueprint\nDiversity: V(D)J recombination generates vast repertoire B T cell receptors antigen encounter, ensuring cells ready recognize almost anything\nRecognition & Compatibility: HLA genes code MHC molecules essential antigen presentation distinguishing self non-self. high polymorphism (many variations) key immune defense also major hurdle transplantation can cause issues like platelet refractoriness TRALI\nAntigens: specific blood group genes inherited individual determine antigens (like ABO, Rh, Kell, Duffy, etc.) present red blood cells. Differences genes donor/fetus recipient/mother basis alloimmunization\nDiversity: V(D)J recombination generates vast repertoire B T cell receptors antigen encounter, ensuring cells ready recognize almost anythingRecognition & Compatibility: HLA genes code MHC molecules essential antigen presentation distinguishing self non-self. high polymorphism (many variations) key immune defense also major hurdle transplantation can cause issues like platelet refractoriness TRALIAntigens: specific blood group genes inherited individual determine antigens (like ABO, Rh, Kell, Duffy, etc.) present red blood cells. Differences genes donor/fetus recipient/mother basis alloimmunization","code":""},{"path":"immune-response.html","id":"why-this-matters-in-blood-bank","chapter":"Immune response","heading":"Why This Matters in Blood Bank","text":"Alloimmunization: primary response explains patient first develops antibody transfusion/pregnancyDelayed Hemolytic Transfusion Reactions (DHTR): secondary response explains patient previously made antibody (even undetectable now) can rapid, potent IgG response upon re-exposure, destroying transfused cells days laterHemolytic Disease Fetus Newborn (HDFN): secondary response sensitized mother produces high levels IgG (like anti-D) cross placentaCompatibility: Understanding HLA genetics vital platelet matching preventing TRALI/GVHD. Knowing blood group genetics foundation red cell compatibility testing","code":""},{"path":"primary-secondary.html","id":"primary-secondary","chapter":"Primary & Secondary","heading":"Primary & Secondary","text":"primary secondary immune responses describe distinct ways body reacts meets foreign antigen first time compared encounters antigen later. Think difference cautious first meeting recognizing old acquaintance. difference, especially terms speed, strength, main antibody type involved (hello IgM vs. IgG!), super important blood banking understanding patients develop antibodies transfusion pregnancy, subsequent exposures can riskier, basis things like delayed transfusion reactions HDFN","code":""},{"path":"primary-secondary.html","id":"the-immune-response-meeting-an-antigen","chapter":"Primary & Secondary","heading":"The Immune Response: Meeting an Antigen","text":"First, remember triggers immune response? antigen! blood banking, ’re mostly concerned antigens red blood cells, platelets, white blood cells foreign patient’s immune system. body encounters antigen hasn’t seen , kicks Primary Immune Response. sees antigen later, mounts Secondary Immune Response","code":""},{"path":"primary-secondary.html","id":"primary-immune-response-the-first-introduction","chapter":"Primary & Secondary","heading":"Primary Immune Response: The First Introduction","text":"body’s first encounter specific foreign antigen (like D antigen Rh-positive red cells transfused Rh-negative patient first time, Rh-negative mother’s first pregnancy Rh-positive baby)Recognition starts Antigen Presenting Cells (APCs), like macrophages dendritic cells, grab foreign antigen, process , show T helper cells (CD4+ T cells)Activation T helper cell gets activated , turn, helps activate naive B cells recognize antigen. T-cell help crucial making high-quality antibodies, especially IgG!Lag Phase ’s noticeable delay lag phase (anywhere several days weeks) antibodies become detectable serum. time, B cells busy proliferating (making copies ) differentiating (changing antibody-producing factories called plasma cells)Antibody Production\nfirst antibody class produced predominantly IgM. Think M “first!” IgM large molecule (pentamer) pretty good activating complement, generally doesn’t cross placenta\nAntibody levels rise slowly reach relatively low peak concentration\naffinity (binding strength) early IgM antibodies often lower compared later responses\nfirst antibody class produced predominantly IgM. Think M “first!” IgM large molecule (pentamer) pretty good activating complement, generally doesn’t cross placentaAntibody levels rise slowly reach relatively low peak concentrationThe affinity (binding strength) early IgM antibodies often lower compared later responsesMemory Cell Formation Crucially, primary response, activated B cells T cells don’t become plasma cells effector T cells. Instead, become long-lived memory B cells memory T cells. cells hang around, “remembering” antigenDecline antigen cleared, antibody level gradually declines, sometimes becoming undetectable. However, memory cells persist!Blood Bank Relevance (Primary)\n* alloimmunization (making antibodies foreign blood group antigens) begins\n* patient might receive unit blood containing antigen lack (e.g., K antigen). might reaction time, immune system starts primary response. Weeks later, might detectable anti-K, usually IgM initially","code":""},{"path":"primary-secondary.html","id":"secondary-immune-response-seeing-an-old-friend-or-foe","chapter":"Primary & Secondary","heading":"Secondary Immune Response: Seeing an Old “Friend” (or Foe!)","text":"happens body encounters antigen . Thanks memory cells generated primary response, things happen much faster effectively. also called anamnestic response (anamnesis means recall memory)Rapid Recognition Memory B cells memory T cells recognize antigen much quickly efficiently naive cells first time. Less antigen usually needed trigger responseShorter Lag Phase delay antibody production significantly shorter (often just hours days)Robust Antibody Production\nMemory B cells rapidly differentiate plasma cells\n’s rapid much higher peak level antibody production\npredominant antibody class produced IgG. happens memory B cells already undergone class switching (isotype switching), changing constant region antibody IgM IgG (sometimes IgA IgE). Think G “Gotcha !” “Greater response!”\nIgG antibodies typically higher affinity antigen due process called affinity maturation occurred primary response\nIgG dominates, small amount IgM might still produced\nMemory B cells rapidly differentiate plasma cellsThere’s rapid much higher peak level antibody productionThe predominant antibody class produced IgG. happens memory B cells already undergone class switching (isotype switching), changing constant region antibody IgM IgG (sometimes IgA IgE). Think G “Gotcha !” “Greater response!”IgG antibodies typically higher affinity antigen due process called affinity maturation occurred primary responseWhile IgG dominates, small amount IgM might still producedPersistence Antibody levels remain higher much longer compared primary response","code":""},{"path":"primary-secondary.html","id":"blood-bank-relevance-secondary","chapter":"Primary & Secondary","heading":"Blood Bank Relevance (Secondary)","text":"Transfusion Reactions: patient made anti-K first exposure receives K-positive blood , memory cells kick high gear. ’ll rapidly produce large amounts high-affinity IgG anti-K, potentially causing Delayed Hemolytic Transfusion Reaction (DHTR) days later antibody levels surge destroy transfused K-positive cells. Sometimes, antibody level primary response dropped detectable limits second transfusion, making antibody screen negative pre-transfusion!HDFN: RhD-negative mother sensitized first pregnancy RhD-positive baby (primary response, mostly IgM) may secondary response subsequent RhD-positive pregnancies. rapidly produces high levels IgG anti-D. Since IgG can cross placenta, attacks fetal red blood cells, causing HDFNPre-transfusion Testing: Knowing patient’s antibody history vital. Even antibody currently undetectable, re-exposure antigen can trigger potent secondary response. must provide antigen-negative blood clinically significant antibodies, regardless current antibody screen result","code":""},{"path":"primary-secondary.html","id":"key-differences-summarized","chapter":"Primary & Secondary","heading":"Key Differences Summarized","text":"","code":""},{"path":"primary-secondary.html","id":"key-terms-48","chapter":"Primary & Secondary","heading":"Key Terms","text":"Antigen: substance (like proteins carbohydrates red blood cells) immune system recognizes foreign mounts response againstPrimary Immune Response: immune system’s initial reaction following first exposure specific antigen. typically involves lag period, produces mainly IgM antibodies, generates memory cellsSecondary Immune Response (Anamnestic Response): faster, stronger, prolonged immune response occurs upon subsequent exposure antigen, driven memory cells characterized mainly IgG antibody productionLag Phase: time delay initial antigen exposure detection antibodies serum; phase notably longer primary response compared secondaryIgM (Immunoglobulin M): main antibody class produced early primary immune response. ’s large molecule (pentamer) effective activating complement usually doesn’t cross placentaIgG (Immunoglobulin G): predominant antibody class produced secondary immune response. ’s smaller (monomer), can cross placenta (important HDFN!), often associated clinically significant red cell antibodies causing hemolysisPlasma Cells: Specialized, differentiated B lymphocytes function antibody-producing factoriesMemory Cells (B T lymphocytes): Long-lived cells formed primary response “remember” antigen. allow rapid enhanced response upon re-exposure (secondary response)Alloimmunization: development antibodies (alloantibodies) response foreign antigens species, developing antibodies red cell antigens blood transfusion pregnancyClass Switching (Isotype Switching): biological mechanism changes B cell’s antibody production one class (like IgM) another (like IgG), preserving antigen specificity. key shift IgM IgG dominance secondary response","code":""},{"path":"b-t-cells-macrophages.html","id":"b-t-cells-macrophages","chapter":"B & T cells, Macrophages","heading":"B & T cells, Macrophages","text":"complex world immunology, especially relates blood banking, three key cell types form backbone adaptive immune response: Macrophages, T lymphocytes (T cells), B lymphocytes (B cells). Macrophages act initial responders messengers, engulfing foreign materials presenting antigens. T cells, particularly T helper cells, orchestrate overall response provide critical activation signals, cytotoxic T cells can eliminate targeted cells. B cells antibody specialists, differentiating plasma cells produce antibodies crucial neutralizing threats memory cells ensure rapid response upon future encounters. Understanding cells interact fundamental explaining processes like alloimmunization, transfusion reactions, hemolytic disease fetus newbornThink immune system like highly coordinated military operation foreign invaders (antigens). cell types specialized job:","code":""},{"path":"b-t-cells-macrophages.html","id":"macrophages-the-sentinels-and-presenters","chapter":"B & T cells, Macrophages","heading":"Macrophages: The Sentinels and Presenters","text":"Macrophages part innate immune system (body’s first line defense) also play crucial role bridging gap adaptive immune system (specific, targeted response involving T B cells)Role 1: Phagocytosis (“Big Eaters”)\nMacrophages patrol tissues, engulfing digesting cellular debris, pathogens, foreign materials – including potentially incompatible red blood cells, especially coated complement antibodies (opsonized)\nMacrophages patrol tissues, engulfing digesting cellular debris, pathogens, foreign materials – including potentially incompatible red blood cells, especially coated complement antibodies (opsonized)Role 2: Antigen Processing Presentation (“Intelligence Officers”)\nengulfing foreign entity (like red blood cell foreign antigen), macrophage breaks smaller pieces (peptides)\ndisplays antigen fragments surface, attached special molecules called Major Histocompatibility Complex (MHC) Class II molecules\n“display” acts like signal flag, presenting antigen T helper cells. Macrophages, along dendritic cells B cells, therefore known Antigen-Presenting Cells (APCs)\nengulfing foreign entity (like red blood cell foreign antigen), macrophage breaks smaller pieces (peptides)displays antigen fragments surface, attached special molecules called Major Histocompatibility Complex (MHC) Class II moleculesThis “display” acts like signal flag, presenting antigen T helper cells. Macrophages, along dendritic cells B cells, therefore known Antigen-Presenting Cells (APCs)Role 3: Producing Cytokines\nActivated macrophages release chemical messengers (cytokines like Interleukin-1, TNF-alpha) help activate immune cells contribute inflammation\nActivated macrophages release chemical messengers (cytokines like Interleukin-1, TNF-alpha) help activate immune cells contribute inflammation","code":""},{"path":"b-t-cells-macrophages.html","id":"blood-bank-relevance","chapter":"B & T cells, Macrophages","heading":"Blood Bank Relevance","text":"Initiation: often first cells encounter foreign antigens transfused bloodClearance: key players extravascular hemolysis, removing antibody- complement-coated red blood cells circulation, primarily spleen liverActivating T cells: antigen presentation function essential initiating T-cell dependent immune response leads B cell antibody production","code":""},{"path":"b-t-cells-macrophages.html","id":"t-lymphocytes-t-cells-the-conductors-and-killers","chapter":"B & T cells, Macrophages","heading":"T Lymphocytes (T cells): The Conductors and Killers","text":"T cells central adaptive immune response. don’t produce antibodies , regulate immune response can directly kill infected foreign cells. mature Thymus (hence name!)T Helper Cells (CD4+ T cells): “Generals”\nRecognition: recognize antigens presented APCs (like macrophages) MHC Class II molecules. can’t see antigen unless ’s properly presented APC\nActivation: activated, orchestrate immune response :\nActivating B cells: Providing essential signals (cell--cell contact cytokine release, like IL-4, IL-5) stimulate B cells proliferate, undergo class switching (e.g., IgM IgG), undergo affinity maturation, differentiate plasma cells memory B cells. T-cell help crucial producing high-affinity IgG antibodies – kind often implicated significant blood bank reactions!\nActivating Macrophages: Making effective killers\nActivating Cytotoxic T cells: Helping become fully functional killers\n\nCytokine Production: Release various cytokines influence direct nature immune response\nRecognition: recognize antigens presented APCs (like macrophages) MHC Class II molecules. can’t see antigen unless ’s properly presented APCActivation: activated, orchestrate immune response :\nActivating B cells: Providing essential signals (cell--cell contact cytokine release, like IL-4, IL-5) stimulate B cells proliferate, undergo class switching (e.g., IgM IgG), undergo affinity maturation, differentiate plasma cells memory B cells. T-cell help crucial producing high-affinity IgG antibodies – kind often implicated significant blood bank reactions!\nActivating Macrophages: Making effective killers\nActivating Cytotoxic T cells: Helping become fully functional killers\nActivating B cells: Providing essential signals (cell--cell contact cytokine release, like IL-4, IL-5) stimulate B cells proliferate, undergo class switching (e.g., IgM IgG), undergo affinity maturation, differentiate plasma cells memory B cells. T-cell help crucial producing high-affinity IgG antibodies – kind often implicated significant blood bank reactions!Activating Macrophages: Making effective killersActivating Cytotoxic T cells: Helping become fully functional killersCytokine Production: Release various cytokines influence direct nature immune responseCytotoxic T Lymphocytes (CTLs CD8+ T cells): “Special Ops Soldiers”\nRecognition: recognize antigens presented MHC Class molecules. MHC Class found almost nucleated cells body typically displays internal antigens (like viral proteins cell infected, abnormal proteins cancer cells)\nFunction: activated (often help T helper cells), main job kill targeted cells directly (e.g., virus-infected cells, tumor cells, foreign cells graft). release cytotoxic granules induce apoptosis (programmed cell death) target cell\nRecognition: recognize antigens presented MHC Class molecules. MHC Class found almost nucleated cells body typically displays internal antigens (like viral proteins cell infected, abnormal proteins cancer cells)Function: activated (often help T helper cells), main job kill targeted cells directly (e.g., virus-infected cells, tumor cells, foreign cells graft). release cytotoxic granules induce apoptosis (programmed cell death) target cellRegulatory T cells (Tregs): “Peacekeepers”\nT cells (often CD4+ also expressing CD25) help suppress immune response. crucial maintaining self-tolerance (preventing autoimmunity) shutting immune responses infection antigen cleared\nT cells (often CD4+ also expressing CD25) help suppress immune response. crucial maintaining self-tolerance (preventing autoimmunity) shutting immune responses infection antigen cleared","code":""},{"path":"b-t-cells-macrophages.html","id":"blood-bank-relevance-1","chapter":"B & T cells, Macrophages","heading":"Blood Bank Relevance","text":"Alloimmunization: T helper cells absolutely essential development clinically significant IgG alloantibodies red cell antigens. Without T cell help, B cell response often weaker, short-lived, primarily IgMTransplantation: T helper Cytotoxic T cells major players graft rejection (recognizing foreign MHC molecules donor cells)Graft-versus-Host Disease (GVHD): transfusion-associated GVHD (TA-GVHD), donor T lymphocytes (present cellular blood components) engraft immunocompromised recipient attack recipient’s tissues foreign. CTLs primary effectors . irradiation blood components susceptible patients critical – inactivates donor T lymphocytes","code":""},{"path":"b-t-cells-macrophages.html","id":"b-lymphocytes-b-cells-the-antibody-factories","chapter":"B & T cells, Macrophages","heading":"B Lymphocytes (B cells): The Antibody Factories","text":"B cells stars humoral immunity (immunity mediated molecules body fluids, .e., antibodies). mature Bone marrowRecognition: Unlike T cells, B cells can recognize intact, whole antigens directly using B Cell Receptor (BCR), essentially membrane-bound antibody molecule B cell surface. B cell BCRs specific one particular antigenic shape (epitope)Activation\nT-dependent: protein antigens (like many blood group antigens), B cell activation requires two signals: 1) Binding antigen BCR, 2) Co-stimulation activated T helper cell recognizes antigen presented B cell (acting APC) MHC Class II molecules. leads robust activation, proliferation, class switching (IgM -> IgG), affinity maturation, formation plasma cells long-lived memory B cells\nT-independent: antigens (often large molecules repeating units, like bacterial polysaccharides) can directly activate B cells without T cell help. response generally faster weaker, produces mainly IgM, generates little immunological memory\nT-dependent: protein antigens (like many blood group antigens), B cell activation requires two signals: 1) Binding antigen BCR, 2) Co-stimulation activated T helper cell recognizes antigen presented B cell (acting APC) MHC Class II molecules. leads robust activation, proliferation, class switching (IgM -> IgG), affinity maturation, formation plasma cells long-lived memory B cellsT-independent: antigens (often large molecules repeating units, like bacterial polysaccharides) can directly activate B cells without T cell help. response generally faster weaker, produces mainly IgM, generates little immunological memoryDifferentiation: Upon successful activation (usually T-dependent), B cells proliferate differentiate :\nPlasma Cells: terminally differentiated B cells – essentially antibody-producing factories. extensive endoplasmic reticulum geared towards synthesizing secreting large quantities specific antibodies blood tissues. relatively short-lived\nMemory B Cells: long-lived B cells persist antigen cleared. retain “memory” antigen primed respond quickly strongly upon subsequent exposure (secondary/anamnestic response), rapidly differentiating plasma cells producing high-affinity IgG\nPlasma Cells: terminally differentiated B cells – essentially antibody-producing factories. extensive endoplasmic reticulum geared towards synthesizing secreting large quantities specific antibodies blood tissues. relatively short-livedMemory B Cells: long-lived B cells persist antigen cleared. retain “memory” antigen primed respond quickly strongly upon subsequent exposure (secondary/anamnestic response), rapidly differentiating plasma cells producing high-affinity IgG","code":""},{"path":"b-t-cells-macrophages.html","id":"blood-bank-relevance-2","chapter":"B & T cells, Macrophages","heading":"Blood Bank Relevance","text":"Antibody Production: B cells (specifically, plasma cells derived ) source antibodies deal blood bank – ABO antibodies, Rh antibodies (like anti-D), antibodies blood group systems (Kell, Duffy, Kidd, etc.), antibodies involved autoimmune hemolytic anemiaPrimary vs. Secondary Response: differentiation plasma cells (producing IgM IgG) memory B cells underlies differences primary secondary immune responses. Memory B cells previously sensitized patient can rapidly produce high levels IgG upon re-exposure antigen, leading delayed hemolytic transfusion reactions HDFNHDFN: Maternal B cells produce IgG antibodies (like anti-D) cross placenta attack fetal red blood cells","code":""},{"path":"b-t-cells-macrophages.html","id":"key-terms-49","chapter":"B & T cells, Macrophages","heading":"Key Terms","text":"Macrophage: large phagocytic cell type acts Antigen Presenting Cell (APC) engulfing pathogens foreign cells (like transfused RBCs) displaying processed antigens surface T helper cells; also involved removing antibody-coated cells (extravascular hemolysis)T Lymphocyte (T cell): type lymphocyte maturing thymus, central cell-mediated immunity regulating humoral immunity. Includes T helper (CD4+) Cytotoxic T (CD8+) subsetsB Lymphocyte (B cell): type lymphocyte maturing bone marrow, responsible humoral immunity. Upon activation, differentiates plasma cells (antibody production) memory cellsAntigen Presenting Cell (APC): cell (like macrophage, dendritic cell, B cell) processes presents antigens surface via MHC molecules T lymphocytes, initiating adaptive immune responseMHC Class II Molecules: Surface proteins found primarily APCs used present processed exogenous antigens (originating outside cell) T helper (CD4+) cellsT Helper Cell (CD4+ T cell): subset T lymphocytes recognizes antigens presented MHC Class II molecules provides essential activation signals (cytokines, co-stimulation) B cells immune cells, orchestrating adaptive response. Crucial IgG antibody productionCytotoxic T Lymphocyte (CTL CD8+ T cell): subset T lymphocytes recognizes antigens presented MHC Class molecules (found nucleated cells) kills target cells (e.g., virus-infected cells, tumor cells, foreign graft cells)Plasma Cell: terminally differentiated B lymphocyte specialized mass production secretion specific antibody isotype (like IgG IgM)Memory Cell (B T): Long-lived B T lymphocytes generated primary immune response remain dormant quickly activated upon re-exposure antigen, mediating faster stronger secondary responseB Cell Receptor (BCR): membrane-bound antibody molecule surface B cell allows recognize bind specifically intact antigen, initiating B cell activation process","code":""},{"path":"genetics-1.html","id":"genetics-1","chapter":"Genetics","heading":"Genetics","text":"Think genes ultimate instruction manual immune system. dictate body builds defense forces, incredible variety B T cell receptors recognize invaders, critical HLA molecules help distinguish cells foreign ones (like transfused blood cells transplanted organs). genetic blueprint inherit blood types, people readily make antibodies transfusion others don’t, finding compatible donors can challenging","code":""},{"path":"genetics-1.html","id":"genetics-of-the-immune-response-the-blueprint-for-defense","chapter":"Genetics","heading":"Genetics of the Immune Response: The Blueprint for Defense","text":"genes control several key aspects immune response:Generating Receptor Diversity: can immune system recognize potentially billions different antigens never seen ?Self vs. Non-Self Recognition: immune system know belongs body foreign?Controlling Response: type strength immune response regulated?Individual Variation: individuals prone making certain antibodies rejecting grafts others?Let’s break :","code":""},{"path":"genetics-1.html","id":"generating-receptor-diversity-the-vdj-shuffle","chapter":"Genetics","heading":"Generating Receptor Diversity: The V(D)J Shuffle","text":"adaptive immune system relies B cells (B cell receptors/antibodies) T cells (T cell receptors TCRs) recognize specific antigens. incredible diversity receptors doesn’t come billions separate genes. Instead, comes clever genetic process called gene rearrangement V(D)J recombinationThe Problem: need potentially billions different antibody TCR specificities handle diverse threatsThe Genetic Toolkit: Within DNA regions code variable parts antibodies (heavy light chains) TCRs (alpha, beta, gamma, delta chains), multiple different gene segments:\nV (Variable): segments\nD (Diversity): segments (heavy chains TCR chains)\nJ (Joining): segments\nV (Variable): segmentsD (Diversity): segments (heavy chains TCR chains)J (Joining): segmentsThe Process: individual B cell T cell develops (bone marrow thymus, respectively), performs “cut paste” operation DNA:\nrandomly selects one V segment, one D segment (applicable), one J segment\ncuts DNA chosen segments\npastes selected V, (D), J segments together\nnewly assembled V(D)J sequence forms variable region gene specific lymphocyte’s receptor\nrandomly selects one V segment, one D segment (applicable), one J segmentIt cuts DNA chosen segmentsIt pastes selected V, (D), J segments togetherThis newly assembled V(D)J sequence forms variable region gene specific lymphocyte’s receptorCombinatorial Diversity: Since many different V, D, J segments choose , number possible combinations huge (thousands x dozens x several = millions!)Junctional Diversity: “pasting” process often imprecise, adding deleting nucleotides junctions segments. creates even variation right critical antigen-binding part receptorSomatic Hypermutation (B cells ): B cell activated antigen T cell help, rearranged antibody genes undergo accelerated point mutations, especially variable region. B cells whose mutated receptors bind antigen better preferentially selected survive proliferate. affinity maturation leads higher-affinity antibodies immune response (especially secondary response)","code":""},{"path":"genetics-1.html","id":"blood-bank-relevance-3","chapter":"Genetics","heading":"Blood Bank Relevance","text":"genetic shuffling can make antibody virtually foreign blood group antigen (like Kell, Duffy, Kidd, etc.) might encounter transfusion pregnancy, even ’ve never seen . body B cells pre-existing BCRs capable recognizing antigen, thanks V(D)J recombination","code":""},{"path":"genetics-1.html","id":"self-vs.-non-self-recognition-the-mhchla-system","chapter":"Genetics","heading":"Self vs. Non-Self Recognition: The MHC/HLA System","text":"critical part immune function distinguishing body’s cells foreign invaders altered self-cells (like infected tumor cells). Major Histocompatibility Complex (MHC) plays central role . humans, MHC called Human Leukocyte Antigen (HLA) systemMHC/HLA Genes: Located dense cluster Chromosome 6, genes code cell surface proteins present antigen fragments T cells\nMHC Class (HLA-, HLA-B, HLA-C): Found almost nucleated cells. present endogenous antigens (peptides within cell, like viral proteins self-proteins) CD8+ Cytotoxic T cells. Think cell showing T cell ’s going inside\nMHC Class II (HLA-DP, HLA-DQ, HLA-DR): Found primarily Antigen Presenting Cells (APCs) like macrophages, dendritic cells, B cells. present exogenous antigens (peptides outside cell engulfed, like bacterial fragments foreign proteins) CD4+ T helper cells. Think APCs showing T helper cells ’ve found outside\nMHC Class (HLA-, HLA-B, HLA-C): Found almost nucleated cells. present endogenous antigens (peptides within cell, like viral proteins self-proteins) CD8+ Cytotoxic T cells. Think cell showing T cell ’s going insideMHC Class II (HLA-DP, HLA-DQ, HLA-DR): Found primarily Antigen Presenting Cells (APCs) like macrophages, dendritic cells, B cells. present exogenous antigens (peptides outside cell engulfed, like bacterial fragments foreign proteins) CD4+ T helper cells. Think APCs showing T helper cells ’ve found outsideExtreme Polymorphism: HLA genes polymorphic genes known humans – meaning hundreds even thousands different versions (alleles) genes human population. individual inherits set alleles parent. vast diversity great survival species (ensuring individuals can always mount response new pathogens), makes finding compatible donors transplantation difficultInheritance: HLA genes inherited together block set called haplotype parent. get one haplotype mother one father. siblings 25% chance HLA-identicalT cell Education: T cell development thymus, T cells learn recognize self-MHC molecules presenting self-peptides. T cells react strongly (potential autoimmunity) weakly (useless) eliminated. ensures T cells self-MHC restricted (recognize antigen presented MHC type) self-tolerant (don’t usually attack tissues)","code":""},{"path":"genetics-1.html","id":"blood-bank-relevance-4","chapter":"Genetics","heading":"Blood Bank Relevance","text":"Transplantation: HLA matching donor recipient CRITICAL solid organ hematopoietic stem cell transplantation. Mismatched HLA molecules seen foreign recipient’s T cells (donor T cells GVHD), leading rejection Graft-versus-Host DiseasePlatelet Refractoriness: patients become refractory (unresponsive) platelet transfusions develop HLA antibodies (usually Class ) previous transfusions pregnancies. antibodies destroy transfused platelets. HLA-matched platelets often requiredTransfusion-Related Acute Lung Injury (TRALI): Often caused antibodies donor’s plasma directed recipient’s HLA (sometimes neutrophil) antigens, triggering neutrophil activation lung injuryFebrile Non-Hemolytic Transfusion Reactions (FNHTR): often caused cytokines, interactions residual donor leukocytes recipient antibodies (including HLA antibodies) can contributeTransfusion-Associated Graft-versus-Host Disease (TA-GVHD): Occurs viable donor T lymphocytes engraft susceptible recipient attack recipient tissues foreign (recognizing different HLA). Irradiation prevents inactivating donor T cells","code":""},{"path":"genetics-1.html","id":"blood-group-genetics-inherited-antigens","chapter":"Genetics","heading":"Blood Group Genetics: Inherited Antigens","text":"Blood group antigens (like ABO, Rh, Kell, Duffy, Kidd, MNS, etc.) molecules surface red blood cells (sometimes cells). presence absence determined specific genes inherited parentsGenes Code Antigens: Genes contain instructions making proteins enzymes\nblood group genes code directly antigen protein (e.g., RHD RHCE genes code RhD RhCE proteins)\ngenes code enzymes (often glycosyltransferases) add specific sugar molecules onto precursor substance cell surface, creating antigen (e.g., ABO genes code transferases create B antigens H antigen precursor)\nblood group genes code directly antigen protein (e.g., RHD RHCE genes code RhD RhCE proteins)genes code enzymes (often glycosyltransferases) add specific sugar molecules onto precursor substance cell surface, creating antigen (e.g., ABO genes code transferases create B antigens H antigen precursor)Alleles Determine Phenotype: Different versions (alleles) genes result different antigens expressed (antigen expressed, like O allele ABO system d allele representing absence RHD)Mendelian Inheritance: Blood group genes inherited according standard Mendelian principles (dominant, recessive, co-dominant). allows us predict antigen types families populations","code":""},{"path":"genetics-1.html","id":"blood-bank-relevance-5","chapter":"Genetics","heading":"Blood Bank Relevance","text":"Compatibility Testing: entire foundation pre-transfusion testing relies understanding genetics ABO Rh systems, clinically significant blood groups, provide antigen-negative blood patients corresponding antibodiesAlloimmunization: Genetic differences blood group antigens blood donor/fetus recipient/mother reason alloimmunization occurs. recipient lacks antigen (due genes) receives blood positive antigen, immune system may recognize foreign produce antibodyHemolytic Disease Fetus Newborn (HDFN): Arises genetic incompatibility (famously RhD) mother fetus, leading maternal antibody production fetal antigensPredicting Antigen Frequency: Population genetics helps us know frequency various blood group antigens, useful finding rare blood units","code":""},{"path":"genetics-1.html","id":"genetic-control-of-response-strength-cytokines","chapter":"Genetics","heading":"Genetic Control of Response Strength & Cytokines","text":"Genes also influence intensity type immune responseCytokine Genes: Genes control production cytokines (chemical messengers immune system like interleukins, interferons, TNF). Polymorphisms (variations) cytokine genes can lead individuals producing higher lower levels certain cytokines, influencing inflammation direction immune response (e.g., favoring antibody production vs. cell-mediated immunity)Immune Regulatory Genes: Genes involved controlling immune cell activation, proliferation, apoptosis influence overall immune responsiveness","code":""},{"path":"genetics-1.html","id":"blood-bank-relevance-6","chapter":"Genetics","heading":"Blood Bank Relevance","text":"Explains variability seen patients – readily form antibodies exposure others exposed antigens notMay influence susceptibility certain transfusion reactions severity HDFN","code":""},{"path":"genetics-1.html","id":"summary","chapter":"Genetics","heading":"Summary","text":"Genetics intricately woven every aspect immune response relevant blood banking:V(D)J recombination: provides genetic mechanism vast diversity antibodies T cell receptors needed recognize foreign antigens, including blood group antigensThe highly polymorphic HLA genes control antigen presentation self/non-self discrimination, making critical determinants transplantation compatibility, platelet refractoriness, TRALI, GVHDBlood group genes: dictate presence absence red cell antigens, forming basis compatibility testing, alloimmunization risk, HDFNGenetic variations cytokine regulatory genes contribute individual differences observed immune responsivenessUnderstanding genetic underpinnings helps us appreciate immune reactions occur transfusion transplantation medicine guides strategies use prevent !","code":""},{"path":"genetics-1.html","id":"key-terms-50","chapter":"Genetics","heading":"Key Terms","text":"Gene Rearrangement (V(D)J Recombination): process developing B T cells randomly select combine V, D, J gene segments create unique variable region gene specific antigen receptor (antibody TCR). primary mechanism generating receptor diversitySomatic Hypermutation: process occurring activated B cells point mutations introduced variable region genes antibodies. Coupled selection, leads affinity maturation (higher binding strength antibodies)Major Histocompatibility Complex (MHC): set genes coding cell surface proteins essential antigen presentation T cells self/non-self recognitionHuman Leukocyte Antigen (HLA): human MHC system, located Chromosome 6. Includes Class (HLA-, -B, -C) Class II (HLA-DP, -DQ, -DR) genesPolymorphism: existence multiple different forms (alleles) gene within population. HLA genes highly polymorphicHaplotype: set closely linked genes (like HLA genes) chromosome typically inherited together single unitAllele: variant form specific gene. example, , B, O alleles ABO geneBlood Group System: group related blood group antigens controlled specific gene set closely linked genes (e.g., ABO system, Rh system, Kell system)Alloimmunization: process developing immune response (specifically antibodies) foreign antigens species, typically encountered transfusion pregnancy. driven genetic differences antigen expression individuals","code":""},{"path":"immunoglobulins.html","id":"immunoglobulins","chapter":"Immunoglobulins","heading":"Immunoglobulins","text":"section covers key aspects immunoglobulins (antibodies) – different types (classes/subclasses), ’re built (structure), actually based structure (biologic/physical properties)Think immunoglobulins highly specialized security force adaptive immune system. proteins made plasma cells (mature B cells) designed recognize neutralize specific foreign targets (antigens). brilliance lies structure, perfectly equips dual role","code":""},{"path":"immunoglobulins.html","id":"the-basic-design-structure-the-y-shape","chapter":"Immunoglobulins","heading":"The Basic Design (Structure): The “Y” Shape","text":"core, immunoglobulin Y-shaped molecule built four protein chains: two identical Heavy (H) chains forming stem inner arms, two identical Light (L) chains forming outer arms. held together disulfide bondsEach arm tip contains Variable (V) region, unique antibody forms antigen-binding site (Fab fragment). antibody specifically latches onto target (like D antigen red cell). incredible diversity comes gene rearrangement (V(D)J)stem lower arms make Constant (C) region (Fc fragment). part consistent within antibody class determines antibody’s effector functions – interacts parts immune system (like complement phagocytic cells) general physical properties","code":""},{"path":"immunoglobulins.html","id":"the-different-models-classes-subclasses-variations-on-the-theme","chapter":"Immunoglobulins","heading":"The Different Models (Classes & Subclasses): Variations on the Theme","text":"type Heavy chain constant region dictates antibody’s class (isotype). five main classes (Remember GAMED):\nIgG (Gamma heavy chain): abundant Ig serum. monomer. workhorse fighting infections blood/tissues star secondary immune response. Crucially, crosses placenta. Comes 4 subclasses (IgG1, IgG2, IgG3, IgG4) differing abilities (esp. complement activation: IgG3 > IgG1 >> IgG2)\nIgM (Mu heavy chain): Usually large pentamer (5 Y-units joined J-chain). first responder primary immune response. Excellent activating complement agglutinating cells due size multiple binding sites. Stays mainly bloodstream cross placenta\nIgA (Alpha heavy chain): monomer serum, dimer (J-chain Secretory Component) mucosal secretions (gut, lungs, tears, saliva). guardian body surfaces. typically activate complement cross placenta\nIgE (Epsilon heavy chain): monomer found low serum levels, mostly bound mast cells/basophils. Triggers allergic reactions\nIgD (Delta heavy chain): monomer primarily found surface naive B cells receptor\nIgG (Gamma heavy chain): abundant Ig serum. monomer. workhorse fighting infections blood/tissues star secondary immune response. Crucially, crosses placenta. Comes 4 subclasses (IgG1, IgG2, IgG3, IgG4) differing abilities (esp. complement activation: IgG3 > IgG1 >> IgG2)IgM (Mu heavy chain): Usually large pentamer (5 Y-units joined J-chain). first responder primary immune response. Excellent activating complement agglutinating cells due size multiple binding sites. Stays mainly bloodstream cross placentaIgA (Alpha heavy chain): monomer serum, dimer (J-chain Secretory Component) mucosal secretions (gut, lungs, tears, saliva). guardian body surfaces. typically activate complement cross placentaIgE (Epsilon heavy chain): monomer found low serum levels, mostly bound mast cells/basophils. Triggers allergic reactionsIgD (Delta heavy chain): monomer primarily found surface naive B cells receptor","code":""},{"path":"immunoglobulins.html","id":"form-dictates-function-biologic-physical-properties","chapter":"Immunoglobulins","heading":"Form Dictates Function (Biologic & Physical Properties)","text":"Size & Structure: Monomeric IgG small enough move tissues cross placenta. Pentameric IgM large, stays blood, great clumping things together (agglutination)Antigen Binding (Fab): Specificity determined Variable regions. IgM high avidity (overall binding strength) due multiple sites; IgG often develops high affinity (single site strength) immune responsesEffector Functions (Fc)\nComplement Activation: IgM champ. IgG (esp. IgG3/IgG1) can also . Leads potential cell lysis (intravascular hemolysis)\nOpsonization: IgG’s Fc region binds well macrophage receptors, tagging cells destruction (extravascular hemolysis)\nPlacental Transfer: IgG Fc structure recognized active transport across placenta\nComplement Activation: IgM champ. IgG (esp. IgG3/IgG1) can also . Leads potential cell lysis (intravascular hemolysis)Opsonization: IgG’s Fc region binds well macrophage receptors, tagging cells destruction (extravascular hemolysis)Placental Transfer: IgG Fc structure recognized active transport across placentaLocation: IgG systemic (blood/tissues); IgM mainly blood; IgA mucosal; IgE mast cellsHalf-life: IgG lasts longest (~3 weeks), IgM much shorter (~5 days)","code":""},{"path":"immunoglobulins.html","id":"blood-bank-relevance---why-we-care","chapter":"Immunoglobulins","heading":"Blood Bank Relevance - Why We Care","text":"HDFN: Caused maternal IgG crossing placenta attacking fetal red cells. IgM thisHTRs\nIgM: (like ABO antibodies) often causes rapid intravascular hemolysis due potent complement activation. Usually detected immediate spin/RT agglutination\nIgG: (like Rh, Kell, Duffy antibodies) often causes extravascular hemolysis via macrophage uptake spleen/liver (opsonization). Complement activation can contribute. Usually requires Antiglobulin Test (IAT/DAT) detection poor agglutinators (“incomplete”). Often react best 37°C\nIgM: (like ABO antibodies) often causes rapid intravascular hemolysis due potent complement activation. Usually detected immediate spin/RT agglutinationIgG: (like Rh, Kell, Duffy antibodies) often causes extravascular hemolysis via macrophage uptake spleen/liver (opsonization). Complement activation can contribute. Usually requires Antiglobulin Test (IAT/DAT) detection poor agglutinators (“incomplete”). Often react best 37°CAntibody Identification: Knowing likely class helps interpret reaction phases (e.g., cold reaction likely IgM, AHG reaction likely IgG). Treating plasma DTT can destroy IgM activity, helping differentiateAnaphylactic Reactions: Usually due anti-IgA (often IgG class) IgA-deficient patients reacting IgA transfused productsAllergic Reactions: Mediated IgE causing histamine release mast cells (hives)","code":""},{"path":"classes-subclasses.html","id":"classes-subclasses","chapter":"Classes & Subclasses","heading":"Classes & Subclasses","text":"Think immunoglobulins, antibodies, specialized tools immune system creates target specific threats. share basic structure, come different “models” – called classes subclasses – designed slightly different jobs locations body. Understanding super important blood banking different antibody classes vastly different clinical significance!class (subclass) immunoglobulin determined heavy chain – larger protein chains structure. five main types heavy chains, corresponding five main Ig classes:Gamma (γ): heavy chains define IgGMu (μ): heavy chains define IgMAlpha (α): heavy chains define IgAEpsilon (ε): heavy chains define IgEDelta (δ): heavy chains define IgD(Remember mnemonic GAMED five classes!)Now, let’s look class subclasses (applicable):","code":""},{"path":"classes-subclasses.html","id":"immunoglobulin-g-igg","chapter":"Classes & Subclasses","heading":"Immunoglobulin G (IgG)","text":"workhorse adaptive immune response, especially blood!Heavy Chain: Gamma (γ)Structure: Monomer (single Y-shaped unit)Concentration: Highest concentration serum (~75-80% total serum Ig). Found blood, lymph, tissue fluidsKey Functions\nMajor player secondary immune responses: Produced large amounts upon re-exposure antigen\nNeutralizes toxins viruses.\nOpsonization: Coats pathogens, making easier phagocytes (like macrophages) engulf (binds via Fc region Fc receptors phagocytes)\nActivates classical complement pathway: requires two IgG molecules close together\nCrosses placenta: Provides passive immunity fetus newborn. Crucial point!\nLong half-life: Persists circulation weeks (around 23 days)\nMajor player secondary immune responses: Produced large amounts upon re-exposure antigenNeutralizes toxins viruses.Opsonization: Coats pathogens, making easier phagocytes (like macrophages) engulf (binds via Fc region Fc receptors phagocytes)Activates classical complement pathway: requires two IgG molecules close togetherCrosses placenta: Provides passive immunity fetus newborn. Crucial point!Long half-life: Persists circulation weeks (around 23 days)Blood Bank Relevance\nclinically significant alloantibodies: (antibodies foreign red cell antigens like Rh, Kell, Duffy, Kidd) cause hemolytic transfusion reactions (HTRs) Hemolytic Disease Fetus Newborn (HDFN) IgG\nMany warm autoantibodies (reacting self-antigens 37°C) IgG\nDetected best Indirect Antiglobulin Test (IAT) Direct Antiglobulin Test (DAT) often non-agglutinating (“incomplete” antibodies)\nclinically significant alloantibodies: (antibodies foreign red cell antigens like Rh, Kell, Duffy, Kidd) cause hemolytic transfusion reactions (HTRs) Hemolytic Disease Fetus Newborn (HDFN) IgGMany warm autoantibodies (reacting self-antigens 37°C) IgGDetected best Indirect Antiglobulin Test (IAT) Direct Antiglobulin Test (DAT) often non-agglutinating (“incomplete” antibodies)","code":""},{"path":"classes-subclasses.html","id":"igg-subclasses","chapter":"Classes & Subclasses","heading":"IgG Subclasses","text":"four subclasses IgG (IgG1, IgG2, IgG3, IgG4), determined slight variations gamma heavy chains. differ primarily abundance functional capabilities:IgG1: abundant (~65% total IgG). Good -around performer: crosses placenta well, activates complement, binds Fc receptors. Many Rh antibodies (like anti-D) IgG1IgG2: Second abundant (~23%). Primarily responds polysaccharide antigens (like bacterial capsules). Poor complement activator crosses placenta less efficiently IgG1 IgG3IgG3: Less abundant (~8%). effective complement activator among IgG subclasses! Crosses placenta well binds Fc receptors effectively. shorter half-life subclasses. potent alloantibodies (like certain anti-Jka) can IgG3IgG4: Least abundant (~4%). activate classical complement pathway. Can cross placenta. role complex, sometimes associated allergy responses immune tolerance. Rarely implicated alone significant red cell hemolysis, can present autoimmune conditionsKey Subclass Takeaway Differences complement activation (IgG3 > IgG1 >> IgG2, None IgG4) placental transfer (cross, IgG2 less ) clinically relevant distinctions blood bankers!","code":""},{"path":"classes-subclasses.html","id":"immunoglobulin-m-igm","chapter":"Classes & Subclasses","heading":"Immunoglobulin M (IgM)","text":"“first responder” antibody!Heavy Chain: Mu (μ)Structure: Pentamer (five Y-shaped units joined together J-chain) secreted form. Looks like snowflake! also exists monomer surface naive B cells B cell receptor (BCR)Concentration: 5-10% total serum Ig. Mostly confined bloodstream due large sizeKey Functions\nPredominant antibody primary immune response.\nExcellent activator classical complement pathway: pentameric structure provides multiple binding sites C1q, making efficient\nEfficient agglutinator: large size multiple binding arms (10 potential binding sites, though usually 5 functional due steric hindrance) make great clumping cells (like red blood cells)\ncross placenta: (generally large)\nShorter half-life IgG (~5 days)\nPredominant antibody primary immune response.Excellent activator classical complement pathway: pentameric structure provides multiple binding sites C1q, making efficientEfficient agglutinator: large size multiple binding arms (10 potential binding sites, though usually 5 functional due steric hindrance) make great clumping cells (like red blood cells)cross placenta: (generally large)Shorter half-life IgG (~5 days)Blood Bank Relevance\nNaturally occurring ABO antibodies (anti-, anti-B): primarily IgM. ABO incompatibility can cause rapid intravascular hemolysis (due potent complement activation)\nMany cold-reactive antibodies (reacting best 37°C), alloantibodies (like anti-M, -N, -P1) autoantibodies (like anti-, anti-associated Cold Agglutinin Disease), IgM\nOften detected immediate spin room temperature phases testing due agglutinating ability (“complete” antibodies)\nNaturally occurring ABO antibodies (anti-, anti-B): primarily IgM. ABO incompatibility can cause rapid intravascular hemolysis (due potent complement activation)Many cold-reactive antibodies (reacting best 37°C), alloantibodies (like anti-M, -N, -P1) autoantibodies (like anti-, anti-associated Cold Agglutinin Disease), IgMOften detected immediate spin room temperature phases testing due agglutinating ability (“complete” antibodies)","code":""},{"path":"classes-subclasses.html","id":"immunoglobulin-a-iga","chapter":"Classes & Subclasses","heading":"Immunoglobulin A (IgA)","text":"guardian mucosal surfaces!Heavy Chain: Alpha (α)Structure\nSerum IgA: Primarily monomer\nSecretory IgA (sIgA): Dimer (two units) joined J-chain complexed Secretory Component. component protects enzymatic digestion harsh mucosal environments\nSerum IgA: Primarily monomerSecretory IgA (sIgA): Dimer (two units) joined J-chain complexed Secretory Component. component protects enzymatic digestion harsh mucosal environmentsConcentration: 10-15% total serum Ig, ’s abundant Ig overall body due high concentration secretions. Found tears, saliva, mucus (respiratory, GI, GU tracts), sweat, breast milkKey Functions\nMucosal Immunity: Prevents attachment bacteria viruses mucous membranes (immune exclusion). Neutralizes toxins locally\ntypically activate classical complement pathway\nPassed newborns via breast milk, providing passive mucosal immunity\nMucosal Immunity: Prevents attachment bacteria viruses mucous membranes (immune exclusion). Neutralizes toxins locallyDoes typically activate classical complement pathwayPassed newborns via breast milk, providing passive mucosal immunityBlood Bank Relevance\nUsually directly involved red cell destruction\nClinically Significant: Patients IgA deficient (common primary immunodeficiency) can produce anti-IgA antibodies exposed IgA plasma-containing blood products. Re-exposure can lead severe anaphylactic transfusion reactions. patients require IgA-deficient blood products (e.g., washed red cells/platelets products IgA-deficient donors)\nUsually directly involved red cell destructionClinically Significant: Patients IgA deficient (common primary immunodeficiency) can produce anti-IgA antibodies exposed IgA plasma-containing blood products. Re-exposure can lead severe anaphylactic transfusion reactions. patients require IgA-deficient blood products (e.g., washed red cells/platelets products IgA-deficient donors)","code":""},{"path":"classes-subclasses.html","id":"iga-subclasses","chapter":"Classes & Subclasses","heading":"IgA Subclasses","text":"IgA1: Predominant serum produced bone marrow plasma cellsIgA2: Predominant secretions, especially colon. resistant bacterial proteases IgA1","code":""},{"path":"classes-subclasses.html","id":"immunoglobulin-e-ige","chapter":"Classes & Subclasses","heading":"Immunoglobulin E (IgE)","text":"allergy parasite defender!Heavy Chain: Epsilon (ε)Structure: MonomerConcentration: Lowest concentration serum. IgE bound surface mast cells basophils via high-affinity Fc receptors (FcεRI)Key Functions\nAllergic Reactions: antigen (allergen) binds IgE mast cells/basophils, triggers degranulation – release histamine, leukotrienes, inflammatory mediators, causing allergic symptoms (hives, asthma, anaphylaxis)\nDefense parasitic worms (helminths).\nAllergic Reactions: antigen (allergen) binds IgE mast cells/basophils, triggers degranulation – release histamine, leukotrienes, inflammatory mediators, causing allergic symptoms (hives, asthma, anaphylaxis)Defense parasitic worms (helminths).Blood Bank Relevance\nResponsible allergic transfusion reactions, ranging mild urticaria (hives) potentially severe anaphylaxis (though anaphylaxis transfusion commonly associated anti-IgA)\nResponsible allergic transfusion reactions, ranging mild urticaria (hives) potentially severe anaphylaxis (though anaphylaxis transfusion commonly associated anti-IgA)","code":""},{"path":"classes-subclasses.html","id":"immunoglobulin-d-igd","chapter":"Classes & Subclasses","heading":"Immunoglobulin D (IgD)","text":"mysterious one, mostly found B cellsHeavy Chain: Delta (δ)Structure: MonomerConcentration: low concentration serum. Primarily found surface naive B lymphocytes, often co-expressed IgM, acting B cell receptor (BCR)Key Functions\nInvolved B cell activation differentiation. Signals naive B cell encounters specific antigen\nSerum function largely unknown\nInvolved B cell activation differentiation. Signals naive B cell encounters specific antigenSerum function largely unknownBlood Bank Relevance\nknown direct role transfusion reactions routine blood bank testing\nknown direct role transfusion reactions routine blood bank testing","code":""},{"path":"classes-subclasses.html","id":"summary-table","chapter":"Classes & Subclasses","heading":"Summary Table","text":"","code":""},{"path":"classes-subclasses.html","id":"key-terms-51","chapter":"Classes & Subclasses","heading":"Key Terms","text":"Immunoglobulin (Ig) / Antibody: Glycoproteins produced plasma cells (differentiated B lymphocytes) specifically bind antigens. key components humoral immune responseClass (Isotype): major categories immunoglobulins (IgG, IgM, IgA, IgE, IgD) determined type heavy chain (gamma, mu, alpha, epsilon, delta, respectively) present molecule. class distinct structural characteristics effector functionsSubclass: divisions within certain immunoglobulin classes (specifically IgG IgA), based minor variations heavy chains (e.g., IgG1, IgG2, IgG3, IgG4; IgA1, IgA2). Subclasses can differ functional properties, complement activation placental transfer efficiencyHeavy Chain: larger two types polypeptide chains make immunoglobulin molecule. amino acid sequence constant region heavy chain determines immunoglobulin’s class subclassIgG (Immunoglobulin G): abundant immunoglobulin class serum, existing monomer. dominates secondary immune responses, readily crosses placenta, includes clinically significant red blood cell alloantibodies responsible HTR HDFNIgM (Immunoglobulin M)\nDefinition: immunoglobulin class existing large pentamer (serum) joined J-chain. first antibody produced primary immune response, efficient activating complement, includes naturally occurring ABO antibodies. cross placenta\nDefinition: immunoglobulin class existing large pentamer (serum) joined J-chain. first antibody produced primary immune response, efficient activating complement, includes naturally occurring ABO antibodies. cross placentaIgA (Immunoglobulin ): immunoglobulin class found monomer serum primarily dimer (secretory IgA) mucosal secretions. main role mucosal immunity. Clinically relevant blood banking due potential anti-IgA antibodies IgA-deficient individuals causing anaphylactic reactionsPlacental Transfer: ability immunoglobulin class, specifically IgG, pass across placental barrier mother fetus via active transport involving Fc receptors placental cells. provides passive immunity newborn also mechanism maternal IgG antibodies cause HDFNComplement Activation (Classical Pathway): ability certain immunoglobulin classes (primarily IgM IgG subclasses, notably IgG3 IgG1) initiate classical complement cascade upon binding antigen. leads inflammation, opsonization, potentially cell lysis (e.g., intravascular hemolysis)J-Chain (Joining Chain): small polypeptide chain links immunoglobulin monomers together form polymeric structures IgM (pentamer) secretory IgA (dimer)","code":""},{"path":"structure.html","id":"structure","chapter":"Structure","heading":"Structure","text":"Understanding immunoglobulinstheir structure absolutely fundamental built directly dictates can – like binding specific antigens red cells, activating complement, crossing placentaThink basic immunoglobulin molecule flexible, Y-shaped protein. shape isn’t accidental; ’s perfectly designed dual roles: recognizing binding specific target (antigen) signaling parts immune system take actionHere’s breakdown key structural components:","code":""},{"path":"structure.html","id":"basic-building-blocks-polypeptide-chains","chapter":"Structure","heading":"Basic Building Blocks: Polypeptide Chains","text":"Every basic immunoglobulin unit (monomer) built four polypeptide chains:Two Identical Heavy (H) Chains: larger chains (~50-77 kDa ). form backbone “Y” shape, including entire stem part arms\ntype Heavy chain determines class (isotype) immunoglobulin:\nGamma (γ) -> IgG\nMu (μ) -> IgM\nAlpha (α) -> IgA\nDelta (δ) -> IgD\nEpsilon (ε) -> IgE\n\ntype Heavy chain determines class (isotype) immunoglobulin:\nGamma (γ) -> IgG\nMu (μ) -> IgM\nAlpha (α) -> IgA\nDelta (δ) -> IgD\nEpsilon (ε) -> IgE\nGamma (γ) -> IgGMu (μ) -> IgMAlpha (α) -> IgADelta (δ) -> IgDEpsilon (ε) -> IgETwo Identical Light (L) Chains: smaller chains (~25 kDa ). light chain bound one heavy chains, forming outer part “Y” arms\ntwo types (isotypes) Light chains:\nKappa (κ)\nLambda (λ)\n\nsingle antibody molecule either two kappa chains two lambda chains, never mix. humans, 60% antibodies kappa chains 40% lambda chains\ntwo types (isotypes) Light chains:\nKappa (κ)\nLambda (λ)\nKappa (κ)Lambda (λ)single antibody molecule either two kappa chains two lambda chains, never mix. humans, 60% antibodies kappa chains 40% lambda chains","code":""},{"path":"structure.html","id":"holding-it-together-disulfide-bonds","chapter":"Structure","heading":"Holding it Together: Disulfide Bonds","text":"polypeptide chains held together strong covalent bonds called disulfide bonds (-S-S-):Inter-chain disulfide bonds: Link heavy chains (usually hinge region) link heavy chain corresponding light chainIntra-chain disulfide bonds: Occur within individual heavy light chain, creating loops. loops fold compact, stable structures called domains","code":""},{"path":"structure.html","id":"functional-regions-variable-and-constant","chapter":"Structure","heading":"Functional Regions: Variable and Constant","text":"heavy light chain can conceptually divided two main regions:Variable (V) Region\nLocation: Found tips “Y” arms (N-terminal end H L chains)\nComposition: Consists one variable domain light chain (VL) one variable domain heavy chain (VH)\nFunction: region highly variable amino acid sequence, especially within specific segments called Hypervariable Regions Complementarity-Determining Regions (CDRs). variability creates unique, three-dimensional antigen-binding site. basic antibody unit two identical antigen-binding sites, one tip arm. antibody recognizes physically binds specific antigen (like D antigen red cell). incredible diversity generated V(D)J gene rearrangement\nLocation: Found tips “Y” arms (N-terminal end H L chains)Composition: Consists one variable domain light chain (VL) one variable domain heavy chain (VH)Function: region highly variable amino acid sequence, especially within specific segments called Hypervariable Regions Complementarity-Determining Regions (CDRs). variability creates unique, three-dimensional antigen-binding site. basic antibody unit two identical antigen-binding sites, one tip arm. antibody recognizes physically binds specific antigen (like D antigen red cell). incredible diversity generated V(D)J gene rearrangementConstant (C) Region\nLocation: Makes rest light chain stem lower part arms heavy chains (C-terminal end)\nComposition: Consists one constant domain light chain (CL) multiple constant domains heavy chain (CH1, CH2, CH3 - sometimes CH4 IgM IgE)\nFunction: amino acid sequence region relatively constant within class subclass. determines antibody’s class (IgG, IgM, etc.) mediates effector functions – antibody interacts immune system components binding antigen. includes:\nBinding Fc receptors cells like macrophages, neutrophils, NK cells, mast cells\nActivating complement system (primarily via CH2 domain IgG CH3 IgM)\nDetermining antibody can cross placenta (mediated Fc receptors placental cells binding IgG Fc region)\n\nLocation: Makes rest light chain stem lower part arms heavy chains (C-terminal end)Composition: Consists one constant domain light chain (CL) multiple constant domains heavy chain (CH1, CH2, CH3 - sometimes CH4 IgM IgE)Function: amino acid sequence region relatively constant within class subclass. determines antibody’s class (IgG, IgM, etc.) mediates effector functions – antibody interacts immune system components binding antigen. includes:\nBinding Fc receptors cells like macrophages, neutrophils, NK cells, mast cells\nActivating complement system (primarily via CH2 domain IgG CH3 IgM)\nDetermining antibody can cross placenta (mediated Fc receptors placental cells binding IgG Fc region)\nBinding Fc receptors cells like macrophages, neutrophils, NK cells, mast cellsActivating complement system (primarily via CH2 domain IgG CH3 IgM)Determining antibody can cross placenta (mediated Fc receptors placental cells binding IgG Fc region)","code":""},{"path":"structure.html","id":"key-structural-domains","chapter":"Structure","heading":"Key Structural Domains","text":"mentioned, chains fold distinct globular domains:Light Chain: VL, CLHeavy Chain: VH, CH1, CH2, CH3 (CH4 IgM/IgE)domain characteristic “immunoglobulin fold” structure","code":""},{"path":"structure.html","id":"functional-fragments-fab-and-fc","chapter":"Structure","heading":"Functional Fragments: Fab and Fc","text":"Experimentally, enzymes like papain can cleave antibody molecule distinct fragments, helps us understand function:Fab (Fragment, antigen-binding)\nStructure: Consists one complete light chain (VL + CL) paired VH CH1 domains one heavy chain. Essentially, one “arm” Y\nFunction: Contains antigen-binding site. monomeric antibody two Fab fragments\nStructure: Consists one complete light chain (VL + CL) paired VH CH1 domains one heavy chain. Essentially, one “arm” YFunction: Contains antigen-binding site. monomeric antibody two Fab fragmentsFc (Fragment, crystallizable)\nStructure: Consists constant region domains stem two heavy chains (CH2 CH3 domains, CH2, CH3, CH4 IgM/IgE)\nFunction: Contains sites responsible effector functions (complement activation, Fc receptor binding, placental transfer). ’s “business end” interacts rest immune system\nStructure: Consists constant region domains stem two heavy chains (CH2 CH3 domains, CH2, CH3, CH4 IgM/IgE)Function: Contains sites responsible effector functions (complement activation, Fc receptor binding, placental transfer). ’s “business end” interacts rest immune system","code":""},{"path":"structure.html","id":"the-hinge-region","chapter":"Structure","heading":"The Hinge Region","text":"Location: Found CH1 CH2 domains heavy chains IgG, IgA, IgDStructure: flexible stretch amino acids, rich proline cysteine residues (form inter-chain disulfide bonds holding heavy chains together )Function: Allows two Fab arms move independently, like hinges door. flexibility important allowing antibody bind effectively antigens might spaced different distances cell surface pathogenNote: IgM IgE lack hinge region extra constant domain (CH4) instead, may provide structural spacing","code":""},{"path":"structure.html","id":"carbohydrates-glycosylation","chapter":"Structure","heading":"Carbohydrates (Glycosylation)","text":"Immunoglobulins glycoproteins, meaning carbohydrate chains attached, typically constant regions (especially CH2). carbohydrates important :Proper folding assembly antibodySolubilityStability protection degradationModulating Fc-mediated effector functions (influencing binding Fc receptors complement)","code":""},{"path":"structure.html","id":"overall-structures-relating-to-classes","chapter":"Structure","heading":"Overall Structures (Relating to Classes)","text":"basic Y-shape monomer unit, classes exist polymers:Monomer: IgG, IgD, IgE (membrane-bound IgM/IgA) - basic 4-chain (2H+2L) structureDimer: Secretory IgA - Two monomer units linked J-chain associated Secretory ComponentPentamer: IgM (secreted form) - Five monomer units linked disulfide bonds central J-chain. structure gives IgM 10 potential antigen-binding sites (though usually 5 readily available due steric hindrance) makes exceptionally good agglutination complement activation","code":""},{"path":"structure.html","id":"blood-bank-relevance-summary","chapter":"Structure","heading":"Blood Bank Relevance Summary","text":"Antigen Binding (Fab): specificity V regions dictates blood group antigen (e.g., D, K, Fya) antibody bindAgglutination: structure (monomer vs. pentamer) influences agglutination ability. Pentameric IgM much better agglutinator (visible clumping) monomeric IgGComplement Activation (Fc): structure Fc region (specifically CH2/CH3) determines well antibody activates complement (IgM > IgG3 > IgG1). relates directly potential intravascular hemolysisPlacental Transfer (Fc): IgG Fc structure allows bind FcRn receptors cross placenta, leading HDFN antibody targets fetal antigensDetection Methods (Overall Structure): Small monomeric IgG often requires enhancement techniques (like Antiglobulin test using anti-IgG) detected, whereas large IgM can often cause direct agglutinationExtravascular Hemolysis (Fc): Fc region IgG binds Fc receptors macrophages spleen liver, leading removal antibody-coated red cells","code":""},{"path":"structure.html","id":"key-terms-52","chapter":"Structure","heading":"Key Terms","text":"Heavy Chain (H Chain): larger polypeptide chain antibody (~50-77 kDa); constant region determines antibody’s class (isotype: γ, μ, α, δ, ε)Light Chain (L Chain): smaller polypeptide chain antibody (~25 kDa); exists either kappa (κ) lambda (λ) isotypeDisulfide Bonds: Covalent bonds (-S-S-) linking cysteine amino acids; crucial holding H L chains together (inter-chain) maintaining folded structure domains (intra-chain)Variable Region (V Region): N-terminal portion H L chains (VH VL domains) characterized high amino acid sequence variability; forms antigen-binding siteConstant Region (C Region): C-terminal portion H L chains (CL, CH1, CH2, CH3, CH4 domains) relatively stable amino acid sequences within class; mediates effector functionsDomain: distinct, compact globular structural unit within polypeptide chain, formed intra-chain disulfide bonds (e.g., VL, CL, VH, CH1, CH2, CH3)Fab Fragment (Fragment, antigen-binding): One arm antibody “Y” (composed VL, CL, VH, CH1), containing one antigen-binding siteFc Fragment (Fragment, crystallizable): stem antibody “Y” (composed CH2 CH3 domains, +/- CH4), responsible effector functions like complement activation binding cellular Fc receptorsHinge Region: flexible segment CH1 CH2 domains IgG, IgA, IgD, allowing movement Fab armsJ-Chain: polypeptide links monomers together polymeric immunoglobulins (IgM pentamer, IgA dimer)Antigen-Binding Site: specific pocket surface within Variable regions (formed VH VL) physically interacts binds antigen epitope. basic antibody monomer two identical sites","code":""},{"path":"properties.html","id":"properties","chapter":"Properties","heading":"Properties","text":"Understanding biologic physical properties immunoglobulins key explain different antibody classes behave way body test tubes. ’s link structure function, directly impacts things like hemolysis, placental transfer, detect labThink like : knowing tool’s size, shape, material (physical properties) helps understand jobs ’s good (biologic properties). idea antibodies!’s breakdown class, focusing properties relevant us:","code":""},{"path":"properties.html","id":"immunoglobulin-g-igg-1","chapter":"Properties","heading":"Immunoglobulin G (IgG)","text":"Physical Properties\nStructure: Monomer (basic Y-shape)\nSize/MW: Relatively small (~150 kDa)\nSedimentation Coefficient: 7S (measure related size shape)\nStability: Generally stable; can withstand temperature variations\nStructure: Monomer (basic Y-shape)Size/MW: Relatively small (~150 kDa)Sedimentation Coefficient: 7S (measure related size shape)Stability: Generally stable; can withstand temperature variationsBiologic Properties\nConcentration: Highest concentration serum\nLocation: Found blood, lymph, tissue fluids (can easily move due size)\nAntigen Binding: Binds antigen via Fab regions. Usually high affinity, especially secondary responses\nAgglutination: Generally poor agglutinator (“incomplete antibody”). monomeric structure means two binding sites often can’t bridge distance red cells suspended saline (due cells’ negative surface charge creating repulsion - zeta potential). Requires enhancement techniques (LISS, PEG) antiglobulin reagent (anti-IgG) detection vitro\nComplement Activation: Can activate classical complement pathway, usually requires two IgG molecules bind close together cell surface. Subclasses differ: IgG3 > IgG1 >> IgG2 (IgG4 activate classical pathway). can lead extravascular sometimes intravascular hemolysis\nOpsonization: Fc region binds effectively Fc receptors (FcγR) phagocytes (macrophages, neutrophils). coating (opsonization) flags antibody-coated cells (like red cells) destruction, primarily spleen liver (extravascular hemolysis)\nPlacental Transfer: Actively transported across placenta via Fc receptors (FcRn) placental cells. unique IgG! Provides passive immunity fetus/newborn also mechanism HDFN. Subclasses vary slightly (IgG1/IgG3 cross best)\nHalf-life: Longest half-life (~23 days), providing sustained protection\nConcentration: Highest concentration serumLocation: Found blood, lymph, tissue fluids (can easily move due size)Antigen Binding: Binds antigen via Fab regions. Usually high affinity, especially secondary responsesAgglutination: Generally poor agglutinator (“incomplete antibody”). monomeric structure means two binding sites often can’t bridge distance red cells suspended saline (due cells’ negative surface charge creating repulsion - zeta potential). Requires enhancement techniques (LISS, PEG) antiglobulin reagent (anti-IgG) detection vitroComplement Activation: Can activate classical complement pathway, usually requires two IgG molecules bind close together cell surface. Subclasses differ: IgG3 > IgG1 >> IgG2 (IgG4 activate classical pathway). can lead extravascular sometimes intravascular hemolysisOpsonization: Fc region binds effectively Fc receptors (FcγR) phagocytes (macrophages, neutrophils). coating (opsonization) flags antibody-coated cells (like red cells) destruction, primarily spleen liver (extravascular hemolysis)Placental Transfer: Actively transported across placenta via Fc receptors (FcRn) placental cells. unique IgG! Provides passive immunity fetus/newborn also mechanism HDFN. Subclasses vary slightly (IgG1/IgG3 cross best)Half-life: Longest half-life (~23 days), providing sustained protection","code":""},{"path":"properties.html","id":"immunoglobulin-m-igm-1","chapter":"Properties","heading":"Immunoglobulin M (IgM)","text":"Physical Properties\nStructure: Large Pentamer (five Y-units joined J-chain)\nSize/MW: large (~900 kDa)\nSedimentation Coefficient: 19S\nStability: Disulfide bonds holding pentamer together can broken reducing agents (like DTT 2-), can useful lab differentiate IgM IgG activity\nStructure: Large Pentamer (five Y-units joined J-chain)Size/MW: large (~900 kDa)Sedimentation Coefficient: 19SStability: Disulfide bonds holding pentamer together can broken reducing agents (like DTT 2-), can useful lab differentiate IgM IgG activityBiologic Properties\nConcentration: Lower IgG serum\nLocation: Mostly confined intravascular space (bloodstream) due large size\nAntigen Binding: Pentameric structure gives 10 potential antigen-binding sites (high valency). Even individual site affinity low (common primary response), overall binding strength (avidity) can high due multiple attachments\nAgglutination: Excellent agglutinator (“complete antibody”). large size multiple binding sites can easily bridge distance red cells, causing visible clumping even saline, often room temperature colder\nComplement Activation: efficient activator classical complement pathway. pentameric structure allows Fc regions readily bind C1q, initiating cascade. can lead potent intravascular hemolysis\nOpsonization: Generally less effective direct opsonization via Fc receptors compared IgG, potent complement activation leads C3b coating, strongly opsonic (via complement receptors phagocytes)\nPlacental Transfer: cross placenta (large). Therefore, maternal IgM antibodies cause HDFN\nHalf-life: Shortest half-life (~5 days)\nConcentration: Lower IgG serumLocation: Mostly confined intravascular space (bloodstream) due large sizeAntigen Binding: Pentameric structure gives 10 potential antigen-binding sites (high valency). Even individual site affinity low (common primary response), overall binding strength (avidity) can high due multiple attachmentsAgglutination: Excellent agglutinator (“complete antibody”). large size multiple binding sites can easily bridge distance red cells, causing visible clumping even saline, often room temperature colderComplement Activation: efficient activator classical complement pathway. pentameric structure allows Fc regions readily bind C1q, initiating cascade. can lead potent intravascular hemolysisOpsonization: Generally less effective direct opsonization via Fc receptors compared IgG, potent complement activation leads C3b coating, strongly opsonic (via complement receptors phagocytes)Placental Transfer: cross placenta (large). Therefore, maternal IgM antibodies cause HDFNHalf-life: Shortest half-life (~5 days)","code":""},{"path":"properties.html","id":"immunoglobulin-a-iga-1","chapter":"Properties","heading":"Immunoglobulin A (IgA)","text":"Physical Properties\nStructure: Monomer serum; Dimer (J-chain Secretory Component) secretions\nSize/MW: Monomer ~160 kDa (7S); Dimer ~385 kDa (11S)\nStructure: Monomer serum; Dimer (J-chain Secretory Component) secretionsSize/MW: Monomer ~160 kDa (7S); Dimer ~385 kDa (11S)Biologic Properties\nLocation: Predominant Ig mucosal secretions (tears, saliva, gut, respiratory tract, milk). Also present serum\nTransport: Dimeric IgA actively transported across epithelial cells secretions, facilitated Secretory Component (also protects digestion)\nFunction: Mucosal immunity - prevents pathogen attachment (immune exclusion). Neutralizes toxins locally\nComplement Activation: activate classical pathway; may activate alternative pathway weakly\nPlacental Transfer: cross placenta\nBlood Bank Relevance: Primarily related IgA deficiency. IgA-deficient patients can make anti-IgA (usually IgG class) can cause severe anaphylactic transfusion reactions upon exposure IgA blood products\nLocation: Predominant Ig mucosal secretions (tears, saliva, gut, respiratory tract, milk). Also present serumTransport: Dimeric IgA actively transported across epithelial cells secretions, facilitated Secretory Component (also protects digestion)Function: Mucosal immunity - prevents pathogen attachment (immune exclusion). Neutralizes toxins locallyComplement Activation: activate classical pathway; may activate alternative pathway weaklyPlacental Transfer: cross placentaBlood Bank Relevance: Primarily related IgA deficiency. IgA-deficient patients can make anti-IgA (usually IgG class) can cause severe anaphylactic transfusion reactions upon exposure IgA blood products","code":""},{"path":"properties.html","id":"immunoglobulin-e-ige-1","chapter":"Properties","heading":"Immunoglobulin E (IgE)","text":"Physical Properties\nStructure: Monomer\nSize/MW: Slightly larger IgG (~190 kDa, 8S)\nStability: heat-labile Ig\nStructure: MonomerSize/MW: Slightly larger IgG (~190 kDa, 8S)Stability: heat-labile IgBiologic Properties\nConcentration: Lowest concentration serum\nLocation: IgE tightly bound Fc receptors (FcεRI) mast cells basophils tissues\nFunction: Triggers allergic reactions. antigen (allergen) cross-links IgE mast cells, causes degranulation release histamine inflammatory mediators. Also involved defense parasites\nComplement Activation: activate complement\nPlacental Transfer: cross placenta\nBlood Bank Relevance: Responsible allergic transfusion reactions (urticaria/hives); severe anaphylaxis possible less common anti-IgA\nConcentration: Lowest concentration serumLocation: IgE tightly bound Fc receptors (FcεRI) mast cells basophils tissuesFunction: Triggers allergic reactions. antigen (allergen) cross-links IgE mast cells, causes degranulation release histamine inflammatory mediators. Also involved defense parasitesComplement Activation: activate complementPlacental Transfer: cross placentaBlood Bank Relevance: Responsible allergic transfusion reactions (urticaria/hives); severe anaphylaxis possible less common anti-IgA","code":""},{"path":"properties.html","id":"immunoglobulin-d-igd-1","chapter":"Properties","heading":"Immunoglobulin D (IgD)","text":"Physical Properties\nStructure: Monomer\nSize/MW: ~185 kDa, 7S\nStructure: MonomerSize/MW: ~185 kDa, 7SBiologic Properties\nConcentration: low serum\nLocation: Primarily found surface naive B lymphocytes (along IgM) B cell receptor (BCR)\nFunction: Involved signaling B cell activation differentiation. Serum function unclear\nComplement Activation: activate complement\nPlacental Transfer: cross placenta\nBlood Bank Relevance: known direct role transfusion reactions testing\nConcentration: low serumLocation: Primarily found surface naive B lymphocytes (along IgM) B cell receptor (BCR)Function: Involved signaling B cell activation differentiation. Serum function unclearComplement Activation: activate complementPlacental Transfer: cross placentaBlood Bank Relevance: known direct role transfusion reactions testing","code":""},{"path":"properties.html","id":"summary-of-key-properties-blood-bank-implications","chapter":"Properties","heading":"Summary of Key Properties & Blood Bank Implications","text":"","code":""},{"path":"properties.html","id":"key-terms-53","chapter":"Properties","heading":"Key Terms","text":"Physical Properties: Characteristics related molecule’s size, shape, charge, stability (e.g., molecular weight, sedimentation coefficient, structure - monomer/pentamer)Biologic Properties: Characteristics related molecule’s function biological system (e.g., complement activation, placental transfer, opsonization, agglutination, half-life)Monomer: single basic structural unit immunoglobulin (one Y-shape, composed 2 heavy 2 light chains). IgG, IgD, IgE primarily monomersPentamer: structure composed five immunoglobulin monomers linked together, characteristic secreted IgMAgglutination: clumping particles (like red blood cells) due antibody cross-linkingComplement Activation: triggering complement cascade, often initiated IgM IgG binding antigen, leading inflammation, opsonization, cell lysisOpsonization: coating particle (e.g., red blood cell) antibodies (like IgG) complement fragments (like C3b) enhances phagocytosis cells bearing Fc complement receptorsPlacental Transfer: active transport IgG across placenta mother fetusHalf-life: time required concentration substance (like immunoglobulin) body decrease halfValency: number antigen-binding sites antibody molecule (e.g., 2 monomeric IgG, theoretically 10 pentameric IgM)Avidity: overall strength binding multivalent antibody multivalent antigen, reflecting combined strength individual binding sitesAffinity: strength binding single antigen-binding site antibody single epitope antigenSedimentation Coefficient (Svedberg unit, S): measure quickly molecule sediments centrifuge, related mass shape. Larger molecules generally higher S values (e.g., IgM 19S vs. IgG 7S)","code":""},{"path":"ag-ab-interactions.html","id":"ag-ab-interactions","chapter":"Ag-Ab Interactions","heading":"Ag-Ab Interactions","text":"immunohematology testing, leverage specific, yet reversible, binding properties antibodies antigens. many clinically significant interactions (especially IgG) don’t cause direct agglutination, rely heavily Antiglobulin Test (newer sensitive methods like Solid Phase/Gel) detect crucial sensitization step, ensuring safe transfusions","code":""},{"path":"ag-ab-interactions.html","id":"the-fundamental-principle-specificity-the-lock-key","chapter":"Ag-Ab Interactions","heading":"The Fundamental Principle: Specificity (The “Lock & Key”)","text":"Antibodies designed recognize bind one specific epitope (small part antigen) using unique antigen-binding site (paratope) located Fab armsThis binding relies precise 3D shape chemical matchWhy matters: specificity allows us use known antibodies (reagents) identify antigens cells (like blood typing) use known antigens (reagent cells) detect antibodies plasma (antibody screening/ID)","code":""},{"path":"ag-ab-interactions.html","id":"the-nature-of-the-bond-weak-forces-reversibility","chapter":"Ag-Ab Interactions","heading":"The Nature of the Bond: Weak Forces & Reversibility","text":"Binding isn’t permanent; ’s based multiple weak non-covalent forces (hydrogen, ionic, van der Waals, hydrophobic)forces require close proximity antibody antigenThe interaction reversible (Ag + Ab <=> AgAb), following Law Mass Action – concentrations Ag Ab drive reactionWhy matters: Factors influencing proximity (like ionic strength cell repulsion/zeta potential) affect binding, especially IgG. Reversibility necessitates careful washing steps tests","code":""},{"path":"ag-ab-interactions.html","id":"binding-strength-affinity-vs.-avidity","chapter":"Ag-Ab Interactions","heading":"Binding Strength: Affinity vs. Avidity","text":"Affinity: Strength single binding site single epitopeAvidity: Overall strength binding multiple sites involved (like pentameric IgM binding multiple antigens cell). High avidity can compensate lower affinityWhy matters: High avidity (IgM) often leads direct agglutination. IgG relies affinity often needs help (AHG) detected","code":""},{"path":"ag-ab-interactions.html","id":"making-it-visible-testing-principles-methods","chapter":"Ag-Ab Interactions","heading":"Making it Visible: Testing Principles & Methods","text":"Since binding invisible, need methods detect , usually looking agglutination (clumping) hemolysis (cell lysis)Two Stages\nSensitization Antibody binds antigen red cell (invisible). Influenced temp, time, pH, ionic strength\nLattice Formation Antibody cross-links multiple cells -> visible agglutination. Influenced antibody class (IgM >> IgG), cell distance, centrifugation\nSensitization Antibody binds antigen red cell (invisible). Influenced temp, time, pH, ionic strengthLattice Formation Antibody cross-links multiple cells -> visible agglutination. Influenced antibody class (IgM >> IgG), cell distance, centrifugation","code":""},{"path":"ag-ab-interactions.html","id":"key-testing-methods","chapter":"Ag-Ab Interactions","heading":"Key Testing Methods","text":"Direct Agglutination (e.g., Tube - Immediate Spin/RT): Relies antibodies (mainly IgM) large enough bridge gap cells saline. Used : ABO typing, detecting strong cold IgM antibodiesAntiglobulin Test (Coombs Test): Detects “invisible” sensitization (usually IgG Complement) using Anti-Human Globulin (AHG) reagent bridge\nDirect Antiglobulin Test (DAT): Detects patient RBCs coated vivo (body). Used : HDFN, AIHA, HTR investigations\nIndirect Antiglobulin Test (IAT): Detects antibodies patient plasma capable coating reagent RBCs vitro (lab). Used : Antibody screening/ID, crossmatching, weak D testing. Requires incubation (often enhancement media like LISS PEG) thorough washing adding AHG. Check cells validate negative results\nDirect Antiglobulin Test (DAT): Detects patient RBCs coated vivo (body). Used : HDFN, AIHA, HTR investigationsIndirect Antiglobulin Test (IAT): Detects antibodies patient plasma capable coating reagent RBCs vitro (lab). Used : Antibody screening/ID, crossmatching, weak D testing. Requires incubation (often enhancement media like LISS PEG) thorough washing adding AHG. Check cells validate negative resultsSolid Phase Red Cell Adherence (SPRCA): Immobilizes antigen antibody microplate wells; positive reaction = adherence indicator cells. Standardized, sensitiveGel Technology (Column Agglutination): Uses microtubes gel; agglutinated cells get trapped centrifugation. Standardized, clear endpoints, widely used","code":""},{"path":"principles.html","id":"principles","chapter":"Principles","heading":"Principles","text":"Understanding fundamental principles govern antibodies find bind specific antigens bedrock virtually everything blood bank lab, typing patient’s blood detecting clinically significant antibodies!Think antigen-antibody binding highly specific molecular “handshake.” ’s permanent bond like superglue, rather precise interaction based shape chemistryHere key principles:","code":""},{"path":"principles.html","id":"specificity-the-lock-and-key-concept","chapter":"Principles","heading":"Specificity: The “Lock and Key” Concept","text":"Core Idea: Antibodies incredibly specific. antibody produced response one antigen (like D antigen) typically bind antigen, sometimes another antigen structurally extremely similar (cross-reactivity, discussed later)Molecular Basis\nantigen-binding site antibody (located Variable regions Fab arms, also called paratope) unique three-dimensional shape chemical profile\nsite precisely fits specific region antigen molecule called epitope (antigenic determinant)\nfit needs complementary shape chemical properties (charge, hydrophobicity)\nantigen-binding site antibody (located Variable regions Fab arms, also called paratope) unique three-dimensional shape chemical profileThis site precisely fits specific region antigen molecule called epitope (antigenic determinant)fit needs complementary shape chemical properties (charge, hydrophobicity)Blood Bank Relevance: Specificity crucial accurate blood typing, antibody identification, compatibility testing. rely specific binding reagent antibodies (like Anti-, Anti-B, Anti-D) antigens patient/donor cells, specific binding patient antibodies antigens reagent cells","code":""},{"path":"principles.html","id":"binding-forces-non-covalent-interactions","chapter":"Principles","heading":"Binding Forces: Non-Covalent Interactions","text":"Nature Bond: binding antigen antibody permanent covalent bond. Instead, ’s sum multiple, relatively weak, non-covalent forces. forces work effectively antibody antigen close together (.e., fit good)Types Forces\nHydrogen Bonds: Sharing hydrogen atoms electronegative atoms (like O N)\nIonic Bonds (Electrostatic): Attraction oppositely charged groups (e.g., amino group NH3+ carboxyl group COO-)\nVan der Waals Forces: Weak attractions electron clouds adjacent atoms due fluctuating dipoles. distance-dependent\nHydrophobic Interactions: Water molecules tend exclude non-polar (hydrophobic) groups, forcing together. major driving force protein interactions aqueous environment like plasma\nHydrogen Bonds: Sharing hydrogen atoms electronegative atoms (like O N)Ionic Bonds (Electrostatic): Attraction oppositely charged groups (e.g., amino group NH3+ carboxyl group COO-)Van der Waals Forces: Weak attractions electron clouds adjacent atoms due fluctuating dipoles. distance-dependentHydrophobic Interactions: Water molecules tend exclude non-polar (hydrophobic) groups, forcing together. major driving force protein interactions aqueous environment like plasmaBlood Bank Relevance: bonds non-covalent require close proximity, factors affect proximity (like ionic strength, see ) significantly impact interaction, especially IgG antibodies trying bind red cells naturally repel (zeta potential)","code":""},{"path":"principles.html","id":"affinity-vs.-avidity-strength-of-binding","chapter":"Principles","heading":"Affinity vs. Avidity: Strength of Binding","text":"Affinity: Refers strength binding single antigen-binding site (Fab arm) single epitope antigen. ’s measure well “lock key” fit. Higher affinity means stronger, stable interaction single siteAvidity: Refers overall strength binding multivalent antibody (multiple binding sites) multivalent antigen (multiple epitopes). ’s combined effect binding sites working together\nExample: Pentameric IgM 10 potential binding sites. Even affinity site relatively low, avidity can high multiple sites bind simultaneously. ’s harder break connections . Monomeric IgG two sites, avidity closely related affinity\nExample: Pentameric IgM 10 potential binding sites. Even affinity site relatively low, avidity can high multiple sites bind simultaneously. ’s harder break connections . Monomeric IgG two sites, avidity closely related affinityBlood Bank Relevance: High avidity interactions (like IgM binding) often lead strong agglutination. IgG antibodies typically need higher affinity mediate strong reactions, techniques like antiglobulin test detect bound IgG regardless whether agglutination occurred initially. Avidity often important functional outcome (like cell clearance agglutination) affinity alone","code":""},{"path":"principles.html","id":"reversibility-and-the-law-of-mass-action-an-equilibrium","chapter":"Principles","heading":"Reversibility and the Law of Mass Action: An Equilibrium","text":"Reversibility: binding forces non-covalent, antigen-antibody interaction reversible. complex can dissociate back free antigen free antibody\nAg + Ab <=> AgAb complex\nAg + Ab <=> AgAb complexLaw Mass Action: rate formation AgAb complex proportional concentration free antigen ([Ag]) free antibody ([Ab]). rate dissociation proportional concentration complex ([AgAb])\nequilibrium, rate formation equals rate dissociation\nK_a = [AgAb] / ([Ag] * [Ab]) (Ka equilibrium constant affinity constant)\nequilibrium, rate formation equals rate dissociationK_a = [AgAb] / ([Ag] * [Ab]) (Ka equilibrium constant affinity constant)Blood Bank Relevance\nIncreasing concentration either antibody antigen drive reaction towards forming complex (point - see Prozone/Postzone). optimize reagent concentrations cell suspensions testing\nreversibility means washing steps procedures like Antiglobulin Test critical – need wash away unbound antibody without causing bound antibody dissociate significantly. Weakly bound (low affinity/avidity) antibodies might partially fully removed washing\nIncreasing concentration either antibody antigen drive reaction towards forming complex (point - see Prozone/Postzone). optimize reagent concentrations cell suspensions testingThe reversibility means washing steps procedures like Antiglobulin Test critical – need wash away unbound antibody without causing bound antibody dissociate significantly. Weakly bound (low affinity/avidity) antibodies might partially fully removed washing","code":""},{"path":"principles.html","id":"influence-of-environmental-factors","chapter":"Principles","heading":"Influence of Environmental Factors","text":"optimal conditions Ag-Ab binding depend specific antibody antigen involved. Key factors include:Temperature\nIgG: react optimally 37°C (body temperature). “warm-reactive” antibodies, often clinically significant\nIgM: Many (!) react optimally colder temperatures (4°C room temp ~22°C). “cold-reactive” antibodies. ABO antibodies exception, reacting well broad range including 37°C\nLab Relevance: Testing performed different temperatures (Immediate Spin/RT, 37°C incubation) detect different types antibodies\nIgG: react optimally 37°C (body temperature). “warm-reactive” antibodies, often clinically significantIgM: Many (!) react optimally colder temperatures (4°C room temp ~22°C). “cold-reactive” antibodies. ABO antibodies exception, reacting well broad range including 37°CLab Relevance: Testing performed different temperatures (Immediate Spin/RT, 37°C incubation) detect different types antibodiespH: Optimal binding usually occurs around physiological pH (6.5-7.5). Extremes pH can denature antibody antigen, destroying binding sites. Lab reagents buffered maintain optimal pHIonic Strength: concentration salt ions medium affects antibody uptake, especially IgG\nstandard saline (0.9% NaCl), positive Na+ ions cluster around negatively charged sialic acid red cells, partially neutralizing charge also creating ionic cloud shields charges needed IgG binding keeps cells apart (zeta potential)\nLow Ionic Strength Saline (LISS): Reduces ionic strength, decreasing shielding effect, allowing IgG antibodies bind readily quickly (“enhancing” reaction)\nLab Relevance: LISS common enhancement medium used antibody screening identification promote IgG binding 37°C incubation\nstandard saline (0.9% NaCl), positive Na+ ions cluster around negatively charged sialic acid red cells, partially neutralizing charge also creating ionic cloud shields charges needed IgG binding keeps cells apart (zeta potential)Low Ionic Strength Saline (LISS): Reduces ionic strength, decreasing shielding effect, allowing IgG antibodies bind readily quickly (“enhancing” reaction)Lab Relevance: LISS common enhancement medium used antibody screening identification promote IgG binding 37°C incubation","code":""},{"path":"principles.html","id":"antigen-factors","chapter":"Principles","heading":"Antigen Factors","text":"Antigen Density: number antigen sites cell surface. Higher density generally leads stronger reactions (antibody can bind, increasing avidity)Antigen Location/Accessibility: antigens may located deeper within cell membrane masked structures, making less accessible antibodies","code":""},{"path":"principles.html","id":"antibody-factors","chapter":"Principles","heading":"Antibody Factors","text":"Antibody Class/Structure: discussed (Avidity), pentameric IgM much better agglutination monomeric IgGAntibody Concentration: little antibody results weak reaction. much antibody can sometimes lead prozone effect (see )","code":""},{"path":"principles.html","id":"cross-reactivity","chapter":"Principles","heading":"Cross-Reactivity","text":"Sometimes, antibody can bind antigen different one stimulated production, epitopes two antigens structurally similarBlood Bank Relevance: Can occasionally lead unexpected confusing results antibody identification. example, antibodies might react closely related antigens within blood group system","code":""},{"path":"principles.html","id":"prozone-and-postzone-phenomena","chapter":"Principles","heading":"Prozone and Postzone Phenomena","text":"relate relative concentrations antigen antibody effect lattice formation (agglutination)Zone Equivalence: Optimal ratio Ag Ab, leading maximum lattice formation visible agglutinationProzone: Antibody excess. Many antibody sites bound single antigen sites, isn’t enough antigen form extensive cross-links cells/particles. Can cause false-negative weaker--expected agglutinationPostzone: Antigen excess. antibody binding sites saturated separate antigens, leaving free sites cross-link cells/particles. Can also cause false-negative resultsBlood Bank Relevance: Important use appropriate concentrations reagent antibodies cell suspensions. Prozone can sometimes issue high-titer antibodies; dilution may needed","code":""},{"path":"principles.html","id":"key-terms-54","chapter":"Principles","heading":"Key Terms","text":"Antigen (Ag): substance (often protein carbohydrate cell) recognized immune system (specifically antibodies T cell receptors)Antibody (Ab): protein (immunoglobulin) produced plasma cells binds specifically antigenEpitope (Antigenic Determinant): specific part antigen molecule recognized bound antibody’s binding siteParatope: antigen-binding site antibody molecule, located variable regions Fab fragmentSpecificity: ability antibody’s binding site react one specific epitope group structurally similar epitopesNon-covalent Bonds: Weak chemical interactions (hydrogen, ionic, van der Waals, hydrophobic) mediate antigen-antibody binding. require close proximity significant effectAffinity: strength binding single antibody binding site (paratope) single antigenic determinant (epitope)Avidity: overall strength attachment multivalent antibody multivalent antigen, resulting sum multiple individual binding interactionsLaw Mass Action: principle rate chemical reaction proportional concentrations reacting substances, driving reversible antigen-antibody binding towards equilibriumReversibility: capacity antigen-antibody complex dissociate back free antigen free antibodyIonic Strength: measure concentration ions solution; lower ionic strength (like LISS) enhances uptake IgG antibodies onto red cellsZeta Potential: electrostatic potential difference surface red blood cell surrounding fluid, contributing repulsion cells salineCross-Reactivity: binding antibody antigen one induced formation, due structural similarity epitopesProzone: phenomenon agglutination tests antibody excess leads reduced absent lattice formation potential false-negative resultPostzone: phenomenon agglutination tests antigen excess leads reduced absent lattice formation potential false-negative result","code":""},{"path":"testing-1.html","id":"testing-1","chapter":"Testing","heading":"Testing","text":"fantastic toolkit detecting antigen-antibody interactions! simple direct agglutination (great IgM like ABO) essential Antiglobulin Test (detecting IgG/Complement DAT IAT), newer technologies like Solid Phase Gel offer standardization sensitivity. Choosing right test depends ’re looking – antigen antibody, IgM IgG, vivo vitro sensitization! Understanding principle behind test crucial performing correctly interpreting results accuratelyLet’s see actually detect antigen-antibody interactions. Think like : know antibodies super specific (“lock key” idea), time, just antibody bind red cell antigen doesn’t produce obvious signal. need clever methods visualize binding event","code":""},{"path":"testing-1.html","id":"overarching-principles-of-testing","chapter":"Testing","heading":"Overarching Principles of Testing","text":"Specificity Key: tests rely highly specific nature antigen-antibody binding. use known antibodies (reagents) detect unknown antigens cells, known antigens (reagent cells) detect unknown antibodies patient plasma/serumNeed Visible Endpoint: Since can’t see individual antibodies binding, need way make reaction visible. common endpoint blood banking agglutination (clumping red cells), hemolysis (red cell destruction) also crucial positive indicator. Newer methods use adherence patternsTwo Stages Agglutination: Visualizing agglutination usually involves two steps:\nStage 1: Sensitization: antibody plasma/serum binds corresponding antigen red blood cell surface. invisible step! Factors influencing include temperature, incubation time, pH, ionic strength\nStage 2: Lattice Formation: Antibody molecules cross-link multiple red blood cells together, forming visible clumps (agglutinates). depends factors like distance cells (zeta potential), antibody class (IgM much better IgG), centrifugation bring cells closer\nStage 1: Sensitization: antibody plasma/serum binds corresponding antigen red blood cell surface. invisible step! Factors influencing include temperature, incubation time, pH, ionic strengthStage 2: Lattice Formation: Antibody molecules cross-link multiple red blood cells together, forming visible clumps (agglutinates). depends factors like distance cells (zeta potential), antibody class (IgM much better IgG), centrifugation bring cells closer","code":""},{"path":"testing-1.html","id":"common-testing-methods-and-their-principles","chapter":"Testing","heading":"Common Testing Methods and Their Principles","text":"Let’s look main techniques use:","code":""},{"path":"testing-1.html","id":"hemagglutination-methods-direct-agglutination","chapter":"Testing","heading":"Hemagglutination Methods (Direct Agglutination)","text":"Principle: Directly visualizing clumping red blood cells caused antibodies cross-linking antigens adjacent cells. works best antibodies large enough present high enough concentration bridge gap red cells suspended salineMethod (Classic Tube Testing)\nCombine known (reagent) unknown (patient/donor) red cells known (reagent) unknown (patient) serum/plasma test tube\nCentrifuge briefly encourage lattice formation (Immediate Spin phase)\nGently resuspend cell button observe clumping (agglutination)\nIncubation different temperatures (Room Temp, 37°C) can added centrifugation, depending antibody suspected\nCombine known (reagent) unknown (patient/donor) red cells known (reagent) unknown (patient) serum/plasma test tubeCentrifuge briefly encourage lattice formation (Immediate Spin phase)Gently resuspend cell button observe clumping (agglutination)Incubation different temperatures (Room Temp, 37°C) can added centrifugation, depending antibody suspectedInterpretation\nPositive: Visible clumping red cells (graded 1+ 4+). Hemolysis also considered positive result (indicates complement activation leading cell lysis)\nNegative: Smooth, homogenous suspension red cells resuspension\nPositive: Visible clumping red cells (graded 1+ 4+). Hemolysis also considered positive result (indicates complement activation leading cell lysis)Negative: Smooth, homogenous suspension red cells resuspensionWhen Used?\nABO Typing (Forward & Reverse): Uses potent IgM anti-anti-B reagents (forward) patient plasma known A1 B cells (reverse). Usually detected Immediate Spin\nDetecting potent cold-reacting IgM antibodies: Often react Immediate Spin Room Temperature phases\nImmediate Spin Crossmatch: rapid check ABO incompatibility\nABO Typing (Forward & Reverse): Uses potent IgM anti-anti-B reagents (forward) patient plasma known A1 B cells (reverse). Usually detected Immediate SpinDetecting potent cold-reacting IgM antibodies: Often react Immediate Spin Room Temperature phasesImmediate Spin Crossmatch: rapid check ABO incompatibilityKey Antibody Class: Primarily detects IgM antibodies, large pentamers excellent agglutinators. high-titer IgG might cause weak direct agglutination","code":""},{"path":"testing-1.html","id":"antiglobulin-testing-the-coombs-test---detecting-invisible-binding","chapter":"Testing","heading":"Antiglobulin Testing (The Coombs Test) - Detecting “Invisible” Binding","text":"Principle: CRITICAL! Many clinically significant antibodies (especially IgG) bind red cells (sensitization) small cause direct agglutination saline. Antiglobulin Test uses special reagent – Anti-Human Globulin (AHG) – contains antibodies human antibodies (anti-IgG) /complement components (anti-C3d). IgG C3d bound red cells, AHG reagent bind act “bridge” cross-link sensitized cells, causing visible agglutinationPrinciple: CRITICAL! Many clinically significant antibodies (especially IgG) bind red cells (sensitization) small cause direct agglutination saline. Antiglobulin Test uses special reagent – Anti-Human Globulin (AHG) – contains antibodies human antibodies (anti-IgG) /complement components (anti-C3d). IgG C3d bound red cells, AHG reagent bind act “bridge” cross-link sensitized cells, causing visible agglutinationThere TWO main types Antiglobulin Tests\nDirect Antiglobulin Test (DAT)\nPrinciple: Detects vivo sensitization – meaning, checks patient’s red blood cells circulating body already coated IgG antibodies /complement\nMethod\nTake sample patient’s red blood cells\nWash cells thoroughly (least 3 times) saline. VITAL remove unbound plasma proteins neutralize AHG reagent\nAdd AHG reagent (polyspecific monospecific)\nCentrifuge briefly\nResuspend examine agglutination\n\nInterpretation\nPositive: Agglutination occurs. means patient’s red cells coated IgG /C3d body\nNegative: agglutination\n\nApplications: Investigating suspected Hemolytic Disease Fetus Newborn (HDFN), Autoimmune Hemolytic Anemia (AIHA), Hemolytic Transfusion Reactions (HTR)\n\nIndirect Antiglobulin Test (IAT)\nPrinciple: Detects vitro sensitization – meaning, checks unexpected antibodies present patient’s serum plasma capable binding specific red cell antigens laboratory conditions\nMethod\nCombine patient’s serum/plasma known reagent red blood cells (expressing specific antigens)\nIncubate 37°C (optimal IgG binding). Often use enhancement media (like LISS PEG) incubation speed sensitization\nWash cells thoroughly (least 3 times) remove unbound antibodies serum. , VITAL!\nAdd AHG reagent\nCentrifuge briefly\nResuspend examine agglutination\nAdd Check Cells (Coombs Control Cells) test negative, add IgG-coated check cells. test must become positive (agglutinate). confirms AHG reagent added, active, washing steps adequate. check cells don’t agglutinate, negative result invalid!\n\nInterpretation\nPositive: Agglutination occurs. means patient’s serum/plasma contains antibody reacted antigen reagent red cells\nNegative: agglutination (check cells work)\n\nApplications: Antibody Screening (detecting presence unexpected antibodies), Antibody Identification (determining specificity antibodies), Crossmatching (checking compatibility patient serum donor cells), Weak D testing, Antigen Typing (using known antisera detect antigens patient/donor cells)\n\nTWO main types Antiglobulin TestsDirect Antiglobulin Test (DAT)\nPrinciple: Detects vivo sensitization – meaning, checks patient’s red blood cells circulating body already coated IgG antibodies /complement\nMethod\nTake sample patient’s red blood cells\nWash cells thoroughly (least 3 times) saline. VITAL remove unbound plasma proteins neutralize AHG reagent\nAdd AHG reagent (polyspecific monospecific)\nCentrifuge briefly\nResuspend examine agglutination\n\nInterpretation\nPositive: Agglutination occurs. means patient’s red cells coated IgG /C3d body\nNegative: agglutination\n\nApplications: Investigating suspected Hemolytic Disease Fetus Newborn (HDFN), Autoimmune Hemolytic Anemia (AIHA), Hemolytic Transfusion Reactions (HTR)\nPrinciple: Detects vivo sensitization – meaning, checks patient’s red blood cells circulating body already coated IgG antibodies /complementMethod\nTake sample patient’s red blood cells\nWash cells thoroughly (least 3 times) saline. VITAL remove unbound plasma proteins neutralize AHG reagent\nAdd AHG reagent (polyspecific monospecific)\nCentrifuge briefly\nResuspend examine agglutination\nTake sample patient’s red blood cellsWash cells thoroughly (least 3 times) saline. VITAL remove unbound plasma proteins neutralize AHG reagentAdd AHG reagent (polyspecific monospecific)Centrifuge brieflyResuspend examine agglutinationInterpretation\nPositive: Agglutination occurs. means patient’s red cells coated IgG /C3d body\nNegative: agglutination\nPositive: Agglutination occurs. means patient’s red cells coated IgG /C3d bodyNegative: agglutinationApplications: Investigating suspected Hemolytic Disease Fetus Newborn (HDFN), Autoimmune Hemolytic Anemia (AIHA), Hemolytic Transfusion Reactions (HTR)Indirect Antiglobulin Test (IAT)\nPrinciple: Detects vitro sensitization – meaning, checks unexpected antibodies present patient’s serum plasma capable binding specific red cell antigens laboratory conditions\nMethod\nCombine patient’s serum/plasma known reagent red blood cells (expressing specific antigens)\nIncubate 37°C (optimal IgG binding). Often use enhancement media (like LISS PEG) incubation speed sensitization\nWash cells thoroughly (least 3 times) remove unbound antibodies serum. , VITAL!\nAdd AHG reagent\nCentrifuge briefly\nResuspend examine agglutination\nAdd Check Cells (Coombs Control Cells) test negative, add IgG-coated check cells. test must become positive (agglutinate). confirms AHG reagent added, active, washing steps adequate. check cells don’t agglutinate, negative result invalid!\n\nInterpretation\nPositive: Agglutination occurs. means patient’s serum/plasma contains antibody reacted antigen reagent red cells\nNegative: agglutination (check cells work)\n\nApplications: Antibody Screening (detecting presence unexpected antibodies), Antibody Identification (determining specificity antibodies), Crossmatching (checking compatibility patient serum donor cells), Weak D testing, Antigen Typing (using known antisera detect antigens patient/donor cells)\nPrinciple: Detects vitro sensitization – meaning, checks unexpected antibodies present patient’s serum plasma capable binding specific red cell antigens laboratory conditionsMethod\nCombine patient’s serum/plasma known reagent red blood cells (expressing specific antigens)\nIncubate 37°C (optimal IgG binding). Often use enhancement media (like LISS PEG) incubation speed sensitization\nWash cells thoroughly (least 3 times) remove unbound antibodies serum. , VITAL!\nAdd AHG reagent\nCentrifuge briefly\nResuspend examine agglutination\nAdd Check Cells (Coombs Control Cells) test negative, add IgG-coated check cells. test must become positive (agglutinate). confirms AHG reagent added, active, washing steps adequate. check cells don’t agglutinate, negative result invalid!\nCombine patient’s serum/plasma known reagent red blood cells (expressing specific antigens)Incubate 37°C (optimal IgG binding). Often use enhancement media (like LISS PEG) incubation speed sensitizationWash cells thoroughly (least 3 times) remove unbound antibodies serum. , VITAL!Add AHG reagentCentrifuge brieflyResuspend examine agglutinationAdd Check Cells (Coombs Control Cells) test negative, add IgG-coated check cells. test must become positive (agglutinate). confirms AHG reagent added, active, washing steps adequate. check cells don’t agglutinate, negative result invalid!Interpretation\nPositive: Agglutination occurs. means patient’s serum/plasma contains antibody reacted antigen reagent red cells\nNegative: agglutination (check cells work)\nPositive: Agglutination occurs. means patient’s serum/plasma contains antibody reacted antigen reagent red cellsNegative: agglutination (check cells work)Applications: Antibody Screening (detecting presence unexpected antibodies), Antibody Identification (determining specificity antibodies), Crossmatching (checking compatibility patient serum donor cells), Weak D testing, Antigen Typing (using known antisera detect antigens patient/donor cells)AHG Reagents\nPolyspecific: Contains anti-IgG anti-C3d (sometimes anti-C3b). Used routine screening (DAT & IAT)\nMonospecific: Contains anti-IgG anti-C3d. Used DATs determine coating cells (IgG, complement, )\nAHG ReagentsPolyspecific: Contains anti-IgG anti-C3d (sometimes anti-C3b). Used routine screening (DAT & IAT)Monospecific: Contains anti-IgG anti-C3d. Used DATs determine coating cells (IgG, complement, )","code":""},{"path":"testing-1.html","id":"enhancement-media-in-iat","chapter":"Testing","heading":"Enhancement Media in IAT","text":"Principle: Used IAT incubation step increase rate sensitivity IgG antibody binding red cell antigensMethods\nLow Ionic Strength Saline (LISS): Reduces “ionic cloud” around red cells, allowing antibodies approach antigens easily quickly. Shortens incubation time (usually 10-15 min)\nPolyethylene Glycol (PEG): Removes water molecules, effectively concentrating antibodies near red cells. sensitive detecting weak IgG antibodies. Requires careful technique (reading 37°C incubation washing, PEG can cause non-specific aggregation)\nBovine Serum Albumin (BSA): Older method, thought reduce zeta potential slightly. Less effective LISS PEG\nEnzymes (e.g., Ficin, Papain): Proteolytic enzymes cleave certain proteins RBC surface. can enhance reactivity antibodies (like Rh, Kidd) removing obstructions reducing negative charge, destroys antigens (like Duffy, MNSs). Used specialized antibody ID panels\nLow Ionic Strength Saline (LISS): Reduces “ionic cloud” around red cells, allowing antibodies approach antigens easily quickly. Shortens incubation time (usually 10-15 min)Polyethylene Glycol (PEG): Removes water molecules, effectively concentrating antibodies near red cells. sensitive detecting weak IgG antibodies. Requires careful technique (reading 37°C incubation washing, PEG can cause non-specific aggregation)Bovine Serum Albumin (BSA): Older method, thought reduce zeta potential slightly. Less effective LISS PEGEnzymes (e.g., Ficin, Papain): Proteolytic enzymes cleave certain proteins RBC surface. can enhance reactivity antibodies (like Rh, Kidd) removing obstructions reducing negative charge, destroys antigens (like Duffy, MNSs). Used specialized antibody ID panels","code":""},{"path":"testing-1.html","id":"solid-phase-red-cell-adherence-sprca-assays","chapter":"Testing","heading":"Solid Phase Red Cell Adherence (SPRCA) Assays","text":"Principle: Instead looking agglutination solution, methods immobilize either antigen antibody onto surface microplate wells. Detection relies adherence red cells well surfaceMethod (Antibody Screen Example - Antigen Capture)\nMicroplate wells coated purified red cell antigens membranes\nPatient serum/plasma added incubated (allows antibody binding immobilized antigen)\nWells washed remove unbound antibody\nIndicator Red Cells (reagent cells coated anti-IgG) added\nPlate centrifuged\nMicroplate wells coated purified red cell antigens membranesPatient serum/plasma added incubated (allows antibody binding immobilized antigen)Wells washed remove unbound antibodyIndicator Red Cells (reagent cells coated anti-IgG) addedPlate centrifugedInterpretation\nPositive: Indicator cells bind antibody captured well surface, forming diffuse layer covering well bottom (adherence)\nNegative: antibody captured, indicator cells pellet tight button bottom well centrifugation\nPositive: Indicator cells bind antibody captured well surface, forming diffuse layer covering well bottom (adherence)Negative: antibody captured, indicator cells pellet tight button bottom well centrifugationApplications: Antibody screening, antibody identification, crossmatching. Often used automated platforms. Can also reversed (antibody capture) antigen typing DAT","code":""},{"path":"testing-1.html","id":"gel-technology-column-agglutination","chapter":"Testing","heading":"Gel Technology (Column Agglutination)","text":"Principle: Uses microtubes (“cards”) containing dextran-acrylamide gel matrix. gel acts sieve. Agglutinated red cells get trapped gel centrifugation, unagglutinated cells pass form pellet bottom. AHG reagent can incorporated gel antiglobulin testsMethod (IAT Example)\nMicrotube contains gel + Anti-IgG\nAdd reagent red cells patient serum/plasma reaction chamber gel\nIncubate (necessary, e.g., IAT)\nCentrifuge card. Red cells pass gel\nMicrotube contains gel + Anti-IgGAdd reagent red cells patient serum/plasma reaction chamber gelIncubate (necessary, e.g., IAT)Centrifuge card. Red cells pass gelInterpretation\nPositive: Agglutinated cells trapped gel matrix, forming line top dispersed throughout gel (depending reaction strength). Clear supernatant\nNegative: Unagglutinated cells pass freely gel form distinct pellet bottom microtube\nPositive: Agglutinated cells trapped gel matrix, forming line top dispersed throughout gel (depending reaction strength). Clear supernatantNegative: Unagglutinated cells pass freely gel form distinct pellet bottom microtubeApplications: ABO/Rh typing, antibody screening, antibody identification, DAT, crossmatching. popular due clear endpoints, stable reactions, standardization","code":""},{"path":"testing-1.html","id":"key-terms-55","chapter":"Testing","heading":"Key Terms","text":"Agglutination: visible clumping particles (e.g., red blood cells) caused cross-linking antibodiesHemolysis: rupture destruction red blood cells, releasing hemoglobin. testing, often indicates complement activation antibodySensitization: binding antibody complement antigens red blood cell surface (Stage 1 agglutination, often invisible)Lattice Formation: cross-linking sensitized red blood cells antibodies form visible clumps (Stage 2 agglutination)Anti-Human Globulin (AHG) / Coombs Reagent: Reagent containing antibodies directed human IgG /complement C3d, used detect sensitization red blood cellsDirect Antiglobulin Test (DAT): Detects vivo sensitization patient red blood cells IgG complementIndirect Antiglobulin Test (IAT): Detects antibodies patient serum/plasma capable sensitizing reagent red blood cells vitroEnhancement Media (LISS, PEG): Solutions used IAT increase rate sensitivity IgG antibody binding red cellsCheck Cells (Coombs Control Cells): IgG-coated red blood cells added negative AHG tests validate result (confirm AHG active washing adequate)Solid Phase Red Cell Adherence (SPRCA): Testing method using microplate wells coated antigen antibody; detects adherence patterns red cellsGel Technology (Column Agglutination): Testing method using microtubes containing gel matrix traps agglutinated cells centrifugation","code":""},{"path":"complement.html","id":"complement","chapter":"Complement","heading":"Complement","text":"Think complement rapid-response security system plasma. ’s cascade proteins , triggered, amplifies quickly neutralize threats. ’s part innate system, works closely antibodies (adaptive system) major implications blood bankingComplement activation starts via antibody binding (Classical) spontaneously (Alternative), converges C3/C5 convertase steps, culminates MAC. fragments generated along way mediate lysis, opsonization, inflammation – critical processes immunity , significantly, pathology hemolytic transfusion reactions","code":""},{"path":"complement.html","id":"activating-the-cascade-the-pathways","chapter":"Complement","heading":"Activating the Cascade: The Pathways","text":"two main ways complement gets started relevant us:Classical Pathway: Antibody-Triggered\nInitiation: Primarily kicked antibodies bound antigens (immune complexes)\nIgM: Extremely efficient; just one molecule bound cell can start \nIgG: Less efficient; needs two IgG molecules close together. IgG3 > IgG1 best IgG activators; IgG4 doesn’t activate \n\nMechanism: C1 complex (C1q recognizes antibody Fc region) -> activates C1r -> activates C1s -> C1s cleaves C4 C2 -> C4b binds cell surface -> C2a binds C4b\nKey Enzyme Formed: C4b2a (Classical Pathway C3 Convertase)\nInitiation: Primarily kicked antibodies bound antigens (immune complexes)\nIgM: Extremely efficient; just one molecule bound cell can start \nIgG: Less efficient; needs two IgG molecules close together. IgG3 > IgG1 best IgG activators; IgG4 doesn’t activate \nIgM: Extremely efficient; just one molecule bound cell can start itIgG: Less efficient; needs two IgG molecules close together. IgG3 > IgG1 best IgG activators; IgG4 doesn’t activate itMechanism: C1 complex (C1q recognizes antibody Fc region) -> activates C1r -> activates C1s -> C1s cleaves C4 C2 -> C4b binds cell surface -> C2a binds C4bKey Enzyme Formed: C4b2a (Classical Pathway C3 Convertase)Alternative Pathway: Spontaneous & Surface-Driven\nInitiation: Doesn’t need antibodies. Starts via:\nSlow, spontaneous “tick-” C3 plasma (C3 -> C3(H2O))\nPresence certain activating surfaces (like microbes) lack protective regulatory proteins found cells\n\nMechanism: C3(H2O) surface-bound C3b binds Factor B -> Factor D cleaves Factor B -> Bb remains bound\nKey Enzyme Formed: C3bBb (Alternative Pathway C3 Convertase). pathway includes important amplification loop C3bBb complex makes C3b, can form C3bBb. Stabilized Properdin\nInitiation: Doesn’t need antibodies. Starts via:\nSlow, spontaneous “tick-” C3 plasma (C3 -> C3(H2O))\nPresence certain activating surfaces (like microbes) lack protective regulatory proteins found cells\nSlow, spontaneous “tick-” C3 plasma (C3 -> C3(H2O))Presence certain activating surfaces (like microbes) lack protective regulatory proteins found cellsMechanism: C3(H2O) surface-bound C3b binds Factor B -> Factor D cleaves Factor B -> Bb remains boundKey Enzyme Formed: C3bBb (Alternative Pathway C3 Convertase). pathway includes important amplification loop C3bBb complex makes C3b, can form C3bBb. Stabilized Properdin","code":""},{"path":"complement.html","id":"the-central-hub-terminal-attack","chapter":"Complement","heading":"The Central Hub & Terminal Attack","text":"Convergence C3: pathways lead formation C3 Convertase (C4b2a C3bBb). enzyme crucial cleaves large amounts C3, abundant complement protein, :\nC3a: anaphylatoxin (inflammation)\nC3b: major opsonin (tagging destruction) key component next step\nC3a: anaphylatoxin (inflammation)C3b: major opsonin (tagging destruction) key component next stepForming C5 Convertase: C3b binds C3 convertase complex (forming C4b2a3b C3bBb3b). new enzyme C5 ConvertaseThe Final Assault (Terminal Pathway)\nC5 Convertase cleaves C5 :\nC5a: potent anaphylatoxin chemoattractant\nC5b: Initiates assembly sequence\n\nC5b sequentially recruits C6, C7, C8, multiple C9 molecules\nforms Membrane Attack Complex (MAC, C5b-9), inserts target cell membrane\nC5 Convertase cleaves C5 :\nC5a: potent anaphylatoxin chemoattractant\nC5b: Initiates assembly sequence\nC5a: potent anaphylatoxin chemoattractantC5b: Initiates assembly sequenceC5b sequentially recruits C6, C7, C8, multiple C9 moleculesThis forms Membrane Attack Complex (MAC, C5b-9), inserts target cell membrane","code":""},{"path":"complement.html","id":"the-consequences-biologic-properties","chapter":"Complement","heading":"The Consequences: Biologic Properties","text":"Activation complement cascade results several powerful biological effects:Cell Lysis (via MAC)\nMAC (C5b-9) forms pores cell membranes, disrupting osmotic balance causing cells burst\nResult: Intravascular Hemolysis (destruction RBCs within blood vessels)\nRelevance: Acute HTRs (e.g., ABO mismatch). Visible hemolysis vitro\nMAC (C5b-9) forms pores cell membranes, disrupting osmotic balance causing cells burstResult: Intravascular Hemolysis (destruction RBCs within blood vessels)Relevance: Acute HTRs (e.g., ABO mismatch). Visible hemolysis vitroOpsonization (via C3b)\nC3b: coats target cells (“tags” )\nPhagocytes (macrophages spleen/liver) recognize C3b via complement receptors (CR1) engulf cell\nResult: Extravascular Hemolysis (removal RBCs outside blood vessels)\nRelevance: Delayed HTRs, AIHA. Leads C3d remaining cells, detectable DAT\nC3b: coats target cells (“tags” )Phagocytes (macrophages spleen/liver) recognize C3b via complement receptors (CR1) engulf cellResult: Extravascular Hemolysis (removal RBCs outside blood vessels)Relevance: Delayed HTRs, AIHA. Leads C3d remaining cells, detectable DATInflammation (via C3a, C4a, C5a)\nanaphylatoxins cause histamine release mast cells (-> vasodilation, increased permeability) act chemoattractants (C5a strongly recruits neutrophils)\nResult: Local systemic inflammatory symptoms\nRelevance: Fever, chills, hypotension, pain often seen HTRs\nanaphylatoxins cause histamine release mast cells (-> vasodilation, increased permeability) act chemoattractants (C5a strongly recruits neutrophils)Result: Local systemic inflammatory symptomsRelevance: Fever, chills, hypotension, pain often seen HTRsImmune Complex Clearance (via C3b)\nC3b coats circulating immune complexes, allowing bind CR1 red blood cells transport liver/spleen disposal macrophages\nC3b coats circulating immune complexes, allowing bind CR1 red blood cells transport liver/spleen disposal macrophages","code":""},{"path":"pathway-mechanisms.html","id":"pathway-mechanisms","chapter":"Pathway Mechanisms","heading":"Pathway Mechanisms","text":"complement system fascinating powerful part immune system – think cascade protein dominos , tipped , leads major downstream effects like inflammation, marking targets destruction, even directly blowing holes cells! ’s part innate immune system forms crucial bridge adaptive system (especially via antibodies)blood banking, complement activation super important ’s major way incompatible red blood cells get destroyed, either inside blood vessels (intravascular hemolysis) flagged removal macrophages (extravascular hemolysis). Understanding gets activated helps us understand transfusion reactions interpret tests (like DAT!)three main pathways activate complement, ’ll focus two relevant us: Classical Alternative pathways. start differently eventually merge create powerful effector molecules","code":""},{"path":"pathway-mechanisms.html","id":"the-classical-pathway-antibody-driven-activation","chapter":"Pathway Mechanisms","heading":"The Classical Pathway: Antibody-Driven Activation","text":"Trigger: pathway typically initiated antibodies bind antigens, forming immune complexes. blood banking, usually means:\nIgM: Just ONE IgM molecule bound red cell antigen enough kick things ! IgM pentamer, structure perfect binding first complement protein, C1q. ABO mismatches (involving IgM anti-/anti-B) can cause rapid severe complement activation\nIgG: ’s less efficient. generally need two IgG molecules bound close together cell surface effectively bind C1q. IgG subclasses equal: IgG3 best activator, followed IgG1. IgG2 poor, IgG4 activate classical pathway. relevant antibodies like anti-K (often IgG1) anti-Jka (can IgG3)\n(Less common triggers include C-reactive protein binding microbes)\nIgM: Just ONE IgM molecule bound red cell antigen enough kick things ! IgM pentamer, structure perfect binding first complement protein, C1q. ABO mismatches (involving IgM anti-/anti-B) can cause rapid severe complement activationIgG: ’s less efficient. generally need two IgG molecules bound close together cell surface effectively bind C1q. IgG subclasses equal: IgG3 best activator, followed IgG1. IgG2 poor, IgG4 activate classical pathway. relevant antibodies like anti-K (often IgG1) anti-Jka (can IgG3)(Less common triggers include C-reactive protein binding microbes)Mechanism (Dominoes Falling)\nInitiation (C1 Complex) process starts C1 complex, consists C1q (recognition unit) two molecules C1r C1s (serine proteases - enzymes cut proteins)\nC1q binds: Fc region (“stem” Y) bound IgM adjacent IgG antibodies\nbinding causes shape change C1q, activates C1r\nActivated C1r cleaves activates C1s. Now C1s active enzyme\n\nActivating C4 C2\nActivated C1s finds cleaves C4 two pieces: C4a (small fragment floats away, acting weak anaphylatoxin - promoting inflammation) C4b (larger fragment)\nC4b: chemically unstable quickly tries form covalent bond nearby cell surface (e.g., red blood cell membrane). doesn’t bind quickly, gets inactivated\nActivated C1s also cleaves C2 C2a C2b. (Note: convention changed; C2a now considered larger enzymatic fragment)\nC2a: binds surface-bound C4b\n\nFormation C3 Convertase\ncomplex formed C4b2a Classical Pathway C3 Convertase. job chop lots C3 molecules. major amplification point!\n\nActivating C3 (Central Step)\nC4b2a enzyme cleaves C3 C3a (another anaphylatoxin, potent C4a, causing inflammation attracting phagocytes) C3b (larger fragment)\nC3b: crucial! Like C4b, tries bind covalently nearby surfaces. acts powerful opsonin, meaning coats cell flags destruction phagocytes (like macrophages spleen/liver) C3b receptors. leads extravascular hemolysis\nC3b also participates forming next enzyme complex\n\nFormation C5 Convertase\nnewly generated C3b binds existing C4b2a complex, forming C4b2a3b. Classical Pathway C5 Convertase\n\nActivating C5\nC4b2a3b enzyme cleaves C5 C5a (potent anaphylatoxin chemotactic factor, strongly recruiting inflammatory cells) C5b (larger fragment)\nC5b: initiating factor final stage – Membrane Attack Complex (MAC)\n\nInitiation (C1 Complex) process starts C1 complex, consists C1q (recognition unit) two molecules C1r C1s (serine proteases - enzymes cut proteins)\nC1q binds: Fc region (“stem” Y) bound IgM adjacent IgG antibodies\nbinding causes shape change C1q, activates C1r\nActivated C1r cleaves activates C1s. Now C1s active enzyme\nC1q binds: Fc region (“stem” Y) bound IgM adjacent IgG antibodiesThis binding causes shape change C1q, activates C1rActivated C1r cleaves activates C1s. Now C1s active enzymeActivating C4 C2\nActivated C1s finds cleaves C4 two pieces: C4a (small fragment floats away, acting weak anaphylatoxin - promoting inflammation) C4b (larger fragment)\nC4b: chemically unstable quickly tries form covalent bond nearby cell surface (e.g., red blood cell membrane). doesn’t bind quickly, gets inactivated\nActivated C1s also cleaves C2 C2a C2b. (Note: convention changed; C2a now considered larger enzymatic fragment)\nC2a: binds surface-bound C4b\nActivated C1s finds cleaves C4 two pieces: C4a (small fragment floats away, acting weak anaphylatoxin - promoting inflammation) C4b (larger fragment)C4b: chemically unstable quickly tries form covalent bond nearby cell surface (e.g., red blood cell membrane). doesn’t bind quickly, gets inactivatedActivated C1s also cleaves C2 C2a C2b. (Note: convention changed; C2a now considered larger enzymatic fragment)C2a: binds surface-bound C4bFormation C3 Convertase\ncomplex formed C4b2a Classical Pathway C3 Convertase. job chop lots C3 molecules. major amplification point!\ncomplex formed C4b2a Classical Pathway C3 Convertase. job chop lots C3 molecules. major amplification point!Activating C3 (Central Step)\nC4b2a enzyme cleaves C3 C3a (another anaphylatoxin, potent C4a, causing inflammation attracting phagocytes) C3b (larger fragment)\nC3b: crucial! Like C4b, tries bind covalently nearby surfaces. acts powerful opsonin, meaning coats cell flags destruction phagocytes (like macrophages spleen/liver) C3b receptors. leads extravascular hemolysis\nC3b also participates forming next enzyme complex\nC4b2a enzyme cleaves C3 C3a (another anaphylatoxin, potent C4a, causing inflammation attracting phagocytes) C3b (larger fragment)C3b: crucial! Like C4b, tries bind covalently nearby surfaces. acts powerful opsonin, meaning coats cell flags destruction phagocytes (like macrophages spleen/liver) C3b receptors. leads extravascular hemolysisC3b also participates forming next enzyme complexFormation C5 Convertase\nnewly generated C3b binds existing C4b2a complex, forming C4b2a3b. Classical Pathway C5 Convertase\nnewly generated C3b binds existing C4b2a complex, forming C4b2a3b. Classical Pathway C5 ConvertaseActivating C5\nC4b2a3b enzyme cleaves C5 C5a (potent anaphylatoxin chemotactic factor, strongly recruiting inflammatory cells) C5b (larger fragment)\nC5b: initiating factor final stage – Membrane Attack Complex (MAC)\nC4b2a3b enzyme cleaves C5 C5a (potent anaphylatoxin chemotactic factor, strongly recruiting inflammatory cells) C5b (larger fragment)C5b: initiating factor final stage – Membrane Attack Complex (MAC)","code":""},{"path":"pathway-mechanisms.html","id":"the-alternative-pathway-spontaneous-activation-amplification","chapter":"Pathway Mechanisms","heading":"The Alternative Pathway: Spontaneous Activation & Amplification","text":"Trigger: pathway doesn’t rely antibodies initiation. ’s triggered :\nSpontaneous “Tick-”: C3 molecules plasma inherently slightly unstable can spontaneously hydrolyze (react water) low rate, forming C3(H2O). happens continuously\nForeign Surfaces: Certain microbial surfaces (like bacterial LPS yeast cell walls) activating surfaces lack regulatory proteins normally protect cells\n(IgA immune complexes can sometimes activate pathway )\nSpontaneous “Tick-”: C3 molecules plasma inherently slightly unstable can spontaneously hydrolyze (react water) low rate, forming C3(H2O). happens continuouslyForeign Surfaces: Certain microbial surfaces (like bacterial LPS yeast cell walls) activating surfaces lack regulatory proteins normally protect cells(IgA immune complexes can sometimes activate pathway )Mechanism\nInitiation (Tick-)\nC3(H2O): forms plasma\naltered C3 can bind plasma protein called Factor B\nAnother plasma protease, Factor D, always active low concentration, cleaves bound Factor B Ba (released) Bb\nforms complex C3(H2O)Bb, fluid-phase C3 convertase. ’s stable, can cleave C3 molecules C3a C3b\n\nDeposition Amplification Surfaces\nC3b generated tick-(classical pathway!) can covalently attach nearby surfaces – including host cells foreign particles (like bacteria potentially even red cells certain conditions)\nCrucial Difference: cells regulatory proteins (like Factor H) quickly bind deposited C3b allow Factor cleave inactivate (preventing damage self). Foreign surfaces often lack regulators\nactivating surface (lacking regulators), bound C3b can bind Factor B\nFactor D: cleaves Factor B Ba Bb\nforms C3bBb, surface-bound Alternative Pathway C3 Convertase\n\nStabilization Amplification\nC3bBb convertase inherently unstable, can stabilized another protein called Properdin (Factor P). Properdin binding extends half-life convertase, allowing cleave many C3 molecules\ncreates powerful amplification loop C3bBb complex generates C3b, can form C3bBb complexes activating surface\n\nFormation C5 Convertase\nadditional C3b molecule binds C3bBb complex, forms C3bBb3b. Alternative Pathway C5 Convertase\n\nActivating C5\nJust like classical pathway C5 convertase, C3bBb3b cleaves C5 C5a (inflammation/chemotaxis) C5b (initiates MAC)\n\nInitiation (Tick-)\nC3(H2O): forms plasma\naltered C3 can bind plasma protein called Factor B\nAnother plasma protease, Factor D, always active low concentration, cleaves bound Factor B Ba (released) Bb\nforms complex C3(H2O)Bb, fluid-phase C3 convertase. ’s stable, can cleave C3 molecules C3a C3b\nC3(H2O): forms plasmaThis altered C3 can bind plasma protein called Factor BAnother plasma protease, Factor D, always active low concentration, cleaves bound Factor B Ba (released) BbThis forms complex C3(H2O)Bb, fluid-phase C3 convertase. ’s stable, can cleave C3 molecules C3a C3bDeposition Amplification Surfaces\nC3b generated tick-(classical pathway!) can covalently attach nearby surfaces – including host cells foreign particles (like bacteria potentially even red cells certain conditions)\nCrucial Difference: cells regulatory proteins (like Factor H) quickly bind deposited C3b allow Factor cleave inactivate (preventing damage self). Foreign surfaces often lack regulators\nactivating surface (lacking regulators), bound C3b can bind Factor B\nFactor D: cleaves Factor B Ba Bb\nforms C3bBb, surface-bound Alternative Pathway C3 Convertase\nC3b generated tick-(classical pathway!) can covalently attach nearby surfaces – including host cells foreign particles (like bacteria potentially even red cells certain conditions)Crucial Difference: cells regulatory proteins (like Factor H) quickly bind deposited C3b allow Factor cleave inactivate (preventing damage self). Foreign surfaces often lack regulatorsOn activating surface (lacking regulators), bound C3b can bind Factor BFactor D: cleaves Factor B Ba BbThis forms C3bBb, surface-bound Alternative Pathway C3 ConvertaseStabilization Amplification\nC3bBb convertase inherently unstable, can stabilized another protein called Properdin (Factor P). Properdin binding extends half-life convertase, allowing cleave many C3 molecules\ncreates powerful amplification loop C3bBb complex generates C3b, can form C3bBb complexes activating surface\nC3bBb convertase inherently unstable, can stabilized another protein called Properdin (Factor P). Properdin binding extends half-life convertase, allowing cleave many C3 moleculesThis creates powerful amplification loop C3bBb complex generates C3b, can form C3bBb complexes activating surfaceFormation C5 Convertase\nadditional C3b molecule binds C3bBb complex, forms C3bBb3b. Alternative Pathway C5 Convertase\nadditional C3b molecule binds C3bBb complex, forms C3bBb3b. Alternative Pathway C5 ConvertaseActivating C5\nJust like classical pathway C5 convertase, C3bBb3b cleaves C5 C5a (inflammation/chemotaxis) C5b (initiates MAC)\nJust like classical pathway C5 convertase, C3bBb3b cleaves C5 C5a (inflammation/chemotaxis) C5b (initiates MAC)","code":""},{"path":"pathway-mechanisms.html","id":"convergence-and-the-terminal-pathway-membrane-attack-complex-mac","chapter":"Pathway Mechanisms","heading":"Convergence and The Terminal Pathway: Membrane Attack Complex (MAC)","text":"Convergence: Classical (C4b2a3b) Alternative (C3bBb3b) pathways generate C5 convertase. point , steps sameMechanism\nInitiation C5b generated binds transiently target cell surface near C5 convertase\nAssembly\nC5b sequentially binds C6, C7. C5b-7 complex undergoes conformational change inserts lipid bilayer target cell membrane\nC8: binds C5b-7 complex also inserts membrane, creating small pore\nC9: molecules (10-16 !) recruited site. bind C5b-8 complex polymerize, inserting membrane form large, ring-like channel\n\nLysis complete structure, C5b-9, Membrane Attack Complex (MAC). forms stable pore cell membrane, disrupting osmotic balance. Water ions rush , causing cell swell burst (lysis)\nInitiation C5b generated binds transiently target cell surface near C5 convertaseAssembly\nC5b sequentially binds C6, C7. C5b-7 complex undergoes conformational change inserts lipid bilayer target cell membrane\nC8: binds C5b-7 complex also inserts membrane, creating small pore\nC9: molecules (10-16 !) recruited site. bind C5b-8 complex polymerize, inserting membrane form large, ring-like channel\nC5b sequentially binds C6, C7. C5b-7 complex undergoes conformational change inserts lipid bilayer target cell membraneC8: binds C5b-7 complex also inserts membrane, creating small poreC9: molecules (10-16 !) recruited site. bind C5b-8 complex polymerize, inserting membrane form large, ring-like channelLysis complete structure, C5b-9, Membrane Attack Complex (MAC). forms stable pore cell membrane, disrupting osmotic balance. Water ions rush , causing cell swell burst (lysis)Blood Bank Relevance: MAC formation red blood cells causes intravascular hemolysis, rapid destruction RBCs within blood vessels. characteristic severe, acute hemolytic transfusion reactions (like ABO incompatibility)","code":""},{"path":"pathway-mechanisms.html","id":"regulation-is-key","chapter":"Pathway Mechanisms","heading":"Regulation is Key!","text":"’s crucial complement activation tightly controlled prevent damaging healthy tissues. Numerous regulatory proteins exist plasma cell surfaces (e.g., C1 Inhibitor, Factor H, Factor , DAF/CD55, Protectin/CD59) limit cascade various steps. Lack regulators foreign surfaces allows complement target effectively","code":""},{"path":"pathway-mechanisms.html","id":"blood-bank-summary-points","chapter":"Pathway Mechanisms","heading":"Blood Bank Summary Points","text":"Classical Pathway: Triggered mainly IgM IgG (subclasses matter!) binding RBC antigens. Key HTRs, HDFN, AIHAAlternative Pathway: Activated surfaces lacking regulators; acts major amplification loop C3b deposited either pathwayC3b Deposition: Leads opsonization extravascular hemolysis (removal macrophages)C3d: stable breakdown product C3b remains RBC surface. Detected anti-C3d AHG reagent (DAT/IAT)MAC Formation (C5b-9): Leads intravascular hemolysis. Visible hemolysis test tubes sign complement activation completionAnaphylatoxins (C3a, C4a, C5a): Contribute inflammatory symptoms sometimes seen transfusion reactions","code":""},{"path":"pathway-mechanisms.html","id":"key-terms-56","chapter":"Pathway Mechanisms","heading":"Key Terms","text":"Complement System: group plasma proteins act cascade opsonize pathogens, recruit inflammatory cells, lyse cellsClassical Pathway: Complement activation pathway typically initiated IgM IgG immune complexes binding C1qAlternative Pathway: Complement activation pathway initiated spontaneous C3 hydrolysis (“tick-”) amplified activating surfaces lacking regulators; involves Factors B, D, ProperdinC3 Convertase: Enzyme complex (C4b2a classical; C3bBb alternative) cleaves C3 C3a C3b. Central amplification stepC5 Convertase: Enzyme complex (C4b2a3b classical; C3bBb3b alternative) cleaves C5 C5a C5b, initiating MACMembrane Attack Complex (MAC): terminal complex complement (C5b-9) forms pore target cell membranes, causing lysisOpsonization: coating particle (e.g., RBC) molecules (like C3b IgG) enhance phagocytosisAnaphylatoxin: Complement fragments (C3a, C4a, C5a) cause histamine release mast cells inflammatory effectsC3b: Major opsonin component C5 convertases; covalently binds surfacesC3d: Stable breakdown product C3b remains bound cell surfaces; detected anti-C3d AHG reagentFactor B, Factor D, Properdin (Factor P): Key protein components unique Alternative Pathway activation regulationFactor H, Factor , C1 Inhibitor (C1-INH): Key regulatory proteins control complement activation prevent damage host tissues","code":""},{"path":"biologic-properties.html","id":"biologic-properties","chapter":"Biologic Properties","heading":"Biologic Properties","text":"’ve talked complement system gets activated (pathways), now let’s focus actually protein dominos start falling. actions reason complement critical protecting us , unfortunately, sometimes causing problems transfusion medicine!Think activated complement components several distinct “job functions” body:","code":""},{"path":"biologic-properties.html","id":"cell-lysis-the-punching-holes-function-via-mac","chapter":"Biologic Properties","heading":"Cell Lysis: The “Punching Holes” Function (via MAC)","text":"Key Player: Membrane Attack Complex (MAC), specifically C5b-9What : dramatic outcome. fully assembled MAC inserts target cell’s membrane (like red blood cell, bacterium, even virus-infected cells), forming transmembrane channel poreBiological Consequence: pore disrupts cell’s osmotic integrity. Water ions flood cell, causing swell burst (lyse). red blood cells, intravascular hemolysis – destruction within blood vessels, releasing free hemoglobin plasmaBlood Bank Relevance\nAcute Hemolytic Transfusion Reactions (AHTRs): Especially ABO incompatibility potent IgM antibodies rapidly activate complement completion, leading massive intravascular hemolysis. medical emergency!\nParoxysmal Nocturnal Hemoglobinuria (PNH): Patients’ red cells lack complement regulatory proteins (CD55, CD59), making highly susceptible spontaneous complement-mediated lysis\nVisible Hemolysis Testing: Seeing hemolysis test tube (e.g., crossmatching antibody ID) often sign complement activation terminal pathway considered positive reaction indicating potential vivo hemolysis\nAcute Hemolytic Transfusion Reactions (AHTRs): Especially ABO incompatibility potent IgM antibodies rapidly activate complement completion, leading massive intravascular hemolysis. medical emergency!Paroxysmal Nocturnal Hemoglobinuria (PNH): Patients’ red cells lack complement regulatory proteins (CD55, CD59), making highly susceptible spontaneous complement-mediated lysisVisible Hemolysis Testing: Seeing hemolysis test tube (e.g., crossmatching antibody ID) often sign complement activation terminal pathway considered positive reaction indicating potential vivo hemolysis","code":""},{"path":"biologic-properties.html","id":"opsonization-the-eat-me-signal","chapter":"Biologic Properties","heading":"Opsonization: The “Eat Me” Signal","text":"Key Player: Primarily C3b (breakdown product iC3b). C4b plays minor roleWhat : C3 cleaved, C3b fragments covalently bind (“stick”) surface target particle (e.g., red cell coated antibody, bacterium). coating process called opsonizationBiological Consequence: Phagocytic cells, particularly macrophages (found abundantly spleen liver) neutrophils, specific complement receptors (like CR1 binds C3b, CR3/CR4 bind iC3b). receptors encounter C3b-coated particle, triggers phagocytosis – engulfment destruction particleBlood Bank Relevance\nExtravascular Hemolysis: primary mechanism removing red cells coated complement (often triggered IgG antibodies activate complement partially, MAC formation inhibited). Macrophages spleen liver recognize C3b-coated cells remove circulation. typically slower less dramatic intravascular hemolysis common cause Delayed Hemolytic Transfusion Reactions (DHTRs) seen Warm Autoimmune Hemolytic Anemia (WAIHA)\nDAT Positivity: stable breakdown product C3d often remains red cell surface C3b cleaved regulatory factors. presence C3d detected anti-C3d AHG reagent Direct Antiglobulin Test (DAT), indicating complement activation occurred vivo\nExtravascular Hemolysis: primary mechanism removing red cells coated complement (often triggered IgG antibodies activate complement partially, MAC formation inhibited). Macrophages spleen liver recognize C3b-coated cells remove circulation. typically slower less dramatic intravascular hemolysis common cause Delayed Hemolytic Transfusion Reactions (DHTRs) seen Warm Autoimmune Hemolytic Anemia (WAIHA)DAT Positivity: stable breakdown product C3d often remains red cell surface C3b cleaved regulatory factors. presence C3d detected anti-C3d AHG reagent Direct Antiglobulin Test (DAT), indicating complement activation occurred vivo","code":""},{"path":"biologic-properties.html","id":"inflammation-sounding-the-alarm","chapter":"Biologic Properties","heading":"Inflammation: Sounding the Alarm","text":"Key Players: small fragments released cleavage: C5a, C3a, C4a. collectively called anaphylatoxinsWhat : peptides diffuse away site activation interact receptors various cells, particularly mast cells basophilsBiological Consequences\nMast Cell Degranulation: Causes release histamine inflammatory mediators. leads increased vascular permeability (leaky blood vessels -> swelling/edema) vasodilation (widening blood vessels -> redness, drop blood pressure)\nSmooth Muscle Contraction: Can affect airways blood vessels\nChemotaxis: C5a powerful chemoattractant, meaning recruits inflammatory cells like neutrophils macrophages site complement activation, amplifying inflammatory response\nMast Cell Degranulation: Causes release histamine inflammatory mediators. leads increased vascular permeability (leaky blood vessels -> swelling/edema) vasodilation (widening blood vessels -> redness, drop blood pressure)Smooth Muscle Contraction: Can affect airways blood vesselsChemotaxis: C5a powerful chemoattractant, meaning recruits inflammatory cells like neutrophils macrophages site complement activation, amplifying inflammatory responseBlood Bank Relevance\nSymptoms Transfusion Reactions: Many systemic symptoms associated hemolytic transfusion reactions (fever, chills, flushing, hypotension, back pain, shortness breath) mediated release anaphylatoxins subsequent inflammatory responses\nC5a-mediated neutrophil activation also implicated pathophysiology Transfusion-Related Acute Lung Injury (TRALI), although primary trigger involves antibodies HLA neutrophil antigens\nSymptoms Transfusion Reactions: Many systemic symptoms associated hemolytic transfusion reactions (fever, chills, flushing, hypotension, back pain, shortness breath) mediated release anaphylatoxins subsequent inflammatory responsesC5a-mediated neutrophil activation also implicated pathophysiology Transfusion-Related Acute Lung Injury (TRALI), although primary trigger involves antibodies HLA neutrophil antigens","code":""},{"path":"biologic-properties.html","id":"immune-complex-clearance-housekeeping-duty","chapter":"Biologic Properties","heading":"Immune Complex Clearance: Housekeeping Duty","text":"Key Players: C3b Red Blood Cell CR1 receptorsWhat : Antibodies binding soluble antigens form circulating immune complexes. Complement activation (specifically C3b deposition) coats complexes. Red blood cells CR1 receptors bind C3b-coated complexesBiological Consequence: Red blood cells act like transport system, shuttling potentially harmful immune complexes circulation liver spleen. , resident macrophages efficiently remove complexes RBC surface (usually without destroying RBC ) disposalBlood Bank Relevance: general immune function, highlights role RBCs beyond oxygen transport. Defects clearance mechanism can contribute autoimmune diseases immune complexes deposit tissues (like lupus)","code":""},{"path":"biologic-properties.html","id":"summary-of-biologic-properties","chapter":"Biologic Properties","heading":"Summary of Biologic Properties","text":"","code":""},{"path":"biologic-properties.html","id":"key-terms-57","chapter":"Biologic Properties","heading":"Key Terms","text":"Biologic Properties: functions effects substance (like complement components) within living systemLysis: disintegration rupture cell membraneMembrane Attack Complex (MAC): terminal complement complex (C5b-9) responsible forming pores cell membranes causing lysisIntravascular Hemolysis: Destruction red blood cells within blood vessels, typically mediated MAC formationOpsonization: process coating particle (e.g., cell, bacterium) molecules (opsonins like C3b IgG) enhance uptake phagocytic cellsC3b: major fragment C3 activation acts opsonin component C5 convertaseComplement Receptors (CR): Cell surface proteins (e.g., CR1 macrophages RBCs) bind specific complement fragments like C3bExtravascular Hemolysis: Destruction red blood cells outside blood vessels, primarily macrophages spleen liver recognizing opsonized (C3b/IgG coated) cellsAnaphylatoxins: Small complement fragments (C5a, C3a, C4a) mediate local systemic inflammatory responses, including mast cell degranulation chemotaxisChemotaxis: directed movement cells (like neutrophils) towards chemical signal (like C5a)Immune Complex: cluster formed binding antibodies soluble antigens. Complement aids clearance","code":""},{"path":"physiology-pathophysiology.html","id":"physiology-pathophysiology","chapter":"Physiology & Pathophysiology","heading":"Physiology & Pathophysiology","text":"broad section explores blood normally functions goes wrong various disease states, underpinning blood components needed potential complications involved","code":""},{"path":"physiology-pathophysiology.html","id":"physiology-of-blood","chapter":"Physiology & Pathophysiology","heading":"Physiology of Blood","text":"Blood complex fluid tissue composed plasma (water, proteins like albumin, globulins/antibodies, fibrinogen) formed elements (RBCs O2 transport, WBCs immunity, platelets clotting). circulates throughout body, driven heart, within specific blood volume, delivering oxygen/nutrients, removing waste, regulating pH/temperature, providing protection. Red blood cells unique metabolism (anaerobic glycolysis ATP, HMP shunt NADPH/oxidative protection) allowing survive ~120 days removal spleen (extravascular hemolysis)Pathophysiology: Imbalances include hypo/hypervolemia (affecting circulation), anemia (reduced O2 capacity due production failure, hemolysis, loss), disruptions plasma components (e.g., low albumin, clotting factor deficiencies). RBC survival can shortened intrinsic defects (membranopathies, enzymopathies, hemoglobinopathies) extrinsic factors (immune attack, mechanical damage)","code":""},{"path":"physiology-pathophysiology.html","id":"hemostasis-and-coagulation","chapter":"Physiology & Pathophysiology","heading":"Hemostasis and Coagulation","text":"process stopping bleeding. involves:Platelets Adhering injury sites (via vWF), activating, releasing granules, aggregating form primary plugCoagulation Factors cascade plasma proteins activated sequentially (Extrinsic, Intrinsic, Common pathways) leading thrombin generation. Thrombin converts fibrinogen fibrin, stabilizes platelet plug. Vitamin K crucial factors II, VII, IX, XPathophysiology: Disorders lead bleeding thrombosis. Includes thrombocytopenia (low platelet count), thrombocytopathy (platelet dysfunction), deficiencies inhibition coagulation factors (e.g., Hemophilia /B, vWD, liver disease, DIC, Vit K deficiency). Detected via PT, aPTT, platelet count/function tests, mixing studies, factor assays","code":""},{"path":"physiology-pathophysiology.html","id":"hemolytic-disease-of-the-fetus-and-newborn-hdfn","chapter":"Physiology & Pathophysiology","heading":"Hemolytic Disease of the Fetus and Newborn (HDFN)","text":"Occurs maternal IgG antibodies (formed via sensitization previous pregnancy/transfusion) cross placenta destroy fetal RBCs possessing corresponding antigen (e.g., D, K, c)Pathophysiology: Fetal extravascular hemolysis leads anemia, compensatory erythropoiesis (erythroblastosis), hepatosplenomegaly, potentially hydrops fetalis. Postnatally, main issue hyperbilirubinemia (due ongoing hemolysis immature liver) leading jaundice risk kernicterusDetection: Antenatal (maternal Ab screen/ID/titer, MCA Doppler fetal anemia), Postnatal (infant ABO/Rh, DAT, bilirubin)Treatment: Antenatal (Intrauterine Transfusion - IUT), Postnatal (Phototherapy, Exchange Transfusion)Prevention: Rh Immune Globulin (RhIG) RhD incompatibility highly effective","code":""},{"path":"physiology-pathophysiology.html","id":"cytopenias","chapter":"Physiology & Pathophysiology","heading":"Cytopenias","text":"Deficiency one blood cell linesAnemia: Low RBCs/Hgb -> tissue hypoxia. Causes: decreased production (nutritional, marrow failure), increased destruction (hemolysis - immune non-immune), blood loss. Detected via CBC, retic count, smear, iron/B12/folate, hemolysis markers, DAT (immune causes). Treated addressing cause +/- RBC transfusionThrombocytopenia: Low platelets -> bleeding risk. Causes: decreased production (marrow failure, chemo), increased destruction/consumption (immune - ITP, HIT; non-immune - DIC, TTP), sequestration (splenomegaly). Detected via CBC, smear, coagulation tests (DIC), HIT assays. Treated addressing cause, immunosuppression (ITP), PEX (TTP), +/- platelet transfusionNeutropenia: Low neutrophils (ANC) -> infection risk. Causes: decreased production (congenital, chemo, drugs, marrow failure), increased destruction (sepsis, immune - AIN, NAN). Detected via CBC/ANC, marrow exam, neutrophil Ab tests. Treated addressing cause, G-CSF, prompt antibiotics fever","code":""},{"path":"physiology-pathophysiology.html","id":"transplantation","chapter":"Physiology & Pathophysiology","heading":"Transplantation","text":"Replacing failing organs (Solid Organ - SOT) hematopoietic systems (HPC Transplant). Immune system interaction keySOT: Main challenge rejection (recipient attacks graft). Requires ABO compatibility, HLA matching, pre-transplant crossmatch, lifelong recipient immunosuppressionHPC Transplant: Replaces marrow/immune system. Allogeneic transplants risk rejection (recipient attacks graft) Graft-versus-Host Disease (GVHD) (donor T-cells attack recipient). Requires strict HLA matching, pre-transplant conditioning, GVHD prophylaxis/treatment. Irradiated blood products essential recipients. ABO compatibility required transplant complicates transfusion support","code":""},{"path":"blood-physiology.html","id":"blood-physiology","chapter":"Blood Physiology","heading":"Blood Physiology","text":"section covers fundamentals blood: moves (Circulation), much (Volume), ’s made (Composition), (Function), specifically main cellular component, Red Blood Cell (RBC), generates energy (Metabolism) stays viable (Survival). Understanding normal physiology essential recognizing Pathophysiology (abnormal function) often necessitates blood transfusion","code":""},{"path":"blood-physiology.html","id":"the-big-picture-blood-flow-and-content","chapter":"Blood Physiology","heading":"The Big Picture: Blood Flow and Content","text":"Circulation & Blood Volume\nBlood constantly circulates closed loop driven heart blood vessels (arteries -> arterioles -> capillaries -> venules -> veins). delivers O2/nutrients removes CO2/waste\nBlood Volume: total amount blood (plasma + cells), normally around 5L adults (~7-8% body weight). ’s tightly regulated kidneys hormones (ADH, Aldosterone, ANP)\nPathophysiology\nHypovolemia: (low volume): Caused hemorrhage, dehydration. Leads low BP, poor perfusion, shock. Requires volume/RBCs\nHypervolemia: (high volume): Caused fluid overload, kidney/heart failure. Leads high BP, edema. Risk Transfusion-Associated Circulatory Overload (TACO)\n\nBlood constantly circulates closed loop driven heart blood vessels (arteries -> arterioles -> capillaries -> venules -> veins). delivers O2/nutrients removes CO2/wasteBlood Volume: total amount blood (plasma + cells), normally around 5L adults (~7-8% body weight). ’s tightly regulated kidneys hormones (ADH, Aldosterone, ANP)Pathophysiology\nHypovolemia: (low volume): Caused hemorrhage, dehydration. Leads low BP, poor perfusion, shock. Requires volume/RBCs\nHypervolemia: (high volume): Caused fluid overload, kidney/heart failure. Leads high BP, edema. Risk Transfusion-Associated Circulatory Overload (TACO)\nHypovolemia: (low volume): Caused hemorrhage, dehydration. Leads low BP, poor perfusion, shock. Requires volume/RBCsHypervolemia: (high volume): Caused fluid overload, kidney/heart failure. Leads high BP, edema. Risk Transfusion-Associated Circulatory Overload (TACO)Blood Composition & Function\nPlasma (~55%): Mostly water, plus vital proteins (albumin oncotic pressure; globulins/antibodies immunity; fibrinogen/clotting factors hemostasis), electrolytes, nutrients, hormones, waste\nFormed Elements (~45%)\nRed Blood Cells (RBCs): numerous; contain hemoglobin O2 transport\nWhite Blood Cells (WBCs): Immune defense (neutrophils, lymphocytes, etc.)\nPlatelets: Initiate clotting (hemostasis)\n\nNormal Functions: Transport (O2, CO2, nutrients, waste), Regulation (pH, temp, fluid balance), Protection (clotting, immunity)\nPathophysiology\nAnemia: Low RBCs/Hgb -> poor O2 delivery. May need RBC transfusion\nClotting Disorders: Factor deficiencies, low platelets (thrombocytopenia) -> bleeding. Need plasma/platelets\nImmune Issues: Low WBCs (neutropenia -> infection risk); presence allo/autoantibodies -> HTR/HDFN/AIHA\n\nPlasma (~55%): Mostly water, plus vital proteins (albumin oncotic pressure; globulins/antibodies immunity; fibrinogen/clotting factors hemostasis), electrolytes, nutrients, hormones, wasteFormed Elements (~45%)\nRed Blood Cells (RBCs): numerous; contain hemoglobin O2 transport\nWhite Blood Cells (WBCs): Immune defense (neutrophils, lymphocytes, etc.)\nPlatelets: Initiate clotting (hemostasis)\nRed Blood Cells (RBCs): numerous; contain hemoglobin O2 transportWhite Blood Cells (WBCs): Immune defense (neutrophils, lymphocytes, etc.)Platelets: Initiate clotting (hemostasis)Normal Functions: Transport (O2, CO2, nutrients, waste), Regulation (pH, temp, fluid balance), Protection (clotting, immunity)Pathophysiology\nAnemia: Low RBCs/Hgb -> poor O2 delivery. May need RBC transfusion\nClotting Disorders: Factor deficiencies, low platelets (thrombocytopenia) -> bleeding. Need plasma/platelets\nImmune Issues: Low WBCs (neutropenia -> infection risk); presence allo/autoantibodies -> HTR/HDFN/AIHA\nAnemia: Low RBCs/Hgb -> poor O2 delivery. May need RBC transfusionClotting Disorders: Factor deficiencies, low platelets (thrombocytopenia) -> bleeding. Need plasma/plateletsImmune Issues: Low WBCs (neutropenia -> infection risk); presence allo/autoantibodies -> HTR/HDFN/AIHA","code":""},{"path":"blood-physiology.html","id":"focus-on-the-red-blood-cell-survival-energy","chapter":"Blood Physiology","heading":"Focus on the Red Blood Cell: Survival & Energy","text":"RBC Survival\nNormal lifespan ~120 days. Limited mature RBCs anucleated (nucleus) can’t repair \nProgressive decline metabolism membrane flexibility leads removal macrophages (Mononuclear Phagocyte System) spleen (Extravascular Hemolysis)\nPathophysiology (Shortened Survival = Hemolytic Anemia)\nIntrinsic Defects: Membrane problems (Spherocytosis), Enzyme issues (G6PD, PK deficiency), Hemoglobin problems (Sickle Cell, Thalassemia)\nExtrinsic Factors: Immune (HTR, HDFN, AIHA - causing extra- intravascular hemolysis via antibodies/complement), Mechanical trauma, Infections, Toxins\nStorage Lesion: Stored RBCs undergo changes (low ATP/2,3-DPG, membrane damage) reducing post-transfusion survival\n\nNormal lifespan ~120 days. Limited mature RBCs anucleated (nucleus) can’t repair themselvesProgressive decline metabolism membrane flexibility leads removal macrophages (Mononuclear Phagocyte System) spleen (Extravascular Hemolysis)Pathophysiology (Shortened Survival = Hemolytic Anemia)\nIntrinsic Defects: Membrane problems (Spherocytosis), Enzyme issues (G6PD, PK deficiency), Hemoglobin problems (Sickle Cell, Thalassemia)\nExtrinsic Factors: Immune (HTR, HDFN, AIHA - causing extra- intravascular hemolysis via antibodies/complement), Mechanical trauma, Infections, Toxins\nStorage Lesion: Stored RBCs undergo changes (low ATP/2,3-DPG, membrane damage) reducing post-transfusion survival\nIntrinsic Defects: Membrane problems (Spherocytosis), Enzyme issues (G6PD, PK deficiency), Hemoglobin problems (Sickle Cell, Thalassemia)Extrinsic Factors: Immune (HTR, HDFN, AIHA - causing extra- intravascular hemolysis via antibodies/complement), Mechanical trauma, Infections, ToxinsStorage Lesion: Stored RBCs undergo changes (low ATP/2,3-DPG, membrane damage) reducing post-transfusion survivalRBC Metabolism\nRBCs rely anaerobic metabolism using glucose\nGlycolysis: Main pathway -> generates 2 ATP per glucose. ATP powers ion pumps (Na+/K+) maintains membrane shape/flexibility\nHMP Shunt: Generates NADPH. NADPH fuels glutathione reductase -> protects oxidative damage (ROS)\nRapoport-Luebering Shunt: Produces 2,3-DPG. 2,3-DPG binds deoxyhemoglobin -> decreases O2 affinity, facilitating O2 release tissues\nMethemoglobin Reductase: Uses NADH (glycolysis) keep hemoglobin iron reduced (Fe2+), ensuring can bind O2\nPathophysiology\nPK Deficiency: Low ATP -> rigid cells -> hemolysis\nG6PD Deficiency: Low NADPH -> vulnerable oxidative stress -> episodic hemolysis\nLow 2,3-DPG (Storage): Increased O2 affinity initially post-transfusion\n\nRBCs rely anaerobic metabolism using glucoseGlycolysis: Main pathway -> generates 2 ATP per glucose. ATP powers ion pumps (Na+/K+) maintains membrane shape/flexibilityHMP Shunt: Generates NADPH. NADPH fuels glutathione reductase -> protects oxidative damage (ROS)Rapoport-Luebering Shunt: Produces 2,3-DPG. 2,3-DPG binds deoxyhemoglobin -> decreases O2 affinity, facilitating O2 release tissuesMethemoglobin Reductase: Uses NADH (glycolysis) keep hemoglobin iron reduced (Fe2+), ensuring can bind O2Pathophysiology\nPK Deficiency: Low ATP -> rigid cells -> hemolysis\nG6PD Deficiency: Low NADPH -> vulnerable oxidative stress -> episodic hemolysis\nLow 2,3-DPG (Storage): Increased O2 affinity initially post-transfusion\nPK Deficiency: Low ATP -> rigid cells -> hemolysisG6PD Deficiency: Low NADPH -> vulnerable oxidative stress -> episodic hemolysisLow 2,3-DPG (Storage): Increased O2 affinity initially post-transfusion","code":""},{"path":"blood-physiology.html","id":"connecting-the-dots-for-blood-banking","chapter":"Blood Physiology","heading":"Connecting the Dots for Blood Banking","text":"physiology underpins transfusion medicine: transfuse components (RBCs, platelets, plasma) correct deficits composition function caused pathophysiology (e.g., anemia, bleeding). must consider recipient’s circulatory status (volume) avoid overload (TACO). need transfused cells (especially RBCs) survive adequately, depends intrinsic health metabolic state (affected storage) recipient’s immune system (risk immune-mediated hemolysis). Understanding normal abnormal blood physiology allows us make safe effective transfusion decisions","code":""},{"path":"circulation-volume.html","id":"circulation-volume","chapter":"Circulation & Volume","heading":"Circulation & Volume","text":"circulatory system acts body’s vital transport network, propelled heart, delivering oxygen nutrients removing waste. Tied closely blood volume, total amount fluid within network, must carefully regulated. Understanding circulation dynamics normal blood volume foundational appreciating patient physiology, reasons behind blood transfusions, potential consequences little much volume","code":""},{"path":"circulation-volume.html","id":"the-circulatory-system-the-bodys-highway-network","chapter":"Circulation & Volume","heading":"The Circulatory System: The Body’s Highway Network","text":": closed loop system designed transport blood throughout body, delivering vital substances (like oxygen, nutrients, hormones) tissues removing waste products (like carbon dioxide, metabolic wastes)Key Components\nHeart: central pump! muscular organ generates pressure needed propel blood vessels. four chambers (two atria, two ventricles) ensure blood flows one direction\nBlood Vessels: “pipes” “roadways.”\nArteries: Carry oxygenated blood away heart (except pulmonary artery). thick-walled elastic withstand high pressure. branch smaller\nArterioles: Smaller arteries regulate blood flow capillary beds constricting dilating\nCapillaries: Tiny, thin-walled vessels forming vast networks within tissues. magic happens! thin walls allow exchange gases (O2/CO2), nutrients, waste products blood body’s cells\nVenules: Small veins collect deoxygenated blood capillaries. merge form larger\nVeins: Carry deoxygenated blood back towards heart (except pulmonary veins). thinner walls arteries operate lower pressure. Many veins (especially limbs) valves prevent backflow blood gravity. Veins also act volume reservoir, holding significant portion blood rest\n\nHeart: central pump! muscular organ generates pressure needed propel blood vessels. four chambers (two atria, two ventricles) ensure blood flows one directionBlood Vessels: “pipes” “roadways.”\nArteries: Carry oxygenated blood away heart (except pulmonary artery). thick-walled elastic withstand high pressure. branch smaller\nArterioles: Smaller arteries regulate blood flow capillary beds constricting dilating\nCapillaries: Tiny, thin-walled vessels forming vast networks within tissues. magic happens! thin walls allow exchange gases (O2/CO2), nutrients, waste products blood body’s cells\nVenules: Small veins collect deoxygenated blood capillaries. merge form larger\nVeins: Carry deoxygenated blood back towards heart (except pulmonary veins). thinner walls arteries operate lower pressure. Many veins (especially limbs) valves prevent backflow blood gravity. Veins also act volume reservoir, holding significant portion blood rest\nArteries: Carry oxygenated blood away heart (except pulmonary artery). thick-walled elastic withstand high pressure. branch smallerArterioles: Smaller arteries regulate blood flow capillary beds constricting dilatingCapillaries: Tiny, thin-walled vessels forming vast networks within tissues. magic happens! thin walls allow exchange gases (O2/CO2), nutrients, waste products blood body’s cellsVenules: Small veins collect deoxygenated blood capillaries. merge form largerVeins: Carry deoxygenated blood back towards heart (except pulmonary veins). thinner walls arteries operate lower pressure. Many veins (especially limbs) valves prevent backflow blood gravity. Veins also act volume reservoir, holding significant portion blood restTwo Main Circuits\nPulmonary Circulation: Blood flows right ventricle -> pulmonary artery -> lungs (picks O2, drops CO2) -> pulmonary veins -> left atrium\nSystemic Circulation: Blood flows left ventricle -> aorta -> rest body (delivers O2/nutrients, picks CO2/waste) -> vena cavae -> right atrium\nPulmonary Circulation: Blood flows right ventricle -> pulmonary artery -> lungs (picks O2, drops CO2) -> pulmonary veins -> left atriumSystemic Circulation: Blood flows left ventricle -> aorta -> rest body (delivers O2/nutrients, picks CO2/waste) -> vena cavae -> right atrium","code":""},{"path":"circulation-volume.html","id":"blood-volume-how-much-fluid-is-in-the-pipes","chapter":"Circulation & Volume","heading":"Blood Volume: How Much Fluid is in the Pipes?","text":"Definition: total amount blood circulating within arteries, arterioles, capillaries, venules, veinsComponents: Blood volume consists two main parts:\nPlasma: liquid component (~55% total volume). ’s mostly water (~92%) also contains vital proteins (albumin, globulins including antibodies, fibrinogen), electrolytes, nutrients, hormones, waste products. Plasma volume crucial maintaining blood pressure transporting substances\nCellular Elements: formed elements suspended plasma (~45% total volume)\nRed Blood Cells (Erythrocytes): far numerous cells; responsible oxygen transport via hemoglobin. percentage total blood volume called hematocrit\nWhite Blood Cells (Leukocytes): Immune system cells (neutrophils, lymphocytes, monocytes, eosinophils, basophils)\nPlatelets (Thrombocytes): Cell fragments essential blood clotting\n\nPlasma: liquid component (~55% total volume). ’s mostly water (~92%) also contains vital proteins (albumin, globulins including antibodies, fibrinogen), electrolytes, nutrients, hormones, waste products. Plasma volume crucial maintaining blood pressure transporting substancesCellular Elements: formed elements suspended plasma (~45% total volume)\nRed Blood Cells (Erythrocytes): far numerous cells; responsible oxygen transport via hemoglobin. percentage total blood volume called hematocrit\nWhite Blood Cells (Leukocytes): Immune system cells (neutrophils, lymphocytes, monocytes, eosinophils, basophils)\nPlatelets (Thrombocytes): Cell fragments essential blood clotting\nRed Blood Cells (Erythrocytes): far numerous cells; responsible oxygen transport via hemoglobin. percentage total blood volume called hematocritWhite Blood Cells (Leukocytes): Immune system cells (neutrophils, lymphocytes, monocytes, eosinophils, basophils)Platelets (Thrombocytes): Cell fragments essential blood clottingNormal Values\naverage adults, total blood volume roughly 5 liters, varies significantly based :\nBody Size: Larger individuals generally blood volume\nSex: Adult males typically slightly higher blood volume per kilogram adult females, partly due hormonal influences differences muscle mass\nAge: Infants children higher blood volume relative body weight lower absolute volume adults. Blood volume calculations pediatrics often use mL/kg\n\ncommon estimate 7-8% ideal body weight kilograms\naverage adults, total blood volume roughly 5 liters, varies significantly based :\nBody Size: Larger individuals generally blood volume\nSex: Adult males typically slightly higher blood volume per kilogram adult females, partly due hormonal influences differences muscle mass\nAge: Infants children higher blood volume relative body weight lower absolute volume adults. Blood volume calculations pediatrics often use mL/kg\nBody Size: Larger individuals generally blood volumeSex: Adult males typically slightly higher blood volume per kilogram adult females, partly due hormonal influences differences muscle massAge: Infants children higher blood volume relative body weight lower absolute volume adults. Blood volume calculations pediatrics often use mL/kgA common estimate 7-8% ideal body weight kilogramsDistribution: rest, large portion blood volume (~60-70%) resides systemic veins venules, acting reservoir can mobilized needed (e.g., exercise blood loss)","code":""},{"path":"circulation-volume.html","id":"regulation-of-blood-volume-maintaining-balance","chapter":"Circulation & Volume","heading":"Regulation of Blood Volume: Maintaining Balance","text":"body works constantly keep blood volume within narrow range, primarily regulating water salt balance. involves complex interplay :Kidneys: main regulators! adjust water sodium excretion based body’s needsHormones\nAntidiuretic Hormone (ADH) / Vasopressin: Released pituitary gland body detects increased blood concentration (osmolality) low blood pressure. tells kidneys reabsorb water, reducing urine output conserving volume\nAldosterone: Released adrenal cortex, often triggered low blood pressure/volume (via renin-angiotensin system). tells kidneys reabsorb sodium, water follows passively, increasing volume\nAtrial Natriuretic Peptide (ANP): Released heart’s atria stretched high blood volume/pressure. promotes sodium water excretion kidneys, lowering volume\nAntidiuretic Hormone (ADH) / Vasopressin: Released pituitary gland body detects increased blood concentration (osmolality) low blood pressure. tells kidneys reabsorb water, reducing urine output conserving volumeAldosterone: Released adrenal cortex, often triggered low blood pressure/volume (via renin-angiotensin system). tells kidneys reabsorb sodium, water follows passively, increasing volumeAtrial Natriuretic Peptide (ANP): Released heart’s atria stretched high blood volume/pressure. promotes sodium water excretion kidneys, lowering volumeThirst Mechanism: Stimulated increased blood osmolality low volume, prompting fluid intake","code":""},{"path":"circulation-volume.html","id":"pathophysiology-when-volume-goes-wrong","chapter":"Circulation & Volume","heading":"Pathophysiology: When Volume Goes Wrong","text":"Imbalances blood volume critical clinical medicine transfusion practice:Hypovolemia (Low Blood Volume)\nCauses: Hemorrhage (blood loss trauma, surgery, GI bleeding), severe dehydration (vomiting, diarrhea, burns, inadequate intake), excessive fluid loss (e.g., certain kidney diseases)\nConsequences: Reduced venous return heart -> decreased cardiac output -> low blood pressure (hypotension) -> reduced tissue perfusion (delivery oxygen nutrients). severe, leads hypovolemic shock, life-threatening condition organs don’t receive enough oxygen\nBlood Bank Relevance: primary reason transfusion! replace lost volume /oxygen-carrying capacity. Acute hemorrhage often requires rapid volume replacement (crystalloids, colloids, plasma) red blood cells oxygen delivery compromised\nCauses: Hemorrhage (blood loss trauma, surgery, GI bleeding), severe dehydration (vomiting, diarrhea, burns, inadequate intake), excessive fluid loss (e.g., certain kidney diseases)Consequences: Reduced venous return heart -> decreased cardiac output -> low blood pressure (hypotension) -> reduced tissue perfusion (delivery oxygen nutrients). severe, leads hypovolemic shock, life-threatening condition organs don’t receive enough oxygenBlood Bank Relevance: primary reason transfusion! replace lost volume /oxygen-carrying capacity. Acute hemorrhage often requires rapid volume replacement (crystalloids, colloids, plasma) red blood cells oxygen delivery compromisedHypervolemia (High Blood Volume)\nCauses: Excessive fluid intake (especially IV fluids), kidney failure (inability excrete fluid), heart failure (impaired pumping ability leading fluid backup), excessive sodium intake, overly rapid excessive blood transfusion\nConsequences: Increased blood pressure (hypertension), edema (fluid leaking tissues), shortness breath (pulmonary edema fluid backs lungs), increased workload heart, potentially leading heart failure\nBlood Bank Relevance: major concern Transfusion-Associated Circulatory Overload (TACO). Giving blood products (especially whole blood large volumes plasma) quickly patient already fluid overload can overwhelm circulatory system, leading respiratory distress complications. Careful monitoring slower infusion rates crucial -risk patients (e.g., elderly, heart kidney disease)\nCauses: Excessive fluid intake (especially IV fluids), kidney failure (inability excrete fluid), heart failure (impaired pumping ability leading fluid backup), excessive sodium intake, overly rapid excessive blood transfusionConsequences: Increased blood pressure (hypertension), edema (fluid leaking tissues), shortness breath (pulmonary edema fluid backs lungs), increased workload heart, potentially leading heart failureBlood Bank Relevance: major concern Transfusion-Associated Circulatory Overload (TACO). Giving blood products (especially whole blood large volumes plasma) quickly patient already fluid overload can overwhelm circulatory system, leading respiratory distress complications. Careful monitoring slower infusion rates crucial -risk patients (e.g., elderly, heart kidney disease)","code":""},{"path":"circulation-volume.html","id":"connecting-circulation-volume-to-blood-banking","chapter":"Circulation & Volume","heading":"Connecting Circulation & Volume to Blood Banking","text":"Understanding physiology helps us:Recognize signs symptoms related volume depletion overloadAppreciate goals transfusion – restoring oxygen-carrying capacity (RBCs), correcting coagulopathy (plasma, platelets), /restoring volume (plasma, crystalloids)Understand risks associated transfusion, particularly TACO, identify patients needing careful monitoringInterpret laboratory values (like hematocrit) context patient’s overall volume status (e.g., hematocrit might appear falsely normal high dehydration)","code":""},{"path":"circulation-volume.html","id":"key-terms-58","chapter":"Circulation & Volume","heading":"Key Terms","text":"Circulation: movement blood vessels body, driven heart’s pumping actionBlood Volume: total amount blood (plasma + cellular elements) present circulatory systemPlasma: liquid matrix blood, composed mainly water, proteins, electrolytes, etcHematocrit: proportion blood volume occupied red blood cells, expressed percentageHypovolemia: Abnormally low circulating blood volumeHypervolemia: Abnormally high circulating blood volumeHypovolemic Shock: life-threatening condition caused insufficient circulating blood volume, leading inadequate tissue perfusionPerfusion: passage fluid (like blood) circulatory lymphatic system organ tissue, usually referring delivery blood capillary bedTransfusion-Associated Circulatory Overload (TACO): Acute respiratory distress occurring transfusion due circulatory system’s inability handle transfused volume, often resulting pulmonary edemaOpsonization: coating particle (e.g., cell, bacterium) molecules (opsonins like C3b IgG) enhance uptake phagocytic cells. (Included relates cell clearance affects circulating cells, though primarily immune term)Extravascular Hemolysis: Destruction red blood cells outside blood vessels, primarily macrophages spleen liver recognizing opsonized (C3b/IgG coated) cells. (Included affects circulating RBC volume)Intravascular Hemolysis: Destruction red blood cells within blood vessels, typically mediated MAC formation. (Included affects circulating RBC volume)","code":""},{"path":"composition-function.html","id":"composition-function","chapter":"Composition & Function","heading":"Composition & Function","text":"Blood dynamic fluid tissue diverse components working concert. Plasma provides transport medium contains vital proteins volume, clotting, immunity. RBCs carry oxygen, WBCs fight infection, platelets stop bleeding. Disruptions number function components (pathophysiology) can lead significant clinical problems, often necessitating transfusion specific blood products restore normal physiological function","code":""},{"path":"composition-function.html","id":"blood-composition-the-ingredients-of-lifes-river","chapter":"Composition & Function","heading":"Blood Composition: The Ingredients of Life’s River","text":"Blood isn’t just simple red fluid; ’s complex connective tissue made two main parts:Plasma (~55% Blood Volume): Liquid Matrix\nThink plasma “broth” transport medium. ’s mostly:\nWater (~92%): Acts solvent, dissolves substances, crucial maintaining blood volume pressure\nPlasma Proteins (~7%): vital!\nAlbumin: abundant protein, made liver. Key function maintaining oncotic pressure (keeping fluid inside blood vessels). Also acts transport protein various molecules (hormones, fatty acids, bilirubin)\nGlobulins: Diverse group including:\nImmunoglobulins (Antibodies): Crucial immune defense (made plasma cells)\nTransport Globulins: Carry specific molecules (e.g., transferrin carries iron, haptoglobin binds free hemoglobin)\n\nFibrinogen: Essential soluble precursor protein blood clotting; converted insoluble fibrin threads\nClotting Factors: Various proteins needed coagulation cascade\nComplement Proteins: Part immune system cascade\n\nSolutes (~1%)\nElectrolytes: Ions like sodium (Na+), potassium (K+), chloride (Cl-), bicarbonate (HCO3-). Essential osmotic balance, pH buffering, nerve muscle function\nNutrients: Glucose, amino acids, lipids, vitamins – absorbed digestion released storage, transported cells\nHormones: Chemical messengers transported glands target organs\nWaste Products: Urea, creatinine, bilirubin, CO2 – transported organs excretion (kidneys, liver, lungs)\n\n\nThink plasma “broth” transport medium. ’s mostly:\nWater (~92%): Acts solvent, dissolves substances, crucial maintaining blood volume pressure\nPlasma Proteins (~7%): vital!\nAlbumin: abundant protein, made liver. Key function maintaining oncotic pressure (keeping fluid inside blood vessels). Also acts transport protein various molecules (hormones, fatty acids, bilirubin)\nGlobulins: Diverse group including:\nImmunoglobulins (Antibodies): Crucial immune defense (made plasma cells)\nTransport Globulins: Carry specific molecules (e.g., transferrin carries iron, haptoglobin binds free hemoglobin)\n\nFibrinogen: Essential soluble precursor protein blood clotting; converted insoluble fibrin threads\nClotting Factors: Various proteins needed coagulation cascade\nComplement Proteins: Part immune system cascade\n\nSolutes (~1%)\nElectrolytes: Ions like sodium (Na+), potassium (K+), chloride (Cl-), bicarbonate (HCO3-). Essential osmotic balance, pH buffering, nerve muscle function\nNutrients: Glucose, amino acids, lipids, vitamins – absorbed digestion released storage, transported cells\nHormones: Chemical messengers transported glands target organs\nWaste Products: Urea, creatinine, bilirubin, CO2 – transported organs excretion (kidneys, liver, lungs)\n\nWater (~92%): Acts solvent, dissolves substances, crucial maintaining blood volume pressurePlasma Proteins (~7%): vital!\nAlbumin: abundant protein, made liver. Key function maintaining oncotic pressure (keeping fluid inside blood vessels). Also acts transport protein various molecules (hormones, fatty acids, bilirubin)\nGlobulins: Diverse group including:\nImmunoglobulins (Antibodies): Crucial immune defense (made plasma cells)\nTransport Globulins: Carry specific molecules (e.g., transferrin carries iron, haptoglobin binds free hemoglobin)\n\nFibrinogen: Essential soluble precursor protein blood clotting; converted insoluble fibrin threads\nClotting Factors: Various proteins needed coagulation cascade\nComplement Proteins: Part immune system cascade\nAlbumin: abundant protein, made liver. Key function maintaining oncotic pressure (keeping fluid inside blood vessels). Also acts transport protein various molecules (hormones, fatty acids, bilirubin)Globulins: Diverse group including:\nImmunoglobulins (Antibodies): Crucial immune defense (made plasma cells)\nTransport Globulins: Carry specific molecules (e.g., transferrin carries iron, haptoglobin binds free hemoglobin)\nImmunoglobulins (Antibodies): Crucial immune defense (made plasma cells)Transport Globulins: Carry specific molecules (e.g., transferrin carries iron, haptoglobin binds free hemoglobin)Fibrinogen: Essential soluble precursor protein blood clotting; converted insoluble fibrin threadsOther Clotting Factors: Various proteins needed coagulation cascadeComplement Proteins: Part immune system cascadeOther Solutes (~1%)\nElectrolytes: Ions like sodium (Na+), potassium (K+), chloride (Cl-), bicarbonate (HCO3-). Essential osmotic balance, pH buffering, nerve muscle function\nNutrients: Glucose, amino acids, lipids, vitamins – absorbed digestion released storage, transported cells\nHormones: Chemical messengers transported glands target organs\nWaste Products: Urea, creatinine, bilirubin, CO2 – transported organs excretion (kidneys, liver, lungs)\nElectrolytes: Ions like sodium (Na+), potassium (K+), chloride (Cl-), bicarbonate (HCO3-). Essential osmotic balance, pH buffering, nerve muscle functionNutrients: Glucose, amino acids, lipids, vitamins – absorbed digestion released storage, transported cellsHormones: Chemical messengers transported glands target organsWaste Products: Urea, creatinine, bilirubin, CO2 – transported organs excretion (kidneys, liver, lungs)Formed Elements (~45% Blood Volume): Cellular Components\ncells cell fragments suspended plasma:\nRed Blood Cells (RBCs / Erythrocytes): far numerous\nStructure: Biconcave disc shape (increases surface area gas exchange, allows flexibility), anucleated (lack nucleus) mature mammals\nKey Component: Hemoglobin (Hgb), iron-containing protein binds transports oxygen\n\nWhite Blood Cells (WBCs / Leukocytes): immune defense force. Much less numerous RBCs. several types:\nGranulocytes: (Contain visible granules) Neutrophils (phagocytosis, bacterial defense), Eosinophils (parasite defense, allergic reactions), Basophils (histamine release, inflammation)\nAgranulocytes: (Lack visible granules) Lymphocytes (specific immunity – T cells, B cells -> plasma cells, NK cells), Monocytes (mature macrophages phagocytosis antigen presentation)\n\nPlatelets (Thrombocytes): Small, irregular-shaped cell fragments derived large bone marrow cells (megakaryocytes). true cells\n\ncells cell fragments suspended plasma:\nRed Blood Cells (RBCs / Erythrocytes): far numerous\nStructure: Biconcave disc shape (increases surface area gas exchange, allows flexibility), anucleated (lack nucleus) mature mammals\nKey Component: Hemoglobin (Hgb), iron-containing protein binds transports oxygen\n\nWhite Blood Cells (WBCs / Leukocytes): immune defense force. Much less numerous RBCs. several types:\nGranulocytes: (Contain visible granules) Neutrophils (phagocytosis, bacterial defense), Eosinophils (parasite defense, allergic reactions), Basophils (histamine release, inflammation)\nAgranulocytes: (Lack visible granules) Lymphocytes (specific immunity – T cells, B cells -> plasma cells, NK cells), Monocytes (mature macrophages phagocytosis antigen presentation)\n\nPlatelets (Thrombocytes): Small, irregular-shaped cell fragments derived large bone marrow cells (megakaryocytes). true cells\nRed Blood Cells (RBCs / Erythrocytes): far numerous\nStructure: Biconcave disc shape (increases surface area gas exchange, allows flexibility), anucleated (lack nucleus) mature mammals\nKey Component: Hemoglobin (Hgb), iron-containing protein binds transports oxygen\nStructure: Biconcave disc shape (increases surface area gas exchange, allows flexibility), anucleated (lack nucleus) mature mammalsKey Component: Hemoglobin (Hgb), iron-containing protein binds transports oxygenWhite Blood Cells (WBCs / Leukocytes): immune defense force. Much less numerous RBCs. several types:\nGranulocytes: (Contain visible granules) Neutrophils (phagocytosis, bacterial defense), Eosinophils (parasite defense, allergic reactions), Basophils (histamine release, inflammation)\nAgranulocytes: (Lack visible granules) Lymphocytes (specific immunity – T cells, B cells -> plasma cells, NK cells), Monocytes (mature macrophages phagocytosis antigen presentation)\nGranulocytes: (Contain visible granules) Neutrophils (phagocytosis, bacterial defense), Eosinophils (parasite defense, allergic reactions), Basophils (histamine release, inflammation)Agranulocytes: (Lack visible granules) Lymphocytes (specific immunity – T cells, B cells -> plasma cells, NK cells), Monocytes (mature macrophages phagocytosis antigen presentation)Platelets (Thrombocytes): Small, irregular-shaped cell fragments derived large bone marrow cells (megakaryocytes). true cells","code":""},{"path":"composition-function.html","id":"normal-function-what-blood-does-day-to-day","chapter":"Composition & Function","heading":"Normal Function: What Blood Does Day-to-Day","text":"Blood three overarching functions: Transport, Regulation, ProtectionTransport\nOxygen Delivery: RBCs pick O2 lungs deliver tissues\nCarbon Dioxide Removal: Blood carries CO2 (dissolved plasma, bound Hgb, bicarbonate ions) tissues back lungs exhalation\nNutrient Distribution: Plasma transports glucose, amino acids, fats, etc., digestive tract/liver cells\nHormone Transport: Carries hormones endocrine glands target cells\nWaste Transport: Moves metabolic wastes (urea, etc.) kidneys excretion\nHeat Distribution: Helps distribute heat throughout body\nOxygen Delivery: RBCs pick O2 lungs deliver tissuesCarbon Dioxide Removal: Blood carries CO2 (dissolved plasma, bound Hgb, bicarbonate ions) tissues back lungs exhalationNutrient Distribution: Plasma transports glucose, amino acids, fats, etc., digestive tract/liver cellsHormone Transport: Carries hormones endocrine glands target cellsWaste Transport: Moves metabolic wastes (urea, etc.) kidneys excretionHeat Distribution: Helps distribute heat throughout bodyRegulation\nTemperature: Absorbs distributes heat, helping maintain core body temperature\npH Balance: Plasma proteins bicarbonate buffer system help maintain blood pH within narrow range (typically 7.35-7.45)\nFluid Volume: Plasma proteins (especially albumin) maintain oncotic pressure, preventing excessive fluid loss capillaries tissues. Total blood volume key maintaining blood pressure\nTemperature: Absorbs distributes heat, helping maintain core body temperaturepH Balance: Plasma proteins bicarbonate buffer system help maintain blood pH within narrow range (typically 7.35-7.45)Fluid Volume: Plasma proteins (especially albumin) maintain oncotic pressure, preventing excessive fluid loss capillaries tissues. Total blood volume key maintaining blood pressureProtection\nHemostasis (Preventing Blood Loss): Platelets form temporary plug injury sites, plasma clotting factors (like fibrinogen) create stable fibrin clot\nImmunity (Fighting Infection): WBCs defend pathogens (bacteria, viruses, fungi, parasites) phagocytosis, antibody production, cell-mediated killing. Complement proteins assist\nHemostasis (Preventing Blood Loss): Platelets form temporary plug injury sites, plasma clotting factors (like fibrinogen) create stable fibrin clotImmunity (Fighting Infection): WBCs defend pathogens (bacteria, viruses, fungi, parasites) phagocytosis, antibody production, cell-mediated killing. Complement proteins assist","code":""},{"path":"composition-function.html","id":"abnormal-physiology-pathophysiology-when-things-go-wrong","chapter":"Composition & Function","heading":"Abnormal Physiology (Pathophysiology): When Things Go Wrong","text":"Deviations normal composition function lead various disease states, many directly relevant blood banking:Plasma Abnormalities\nHypovolemia: Reduced plasma volume (due hemorrhage, dehydration) leads low blood pressure, poor tissue perfusion. Need volume replacement (crystalloids, plasma)\nHypervolemia: Excess plasma volume (kidney failure, heart failure, transfusion overload) leads high blood pressure, edema, risk TACO\nLow Plasma Proteins (e.g., low albumin): Reduces oncotic pressure -> edema. Impaired transport\nClotting Factor Deficiencies (e.g., Hemophilia, Liver Disease, DIC): Impaired coagulation -> excessive bleeding. Need plasma products (FFP, Cryoprecipitate) factor concentrates\nPresence Abnormal Proteins (Paraproteins): Seen conditions like Multiple Myeloma. Can cause rouleaux (RBC stacking interfering testing), hyperviscosity\nPresence Pathological Antibodies\nAlloantibodies: foreign antigens (e.g., anti-D, anti-K previous transfusion/pregnancy) -> risk HTR, HDFN. Need antigen-negative blood\nAutoantibodies: self-antigens (e.g., AIHA) -> destruction RBCs, compatibility testing challenges\n\nHypovolemia: Reduced plasma volume (due hemorrhage, dehydration) leads low blood pressure, poor tissue perfusion. Need volume replacement (crystalloids, plasma)Hypervolemia: Excess plasma volume (kidney failure, heart failure, transfusion overload) leads high blood pressure, edema, risk TACOLow Plasma Proteins (e.g., low albumin): Reduces oncotic pressure -> edema. Impaired transportClotting Factor Deficiencies (e.g., Hemophilia, Liver Disease, DIC): Impaired coagulation -> excessive bleeding. Need plasma products (FFP, Cryoprecipitate) factor concentratesPresence Abnormal Proteins (Paraproteins): Seen conditions like Multiple Myeloma. Can cause rouleaux (RBC stacking interfering testing), hyperviscosityPresence Pathological Antibodies\nAlloantibodies: foreign antigens (e.g., anti-D, anti-K previous transfusion/pregnancy) -> risk HTR, HDFN. Need antigen-negative blood\nAutoantibodies: self-antigens (e.g., AIHA) -> destruction RBCs, compatibility testing challenges\nAlloantibodies: foreign antigens (e.g., anti-D, anti-K previous transfusion/pregnancy) -> risk HTR, HDFN. Need antigen-negative bloodAutoantibodies: self-antigens (e.g., AIHA) -> destruction RBCs, compatibility testing challengesRed Blood Cell Abnormalities\nAnemia (Low RBC count / Low Hemoglobin): Reduced oxygen-carrying capacity. Symptoms: fatigue, pallor, shortness breath\nCauses\nBlood Loss: Acute (trauma, surgery) Chronic (GI bleed). Need RBC transfusion\nDecreased Production: Iron/B12/Folate deficiency, Aplastic anemia, Kidney disease (low erythropoietin), Bone marrow disorders. May need RBC transfusion\nIncreased Destruction (Hemolysis):\nImmune: AIHA, HTR, HDFN. May need RBC transfusion (compatible units crucial)\nNon-Immune: Mechanical heart valves, Infections (malaria), Inherited defects (Sickle Cell Disease, Thalassemia, Spherocytosis). Sickle cell/Thalassemia may need chronic transfusion therapy\n\n\n\nPolycythemia (High RBC Count): Increased blood viscosity, risk clotting (thrombosis)\nAnemia (Low RBC count / Low Hemoglobin): Reduced oxygen-carrying capacity. Symptoms: fatigue, pallor, shortness breath\nCauses\nBlood Loss: Acute (trauma, surgery) Chronic (GI bleed). Need RBC transfusion\nDecreased Production: Iron/B12/Folate deficiency, Aplastic anemia, Kidney disease (low erythropoietin), Bone marrow disorders. May need RBC transfusion\nIncreased Destruction (Hemolysis):\nImmune: AIHA, HTR, HDFN. May need RBC transfusion (compatible units crucial)\nNon-Immune: Mechanical heart valves, Infections (malaria), Inherited defects (Sickle Cell Disease, Thalassemia, Spherocytosis). Sickle cell/Thalassemia may need chronic transfusion therapy\n\n\nCauses\nBlood Loss: Acute (trauma, surgery) Chronic (GI bleed). Need RBC transfusion\nDecreased Production: Iron/B12/Folate deficiency, Aplastic anemia, Kidney disease (low erythropoietin), Bone marrow disorders. May need RBC transfusion\nIncreased Destruction (Hemolysis):\nImmune: AIHA, HTR, HDFN. May need RBC transfusion (compatible units crucial)\nNon-Immune: Mechanical heart valves, Infections (malaria), Inherited defects (Sickle Cell Disease, Thalassemia, Spherocytosis). Sickle cell/Thalassemia may need chronic transfusion therapy\n\nBlood Loss: Acute (trauma, surgery) Chronic (GI bleed). Need RBC transfusionDecreased Production: Iron/B12/Folate deficiency, Aplastic anemia, Kidney disease (low erythropoietin), Bone marrow disorders. May need RBC transfusionIncreased Destruction (Hemolysis):\nImmune: AIHA, HTR, HDFN. May need RBC transfusion (compatible units crucial)\nNon-Immune: Mechanical heart valves, Infections (malaria), Inherited defects (Sickle Cell Disease, Thalassemia, Spherocytosis). Sickle cell/Thalassemia may need chronic transfusion therapy\nImmune: AIHA, HTR, HDFN. May need RBC transfusion (compatible units crucial)Non-Immune: Mechanical heart valves, Infections (malaria), Inherited defects (Sickle Cell Disease, Thalassemia, Spherocytosis). Sickle cell/Thalassemia may need chronic transfusion therapyPolycythemia (High RBC Count): Increased blood viscosity, risk clotting (thrombosis)White Blood Cell Abnormalities\nLeukopenia (Low WBC Count)\nNeutropenia: Increased risk severe bacterial infections. May rarely require granulocyte transfusion specific severe cases\n\nLeukocytosis (High WBC Count): Often indicates infection inflammation. high counts (leukemia) can cause hyperviscosity\nLeukemias/Lymphomas: Cancers WBCs, leading abnormal cell production function. Can cause anemia thrombocytopenia due bone marrow crowding\nLeukopenia (Low WBC Count)\nNeutropenia: Increased risk severe bacterial infections. May rarely require granulocyte transfusion specific severe cases\nNeutropenia: Increased risk severe bacterial infections. May rarely require granulocyte transfusion specific severe casesLeukocytosis (High WBC Count): Often indicates infection inflammation. high counts (leukemia) can cause hyperviscosityLeukemias/Lymphomas: Cancers WBCs, leading abnormal cell production function. Can cause anemia thrombocytopenia due bone marrow crowdingPlatelet Abnormalities\nThrombocytopenia (Low Platelet Count): Increased risk bleeding (petechiae, purpura, severe hemorrhage)\nCauses\nDecreased Production: Bone marrow failure, chemotherapy\nIncreased Destruction: Immune Thrombocytopenia (ITP), Heparin-Induced Thrombocytopenia (HIT), Disseminated Intravascular Coagulation (DIC), Thrombotic Thrombocytopenic Purpura (TTP), Alloimmune (Post-Transfusion Purpura-PTP, Neonatal Alloimmune Thrombocytopenia-NAIT)\nSequestration: Enlarged spleen\n\nNeed platelet transfusion count critically low patient bleeding\n\nThrombocytosis (High Platelet Count): Increased risk thrombosis\nPlatelet Function Disorders (Thrombocytopathy): Normal platelet count abnormal function -> bleeding risk. May need platelet transfusion\n## Key Terms {-}\nThrombocytopenia (Low Platelet Count): Increased risk bleeding (petechiae, purpura, severe hemorrhage)\nCauses\nDecreased Production: Bone marrow failure, chemotherapy\nIncreased Destruction: Immune Thrombocytopenia (ITP), Heparin-Induced Thrombocytopenia (HIT), Disseminated Intravascular Coagulation (DIC), Thrombotic Thrombocytopenic Purpura (TTP), Alloimmune (Post-Transfusion Purpura-PTP, Neonatal Alloimmune Thrombocytopenia-NAIT)\nSequestration: Enlarged spleen\n\nNeed platelet transfusion count critically low patient bleeding\nCauses\nDecreased Production: Bone marrow failure, chemotherapy\nIncreased Destruction: Immune Thrombocytopenia (ITP), Heparin-Induced Thrombocytopenia (HIT), Disseminated Intravascular Coagulation (DIC), Thrombotic Thrombocytopenic Purpura (TTP), Alloimmune (Post-Transfusion Purpura-PTP, Neonatal Alloimmune Thrombocytopenia-NAIT)\nSequestration: Enlarged spleen\nDecreased Production: Bone marrow failure, chemotherapyIncreased Destruction: Immune Thrombocytopenia (ITP), Heparin-Induced Thrombocytopenia (HIT), Disseminated Intravascular Coagulation (DIC), Thrombotic Thrombocytopenic Purpura (TTP), Alloimmune (Post-Transfusion Purpura-PTP, Neonatal Alloimmune Thrombocytopenia-NAIT)Sequestration: Enlarged spleenNeed platelet transfusion count critically low patient bleedingThrombocytosis (High Platelet Count): Increased risk thrombosisPlatelet Function Disorders (Thrombocytopathy): Normal platelet count abnormal function -> bleeding risk. May need platelet transfusion\n## Key Terms {-}Plasma: liquid component blood, containing water, proteins, electrolytes, nutrients, hormones, waste productsFormed Elements: cellular components blood: red blood cells, white blood cells, plateletsRed Blood Cells (RBCs/Erythrocytes): Anucleated, biconcave cells containing hemoglobin, responsible oxygen transportHemoglobin (Hgb): iron-containing protein within RBCs binds oxygenWhite Blood Cells (WBCs/Leukocytes): Diverse group immune cells involved defending body pathogensPlatelets (Thrombocytes): Small cell fragments involved blood clotting (hemostasis)Albumin: abundant plasma protein, crucial maintaining oncotic pressureImmunoglobulins (Antibodies): Plasma proteins produced B cells/plasma cells specific immune defenseFibrinogen: soluble plasma protein precursor converted insoluble fibrin blood clottingHemostasis: process stopping bleeding, involving platelet plug formation coagulationAnemia: condition characterized deficiency red blood cells hemoglobin, resulting reduced oxygen transportHemolysis: destruction red blood cellsThrombocytopenia: condition characterized abnormally low number platelets bloodNeutropenia: condition characterized abnormally low number neutrophils (type WBC)Oncotic Pressure: pressure exerted plasma proteins (mainly albumin) tends pull water circulatory systemPathophysiology: study functional changes associated resulting disease injury","code":""},{"path":"cell-survival.html","id":"cell-survival","chapter":"Cell Survival","heading":"Cell Survival","text":"section covers cell survival, focusing specifically Red Blood Cell (RBC) Erythrocyte. ? survival absolutely central transfusion medicine! need transfused RBCs survive long enough recipient job (carry oxygen), understanding RBCs die – normally prematurely – key understanding hemolytic anemias transfusion reactions","code":""},{"path":"cell-survival.html","id":"the-normal-lifespan-of-a-red-blood-cell-a-finite-journey","chapter":"Cell Survival","heading":"The Normal Lifespan of a Red Blood Cell: A Finite Journey","text":"Clock: healthy individual, mature red blood cell circulates approximately 120 days released bone marrowWhy Limit? Anucleate Factor: defining feature limiting RBC survival mature mammalian RBCs anucleated – lack nucleus. means:\nDNA blueprint making new proteins\nability synthesize RNA proteins\ncapacity self-repair replacing damaged components\nDNA blueprint making new proteinsNo ability synthesize RNA proteinsNo capacity self-repair replacing damaged componentsThe Consequences: 120-day journey, RBC undergoes progressive “wear tear” fix:\nMetabolic Decline: Key enzymes involved energy production (primarily anaerobic glycolysis) degrade time. leads decreased production ATP, vital :\nMaintaining ion gradients across cell membrane (e.g., via Na+/K+ pump). Failure leads electrolyte imbalance, cell swelling, loss shape\nMaintaining membrane flexibility characteristic biconcave shape\nKeeping hemoglobin iron functional reduced state (Fe2+)\n\nMembrane Damage: RBC membrane loses lipids proteins (like spectrin, provides cytoskeletal support), becoming less flexible fragile. Deformability decreases significantly\nOxidative Damage: Continuous exposure oxygen creates reactive oxygen species (ROS). RBCs protective mechanisms (like glutathione pathway fueled NADPH Hexose Monophosphate Shunt), systems also decline time, allowing damage accumulate\nMetabolic Decline: Key enzymes involved energy production (primarily anaerobic glycolysis) degrade time. leads decreased production ATP, vital :\nMaintaining ion gradients across cell membrane (e.g., via Na+/K+ pump). Failure leads electrolyte imbalance, cell swelling, loss shape\nMaintaining membrane flexibility characteristic biconcave shape\nKeeping hemoglobin iron functional reduced state (Fe2+)\nMaintaining ion gradients across cell membrane (e.g., via Na+/K+ pump). Failure leads electrolyte imbalance, cell swelling, loss shapeMaintaining membrane flexibility characteristic biconcave shapeKeeping hemoglobin iron functional reduced state (Fe2+)Membrane Damage: RBC membrane loses lipids proteins (like spectrin, provides cytoskeletal support), becoming less flexible fragile. Deformability decreases significantlyOxidative Damage: Continuous exposure oxygen creates reactive oxygen species (ROS). RBCs protective mechanisms (like glutathione pathway fueled NADPH Hexose Monophosphate Shunt), systems also decline time, allowing damage accumulate","code":""},{"path":"cell-survival.html","id":"normal-removal-the-end-of-the-line","chapter":"Cell Survival","heading":"Normal Removal: The End of the Line","text":"Mechanism: Extravascular Hemolysis: RBCs age become less deformable display subtle changes surface, recognized removed circulation primarily macrophages Mononuclear Phagocyte System (MPS) (formerly Reticuloendothelial System - RES)Location: process occurs mainly spleen, whose narrow sinusoids act filter, trapping rigid, older cells. Liver macrophages also play roleThe Process: Macrophages engulf (phagocytose) senescent RBCs. Inside macrophage, hemoglobin broken :\nGlobin: Broken amino acids, recycled\nHeme: Iron (Fe2+) released, bound transferrin, transported reuse (mostly new RBC production). remaining porphyrin ring converted bilirubin, processed liver, eventually excreted bile\nGlobin: Broken amino acids, recycledHeme: Iron (Fe2+) released, bound transferrin, transported reuse (mostly new RBC production). remaining porphyrin ring converted bilirubin, processed liver, eventually excreted bileKey Point: normal removal process orderly efficient, recycling valuable components like iron","code":""},{"path":"cell-survival.html","id":"factors-essential-for-normal-rbc-survival","chapter":"Cell Survival","heading":"Factors Essential for Normal RBC Survival","text":"RBC reach full 120-day potential, several things need right:Intact Functional Cell Membrane Needs correct lipid composition healthy cytoskeleton (spectrin, ankyrin, etc.) maintain biconcave shape, provide deformability (squeeze capillaries), control permeabilityFunctional Hemoglobin Must able bind, transport, release oxygen effectively. requires correct globin chain structure iron reduced ferrous (Fe2+) stateAdequate Metabolic Machinery Needs sufficient ATP (glycolysis) membrane function ion transport, sufficient NADPH (Hexose Monophosphate/Pentose Phosphate Shunt) protect oxidative damage","code":""},{"path":"cell-survival.html","id":"pathophysiology-shortened-rbc-survival-hemolysis","chapter":"Cell Survival","heading":"Pathophysiology: Shortened RBC Survival (Hemolysis)","text":"RBCs destroyed normal 120-day lifespan, leads hemolytic anemia. causes shortened survival (hemolysis) can broadly divided intrinsic problems (defects within RBC) extrinsic factors (something outside attacking RBC)","code":""},{"path":"cell-survival.html","id":"intrinsic-rbc-defects-often-inherited","chapter":"Cell Survival","heading":"Intrinsic RBC Defects (Often Inherited)","text":"Membrane Abnormalities (Membranopathies)\nHereditary Spherocytosis: Defects membrane proteins (spectrin, ankyrin) cause cell lose membrane surface area, become spherical, rigid, easily trapped/destroyed spleen\nHereditary Elliptocytosis: Similar protein defects lead elliptical-shaped, less deformable cells\nHereditary Spherocytosis: Defects membrane proteins (spectrin, ankyrin) cause cell lose membrane surface area, become spherical, rigid, easily trapped/destroyed spleenHereditary Elliptocytosis: Similar protein defects lead elliptical-shaped, less deformable cellsEnzyme Deficiencies (Enzymopathies)\nG6PD Deficiency: Deficiency Glucose-6-Phosphate Dehydrogenase (first enzyme HMP shunt) -> insufficient NADPH -> poor protection oxidative stress. Hemolysis occurs exposed certain drugs, infections, fava beans\nPyruvate Kinase Deficiency: Defect key glycolytic enzyme -> reduced ATP production -> membrane instability hemolysis\nG6PD Deficiency: Deficiency Glucose-6-Phosphate Dehydrogenase (first enzyme HMP shunt) -> insufficient NADPH -> poor protection oxidative stress. Hemolysis occurs exposed certain drugs, infections, fava beansPyruvate Kinase Deficiency: Defect key glycolytic enzyme -> reduced ATP production -> membrane instability hemolysisHemoglobin Abnormalities (Hemoglobinopathies)\nSickle Cell Disease: Abnormal hemoglobin (HbS) polymerizes deoxygenated, causing RBCs become rigid sickle-shaped. Leads membrane damage, hemolysis, vaso-occlusion\nThalassemias: Reduced absent synthesis normal globin chains -> unbalanced chain production, ineffective erythropoiesis, fragile RBCs prone hemolysis\nSickle Cell Disease: Abnormal hemoglobin (HbS) polymerizes deoxygenated, causing RBCs become rigid sickle-shaped. Leads membrane damage, hemolysis, vaso-occlusionThalassemias: Reduced absent synthesis normal globin chains -> unbalanced chain production, ineffective erythropoiesis, fragile RBCs prone hemolysis","code":""},{"path":"cell-survival.html","id":"extrinsic-factors-often-acquired","chapter":"Cell Survival","heading":"Extrinsic Factors (Often Acquired)","text":"Immune-Mediated Hemolysis: (Core Blood Bank Area!) Antibodies +/- complement bind RBCs, leading destruction\nAlloimmune: Antibodies foreign RBC antigens\nHemolytic Transfusion Reactions (HTRs): Recipient antibodies destroy transfused donor RBCs\nHemolytic Disease Fetus Newborn (HDFN): Maternal IgG antibodies cross placenta destroy fetal RBCs\n\nAutoimmune: Antibodies self RBC antigens\nAutoimmune Hemolytic Anemia (AIHA): Warm AIHA (usually IgG), Cold Agglutinin Disease (usually IgM)\n\nDrug-Induced: Drugs trigger antibody production targets RBCs\nMechanism: Destruction occurs via Extravascular Hemolysis (opsonization IgG/C3b -> phagocytosis MPS) Intravascular Hemolysis (complement activation MAC -> direct lysis circulation)\nAlloimmune: Antibodies foreign RBC antigens\nHemolytic Transfusion Reactions (HTRs): Recipient antibodies destroy transfused donor RBCs\nHemolytic Disease Fetus Newborn (HDFN): Maternal IgG antibodies cross placenta destroy fetal RBCs\nHemolytic Transfusion Reactions (HTRs): Recipient antibodies destroy transfused donor RBCsHemolytic Disease Fetus Newborn (HDFN): Maternal IgG antibodies cross placenta destroy fetal RBCsAutoimmune: Antibodies self RBC antigens\nAutoimmune Hemolytic Anemia (AIHA): Warm AIHA (usually IgG), Cold Agglutinin Disease (usually IgM)\nAutoimmune Hemolytic Anemia (AIHA): Warm AIHA (usually IgG), Cold Agglutinin Disease (usually IgM)Drug-Induced: Drugs trigger antibody production targets RBCsMechanism: Destruction occurs via Extravascular Hemolysis (opsonization IgG/C3b -> phagocytosis MPS) Intravascular Hemolysis (complement activation MAC -> direct lysis circulation)Non-Immune Extrinsic Factors\nMechanical Trauma: Physical shearing RBCs (Microangiopathic Hemolytic Anemias like TTP, HUS, DIC; malfunctioning prosthetic heart valves)\nInfections: Malaria parasites invade destroy RBCs; certain bacterial toxins (e.g., Clostridium perfringens) damage membranes\nChemicals/Drugs/Toxins: Oxidative drugs (G6PD deficiency), lead poisoning, snake/spider venoms\nPhysical Agents: Severe burns (thermal damage)\nMechanical Trauma: Physical shearing RBCs (Microangiopathic Hemolytic Anemias like TTP, HUS, DIC; malfunctioning prosthetic heart valves)Infections: Malaria parasites invade destroy RBCs; certain bacterial toxins (e.g., Clostridium perfringens) damage membranesChemicals/Drugs/Toxins: Oxidative drugs (G6PD deficiency), lead poisoning, snake/spider venomsPhysical Agents: Severe burns (thermal damage)","code":""},{"path":"cell-survival.html","id":"blood-storage-and-survival-the-storage-lesion","chapter":"Cell Survival","heading":"Blood Storage and Survival: The “Storage Lesion”","text":"Even outside body, RBC survival limited. stored blood bags, RBCs undergo changes collectively known storage lesion:Decrease ATP 2,3-Diphosphoglycerate (2,3-DPG, affects oxygen release)Loss membrane lipids, increased fragility, shape changes (spheroechinocytes)Leakage intracellular potassium (K+) supernatantAccumulation lactic acid, decreased pHOxidative damageThese changes reduce post-transfusion survival function stored RBCs. Regulatory limits storage time (e.g., 42 days certain additive solutions) based ensuring least 75% transfused cells still circulating 24 hours transfusion","code":""},{"path":"cell-survival.html","id":"key-terms-59","chapter":"Cell Survival","heading":"Key Terms","text":"Erythrocyte (RBC): Red blood cell, responsible oxygen transportAnucleated: Lacking nucleusATP (Adenosine Triphosphate): main energy currency cellNADPH (Nicotinamide Adenine Dinucleotide Phosphate): essential cofactor, particularly protecting oxidative stress via glutathione pathwayGlycolysis: metabolic pathway breaks glucose produce ATP (anaerobic mature RBCs)Hexose Monophosphate Shunt (Pentose Phosphate Pathway): Metabolic pathway produces NADPHDeformability: ability RBC change shape pass narrow capillaries splenic sinusoidsMononuclear Phagocyte System (MPS) / Reticuloendothelial System (RES): Network phagocytic cells (mainly macrophages) tissues like spleen, liver, lymph nodes, responsible removing old/damaged cells pathogensExtravascular Hemolysis: Destruction RBCs outside blood vessels, primarily macrophages spleen liverIntravascular Hemolysis: Destruction RBCs within blood vessels, usually complement activation (MAC) severe mechanical traumaHemolysis: breakdown destruction red blood cellsHemolytic Anemia: Anemia resulting excessive destruction red blood cellsOpsonization: Coating cell antibodies complement fragments (like C3b) enhance phagocytosisStorage Lesion: collection biochemical morphological changes occur red blood cells storage","code":""},{"path":"cell-metabolism.html","id":"cell-metabolism","chapter":"Cell Metabolism","heading":"Cell Metabolism","text":"Cell Metabolism engine room Red Blood Cell! Understanding RBC metabolism crucial , even though ’s relatively simple compared cells, ’s perfectly tailored main jobs: carrying oxygen surviving 120 days. Since mature RBCs nucleus mitochondria (ditch development!), can’t perform aerobic respiration make new proteins. rely entirely anaerobic pathways using glucose fuel sourceThink RBC metabolism four main goals:Generate ATP (energy currency) maintain cell shape flexibilityGenerate NADPH (reducing power) protect oxidative damageMaintain Hemoglobin iron functional (Fe2+) stateModulate Oxygen Affinity hemoglobin efficient deliveryLet’s break key pathways achieve goals:","code":""},{"path":"cell-metabolism.html","id":"normal-rbc-metabolism-keeping-the-engine-running","chapter":"Cell Metabolism","heading":"Normal RBC Metabolism: Keeping the Engine Running","text":"","code":""},{"path":"cell-metabolism.html","id":"glycolysis-embden-meyerhof-pathway-the-atp-factory","chapter":"Cell Metabolism","heading":"Glycolysis (Embden-Meyerhof Pathway): The ATP Factory","text":"Goal: Primary source ATP RBCThe Process: main route glucose breakdown. ’s anaerobic pathway (doesn’t require oxygen). Glucose enters cell (facilitated diffusion) broken series enzymatic steps pyruvate. Since mitochondria aerobic breakdown, pyruvate primarily converted lactate, exits cellThe Payoff: Yields net gain 2 ATP molecules per molecule glucose metabolizedWhy ATP Vital\nIon Pumps: Powers Na+/K+-ATPase Ca2+-ATPase pumps cell membrane. maintain proper balance ions (low intracellular Na+ Ca2+, high K+), essential cell volume regulation membrane integrity\nMembrane Maintenance: Helps maintain phosphorylation state membrane proteins (like spectrin), contributing RBC’s characteristic biconcave shape deformability (flexibility)\nPriming Glycolysis: ATP actually needed start process (phosphorylating glucose)\nIon Pumps: Powers Na+/K+-ATPase Ca2+-ATPase pumps cell membrane. maintain proper balance ions (low intracellular Na+ Ca2+, high K+), essential cell volume regulation membrane integrityMembrane Maintenance: Helps maintain phosphorylation state membrane proteins (like spectrin), contributing RBC’s characteristic biconcave shape deformability (flexibility)Priming Glycolysis: ATP actually needed start process (phosphorylating glucose)","code":""},{"path":"cell-metabolism.html","id":"hexose-monophosphate-shunt-hmp-shunt-pentose-phosphate-pathway-the-antioxidant-shield","chapter":"Cell Metabolism","heading":"Hexose Monophosphate Shunt (HMP Shunt) / Pentose Phosphate Pathway: The Antioxidant Shield","text":"Goal: Generate NADPH, cell’s main defense oxidative stressThe Process: pathway branches glycolysis Glucose-6-Phosphate step. key regulatory enzyme Glucose-6-Phosphate Dehydrogenase (G6PD). converts NADP+ NADPHWhy NADPH Vital\nGlutathione Reduction: NADPH absolutely essential enzyme glutathione reductase. enzyme keeps glutathione (small peptide) reduced state\nDetoxification: Reduced glutathione used glutathione peroxidase neutralize harmful reactive oxygen species (ROS), hydrogen peroxide (H2O2), converting harmless water\nProtection: system protects vital cell components, especially hemoglobin (preventing iron oxidizing) membrane lipids/proteins, oxidative damage caused ROS generated normal metabolism exposure external oxidants\nGlutathione Reduction: NADPH absolutely essential enzyme glutathione reductase. enzyme keeps glutathione (small peptide) reduced stateDetoxification: Reduced glutathione used glutathione peroxidase neutralize harmful reactive oxygen species (ROS), hydrogen peroxide (H2O2), converting harmless waterProtection: system protects vital cell components, especially hemoglobin (preventing iron oxidizing) membrane lipids/proteins, oxidative damage caused ROS generated normal metabolism exposure external oxidants","code":""},{"path":"cell-metabolism.html","id":"rapoport-luebering-shunt-the-oxygen-release-lever","chapter":"Cell Metabolism","heading":"Rapoport-Luebering Shunt: The Oxygen Release Lever","text":"Goal: Produce 2,3-Diphosphoglycerate (2,3-DPG), formerly known 2,3-Bisphosphoglycerate (2,3-BPG)Process: unique “bypass” loop within glycolysis. takes intermediate (1,3-DPG) converts 2,3-DPG via enzyme DPG mutase, eventually rejoining main glycolytic pathwayWhy 2,3-DPG Vital\nOxygen Affinity Regulator: 2,3-DPG binds preferentially deoxygenated hemoglobin. binding stabilizes “T” (tense) state hemoglobin, lower affinity oxygen\nFacilitates O2 Release: reducing hemoglobin’s oxygen affinity, 2,3-DPG promotes release oxygen hemoglobin tissues ’s needed . Without 2,3-DPG, hemoglobin hold onto oxygen tightly tissue oxygen levels\nTrade-: shunt bypasses one ATP-generating steps glycolysis (phosphoglycerate kinase step). , making 2,3-DPG comes cost slightly reduced overall ATP production\nOxygen Affinity Regulator: 2,3-DPG binds preferentially deoxygenated hemoglobin. binding stabilizes “T” (tense) state hemoglobin, lower affinity oxygenFacilitates O2 Release: reducing hemoglobin’s oxygen affinity, 2,3-DPG promotes release oxygen hemoglobin tissues ’s needed . Without 2,3-DPG, hemoglobin hold onto oxygen tightly tissue oxygen levelsTrade-: shunt bypasses one ATP-generating steps glycolysis (phosphoglycerate kinase step). , making 2,3-DPG comes cost slightly reduced overall ATP production","code":""},{"path":"cell-metabolism.html","id":"methemoglobin-reductase-pathway-keeping-iron-happy","chapter":"Cell Metabolism","heading":"Methemoglobin Reductase Pathway: Keeping Iron Happy","text":"Goal: Maintain hemoglobin iron reduced ferrous (Fe2+) state, state capable binding oxygenThe Problem: Hemoglobin iron can spontaneously (due oxidative stress) oxidize ferric (Fe3+) state. Hemoglobin iron Fe3+ state called methemoglobin, transport oxygen. Normally, 1% hemoglobin auto-oxidizes dailyThe Solution: RBC uses enzyme cytochrome b5 reductase (also called NADH-methemoglobin reductase). enzyme utilizes NADH (produced glyceraldehyde-3-phosphate dehydrogenase step glycolysis) reduce methemoglobin (Fe3+) back functional hemoglobin (Fe2+)","code":""},{"path":"cell-metabolism.html","id":"abnormal-physiology-pathophysiology-when-metabolism-fails","chapter":"Cell Metabolism","heading":"Abnormal Physiology (Pathophysiology): When Metabolism Fails","text":"Defects metabolic pathways lead directly red blood cell dysfunction shortened survival (hemolytic anemia):Defects Glycolysis (e.g., Pyruvate Kinase (PK) Deficiency)\nProblem: Impaired ATP production. Without sufficient ATP, ion pumps fail, leading loss potassium water, cell dehydration, increased membrane rigidity. cell maintain shape\nResult: Chronic nonspherocytic hemolytic anemia. rigid cells prematurely destroyed macrophages spleen (extravascular hemolysis). Severity varies widely\nProblem: Impaired ATP production. Without sufficient ATP, ion pumps fail, leading loss potassium water, cell dehydration, increased membrane rigidity. cell maintain shapeResult: Chronic nonspherocytic hemolytic anemia. rigid cells prematurely destroyed macrophages spleen (extravascular hemolysis). Severity varies widelyDefects HMP Shunt (e.g., G6PD Deficiency)\nProblem: common human enzyme deficiency! Reduced NADPH production leads insufficient reduced glutathione. RBC protect adequately oxidative stress\nResult: Usually asymptomatic exposed oxidative stressors (certain drugs like sulfonamides antimalarials, fava beans, infections). Oxidative stress overwhelms weakened defense system -> hemoglobin denatures precipitates (forming Heinz bodies) -> membrane damage -> episodic hemolytic anemia, can severe involve intravascular extravascular hemolysis\nProblem: common human enzyme deficiency! Reduced NADPH production leads insufficient reduced glutathione. RBC protect adequately oxidative stressResult: Usually asymptomatic exposed oxidative stressors (certain drugs like sulfonamides antimalarials, fava beans, infections). Oxidative stress overwhelms weakened defense system -> hemoglobin denatures precipitates (forming Heinz bodies) -> membrane damage -> episodic hemolytic anemia, can severe involve intravascular extravascular hemolysisDefects Methemoglobin Reduction\nProblem: Deficiency cytochrome b5 reductase presence abnormal hemoglobins (HbM) resistant reduction leads accumulation methemoglobin\nResult: Methemoglobinemia. Blood appears chocolate-brown. Although RBC count might normal, oxygen-carrying capacity reduced (functional anemia). Patients may appear cyanotic (bluish skin)\nProblem: Deficiency cytochrome b5 reductase presence abnormal hemoglobins (HbM) resistant reduction leads accumulation methemoglobinResult: Methemoglobinemia. Blood appears chocolate-brown. Although RBC count might normal, oxygen-carrying capacity reduced (functional anemia). Patients may appear cyanotic (bluish skin)","code":""},{"path":"cell-metabolism.html","id":"blood-storage-metabolism-the-storage-lesion-revisited","chapter":"Cell Metabolism","heading":"Blood Storage & Metabolism: The “Storage Lesion” Revisited","text":"storage blood bags, RBC metabolism progressively declines even optimal preservative solutions:ATP levels decrease: Affecting membrane integrity deformability2,3-DPG levels decrease: Stored RBCs initially increased oxygen affinity (“left shift”), potentially impairing immediate oxygen release upon transfusion (though levels recover within hours recipient)Increased oxidative damage: Despite antioxidants storage solutionsLactate increases, pH decreases: Due ongoing anaerobic glycolysisThese metabolic changes contribute storage lesion, reducing viability function transfused red cells time","code":""},{"path":"cell-metabolism.html","id":"key-terms-60","chapter":"Cell Metabolism","heading":"Key Terms","text":"Anaerobic Metabolism: Metabolic processes occur absence oxygenGlycolysis (Embden-Meyerhof Pathway): primary pathway glucose breakdown RBCs, generating ATP NADHATP (Adenosine Triphosphate): main energy molecule used power cellular processes like ion pumping maintaining membrane shapeHexose Monophosphate (HMP) Shunt / Pentose Phosphate Pathway: Metabolic pathway generating NADPH protection oxidative stressNADPH (Nicotinamide Adenine Dinucleotide Phosphate): essential electron carrier providing reducing power, primarily used keep glutathione reducedG6PD (Glucose-6-Phosphate Dehydrogenase): key regulatory enzyme HMP shunt. Deficiency causes hemolytic anemia upon oxidative stressGlutathione: peptide crucial detoxifying reactive oxygen species; kept active reduced state NADPHReactive Oxygen Species (ROS): Chemically reactive molecules containing oxygen (e.g., hydrogen peroxide) can damage cell componentsRapoport-Luebering Shunt: bypass pathway RBC glycolysis produces 2,3-DPG2,3-Diphosphoglycerate (2,3-DPG): molecule RBCs binds hemoglobin decreases affinity oxygen, facilitating oxygen release tissuesMethemoglobin: Hemoglobin iron atom oxidized ferric (Fe3+) state bind oxygenMethemoglobin Reductase Pathway (Cytochrome b5 Reductase): Enzymatic pathway using NADH reduce methemoglobin (Fe3+) back functional hemoglobin (Fe2+)Heinz Bodies: Precipitates denatured hemoglobin seen within RBCs, typically G6PD deficiency oxidative stress","code":""},{"path":"hemostasis-coagulation.html","id":"hemostasis-coagulation","chapter":"Hemostasis & Coagulation","heading":"Hemostasis & Coagulation","text":"Hemostasis body’s essential mechanism stop bleeding, relying coordinated effort platelets (forming initial plug) coagulation factors (creating reinforcing fibrin clot)","code":""},{"path":"hemostasis-coagulation.html","id":"the-players-processes","chapter":"Hemostasis & Coagulation","heading":"The Players & Processes","text":"Platelets: First Responders\nFunction: Tiny cell fragments circulate passively injury exposes subendothelial structures (like collagen)\nAdhesion: Stick injury site, primarily via von Willebrand Factor (vWF) binding platelet GPIb/IX/V\nActivation: Triggered adhesion agonists (thrombin, ADP, collagen), change shape, release granule contents (ADP, Ca++, Factor V, vWF), synthesize Thromboxane A2\nAggregation: Activated platelets link together via fibrinogen binding GPIIb/IIIa receptors, forming primary platelet plug\n\nDisorders\nThrombocytopenia (Low Count): Due decreased production, increased destruction (immune - ITP, HIT; non-immune - DIC, TTP), sequestration. Leads mucocutaneous bleeding (petechiae, purpura)\nThrombocytopathy (Dysfunction): Platelets don’t work properly. Inherited (rare - Glanzmann, Bernard-Soulier) Acquired (common - Aspirin, NSAIDs, uremia). Also causes mucocutaneous bleeding\n\nFunction: Tiny cell fragments circulate passively injury exposes subendothelial structures (like collagen)\nAdhesion: Stick injury site, primarily via von Willebrand Factor (vWF) binding platelet GPIb/IX/V\nActivation: Triggered adhesion agonists (thrombin, ADP, collagen), change shape, release granule contents (ADP, Ca++, Factor V, vWF), synthesize Thromboxane A2\nAggregation: Activated platelets link together via fibrinogen binding GPIIb/IIIa receptors, forming primary platelet plug\nAdhesion: Stick injury site, primarily via von Willebrand Factor (vWF) binding platelet GPIb/IX/VActivation: Triggered adhesion agonists (thrombin, ADP, collagen), change shape, release granule contents (ADP, Ca++, Factor V, vWF), synthesize Thromboxane A2Aggregation: Activated platelets link together via fibrinogen binding GPIIb/IIIa receptors, forming primary platelet plugDisorders\nThrombocytopenia (Low Count): Due decreased production, increased destruction (immune - ITP, HIT; non-immune - DIC, TTP), sequestration. Leads mucocutaneous bleeding (petechiae, purpura)\nThrombocytopathy (Dysfunction): Platelets don’t work properly. Inherited (rare - Glanzmann, Bernard-Soulier) Acquired (common - Aspirin, NSAIDs, uremia). Also causes mucocutaneous bleeding\nThrombocytopenia (Low Count): Due decreased production, increased destruction (immune - ITP, HIT; non-immune - DIC, TTP), sequestration. Leads mucocutaneous bleeding (petechiae, purpura)Thrombocytopathy (Dysfunction): Platelets don’t work properly. Inherited (rare - Glanzmann, Bernard-Soulier) Acquired (common - Aspirin, NSAIDs, uremia). Also causes mucocutaneous bleedingCoagulation Factors: Reinforcement Crew\nFunction: Mostly inactive plasma proteins (zymogens, mainly liver), designated Roman numerals. Act cascade (Intrinsic, Extrinsic, Common pathways) triggered injury\nKey Steps: Activation leads generation Thrombin (Factor IIa). Thrombin converts Fibrinogen (Factor ) Fibrin, polymerizes. Factor XIIIa cross-links fibrin stabilize clot\nVitamin K: Essential synthesizing functional Factors II, VII, IX, X\nPlatelet Surface: activated platelet membrane provides crucial phospholipid surface key factor complexes (tenase, prothrombinase) assemble efficiently\n\nDisorders\nDeficiencies: Often lead bleeding. Inherited (Hemophilia - FVIII, Hemophilia B - FIX, vWD - affects FVIII also, others rarer) Acquired (Liver disease, Vit K deficiency, DIC - consumption)\nInhibitors: Antibodies factors (e.g., FVIII inhibitor) interfering antibodies (Lupus Anticoagulant - associated thrombosis despite prolonged aPTT)\n\nFunction: Mostly inactive plasma proteins (zymogens, mainly liver), designated Roman numerals. Act cascade (Intrinsic, Extrinsic, Common pathways) triggered injury\nKey Steps: Activation leads generation Thrombin (Factor IIa). Thrombin converts Fibrinogen (Factor ) Fibrin, polymerizes. Factor XIIIa cross-links fibrin stabilize clot\nVitamin K: Essential synthesizing functional Factors II, VII, IX, X\nPlatelet Surface: activated platelet membrane provides crucial phospholipid surface key factor complexes (tenase, prothrombinase) assemble efficiently\nKey Steps: Activation leads generation Thrombin (Factor IIa). Thrombin converts Fibrinogen (Factor ) Fibrin, polymerizes. Factor XIIIa cross-links fibrin stabilize clotVitamin K: Essential synthesizing functional Factors II, VII, IX, XPlatelet Surface: activated platelet membrane provides crucial phospholipid surface key factor complexes (tenase, prothrombinase) assemble efficientlyDisorders\nDeficiencies: Often lead bleeding. Inherited (Hemophilia - FVIII, Hemophilia B - FIX, vWD - affects FVIII also, others rarer) Acquired (Liver disease, Vit K deficiency, DIC - consumption)\nInhibitors: Antibodies factors (e.g., FVIII inhibitor) interfering antibodies (Lupus Anticoagulant - associated thrombosis despite prolonged aPTT)\nDeficiencies: Often lead bleeding. Inherited (Hemophilia - FVIII, Hemophilia B - FIX, vWD - affects FVIII also, others rarer) Acquired (Liver disease, Vit K deficiency, DIC - consumption)Inhibitors: Antibodies factors (e.g., FVIII inhibitor) interfering antibodies (Lupus Anticoagulant - associated thrombosis despite prolonged aPTT)","code":""},{"path":"hemostasis-coagulation.html","id":"laboratory-assessment","chapter":"Hemostasis & Coagulation","heading":"Laboratory Assessment","text":"Platelets: Platelet count (CBC), Platelet Function Analyzer (PFA), Platelet AggregometryCoagulation\nPT (Prothrombin Time): Screens Extrinsic/Common pathways (Factors VII, X, V, II, ). Monitors Warfarin (INR)\naPTT (Activated Partial Thromboplastin Time): Screens Intrinsic/Common pathways (Factors XII, XI, IX, VIII, X, V, II, ). Monitors Heparin\nTT (Thrombin Time): Assesses fibrinogen conversion. Sensitive heparin\nFibrinogen Assay: Quantifies Factor \nMixing Studies: Differentiate factor deficiency (corrects) inhibitor (doesn’t correct)\nFactor Assays: Measure specific factor activity (%)\nPT (Prothrombin Time): Screens Extrinsic/Common pathways (Factors VII, X, V, II, ). Monitors Warfarin (INR)aPTT (Activated Partial Thromboplastin Time): Screens Intrinsic/Common pathways (Factors XII, XI, IX, VIII, X, V, II, ). Monitors HeparinTT (Thrombin Time): Assesses fibrinogen conversion. Sensitive heparinFibrinogen Assay: Quantifies Factor IMixing Studies: Differentiate factor deficiency (corrects) inhibitor (doesn’t correct)Factor Assays: Measure specific factor activity (%)","code":""},{"path":"hemostasis-coagulation.html","id":"interplay-clinical-significance","chapter":"Hemostasis & Coagulation","heading":"Interplay & Clinical Significance","text":"Platelets coagulation factors work together. Platelets provide surface initial plug; coagulation stabilizes fibrinDefects either system lead bleeding, though type bleeding often differs (platelet issues -> mucocutaneous; severe factor issues -> deep tissue/joint bleeds)Understanding pathways disorders crucial diagnosing bleeding causes guiding therapy, including appropriate use blood components like platelets, Fresh Frozen Plasma (FFP), Cryoprecipitate","code":""},{"path":"factors-disorders.html","id":"factors-disorders","chapter":"Factors & Disorders","heading":"Factors & Disorders","text":"Think hemostasis coagulation body’s emergency repair crew blood vessels. ’s breach, complex process kicks form stable plug (clot) stop bleeding. Coagulation factors specialized protein “workers” crew, acting precise sequence called coagulation cascade. Understanding factors, happens ’re missing dysfunctional (disorders), measure activity (assay interpretation) absolutely vital lab patient care","code":""},{"path":"factors-disorders.html","id":"the-coagulation-factors-the-protein-crew","chapter":"Factors & Disorders","heading":"The Coagulation Factors: The Protein Crew","text":"mostly inactive enzyme precursors (zymogens) circulating plasma, produced primarily liver. activated, trigger next step cascade. designated Roman numerals (often assigned order discovery, necessarily sequence action)Key PointsVitamin K Dependency: Factors II, VII, IX, X (regulatory proteins C & S) require Vitamin K post-translational modification (gamma-carboxylation) allows bind calcium phospholipid surfaces – essential function!Liver Synthesis: factors made liver. Liver disease significantly impacts coagulationZymogens & Cofactors: zymogen proteases (inactive enzymes). Factors V, VIII, Tissue Factor, HMWK primarily cofactors accelerate enzyme activity","code":""},{"path":"factors-disorders.html","id":"the-coagulation-cascade-a-simplified-view","chapter":"Factors & Disorders","heading":"The Coagulation Cascade: A Simplified View","text":"Think three intersecting pathways leading common goal: forming stable fibrin clotExtrinsic Pathway (Tissue Factor Pathway): “Spark”\nInitiation: Triggered damage exposing Tissue Factor (Factor III) cells outside blood vessels\nTF binds Factor VII, activating VIIa\nTF/VIIa complex potent activator Factor X (Xa) , lesser extent, Factor IX\nMeasured : Prothrombin Time (PT)\nInitiation: Triggered damage exposing Tissue Factor (Factor III) cells outside blood vesselsTF binds Factor VII, activating VIIaThe TF/VIIa complex potent activator Factor X (Xa) , lesser extent, Factor IXMeasured : Prothrombin Time (PT)Intrinsic Pathway: “Amplification Loop” (mainly vitro)\nInitiation (vitro): Activated blood contacts negatively charged surface (like glass test tube), involving Factor XII, Prekallikrein, HMWK\nCascade: XIIa -> XIa -> IXa\nFactor IXa, along cofactor VIIIa: (activated thrombin) Ca++/phospholipids, forms “intrinsic tenase” complex, also activates Factor X Xa\nMeasured : Activated Partial Thromboplastin Time (aPTT)\nInitiation (vitro): Activated blood contacts negatively charged surface (like glass test tube), involving Factor XII, Prekallikrein, HMWKCascade: XIIa -> XIa -> IXaFactor IXa, along cofactor VIIIa: (activated thrombin) Ca++/phospholipids, forms “intrinsic tenase” complex, also activates Factor X XaMeasured : Activated Partial Thromboplastin Time (aPTT)Common Pathway: Meet\nInitiation: Begins activation Factor X Xa (either extrinsic intrinsic pathways)\nProthrombinase Complex: Factor Xa combines cofactor Va (activated thrombin), Ca++, phospholipids platelet surface. complex incredibly efficient!\nThrombin Generation: prothrombinase complex converts Prothrombin (Factor II) active Thrombin (Factor IIa). MAJOR amplification step – little Xa makes lot thrombin!\nFibrin Formation: Thrombin cleaves soluble Fibrinogen (Factor ) insoluble Fibrin monomers, spontaneously polymerize\nClot Stabilization: Thrombin also activates Factor XIII XIIIa. Factor XIIIa cross-links fibrin polymers, creating strong, stable mesh clot\nMeasured : PT aPTT assess pathway\nInitiation: Begins activation Factor X Xa (either extrinsic intrinsic pathways)Prothrombinase Complex: Factor Xa combines cofactor Va (activated thrombin), Ca++, phospholipids platelet surface. complex incredibly efficient!Thrombin Generation: prothrombinase complex converts Prothrombin (Factor II) active Thrombin (Factor IIa). MAJOR amplification step – little Xa makes lot thrombin!Fibrin Formation: Thrombin cleaves soluble Fibrinogen (Factor ) insoluble Fibrin monomers, spontaneously polymerizeClot Stabilization: Thrombin also activates Factor XIII XIIIa. Factor XIIIa cross-links fibrin polymers, creating strong, stable mesh clotMeasured : PT aPTT assess pathway","code":""},{"path":"factors-disorders.html","id":"coagulation-factor-disorders-pathophysiology","chapter":"Factors & Disorders","heading":"Coagulation Factor Disorders (Pathophysiology)","text":"occur one factors deficient dysfunctional, usually leading bleeding (though sometimes thrombosis regulatory factors affected)Inherited Disorders\nHemophilia : Deficiency Factor VIII. X-linked recessive (mostly affects males). Severity correlates factor level. Bleeding joints (hemarthrosis), muscles\nHemophilia B (Christmas Disease): Deficiency Factor IX. X-linked recessive. Clinically similar Hemophilia \nVon Willebrand Disease (vWD): Deficiency dysfunction von Willebrand Factor (vWF). common inherited bleeding disorder. vWF two roles: 1) helps platelets adhere injury sites, 2) carries protects Factor VIII. Leads platelet-type bleeding (mucocutaneous) potentially Factor VIII deficiency symptoms. Various subtypes exist\nFactor Deficiencies: Rare deficiencies Factors , II, V, VII, X, XI, XIII exist, varying severity\nHemophilia : Deficiency Factor VIII. X-linked recessive (mostly affects males). Severity correlates factor level. Bleeding joints (hemarthrosis), musclesHemophilia B (Christmas Disease): Deficiency Factor IX. X-linked recessive. Clinically similar Hemophilia AVon Willebrand Disease (vWD): Deficiency dysfunction von Willebrand Factor (vWF). common inherited bleeding disorder. vWF two roles: 1) helps platelets adhere injury sites, 2) carries protects Factor VIII. Leads platelet-type bleeding (mucocutaneous) potentially Factor VIII deficiency symptoms. Various subtypes existOther Factor Deficiencies: Rare deficiencies Factors , II, V, VII, X, XI, XIII exist, varying severityAcquired Disorders\nLiver Disease: Decreased synthesis factors (except FVIII, also made elsewhere) regulatory proteins. Leads complex coagulopathy\nVitamin K Deficiency: Impaired synthesis Factors II, VII, IX, X. Caused poor diet, malabsorption, antibiotics, Warfarin therapy\nDisseminated Intravascular Coagulation (DIC): Widespread activation coagulation leads consumption factors platelets -> bleeding thrombosis (clots small vessels)\nAcquired Inhibitors (Antibodies): Antibodies develop neutralize specific factors (e.g., Factor VIII inhibitor) interfere tests (e.g., Lupus Anticoagulant - paradoxically associated thrombosis despite prolonging aPTT)\nLiver Disease: Decreased synthesis factors (except FVIII, also made elsewhere) regulatory proteins. Leads complex coagulopathyVitamin K Deficiency: Impaired synthesis Factors II, VII, IX, X. Caused poor diet, malabsorption, antibiotics, Warfarin therapyDisseminated Intravascular Coagulation (DIC): Widespread activation coagulation leads consumption factors platelets -> bleeding thrombosis (clots small vessels)Acquired Inhibitors (Antibodies): Antibodies develop neutralize specific factors (e.g., Factor VIII inhibitor) interfere tests (e.g., Lupus Anticoagulant - paradoxically associated thrombosis despite prolonging aPTT)","code":""},{"path":"factors-disorders.html","id":"coagulation-factor-assay-result-interpretation","chapter":"Factors & Disorders","heading":"Coagulation Factor Assay Result Interpretation","text":"use laboratory tests screen problems pinpoint specific issues","code":""},{"path":"factors-disorders.html","id":"screening-tests","chapter":"Factors & Disorders","heading":"Screening Tests","text":"Prothrombin Time (PT)\nMeasures: Extrinsic (VII) Common (X, V, II, ) pathways\nReagent: Thromboplastin (contains Tissue Factor phospholipid) + Calcium\nInterpretation\nProlonged PT (Normal aPTT): Suggests Factor VII deficiency/inhibitor. Also prolonged Vitamin K deficiency, Warfarin, liver disease (Factor VII shortest half-life)\n\nInternational Normalized Ratio (INR): Standardized PT result used primarily monitoring Warfarin (Coumadin) therapy. Calculated INR = (Patient PT / Mean Normal PT)^ISI ISI International Sensitivity Index specific reagent lot\nMeasures: Extrinsic (VII) Common (X, V, II, ) pathwaysReagent: Thromboplastin (contains Tissue Factor phospholipid) + CalciumInterpretation\nProlonged PT (Normal aPTT): Suggests Factor VII deficiency/inhibitor. Also prolonged Vitamin K deficiency, Warfarin, liver disease (Factor VII shortest half-life)\nProlonged PT (Normal aPTT): Suggests Factor VII deficiency/inhibitor. Also prolonged Vitamin K deficiency, Warfarin, liver disease (Factor VII shortest half-life)International Normalized Ratio (INR): Standardized PT result used primarily monitoring Warfarin (Coumadin) therapy. Calculated INR = (Patient PT / Mean Normal PT)^ISI ISI International Sensitivity Index specific reagent lotActivated Partial Thromboplastin Time (aPTT)\nMeasures: Intrinsic (XII, XI, IX, VIII, PK, HMWK) Common (X, V, II, ) pathways. measure VII XIII\nReagents: activator (e.g., silica, kaolin) + partial thromboplastin (phospholipid , TF) + Calcium\nInterpretation\nProlonged aPTT (Normal PT): Suggests deficiency/inhibitor Intrinsic pathway (VIII, IX, XI, XII, PK, HMWK). Common causes include Hemophilia /B, Factor XI deficiency, presence heparin, Lupus Anticoagulant. Note: XII, PK, HMWK deficiency prolong aPTT usually don’t cause bleeding\n\nMeasures: Intrinsic (XII, XI, IX, VIII, PK, HMWK) Common (X, V, II, ) pathways. measure VII XIIIReagents: activator (e.g., silica, kaolin) + partial thromboplastin (phospholipid , TF) + CalciumInterpretation\nProlonged aPTT (Normal PT): Suggests deficiency/inhibitor Intrinsic pathway (VIII, IX, XI, XII, PK, HMWK). Common causes include Hemophilia /B, Factor XI deficiency, presence heparin, Lupus Anticoagulant. Note: XII, PK, HMWK deficiency prolong aPTT usually don’t cause bleeding\nProlonged aPTT (Normal PT): Suggests deficiency/inhibitor Intrinsic pathway (VIII, IX, XI, XII, PK, HMWK). Common causes include Hemophilia /B, Factor XI deficiency, presence heparin, Lupus Anticoagulant. Note: XII, PK, HMWK deficiency prolong aPTT usually don’t cause bleedingThrombin Time (TT)\nMeasures: Conversion Fibrinogen () Fibrin Thrombin (IIa)\nReagent: Thrombin + Calcium\nInterpretation\nProlonged TT: Suggests low fibrinogen (hypofibrinogenemia), abnormal fibrinogen (dysfibrinogenemia), presence thrombin inhibitors (like heparin direct thrombin inhibitors)\n\nMeasures: Conversion Fibrinogen () Fibrin Thrombin (IIa)Reagent: Thrombin + CalciumInterpretation\nProlonged TT: Suggests low fibrinogen (hypofibrinogenemia), abnormal fibrinogen (dysfibrinogenemia), presence thrombin inhibitors (like heparin direct thrombin inhibitors)\nProlonged TT: Suggests low fibrinogen (hypofibrinogenemia), abnormal fibrinogen (dysfibrinogenemia), presence thrombin inhibitors (like heparin direct thrombin inhibitors)Fibrinogen Assay\nMeasures: Quantifies Factor (Fibrinogen) level, usually functionally immunologically\nInterpretation: Low levels seen DIC, severe liver disease, inherited deficiency\nMeasures: Quantifies Factor (Fibrinogen) level, usually functionally immunologicallyInterpretation: Low levels seen DIC, severe liver disease, inherited deficiency","code":""},{"path":"factors-disorders.html","id":"mixing-studies-differentiating-deficiency-vs.-inhibitor","chapter":"Factors & Disorders","heading":"Mixing Studies: Differentiating Deficiency vs. Inhibitor","text":"CRUCIAL PT aPTT prolonged!Principle: Mix patient plasma 1:1 Normal Pooled Plasma (NPP), contains normal levels factorsProcedure: Perform prolonged test (PT aPTT) mixture immediately sometimes incubation (e.g., 1-2 hours 37°C)Interpretation\nCorrection: mixture result corrects normal range, indicates Factor Deficiency. normal plasma supplied enough missing factor(s)\nCorrection / Partial Correction: mixture result remains prolonged, indicates presence Inhibitor (e.g., antibody like factor inhibitor Lupus Anticoagulant, heparin). inhibitor patient plasma neutralizing factors normal plasma\nIncubation Effect: inhibitors (especially Factor VIII inhibitors) time- temperature-dependent. mixing study might show initial correction become prolonged incubation\nCorrection: mixture result corrects normal range, indicates Factor Deficiency. normal plasma supplied enough missing factor(s)Correction / Partial Correction: mixture result remains prolonged, indicates presence Inhibitor (e.g., antibody like factor inhibitor Lupus Anticoagulant, heparin). inhibitor patient plasma neutralizing factors normal plasmaIncubation Effect: inhibitors (especially Factor VIII inhibitors) time- temperature-dependent. mixing study might show initial correction become prolonged incubation","code":""},{"path":"factors-disorders.html","id":"specific-factor-assays","chapter":"Factors & Disorders","heading":"Specific Factor Assays","text":"Principle: Based PT aPTT. Patient plasma dilutions added plasma known deficient specific factor tested. degree patient plasma corrects clotting time deficient plasma proportional factor activity patient sampleInterpretation: Results reported % activity compared normal (100%). Helps pinpoint specific factor deficiencies identified screening tests mixing studies (e.g., confirming Hemophilia low Factor VIII activity)","code":""},{"path":"factors-disorders.html","id":"summary-interpretation-patterns","chapter":"Factors & Disorders","heading":"Summary Interpretation Patterns","text":"","code":""},{"path":"factors-disorders.html","id":"blood-bank-relevance-7","chapter":"Factors & Disorders","heading":"Blood Bank Relevance","text":"Understanding coagulation essential managing bleeding patientsBlood components used treat deficiencies include:\nFresh Frozen Plasma (FFP): Contains coagulation factors\nCryoprecipitate: Concentrated source Fibrinogen, Factor VIII, Factor XIII, vWF\nFactor Concentrates: Specific purified factors (e.g., Factor VIII concentrate Hemophilia )\nPlatelets: Often needed DIC massive transfusion platelet consumption occurs\nFresh Frozen Plasma (FFP): Contains coagulation factorsCryoprecipitate: Concentrated source Fibrinogen, Factor VIII, Factor XIII, vWFFactor Concentrates: Specific purified factors (e.g., Factor VIII concentrate Hemophilia )Platelets: Often needed DIC massive transfusion platelet consumption occurs","code":""},{"path":"factors-disorders.html","id":"key-terms-61","chapter":"Factors & Disorders","heading":"Key Terms","text":"Hemostasis: physiological process stops bleedingCoagulation Factors: Plasma proteins (mostly enzymes cofactors) involved blood clotting cascadeZymogen: inactive precursor enzymeCoagulation Cascade: series amplifying enzymatic reactions involving coagulation factors, leading fibrin clot formationExtrinsic Pathway: Initiated Tissue Factor; measured PTIntrinsic Pathway: Initiated contact activation (vitro); measured aPTTCommon Pathway: Convergence point involving Factors X, V, II, ; measured PT aPTTProthrombin Time (PT): Test measuring extrinsic common pathwaysInternational Normalized Ratio (INR): Standardized PT result Warfarin monitoringActivated Partial Thromboplastin Time (aPTT): Test measuring intrinsic common pathwaysThrombin Time (TT): Test measuring fibrinogen conversion fibrinMixing Study: Test using patient plasma mixed normal plasma differentiate factor deficiency (corrects) inhibitor (correct)Factor Assay: Test quantifying activity level specific coagulation factorInhibitor: antibody substance interferes coagulation factor function coagulation testVitamin K Dependent Factors: Factors II, VII, IX, X (require Vitamin K synthesis/function)","code":""},{"path":"plt-functions-disorders.html","id":"plt-functions-disorders","chapter":"PLT Functions & Disorders","heading":"PLT Functions & Disorders","text":"tiny, anucleated cell fragments unsung heroes hemostasis, body’s process stopping bleeding. ’re first responders site vascular injury, quickly forming temporary plug providing crucial surface coagulation cascade build uponUnderstanding platelets normally function happens numbers low function impaired absolutely critical diagnosing bleeding disorders managing patients, especially considering platelet transfusions","code":""},{"path":"plt-functions-disorders.html","id":"normal-platelet-function-the-steps-to-plugging-the-hole","chapter":"PLT Functions & Disorders","heading":"Normal Platelet Function: The Steps to Plugging the Hole","text":"blood vessel injured, normally smooth endothelial lining disrupted, exposing underlying structures like collagen. triggers rapid sequence events involving platelets:Adhesion: Sticking Site\nTrigger: Exposure subendothelial collagen release von Willebrand Factor (vWF) damaged endothelial cells platelets . vWF rapidly binds exposed collagen\nMechanism: Platelets initially tether roll along injured surface. mediated primarily platelet surface receptor complex Glycoprotein Ib/IX/V (GPIb/IX/V) binding immobilized vWF. Think vWF molecular glue bridging platelet damaged vessel wall. Direct binding collagen via receptors (like GPVI) also occurs provides stronger adhesion\nTrigger: Exposure subendothelial collagen release von Willebrand Factor (vWF) damaged endothelial cells platelets . vWF rapidly binds exposed collagenMechanism: Platelets initially tether roll along injured surface. mediated primarily platelet surface receptor complex Glycoprotein Ib/IX/V (GPIb/IX/V) binding immobilized vWF. Think vWF molecular glue bridging platelet damaged vessel wall. Direct binding collagen via receptors (like GPVI) also occurs provides stronger adhesionActivation: Getting Fired \nAdhesion , plus exposure various agonists (substances trigger activation) released injury site (like collagen, thrombin generated coagulation cascade, ADP released damaged cells platelets, Thromboxane A2 (TXA2) synthesized activated platelets), causes platelets undergo dramatic changes:\nShape Change: transform smooth discs spiny spheres extending pseudopods. dramatically increases surface area interaction\nGranule Release (Secretion): Activated platelets release contents internal storage granules:\nDense Granules: Contain potent platelet agonists like ADP, ATP, Calcium (Ca++) (essential coagulation), serotonin (vasoconstrictor)\nAlpha Granules: Contain adhesive proteins (vWF, fibrinogen, fibronectin), coagulation factors (Factor V, Factor XI), growth factors (PDGF), platelet-specific proteins (like Platelet Factor 4 - PF4)\nPurpose: released substances (especially ADP TXA2) recruit activate platelets site, amplifying response\n\nThromboxane A2 (TXA2) Synthesis: Activation triggers platelet’s internal enzymatic machinery (via cyclooxygenase - COX enzyme) produce TXA2, potent vasoconstrictor powerful platelet activator/aggregator\nMembrane Changes\nGPIIb/IIIa Activation: abundant platelet receptor, Glycoprotein IIb/IIIa (GPIIb/IIIa), undergoes conformational change, enabling bind fibrinogen (vWF)\nPhospholipid Exposure: Negatively charged phospholipids (like phosphatidylserine) flip outer surface platelet membrane. creates essential binding surface (“platelet phospholipid”) coagulation factor complexes (tenase prothrombinase), localizing accelerating clot formation\n\n\nAdhesion , plus exposure various agonists (substances trigger activation) released injury site (like collagen, thrombin generated coagulation cascade, ADP released damaged cells platelets, Thromboxane A2 (TXA2) synthesized activated platelets), causes platelets undergo dramatic changes:\nShape Change: transform smooth discs spiny spheres extending pseudopods. dramatically increases surface area interaction\nGranule Release (Secretion): Activated platelets release contents internal storage granules:\nDense Granules: Contain potent platelet agonists like ADP, ATP, Calcium (Ca++) (essential coagulation), serotonin (vasoconstrictor)\nAlpha Granules: Contain adhesive proteins (vWF, fibrinogen, fibronectin), coagulation factors (Factor V, Factor XI), growth factors (PDGF), platelet-specific proteins (like Platelet Factor 4 - PF4)\nPurpose: released substances (especially ADP TXA2) recruit activate platelets site, amplifying response\n\nThromboxane A2 (TXA2) Synthesis: Activation triggers platelet’s internal enzymatic machinery (via cyclooxygenase - COX enzyme) produce TXA2, potent vasoconstrictor powerful platelet activator/aggregator\nMembrane Changes\nGPIIb/IIIa Activation: abundant platelet receptor, Glycoprotein IIb/IIIa (GPIIb/IIIa), undergoes conformational change, enabling bind fibrinogen (vWF)\nPhospholipid Exposure: Negatively charged phospholipids (like phosphatidylserine) flip outer surface platelet membrane. creates essential binding surface (“platelet phospholipid”) coagulation factor complexes (tenase prothrombinase), localizing accelerating clot formation\n\nShape Change: transform smooth discs spiny spheres extending pseudopods. dramatically increases surface area interactionGranule Release (Secretion): Activated platelets release contents internal storage granules:\nDense Granules: Contain potent platelet agonists like ADP, ATP, Calcium (Ca++) (essential coagulation), serotonin (vasoconstrictor)\nAlpha Granules: Contain adhesive proteins (vWF, fibrinogen, fibronectin), coagulation factors (Factor V, Factor XI), growth factors (PDGF), platelet-specific proteins (like Platelet Factor 4 - PF4)\nPurpose: released substances (especially ADP TXA2) recruit activate platelets site, amplifying response\nDense Granules: Contain potent platelet agonists like ADP, ATP, Calcium (Ca++) (essential coagulation), serotonin (vasoconstrictor)Alpha Granules: Contain adhesive proteins (vWF, fibrinogen, fibronectin), coagulation factors (Factor V, Factor XI), growth factors (PDGF), platelet-specific proteins (like Platelet Factor 4 - PF4)Purpose: released substances (especially ADP TXA2) recruit activate platelets site, amplifying responseThromboxane A2 (TXA2) Synthesis: Activation triggers platelet’s internal enzymatic machinery (via cyclooxygenase - COX enzyme) produce TXA2, potent vasoconstrictor powerful platelet activator/aggregatorMembrane Changes\nGPIIb/IIIa Activation: abundant platelet receptor, Glycoprotein IIb/IIIa (GPIIb/IIIa), undergoes conformational change, enabling bind fibrinogen (vWF)\nPhospholipid Exposure: Negatively charged phospholipids (like phosphatidylserine) flip outer surface platelet membrane. creates essential binding surface (“platelet phospholipid”) coagulation factor complexes (tenase prothrombinase), localizing accelerating clot formation\nGPIIb/IIIa Activation: abundant platelet receptor, Glycoprotein IIb/IIIa (GPIIb/IIIa), undergoes conformational change, enabling bind fibrinogen (vWF)Phospholipid Exposure: Negatively charged phospholipids (like phosphatidylserine) flip outer surface platelet membrane. creates essential binding surface (“platelet phospholipid”) coagulation factor complexes (tenase prothrombinase), localizing accelerating clot formationAggregation: Sticking Together\nMechanism: Activated GPIIb/IIIa receptors one platelet bind fibrinogen, bridges activated GPIIb/IIIa receptors platelets\nResult: Platelets stick firmly , building layer upon layer form primary platelet plug. plug initially unstable effectively seals small breaches provides scaffold coagulation cascade\nStabilization: primary plug later reinforced fibrin mesh generated coagulation cascade, forming stable secondary hemostatic plug (true clot)\nMechanism: Activated GPIIb/IIIa receptors one platelet bind fibrinogen, bridges activated GPIIb/IIIa receptors plateletsResult: Platelets stick firmly , building layer upon layer form primary platelet plug. plug initially unstable effectively seals small breaches provides scaffold coagulation cascadeStabilization: primary plug later reinforced fibrin mesh generated coagulation cascade, forming stable secondary hemostatic plug (true clot)","code":""},{"path":"plt-functions-disorders.html","id":"platelet-disorders-pathophysiology-when-the-plug-fails","chapter":"PLT Functions & Disorders","heading":"Platelet Disorders (Pathophysiology): When the Plug Fails","text":"Problems platelets can broadly categorized two types: enough platelets (quantitative) platelets don’t work properly (qualitative)","code":""},{"path":"plt-functions-disorders.html","id":"quantitative-disorders-thrombocytopenia-low-platelet-count","chapter":"PLT Functions & Disorders","heading":"Quantitative Disorders: Thrombocytopenia (Low Platelet Count)","text":"Definition: Platelet count lower limit reference range (typically < 150,000/µL 150 x 109/L)Causes: Diverse, falling three main categories:\nDecreased Production: Problems bone marrow prevent sufficient platelet production (e.g., Aplastic anemia, leukemia, chemotherapy, radiation, certain viral infections, nutritional deficiencies like B12/folate)\nIncreased Destruction/Consumption: Platelets destroyed used faster can made:\nImmune Mediated: Antibodies target platelets (e.g., Immune Thrombocytopenia - ITP, Heparin-Induced Thrombocytopenia - HIT, Neonatal Alloimmune Thrombocytopenia - NAIT, Post-Transfusion Purpura - PTP, drug-induced)\nNon-Immune: Platelets consumed clotting processes damaged mechanically (e.g., Disseminated Intravascular Coagulation - DIC, Thrombotic Thrombocytopenic Purpura - TTP, Hemolytic Uremic Syndrome - HUS, mechanical heart valves)\n\nSequestration: enlarged spleen (hypersplenism) traps larger--normal proportion platelets, lowering circulating count\nDecreased Production: Problems bone marrow prevent sufficient platelet production (e.g., Aplastic anemia, leukemia, chemotherapy, radiation, certain viral infections, nutritional deficiencies like B12/folate)Increased Destruction/Consumption: Platelets destroyed used faster can made:\nImmune Mediated: Antibodies target platelets (e.g., Immune Thrombocytopenia - ITP, Heparin-Induced Thrombocytopenia - HIT, Neonatal Alloimmune Thrombocytopenia - NAIT, Post-Transfusion Purpura - PTP, drug-induced)\nNon-Immune: Platelets consumed clotting processes damaged mechanically (e.g., Disseminated Intravascular Coagulation - DIC, Thrombotic Thrombocytopenic Purpura - TTP, Hemolytic Uremic Syndrome - HUS, mechanical heart valves)\nImmune Mediated: Antibodies target platelets (e.g., Immune Thrombocytopenia - ITP, Heparin-Induced Thrombocytopenia - HIT, Neonatal Alloimmune Thrombocytopenia - NAIT, Post-Transfusion Purpura - PTP, drug-induced)Non-Immune: Platelets consumed clotting processes damaged mechanically (e.g., Disseminated Intravascular Coagulation - DIC, Thrombotic Thrombocytopenic Purpura - TTP, Hemolytic Uremic Syndrome - HUS, mechanical heart valves)Sequestration: enlarged spleen (hypersplenism) traps larger--normal proportion platelets, lowering circulating countClinical Features: Risk bleeding increases count drops. Characteristic mucocutaneous bleeding:\nPetechiae (pinpoint hemorrhages)\nPurpura (larger bruises)\nEpistaxis (nosebleeds)\nGingival (gum) bleeding\nMenorrhagia (heavy menstrual bleeding)\nSevere internal bleeding (GI, intracranial) can occur low counts (<10-20,000/µL)\nPetechiae (pinpoint hemorrhages)Purpura (larger bruises)Epistaxis (nosebleeds)Gingival (gum) bleedingMenorrhagia (heavy menstrual bleeding)Severe internal bleeding (GI, intracranial) can occur low counts (<10-20,000/µL)","code":""},{"path":"plt-functions-disorders.html","id":"qualitative-disorders-thrombocytopathy-platelet-dysfunction","chapter":"PLT Functions & Disorders","heading":"Qualitative Disorders: Thrombocytopathy (Platelet Dysfunction)","text":"Definition: Platelet count may normal (sometimes mildly decreased), platelets function correctly one steps (adhesion, activation, aggregation, secretion)Causes: Can inherited acquired\nInherited Platelet Function Disorders: Relatively rare genetic conditions affecting specific platelet components:\nDisorders Adhesion\nBernard-Soulier Syndrome: Deficiency dysfunction GPIb/IX/V complex. Platelets bind vWF effectively. Characterized giant platelets moderate/severe thrombocytopenia\n\nDisorders Aggregation\nGlanzmann Thrombasthenia: Deficiency dysfunction GPIIb/IIIa. Platelets bind fibrinogen therefore aggregate\n\nDisorders Secretion (Storage Pool Disease): Deficiency dense granules alpha granules, defects release mechanism. Leads impaired activation/aggregation amplification\nDisorders Signal Transduction/Activation: Defects pathways leading TXA2 synthesis response agonists\n\nAcquired Platelet Function Disorders: common inherited disorders:\nDrugs: common cause!\nAspirin: Irreversibly inhibits COX-1 enzyme, blocking TXA2 synthesis life platelet (~7-10 days)\nNSAIDs (e.g., Ibuprofen): Reversibly inhibit COX-1\nADP Receptor Inhibitors (e.g., Clopidogrel, Ticagrelor): Block platelet activation ADP\nGPIIb/IIIa Inhibitors (e.g., Abciximab, Tirofiban): Directly block fibrinogen binding aggregation (used therapeutically cardiology)\n: High-dose penicillin, SSRIs, etc\n\nSystemic Conditions\nUremia (Kidney Failure): Circulating toxins impair multiple aspects platelet function\nMyeloproliferative Neoplasms / Myelodysplastic Syndromes: Abnormal platelet production can lead dysfunctional platelets\nCardiopulmonary Bypass: Mechanical stress activation surgery can lead temporary dysfunction\nParaproteinemias (e.g., Multiple Myeloma): Abnormal proteins can coat platelets interfere function\n\n\nInherited Platelet Function Disorders: Relatively rare genetic conditions affecting specific platelet components:\nDisorders Adhesion\nBernard-Soulier Syndrome: Deficiency dysfunction GPIb/IX/V complex. Platelets bind vWF effectively. Characterized giant platelets moderate/severe thrombocytopenia\n\nDisorders Aggregation\nGlanzmann Thrombasthenia: Deficiency dysfunction GPIIb/IIIa. Platelets bind fibrinogen therefore aggregate\n\nDisorders Secretion (Storage Pool Disease): Deficiency dense granules alpha granules, defects release mechanism. Leads impaired activation/aggregation amplification\nDisorders Signal Transduction/Activation: Defects pathways leading TXA2 synthesis response agonists\nDisorders Adhesion\nBernard-Soulier Syndrome: Deficiency dysfunction GPIb/IX/V complex. Platelets bind vWF effectively. Characterized giant platelets moderate/severe thrombocytopenia\nBernard-Soulier Syndrome: Deficiency dysfunction GPIb/IX/V complex. Platelets bind vWF effectively. Characterized giant platelets moderate/severe thrombocytopeniaDisorders Aggregation\nGlanzmann Thrombasthenia: Deficiency dysfunction GPIIb/IIIa. Platelets bind fibrinogen therefore aggregate\nGlanzmann Thrombasthenia: Deficiency dysfunction GPIIb/IIIa. Platelets bind fibrinogen therefore aggregateDisorders Secretion (Storage Pool Disease): Deficiency dense granules alpha granules, defects release mechanism. Leads impaired activation/aggregation amplificationDisorders Signal Transduction/Activation: Defects pathways leading TXA2 synthesis response agonistsAcquired Platelet Function Disorders: common inherited disorders:\nDrugs: common cause!\nAspirin: Irreversibly inhibits COX-1 enzyme, blocking TXA2 synthesis life platelet (~7-10 days)\nNSAIDs (e.g., Ibuprofen): Reversibly inhibit COX-1\nADP Receptor Inhibitors (e.g., Clopidogrel, Ticagrelor): Block platelet activation ADP\nGPIIb/IIIa Inhibitors (e.g., Abciximab, Tirofiban): Directly block fibrinogen binding aggregation (used therapeutically cardiology)\n: High-dose penicillin, SSRIs, etc\n\nSystemic Conditions\nUremia (Kidney Failure): Circulating toxins impair multiple aspects platelet function\nMyeloproliferative Neoplasms / Myelodysplastic Syndromes: Abnormal platelet production can lead dysfunctional platelets\nCardiopulmonary Bypass: Mechanical stress activation surgery can lead temporary dysfunction\nParaproteinemias (e.g., Multiple Myeloma): Abnormal proteins can coat platelets interfere function\n\nDrugs: common cause!\nAspirin: Irreversibly inhibits COX-1 enzyme, blocking TXA2 synthesis life platelet (~7-10 days)\nNSAIDs (e.g., Ibuprofen): Reversibly inhibit COX-1\nADP Receptor Inhibitors (e.g., Clopidogrel, Ticagrelor): Block platelet activation ADP\nGPIIb/IIIa Inhibitors (e.g., Abciximab, Tirofiban): Directly block fibrinogen binding aggregation (used therapeutically cardiology)\n: High-dose penicillin, SSRIs, etc\nAspirin: Irreversibly inhibits COX-1 enzyme, blocking TXA2 synthesis life platelet (~7-10 days)NSAIDs (e.g., Ibuprofen): Reversibly inhibit COX-1ADP Receptor Inhibitors (e.g., Clopidogrel, Ticagrelor): Block platelet activation ADPGPIIb/IIIa Inhibitors (e.g., Abciximab, Tirofiban): Directly block fibrinogen binding aggregation (used therapeutically cardiology): High-dose penicillin, SSRIs, etcSystemic Conditions\nUremia (Kidney Failure): Circulating toxins impair multiple aspects platelet function\nMyeloproliferative Neoplasms / Myelodysplastic Syndromes: Abnormal platelet production can lead dysfunctional platelets\nCardiopulmonary Bypass: Mechanical stress activation surgery can lead temporary dysfunction\nParaproteinemias (e.g., Multiple Myeloma): Abnormal proteins can coat platelets interfere function\nUremia (Kidney Failure): Circulating toxins impair multiple aspects platelet functionMyeloproliferative Neoplasms / Myelodysplastic Syndromes: Abnormal platelet production can lead dysfunctional plateletsCardiopulmonary Bypass: Mechanical stress activation surgery can lead temporary dysfunctionParaproteinemias (e.g., Multiple Myeloma): Abnormal proteins can coat platelets interfere functionClinical Features: Similar thrombocytopenia (mucocutaneous bleeding), platelet count normal near normal. Severity varies greatly","code":""},{"path":"plt-functions-disorders.html","id":"laboratory-evaluation","chapter":"PLT Functions & Disorders","heading":"Laboratory Evaluation","text":"Platelet Count: Measured part Complete Blood Count (CBC)Platelet Function Tests\nPlatelet Function Analyzer (PFA-100/PFA-200): Automated screening test simulating primary hemostasis vitro. Measures closure time high shear stress using collagen/epinephrine collagen/ADP cartridges. Prolonged closure times suggest platelet dysfunction low vWF. Sensitive Aspirin, vWD, severe platelet defects\nPlatelet Aggregometry: Gold standard. Measures change light transmission platelet-rich plasma platelets aggregate response various added agonists (ADP, collagen, epinephrine, ristocetin, arachidonic acid). Specific patterns aggregation help diagnose different types platelet dysfunction (e.g., absent aggregation agonists Glanzmann; absent aggregation ristocetin Bernard-Soulier)\nBleeding Time (Historical): Largely replaced PFA due poor standardization reproducibility\nPlatelet Function Analyzer (PFA-100/PFA-200): Automated screening test simulating primary hemostasis vitro. Measures closure time high shear stress using collagen/epinephrine collagen/ADP cartridges. Prolonged closure times suggest platelet dysfunction low vWF. Sensitive Aspirin, vWD, severe platelet defectsPlatelet Aggregometry: Gold standard. Measures change light transmission platelet-rich plasma platelets aggregate response various added agonists (ADP, collagen, epinephrine, ristocetin, arachidonic acid). Specific patterns aggregation help diagnose different types platelet dysfunction (e.g., absent aggregation agonists Glanzmann; absent aggregation ristocetin Bernard-Soulier)Bleeding Time (Historical): Largely replaced PFA due poor standardization reproducibility","code":""},{"path":"plt-functions-disorders.html","id":"blood-bank-relevance-8","chapter":"PLT Functions & Disorders","heading":"Blood Bank Relevance","text":"Platelet Transfusion: Primary treatment severe thrombocytopenia bleeding due platelet dysfunction. Platelets collected apheresis pooled whole blood donationsPlatelet Refractoriness: patients fail achieve expected increase platelet count transfusion. Causes can :\nNon-Immune: Fever, sepsis, splenomegaly, DIC, medications (e.g., Amphotericin B) - common\nImmune: Antibodies HLA Class antigens , less commonly, Human Platelet Antigens (HPAs). Requires HLA-matched crossmatched platelets\nNon-Immune: Fever, sepsis, splenomegaly, DIC, medications (e.g., Amphotericin B) - commonImmune: Antibodies HLA Class antigens , less commonly, Human Platelet Antigens (HPAs). Requires HLA-matched crossmatched plateletsNAIT/PTP: Specific alloimmune conditions requiring HPA-compatible platelets specialized management","code":""},{"path":"plt-functions-disorders.html","id":"key-terms-62","chapter":"PLT Functions & Disorders","heading":"Key Terms","text":"Platelet (Thrombocyte): Anucleated cell fragment derived megakaryocytes, essential primary hemostasisHemostasis: process stopping bleedingAdhesion: process platelets sticking non-platelet surface (like exposed collagen via vWF)Activation: process platelets undergo shape change, granule release, membrane alterations stimulationAggregation: process platelets sticking , mediated primarily fibrinogen binding GPIIb/IIIavon Willebrand Factor (vWF): Adhesive plasma protein crucial platelet adhesion collagen carrier Factor VIIIGlycoprotein Ib/IX/V (GPIb/IX/V): Platelet receptor complex binds vWF adhesionGlycoprotein IIb/IIIa (GPIIb/IIIa): Platelet receptor (integrin αIIbβ3) binds fibrinogen (vWF) aggregationDense Granules: Platelet storage organelles containing ADP, Ca++, serotoninAlpha Granules: Platelet storage organelles containing vWF, fibrinogen, Factor V, PF4Thromboxane A2 (TXA2): Potent platelet activator vasoconstrictor synthesized platelets via COX enzymePrimary Platelet Plug: initial aggregate platelets formed site injuryThrombocytopenia: Low platelet countThrombocytopathy: Abnormal platelet function (qualitative defect)Petechiae: Pinpoint, non-blanching capillary hemorrhages skinPurpura: Larger areas bruising/bleeding skinBernard-Soulier Syndrome: Inherited adhesion disorder due GPIb/IX/V defectGlanzmann Thrombasthenia: Inherited aggregation disorder due GPIIb/IIIa defectStorage Pool Disease: Inherited secretion disorder due granule deficiencyPlatelet Refractoriness: Poor increment platelet count following transfusion","code":""},{"path":"hdfn.html","id":"hdfn","chapter":"HDFN","heading":"HDFN","text":"Hemolytic Disease Fetus Newborn (HDFN) condition maternal antibodies destroy fetal/newborn red blood cells (RBCs). ’ll look happens (Pathophysiology), find (Detection), fix (Treatment), stop starts (Prevention)","code":""},{"path":"hdfn.html","id":"pathophysiology-how-hdfn-happens","chapter":"HDFN","heading":"Pathophysiology: How HDFN Happens","text":"Incompatibility & Sensitization: mother lacks RBC antigen (e.g., D, K, c) fetus inherits father. pregnancy delivery, fetal RBCs can enter maternal circulation (Fetal-Maternal Hemorrhage - FMH). mother’s immune system sees fetal antigen foreign becomes sensitized, producing antibodies (initially IgM, IgG) memory cellsSubsequent Pregnancy & Anamnestic Response: later pregnancy fetus positive antigen, even small FMH triggers rapid secondary immune response, producing large amounts high-affinity IgG antibodiesPlacental Transfer: Maternal IgG (Ig class ) actively crosses placenta fetal circulationFetal Hemolysis: Maternal IgG binds fetal RBCs possessing target antigen. antibody-coated cells destroyed primarily macrophages fetal spleen (Extravascular Hemolysis)Fetal Consequences\nAnemia: Leads increased fetal RBC production (erythropoiesis), including liver/spleen (extramedullary hematopoiesis -> hepatosplenomegaly) release immature RBCs (erythroblastosis fetalis)\nBilirubin: Increased RBC breakdown produces bilirubin, ’s cleared mother’s liver utero\nHydrops Fetalis: severe cases, profound anemia leads heart failure, liver damage (low albumin), massive fluid accumulation (edema, effusions) – often fatal untreated\nAnemia: Leads increased fetal RBC production (erythropoiesis), including liver/spleen (extramedullary hematopoiesis -> hepatosplenomegaly) release immature RBCs (erythroblastosis fetalis)Bilirubin: Increased RBC breakdown produces bilirubin, ’s cleared mother’s liver uteroHydrops Fetalis: severe cases, profound anemia leads heart failure, liver damage (low albumin), massive fluid accumulation (edema, effusions) – often fatal untreatedNeonatal Consequences\nHyperbilirubinemia: birth, immature newborn liver cope ongoing bilirubin load continued hemolysis (maternal IgG persists weeks). Unconjugated bilirubin accumulates\nKernicterus: bilirubin levels get high, crosses blood-brain barrier, causing permanent brain damage\nAnemia: Can persist weeks/months birth\nHyperbilirubinemia: birth, immature newborn liver cope ongoing bilirubin load continued hemolysis (maternal IgG persists weeks). Unconjugated bilirubin accumulatesKernicterus: bilirubin levels get high, crosses blood-brain barrier, causing permanent brain damageAnemia: Can persist weeks/months birth","code":""},{"path":"hdfn.html","id":"detection-finding-the-problem","chapter":"HDFN","heading":"Detection: Finding the Problem","text":"Antenatal (Pregnancy)\nScreening (Mothers): ABO/RhD typing, Antibody Screen (IAT) first visit & ~28 weeks\nScreen Positive: Antibody Identification, Titers (significant IgG)\nMonitoring (Clinically Significant Antibody)\nAssess Fetal Antigen Status (Paternal testing, Fetal DNA maternal plasma - cffDNA)\nMonitor Fetal Anemia: Middle Cerebral Artery Peak Systolic Velocity (MCA-PSV) Doppler (key non-invasive tool). Values >1.5 MoM suggest significant anemia\nSelective Use: Amniotic fluid ΔOD 450, Fetal Blood Sampling (Cordocentesis)\n\nScreening (Mothers): ABO/RhD typing, Antibody Screen (IAT) first visit & ~28 weeksIf Screen Positive: Antibody Identification, Titers (significant IgG)Monitoring (Clinically Significant Antibody)\nAssess Fetal Antigen Status (Paternal testing, Fetal DNA maternal plasma - cffDNA)\nMonitor Fetal Anemia: Middle Cerebral Artery Peak Systolic Velocity (MCA-PSV) Doppler (key non-invasive tool). Values >1.5 MoM suggest significant anemia\nSelective Use: Amniotic fluid ΔOD 450, Fetal Blood Sampling (Cordocentesis)\nAssess Fetal Antigen Status (Paternal testing, Fetal DNA maternal plasma - cffDNA)Monitor Fetal Anemia: Middle Cerebral Artery Peak Systolic Velocity (MCA-PSV) Doppler (key non-invasive tool). Values >1.5 MoM suggest significant anemiaSelective Use: Amniotic fluid ΔOD 450, Fetal Blood Sampling (Cordocentesis)Postnatal (Birth)\nCord/Neonatal Blood: ABO/RhD typing, Direct Antiglobulin Test (DAT) (key diagnostic test - detects IgG/complement newborn RBCs)\nMonitoring: Hemoglobin/Hematocrit, Bilirubin levels (total & unconjugated), Reticulocyte count\nConfirmation (needed): Antibody elution infant RBCs identify coating antibody\nCord/Neonatal Blood: ABO/RhD typing, Direct Antiglobulin Test (DAT) (key diagnostic test - detects IgG/complement newborn RBCs)Monitoring: Hemoglobin/Hematocrit, Bilirubin levels (total & unconjugated), Reticulocyte countConfirmation (needed): Antibody elution infant RBCs identify coating antibody","code":""},{"path":"hdfn.html","id":"treatment-managing-the-condition","chapter":"HDFN","heading":"Treatment: Managing the Condition","text":"Antenatal\nIntrauterine Transfusion (IUT): Mainstay severe fetal anemia. Transfusion compatible RBCs (O neg, Ag-neg maternal Ab, irradiated, fresh, high Hct, CMV-safe, compatible maternal plasma) directly fetal circulation (umbilical vein)\nTiming Delivery: Balancing risks prematurity vs. ongoing hemolysis\nAdjunctive: Maternal IVIg plasmapheresis (rarely used)\nIntrauterine Transfusion (IUT): Mainstay severe fetal anemia. Transfusion compatible RBCs (O neg, Ag-neg maternal Ab, irradiated, fresh, high Hct, CMV-safe, compatible maternal plasma) directly fetal circulation (umbilical vein)Timing Delivery: Balancing risks prematurity vs. ongoing hemolysisAdjunctive: Maternal IVIg plasmapheresis (rarely used)Postnatal\nHyperbilirubinemia Management\nPhototherapy: Primary treatment; uses light make bilirubin excretable\nExchange Transfusion: severe cases; removes bilirubin, maternal antibody, coated cells, providing compatible blood\n\nAnemia Management: Simple RBC transfusion needed later; IVIg may reduce hemolysis\nHyperbilirubinemia Management\nPhototherapy: Primary treatment; uses light make bilirubin excretable\nExchange Transfusion: severe cases; removes bilirubin, maternal antibody, coated cells, providing compatible blood\nPhototherapy: Primary treatment; uses light make bilirubin excretableExchange Transfusion: severe cases; removes bilirubin, maternal antibody, coated cells, providing compatible bloodAnemia Management: Simple RBC transfusion needed later; IVIg may reduce hemolysis","code":""},{"path":"hdfn.html","id":"prevention-stopping-sensitization-primarily-for-anti-d","chapter":"HDFN","heading":"Prevention: Stopping Sensitization (Primarily for Anti-D)","text":"Rh Immune Globulin (RhIG): cornerstone! Concentrated IgG anti-D given RhD-negative, unsensitized mothers\nMechanism: Passive anti-D clears fetal RhD+ cells maternal circulation mother mounts active immune response\nAdministration\nRoutine antenatal dose (~28 weeks)\nRoutine postnatal dose (within 72 hrs delivering RhD+ infant)\npotential sensitizing event (miscarriage, amnio, trauma, etc.)\n\nLarge FMH: Screen (Rosette test) quantify (KB stain/Flow Cytometry) post-delivery determine >1 standard dose RhIG needed\nMechanism: Passive anti-D clears fetal RhD+ cells maternal circulation mother mounts active immune responseAdministration\nRoutine antenatal dose (~28 weeks)\nRoutine postnatal dose (within 72 hrs delivering RhD+ infant)\npotential sensitizing event (miscarriage, amnio, trauma, etc.)\nRoutine antenatal dose (~28 weeks)Routine postnatal dose (within 72 hrs delivering RhD+ infant)potential sensitizing event (miscarriage, amnio, trauma, etc.)Large FMH: Screen (Rosette test) quantify (KB stain/Flow Cytometry) post-delivery determine >1 standard dose RhIG neededOther Antibodies: specific immune globulin exists. Prevention relies judicious transfusion policies women childbearing potential (avoiding unnecessary transfusion, providing antigen-negative blood like K-negative feasible)","code":""},{"path":"pathophysiology.html","id":"pathophysiology","chapter":"Pathophysiology","heading":"Pathophysiology","text":"pathophysiology Hemolytic Disease Fetus Newborn (HDFN) classic example immunology action, mother’s immune system inadvertently harms fetus newborn. Understanding happens key prevention treatment","code":""},{"path":"pathophysiology.html","id":"the-core-problem","chapter":"Pathophysiology","heading":"The Core Problem","text":"HDFN occurs maternal IgG antibodies, specific antigens present fetal/newborn red blood cells (RBCs) absent maternal RBCs, cross placenta cause destruction fetal/newborn RBCsHere’s step--step breakdown pathophysiology:","code":""},{"path":"pathophysiology.html","id":"prerequisite-antigen-incompatibility-maternal-sensitization-alloimmunization","chapter":"Pathophysiology","heading":"Prerequisite: Antigen Incompatibility & Maternal Sensitization (Alloimmunization)","text":"Incompatibility: fundamental requirement fetus must inherit red blood cell antigen father mother lacks. famous example RhD-negative mother carrying RhD-positive fetus. common examples involve ABO incompatibility (Group O mother, Group B fetus) antibodies blood group antigens like Kell (K), Duffy (Fya), Kidd (Jka), c, E, etcSensitization Event: mother’s immune system must exposed foreign fetal RBC antigen. usually happens Fetal-Maternal Hemorrhage (FMH), small amounts fetal RBCs leak across placenta maternal circulation\nTiming: FMH can occur anytime pregnancy, largest volumes typically occur delivery. can also happen miscarriage, abortion, ectopic pregnancy, amniocentesis, chorionic villus sampling (CVS), abdominal trauma\nPrior Transfusion: Less commonly, sensitization can occur mother previously received transfusion blood positive antigen lacks (e.g., RhD-negative woman transfused RhD-positive blood years pregnancy)\nTiming: FMH can occur anytime pregnancy, largest volumes typically occur delivery. can also happen miscarriage, abortion, ectopic pregnancy, amniocentesis, chorionic villus sampling (CVS), abdominal traumaPrior Transfusion: Less commonly, sensitization can occur mother previously received transfusion blood positive antigen lacks (e.g., RhD-negative woman transfused RhD-positive blood years pregnancy)Immune Response (Primary): mother’s immune system encounters foreign fetal antigen first time, mounts primary immune response\nAPCs present antigen T helper cells, activate B cells\nInitially, IgM antibodies produced. IgM large cross placenta, typically doesn’t harm fetus first sensitizing pregnancy (unless sensitization happened early)\nCrucially, class switching occurs, leading production IgG antibodies, long-lived memory B cells specific fetal antigen generated\nAPCs present antigen T helper cells, activate B cellsInitially, IgM antibodies produced. IgM large cross placenta, typically doesn’t harm fetus first sensitizing pregnancy (unless sensitization happened early)Crucially, class switching occurs, leading production IgG antibodies, long-lived memory B cells specific fetal antigen generated","code":""},{"path":"pathophysiology.html","id":"subsequent-pregnancy-with-an-antigen-positive-fetus-the-anamnestic-response","chapter":"Pathophysiology","heading":"Subsequent Pregnancy with an Antigen-Positive Fetus: The Anamnestic Response","text":"Re-exposure: mother becomes pregnant fetus positive antigen, even tiny FMH (almost inevitable) re-expose immune system antigenSecondary (Anamnestic) Response: memory B cells rapidly activated. results faster, stronger production high-titer IgG antibodies specific fetal antigen","code":""},{"path":"pathophysiology.html","id":"placental-transfer-of-maternal-igg","chapter":"Pathophysiology","heading":"Placental Transfer of Maternal IgG","text":"Mechanism: IgG immunoglobulin class actively transported across placenta. occurs via specific Fc receptors (FcRn) placental cells (syncytiotrophoblasts)Consequence: harmful maternal IgG antibodies efficiently delivered fetal circulation","code":""},{"path":"pathophysiology.html","id":"antibody-binding-and-red-cell-destruction-in-the-fetus-hemolysis","chapter":"Pathophysiology","heading":"Antibody Binding and Red Cell Destruction in the Fetus (Hemolysis)","text":"Binding: Maternal IgG antibodies circulate fetus bind specifically corresponding antigen fetal RBC membraneMechanism Destruction: primary mechanism Extravascular Hemolysis\nOpsonization: IgG-coated fetal RBCs recognized Fc receptors phagocytic cells (macrophages) within fetal Mononuclear Phagocyte System (MPS), primarily located spleen , lesser extent, liver\nPhagocytosis: macrophages engulf destroy antibody-coated RBCs\n(Complement Role): IgG subclasses (IgG1, IgG3) can activate complement, leading potentially C3b deposition (opsonization) rarely intravascular lysis (MAC formation), dominant mechanism HDFN Fc-mediated phagocytosis spleen\nOpsonization: IgG-coated fetal RBCs recognized Fc receptors phagocytic cells (macrophages) within fetal Mononuclear Phagocyte System (MPS), primarily located spleen , lesser extent, liverPhagocytosis: macrophages engulf destroy antibody-coated RBCs(Complement Role): IgG subclasses (IgG1, IgG3) can activate complement, leading potentially C3b deposition (opsonization) rarely intravascular lysis (MAC formation), dominant mechanism HDFN Fc-mediated phagocytosis spleen","code":""},{"path":"pathophysiology.html","id":"fetal-consequences-of-hemolysis","chapter":"Pathophysiology","heading":"Fetal Consequences of Hemolysis","text":"Anemia: Progressive destruction RBCs leads fetal anemia. severity depends amount specificity maternal antibody, antigen density fetal cells, fetus’s ability compensateCompensatory Erythropoiesis: fetus attempts compensate anemia increasing RBC production (erythropoiesis)\nBone Marrow: Production increases significantly\nExtramedullary Hematopoiesis: anemia severe, RBC production also occurs outside bone marrow, primarily liver spleen. causes organs enlarge (hepatosplenomegaly)\nErythroblastosis Fetalis: Increased erythropoiesis leads release immature RBC precursors, including nucleated red blood cells (NRBCs erythroblasts), fetal circulation. gives disease older name\nBone Marrow: Production increases significantlyExtramedullary Hematopoiesis: anemia severe, RBC production also occurs outside bone marrow, primarily liver spleen. causes organs enlarge (hepatosplenomegaly)Erythroblastosis Fetalis: Increased erythropoiesis leads release immature RBC precursors, including nucleated red blood cells (NRBCs erythroblasts), fetal circulation. gives disease older nameBilirubin Production: breakdown hemoglobin destroyed RBCs releases large amounts bilirubin\nFetal Clearance: utero, unconjugated bilirubin crosses placenta maternal circulation, efficiently conjugated excreted mother’s liver. Therefore, significant jaundice typically seen fetus .\nFetal Clearance: utero, unconjugated bilirubin crosses placenta maternal circulation, efficiently conjugated excreted mother’s liver. Therefore, significant jaundice typically seen fetus .Hydrops Fetalis: severe form fetal HDFN, characterized excessive fluid accumulation tissues body cavities (ascites, pleural effusion, pericardial effusion, skin edema)\nMechanism: combination factors resulting severe, chronic anemia:\nHigh-Output Cardiac Failure: fetal heart works harder deliver oxygen fewer RBCs, eventually failing\nHypoproteinemia: Decreased plasma protein (especially albumin) production damaged/overworked liver (due extramedullary hematopoiesis hypoxic damage) reduces plasma oncotic pressure\nIncreased Capillary Permeability: Possibly due hypoxia\n\nHydrops fetalis often leads fetal death treated aggressively utero (e.g., intrauterine transfusions)\nMechanism: combination factors resulting severe, chronic anemia:\nHigh-Output Cardiac Failure: fetal heart works harder deliver oxygen fewer RBCs, eventually failing\nHypoproteinemia: Decreased plasma protein (especially albumin) production damaged/overworked liver (due extramedullary hematopoiesis hypoxic damage) reduces plasma oncotic pressure\nIncreased Capillary Permeability: Possibly due hypoxia\nHigh-Output Cardiac Failure: fetal heart works harder deliver oxygen fewer RBCs, eventually failingHypoproteinemia: Decreased plasma protein (especially albumin) production damaged/overworked liver (due extramedullary hematopoiesis hypoxic damage) reduces plasma oncotic pressureIncreased Capillary Permeability: Possibly due hypoxiaHydrops fetalis often leads fetal death treated aggressively utero (e.g., intrauterine transfusions)","code":""},{"path":"pathophysiology.html","id":"neonatal-consequences-after-birth","chapter":"Pathophysiology","heading":"Neonatal Consequences (After Birth)","text":"Transition: birth, placental “lifeline” bilirubin removal severedHyperbilirubinemia (Neonatal Jaundice): becomes major problem birth\nOngoing Hemolysis: Maternal IgG antibodies persist newborn’s circulation weeks months, continuing destroy neonatal RBCs\nImmature Liver: newborn’s liver limited capacity conjugate bilirubin (due low levels enzyme UDP-glucuronosyltransferase)\nAccumulation: combination increased bilirubin production (hemolysis) decreased conjugation/excretion leads rapid rise unconjugated bilirubin levels newborn’s blood\nOngoing Hemolysis: Maternal IgG antibodies persist newborn’s circulation weeks months, continuing destroy neonatal RBCsImmature Liver: newborn’s liver limited capacity conjugate bilirubin (due low levels enzyme UDP-glucuronosyltransferase)Accumulation: combination increased bilirubin production (hemolysis) decreased conjugation/excretion leads rapid rise unconjugated bilirubin levels newborn’s bloodKernicterus (Bilirubin Encephalopathy)\nMechanism: Unconjugated bilirubin lipid-soluble can cross immature blood-brain barrier. levels become excessively high, deposits brain tissues, particularly basal ganglia\nConsequence: deposition toxic neurons, causing permanent neurological damage, developmental problems, hearing loss, even death. feared neonatal complication HDFN primary reason treating neonatal hyperbilirubinemia (e.g., phototherapy exchange transfusion)\nMechanism: Unconjugated bilirubin lipid-soluble can cross immature blood-brain barrier. levels become excessively high, deposits brain tissues, particularly basal gangliaConsequence: deposition toxic neurons, causing permanent neurological damage, developmental problems, hearing loss, even death. feared neonatal complication HDFN primary reason treating neonatal hyperbilirubinemia (e.g., phototherapy exchange transfusion)Persistent Anemia: Even bilirubin levels controlled, ongoing destruction RBCs persistent maternal IgG can cause anemia first weeks months life, potentially requiring simple RBC transfusions","code":""},{"path":"pathophysiology.html","id":"antigen-specificity-matters","chapter":"Pathophysiology","heading":"Antigen Specificity Matters","text":"Anti-D: Historically caused severe HDFN, often leading hydrops. Incidence drastically reduced Rh Immune Globulin (RhIG)Anti-K (Kell): Can cause severe HDFN, hemolysis also Kell antigen present early erythroid precursors, anti-K can suppress fetal erythropoiesis, worsening anemiaABO HDFN: common type overall (usually group O mother B baby). Typically much milder Rh blood group HDFN. Often presents neonatal jaundice, rarely requires intrauterine treatment. Milder : (1) fetal /B antigens less developed; (2) /B antigens widely distributed tissues, absorbing maternal antibody; (3) much maternal anti-/anti-B IgM, doesn’t cross placenta (though IgG components )","code":""},{"path":"pathophysiology.html","id":"key-terms-63","chapter":"Pathophysiology","heading":"Key Terms","text":"Alloimmunization (Sensitization): process individual produces immune response (antibodies) foreign antigens species (e.g., mother fetal antigens)Fetal-Maternal Hemorrhage (FMH): leakage fetal blood cells maternal circulationAnamnestic Response: rapid enhanced secondary immune response upon re-exposure antigen, mediated memory cellsPlacental Transfer: active transport maternal IgG antibodies across placenta fetal circulation via FcRn receptorsExtravascular Hemolysis: Destruction antibody-coated red blood cells phagocytic cells (macrophages) spleen liverOpsonization: Coating cells antibodies (complement) enhance phagocytosisErythropoiesis: production red blood cellsExtramedullary Hematopoiesis: Blood cell production occurring outside bone marrow (e.g., liver spleen)Hepatosplenomegaly: Enlargement liver spleenErythroblastosis Fetalis: presence excessive numbers nucleated red blood cells (erythroblasts) fetal circulation due severe hemolysisHydrops Fetalis: Severe, abnormal accumulation fluid fetal tissues body cavities, usually due severe anemia heart failureHyperbilirubinemia: Excessively high levels bilirubin blood, causing jaundiceKernicterus (Bilirubin Encephalopathy): Neurological damage caused deposition unconjugated bilirubin brain tissue newborns","code":""},{"path":"detection.html","id":"detection","chapter":"Detection","heading":"Detection","text":"Finding HDFN early crucial managing effectively preventing severe outcomes like hydrops fetalis kernicterus. Detection involves combination antenatal (pregnancy) postnatal (birth) testing, aimed identifying -risk mothers, assessing degree fetal jeopardy, diagnosing condition newborn","code":""},{"path":"detection.html","id":"antenatal-detection-screening-and-monitoring-during-pregnancy","chapter":"Detection","heading":"Antenatal Detection: Screening and Monitoring During Pregnancy","text":"goal identify mothers whose fetuses risk HDFN monitor appropriately","code":""},{"path":"detection.html","id":"identifying-at-risk-mothers","chapter":"Detection","heading":"Identifying At-Risk Mothers","text":"ABO/RhD Typing: Essential first step pregnant women first prenatal visit\nDetermines mother’s ABO group RhD type (positive negative)\nDetermines mother’s ABO group RhD type (positive negative)Antibody Screen (Indirect Antiglobulin Test - IAT): Essential pregnant women, regardless RhD type, performed first prenatal visit\nPurpose: Detects presence unexpected, clinically significant IgG red cell alloantibodies mother’s plasma potentially cross placenta cause HDFN (e.g., anti-D, anti-K, anti-c, anti-E, anti-Fya, anti-Jka, etc.)\nInterpretation\nNegative Screen: Routine care. Repeat screen typically done around 28 weeks gestation, especially RhD-negative women administering Rh Immune Globulin (RhIG), sometimes delivery\nPositive Screen: Requires Antibody Identification\n\nPurpose: Detects presence unexpected, clinically significant IgG red cell alloantibodies mother’s plasma potentially cross placenta cause HDFN (e.g., anti-D, anti-K, anti-c, anti-E, anti-Fya, anti-Jka, etc.)Interpretation\nNegative Screen: Routine care. Repeat screen typically done around 28 weeks gestation, especially RhD-negative women administering Rh Immune Globulin (RhIG), sometimes delivery\nPositive Screen: Requires Antibody Identification\nNegative Screen: Routine care. Repeat screen typically done around 28 weeks gestation, especially RhD-negative women administering Rh Immune Globulin (RhIG), sometimes deliveryPositive Screen: Requires Antibody IdentificationAntibody Identification: screen positive, specific antibody(ies) must identified using panel reagent red cells known antigen profiles\nDetermining Clinical Significance: identified, antibody’s potential cause HDFN must assessed. Anti-D, anti-K, anti-c, anti-E, anti-Fya, anti-Jka, anti-S, anti-s commonly implicated. Antibodies typically IgM (like anti-Lea, anti-Leb, anti-, anti-P1) rarely cause HDFN noted usually don’t require intensive monitoring\nDetermining Clinical Significance: identified, antibody’s potential cause HDFN must assessed. Anti-D, anti-K, anti-c, anti-E, anti-Fya, anti-Jka, anti-S, anti-s commonly implicated. Antibodies typically IgM (like anti-Lea, anti-Leb, anti-, anti-P1) rarely cause HDFN noted usually don’t require intensive monitoringAntibody Titer: clinically significant IgG antibodies (especially anti-D, anti-K, etc.), serial titrations performed quantify amount antibody present\nMethod: Two-fold serial dilutions mother’s plasma tested reagent red cells positive corresponding antigen (using IAT technique). titer reciprocal highest dilution showing 1+ macroscopic reaction\nMonitoring: Titers performed regularly throughout pregnancy (e.g., every 2-4 weeks 18-20 weeks gestation). rising titer (increase two dilutions , e.g., 16 64) reaching pre-determined critical titer (often 16 32 anti-D, may lower anti-K) indicates higher risk significant fetal hemolysis triggers invasive monitoring\nLimitations: Titer levels don’t always perfectly correlate severity HDFN, especially antibodies anti-D subsequent affected pregnancies\nMethod: Two-fold serial dilutions mother’s plasma tested reagent red cells positive corresponding antigen (using IAT technique). titer reciprocal highest dilution showing 1+ macroscopic reactionMonitoring: Titers performed regularly throughout pregnancy (e.g., every 2-4 weeks 18-20 weeks gestation). rising titer (increase two dilutions , e.g., 16 64) reaching pre-determined critical titer (often 16 32 anti-D, may lower anti-K) indicates higher risk significant fetal hemolysis triggers invasive monitoringLimitations: Titer levels don’t always perfectly correlate severity HDFN, especially antibodies anti-D subsequent affected pregnancies","code":""},{"path":"detection.html","id":"assessing-fetal-status-when-a-clinically-significant-antibody-is-present","chapter":"Detection","heading":"Assessing Fetal Status (When a Clinically Significant Antibody is Present)","text":"mother potentially harmful antibody, especially titer rising critical, steps needed assess fetus directly indirectlyDetermining Fetal Antigen Status (Possible & Necessary): Knowing fetus actually antigen targeted maternal antibody key. fetus antigen-negative, HDFN due antibody occur\nPaternal Phenotyping/Genotyping: Testing father can help predict likelihood fetus inheriting antigen (e.g., father homozygous DD, fetus D-positive; heterozygous Dd, ’s 50% chance)\nFetal DNA Testing (Non-Invasive): Cell-free fetal DNA (cffDNA) circulating maternal plasma can tested certain fetal blood group genes (like RHD). Highly accurate determining fetal RhD status RhD-negative mothers. Increasingly available antigens like K, c, E, Fya\nAmniocentesis/CVS (Invasive): Fetal cells obtained via amniocentesis CVS can genotyped, procedures carry small risk complications can worsen sensitization causing FMH. Generally reserved situations cffDNA testing unavailable inconclusive\nPaternal Phenotyping/Genotyping: Testing father can help predict likelihood fetus inheriting antigen (e.g., father homozygous DD, fetus D-positive; heterozygous Dd, ’s 50% chance)Fetal DNA Testing (Non-Invasive): Cell-free fetal DNA (cffDNA) circulating maternal plasma can tested certain fetal blood group genes (like RHD). Highly accurate determining fetal RhD status RhD-negative mothers. Increasingly available antigens like K, c, E, FyaAmniocentesis/CVS (Invasive): Fetal cells obtained via amniocentesis CVS can genotyped, procedures carry small risk complications can worsen sensitization causing FMH. Generally reserved situations cffDNA testing unavailable inconclusiveMonitoring Fetal Anemia (Non-Invasive): primary goal detect fetal anemia hydrops develops\nMiddle Cerebral Artery Peak Systolic Velocity (MCA-PSV) Doppler Ultrasound: cornerstone modern non-invasive monitoring. Increased blood flow velocity fetal MCA correlates strongly severity fetal anemia. fetus becomes anemic, blood viscosity decreases, cardiac output increases compensate, leading faster flow velocity. Regular MCA-PSV measurements (e.g., every 1-2 weeks) performed titers critical rising. Values certain threshold (typically >1.5 Multiples Median - MoM) indicate significant fetal anemia may warrant fetal blood sampling intrauterine transfusion\nMiddle Cerebral Artery Peak Systolic Velocity (MCA-PSV) Doppler Ultrasound: cornerstone modern non-invasive monitoring. Increased blood flow velocity fetal MCA correlates strongly severity fetal anemia. fetus becomes anemic, blood viscosity decreases, cardiac output increases compensate, leading faster flow velocity. Regular MCA-PSV measurements (e.g., every 1-2 weeks) performed titers critical rising. Values certain threshold (typically >1.5 Multiples Median - MoM) indicate significant fetal anemia may warrant fetal blood sampling intrauterine transfusionMonitoring Fetal Anemia (Invasive - Historical/Selective Use)\nAmniotic Fluid Spectrophotometry (ΔOD 450): Historically important. Measures bilirubin pigment levels amniotic fluid obtained via amniocentesis. Bilirubin absorbs light 450 nm. Plotted Liley chart (modified Queenan chart) predict HDFN severity. Largely replaced MCA-PSV Doppler due non-invasive nature better correlation anemia, may still used specific circumstances Doppler unavailable/unreliable\nAmniotic Fluid Spectrophotometry (ΔOD 450): Historically important. Measures bilirubin pigment levels amniotic fluid obtained via amniocentesis. Bilirubin absorbs light 450 nm. Plotted Liley chart (modified Queenan chart) predict HDFN severity. Largely replaced MCA-PSV Doppler due non-invasive nature better correlation anemia, may still used specific circumstances Doppler unavailable/unreliableFetal Blood Sampling (FBS) / Cordocentesis: definitive test fetal anemia\nMethod: Ultrasound-guided needle aspiration blood umbilical cord vein\nMeasurements: Directly measures fetal hemoglobin/hematocrit, bilirubin, blood type, DAT\nUse: Reserved cases high suspicion severe anemia based MCA-PSV findings, often performed immediately prior planned intrauterine transfusion (IUT)\nMethod: Ultrasound-guided needle aspiration blood umbilical cord veinMeasurements: Directly measures fetal hemoglobin/hematocrit, bilirubin, blood type, DATUse: Reserved cases high suspicion severe anemia based MCA-PSV findings, often performed immediately prior planned intrauterine transfusion (IUT)","code":""},{"path":"detection.html","id":"postnatal-detection-diagnosing-hdfn-in-the-newborn","chapter":"Detection","heading":"Postnatal Detection: Diagnosing HDFN in the Newborn","text":"Testing performed cord blood collected delivery neonatal samples soon birthEssential Tests Cord Blood (Especially Mother RhD-Negative Known Antibodies)\nABO/RhD Typing: Determines infant’s blood group RhD type\nDirect Antiglobulin Test (DAT): Key diagnostic test! Detects IgG antibodies (/complement) coating newborn’s RBCs vivo\nPositive DAT: Strongly suggests HDFN maternal antibody corresponding fetal antigen known suspected. strength DAT reaction always correlate clinical severity\nNegative DAT: Makes classical HDFN less likely, although mild ABO HDFN can sometimes present weakly positive even negative DAT\n\nABO/RhD Typing: Determines infant’s blood group RhD typeDirect Antiglobulin Test (DAT): Key diagnostic test! Detects IgG antibodies (/complement) coating newborn’s RBCs vivo\nPositive DAT: Strongly suggests HDFN maternal antibody corresponding fetal antigen known suspected. strength DAT reaction always correlate clinical severity\nNegative DAT: Makes classical HDFN less likely, although mild ABO HDFN can sometimes present weakly positive even negative DAT\nPositive DAT: Strongly suggests HDFN maternal antibody corresponding fetal antigen known suspected. strength DAT reaction always correlate clinical severityNegative DAT: Makes classical HDFN less likely, although mild ABO HDFN can sometimes present weakly positive even negative DATOther Important Neonatal Tests (Depending Clinical Picture)\nHemoglobin (Hgb) / Hematocrit (Hct): Assesses degree anemia birth\nBilirubin Levels (Total Direct/Unconjugated): Monitors hyperbilirubinemia. Serial measurements crucial first days life\nReticulocyte Count: Usually elevated due compensatory erythropoiesis\nPeripheral Blood Smear: May show increased nucleated RBCs (erythroblastosis), spherocytes (especially ABO HDFN), polychromasia (immature RBCs)\nAntibody Elution (Infant RBCs): DAT positive maternal antibody specificity unknown complex, elution can performed remove coating antibody infant’s RBCs identify specificity eluate. confirms antibody causing hemolysis\nMaternal Serum Testing: Confirms presence specificity maternal antibody fully worked antenatally\nHemoglobin (Hgb) / Hematocrit (Hct): Assesses degree anemia birthBilirubin Levels (Total Direct/Unconjugated): Monitors hyperbilirubinemia. Serial measurements crucial first days lifeReticulocyte Count: Usually elevated due compensatory erythropoiesisPeripheral Blood Smear: May show increased nucleated RBCs (erythroblastosis), spherocytes (especially ABO HDFN), polychromasia (immature RBCs)Antibody Elution (Infant RBCs): DAT positive maternal antibody specificity unknown complex, elution can performed remove coating antibody infant’s RBCs identify specificity eluate. confirms antibody causing hemolysisMaternal Serum Testing: Confirms presence specificity maternal antibody fully worked antenatally","code":""},{"path":"detection.html","id":"summary-of-detection-strategies","chapter":"Detection","heading":"Summary of Detection Strategies","text":"Antenatal\nScreen mothers: ABO/RhD type, Antibody Screen (IAT)\nscreen positive: Antibody ID, Titers (significant IgG)\nantibody significant/titer critical: Fetal antigen prediction (paternal/cffDNA), MCA-PSV Doppler monitor anemia, FBS/IUT indicated\nScreen mothers: ABO/RhD type, Antibody Screen (IAT)screen positive: Antibody ID, Titers (significant IgG)antibody significant/titer critical: Fetal antigen prediction (paternal/cffDNA), MCA-PSV Doppler monitor anemia, FBS/IUT indicatedPostnatal\nTest Newborn (esp. risk): ABO/RhD type, DAT\nMonitor: Hgb/Hct, Bilirubin, Reticulocytes\nConfirm (needed): Elution infant RBCs\nTest Newborn (esp. risk): ABO/RhD type, DATMonitor: Hgb/Hct, Bilirubin, ReticulocytesConfirm (needed): Elution infant RBCs","code":""},{"path":"detection.html","id":"key-terms-64","chapter":"Detection","heading":"Key Terms","text":"Antibody Screen (IAT): Test performed maternal serum/plasma detect unexpected IgG red cell alloantibodiesAntibody Identification: Determining specificity antibody detected screen using panel reagent cellsAntibody Titer: Semi-quantitative measure antibody concentration, determined serial dilutionCritical Titer: predefined antibody titer level significant risk severe HDFN, warranting closer fetal monitoringFetal DNA Testing (cffDNA): Non-invasive method using maternal plasma determine fetal genotype specific blood group antigens (like RHD)Middle Cerebral Artery Peak Systolic Velocity (MCA-PSV): Ultrasound Doppler measurement blood flow speed fetal brain artery; increased velocity indicates fetal anemiaMultiples Median (MoM): Unit used report MCA-PSV results relative expected median velocity gestational ageFetal Blood Sampling (FBS) / Cordocentesis: Invasive procedure obtain fetal blood sample directly umbilical cordDirect Antiglobulin Test (DAT): Test performed newborn (patient) red blood cells detect vivo coating IgG complementElution: procedure remove antibodies bound red blood cells antibody specificity can determinedHyperbilirubinemia: Elevated levels bilirubin bloodCord Blood: Blood collected umbilical cord immediately delivery","code":""},{"path":"treatment.html","id":"treatment","chapter":"Treatment","heading":"Treatment","text":"Treating Hemolytic Disease Fetus Newborn (HDFN) requires addressing core problems: destruction fetal/newborn red blood cells maternal IgG antibodies, resulting anemia, dangerous buildup bilirubin birth. Treatment strategies vary depending whether applied antenatally (pregnancy) postnatally (birth)","code":""},{"path":"treatment.html","id":"antenatal-treatment-managing-the-fetus","chapter":"Treatment","heading":"Antenatal Treatment: Managing the Fetus","text":"primary goal pregnancy detect manage fetal anemia prevent hydrops fetalis fetal demiseIntrauterine Transfusion (IUT)\nGoal: cornerstone treating severe fetal anemia. Aims directly provide compatible red blood cells fetus, increasing oxygen-carrying capacity suppressing fetus’s (ineffective targeted) erythropoiesis\nIndications: Evidence significant fetal anemia, typically indicated :\nMiddle Cerebral Artery Peak Systolic Velocity (MCA-PSV) Doppler values >1.5 MoM (Multiples Median)\nDevelopment fetal hydrops (though ideally initiated hydrops occurs)\nDirect measurement severe anemia via Fetal Blood Sampling (FBS/Cordocentesis)\n\nProcedure: Ultrasound-guided procedure compatible red blood cells transfused directly fetal circulation. commonly performed via intravascular transfusion umbilical vein. Intraperitoneal transfusion less common less efficient now\nBlood Product Selection (CRITICAL): RBC unit must carefully selected:\nGroup O, RhD-negative: Usually chosen avoid reaction maternal anti-, anti-B, anti-D. mother antibodies, unit must also antigen-negative corresponding antigen(s) (e.g., mom anti-K, use K-negative blood)\nCMV-safe: Either CMV-seronegative leukocyte-reduced prevent Cytomegalovirus transmission\nIrradiated: prevent Transfusion-Associated Graft-versus-Host Disease (TA-GVHD) fetus, whose immune system immature\nFresh: Ideally less 7 days old ensure optimal oxygen delivery (higher 2,3-DPG) post-transfusion survival\nHigh Hematocrit (70-85%): deliver maximum number RBCs smallest possible volume\nCrossmatch Compatible: Must compatible mother’s plasma (antibodies causing problem)\n\nFrequency: Repeated every 1-4 weeks, depending rate hemolysis fetal hematocrit, fetus reaches sufficient maturity delivery\nGoal: cornerstone treating severe fetal anemia. Aims directly provide compatible red blood cells fetus, increasing oxygen-carrying capacity suppressing fetus’s (ineffective targeted) erythropoiesisIndications: Evidence significant fetal anemia, typically indicated :\nMiddle Cerebral Artery Peak Systolic Velocity (MCA-PSV) Doppler values >1.5 MoM (Multiples Median)\nDevelopment fetal hydrops (though ideally initiated hydrops occurs)\nDirect measurement severe anemia via Fetal Blood Sampling (FBS/Cordocentesis)\nMiddle Cerebral Artery Peak Systolic Velocity (MCA-PSV) Doppler values >1.5 MoM (Multiples Median)Development fetal hydrops (though ideally initiated hydrops occurs)Direct measurement severe anemia via Fetal Blood Sampling (FBS/Cordocentesis)Procedure: Ultrasound-guided procedure compatible red blood cells transfused directly fetal circulation. commonly performed via intravascular transfusion umbilical vein. Intraperitoneal transfusion less common less efficient nowBlood Product Selection (CRITICAL): RBC unit must carefully selected:\nGroup O, RhD-negative: Usually chosen avoid reaction maternal anti-, anti-B, anti-D. mother antibodies, unit must also antigen-negative corresponding antigen(s) (e.g., mom anti-K, use K-negative blood)\nCMV-safe: Either CMV-seronegative leukocyte-reduced prevent Cytomegalovirus transmission\nIrradiated: prevent Transfusion-Associated Graft-versus-Host Disease (TA-GVHD) fetus, whose immune system immature\nFresh: Ideally less 7 days old ensure optimal oxygen delivery (higher 2,3-DPG) post-transfusion survival\nHigh Hematocrit (70-85%): deliver maximum number RBCs smallest possible volume\nCrossmatch Compatible: Must compatible mother’s plasma (antibodies causing problem)\nGroup O, RhD-negative: Usually chosen avoid reaction maternal anti-, anti-B, anti-D. mother antibodies, unit must also antigen-negative corresponding antigen(s) (e.g., mom anti-K, use K-negative blood)CMV-safe: Either CMV-seronegative leukocyte-reduced prevent Cytomegalovirus transmissionIrradiated: prevent Transfusion-Associated Graft-versus-Host Disease (TA-GVHD) fetus, whose immune system immatureFresh: Ideally less 7 days old ensure optimal oxygen delivery (higher 2,3-DPG) post-transfusion survivalHigh Hematocrit (70-85%): deliver maximum number RBCs smallest possible volumeCrossmatch Compatible: Must compatible mother’s plasma (antibodies causing problem)Frequency: Repeated every 1-4 weeks, depending rate hemolysis fetal hematocrit, fetus reaches sufficient maturity deliveryTiming Delivery\nGoal: Balance risks continuing pregnancy (ongoing hemolysis, potential IUT complications) risks prematurity newborn\nDecision: Based gestational age, severity HDFN, response IUT, assessment fetal lung maturity (may require amniocentesis lecithin/sphingomyelin ratio tests)\nGeneral Approach: Delivery often induced 35-38 weeks HDFN well-managed IUTs. Earlier delivery might necessary severe HDFN difficult manage utero\nGoal: Balance risks continuing pregnancy (ongoing hemolysis, potential IUT complications) risks prematurity newbornDecision: Based gestational age, severity HDFN, response IUT, assessment fetal lung maturity (may require amniocentesis lecithin/sphingomyelin ratio tests)General Approach: Delivery often induced 35-38 weeks HDFN well-managed IUTs. Earlier delivery might necessary severe HDFN difficult manage uteroMaternal Therapies (Less Common/Adjunctive)\nIntravenous Immune Globulin (IVIg): High-dose IVIg given mother may reduce severity HDFN selected cases, potentially saturating placental FcRn receptors (reducing antibody transport) modulating maternal immune response. effectiveness debated often reserved severe cases early gestation IUT problematic\nPlasma Exchange (Plasmapheresis): Physically removes antibody mother’s circulation. Rarely used due effectiveness IUT, logistical challenges, temporary effect. May considered extreme cases early gestation IUT feasible\nIntravenous Immune Globulin (IVIg): High-dose IVIg given mother may reduce severity HDFN selected cases, potentially saturating placental FcRn receptors (reducing antibody transport) modulating maternal immune response. effectiveness debated often reserved severe cases early gestation IUT problematicPlasma Exchange (Plasmapheresis): Physically removes antibody mother’s circulation. Rarely used due effectiveness IUT, logistical challenges, temporary effect. May considered extreme cases early gestation IUT feasible","code":""},{"path":"treatment.html","id":"postnatal-treatment-managing-the-newborn","chapter":"Treatment","heading":"Postnatal Treatment: Managing the Newborn","text":"focus shifts immediately birth managing hyperbilirubinemia (prevent kernicterus) anemiaPhototherapy\nGoal: Primary treatment neonatal jaundice. Converts toxic unconjugated bilirubin skin water-soluble isomers can excreted infant’s liver kidneys without needing conjugation\nMechanism: Exposure infant’s skin specific wavelengths light (blue-green spectrum, typically 460-490 nm) causes photoisomerization photo-oxidation bilirubin\nIndications: Initiated based total serum bilirubin levels, adjusted gestational age, postnatal age (hours), risk factors (including HDFN ). Nomograms (e.g., Bhutani nomogram) guide initiation thresholds\nAdministration: Infant placed special lights fiberoptic blanket maximum skin exposure (eyes shielded)\nGoal: Primary treatment neonatal jaundice. Converts toxic unconjugated bilirubin skin water-soluble isomers can excreted infant’s liver kidneys without needing conjugationMechanism: Exposure infant’s skin specific wavelengths light (blue-green spectrum, typically 460-490 nm) causes photoisomerization photo-oxidation bilirubinIndications: Initiated based total serum bilirubin levels, adjusted gestational age, postnatal age (hours), risk factors (including HDFN ). Nomograms (e.g., Bhutani nomogram) guide initiation thresholdsAdministration: Infant placed special lights fiberoptic blanket maximum skin exposure (eyes shielded)Exchange Transfusion\nGoal: Rapidly remove bilirubin circulation, remove circulating maternal antibodies, remove antibody-coated neonatal RBCs, provide compatible antigen-negative RBCs, correct severe anemia\nIndications: Reserved severe hyperbilirubinemia unresponsive intensive phototherapy, bilirubin levels reaching critical thresholds associated kernicterus risk, signs acute bilirubin encephalopathy. Also indicated severe anemia signs cardiac decompensation birth\nProcedure: catheter usually placed umbilical vein. Small volumes infant’s blood withdrawn replaced sequentially aliquots compatible donor blood. “double volume” exchange (approx. 160-180 mL/kg) replaces 85% infant’s blood volume\nBlood Product Selection: Similar principles IUT:\nGroup O RBCs: (often RhD-negative unless ABO HDFN excluded infant/mother type allows otherwise), antigen-negative maternal antibody(ies)\nRBCs suspended Group AB plasma (contains anti-anti-B) create reconstituted whole blood, compatible plasma type. Albumin may added enhance bilirubin binding\nCMV-safe, Irradiated, Fresh (< 7 days), High Hematocrit: (unit adjusted desired Hct exchange)\nCrossmatch Compatible: maternal plasma eluate prepared infant’s RBCs (ensure compatibility antibody causing hemolysis)\n\nRisks: Invasive procedure potential complications (cardiac arrhythmias, electrolyte imbalance, infection, thrombosis, air embolism, hypothermia, thrombocytopenia, NEC)\nGoal: Rapidly remove bilirubin circulation, remove circulating maternal antibodies, remove antibody-coated neonatal RBCs, provide compatible antigen-negative RBCs, correct severe anemiaIndications: Reserved severe hyperbilirubinemia unresponsive intensive phototherapy, bilirubin levels reaching critical thresholds associated kernicterus risk, signs acute bilirubin encephalopathy. Also indicated severe anemia signs cardiac decompensation birthProcedure: catheter usually placed umbilical vein. Small volumes infant’s blood withdrawn replaced sequentially aliquots compatible donor blood. “double volume” exchange (approx. 160-180 mL/kg) replaces 85% infant’s blood volumeBlood Product Selection: Similar principles IUT:\nGroup O RBCs: (often RhD-negative unless ABO HDFN excluded infant/mother type allows otherwise), antigen-negative maternal antibody(ies)\nRBCs suspended Group AB plasma (contains anti-anti-B) create reconstituted whole blood, compatible plasma type. Albumin may added enhance bilirubin binding\nCMV-safe, Irradiated, Fresh (< 7 days), High Hematocrit: (unit adjusted desired Hct exchange)\nCrossmatch Compatible: maternal plasma eluate prepared infant’s RBCs (ensure compatibility antibody causing hemolysis)\nGroup O RBCs: (often RhD-negative unless ABO HDFN excluded infant/mother type allows otherwise), antigen-negative maternal antibody(ies)RBCs suspended Group AB plasma (contains anti-anti-B) create reconstituted whole blood, compatible plasma type. Albumin may added enhance bilirubin bindingCMV-safe, Irradiated, Fresh (< 7 days), High Hematocrit: (unit adjusted desired Hct exchange)Crossmatch Compatible: maternal plasma eluate prepared infant’s RBCs (ensure compatibility antibody causing hemolysis)Risks: Invasive procedure potential complications (cardiac arrhythmias, electrolyte imbalance, infection, thrombosis, air embolism, hypothermia, thrombocytopenia, NEC)Simple Red Blood Cell Transfusion\nGoal: Correct anemia persists develops initial hyperbilirubinemia phase managed\nIndications: Significant anemia (Hgb/Hct threshold age) occurring later neonatal period (weeks months) due continued destruction RBCs residual maternal IgG suppressed erythropoiesis\nBlood Product Selection: Compatible RBC unit, antigen-negative implicated maternal antibody(ies). CMV-safe irradiated policies neonates apply\nGoal: Correct anemia persists develops initial hyperbilirubinemia phase managedIndications: Significant anemia (Hgb/Hct threshold age) occurring later neonatal period (weeks months) due continued destruction RBCs residual maternal IgG suppressed erythropoiesisBlood Product Selection: Compatible RBC unit, antigen-negative implicated maternal antibody(ies). CMV-safe irradiated policies neonates applyIntravenous Immune Globulin (IVIg) - Neonatal\nGoal: Reduce rate hemolysis, potentially decreasing peak bilirubin levels need exchange transfusion\nMechanism: Thought block Fc receptors macrophages infant’s reticuloendothelial system, preventing clearing antibody-coated RBCs\nIndications: Often used adjunctively phototherapy newborns significant ongoing hemolysis (isoimmune HDFN positive DAT) rapidly rising bilirubin levels approaching exchange transfusion thresholds\nAdministration: Given intravenously several hours\nGoal: Reduce rate hemolysis, potentially decreasing peak bilirubin levels need exchange transfusionMechanism: Thought block Fc receptors macrophages infant’s reticuloendothelial system, preventing clearing antibody-coated RBCsIndications: Often used adjunctively phototherapy newborns significant ongoing hemolysis (isoimmune HDFN positive DAT) rapidly rising bilirubin levels approaching exchange transfusion thresholdsAdministration: Given intravenously several hoursSupportive Care\nMaintaining adequate hydration nutrition\nMonitoring electrolytes, glucose, vital signs, especially exchange transfusion\nCorrecting associated complications (e.g., thrombocytopenia present)\nMaintaining adequate hydration nutritionMonitoring electrolytes, glucose, vital signs, especially exchange transfusionCorrecting associated complications (e.g., thrombocytopenia present)","code":""},{"path":"treatment.html","id":"key-terms-65","chapter":"Treatment","heading":"Key Terms","text":"Intrauterine Transfusion (IUT): Transfusion red blood cells directly fetal circulation (usually umbilical vein) pregnancy treat severe fetal anemiaHydrops Fetalis: Severe fetal condition characterized abnormal fluid accumulation tissues body cavities, often due severe anemiaMiddle Cerebral Artery Peak Systolic Velocity (MCA-PSV): Ultrasound measurement used non-invasively assess degree fetal anemiaPhototherapy: Treatment using specific wavelengths light convert unconjugated bilirubin skin excretable isomers, used neonatal jaundiceExchange Transfusion: Procedure infant’s blood removed small volumes replaced compatible donor blood rapidly lower bilirubin levels, remove antibodies, correct anemiaKernicterus: Permanent neurological damage caused deposition unconjugated bilirubin brain tissue newbornsIntravenous Immune Globulin (IVIg): preparation concentrated human antibodies used therapeutically; HDFN, may reduce hemolysis blocking Fc receptors modulating immune responsesPlasma Exchange (Plasmapheresis): Procedure remove plasma (containing antibodies) blood replace replacement fluidIrradiation (Blood Products): Treatment cellular blood components gamma rays X-rays inactivate donor T-lymphocytes prevent TA-GVHDCMV-Safe: Blood products processed (leukocyte reduced) tested (seronegative) minimize risk transmitting Cytomegalovirus","code":""},{"path":"prevention.html","id":"prevention","chapter":"Prevention","heading":"Prevention","text":"truly one great success stories transfusion medicine! Preventing Hemolytic Disease Fetus Newborn (HDFN), particularly severe form caused anti-D, relies almost entirely preventing mother becoming alloimmunized (sensitized) specific fetal red blood cell antigen first place","code":""},{"path":"prevention.html","id":"the-cornerstone-rh-immune-globulin-rhig-prophylaxis-for-anti-d","chapter":"Prevention","heading":"The Cornerstone: Rh Immune Globulin (RhIG) Prophylaxis for Anti-D","text":"strategy focuses specifically preventing RhD-negative individuals developing anti-D antibodies exposure RhD-positive red blood cellsWhat RhIG?: sterile solution containing concentrated IgG anti-D antibodies, derived plasma screened human donors high levels anti-D. ’s form passive immunizationMechanism Action (Prevents Sensitization): exact mechanism complex, leading theory involves immune clearance suppression:\nRhD-positive fetal red blood cells enter RhD-negative mother’s circulation (Fetal-Maternal Hemorrhage - FMH), injected RhIG antibodies (passive anti-D) quickly bind D antigens fetal cells\nantibody-coated fetal cells rapidly cleared maternal circulation, primarily macrophages spleen, likely via Fc receptor interactions\nrapid clearance occurs mother’s adaptive immune system (B cells T cells) chance fully recognize foreign D antigen mount active, long-lasting immune response (.e., produce anti-D form memory cells)\nEssentially, passive antibody “masks” antigen facilitates removal, preventing primary immunization\nRhD-positive fetal red blood cells enter RhD-negative mother’s circulation (Fetal-Maternal Hemorrhage - FMH), injected RhIG antibodies (passive anti-D) quickly bind D antigens fetal cellsThese antibody-coated fetal cells rapidly cleared maternal circulation, primarily macrophages spleen, likely via Fc receptor interactionsThis rapid clearance occurs mother’s adaptive immune system (B cells T cells) chance fully recognize foreign D antigen mount active, long-lasting immune response (.e., produce anti-D form memory cells)Essentially, passive antibody “masks” antigen facilitates removal, preventing primary immunizationCrucial Point: RhIG prophylactic, meaning prevents sensitization. effective mother already developed anti-D antibodies (.e., already alloimmunized)","code":""},{"path":"prevention.html","id":"standard-administration-protocols-for-rhig","chapter":"Prevention","heading":"Standard Administration Protocols for RhIG","text":"effective, RhIG must given strategically around times FMH likely occurAntenatal Prophylaxis (Routine)\n: standard dose (typically 300 µg US) recommended RhD-negative, unsensitized (anti-D negative) pregnant women around 28 weeks gestation\n: Recognizes small, often silent, FMHs can occur third trimester, potentially sensitizing mother delivery. dose provides passive protection remainder pregnancy\n: standard dose (typically 300 µg US) recommended RhD-negative, unsensitized (anti-D negative) pregnant women around 28 weeks gestationWhy: Recognizes small, often silent, FMHs can occur third trimester, potentially sensitizing mother delivery. dose provides passive protection remainder pregnancyPostnatal Prophylaxis\n: standard dose (e.g., 300 µg) given RhD-negative, unsensitized mother within 72 hours delivery RhD-positive infant\n: Delivery associated highest risk potentially largest volume FMH. 72-hour window critical intercept fetal cells mother’s immune response fully initiated\nConfirmation: infant’s RhD type determined cord blood testing birth\n: standard dose (e.g., 300 µg) given RhD-negative, unsensitized mother within 72 hours delivery RhD-positive infantWhy: Delivery associated highest risk potentially largest volume FMH. 72-hour window critical intercept fetal cells mother’s immune response fully initiatedConfirmation: infant’s RhD type determined cord blood testing birthAfter Potential Sensitizing Events: RhIG also recommended RhD-negative, unsensitized women following event pregnancy potentially cause FMH, including:\nAmniocentesis, Chorionic Villus Sampling (CVS), Fetal Blood Sampling (FBS)\nMiscarriage, therapeutic abortion, ectopic pregnancy\nSignificant abdominal trauma\nExternal cephalic version (attempting turn breech baby)\nAntepartum bleeding\nDose Consideration: Smaller doses (e.g., 50 µg) may sufficient events occurring first trimester\nAmniocentesis, Chorionic Villus Sampling (CVS), Fetal Blood Sampling (FBS)Miscarriage, therapeutic abortion, ectopic pregnancySignificant abdominal traumaExternal cephalic version (attempting turn breech baby)Antepartum bleedingDose Consideration: Smaller doses (e.g., 50 µg) may sufficient events occurring first trimester","code":""},{"path":"prevention.html","id":"detecting-and-managing-excessive-fetal-maternal-hemorrhage-fmh","chapter":"Prevention","heading":"Detecting and Managing Excessive Fetal-Maternal Hemorrhage (FMH)","text":"Problem: standard 300 µg dose RhIG reliably protects sensitization FMH approximately 15 mL fetal RBCs (30 mL fetal whole blood)Risk: Occasionally, much larger FMH can occur, especially complicated delivery trauma. FMH exceeds 15 mL fetal RBCs, standard dose RhIG may insufficient, mother still become sensitizedThe Solution: Screening Quantification\nScreening Test (Qualitative): Rosette Test\nPerformed post-delivery maternal blood sample (RhD-negative mother delivering RhD-positive infant)\nPrinciple: Maternal sample incubated reagent anti-D. D-positive fetal cells present, anti-D coats . Indicator D-positive cells added, bind antibody-coated fetal cells, forming visible clusters “rosettes” around fetal cells viewed microscopically\nInterpretation: positive rosette test suggests FMH potentially larger 15 mL RBCs indicates need quantitative test\n\nQuantitative Test: Kleihauer-Betke (KB) Stain Flow Cytometry\nKleihauer-Betke (KB) Stain: Classic method. Based principle fetal hemoglobin (HbF) resistant acid elution, adult hemoglobin (HbA) . maternal blood smear treated acid buffer, lysing adult cells leaving fetal cells intact. smear stained, fetal cells (containing HbF) appear bright pink/red, adult “ghost” cells pale. percentage fetal cells counted microscopically\nFlow Cytometry: accurate, objective, reproducible method. Uses fluorescently labeled antibodies HbF (sometimes anti-D) quantify proportion fetal cells maternal sample\n\nCalculating Additional RhIG Dose\nDetermine percentage fetal cells (KB flow)\nCalculate volume FMH (whole blood): % Fetal Cells x Maternal Blood Volume (est. 5000 mL)\nCalculate volume fetal RBCs: Volume FMH (WB) x Fetal Hct (estimated use 0.5) [Simpler calculation often used: `% Fetal Cells x 50 = mL Fetal WB]\nDetermine number 300 µg RhIG vials needed: Volume Fetal RBCs / 15 mL per vial (Volume Fetal WB / 30 mL per vial)\nAlways round next whole vial add one extra vial safety margin\nExample: KB shows 1% fetal cells. FMH = 0.01 x 5000 mL = 50 mL WB. Vials needed = (50 mL WB / 30 mL per vial) = 1.67 -> Round 2 vials, add 1 extra = 3 vials total\n\nAdministration: calculated dose RhIG given within 72 hours sensitizing event (delivery)\nScreening Test (Qualitative): Rosette Test\nPerformed post-delivery maternal blood sample (RhD-negative mother delivering RhD-positive infant)\nPrinciple: Maternal sample incubated reagent anti-D. D-positive fetal cells present, anti-D coats . Indicator D-positive cells added, bind antibody-coated fetal cells, forming visible clusters “rosettes” around fetal cells viewed microscopically\nInterpretation: positive rosette test suggests FMH potentially larger 15 mL RBCs indicates need quantitative test\nPerformed post-delivery maternal blood sample (RhD-negative mother delivering RhD-positive infant)Principle: Maternal sample incubated reagent anti-D. D-positive fetal cells present, anti-D coats . Indicator D-positive cells added, bind antibody-coated fetal cells, forming visible clusters “rosettes” around fetal cells viewed microscopicallyInterpretation: positive rosette test suggests FMH potentially larger 15 mL RBCs indicates need quantitative testQuantitative Test: Kleihauer-Betke (KB) Stain Flow Cytometry\nKleihauer-Betke (KB) Stain: Classic method. Based principle fetal hemoglobin (HbF) resistant acid elution, adult hemoglobin (HbA) . maternal blood smear treated acid buffer, lysing adult cells leaving fetal cells intact. smear stained, fetal cells (containing HbF) appear bright pink/red, adult “ghost” cells pale. percentage fetal cells counted microscopically\nFlow Cytometry: accurate, objective, reproducible method. Uses fluorescently labeled antibodies HbF (sometimes anti-D) quantify proportion fetal cells maternal sample\nKleihauer-Betke (KB) Stain: Classic method. Based principle fetal hemoglobin (HbF) resistant acid elution, adult hemoglobin (HbA) . maternal blood smear treated acid buffer, lysing adult cells leaving fetal cells intact. smear stained, fetal cells (containing HbF) appear bright pink/red, adult “ghost” cells pale. percentage fetal cells counted microscopicallyFlow Cytometry: accurate, objective, reproducible method. Uses fluorescently labeled antibodies HbF (sometimes anti-D) quantify proportion fetal cells maternal sampleCalculating Additional RhIG Dose\nDetermine percentage fetal cells (KB flow)\nCalculate volume FMH (whole blood): % Fetal Cells x Maternal Blood Volume (est. 5000 mL)\nCalculate volume fetal RBCs: Volume FMH (WB) x Fetal Hct (estimated use 0.5) [Simpler calculation often used: `% Fetal Cells x 50 = mL Fetal WB]\nDetermine number 300 µg RhIG vials needed: Volume Fetal RBCs / 15 mL per vial (Volume Fetal WB / 30 mL per vial)\nAlways round next whole vial add one extra vial safety margin\nExample: KB shows 1% fetal cells. FMH = 0.01 x 5000 mL = 50 mL WB. Vials needed = (50 mL WB / 30 mL per vial) = 1.67 -> Round 2 vials, add 1 extra = 3 vials total\nDetermine percentage fetal cells (KB flow)Calculate volume FMH (whole blood): % Fetal Cells x Maternal Blood Volume (est. 5000 mL)Calculate volume fetal RBCs: Volume FMH (WB) x Fetal Hct (estimated use 0.5) [Simpler calculation often used: `% Fetal Cells x 50 = mL Fetal WB]Determine number 300 µg RhIG vials needed: Volume Fetal RBCs / 15 mL per vial (Volume Fetal WB / 30 mL per vial)Always round next whole vial add one extra vial safety margin\nExample: KB shows 1% fetal cells. FMH = 0.01 x 5000 mL = 50 mL WB. Vials needed = (50 mL WB / 30 mL per vial) = 1.67 -> Round 2 vials, add 1 extra = 3 vials totalAdministration: calculated dose RhIG given within 72 hours sensitizing event (delivery)","code":""},{"path":"prevention.html","id":"prevention-of-hdfn-due-to-other-blood-group-antibodies","chapter":"Prevention","heading":"Prevention of HDFN Due to Other Blood Group Antibodies","text":"Challenge: Currently, equivalent immune globulin prophylaxis available prevent sensitization clinically significant red cell antigens like K, c, E, Fya, Jka, etcPreventative Strategies (Limited)\nTransfusion Practices: effective strategy careful transfusion practice women childbearing potential:\nAvoid unnecessary transfusions\ntransfusion required, provide antigen-negative units whenever possible, especially highly immunogenic antigens like K (.e., give K-negative blood K-negative individuals) potentially Rh antigens (c, E) RhD-positive women. reduces chance primary alloimmunization via transfusion\n\nEarly Detection: prevention sensitization, early detection antibodies routine prenatal antibody screening allows appropriate monitoring management pregnancy fetus risk\nTransfusion Practices: effective strategy careful transfusion practice women childbearing potential:\nAvoid unnecessary transfusions\ntransfusion required, provide antigen-negative units whenever possible, especially highly immunogenic antigens like K (.e., give K-negative blood K-negative individuals) potentially Rh antigens (c, E) RhD-positive women. reduces chance primary alloimmunization via transfusion\nAvoid unnecessary transfusionsIf transfusion required, provide antigen-negative units whenever possible, especially highly immunogenic antigens like K (.e., give K-negative blood K-negative individuals) potentially Rh antigens (c, E) RhD-positive women. reduces chance primary alloimmunization via transfusionEarly Detection: prevention sensitization, early detection antibodies routine prenatal antibody screening allows appropriate monitoring management pregnancy fetus risk","code":""},{"path":"prevention.html","id":"key-terms-66","chapter":"Prevention","heading":"Key Terms","text":"Rh Immune Globulin (RhIG): solution concentrated IgG anti-D antibodies used prevent RhD alloimmunization RhD-negative individualsAlloimmunization (Sensitization): development antibodies foreign antigens speciesProphylaxis: Action taken prevent diseasePassive Immunization: Providing temporary immunity administering pre-formed antibodies (like RhIG)Fetal-Maternal Hemorrhage (FMH): Leakage fetal blood maternal circulationRosette Test: qualitative screening test used detect FMH exceeding coverage standard RhIG doseKleihauer-Betke (KB) Stain: quantitative test using acid elution determine percentage fetal red blood cells (containing HbF) maternal blood sampleFlow Cytometry (FMH): automated quantitative method using fluorescent antibodies detect quantify fetal cells maternal blood","code":""},{"path":"cytopenias-1.html","id":"cytopenias-1","chapter":"Cytopenias","heading":"Cytopenias","text":"Cytopenias conditions one blood cell lines low. ’ll look Anemia (low red cells/hemoglobin), Thrombocytopenia (low platelets), Neutropenia (low neutrophils), focusing happen (Pathophysiology), figure cause (Detection), (Treatment)","code":""},{"path":"cytopenias-1.html","id":"cytopenias-an-overview","chapter":"Cytopenias","heading":"Cytopenias: An Overview","text":"Cytopenias indicate problem blood cell production, survival, loss. Identifying specific cell line(s) affected underlying mechanism (immune vs. non-immune, production vs. destruction) crucial diagnosis management","code":""},{"path":"cytopenias-1.html","id":"anemia-too-few-red-blood-cells-too-little-hemoglobin","chapter":"Cytopenias","heading":"Anemia: Too Few Red Blood Cells / Too Little Hemoglobin","text":"","code":""},{"path":"cytopenias-1.html","id":"pathophysiology-1","chapter":"Cytopenias","heading":"Pathophysiology","text":"Decreased Production\nNon-Immune: Nutritional deficiency (Iron, B12, Folate), Bone marrow failure/suppression (Aplastic anemia, CKD - low EPO, Anemia Chronic Disease, Chemo/Radiation, Infiltration), Inherited defects (Thalassemia)\nNon-Immune: Nutritional deficiency (Iron, B12, Folate), Bone marrow failure/suppression (Aplastic anemia, CKD - low EPO, Anemia Chronic Disease, Chemo/Radiation, Infiltration), Inherited defects (Thalassemia)Increased Destruction (Hemolysis)\nNon-Immune: Intrinsic RBC defects (Membranopathies - Spherocytosis; Enzymopathies - G6PD def; Hemoglobinopathies - Sickle Cell), Extrinsic factors (MAHA - TTP/HUS/DIC, Mechanical valves, Infections, Toxins)\nImmune: Antibodies +/- Complement destroy RBCs\nAlloimmune: HTR, HDFN\nAutoimmune: WAIHA (IgG), CAD (IgM+C3d), PCH (IgG+C3d)\nDrug-Induced: Various mechanisms (Hapten, Immune Complex, Autoantibody induction)\n\nNon-Immune: Intrinsic RBC defects (Membranopathies - Spherocytosis; Enzymopathies - G6PD def; Hemoglobinopathies - Sickle Cell), Extrinsic factors (MAHA - TTP/HUS/DIC, Mechanical valves, Infections, Toxins)Immune: Antibodies +/- Complement destroy RBCs\nAlloimmune: HTR, HDFN\nAutoimmune: WAIHA (IgG), CAD (IgM+C3d), PCH (IgG+C3d)\nDrug-Induced: Various mechanisms (Hapten, Immune Complex, Autoantibody induction)\nAlloimmune: HTR, HDFNAutoimmune: WAIHA (IgG), CAD (IgM+C3d), PCH (IgG+C3d)Drug-Induced: Various mechanisms (Hapten, Immune Complex, Autoantibody induction)Blood Loss\nAcute: Trauma, Surgery -> Hypovolemia initially\nChronic: Slow GI bleed, Menstruation -> Iron Deficiency Anemia\nAcute: Trauma, Surgery -> Hypovolemia initiallyChronic: Slow GI bleed, Menstruation -> Iron Deficiency Anemia","code":""},{"path":"cytopenias-1.html","id":"detection-1","chapter":"Cytopenias","heading":"Detection","text":"CBC: Low Hgb/Hct. RBC Indices (MCV, MCHC) classify micro/normo/macrocytic, hypo/normochromicReticulocyte Count: Key! High suggests destruction/loss; Low suggests production problemPeripheral Smear: Essential morphology (size, shape, color, inclusions like schistocytes, spherocytes, sickle cells)Specific Tests: Iron studies, B12/Folate, Hemolysis markers (LDH, Bili, Haptoglobin), Hb Electrophoresis, Enzyme assaysImmunohematologic Tests: DAT (detects vivo coating - IgG/C3d), IAT (detects plasma Abs), Elution (identifies coating Ab) - Crucial immune causes!Bone Marrow Exam: Assesses production, infiltration","code":""},{"path":"cytopenias-1.html","id":"treatment-1","chapter":"Cytopenias","heading":"Treatment","text":"Treat Underlying Cause: Nutrient replacement, stop offending drug, manage chronic disease, immunosuppression AIHA (steroids, Rituximab), Hydroxyurea Sickle CellSupportive Care: EPO CKD/ACDRed Blood Cell Transfusion: Key supportive therapy symptomatic anemia critical Hgb levels. Requires careful compatibility testing, especially challenging AIHA. Antigen-negative blood essential alloantibodies (HTR/HDFN)","code":""},{"path":"cytopenias-1.html","id":"thrombocytopenia-too-few-platelets","chapter":"Cytopenias","heading":"Thrombocytopenia: Too Few Platelets","text":"","code":""},{"path":"cytopenias-1.html","id":"pathophysiology-2","chapter":"Cytopenias","heading":"Pathophysiology","text":"Decreased Production\nNon-Immune: Bone marrow failure/suppression (Aplastic anemia, Chemo/Radiation, Alcohol), Infiltration (Leukemia), Nutritional (severe B12/Folate), Inherited syndromes\nNon-Immune: Bone marrow failure/suppression (Aplastic anemia, Chemo/Radiation, Alcohol), Infiltration (Leukemia), Nutritional (severe B12/Folate), Inherited syndromesIncreased Destruction / Consumption\nNon-Immune: DIC, TTP, HUS, Mechanical destruction, Hypersplenism (Sequestration)\nImmune: Antibodies destroy platelets\nAutoimmune: ITP (primary secondary)\nAlloimmune: NAIT, PTP\nDrug-Induced: DITP (various drugs), HIT (Heparin-PF4 complex Abs - prothrombotic!)\n\nNon-Immune: DIC, TTP, HUS, Mechanical destruction, Hypersplenism (Sequestration)Immune: Antibodies destroy platelets\nAutoimmune: ITP (primary secondary)\nAlloimmune: NAIT, PTP\nDrug-Induced: DITP (various drugs), HIT (Heparin-PF4 complex Abs - prothrombotic!)\nAutoimmune: ITP (primary secondary)Alloimmune: NAIT, PTPDrug-Induced: DITP (various drugs), HIT (Heparin-PF4 complex Abs - prothrombotic!)Pseudothrombocytopenia: vitro clumping artifact (EDTA-dependent)","code":""},{"path":"cytopenias-1.html","id":"detection-2","chapter":"Cytopenias","heading":"Detection","text":"CBC: Low platelet countPeripheral Smear: Essential confirm low count, rule clumping/pseudothrombocytopenia, assess size (giant platelets ITP, Bernard-Soulier)Coagulation Studies (PT/aPTT/Fibrinogen/D-dimer): Important DIC suspectedADAMTS13 Activity: TTP diagnosisBone Marrow Exam: Assess megakaryocytes production defect suspectedSpecialized Immune Testing: HIT assays (Immunoassay & Functional), HPA antibody testing (NAIT/PTP). Platelet autoantibody tests ITP generally useful","code":""},{"path":"cytopenias-1.html","id":"treatment-2","chapter":"Cytopenias","heading":"Treatment","text":"Treat Underlying Cause: Stop drug, treat infection/malignancy, Plasma Exchange (TTP!), Non-heparin anticoagulants (HIT!)Immune Modulation (ITP/NAIT/PTP): Corticosteroids, IVIg, Rituximab, TPO-RAs, Splenectomy (ITP)Platelet Transfusion: active bleeding prophylaxis low counts (<10-20k). Transfused platelets rapidly destroyed ITP. Avoid TTP/HIT unless life-threatening bleed. Special requirements NAIT/PTP (HPA-matched) immune refractoriness (HLA-matched)","code":""},{"path":"cytopenias-1.html","id":"neutropenia-too-few-neutrophils","chapter":"Cytopenias","heading":"Neutropenia: Too Few Neutrophils","text":"","code":""},{"path":"cytopenias-1.html","id":"pathophysiology-3","chapter":"Cytopenias","heading":"Pathophysiology","text":"Decreased Production\nNon-Immune: Congenital (SCN, Cyclic), Acquired marrow failure/suppression (Chemo/Radiation, Drugs, Aplastic anemia, Alcohol), Infiltration (Leukemia), Nutritional (severe B12/Folate/Copper)\nNon-Immune: Congenital (SCN, Cyclic), Acquired marrow failure/suppression (Chemo/Radiation, Drugs, Aplastic anemia, Alcohol), Infiltration (Leukemia), Nutritional (severe B12/Folate/Copper)Increased Destruction / Consumption / Margination\nNon-Immune: Overwhelming sepsis, Hypersplenism (Sequestration), Pseudoneutropenia (margination shift)\nImmune: Antibodies destroy neutrophils\nAutoimmune: AIN (primary infants, secondary SLE, RA, etc.)\nAlloimmune: NAN\nDrug-Induced: DIIN\n\nNon-Immune: Overwhelming sepsis, Hypersplenism (Sequestration), Pseudoneutropenia (margination shift)Immune: Antibodies destroy neutrophils\nAutoimmune: AIN (primary infants, secondary SLE, RA, etc.)\nAlloimmune: NAN\nDrug-Induced: DIIN\nAutoimmune: AIN (primary infants, secondary SLE, RA, etc.)Alloimmune: NANDrug-Induced: DIIN","code":""},{"path":"cytopenias-1.html","id":"detection-3","chapter":"Cytopenias","heading":"Detection","text":"CBC w/ Differential: Low Absolute Neutrophil Count (ANC). Note severity (mild/mod/severe <500)Serial CBCs: cyclic pattern suspectedPeripheral Smear: Confirm differential, assess morphologyBone Marrow Exam: Assess cellularity, granulopoiesis (maturation arrest common immune/congenital forms), rule infiltrationSpecialized Testing: Neutrophil antibody testing (AIN/NAN), Genetic testing (congenital), Autoimmune markers","code":""},{"path":"cytopenias-1.html","id":"treatment-3","chapter":"Cytopenias","heading":"Treatment","text":"Treat Underlying Cause: Stop drug, treat infection/malignancyInfection Prevention/Management: Prompt broad-spectrum antibiotics febrile neutropenia (medical emergency!). Prophylactic antimicrobials sometimes. Patient educationGranulocyte Colony-Stimulating Factor (G-CSF): Mainstay many causes (Chemo-induced, Congenital, AIN) boost neutrophil productionImmunosuppression (AIN): Steroids, IVIg, RituximabGranulocyte Transfusion: rarely used, specific indications/risks","code":""},{"path":"cytopenias-1.html","id":"overall-clinical-relevance","chapter":"Cytopenias","heading":"Overall Clinical Relevance","text":"Cytopenias common laboratory findings requiring careful investigation. clinical presentation (hypoxia symptoms vs. bleeding vs. infections), CBC results (indices, cell lines), reticulocyte count, peripheral smear morphology provide crucial initial clues. Specific testing, including immunohematology (DAT/IAT/Elution) bone marrow evaluation, often needed pinpoint cause. Treatment must directed underlying pathophysiology, blood component therapy (RBCs, Platelets, rarely Granulocytes) serving vital supportive care","code":""},{"path":"anemia.html","id":"anemia","chapter":"Anemia","heading":"Anemia","text":"super common finding, ’s crucial remember anemia isn’t disease, rather sign symptom underlying problem. Essentially, means reduction oxygen-carrying capacity bloodClinically, define decrease one key measurements:\n* Hemoglobin (Hgb): concentration\n* Hematocrit (Hct): (percentage blood volume occupied red cells)\n* Red Blood Cell (RBC): countThe consequence? Tissue hypoxia (lack oxygen), leads classic symptoms like fatigue, shortness breath, pallor (paleness), dizziness, headacheWe can broadly classify causes anemia two main buckets: Non-Immune (problems production, non-antibody destruction, blood loss) Immune (body’s immune system destroys RBCs). Understanding specific cause absolutely vital dictates investigate lab patient treated","code":""},{"path":"anemia.html","id":"non-immune-anemia-when-the-problem-isnt-antibodies","chapter":"Anemia","heading":"Non-Immune Anemia: When the Problem Isn’t Antibodies","text":"category covers wide range conditions RBCs lost, underproduced, destroyed mechanisms primarily involving adaptive immune response (antibodies/complement) RBCs ","code":""},{"path":"anemia.html","id":"pathophysiology-how-it-happens","chapter":"Anemia","heading":"Pathophysiology (How it Happens)","text":"can think non-immune causes three main groups:Decreased Red Blood Cell Production “factory” (bone marrow) isn’t making enough RBCs\nNutritional Deficiencies: Lack essential building blocks\nIron Deficiency Anemia (IDA): common type worldwide. Insufficient iron hemoglobin synthesis -> small (microcytic), pale (hypochromic) RBCs. Caused chronic blood loss (GI, menstruation), poor diet, malabsorption\nMegaloblastic Anemias (Vitamin B12 Folate Deficiency): Impaired DNA synthesis affects rapidly dividing cells, including RBC precursors. Leads large (macrocytic), oval RBCs often low WBC/platelet counts. Causes include pernicious anemia (lack intrinsic factor B12 absorption), poor diet, malabsorption, certain drugs\n\nBone Marrow Failure/Suppression\nAplastic Anemia: Bone marrow fails produce blood cell types (pancytopenia). Can idiopathic, drug/toxin-induced, viral\nAnemia Chronic Disease/Inflammation (ACD/AI): Common chronic infections, inflammation, malignancy. Complex mechanisms involving inflammatory cytokines block iron utilization, suppress erythropoietin (EPO) response, shorten RBC survival slightly. Often normocytic, can microcytic\nAnemia Chronic Kidney Disease (CKD): Kidneys don’t produce enough EPO (hormone stimulating RBC production). Usually normocytic\nBone Marrow Infiltration: Leukemia, lymphoma, metastatic cancer crowd normal hematopoietic cells\n\nInherited Production Defects\nThalassemias: Genetic defects globin chain synthesis (alpha beta) -> ineffective erythropoiesis, microcytic/hypochromic anemia, varying severity\nCongenital Sideroblastic Anemias: Defects heme synthesis pathway -> iron accumulation mitochondria (ring sideroblasts)\n\nNutritional Deficiencies: Lack essential building blocks\nIron Deficiency Anemia (IDA): common type worldwide. Insufficient iron hemoglobin synthesis -> small (microcytic), pale (hypochromic) RBCs. Caused chronic blood loss (GI, menstruation), poor diet, malabsorption\nMegaloblastic Anemias (Vitamin B12 Folate Deficiency): Impaired DNA synthesis affects rapidly dividing cells, including RBC precursors. Leads large (macrocytic), oval RBCs often low WBC/platelet counts. Causes include pernicious anemia (lack intrinsic factor B12 absorption), poor diet, malabsorption, certain drugs\nIron Deficiency Anemia (IDA): common type worldwide. Insufficient iron hemoglobin synthesis -> small (microcytic), pale (hypochromic) RBCs. Caused chronic blood loss (GI, menstruation), poor diet, malabsorptionMegaloblastic Anemias (Vitamin B12 Folate Deficiency): Impaired DNA synthesis affects rapidly dividing cells, including RBC precursors. Leads large (macrocytic), oval RBCs often low WBC/platelet counts. Causes include pernicious anemia (lack intrinsic factor B12 absorption), poor diet, malabsorption, certain drugsBone Marrow Failure/Suppression\nAplastic Anemia: Bone marrow fails produce blood cell types (pancytopenia). Can idiopathic, drug/toxin-induced, viral\nAnemia Chronic Disease/Inflammation (ACD/AI): Common chronic infections, inflammation, malignancy. Complex mechanisms involving inflammatory cytokines block iron utilization, suppress erythropoietin (EPO) response, shorten RBC survival slightly. Often normocytic, can microcytic\nAnemia Chronic Kidney Disease (CKD): Kidneys don’t produce enough EPO (hormone stimulating RBC production). Usually normocytic\nBone Marrow Infiltration: Leukemia, lymphoma, metastatic cancer crowd normal hematopoietic cells\nAplastic Anemia: Bone marrow fails produce blood cell types (pancytopenia). Can idiopathic, drug/toxin-induced, viralAnemia Chronic Disease/Inflammation (ACD/AI): Common chronic infections, inflammation, malignancy. Complex mechanisms involving inflammatory cytokines block iron utilization, suppress erythropoietin (EPO) response, shorten RBC survival slightly. Often normocytic, can microcyticAnemia Chronic Kidney Disease (CKD): Kidneys don’t produce enough EPO (hormone stimulating RBC production). Usually normocyticBone Marrow Infiltration: Leukemia, lymphoma, metastatic cancer crowd normal hematopoietic cellsInherited Production Defects\nThalassemias: Genetic defects globin chain synthesis (alpha beta) -> ineffective erythropoiesis, microcytic/hypochromic anemia, varying severity\nCongenital Sideroblastic Anemias: Defects heme synthesis pathway -> iron accumulation mitochondria (ring sideroblasts)\nThalassemias: Genetic defects globin chain synthesis (alpha beta) -> ineffective erythropoiesis, microcytic/hypochromic anemia, varying severityCongenital Sideroblastic Anemias: Defects heme synthesis pathway -> iron accumulation mitochondria (ring sideroblasts)Increased Red Blood Cell Destruction (Non-Immune Hemolysis) RBCs destroyed prematurely (<120 days) non-antibody mechanisms\nIntrinsic RBC Defects (Inherited): Problems within RBC make fragile\nMembranopathies: Defects membrane proteins -> abnormal shape, reduced deformability (e.g., Hereditary Spherocytosis, Elliptocytosis). Cells destroyed spleen\nEnzymopathies: Deficiencies key metabolic enzymes -> reduced ATP protection oxidation (e.g., G6PD Deficiency, Pyruvate Kinase Deficiency)\nHemoglobinopathies: Abnormal hemoglobin structure (e.g., Sickle Cell Disease - HbS polymerizes, causing sickling, hemolysis, vaso-occlusion)\n\nExtrinsic Factors (Acquired): External forces destroy normal RBCs\nMechanical Trauma: Physical shearing forces (e.g., malfunctioning prosthetic heart valves; Microangiopathic Hemolytic Anemias - MAHA - seen TTP, HUS, DIC clots shred RBCs)\nInfections: Direct invasion (Malaria) toxin production (Clostridium perfringens)\nChemicals/Drugs/Toxins: Oxidative damage (especially G6PD deficiency), lead poisoning, venoms\nPhysical Agents: Severe burns\n\nIntrinsic RBC Defects (Inherited): Problems within RBC make fragile\nMembranopathies: Defects membrane proteins -> abnormal shape, reduced deformability (e.g., Hereditary Spherocytosis, Elliptocytosis). Cells destroyed spleen\nEnzymopathies: Deficiencies key metabolic enzymes -> reduced ATP protection oxidation (e.g., G6PD Deficiency, Pyruvate Kinase Deficiency)\nHemoglobinopathies: Abnormal hemoglobin structure (e.g., Sickle Cell Disease - HbS polymerizes, causing sickling, hemolysis, vaso-occlusion)\nMembranopathies: Defects membrane proteins -> abnormal shape, reduced deformability (e.g., Hereditary Spherocytosis, Elliptocytosis). Cells destroyed spleenEnzymopathies: Deficiencies key metabolic enzymes -> reduced ATP protection oxidation (e.g., G6PD Deficiency, Pyruvate Kinase Deficiency)Hemoglobinopathies: Abnormal hemoglobin structure (e.g., Sickle Cell Disease - HbS polymerizes, causing sickling, hemolysis, vaso-occlusion)Extrinsic Factors (Acquired): External forces destroy normal RBCs\nMechanical Trauma: Physical shearing forces (e.g., malfunctioning prosthetic heart valves; Microangiopathic Hemolytic Anemias - MAHA - seen TTP, HUS, DIC clots shred RBCs)\nInfections: Direct invasion (Malaria) toxin production (Clostridium perfringens)\nChemicals/Drugs/Toxins: Oxidative damage (especially G6PD deficiency), lead poisoning, venoms\nPhysical Agents: Severe burns\nMechanical Trauma: Physical shearing forces (e.g., malfunctioning prosthetic heart valves; Microangiopathic Hemolytic Anemias - MAHA - seen TTP, HUS, DIC clots shred RBCs)Infections: Direct invasion (Malaria) toxin production (Clostridium perfringens)Chemicals/Drugs/Toxins: Oxidative damage (especially G6PD deficiency), lead poisoning, venomsPhysical Agents: Severe burnsBlood Loss (Hemorrhage) Direct loss RBCs circulation\nAcute: Rapid loss (trauma, surgery, ruptured aneurysm). Leads initially hypovolemia; anemia develops volume replaced interstitial fluid IV fluids. RBCs normocytic initially\nChronic: Slow, persistent loss (e.g., slow GI bleed, heavy menstruation). Body compensates initially, eventually leads Iron Deficiency Anemia iron stores depleted\nAcute: Rapid loss (trauma, surgery, ruptured aneurysm). Leads initially hypovolemia; anemia develops volume replaced interstitial fluid IV fluids. RBCs normocytic initiallyChronic: Slow, persistent loss (e.g., slow GI bleed, heavy menstruation). Body compensates initially, eventually leads Iron Deficiency Anemia iron stores depleted","code":""},{"path":"anemia.html","id":"detection-finding-the-cause","chapter":"Anemia","heading":"Detection (Finding the Cause)","text":"Diagnosing specific type non-immune anemia involves integrating clinical information laboratory tests:Clinical Assessment: Patient history (diet, medications, family history, bleeding symptoms, chronic diseases), physical exam (pallor, jaundice, splenomegaly)Laboratory Tests\nComplete Blood Count (CBC) Differential\nHgb/Hct/RBC count: Confirm anemia severity\nRBC Indices: CRITICAL initial classification!\nMCV (Mean Corpuscular Volume): Size (Microcytic <80 fL; Normocytic 80-100 fL; Macrocytic >100 fL)\nMCH/MCHC (Mean Corpuscular Hgb/Concentration): Color (Hypochromic = pale; Normochromic)\nRDW (Red Cell Distribution Width): Variation RBC size (anisocytosis). Often increased different populations cells present (e.g., IDA)\n\nWBC & Platelet Count: Assess pancytopenia (aplastic anemia) associated changes (e.g., reactive thrombocytosis IDA)\n\nReticulocyte Count: Measures young RBCs released marrow. Crucial distinction\nHigh Retic Count (Appropriate Response): Suggests bone marrow responding loss/destruction (hemolysis, acute blood loss)\nLow/Normal Retic Count (Inadequate Response): Suggests production problem (nutritional deficiency, marrow failure, CKD, ACD)\n\nPeripheral Blood Smear Review: Microscopic examination essential! Look :\nSize/Color variations: Micro/macro/hypo/normo\nShape abnormalities: Spherocytes, elliptocytes, sickle cells, target cells, schistocytes (fragmented RBCs - hallmark MAHA)\nInclusions: Basophilic stippling (lead poisoning), Howell-Jolly bodies (post-splenectomy), Heinz bodies (G6PD def - special stain needed)\nWBC/Platelet morphology\n\nSpecific Tests (Guided initial findings)\nIron Studies: Serum Iron, Ferritin (storage iron - best indicator IDA), Transferrin, TIBC (Total Iron Binding Capacity)\nVitamin B12 / Folate levels\nHemoglobin Electrophoresis / HPLC: Detects hemoglobin variants (HbS, HbC) quantifies HbA2/HbF (Thalassemia)\nTests Hemolysis: LDH (Lactate Dehydrogenase - increased), Indirect Bilirubin (increased), Haptoglobin (decreased - binds free Hgb)\nEnzyme Assays: G6PD activity level, PK activity\nBone Marrow Aspirate/Biopsy: Assesses cellularity, morphology, iron stores, infiltrative processes\nEPO Level: Assess appropriate degree anemia (low CKD)\n\nComplete Blood Count (CBC) Differential\nHgb/Hct/RBC count: Confirm anemia severity\nRBC Indices: CRITICAL initial classification!\nMCV (Mean Corpuscular Volume): Size (Microcytic <80 fL; Normocytic 80-100 fL; Macrocytic >100 fL)\nMCH/MCHC (Mean Corpuscular Hgb/Concentration): Color (Hypochromic = pale; Normochromic)\nRDW (Red Cell Distribution Width): Variation RBC size (anisocytosis). Often increased different populations cells present (e.g., IDA)\n\nWBC & Platelet Count: Assess pancytopenia (aplastic anemia) associated changes (e.g., reactive thrombocytosis IDA)\nHgb/Hct/RBC count: Confirm anemia severityRBC Indices: CRITICAL initial classification!\nMCV (Mean Corpuscular Volume): Size (Microcytic <80 fL; Normocytic 80-100 fL; Macrocytic >100 fL)\nMCH/MCHC (Mean Corpuscular Hgb/Concentration): Color (Hypochromic = pale; Normochromic)\nRDW (Red Cell Distribution Width): Variation RBC size (anisocytosis). Often increased different populations cells present (e.g., IDA)\nMCV (Mean Corpuscular Volume): Size (Microcytic <80 fL; Normocytic 80-100 fL; Macrocytic >100 fL)MCH/MCHC (Mean Corpuscular Hgb/Concentration): Color (Hypochromic = pale; Normochromic)RDW (Red Cell Distribution Width): Variation RBC size (anisocytosis). Often increased different populations cells present (e.g., IDA)WBC & Platelet Count: Assess pancytopenia (aplastic anemia) associated changes (e.g., reactive thrombocytosis IDA)Reticulocyte Count: Measures young RBCs released marrow. Crucial distinction\nHigh Retic Count (Appropriate Response): Suggests bone marrow responding loss/destruction (hemolysis, acute blood loss)\nLow/Normal Retic Count (Inadequate Response): Suggests production problem (nutritional deficiency, marrow failure, CKD, ACD)\nHigh Retic Count (Appropriate Response): Suggests bone marrow responding loss/destruction (hemolysis, acute blood loss)Low/Normal Retic Count (Inadequate Response): Suggests production problem (nutritional deficiency, marrow failure, CKD, ACD)Peripheral Blood Smear Review: Microscopic examination essential! Look :\nSize/Color variations: Micro/macro/hypo/normo\nShape abnormalities: Spherocytes, elliptocytes, sickle cells, target cells, schistocytes (fragmented RBCs - hallmark MAHA)\nInclusions: Basophilic stippling (lead poisoning), Howell-Jolly bodies (post-splenectomy), Heinz bodies (G6PD def - special stain needed)\nWBC/Platelet morphology\nSize/Color variations: Micro/macro/hypo/normoShape abnormalities: Spherocytes, elliptocytes, sickle cells, target cells, schistocytes (fragmented RBCs - hallmark MAHA)Inclusions: Basophilic stippling (lead poisoning), Howell-Jolly bodies (post-splenectomy), Heinz bodies (G6PD def - special stain needed)WBC/Platelet morphologySpecific Tests (Guided initial findings)\nIron Studies: Serum Iron, Ferritin (storage iron - best indicator IDA), Transferrin, TIBC (Total Iron Binding Capacity)\nVitamin B12 / Folate levels\nHemoglobin Electrophoresis / HPLC: Detects hemoglobin variants (HbS, HbC) quantifies HbA2/HbF (Thalassemia)\nTests Hemolysis: LDH (Lactate Dehydrogenase - increased), Indirect Bilirubin (increased), Haptoglobin (decreased - binds free Hgb)\nEnzyme Assays: G6PD activity level, PK activity\nBone Marrow Aspirate/Biopsy: Assesses cellularity, morphology, iron stores, infiltrative processes\nEPO Level: Assess appropriate degree anemia (low CKD)\nIron Studies: Serum Iron, Ferritin (storage iron - best indicator IDA), Transferrin, TIBC (Total Iron Binding Capacity)Vitamin B12 / Folate levelsHemoglobin Electrophoresis / HPLC: Detects hemoglobin variants (HbS, HbC) quantifies HbA2/HbF (Thalassemia)Tests Hemolysis: LDH (Lactate Dehydrogenase - increased), Indirect Bilirubin (increased), Haptoglobin (decreased - binds free Hgb)Enzyme Assays: G6PD activity level, PK activityBone Marrow Aspirate/Biopsy: Assesses cellularity, morphology, iron stores, infiltrative processesEPO Level: Assess appropriate degree anemia (low CKD)","code":""},{"path":"anemia.html","id":"treatment-4","chapter":"Anemia","heading":"Treatment","text":"Treatment MUST target underlying cause:Nutritional Deficiencies: Replace missing nutrient (Iron supplements, Vitamin B12 injections, Folic acid)Anemia Chronic Disease/CKD: Treat underlying condition, consider EPO stimulating agents (ESAs), +/- ironBone Marrow Failure: Immunosuppression, stem cell transplantHemolysis: Treat underlying cause possible (e.g., stop offending drug); supportive care; splenectomy may help certain membranopathies (e.g., Spherocytosis). Hydroxyurea Sickle Cell DiseaseBlood Loss: Stop bleeding! Replace lost volumeRed Blood Cell Transfusion: Key supportive therapy! Used rapidly increase oxygen-carrying capacity cases :\nSymptomatic anemia (regardless Hgb level)\nAcute, massive blood loss\nCritically low hemoglobin levels (transfusion triggers vary, often consider <7-8 g/dL stable patients, higher thresholds cardiac disease active bleeding)\nImportant: Transfusion treats symptom (anemia), underlying cause. Compatibility testing (Type & Screen, Crossmatch) essential\nSymptomatic anemia (regardless Hgb level)Acute, massive blood lossCritically low hemoglobin levels (transfusion triggers vary, often consider <7-8 g/dL stable patients, higher thresholds cardiac disease active bleeding)Important: Transfusion treats symptom (anemia), underlying cause. Compatibility testing (Type & Screen, Crossmatch) essential","code":""},{"path":"anemia.html","id":"immune-mediated-hemolytic-anemia-imha-when-the-immune-system-attacks","chapter":"Anemia","heading":"Immune-Mediated Hemolytic Anemia (IMHA): When the Immune System Attacks","text":", RBC destruction driven antibodies /complement binding red cell surface. major focus Blood Bank!","code":""},{"path":"anemia.html","id":"pathophysiology-how-it-happens-1","chapter":"Anemia","heading":"Pathophysiology (How it Happens)","text":"Antibodies target either foreign (allo-) self (auto-) antigens RBCs:Alloimmune Hemolysis Antibodies formed non-self RBC antigens encountered via transfusion pregnancy\nHemolytic Transfusion Reactions (HTRs): Recipient antibodies react donor RBC antigens\nAcute HTR: Usually IgM (e.g., ABO incompatibility) complement-fixing IgG -> rapid intravascular hemolysis (complement activation MAC). Severe, life-threatening\nDelayed HTR: Usually IgG (e.g., anti-Jka, anti-Fya) previous sensitization -> antibody levels rise days/weeks post-transfusion -> coating donor cells -> extravascular hemolysis splenic macrophages. Less severe initially can cause significant anemia\n\nHemolytic Disease Fetus Newborn (HDFN): Maternal IgG crosses placenta, attacks fetal RBCs -> extravascular hemolysis fetus/newborn\nHemolytic Transfusion Reactions (HTRs): Recipient antibodies react donor RBC antigens\nAcute HTR: Usually IgM (e.g., ABO incompatibility) complement-fixing IgG -> rapid intravascular hemolysis (complement activation MAC). Severe, life-threatening\nDelayed HTR: Usually IgG (e.g., anti-Jka, anti-Fya) previous sensitization -> antibody levels rise days/weeks post-transfusion -> coating donor cells -> extravascular hemolysis splenic macrophages. Less severe initially can cause significant anemia\nAcute HTR: Usually IgM (e.g., ABO incompatibility) complement-fixing IgG -> rapid intravascular hemolysis (complement activation MAC). Severe, life-threateningDelayed HTR: Usually IgG (e.g., anti-Jka, anti-Fya) previous sensitization -> antibody levels rise days/weeks post-transfusion -> coating donor cells -> extravascular hemolysis splenic macrophages. Less severe initially can cause significant anemiaHemolytic Disease Fetus Newborn (HDFN): Maternal IgG crosses placenta, attacks fetal RBCs -> extravascular hemolysis fetus/newbornAutoimmune Hemolytic Anemia (AIHA) Antibodies directed individual’s RBC antigens\nWarm AIHA (WAIHA): common type. IgG antibodies (sometimes complement C3d) react optimally 37°C. Cause extravascular hemolysis IgG-coated (+/- C3d) cells cleared macrophages (mainly spleen). Can idiopathic secondary conditions (lymphoma, autoimmune diseases like lupus)\nCold Agglutinin Disease (CAD): IgM antibodies react optimally cold (extremities), binding RBCs efficiently activating complement. cells return core body temp (37°C), IgM dissociates, C3d remains. Hemolysis primarily extravascular (macrophages recognize C3d), severe complement activation can cause intravascular hemolysis. Often targets ‘’ antigen. Can idiopathic secondary (e.g., Mycoplasma infection, lymphoma)\nParoxysmal Cold Hemoglobinuria (PCH): Rare. Caused biphasic IgG antibody (Donath-Landsteiner antibody, usually anti-P). Binds RBCs cold, causes potent complement activation intravascular hemolysis upon warming 37°C. Often seen post-virally children\nMixed-Type AIHA: Features warm cold AIHA (IgG + C3d IgM present)\nWarm AIHA (WAIHA): common type. IgG antibodies (sometimes complement C3d) react optimally 37°C. Cause extravascular hemolysis IgG-coated (+/- C3d) cells cleared macrophages (mainly spleen). Can idiopathic secondary conditions (lymphoma, autoimmune diseases like lupus)Cold Agglutinin Disease (CAD): IgM antibodies react optimally cold (extremities), binding RBCs efficiently activating complement. cells return core body temp (37°C), IgM dissociates, C3d remains. Hemolysis primarily extravascular (macrophages recognize C3d), severe complement activation can cause intravascular hemolysis. Often targets ‘’ antigen. Can idiopathic secondary (e.g., Mycoplasma infection, lymphoma)Paroxysmal Cold Hemoglobinuria (PCH): Rare. Caused biphasic IgG antibody (Donath-Landsteiner antibody, usually anti-P). Binds RBCs cold, causes potent complement activation intravascular hemolysis upon warming 37°C. Often seen post-virally childrenMixed-Type AIHA: Features warm cold AIHA (IgG + C3d IgM present)Drug-Induced Immune Hemolytic Anemia (DIHA) Drugs trigger antibody production leads RBC destruction. Mechanisms vary:\nDrug Adsorption (Hapten): Drug binds firmly RBC; IgG antibody forms drug-RBC complex (e.g., high-dose Penicillin). Extravascular hemolysis\nImmune Complex (Innocent Bystander): Antibody forms drug; Ab-drug complexes loosely attach RBCs, activating complement -> often intravascular hemolysis (e.g., Quinidine)\nAutoantibody Induction: Drug induces formation true autoantibody indistinguishable WAIHA antibodies (e.g., Methyldopa). Extravascular hemolysis\nDrug Adsorption (Hapten): Drug binds firmly RBC; IgG antibody forms drug-RBC complex (e.g., high-dose Penicillin). Extravascular hemolysisImmune Complex (Innocent Bystander): Antibody forms drug; Ab-drug complexes loosely attach RBCs, activating complement -> often intravascular hemolysis (e.g., Quinidine)Autoantibody Induction: Drug induces formation true autoantibody indistinguishable WAIHA antibodies (e.g., Methyldopa). Extravascular hemolysis","code":""},{"path":"anemia.html","id":"detection-finding-the-immune-cause","chapter":"Anemia","heading":"Detection (Finding the Immune Cause)","text":"Diagnosing IMHA requires specific immunohematologic testing:Clinical Assessment: Signs/symptoms anemia PLUS signs hemolysis (jaundice, dark urine - hemoglobinuria intravascular cases, splenomegaly). History critical (transfusions, pregnancies, drugs, underlying diseases)Laboratory Tests\nCBC/Retic/Smear: Anemia, high reticulocyte count, spherocytes often prominent (especially WAIHA ABO HDFN), polychromasia. Agglutination may seen smear/tube CAD\nHemolysis Markers: Increased LDH, Indirect Bilirubin; Decreased Haptoglobin (especially low/absent intravascular hemolysis)\nDirect Antiglobulin Test (DAT / Direct Coombs): CORNERSTONE TEST! Detects vivo coating patient RBCs IgG /C3d\nPolyspecific AHG: Screens IgG C3d\nMonospecific AHG: Differentiates coating (Anti-IgG, Anti-C3d). Patterns help classify IMHA:\nIgG IgG + C3d: Common WAIHA, DIHA (types), HDFN, delayed HTR\nC3d : Common CAD, PCH, DIHA (immune complex), WAIHA\nNegative DAT: Rules significant IMHA, rare cases exist\n\n\nIndirect Antiglobulin Test (IAT / Antibody Screen): Detects antibodies patient plasma\nMay detect underlying alloantibodies (HTR investigation)\nOften positive WAIHA autoantibody also plasma, reacting screen/panel cells (panreactivity)\nUsually negative CAD 37°C testing (unless underlying alloantibodies)\n\nAntibody Identification Panel: Determines specificity alloantibodies. Helps differentiate underlying alloantibodies panreactive autoantibodies WAIHA\nElution: Removes bound antibody (usually IgG) patient’s DAT-positive RBCs. Testing eluate helps determine antibody specificity (confirms autoantibody reactivity identifies alloantibody causing delayed HTR)\nCold Agglutinin Titer: Quantifies IgM cold autoantibody suspected CAD. Performed 4°C\nDonath-Landsteiner Test: Specific test PCH biphasic antibody\nCBC/Retic/Smear: Anemia, high reticulocyte count, spherocytes often prominent (especially WAIHA ABO HDFN), polychromasia. Agglutination may seen smear/tube CADHemolysis Markers: Increased LDH, Indirect Bilirubin; Decreased Haptoglobin (especially low/absent intravascular hemolysis)Direct Antiglobulin Test (DAT / Direct Coombs): CORNERSTONE TEST! Detects vivo coating patient RBCs IgG /C3d\nPolyspecific AHG: Screens IgG C3d\nMonospecific AHG: Differentiates coating (Anti-IgG, Anti-C3d). Patterns help classify IMHA:\nIgG IgG + C3d: Common WAIHA, DIHA (types), HDFN, delayed HTR\nC3d : Common CAD, PCH, DIHA (immune complex), WAIHA\nNegative DAT: Rules significant IMHA, rare cases exist\n\nPolyspecific AHG: Screens IgG C3dMonospecific AHG: Differentiates coating (Anti-IgG, Anti-C3d). Patterns help classify IMHA:\nIgG IgG + C3d: Common WAIHA, DIHA (types), HDFN, delayed HTR\nC3d : Common CAD, PCH, DIHA (immune complex), WAIHA\nNegative DAT: Rules significant IMHA, rare cases exist\nIgG IgG + C3d: Common WAIHA, DIHA (types), HDFN, delayed HTRC3d : Common CAD, PCH, DIHA (immune complex), WAIHANegative DAT: Rules significant IMHA, rare cases existIndirect Antiglobulin Test (IAT / Antibody Screen): Detects antibodies patient plasma\nMay detect underlying alloantibodies (HTR investigation)\nOften positive WAIHA autoantibody also plasma, reacting screen/panel cells (panreactivity)\nUsually negative CAD 37°C testing (unless underlying alloantibodies)\nMay detect underlying alloantibodies (HTR investigation)Often positive WAIHA autoantibody also plasma, reacting screen/panel cells (panreactivity)Usually negative CAD 37°C testing (unless underlying alloantibodies)Antibody Identification Panel: Determines specificity alloantibodies. Helps differentiate underlying alloantibodies panreactive autoantibodies WAIHAElution: Removes bound antibody (usually IgG) patient’s DAT-positive RBCs. Testing eluate helps determine antibody specificity (confirms autoantibody reactivity identifies alloantibody causing delayed HTR)Cold Agglutinin Titer: Quantifies IgM cold autoantibody suspected CAD. Performed 4°CDonath-Landsteiner Test: Specific test PCH biphasic antibody","code":""},{"path":"anemia.html","id":"treatment-5","chapter":"Anemia","heading":"Treatment","text":"Treatment depends heavily type IMHA:Alloimmune (HTR/HDFN)\nHTR: STOP TRANSFUSION IMMEDIATELY! Supportive care (maintain BP, renal function). Provide antigen-negative blood transfusion needed\nHDFN: Antenatal (IUTs), Postnatal (Phototherapy, Exchange Transfusion, IVIg). Prevention RhIG key anti-D\nHTR: STOP TRANSFUSION IMMEDIATELY! Supportive care (maintain BP, renal function). Provide antigen-negative blood transfusion neededHDFN: Antenatal (IUTs), Postnatal (Phototherapy, Exchange Transfusion, IVIg). Prevention RhIG key anti-DAutoimmune (AIHA)\nWAIHA: Corticosteroids (prednisone) first-line therapy. Second-line: Rituximab (anti-CD20 antibody), splenectomy, immunosuppressants (azathioprine, cyclosporine)\nCAD: Keep patient warm! Avoid cold exposure. Treat underlying condition secondary. Rituximab may effective. Steroids/splenectomy usually effective. Plasma exchange severe acute episodes?\nPCH: Supportive care, keep warm, treat underlying infection. Usually self-limiting\nWAIHA: Corticosteroids (prednisone) first-line therapy. Second-line: Rituximab (anti-CD20 antibody), splenectomy, immunosuppressants (azathioprine, cyclosporine)CAD: Keep patient warm! Avoid cold exposure. Treat underlying condition secondary. Rituximab may effective. Steroids/splenectomy usually effective. Plasma exchange severe acute episodes?PCH: Supportive care, keep warm, treat underlying infection. Usually self-limitingDrug-Induced (DIHA): Stop offending drug! Hemolysis usually resolves, though autoantibody type may persist longerRed Blood Cell Transfusion: Can life-saving often challenging, especially WAIHA autoantibodies react virtually donor units\nGoal: Find “least incompatible” units transfusion unavoidable (life-threatening anemia)\nRequires careful pretransfusion testing, often including auto-adsorption testing rare antigen-negative cells underlying alloantibodies suspected\nTransfuse slowly close monitoring\nCAD, use blood warmer\nalloantibodies (HTR/HDFN), providing antigen-negative units essential\nGoal: Find “least incompatible” units transfusion unavoidable (life-threatening anemia)Requires careful pretransfusion testing, often including auto-adsorption testing rare antigen-negative cells underlying alloantibodies suspectedTransfuse slowly close monitoringFor CAD, use blood warmerFor alloantibodies (HTR/HDFN), providing antigen-negative units essential","code":""},{"path":"anemia.html","id":"key-terms-67","chapter":"Anemia","heading":"Key Terms","text":"Anemia: Reduced oxygen-carrying capacity blood (low Hgb/Hct/RBCs)Hypoxia: Deficiency amount oxygen reaching tissuesRBC Indices (MCV, MCH, MCHC, RDW): Measures red blood cell size, hemoglobin content, size variationReticulocyte Count: Measure young red blood cells, indicating bone marrow responseHemolysis: Destruction red blood cellsIntravascular Hemolysis: RBC destruction within blood vesselsExtravascular Hemolysis: RBC destruction outside blood vessels (macrophages, mainly spleen/liver)Immune-Mediated Hemolytic Anemia (IMHA): Group disorders antibodies +/- complement cause RBC destructionAlloimmune: Immune response foreign antigens speciesAutoimmune: Immune response directed self-antigensDirect Antiglobulin Test (DAT): Detects IgG C3d coating RBCs vivoIndirect Antiglobulin Test (IAT): Detects antibodies plasma/serum vitroElution: Procedure remove antibodies bound RBCs identificationWarm AIHA (WAIHA): AIHA caused IgG autoantibodies reacting 37°CCold Agglutinin Disease (CAD): AIHA caused IgM autoantibodies reacting cold activating complementParoxysmal Cold Hemoglobinuria (PCH): AIHA caused biphasic IgG Donath-Landsteiner antibody activating complementDrug-Induced Immune Hemolytic Anemia (DIHA): IMHA triggered medication","code":""},{"path":"thrombocytopenia.html","id":"thrombocytopenia","chapter":"Thrombocytopenia","heading":"Thrombocytopenia","text":"Thrombocytopenia simply means lower--normal number platelets circulating blood (typically defined <150,000/µL <150 x 109/L). Platelets tiny “first responders” stopping bleeding, numbers drop, primary risk bleedingJust like anemia, thrombocytopenia isn’t disease sign underlying issue. need figure platelet count low. causes fall nicely non-immune immune categories","code":""},{"path":"thrombocytopenia.html","id":"non-immune-thrombocytopenia-when-antibodies-arent-the-main-culprit","chapter":"Thrombocytopenia","heading":"Non-Immune Thrombocytopenia: When Antibodies Aren’t the Main Culprit","text":"causes involve problems platelet production, non-antibody-mediated destruction consumption, platelets getting stuck somewhere","code":""},{"path":"thrombocytopenia.html","id":"pathophysiology-how-it-happens-2","chapter":"Thrombocytopenia","heading":"Pathophysiology (How it Happens)","text":"Decreased Platelet Production: bone marrow “factory” isn’t making enough platelets\nBone Marrow Failure/Suppression\nAplastic Anemia: Failure marrow produce cell lines, including megakaryocytes (platelet precursors)\nLeukemia, Lymphoma, Myelodysplastic Syndromes (MDS): Malignant cells infiltrate crowd normal marrow elements, including megakaryocytes\nMetastatic Cancer: Cancer cells elsewhere invade marrow\nChemotherapy/Radiation Therapy: treatments damage rapidly dividing cells, including hematopoietic stem cells megakaryocytes\nCertain Viral Infections: (e.g., HIV, Hepatitis C, CMV, EBV) can directly suppress marrow production\nAlcohol Toxicity: Chronic heavy alcohol use suppresses marrow function\n\nNutritional Deficiencies: Severe Vitamin B12 Folate deficiency can impair DNA synthesis, affecting megakaryocyte maturation platelet production (often part pancytopenia megaloblastic anemia)\nInherited Syndromes: Rare genetic conditions affect megakaryocyte development (e.g., Congenital Amegakaryocytic Thrombocytopenia - CAMT, Thrombocytopenia Absent Radii - TAR syndrome)\nBone Marrow Failure/Suppression\nAplastic Anemia: Failure marrow produce cell lines, including megakaryocytes (platelet precursors)\nLeukemia, Lymphoma, Myelodysplastic Syndromes (MDS): Malignant cells infiltrate crowd normal marrow elements, including megakaryocytes\nMetastatic Cancer: Cancer cells elsewhere invade marrow\nChemotherapy/Radiation Therapy: treatments damage rapidly dividing cells, including hematopoietic stem cells megakaryocytes\nCertain Viral Infections: (e.g., HIV, Hepatitis C, CMV, EBV) can directly suppress marrow production\nAlcohol Toxicity: Chronic heavy alcohol use suppresses marrow function\nAplastic Anemia: Failure marrow produce cell lines, including megakaryocytes (platelet precursors)Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS): Malignant cells infiltrate crowd normal marrow elements, including megakaryocytesMetastatic Cancer: Cancer cells elsewhere invade marrowChemotherapy/Radiation Therapy: treatments damage rapidly dividing cells, including hematopoietic stem cells megakaryocytesCertain Viral Infections: (e.g., HIV, Hepatitis C, CMV, EBV) can directly suppress marrow productionAlcohol Toxicity: Chronic heavy alcohol use suppresses marrow functionNutritional Deficiencies: Severe Vitamin B12 Folate deficiency can impair DNA synthesis, affecting megakaryocyte maturation platelet production (often part pancytopenia megaloblastic anemia)Inherited Syndromes: Rare genetic conditions affect megakaryocyte development (e.g., Congenital Amegakaryocytic Thrombocytopenia - CAMT, Thrombocytopenia Absent Radii - TAR syndrome)Increased Platelet Destruction Consumption (Non-Immune): Platelets used destroyed quickly mechanisms primarily involving anti-platelet antibodies\nDisseminated Intravascular Coagulation (DIC): Widespread, uncontrolled activation coagulation fibrinolysis. Platelets consumed rapidly formation microthrombi throughout circulation\nThrombotic Microangiopathies (TMAs): Conditions characterized platelet aggregation small blood vessels, leading consumption organ damage\nThrombotic Thrombocytopenic Purpura (TTP): Usually due deficiency (often autoimmune) enzyme ADAMTS13, normally cleaves large von Willebrand Factor (vWF) multimers. Uncleaved large vWF multimers cause spontaneous platelet aggregation microvasculature\nHemolytic Uremic Syndrome (HUS): Often triggered Shiga toxin-producing bacteria (like E. coli O157:H7). Toxin damages endothelial cells, leading platelet activation microthrombi formation, particularly affecting kidneys\n\nMechanical Destruction: Physical shearing forces damage platelets (e.g., malfunctioning prosthetic heart valves, extracorporeal circuits like ECMO cardiopulmonary bypass)\nGiant Hemangiomas (Kasabach-Merritt Syndrome): Platelets become trapped consumed within large vascular tumors\nDisseminated Intravascular Coagulation (DIC): Widespread, uncontrolled activation coagulation fibrinolysis. Platelets consumed rapidly formation microthrombi throughout circulationThrombotic Microangiopathies (TMAs): Conditions characterized platelet aggregation small blood vessels, leading consumption organ damage\nThrombotic Thrombocytopenic Purpura (TTP): Usually due deficiency (often autoimmune) enzyme ADAMTS13, normally cleaves large von Willebrand Factor (vWF) multimers. Uncleaved large vWF multimers cause spontaneous platelet aggregation microvasculature\nHemolytic Uremic Syndrome (HUS): Often triggered Shiga toxin-producing bacteria (like E. coli O157:H7). Toxin damages endothelial cells, leading platelet activation microthrombi formation, particularly affecting kidneys\nThrombotic Thrombocytopenic Purpura (TTP): Usually due deficiency (often autoimmune) enzyme ADAMTS13, normally cleaves large von Willebrand Factor (vWF) multimers. Uncleaved large vWF multimers cause spontaneous platelet aggregation microvasculatureHemolytic Uremic Syndrome (HUS): Often triggered Shiga toxin-producing bacteria (like E. coli O157:H7). Toxin damages endothelial cells, leading platelet activation microthrombi formation, particularly affecting kidneysMechanical Destruction: Physical shearing forces damage platelets (e.g., malfunctioning prosthetic heart valves, extracorporeal circuits like ECMO cardiopulmonary bypass)Giant Hemangiomas (Kasabach-Merritt Syndrome): Platelets become trapped consumed within large vascular tumorsSequestration: Platelets get pooled trapped, reducing number active circulation\nHypersplenism: enlarged spleen (due various causes like liver cirrhosis, portal hypertension, lymphoma, infections) traps excessive proportion platelets (normally holds ~1/3, can hold 90% enlarged)\nHypersplenism: enlarged spleen (due various causes like liver cirrhosis, portal hypertension, lymphoma, infections) traps excessive proportion platelets (normally holds ~1/3, can hold 90% enlarged)","code":""},{"path":"thrombocytopenia.html","id":"detection-finding-the-cause-1","chapter":"Thrombocytopenia","heading":"Detection (Finding the Cause)","text":"Clinical Assessment: History (meds, alcohol, infections, bleeding pattern, family history), physical exam (petechiae, purpura, ecchymoses, splenomegaly, signs underlying disease)Laboratory Tests\nComplete Blood Count (CBC) Differential & Platelet Count: Confirms thrombocytopenia. Check WBC RBC lines cytopenias (pancytopenia suggests marrow failure)\nPeripheral Blood Smear Review: ESSENTIAL!\nConfirms low platelet count (visual estimate)\nRules pseudothrombocytopenia (platelet clumping, usually EDTA-dependent artifact - redraw sodium citrate tube!)\nAssesses platelet morphology: Giant platelets (inherited syndromes like Bernard-Soulier, ITP), platelet fragments?\nLooks associated findings: Schistocytes (fragmented RBCs - hallmark TTP/HUS/DIC), blasts (leukemia), teardrop cells (marrow infiltration), hypersegmented neutrophils (B12/folate deficiency)\n\nCoagulation Studies (PT, aPTT, Fibrinogen, D-dimer): Crucial DIC suspected (prolonged PT/aPTT, low fibrinogen, high D-dimer)\nLiver Function Tests / Renal Function Tests: Assess underlying organ disease\nBone Marrow Aspirate/Biopsy: Indicated decreased production suspected cause remains unclear. Assesses cellularity, presence/morphology megakaryocytes, infiltrative processes\nADAMTS13 Activity: Specific test TTP (activity usually <10%)\nInfectious Disease Testing: (HIV, HCV, etc., suspected)\nComplete Blood Count (CBC) Differential & Platelet Count: Confirms thrombocytopenia. Check WBC RBC lines cytopenias (pancytopenia suggests marrow failure)Peripheral Blood Smear Review: ESSENTIAL!\nConfirms low platelet count (visual estimate)\nRules pseudothrombocytopenia (platelet clumping, usually EDTA-dependent artifact - redraw sodium citrate tube!)\nAssesses platelet morphology: Giant platelets (inherited syndromes like Bernard-Soulier, ITP), platelet fragments?\nLooks associated findings: Schistocytes (fragmented RBCs - hallmark TTP/HUS/DIC), blasts (leukemia), teardrop cells (marrow infiltration), hypersegmented neutrophils (B12/folate deficiency)\nConfirms low platelet count (visual estimate)Rules pseudothrombocytopenia (platelet clumping, usually EDTA-dependent artifact - redraw sodium citrate tube!)Assesses platelet morphology: Giant platelets (inherited syndromes like Bernard-Soulier, ITP), platelet fragments?Looks associated findings: Schistocytes (fragmented RBCs - hallmark TTP/HUS/DIC), blasts (leukemia), teardrop cells (marrow infiltration), hypersegmented neutrophils (B12/folate deficiency)Coagulation Studies (PT, aPTT, Fibrinogen, D-dimer): Crucial DIC suspected (prolonged PT/aPTT, low fibrinogen, high D-dimer)Liver Function Tests / Renal Function Tests: Assess underlying organ diseaseBone Marrow Aspirate/Biopsy: Indicated decreased production suspected cause remains unclear. Assesses cellularity, presence/morphology megakaryocytes, infiltrative processesADAMTS13 Activity: Specific test TTP (activity usually <10%)Infectious Disease Testing: (HIV, HCV, etc., suspected)","code":""},{"path":"thrombocytopenia.html","id":"treatment-6","chapter":"Thrombocytopenia","heading":"Treatment","text":"Treatment MUST address underlying cause:Decreased Production: Treat underlying condition (e.g., leukemia chemo, B12/folate replacement, stop offending drug/alcohol). Thrombopoietin Receptor Agonists (TPO-RAs like Romiplostim, Eltrombopag) can stimulate platelet production settings (e.g., aplastic anemia, chemo-induced). Stem cell transplant aplastic anemia/leukemiaIncreased Destruction/Consumption\nDIC: Treat underlying trigger (sepsis, trauma), supportive care blood components (FFP, Cryo, Platelets)\nTTP: Plasma Exchange (PEX) life-saving! Removes autoantibodies large vWF multimers, replenishes ADAMTS13. Immunosuppression often added\nHUS: Primarily supportive care (especially renal support). PEX less effective TTP. Eculizumab (anti-C5 antibody) atypical HUS\nDIC: Treat underlying trigger (sepsis, trauma), supportive care blood components (FFP, Cryo, Platelets)TTP: Plasma Exchange (PEX) life-saving! Removes autoantibodies large vWF multimers, replenishes ADAMTS13. Immunosuppression often addedHUS: Primarily supportive care (especially renal support). PEX less effective TTP. Eculizumab (anti-C5 antibody) atypical HUSSequestration: Treat underlying cause splenomegaly possible. Splenectomy rarely done just sequestration may improve counts done another reasonPlatelet Transfusion: Key supportive measure counts critically low (<10-20,000/µL prophylaxis spontaneous bleeding) patient active, significant bleeding. Transfusion treats symptom (low count/bleeding), cause","code":""},{"path":"thrombocytopenia.html","id":"immune-thrombocytopenia-when-the-immune-system-attacks-platelets","chapter":"Thrombocytopenia","heading":"Immune Thrombocytopenia: When the Immune System Attacks Platelets","text":", antibodies primary drivers platelet destruction","code":""},{"path":"thrombocytopenia.html","id":"pathophysiology-how-it-happens-3","chapter":"Thrombocytopenia","heading":"Pathophysiology (How it Happens)","text":"Immune Thrombocytopenia (ITP): (Formerly Idiopathic Thrombocytopenic Purpura)\nMechanism: Autoantibodies (usually IgG) produced platelet surface glycoproteins (commonly GPIIb/IIIa GPIb/IX). antibody-coated platelets recognized Fc receptors macrophages, primarily spleen, leading premature clearance (opsonization phagocytosis). antibodies may also impair megakaryocyte function, contributing reduced production\nTypes\nPrimary ITP: identifiable underlying cause\nSecondary ITP: Associated conditions (e.g., SLE, HIV, HCV, CLL, certain drugs)\n\nMechanism: Autoantibodies (usually IgG) produced platelet surface glycoproteins (commonly GPIIb/IIIa GPIb/IX). antibody-coated platelets recognized Fc receptors macrophages, primarily spleen, leading premature clearance (opsonization phagocytosis). antibodies may also impair megakaryocyte function, contributing reduced productionTypes\nPrimary ITP: identifiable underlying cause\nSecondary ITP: Associated conditions (e.g., SLE, HIV, HCV, CLL, certain drugs)\nPrimary ITP: identifiable underlying causeSecondary ITP: Associated conditions (e.g., SLE, HIV, HCV, CLL, certain drugs)Alloimmune Thrombocytopenia: Antibodies non-self platelet antigens\nNeonatal Alloimmune Thrombocytopenia (NAIT): Mother lacks specific Human Platelet Antigen (HPA, commonly HPA-1a) fetus inherits father. Mother produces IgG alloantibodies fetal HPA pregnancy. antibodies cross placenta destroy fetal/neonatal platelets. Can cause severe thrombocytopenia risk intracranial hemorrhage fetus/newborn. Analogous HDFN, platelets\nPost-Transfusion Purpura (PTP): Rare serious. Occurs ~1-2 weeks transfusion. Patients (usually multiparous women negative HPA-1a) develop high-titer anti-HPA-1a (HPA antibodies). Paradoxically, antibodies destroy transfused antigen-positive platelets patient’s antigen-negative platelets (mechanism unclear, possibly bystander destruction immune complex formation). Results sudden, severe thrombocytopenia\nNeonatal Alloimmune Thrombocytopenia (NAIT): Mother lacks specific Human Platelet Antigen (HPA, commonly HPA-1a) fetus inherits father. Mother produces IgG alloantibodies fetal HPA pregnancy. antibodies cross placenta destroy fetal/neonatal platelets. Can cause severe thrombocytopenia risk intracranial hemorrhage fetus/newborn. Analogous HDFN, plateletsPost-Transfusion Purpura (PTP): Rare serious. Occurs ~1-2 weeks transfusion. Patients (usually multiparous women negative HPA-1a) develop high-titer anti-HPA-1a (HPA antibodies). Paradoxically, antibodies destroy transfused antigen-positive platelets patient’s antigen-negative platelets (mechanism unclear, possibly bystander destruction immune complex formation). Results sudden, severe thrombocytopeniaDrug-Induced Immune Thrombocytopenia (DITP): (Excluding HIT)\nMechanism: Similar DIHA. Drugs can act haptens, trigger immune complex formation, induce drug-dependent antibodies bind platelet glycoproteins drug present. Leads antibody-mediated platelet clearance\nCommon culprits: Quinine, Quinidine, Sulfonamides, Vancomycin, Rifampin, NSAIDs\nMechanism: Similar DIHA. Drugs can act haptens, trigger immune complex formation, induce drug-dependent antibodies bind platelet glycoproteins drug present. Leads antibody-mediated platelet clearanceCommon culprits: Quinine, Quinidine, Sulfonamides, Vancomycin, Rifampin, NSAIDsHeparin-Induced Thrombocytopenia (HIT): (CRITICAL RECOGNIZE!)\nMechanism: specific, dangerous form DITP. Occurs 5-10 days heparin exposure (sooner prior exposure). Patients develop IgG antibodies complexes Platelet Factor 4 (PF4) (protein released platelet alpha granules) heparin\nParadox: PF4-heparin-IgG immune complexes bind Fc receptors (FcγRIIa) platelet surfaces, causing massive platelet activation, aggregation, degranulation. leads :\nProthrombotic State Release procoagulant microparticles platelet consumption -> high risk venous arterial thrombosis (DVT, PE, limb ischemia, stroke, MI)\nThrombocytopenia Activated platelets rapidly cleared circulation MPS\n\nKey Feature: HIT primarily prothrombotic disorder thrombocytopenia marker, necessarily main clinical problem\nMechanism: specific, dangerous form DITP. Occurs 5-10 days heparin exposure (sooner prior exposure). Patients develop IgG antibodies complexes Platelet Factor 4 (PF4) (protein released platelet alpha granules) heparinThe Paradox: PF4-heparin-IgG immune complexes bind Fc receptors (FcγRIIa) platelet surfaces, causing massive platelet activation, aggregation, degranulation. leads :\nProthrombotic State Release procoagulant microparticles platelet consumption -> high risk venous arterial thrombosis (DVT, PE, limb ischemia, stroke, MI)\nThrombocytopenia Activated platelets rapidly cleared circulation MPS\nProthrombotic State Release procoagulant microparticles platelet consumption -> high risk venous arterial thrombosis (DVT, PE, limb ischemia, stroke, MI)Thrombocytopenia Activated platelets rapidly cleared circulation MPSKey Feature: HIT primarily prothrombotic disorder thrombocytopenia marker, necessarily main clinical problem","code":""},{"path":"thrombocytopenia.html","id":"detection-finding-the-immune-cause-1","chapter":"Thrombocytopenia","heading":"Detection (Finding the Immune Cause)","text":"Clinical Assessment: History paramount! (New drugs? Heparin exposure? Recent transfusion/pregnancy? Autoimmune symptoms?). Bleeding pattern (ITP, NAIT, PTP, DITP) vs. Thrombosis (HIT)Laboratory Tests\nCBC/Smear: Confirm thrombocytopenia. Rule pseudothrombocytopenia. Giant platelets common ITP. Schistocytes prominent (present, consider TTP/HUS/DIC instead concurrently)\nITP Diagnosis: Primarily diagnosis exclusion. Platelet autoantibody testing generally recommended due poor sensitivity specificity\nNAIT Diagnosis: Test maternal serum HPA antibodies; HPA genotype mother, father, infant (possible)\nPTP Diagnosis: Test patient serum HPA antibodies (usually anti-HPA-1a)\nDITP Diagnosis: Requires high clinical suspicion temporal association drug initiation. Drug withdrawal leads recovery. Specialized testing drug-dependent antibodies complex widely available\nHIT Diagnosis: Requires clinical suspicion (using scoring systems like “4Ts”) laboratory confirmation:\nImmunoassays: Detect antibodies binding PF4/heparin complexes (e.g., ELISA). High sensitivity moderate specificity (can positive without clinical HIT)\nFunctional Assays: Detect platelet activation patient serum presence heparin (e.g., Serotonin Release Assay - SRA, Heparin-Induced Platelet Aggregation - HIPA). High specificity technically demanding. Considered gold standard\n\nCBC/Smear: Confirm thrombocytopenia. Rule pseudothrombocytopenia. Giant platelets common ITP. Schistocytes prominent (present, consider TTP/HUS/DIC instead concurrently)ITP Diagnosis: Primarily diagnosis exclusion. Platelet autoantibody testing generally recommended due poor sensitivity specificityNAIT Diagnosis: Test maternal serum HPA antibodies; HPA genotype mother, father, infant (possible)PTP Diagnosis: Test patient serum HPA antibodies (usually anti-HPA-1a)DITP Diagnosis: Requires high clinical suspicion temporal association drug initiation. Drug withdrawal leads recovery. Specialized testing drug-dependent antibodies complex widely availableHIT Diagnosis: Requires clinical suspicion (using scoring systems like “4Ts”) laboratory confirmation:\nImmunoassays: Detect antibodies binding PF4/heparin complexes (e.g., ELISA). High sensitivity moderate specificity (can positive without clinical HIT)\nFunctional Assays: Detect platelet activation patient serum presence heparin (e.g., Serotonin Release Assay - SRA, Heparin-Induced Platelet Aggregation - HIPA). High specificity technically demanding. Considered gold standard\nImmunoassays: Detect antibodies binding PF4/heparin complexes (e.g., ELISA). High sensitivity moderate specificity (can positive without clinical HIT)Functional Assays: Detect platelet activation patient serum presence heparin (e.g., Serotonin Release Assay - SRA, Heparin-Induced Platelet Aggregation - HIPA). High specificity technically demanding. Considered gold standard","code":""},{"path":"thrombocytopenia.html","id":"treatment-7","chapter":"Thrombocytopenia","heading":"Treatment","text":"ITP\nGoal: Raise platelet count safe level (prevent major bleeding), necessarily normalize \nFirst-line: Corticosteroids (suppress antibody production/clearance), Intravenous Immune Globulin (IVIg - rapidly blocks Fc receptors macrophages, temporary effect)\nSecond-line: Rituximab (anti-CD20, depletes B cells), TPO-RAs, Splenectomy (removes primary site destruction antibody production), immunosuppressants\nPlatelet Transfusion: Generally reserved life-threatening bleeding, transfused platelets rapidly destroyed\nGoal: Raise platelet count safe level (prevent major bleeding), necessarily normalize itFirst-line: Corticosteroids (suppress antibody production/clearance), Intravenous Immune Globulin (IVIg - rapidly blocks Fc receptors macrophages, temporary effect)Second-line: Rituximab (anti-CD20, depletes B cells), TPO-RAs, Splenectomy (removes primary site destruction antibody production), immunosuppressantsPlatelet Transfusion: Generally reserved life-threatening bleeding, transfused platelets rapidly destroyedNAIT\nAntenatal: diagnosed prenatally high-risk cases: Maternal IVIg +/- steroids\nPostnatal: HPA-matched platelets (e.g., HPA-1a negative platelets mother anti-HPA-1a) ideal often unavailable emergently. Washed, irradiated maternal platelets alternative. IVIg infant. Exchange transfusion rarely needed\nAntenatal: diagnosed prenatally high-risk cases: Maternal IVIg +/- steroidsPostnatal: HPA-matched platelets (e.g., HPA-1a negative platelets mother anti-HPA-1a) ideal often unavailable emergently. Washed, irradiated maternal platelets alternative. IVIg infant. Exchange transfusion rarely neededPTP\nFirst-line: IVIg. Plasma exchange may considered\nPlatelet Transfusion: Generally avoided unless life-threatening bleeding. needed, HPA-matched platelets (e.g., HPA-1a negative) required\nFirst-line: IVIg. Plasma exchange may consideredPlatelet Transfusion: Generally avoided unless life-threatening bleeding. needed, HPA-matched platelets (e.g., HPA-1a negative) requiredDITP\nSTOP OFFENDING DRUG!: Platelet count usually recovers within days weeks\nSupportive care, platelet transfusion severe bleeding\nSTOP OFFENDING DRUG!: Platelet count usually recovers within days weeksSupportive care, platelet transfusion severe bleedingHIT\nSTOP HEPARIN EXPOSURE IMMEDIATELY: (including flushes, coated catheters)!\nInitiate non-heparin anticoagulant: (e.g., Direct Thrombin Inhibitors like Argatroban Bivalirudin; Fondaparinux cases) even thrombosis yet evident\nTRANSFUSE PLATELETS routinely,: may “fuel fire” increase thrombotic risk. consider life-threatening hemorrhage\nSTOP HEPARIN EXPOSURE IMMEDIATELY: (including flushes, coated catheters)!Initiate non-heparin anticoagulant: (e.g., Direct Thrombin Inhibitors like Argatroban Bivalirudin; Fondaparinux cases) even thrombosis yet evidentDO TRANSFUSE PLATELETS routinely,: may “fuel fire” increase thrombotic risk. consider life-threatening hemorrhage","code":""},{"path":"thrombocytopenia.html","id":"key-terms-68","chapter":"Thrombocytopenia","heading":"Key Terms","text":"Thrombocytopenia: Low platelet count (<150,000/µL)Megakaryocyte: Large bone marrow cell platelets bud offPseudothrombocytopenia: Artificially low platelet count automated analyzers due vitro platelet clumping (usually EDTA-dependent)Petechiae: Pinpoint skin hemorrhages characteristic low plateletsPurpura: Larger bruises/skin hemorrhagesSequestration: Trapping platelets, typically enlarged spleen (hypersplenism)Disseminated Intravascular Coagulation (DIC): Pathological widespread activation clotting fibrinolysis, consuming platelets factorsThrombotic Thrombocytopenic Purpura (TTP): TMA usually due ADAMTS13 deficiency, causing microthrombiHemolytic Uremic Syndrome (HUS): TMA often toxin-induced, causing microthrombi, primarily affecting kidneysImmune Thrombocytopenia (ITP): Autoimmune disorder antibodies targeting platelet glycoproteinsNeonatal Alloimmune Thrombocytopenia (NAIT): Alloimmune disorder maternal IgG antibodies target fetal platelet antigensPost-Transfusion Purpura (PTP): Alloimmune disorder antibodies develop post-transfusion, destroying transfused autologous plateletsHeparin-Induced Thrombocytopenia (HIT): Prothrombotic disorder caused antibodies PF4/heparin complexes, leading platelet activation consumptionHuman Platelet Antigens (HPAs): Polymorphic antigens expressed platelet glycoproteins, targets NAIT/PTPPlatelet Factor 4 (PF4): Protein released platelet alpha granules, target antigen HITPlasma Exchange (PEX): Therapeutic procedure remove patient plasma replace donor plasma albuminIntravenous Immune Globulin (IVIg): Concentrated human IgG used treat various immune cytopeniasThrombopoietin Receptor Agonists (TPO-RAs): Drugs stimulate platelet production mimicking thrombopoietin","code":""},{"path":"neutropenia.html","id":"neutropenia","chapter":"Neutropenia","heading":"Neutropenia","text":"Neutropenia condition abnormally low number neutrophils blood. Neutrophils abundant type granulocyte primary defenders bacterial infections. numbers drop significantly, patients become highly susceptible potentially life-threatening infectionsWe typically define neutropenia based Absolute Neutrophil Count (ANC), calculated :\nANC = Total White Blood Cell (WBC) Count × (% Segmented Neutrophils + % Band Neutrophils)Normal ANC: Usually > 1500 cells/µL (1.5 x 109/L)Mild Neutropenia: ANC 1000-1500/µLModerate Neutropenia: ANC 500-1000/µLSevere Neutropenia: ANC < 500/µLAgranulocytosis: Refers virtual absence neutrophils (often ANC < 100-200/µL)risk infection increases significantly ANC falls 1000/µL, becoming critical 500/µLLike cytopenias, causes can broadly grouped Non-Immune Immune mechanisms","code":""},{"path":"neutropenia.html","id":"non-immune-neutropenia-production-problems-or-overconsumption","chapter":"Neutropenia","heading":"Non-Immune Neutropenia: Production Problems or Overconsumption","text":"causes involve issues making neutrophils bone marrow using quickly, without primary antibody-mediated attack","code":""},{"path":"neutropenia.html","id":"pathophysiology-how-it-happens-4","chapter":"Neutropenia","heading":"Pathophysiology (How it Happens)","text":"Decreased Neutrophil Production: bone marrow “factory” isn’t producing enough\nCongenital Neutropenias (Inherited): Genetic defects present birth affecting neutrophil development (granulopoiesis)\nSevere Congenital Neutropenia (SCN, e.g., Kostmann Syndrome): Various gene mutations (e.g., ELANE, HAX1) lead profound, persistent neutropenia (ANC often < 200/µL) due maturation arrest promyelocyte stage marrow. High risk severe bacterial infections infancy\nCyclic Neutropenia: Usually caused ELANE mutations. Characterized regular, periodic oscillations neutrophil counts (typically ~21-day cycles), ANC dropping < 200/µL 3-5 days nadir, leading recurrent fevers, mouth sores, infections low points\nrare syndromes: Shwachman-Diamond syndrome, Chédiak-Higashi syndrome, etc., can include neutropenia\n\nAcquired Bone Marrow Failure/Suppression\nAplastic Anemia: Global marrow failure affecting cell lines\nDrug-Induced Suppression (Direct Toxicity): Chemotherapy common cause severe acquired neutropenia. Many drugs can suppress marrow (e.g., certain antibiotics like chloramphenicol, anti-thyroid drugs, phenothiazines, NSAIDs - idiosyncratic reactions)\nRadiation Therapy: Damages hematopoietic stem cells\nToxins: Benzene, pesticides\nAlcohol Abuse: Chronic heavy use suppresses marrow\n\nBone Marrow Infiltration: Malignant cells crowd normal hematopoiesis (Leukemia, Lymphoma, Myeloma, Metastatic solid tumors)\nNutritional Deficiencies: Severe Vitamin B12 Folate deficiency impairs DNA synthesis, affecting rapidly dividing cells, including neutrophil precursors. Severe Copper deficiency can also cause neutropenia\nCertain Infections: viral infections (Hepatitis, HIV, EBV, CMV, Parvovirus B19) can directly suppress marrow production\nCongenital Neutropenias (Inherited): Genetic defects present birth affecting neutrophil development (granulopoiesis)\nSevere Congenital Neutropenia (SCN, e.g., Kostmann Syndrome): Various gene mutations (e.g., ELANE, HAX1) lead profound, persistent neutropenia (ANC often < 200/µL) due maturation arrest promyelocyte stage marrow. High risk severe bacterial infections infancy\nCyclic Neutropenia: Usually caused ELANE mutations. Characterized regular, periodic oscillations neutrophil counts (typically ~21-day cycles), ANC dropping < 200/µL 3-5 days nadir, leading recurrent fevers, mouth sores, infections low points\nrare syndromes: Shwachman-Diamond syndrome, Chédiak-Higashi syndrome, etc., can include neutropenia\nSevere Congenital Neutropenia (SCN, e.g., Kostmann Syndrome): Various gene mutations (e.g., ELANE, HAX1) lead profound, persistent neutropenia (ANC often < 200/µL) due maturation arrest promyelocyte stage marrow. High risk severe bacterial infections infancyCyclic Neutropenia: Usually caused ELANE mutations. Characterized regular, periodic oscillations neutrophil counts (typically ~21-day cycles), ANC dropping < 200/µL 3-5 days nadir, leading recurrent fevers, mouth sores, infections low pointsOther rare syndromes: Shwachman-Diamond syndrome, Chédiak-Higashi syndrome, etc., can include neutropeniaAcquired Bone Marrow Failure/Suppression\nAplastic Anemia: Global marrow failure affecting cell lines\nDrug-Induced Suppression (Direct Toxicity): Chemotherapy common cause severe acquired neutropenia. Many drugs can suppress marrow (e.g., certain antibiotics like chloramphenicol, anti-thyroid drugs, phenothiazines, NSAIDs - idiosyncratic reactions)\nRadiation Therapy: Damages hematopoietic stem cells\nToxins: Benzene, pesticides\nAlcohol Abuse: Chronic heavy use suppresses marrow\nAplastic Anemia: Global marrow failure affecting cell linesDrug-Induced Suppression (Direct Toxicity): Chemotherapy common cause severe acquired neutropenia. Many drugs can suppress marrow (e.g., certain antibiotics like chloramphenicol, anti-thyroid drugs, phenothiazines, NSAIDs - idiosyncratic reactions)Radiation Therapy: Damages hematopoietic stem cellsToxins: Benzene, pesticidesAlcohol Abuse: Chronic heavy use suppresses marrowBone Marrow Infiltration: Malignant cells crowd normal hematopoiesis (Leukemia, Lymphoma, Myeloma, Metastatic solid tumors)Nutritional Deficiencies: Severe Vitamin B12 Folate deficiency impairs DNA synthesis, affecting rapidly dividing cells, including neutrophil precursors. Severe Copper deficiency can also cause neutropeniaCertain Infections: viral infections (Hepatitis, HIV, EBV, CMV, Parvovirus B19) can directly suppress marrow productionIncreased Neutrophil Destruction Consumption (Peripheral)\nOverwhelming Infection (Sepsis): severe bacterial fungal infections, neutrophils migrate rapidly tissues can consumed faster bone marrow can replace , leading paradoxical neutropenia (poor prognostic sign)\nHypersplenism: enlarged spleen traps neutrophils (along RBCs platelets), leading mild moderate neutropenia\nOverwhelming Infection (Sepsis): severe bacterial fungal infections, neutrophils migrate rapidly tissues can consumed faster bone marrow can replace , leading paradoxical neutropenia (poor prognostic sign)Hypersplenism: enlarged spleen traps neutrophils (along RBCs platelets), leading mild moderate neutropeniaIncreased Margination (Pseudoneutropenia)\nNeutrophils shift circulating pool marginated pool (adhering temporarily blood vessel walls), often due stress, exercise, endotoxemia. total body neutrophil count isn’t truly low, just redistributed. ANC typically normalizes quickly\nNeutrophils shift circulating pool marginated pool (adhering temporarily blood vessel walls), often due stress, exercise, endotoxemia. total body neutrophil count isn’t truly low, just redistributed. ANC typically normalizes quickly","code":""},{"path":"neutropenia.html","id":"detection-finding-the-cause-2","chapter":"Neutropenia","heading":"Detection (Finding the Cause)","text":"Clinical Assessment: Key history! Focus : onset (acute vs. chronic), pattern (cyclic?), severity/frequency infections (especially bacterial - skin, oral, respiratory, perianal), medication history (prescription, OTC, supplements), toxin exposure, alcohol use, family history, signs underlying disease (autoimmune, malignancy)Laboratory Tests\nCBC Differential & ANC Calculation: Essential first step. Confirm low ANC. Note severity. Look cytopenias (pancytopenia? isolated neutropenia?)\nSerial CBCs: Required cyclic neutropenia suspected (e.g., 2-3 times/week 6-8 weeks)\nPeripheral Blood Smear Review: Confirm automated differential. Assess neutrophil morphology (toxic changes? dysplastic features? blasts?). Examine cell lines\nBone Marrow Aspirate Biopsy: Crucial decreased production suspected cause unclear. Assess:\nCellularity: Normal, hyper-, hypo-cellular?\nMyeloid:Erythroid (M:E) Ratio: Usually decreased isolated neutropenia due production defect, normal/increased maturation arrest\nGranulopoiesis: Assess maturation sequence. Look “maturation arrest” (common SCN, AIN). Rule infiltration (leukemia, etc.)\nCytogenetics/Molecular Studies: suspected malignancy congenital syndromes\n\nSpecific Tests: Vitamin B12/Folate/Copper levels, genetic testing congenital neutropenias (ELANE, etc.), infectious workup (blood cultures, viral serologies) indicated\nCBC Differential & ANC Calculation: Essential first step. Confirm low ANC. Note severity. Look cytopenias (pancytopenia? isolated neutropenia?)Serial CBCs: Required cyclic neutropenia suspected (e.g., 2-3 times/week 6-8 weeks)Peripheral Blood Smear Review: Confirm automated differential. Assess neutrophil morphology (toxic changes? dysplastic features? blasts?). Examine cell linesBone Marrow Aspirate Biopsy: Crucial decreased production suspected cause unclear. Assess:\nCellularity: Normal, hyper-, hypo-cellular?\nMyeloid:Erythroid (M:E) Ratio: Usually decreased isolated neutropenia due production defect, normal/increased maturation arrest\nGranulopoiesis: Assess maturation sequence. Look “maturation arrest” (common SCN, AIN). Rule infiltration (leukemia, etc.)\nCytogenetics/Molecular Studies: suspected malignancy congenital syndromes\nCellularity: Normal, hyper-, hypo-cellular?Myeloid:Erythroid (M:E) Ratio: Usually decreased isolated neutropenia due production defect, normal/increased maturation arrestGranulopoiesis: Assess maturation sequence. Look “maturation arrest” (common SCN, AIN). Rule infiltration (leukemia, etc.)Cytogenetics/Molecular Studies: suspected malignancy congenital syndromesSpecific Tests: Vitamin B12/Folate/Copper levels, genetic testing congenital neutropenias (ELANE, etc.), infectious workup (blood cultures, viral serologies) indicated","code":""},{"path":"neutropenia.html","id":"treatment-8","chapter":"Neutropenia","heading":"Treatment","text":"Focuses treating underlying cause preventing/managing infections:Treat Underlying Cause: Stop offending drug, treat infection, manage malignancy, nutritional replacement, etcGranulocyte Colony-Stimulating Factor (G-CSF): Recombinant human G-CSF (Filgrastim, Pegfilgrastim - long-acting) stimulates bone marrow produce release neutrophils. Mainstay therapy \nChemotherapy-induced neutropenia (prophylaxis treatment)\nSevere Congenital Neutropenia\nCyclic Neutropenia\nAplastic Anemia (adjunctive)\nAIDS-related neutropenia\nChemotherapy-induced neutropenia (prophylaxis treatment)Severe Congenital NeutropeniaCyclic NeutropeniaAplastic Anemia (adjunctive)AIDS-related neutropeniaInfection Management: CRITICAL!\nFebrile Neutropenia (Fever + ANC <500 expected fall <500): Medical emergency! Requires prompt evaluation, cultures, empiric broad-spectrum IV antibiotics\nProphylactic Antibiotics/Antifungals: Sometimes used patients prolonged severe neutropenia\nPatient Education: Meticulous hygiene, avoiding sick contacts, prompt reporting fever/symptoms\nFebrile Neutropenia (Fever + ANC <500 expected fall <500): Medical emergency! Requires prompt evaluation, cultures, empiric broad-spectrum IV antibioticsProphylactic Antibiotics/Antifungals: Sometimes used patients prolonged severe neutropeniaPatient Education: Meticulous hygiene, avoiding sick contacts, prompt reporting fever/symptomsHematopoietic Stem Cell Transplantation (HSCT): Curative option severe aplastic anemia, SCN unresponsive G-CSF, leukemiaGranulocyte Transfusions: RARELY used. Considered patients severe neutropenia (<500), documented bacterial/fungal infection unresponsive appropriate antimicrobials +/- G-CSF, reasonable expectation marrow recovery. Difficult collect adequate doses, short neutrophil half-life, significant risks (alloimmunization, TRALI, CMV transmission, febrile reactions). Requires irradiated, crossmatch-compatible (possible) granulocytes","code":""},{"path":"neutropenia.html","id":"immune-neutropenia-when-antibodies-attack","chapter":"Neutropenia","heading":"Immune Neutropenia: When Antibodies Attack","text":", neutrophils destroyed prematurely due antibodies targeting neutrophil-specific antigens immune mechanisms","code":""},{"path":"neutropenia.html","id":"pathophysiology-how-it-happens-5","chapter":"Neutropenia","heading":"Pathophysiology (How it Happens)","text":"Autoimmune Neutropenia (AIN): Antibodies directed patient’s neutrophil antigens\nMechanism: IgG (sometimes IgM/IgA) antibodies bind antigens neutrophil surface (e.g., Human Neutrophil Antigens - HNAs, like HNA-1, HNA-2). Antibody-coated neutrophils cleared prematurely Mononuclear Phagocyte System (primarily spleen), antibodies may interfere function cause complement activation\nTypes\nPrimary AIN: Occurs isolation, common cause chronic benign neutropenia infants/young children (typically presents 6-12 months old, often resolves spontaneously within 1-3 years)\nSecondary AIN: Associated conditions:\nAutoimmune Diseases: Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Felty’s Syndrome (RA + splenomegaly + neutropenia)\nLymphoproliferative Disorders: Chronic Lymphocytic Leukemia (CLL), Large Granular Lymphocyte (LGL) Leukemia\nInfections: HIV, EBV, Hepatitis\nPost-Transplant\n\n\nMechanism: IgG (sometimes IgM/IgA) antibodies bind antigens neutrophil surface (e.g., Human Neutrophil Antigens - HNAs, like HNA-1, HNA-2). Antibody-coated neutrophils cleared prematurely Mononuclear Phagocyte System (primarily spleen), antibodies may interfere function cause complement activationTypes\nPrimary AIN: Occurs isolation, common cause chronic benign neutropenia infants/young children (typically presents 6-12 months old, often resolves spontaneously within 1-3 years)\nSecondary AIN: Associated conditions:\nAutoimmune Diseases: Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Felty’s Syndrome (RA + splenomegaly + neutropenia)\nLymphoproliferative Disorders: Chronic Lymphocytic Leukemia (CLL), Large Granular Lymphocyte (LGL) Leukemia\nInfections: HIV, EBV, Hepatitis\nPost-Transplant\n\nPrimary AIN: Occurs isolation, common cause chronic benign neutropenia infants/young children (typically presents 6-12 months old, often resolves spontaneously within 1-3 years)Secondary AIN: Associated conditions:\nAutoimmune Diseases: Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Felty’s Syndrome (RA + splenomegaly + neutropenia)\nLymphoproliferative Disorders: Chronic Lymphocytic Leukemia (CLL), Large Granular Lymphocyte (LGL) Leukemia\nInfections: HIV, EBV, Hepatitis\nPost-Transplant\nAutoimmune Diseases: Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Felty’s Syndrome (RA + splenomegaly + neutropenia)Lymphoproliferative Disorders: Chronic Lymphocytic Leukemia (CLL), Large Granular Lymphocyte (LGL) LeukemiaInfections: HIV, EBV, HepatitisPost-TransplantAlloimmune Neutropenia: Antibodies non-self neutrophil antigens\nNeonatal Alloimmune Neutropenia (NAN): Mother lacks HNA expressed fetal neutrophils (inherited father). Maternal IgG anti-HNA crosses placenta, destroying fetal/neonatal neutrophils. Presents severe neutropenia risk infection first weeks/months life. Resolves maternal IgG declines. Analogous HDFN/NAIT\nTransfusion-Related: Antibodies transfused plasma (e.g., multiparous female donors) reacting recipient neutrophils. mechanism behind Transfusion-Related Acute Lung Injury (TRALI), neutrophil activation/sequestration lungs causes acute respiratory distress. TRALI involves anti-neutrophil antibodies, typically doesn’t present neutropenia recipient’s CBC\nNeonatal Alloimmune Neutropenia (NAN): Mother lacks HNA expressed fetal neutrophils (inherited father). Maternal IgG anti-HNA crosses placenta, destroying fetal/neonatal neutrophils. Presents severe neutropenia risk infection first weeks/months life. Resolves maternal IgG declines. Analogous HDFN/NAITTransfusion-Related: Antibodies transfused plasma (e.g., multiparous female donors) reacting recipient neutrophils. mechanism behind Transfusion-Related Acute Lung Injury (TRALI), neutrophil activation/sequestration lungs causes acute respiratory distress. TRALI involves anti-neutrophil antibodies, typically doesn’t present neutropenia recipient’s CBCDrug-Induced Immune Neutropenia (DIIN)\nMechanism: Drug acts hapten triggers antibodies react neutrophils presence drug (similar DIHA/DITP). Leads rapid neutrophil destruction\nOnset: Often abrupt, 7-14 days starting new drug\nCommon culprits: Many drugs implicated, including anti-thyroid drugs (propylthiouracil, methimazole), antibiotics (beta-lactams, sulfonamides), anti-inflammatories, anti-convulsants, antipsychotics\nMechanism: Drug acts hapten triggers antibodies react neutrophils presence drug (similar DIHA/DITP). Leads rapid neutrophil destructionOnset: Often abrupt, 7-14 days starting new drugCommon culprits: Many drugs implicated, including anti-thyroid drugs (propylthiouracil, methimazole), antibiotics (beta-lactams, sulfonamides), anti-inflammatories, anti-convulsants, antipsychotics","code":""},{"path":"neutropenia.html","id":"detection-finding-the-immune-cause-2","chapter":"Neutropenia","heading":"Detection (Finding the Immune Cause)","text":"Clinical Assessment: History key (age onset, infections, associated autoimmune disease, drugs, pregnancy/transfusion history alloimmune causes)Laboratory Tests\nCBC/Smear: Confirm isolated neutropenia (often moderate severe). cell lines usually normal unless secondary cause\nBone Marrow: Typically shows normal increased myeloid cellularity adequate precursors, often “maturation arrest” pattern – meaning plenty early forms (promyelocytes, myelocytes) mature neutrophils, suggesting peripheral destruction outpacing release\nNeutrophil Antibody Testing: Specialized testing, always necessary diagnosis (especially primary AIN). Can detect antibodies serum bound neutrophils (direct test). Methods include:\nGranulocyte Agglutination Test (GAT)\nGranulocyte Immunofluorescence Test (GIFT) (indirect serum Ab, direct bound Ab)\nMonoclonal Antibody Immobilization Granulocyte Antigens (MAIGA)\nTesting can performed panel neutrophils paternal neutrophils (NAN workup)\nLimitations: Variable sensitivity/specificity, standardized across labs\n\nHNA Typing: Useful NAN workup (mother, father, infant)\nAutoimmune Markers: ANA, RF, etc., secondary AIN suspected\nCBC/Smear: Confirm isolated neutropenia (often moderate severe). cell lines usually normal unless secondary causeBone Marrow: Typically shows normal increased myeloid cellularity adequate precursors, often “maturation arrest” pattern – meaning plenty early forms (promyelocytes, myelocytes) mature neutrophils, suggesting peripheral destruction outpacing releaseNeutrophil Antibody Testing: Specialized testing, always necessary diagnosis (especially primary AIN). Can detect antibodies serum bound neutrophils (direct test). Methods include:\nGranulocyte Agglutination Test (GAT)\nGranulocyte Immunofluorescence Test (GIFT) (indirect serum Ab, direct bound Ab)\nMonoclonal Antibody Immobilization Granulocyte Antigens (MAIGA)\nTesting can performed panel neutrophils paternal neutrophils (NAN workup)\nLimitations: Variable sensitivity/specificity, standardized across labs\nGranulocyte Agglutination Test (GAT)Granulocyte Immunofluorescence Test (GIFT) (indirect serum Ab, direct bound Ab)Monoclonal Antibody Immobilization Granulocyte Antigens (MAIGA)Testing can performed panel neutrophils paternal neutrophils (NAN workup)Limitations: Variable sensitivity/specificity, standardized across labsHNA Typing: Useful NAN workup (mother, father, infant)Autoimmune Markers: ANA, RF, etc., secondary AIN suspected","code":""},{"path":"neutropenia.html","id":"treatment-9","chapter":"Neutropenia","heading":"Treatment","text":"Observation: Many cases, especially primary AIN infants, benign self-limiting. Focus infection prevention prompt antibiotic treatment fever occursStop Offending Drug: Essential first step DIIN. Recovery usually occurs within 1-2 weeksAntibiotics: Prompt treatment infectionsG-CSF: Often effective raising neutrophil counts AIN NAN, used needed based ANC infection frequencyImmunosuppression (severe/persistent AIN)\nCorticosteroids: May used, often require long courses/high doses\nIVIg: Can provide temporary increases ANC\nRituximab, Cyclosporine, Mycophenolate: options refractory cases\nCorticosteroids: May used, often require long courses/high dosesIVIg: Can provide temporary increases ANCRituximab, Cyclosporine, Mycophenolate: options refractory casesSplenectomy: Can effective refractory AIN removing primary site destruction, carries risks (infection, thrombosis) less frequently performed nowNAN Management: Supportive care, prompt antibiotics infection, G-CSF severe/prolonged. Usually resolves within weeks months maternal IgG fades. Washed maternal granulocytes rarely considered","code":""},{"path":"neutropenia.html","id":"key-terms-69","chapter":"Neutropenia","heading":"Key Terms","text":"Neutropenia: Low absolute neutrophil count (ANC)Absolute Neutrophil Count (ANC): Total WBC x (% Segs + % Bands)Agranulocytosis: Severe neutropenia, near absence neutrophilsGranulopoiesis: production granulocytes (including neutrophils) bone marrowFebrile Neutropenia: Fever patient neutropenia; medical emergencyGranulocyte Colony-Stimulating Factor (G-CSF): Growth factor stimulates neutrophil production (e.g., Filgrastim)Severe Congenital Neutropenia (SCN): Inherited disorders causing profound neutropenia birthCyclic Neutropenia: Inherited disorder periodic fluctuations neutrophil countsAutoimmune Neutropenia (AIN): Neutropenia caused autoantibodies neutrophil antigensNeonatal Alloimmune Neutropenia (NAN): Neutropenia newborn caused maternal IgG antibodies fetal neutrophil antigensHuman Neutrophil Antigens (HNAs): Antigens expressed surface neutrophilsMaturation Arrest: pattern seen bone marrow hematopoietic precursors develop normally certain stage fail mature beyond ","code":""},{"path":"transplantation-1.html","id":"transplantation-1","chapter":"Transplantation","heading":"Transplantation","text":"Transplantation offers life-saving solution irreversible organ failure (Solid Organ Transplantation - SOT) bone marrow/immune system dysfunction (Hematopoietic Progenitor Cell - HPC Transplant). surgical techniques differ, fields grapple fundamental physiological challenge recipient’s immune system recognizing donor tissue cells foreign. resulting pathophysiology manifests primarily rejection SOT, recipient attacks graft, uniquely includes Graft-versus-Host Disease (GVHD) allogeneic HPC transplants, donor immune cells attack recipient. Understanding immune interactions, driven largely HLA incompatibility, paramount successful transplantation managing complications","code":""},{"path":"transplantation-1.html","id":"solid-organ-transplantation-sot","chapter":"Transplantation","heading":"Solid Organ Transplantation (SOT)","text":"Goal: Replace failing organ (kidney, liver, heart, lung, etc.) healthy donor organ (allograft)Core Problem: Recipient’s immune system recognizes donor organ foreign (via HLA ABO antigens) attacks (Rejection)Rejection Types: Hyperacute (immediate, pre-formed antibodies), Acute (days/weeks, T-cell antibody mediated), Chronic (months/years, slow fibrosis/vascular damage)Prevention Strategy: ABO compatibility essential. HLA matching prioritized (especially kidney). Pre-transplant crossmatching detects donor-specific antibodies (DSA). Lifelong immunosuppression required recipientKey Complication Focus: Preventing rejection graft recipient","code":""},{"path":"transplantation-1.html","id":"hematopoietic-progenitor-cell-hpc-transplantation-stem-cellbone-marrow-transplant","chapter":"Transplantation","heading":"Hematopoietic Progenitor Cell (HPC) Transplantation (Stem Cell/Bone Marrow Transplant)","text":"Goal: Replace patient’s diseased damaged bone marrow immune system (leukemia, marrow failure, immune deficiencies, etc.)Sources: Bone Marrow, Peripheral Blood Stem Cells (PBSC, common), Umbilical Cord BloodTypes: Autologous (patient’s cells - rejection/GVHD), Allogeneic (donor cells - risk rejection/GVHD, potential Graft-vs-Tumor effect)Core Problems (Allogeneic)\nGraft Rejection: Recipient’s immune system destroys donor cells\nGraft-versus-Host Disease (GVHD): Donor T-cells attack recipient’s tissues (skin, gut, liver) - major complication unique allo-HPC\nInfection: Due intense pre-transplant conditioning (chemo/radiation) immunosuppression\nGraft Rejection: Recipient’s immune system destroys donor cellsGraft-versus-Host Disease (GVHD): Donor T-cells attack recipient’s tissues (skin, gut, liver) - major complication unique allo-HPCInfection: Due intense pre-transplant conditioning (chemo/radiation) immunosuppressionPrevention Strategy: High-resolution HLA matching critical. Conditioning regimen eradicates disease suppresses recipient immunity. GVHD prophylaxis (immunosuppression) standard allogeneic. ABO compatibility barrier transplant requires careful transfusion managementKey Complication Focus: Preventing/managing GVHD infection, ensuring engraftmentBlood Support: Irradiated cellular blood products mandatory HPC recipients prevent Transfusion-Associated GVHD","code":""},{"path":"solid-organ.html","id":"solid-organ","chapter":"Solid Organ","heading":"Solid Organ","text":"Solid Organ Transplantation (SOT) remarkable medical achievement failing organ replaced healthy one donor. Blood Bank Immunology perspective, major challenge isn’t just surgery , overcoming body’s natural defense system, primed attack anything sees “foreign”—including life-saving new organ!","code":""},{"path":"solid-organ.html","id":"the-goal-replacing-failing-organs","chapter":"Solid Organ","heading":"The Goal: Replacing Failing Organs","text":"Transplant?: SOT typically performed end-stage organ failure, organ damaged beyond repair disease injury, medical therapies longer effective. goal restore normal function, improve quality life, extend survivalCommonly Transplanted Organs: Kidney (common), Liver, Heart, Lung, Pancreas, Intestine. Sometimes multiple organs transplanted together (e.g., heart-lung, kidney-pancreas)","code":""},{"path":"solid-organ.html","id":"the-major-hurdle-the-immune-system-rejection","chapter":"Solid Organ","heading":"The Major Hurdle: The Immune System & Rejection","text":"immune system brilliant recognizing eliminating foreign invaders (like bacteria viruses). Unfortunately, uses mechanisms recognize transplanted organ (allograft) another person (unless ’s identical twin) foreign. immune attack graft called rejectionThe Targets (Alloantigens): main molecules recipient’s immune system recognizes foreign donor organ cells :\nMajor Histocompatibility Complex (MHC) Molecules: humans, called Human Leukocyte Antigens (HLA). proteins found surface cells responsible presenting antigens T cells. highly polymorphic, meaning thousands different versions (alleles) human population. Differences HLA donor recipient primary trigger rejection\nClass HLA (HLA-, HLA-B, HLA-C): Found almost nucleated cells. Present antigens CD8+ Cytotoxic T cells\nClass II HLA (HLA-DR, HLA-DQ, HLA-DP): Found primarily Antigen Presenting Cells (APCs like macrophages, dendritic cells, B cells) within graft, can induced cells inflammation. Present antigens CD4+ Helper T cells\n\nABO Blood Group Antigens: carbohydrate antigens expressed red blood cells also vascular endothelium (lining blood vessels) organ graft. ABO incompatibility major barrier\nMinor Histocompatibility Antigens: polymorphic proteins can elicit weaker, slower immune response\nMajor Histocompatibility Complex (MHC) Molecules: humans, called Human Leukocyte Antigens (HLA). proteins found surface cells responsible presenting antigens T cells. highly polymorphic, meaning thousands different versions (alleles) human population. Differences HLA donor recipient primary trigger rejection\nClass HLA (HLA-, HLA-B, HLA-C): Found almost nucleated cells. Present antigens CD8+ Cytotoxic T cells\nClass II HLA (HLA-DR, HLA-DQ, HLA-DP): Found primarily Antigen Presenting Cells (APCs like macrophages, dendritic cells, B cells) within graft, can induced cells inflammation. Present antigens CD4+ Helper T cells\nClass HLA (HLA-, HLA-B, HLA-C): Found almost nucleated cells. Present antigens CD8+ Cytotoxic T cellsClass II HLA (HLA-DR, HLA-DQ, HLA-DP): Found primarily Antigen Presenting Cells (APCs like macrophages, dendritic cells, B cells) within graft, can induced cells inflammation. Present antigens CD4+ Helper T cellsABO Blood Group Antigens: carbohydrate antigens expressed red blood cells also vascular endothelium (lining blood vessels) organ graft. ABO incompatibility major barrierMinor Histocompatibility Antigens: polymorphic proteins can elicit weaker, slower immune response","code":""},{"path":"solid-organ.html","id":"pre-transplant-evaluation-minimizing-the-risk","chapter":"Solid Organ","heading":"Pre-Transplant Evaluation: Minimizing the Risk","text":"maximize chances graft survival, extensive laboratory testing done transplantation:ABO Blood Group Typing: CRITICAL! donor recipient must ABO compatible (identical). Transplants across ABO barriers (e.g., Group donor organ Group O recipient) usually lead hyperacute rejection people pre-formed antibodies (isohemagglutinins like anti-, anti-B) ABO antigens lack. antibodies attack graft endothelium immediately\nRule: Donor organ must compatible recipient plasma (similar RBC transfusion rules: O can give /B/AB; can give /AB; B can give B/AB; AB can give AB)\nRule: Donor organ must compatible recipient plasma (similar RBC transfusion rules: O can give /B/AB; can give /AB; B can give B/AB; AB can give AB)HLA Typing: Determining specific HLA-, -B, -DR (sometimes -C, -DQ, -DP) alleles donor recipient\nGoal: Achieve best possible HLA match, especially kidney transplants. “zero mismatch” (identical HLA-, -B, -DR) offers best long-term graft survival. However, due HLA polymorphism, perfect matches rare outside sibling donors. Matching less critical (still considered) liver heart transplants\nGoal: Achieve best possible HLA match, especially kidney transplants. “zero mismatch” (identical HLA-, -B, -DR) offers best long-term graft survival. However, due HLA polymorphism, perfect matches rare outside sibling donors. Matching less critical (still considered) liver heart transplantsHLA Antibody Screening Identification: Detecting pre-formed anti-HLA antibodies recipient’s serum vital!\nSensitization: Recipients can develop anti-HLA antibodies previous exposure foreign HLA antigens via:\nPregnancy\nBlood Transfusions (WBCs/platelets carry HLA)\nPrevious Transplants\n\nTesting Methods: Usually involves testing recipient serum panels beads coated known HLA antigens (Luminex platform)\nPanel Reactive Antibody (PRA): Historically reported percentage, indicating proportion population recipient antibodies . Now often expressed calculated PRA (cPRA) based identified unacceptable antigens. high PRA/cPRA indicates recipient highly sensitized finding compatible donor difficult\nAntibody Specificity: ’s crucial identify specific HLA antigens recipient antibodies . considered “unacceptable antigens” recipient\nSensitization: Recipients can develop anti-HLA antibodies previous exposure foreign HLA antigens via:\nPregnancy\nBlood Transfusions (WBCs/platelets carry HLA)\nPrevious Transplants\nPregnancyBlood Transfusions (WBCs/platelets carry HLA)Previous TransplantsTesting Methods: Usually involves testing recipient serum panels beads coated known HLA antigens (Luminex platform)Panel Reactive Antibody (PRA): Historically reported percentage, indicating proportion population recipient antibodies . Now often expressed calculated PRA (cPRA) based identified unacceptable antigens. high PRA/cPRA indicates recipient highly sensitized finding compatible donor difficultAntibody Specificity: ’s crucial identify specific HLA antigens recipient antibodies . considered “unacceptable antigens” recipientCrossmatching: final compatibility check transplant! Mixes recipient serum donor lymphocytes (T cells B cells) detect pre-formed Donor-Specific Antibodies (DSA) – antibodies recipient directly target specific donor’s HLA antigens\nComplement-Dependent Cytotoxicity (CDC) Crossmatch: Traditional method. Recipient serum + donor lymphocytes + complement. DSA present, bind, activate complement, lyse donor cells (positive crossmatch). positive CDC crossmatch generally absolute contraindication transplantation due high risk hyperacute rejection.\nFlow Cytometry Crossmatch: sensitive method. Uses fluorescently labeled anti-human IgG detect recipient antibodies binding donor lymphocytes, even don’t fix complement strongly. Can detect lower levels DSA. positive flow crossmatch indicates increased risk antibody-mediated rejection\nVirtual Crossmatch: Based comparing recipient’s identified unacceptable HLA antibody specificities donor’s HLA type. donor antigens recipient antibodies , virtual crossmatch negative\nComplement-Dependent Cytotoxicity (CDC) Crossmatch: Traditional method. Recipient serum + donor lymphocytes + complement. DSA present, bind, activate complement, lyse donor cells (positive crossmatch). positive CDC crossmatch generally absolute contraindication transplantation due high risk hyperacute rejection.Flow Cytometry Crossmatch: sensitive method. Uses fluorescently labeled anti-human IgG detect recipient antibodies binding donor lymphocytes, even don’t fix complement strongly. Can detect lower levels DSA. positive flow crossmatch indicates increased risk antibody-mediated rejectionVirtual Crossmatch: Based comparing recipient’s identified unacceptable HLA antibody specificities donor’s HLA type. donor antigens recipient antibodies , virtual crossmatch negative","code":""},{"path":"solid-organ.html","id":"types-of-rejection-pathophysiology","chapter":"Solid Organ","heading":"Types of Rejection (Pathophysiology)","text":"Even compatibility testing immunosuppression, rejection can still occur:Hyperacute Rejection\nTiming: Minutes hours transplant blood flow restored\nMechanism: Caused pre-formed donor-specific antibodies (DSA), usually anti-ABO anti-HLA, already present recipient. Antibodies bind vascular endothelium graft, activate complement clotting cascades, leading widespread thrombosis (clotting), ischemia (lack blood flow), rapid, irreversible graft destruction\nPrevention: Primarily prevented ABO compatibility negative pre-transplant crossmatch\nTiming: Minutes hours transplant blood flow restoredMechanism: Caused pre-formed donor-specific antibodies (DSA), usually anti-ABO anti-HLA, already present recipient. Antibodies bind vascular endothelium graft, activate complement clotting cascades, leading widespread thrombosis (clotting), ischemia (lack blood flow), rapid, irreversible graft destructionPrevention: Primarily prevented ABO compatibility negative pre-transplant crossmatchAcute Rejection\nTiming: Days weeks (even months) transplant. Can occur suddenly\nMechanisms: Can T-cell mediated, antibody-mediated, \nAcute Cellular Rejection (ACR): Recipient T lymphocytes (primarily CD8+ cytotoxic T cells CD4+ helper T cells) recognize donor HLA antigens (presented donor APCs migrating graft recipient APCs presenting donor peptides) infiltrate graft, causing inflammation killing graft cells\nAntibody-Mediated Rejection (AMR): Involves antibodies (often DSA, can pre-formed low levels develop transplant - de novo DSA). Antibodies bind graft endothelium, activating complement, attracting inflammatory cells (neutrophils, NK cells), causing endothelial injury, inflammation (endothelialitis, capillaritis), microvascular thrombosis\n\nDetection: Often suspected due clinical signs graft dysfunction (e.g., rising creatinine kidney, abnormal liver enzymes liver), confirmed biopsy graft tissue\nTreatment: Usually treatable increased immunosuppression (e.g., high-dose steroids, anti-T cell antibodies ACR; plasmapheresis, IVIg, Rituximab AMR)\nTiming: Days weeks (even months) transplant. Can occur suddenlyMechanisms: Can T-cell mediated, antibody-mediated, \nAcute Cellular Rejection (ACR): Recipient T lymphocytes (primarily CD8+ cytotoxic T cells CD4+ helper T cells) recognize donor HLA antigens (presented donor APCs migrating graft recipient APCs presenting donor peptides) infiltrate graft, causing inflammation killing graft cells\nAntibody-Mediated Rejection (AMR): Involves antibodies (often DSA, can pre-formed low levels develop transplant - de novo DSA). Antibodies bind graft endothelium, activating complement, attracting inflammatory cells (neutrophils, NK cells), causing endothelial injury, inflammation (endothelialitis, capillaritis), microvascular thrombosis\nAcute Cellular Rejection (ACR): Recipient T lymphocytes (primarily CD8+ cytotoxic T cells CD4+ helper T cells) recognize donor HLA antigens (presented donor APCs migrating graft recipient APCs presenting donor peptides) infiltrate graft, causing inflammation killing graft cellsAntibody-Mediated Rejection (AMR): Involves antibodies (often DSA, can pre-formed low levels develop transplant - de novo DSA). Antibodies bind graft endothelium, activating complement, attracting inflammatory cells (neutrophils, NK cells), causing endothelial injury, inflammation (endothelialitis, capillaritis), microvascular thrombosisDetection: Often suspected due clinical signs graft dysfunction (e.g., rising creatinine kidney, abnormal liver enzymes liver), confirmed biopsy graft tissueTreatment: Usually treatable increased immunosuppression (e.g., high-dose steroids, anti-T cell antibodies ACR; plasmapheresis, IVIg, Rituximab AMR)Chronic Rejection (Chronic Allograft Dysfunction)\nTiming: Months years transplant. Slow, progressive decline graft function\nMechanism: Complex multifactorial, fully understood. Involves immune factors (low-level chronic inflammation, possibly related DSA cellular responses) non-immune factors (injury hypertension, diabetes, drug toxicity, initial ischemia-reperfusion injury). Leads characteristic changes like fibrosis (scarring), vascular narrowing (graft arteriosclerosis), eventual graft failure\nTreatment: Difficult treat effectively. Focus optimizing immunosuppression, managing comorbidities (BP, lipids, glucose), ultimately may require re-transplantation\nTiming: Months years transplant. Slow, progressive decline graft functionMechanism: Complex multifactorial, fully understood. Involves immune factors (low-level chronic inflammation, possibly related DSA cellular responses) non-immune factors (injury hypertension, diabetes, drug toxicity, initial ischemia-reperfusion injury). Leads characteristic changes like fibrosis (scarring), vascular narrowing (graft arteriosclerosis), eventual graft failureTreatment: Difficult treat effectively. Focus optimizing immunosuppression, managing comorbidities (BP, lipids, glucose), ultimately may require re-transplantation","code":""},{"path":"solid-organ.html","id":"immunosuppression-keeping-the-immune-system-in-check","chapter":"Solid Organ","heading":"Immunosuppression: Keeping the Immune System in Check","text":"Necessity: Lifelong immunosuppressive medication required almost transplant recipients prevent rejectionGoal: Suppress recipient’s immune response enough prevent graft rejection, minimizing side effects maintaining enough immunity fight infections cancers. ’s delicate balancing act!Drug Classes: Typically involves combination drugs targeting different pathways:\nCalcineurin Inhibitors (e.g., Tacrolimus, Cyclosporine): Block T cell activation signals\nAntiproliferative Agents (e.g., Mycophenolate Mofetil, Azathioprine): Inhibit lymphocyte proliferation\nCorticosteroids (e.g., Prednisone): Broad anti-inflammatory immunosuppressive effects. Often used induction treating acute rejection, tapered time\nmTOR Inhibitors (e.g., Sirolimus, Everolimus): Inhibit cell growth proliferation\nBiologics/Antibodies: Used induction (time transplant) rejection treatment (e.g., anti-thymocyte globulin, anti-IL-2 receptor antibodies like Basiliximab, anti-CD20 like Rituximab)\nCalcineurin Inhibitors (e.g., Tacrolimus, Cyclosporine): Block T cell activation signalsAntiproliferative Agents (e.g., Mycophenolate Mofetil, Azathioprine): Inhibit lymphocyte proliferationCorticosteroids (e.g., Prednisone): Broad anti-inflammatory immunosuppressive effects. Often used induction treating acute rejection, tapered timemTOR Inhibitors (e.g., Sirolimus, Everolimus): Inhibit cell growth proliferationBiologics/Antibodies: Used induction (time transplant) rejection treatment (e.g., anti-thymocyte globulin, anti-IL-2 receptor antibodies like Basiliximab, anti-CD20 like Rituximab)Side Effects: Immunosuppression increases risk :\nInfections: Bacterial, viral (CMV, EBV, BK virus), fungal – especially opportunistic infections\nMalignancies: Skin cancers, post-transplant lymphoproliferative disorder (PTLD, often EBV-related)\nOrgan toxicity (e.g., nephrotoxicity calcineurin inhibitors), metabolic changes (diabetes, hyperlipidemia)\nInfections: Bacterial, viral (CMV, EBV, BK virus), fungal – especially opportunistic infectionsMalignancies: Skin cancers, post-transplant lymphoproliferative disorder (PTLD, often EBV-related)Organ toxicity (e.g., nephrotoxicity calcineurin inhibitors), metabolic changes (diabetes, hyperlipidemia)","code":""},{"path":"solid-organ.html","id":"other-complications","chapter":"Solid Organ","heading":"Other Complications","text":"Infection: major cause morbidity mortality due immunosuppressionMalignancy: Increased long-term riskGraft-versus-Host Disease (GVHD): RARE SOT compared stem cell transplant. Occurs viable donor lymphocytes within graft (especially liver intestine, rich lymphoid tissue) engraft attack recipient’s tissues. Irradiation blood products may considered SOT recipients specific high-risk situations, although less routinely stem cell transplant","code":""},{"path":"solid-organ.html","id":"post-transplant-monitoring","chapter":"Solid Organ","heading":"Post-Transplant Monitoring","text":"Graft Function Tests: Regular monitoring (e.g., creatinine kidney, LFTs liver)Therapeutic Drug Monitoring (TDM): Measuring levels immunosuppressants (Tacrolimus, Cyclosporine) ensure within target range (effective toxic)Infection Surveillance: Monitoring CMV, EBV, BK virus, etcBiopsy: Performed routinely (protocol biopsy) rejection/dysfunction suspectedDSA Monitoring: Increasingly performed post-transplant detect development de novo DSA, associated AMR poor long-term outcomes","code":""},{"path":"solid-organ.html","id":"blood-bank-relevance-9","chapter":"Solid Organ","heading":"Blood Bank Relevance","text":"ABO/Rh Typing: Essential donor/recipient matchingAntibody Screening/ID: Identifying pre-formed HLA antibodies recipientsCrossmatching: Performing CDC /flow crossmatches pre-transplantBlood Product Support: Providing ABO-compatible, potentially leukocyte-reduced, sometimes irradiated blood components transplant surgery post-operative care. Ensuring antigen-negative units recipient red cell alloantibodies","code":""},{"path":"solid-organ.html","id":"key-terms-70","chapter":"Solid Organ","heading":"Key Terms","text":"Allograft: organ tissue transplanted genetically non-identical individuals speciesAlloantigen: antigen differs members species (e.g., HLA, ABO)Rejection: Immune response mounted recipient transplanted organHLA (Human Leukocyte Antigen): Human MHC molecules, primary targets graft rejectionPolymorphism: existence many different forms (alleles) gene (like HLA) populationSensitization: Development antibodies alloantigens (e.g., HLA) due prior exposure (pregnancy, transfusion, transplant)Panel Reactive Antibody (PRA) / Calculated PRA (cPRA): Measure breadth HLA sensitization potential recipientCrossmatch: Laboratory test mixing recipient serum donor lymphocytes detect pre-formed donor-specific antibodies (DSA)Donor-Specific Antibody (DSA): Antibodies recipient directed specifically HLA antigens organ donorHyperacute Rejection: Immediate rejection (minutes/hours) due pre-formed DSAAcute Cellular Rejection (ACR): Rejection mediated primarily T lymphocytes infiltrating graft (days/weeks)Antibody-Mediated Rejection (AMR): Rejection mediated primarily antibodies (often DSA) targeting graft endothelium (days/weeks/months)Chronic Rejection / Chronic Allograft Dysfunction: Slow, progressive graft damage fibrosis occurring months/yearsImmunosuppression: Use medications reduce activity immune system prevent rejectionOpportunistic Infection: Infection caused pathogens normally cause disease individuals healthy immune systems","code":""},{"path":"hpc.html","id":"hpc","chapter":"HPC","heading":"HPC","text":"Hematopoietic Progenitor Cell (HPC) Transplantation, often called stem cell transplant bone marrow transplant, shares principles solid organ transplantation (like HLA matching), immunology fascinatingly different, unique challenges like Graft-versus-Host Disease (GVHD) major focus","code":""},{"path":"hpc.html","id":"the-goal-rebuilding-the-blood-and-immune-system","chapter":"HPC","heading":"The Goal: Rebuilding the Blood and Immune System","text":"Transplant?: HPC transplantation aims replace patient’s diseased damaged hematopoietic system (bone marrow blood/immune cells produces) healthy progenitor cells. ’s used treat:\nMalignant Diseases: Leukemias (AML, , CML, CLL), Lymphomas (Hodgkin, Non-Hodgkin), Multiple Myeloma. goal often allow high-dose chemotherapy/radiation kill cancer cells (also destroys patient’s marrow) “rescue” patient new stem cells. Sometimes, donor cells also exert Graft-versus-Tumor (GvT) Graft-versus-Leukemia (GvL) effect, donor immune cells help eliminate residual cancer cells\nBone Marrow Failure Syndromes: Aplastic Anemia, Fanconi Anemia\nInherited Immune Deficiencies: Severe Combined Immunodeficiency (SCID), Wiskott-Aldrich Syndrome\nHemoglobinopathies: Severe Sickle Cell Disease, Thalassemia Major\nInherited Metabolic Disorders: Certain storage diseases\nMalignant Diseases: Leukemias (AML, , CML, CLL), Lymphomas (Hodgkin, Non-Hodgkin), Multiple Myeloma. goal often allow high-dose chemotherapy/radiation kill cancer cells (also destroys patient’s marrow) “rescue” patient new stem cells. Sometimes, donor cells also exert Graft-versus-Tumor (GvT) Graft-versus-Leukemia (GvL) effect, donor immune cells help eliminate residual cancer cellsBone Marrow Failure Syndromes: Aplastic Anemia, Fanconi AnemiaInherited Immune Deficiencies: Severe Combined Immunodeficiency (SCID), Wiskott-Aldrich SyndromeHemoglobinopathies: Severe Sickle Cell Disease, Thalassemia MajorInherited Metabolic Disorders: Certain storage diseasesThe Cells: Hematopoietic Progenitor Cells (HPCs) multipotent stem cells residing primarily bone marrow. remarkable ability self-renew differentiate lineages blood immune cells (red cells, white cells types, platelets). often identified quantified presence CD34 surface marker","code":""},{"path":"hpc.html","id":"sources-of-hpcs-1","chapter":"HPC","heading":"Sources of HPCs","text":"Bone Marrow (BM): traditional source. Collected via multiple aspirations donor’s posterior iliac crests general spinal anesthesia. Rich stem cells requires anesthesia donor discomfortPeripheral Blood Stem Cells (PBSC): common source now. Donors receive injections Granulocyte Colony-Stimulating Factor (G-CSF) +/- Plerixafor several days. G-CSF “mobilizes” HPCs bone marrow peripheral circulation. donor undergoes apheresis (similar platelet donation), blood drawn, passed machine collect CD34+ cells, remaining blood components returned donor. Provides higher yield HPCs usually faster engraftment BM, less donor discomfort BM harvestUmbilical Cord Blood (UCB): Collected umbilical cord placenta birth. Contains rich source HPCs. Advantages include readily available (stored cord blood banks), lower risk transmitting infections, less stringent HLA matching required due immunological naivety cord blood T cells (leading less Graft-versus-Host Disease). Disadvantages include lower cell dose (may insufficient larger adults), slower engraftment time, inability recall donor additional cells needed","code":""},{"path":"hpc.html","id":"types-of-hpc-transplants-based-on-donor","chapter":"HPC","heading":"Types of HPC Transplants (Based on Donor)","text":"Autologous Transplant (“Auto”): patient’s HPCs collected (usually PBSC) period remission, stored (often cryopreserved), re-infused patient receives high-dose chemotherapy/radiation\nAdvantage: risk rejection GVHD\nDisadvantage: Graft-versus-Tumor effect; higher risk relapse cancer cells inadvertently collected stem cells\nAdvantage: risk rejection GVHDDisadvantage: Graft-versus-Tumor effect; higher risk relapse cancer cells inadvertently collected stem cellsAllogeneic Transplant (“Allo”): HPCs collected donor patient\nSyngeneic: Donor identical twin (genetically identical). GVHD risk, also GvT effect\nRelated Donor: Donor usually HLA-matched sibling. Historically preferred donor type\nUnrelated Donor (MUD - Matched Unrelated Donor): Donor found international registries (like NMDP/Match). Requires extensive HLA typing find best match\nHaploidentical Donor (“Haplo”): Donor shares exactly one HLA haplotype (usually parent, child, half-matched sibling). Requires special techniques (like T-cell depletion post-transplant cyclophosphamide) manage high risk rejection GVHD due significant HLA mismatch. Becoming common due donor availability\nCord Blood Donor: Uses unrelated UCB units\nSyngeneic: Donor identical twin (genetically identical). GVHD risk, also GvT effectRelated Donor: Donor usually HLA-matched sibling. Historically preferred donor typeUnrelated Donor (MUD - Matched Unrelated Donor): Donor found international registries (like NMDP/Match). Requires extensive HLA typing find best matchHaploidentical Donor (“Haplo”): Donor shares exactly one HLA haplotype (usually parent, child, half-matched sibling). Requires special techniques (like T-cell depletion post-transplant cyclophosphamide) manage high risk rejection GVHD due significant HLA mismatch. Becoming common due donor availabilityCord Blood Donor: Uses unrelated UCB unitsKey Difference “Auto”: Allogeneic transplants introduce new immune system donor. allows beneficial Graft-versus-Tumor effect carries major risk Graft-versus-Host Disease (GVHD) rejection","code":""},{"path":"hpc.html","id":"the-transplant-process","chapter":"HPC","heading":"The Transplant Process","text":"Conditioning Regimen receiving HPC infusion, patient undergoes intensive therapy\nGoals\nEradicate underlying disease (e.g., leukemia)\nProvide sufficient immunosuppression prevent recipient’s immune system rejecting donor stem cells (critical allogeneic)\nCreate physical “space” bone marrow new stem cells engraft\n\nMethods: High-dose chemotherapy, Total Body Irradiation (TBI), combination. Reduced-Intensity Conditioning (RIC) regimens use lower doses, relying GvT effect, allowing older less fit patients undergo transplant\nConsequence: Profound pancytopenia (low RBCs, WBCs, Platelets) immunosuppression, making patient highly vulnerable infection bleeding. Significant organ toxicities (mucositis, nausea, liver/kidney/lung damage) common\nGoals\nEradicate underlying disease (e.g., leukemia)\nProvide sufficient immunosuppression prevent recipient’s immune system rejecting donor stem cells (critical allogeneic)\nCreate physical “space” bone marrow new stem cells engraft\nEradicate underlying disease (e.g., leukemia)Provide sufficient immunosuppression prevent recipient’s immune system rejecting donor stem cells (critical allogeneic)Create physical “space” bone marrow new stem cells engraftMethods: High-dose chemotherapy, Total Body Irradiation (TBI), combination. Reduced-Intensity Conditioning (RIC) regimens use lower doses, relying GvT effect, allowing older less fit patients undergo transplantConsequence: Profound pancytopenia (low RBCs, WBCs, Platelets) immunosuppression, making patient highly vulnerable infection bleeding. Significant organ toxicities (mucositis, nausea, liver/kidney/lung damage) commonHPC Infusion collected HPC product (fresh thawed cryopreserved) infused intravenously recipient, much like standard blood transfusion. often referred “Day 0”Engraftment infused HPCs travel (“home”) bone marrow niches, begin proliferate, differentiate. Engraftment defined sustained recovery blood counts, typically:\nNeutrophil engraftment: ANC > 500/µL 3 consecutive days (usually occurs ~10-21 days post-infusion, slower cord blood)\nPlatelet engraftment: Platelet count > 20,000/µL without transfusion support (often takes longer neutrophils)\nNeutrophil engraftment: ANC > 500/µL 3 consecutive days (usually occurs ~10-21 days post-infusion, slower cord blood)Platelet engraftment: Platelet count > 20,000/µL without transfusion support (often takes longer neutrophils)","code":""},{"path":"hpc.html","id":"immune-complications-the-major-challenges-of-allogeneic-hct","chapter":"HPC","heading":"Immune Complications: The Major Challenges of Allogeneic HCT","text":"Graft Rejection (Graft Failure): recipient’s residual immune cells (especially T cells NK cells) recognize donor HPCs foreign destroy . graft fails engraft, engraftment lost initially occurring. common reduced-intensity conditioning, T-cell depleted grafts, significant HLA mismatch. Leads persistent pancytopeniaGraft-versus-Host Disease (GVHD): hallmark complication allogeneic HCT. Occurs mature, immunocompetent donor T lymphocytes (present HPC graft) recognize recipient’s tissues foreign (due differences HLA minor histocompatibility antigens) mount immune attack \nAcute GVHD (aGVHD): Typically occurs within first 100 days post-transplant. Primarily affects:\nSkin: Rash (maculopapular)\nLiver: Jaundice, elevated liver enzymes\nGastrointestinal Tract: Diarrhea (often profuse, watery, bloody), nausea, vomiting, abdominal pain\nSeverity graded (-IV). Can life-threatening\n\nChronic GVHD (cGVHD): Usually occurs >100 days post-transplant (can occur earlier evolve acute GVHD). Can affect almost organ system, often resembling autoimmune/collagen vascular diseases. Common features include skin changes (sclerosis, pigment changes), dry eyes/mouth (sicca syndrome), lung problems (bronchiolitis obliterans), liver dysfunction, joint contractures, GI issues. Major cause late morbidity mortality\nPrevention/Treatment: Prophylactic immunosuppression (similar drugs SOT: calcineurin inhibitors, methotrexate, mycophenolate, etc.) standard. Treatment involves increasing immunosuppression (steroids first-line), potentially adding agents (Rituximab, IVIg, ECP - extracorporeal photopheresis)\nAcute GVHD (aGVHD): Typically occurs within first 100 days post-transplant. Primarily affects:\nSkin: Rash (maculopapular)\nLiver: Jaundice, elevated liver enzymes\nGastrointestinal Tract: Diarrhea (often profuse, watery, bloody), nausea, vomiting, abdominal pain\nSeverity graded (-IV). Can life-threatening\nSkin: Rash (maculopapular)Liver: Jaundice, elevated liver enzymesGastrointestinal Tract: Diarrhea (often profuse, watery, bloody), nausea, vomiting, abdominal painSeverity graded (-IV). Can life-threateningChronic GVHD (cGVHD): Usually occurs >100 days post-transplant (can occur earlier evolve acute GVHD). Can affect almost organ system, often resembling autoimmune/collagen vascular diseases. Common features include skin changes (sclerosis, pigment changes), dry eyes/mouth (sicca syndrome), lung problems (bronchiolitis obliterans), liver dysfunction, joint contractures, GI issues. Major cause late morbidity mortalityPrevention/Treatment: Prophylactic immunosuppression (similar drugs SOT: calcineurin inhibitors, methotrexate, mycophenolate, etc.) standard. Treatment involves increasing immunosuppression (steroids first-line), potentially adding agents (Rituximab, IVIg, ECP - extracorporeal photopheresis)","code":""},{"path":"hpc.html","id":"hla-matching-critical-for-success","chapter":"HPC","heading":"HLA Matching: Critical for Success","text":"Importance: Minimizing HLA differences donor recipient paramount allogeneic HCT reduce risk severity GVHD graft rejectionRequired Typing: High-resolution typing (identifying specific alleles) HLA-, -B, -C, -DRB1 considered essential. Matching loci (DQB1, DPB1) increasingly consideredDonor Hierarchy\nHLA-matched sibling (identical twin perfect rare)\nHLA-matched unrelated donor (MUD) (8/8 10/10 match preferred)\nHLA-mismatched unrelated donor\nUmbilical Cord Blood unit(s) (less stringent matching acceptable)\nHaploidentical relative\nHLA-matched sibling (identical twin perfect rare)HLA-matched unrelated donor (MUD) (8/8 10/10 match preferred)HLA-mismatched unrelated donorUmbilical Cord Blood unit(s) (less stringent matching acceptable)Haploidentical relative","code":""},{"path":"hpc.html","id":"abo-compatibility-secondary-but-important","chapter":"HPC","heading":"ABO Compatibility: Secondary but Important","text":"ABO antigens expressed strongly HPCs , ABO incompatibility barrier performing transplant (unlike SOT). However, significant implications transfusion support potential immune hemolysis transplantTypes ABO Incompatibility\nMajor: Donor ABO antigens recipient lacks (e.g., Group donor -> Group O recipient). Recipient pre-formed anti-/anti-B (isohemagglutinins) can attack donor RBCs produced engraftment passenger lymphocytes graft making antibody. Risk immediate delayed hemolysis. HPC product may plasma-reduced RBC-depleted infusion\nMinor: Recipient ABO antigens donor lacks (e.g., Group O donor -> Group recipient). Donor graft contains plasma anti-/anti-B (isohemagglutinins) donor donor B cells produce anti-/anti-B engraftment. Risk hemolysis recipient RBCs shortly infusion (“passenger lymphocyte syndrome”) later donor immune system takes . HPC product may plasma-reduced\nBidirectional: major minor incompatibility exist (e.g., Group donor -> Group B recipient). Risks scenarios\nMajor: Donor ABO antigens recipient lacks (e.g., Group donor -> Group O recipient). Recipient pre-formed anti-/anti-B (isohemagglutinins) can attack donor RBCs produced engraftment passenger lymphocytes graft making antibody. Risk immediate delayed hemolysis. HPC product may plasma-reduced RBC-depleted infusionMinor: Recipient ABO antigens donor lacks (e.g., Group O donor -> Group recipient). Donor graft contains plasma anti-/anti-B (isohemagglutinins) donor donor B cells produce anti-/anti-B engraftment. Risk hemolysis recipient RBCs shortly infusion (“passenger lymphocyte syndrome”) later donor immune system takes . HPC product may plasma-reducedBidirectional: major minor incompatibility exist (e.g., Group donor -> Group B recipient). Risks scenariosBlood Bank Management: Requires careful planning transfusion support around time transplant, often needing specific ABO group products depending incompatibility phase engraftment (e.g., using Group O RBCs Group AB plasma initially major incompatibility). Monitoring hemolysis crucial. Recipient’s blood type may eventually change donor’s type full engraftment","code":""},{"path":"hpc.html","id":"other-complications-1","chapter":"HPC","heading":"Other Complications","text":"Infections: Profound prolonged immunosuppression leads high risk bacterial, fungal, viral (CMV, EBV, Adenovirus, BK virus), protozoal infections. Requires intensive monitoring prophylactic/pre-emptive therapiesOrgan Toxicity: conditioning regimens (mucositis, VOD/SOS - hepatic veno-occlusive disease/sinusoidal obstruction syndrome, lung injury, kidney injury, cardiotoxicity)Secondary Malignancies: Increased long-term risk due radiation, chemotherapy, chronic immunosuppression/GVHDEndocrine Issues: Hypothyroidism, hypogonadism, infertility, growth impairment childrenRelapse: Return original underlying disease remains major cause treatment failure","code":""},{"path":"hpc.html","id":"blood-bank-role-essential-support","chapter":"HPC","heading":"Blood Bank Role: Essential Support","text":"HLA Typing Coordination: Working specialized HLA laboratoriesBlood Product Support: Providing necessary RBCs Platelets period marrow aplasia post-conditioning. CRITICAL Requirements\nIrradiation: Mandatory cellular components prevent Transfusion-Associated GVHD (TA-GVHD) caused viable donor lymphocytes blood product attacking immunocompromised recipient\nCMV-Safe: Leukocyte reduction CMV-seronegative products essential prevent CMV transmission\nLeukocyte Reduction: Standard practice\nManaging ABO Incompatibility: Providing appropriate ABO group components pre- post-engraftment based type incompatibility (see )\nIrradiation: Mandatory cellular components prevent Transfusion-Associated GVHD (TA-GVHD) caused viable donor lymphocytes blood product attacking immunocompromised recipientCMV-Safe: Leukocyte reduction CMV-seronegative products essential prevent CMV transmissionLeukocyte Reduction: Standard practiceManaging ABO Incompatibility: Providing appropriate ABO group components pre- post-engraftment based type incompatibility (see )Therapeutic Apheresis: Plasma exchange TTP post-transplant, ECP GVHD treatmentHPC Collection/Processing/Cryopreservation: centers Blood Bank/Transfusion Service manages HPC laboratory. Includes CD34+ cell enumeration, processing (e.g., plasma reduction, RBC depletion), adding cryoprotectant (DMSO), controlled-rate freezing, storage liquid nitrogen. Thawing bedside prior infusion","code":""},{"path":"hpc.html","id":"key-terms-71","chapter":"HPC","heading":"Key Terms","text":"Hematopoietic Progenitor Cells (HPCs): Multipotent stem cells give rise blood cell lineagesCD34: Surface marker commonly used identify quantify HPCsMobilization: Process stimulating HPCs move bone marrow peripheral blood (using G-CSF)Apheresis: Procedure collect specific blood components (like PBSCs) returning rest donorConditioning Regimen: High-dose chemotherapy /radiation given HPC infusion eradicate disease suppress recipient’s immune systemEngraftment: process infused HPCs establish bone marrow begin producing new blood cellsAutologous Transplant: Using patient’s HPCsAllogeneic Transplant: Using HPCs donorGraft-versus-Host Disease (GVHD): Immune attack donor T cells recipient tissues; major complication allogeneic HCTGraft-versus-Tumor (GvT) / Graft-versus-Leukemia (GvL): Beneficial effect donor immune cells eliminate residual cancer cells recipientHLA Matching: Assessing compatibility Human Leukocyte Antigens donor recipient; crucial allogeneic HCT successChimerism: presence cells two genetically distinct individuals (donor recipient) one person transplantIrradiation (Blood Products): Treatment inactivate T lymphocytes cellular blood components prevent TA-GVHDVeno-occlusive Disease (VOD) / Sinusoidal Obstruction Syndrome (SOS): Serious liver complication, often related conditioning toxicity","code":""},{"path":"routine-tests.html","id":"routine-tests","chapter":"Routine Tests","heading":"Routine Tests","text":"start identifying patient’s fundamental blood type (ABO/Rh). , screen plasma unexpected “weapons” (Antibody Screen). find , identify assess danger level (Antibody ID/Significance). transfusion, final check patient specific donor unit (Crossmatch). Separately, suspect red cells already attacked vivo, perform DATEach step builds last, creating robust safety system. Keep practicing concepts – heart safe transfusion practice!","code":""},{"path":"routine-tests.html","id":"blood-grouping-tests-aborh","chapter":"Routine Tests","heading":"Blood Grouping Tests (ABO/Rh)","text":"Goal: Establish patient’s (donor’s) identity two critical blood group systemsWhat \nABO: Determine ABO group (, B, AB, O). two ways, MUST match:\nForward Type: Testing patient’s Red Cells known Anti-Anti-B reagents see antigens (B) present\nReverse Type: Testing patient’s Plasma/Serum known A1 B Red Cells see expected antibodies (Anti-Anti-B) present (Landsteiner’s Rule!)\n\nRh(D): Determine D antigen present (+) absent (-) patient’s Red Cells using Anti-D reagent. Includes Weak D testing (IAT procedure) initial D test negative, especially crucial donors sometimes newborns\nABO: Determine ABO group (, B, AB, O). two ways, MUST match:\nForward Type: Testing patient’s Red Cells known Anti-Anti-B reagents see antigens (B) present\nReverse Type: Testing patient’s Plasma/Serum known A1 B Red Cells see expected antibodies (Anti-Anti-B) present (Landsteiner’s Rule!)\nForward Type: Testing patient’s Red Cells known Anti-Anti-B reagents see antigens (B) presentReverse Type: Testing patient’s Plasma/Serum known A1 B Red Cells see expected antibodies (Anti-Anti-B) present (Landsteiner’s Rule!)Rh(D): Determine D antigen present (+) absent (-) patient’s Red Cells using Anti-D reagent. Includes Weak D testing (IAT procedure) initial D test negative, especially crucial donors sometimes newbornsWhy Matters: ABO incompatibility can cause rapid, severe intravascular hemolysis – potentially fatal. Rh(D) highly immunogenic, giving Rh(D)+ blood Rh(D)- person can easily stimulate anti-D production, causing issues future transfusions pregnancies (HDFN)","code":""},{"path":"routine-tests.html","id":"compatibility-tests-antibody-screen-crossmatch","chapter":"Routine Tests","heading":"Compatibility Tests (Antibody Screen & Crossmatch)","text":"Goal: Ensure patient’s plasma won’t attack donor red cells plan transfuse. pre-transfusion safety checkWhat \nAntibody Screen (Detection): broad search using patient’s Plasma/Serum Screening Cells (Group O cells known profile common, clinically significant antigens). ’re looking unexpected antibodies (beyond anti-/anti-B). Usually performed using Indirect Antiglobulin Test (IAT) principle (incubate 37°C, wash, add AHG)\nNegative Screen: Generally means common antibodies detected\nPositive Screen: antibody likely present; requires investigation (Antibody ID)\n\nCrossmatch: final check. Mixes patient Plasma/Serum directly red cells specific Donor Unit selected\nTypes: Can Immediate Spin (- primarily ABO check), Antiglobulin (AHG - full IAT antibodies known/suspected), Electronic (computer verification strict criteria screen negative rules met)\nResult: Compatible = Okay transfuse. Incompatible = STOP, investigate!\n\nAntibody Screen (Detection): broad search using patient’s Plasma/Serum Screening Cells (Group O cells known profile common, clinically significant antigens). ’re looking unexpected antibodies (beyond anti-/anti-B). Usually performed using Indirect Antiglobulin Test (IAT) principle (incubate 37°C, wash, add AHG)\nNegative Screen: Generally means common antibodies detected\nPositive Screen: antibody likely present; requires investigation (Antibody ID)\nNegative Screen: Generally means common antibodies detectedPositive Screen: antibody likely present; requires investigation (Antibody ID)Crossmatch: final check. Mixes patient Plasma/Serum directly red cells specific Donor Unit selected\nTypes: Can Immediate Spin (- primarily ABO check), Antiglobulin (AHG - full IAT antibodies known/suspected), Electronic (computer verification strict criteria screen negative rules met)\nResult: Compatible = Okay transfuse. Incompatible = STOP, investigate!\nTypes: Can Immediate Spin (- primarily ABO check), Antiglobulin (AHG - full IAT antibodies known/suspected), Electronic (computer verification strict criteria screen negative rules met)Result: Compatible = Okay transfuse. Incompatible = STOP, investigate!Matters: Detects antibodies cause hemolytic transfusion reaction. crossmatch ultimate confirmation ABO compatibility detects patient antibodies reactive specific donor cells","code":""},{"path":"routine-tests.html","id":"antibody-identification-clinical-significance","chapter":"Routine Tests","heading":"Antibody Identification & Clinical Significance","text":"Goal: Antibody Screen positive, need figure exactly antibody(ies) /present whether likely cause problemsWhat \nIdentification: Test patient Plasma/Serum larger Panel reagent red cells extensive, known antigen profiles. matching pattern reactivity (positive negative reactions) antigen profiles (using “rule-” method), determine antibody’s specificity (e.g., anti-K, anti-Fya). May involve special techniques (enzymes, adsorption). Autocontrol (patient plasma vs patient cells) helps distinguish allo- vs. autoantibodies\nClinical Significance: Assess identified antibody capable causing HTRs HDFN. Key factors: IgG? react 37°C? known cause hemolysis (e.g., Rh, Kell, Duffy, Kidd antibodies usually significant; Lewis, P1, M often aren’t)?\nIdentification: Test patient Plasma/Serum larger Panel reagent red cells extensive, known antigen profiles. matching pattern reactivity (positive negative reactions) antigen profiles (using “rule-” method), determine antibody’s specificity (e.g., anti-K, anti-Fya). May involve special techniques (enzymes, adsorption). Autocontrol (patient plasma vs patient cells) helps distinguish allo- vs. autoantibodiesClinical Significance: Assess identified antibody capable causing HTRs HDFN. Key factors: IgG? react 37°C? known cause hemolysis (e.g., Rh, Kell, Duffy, Kidd antibodies usually significant; Lewis, P1, M often aren’t)?Matters: Identification essential select antigen-negative blood transfusion. Assessing significance determines special selection necessary","code":""},{"path":"routine-tests.html","id":"direct-antiglobulin-test-dat","chapter":"Routine Tests","heading":"Direct Antiglobulin Test (DAT)","text":"Goal: Determine patient’s red blood cells coated immunoglobulin (IgG) complement components vivo (inside body right now): Take patient WASHED Red Blood Cells directly add Anti-Human Globulin (AHG) reagent (initially Polyspecific, Monospecific anti-IgG anti-C3d positive). Agglutination indicates cells coated blood drawnWhy Matters: typically part routine pre-transfusion testing crucial investigating:\nHemolytic Transfusion Reactions (HTRs)\nHemolytic Disease Fetus Newborn (HDFN)\nAutoimmune Hemolytic Anemias (AIHA)\nDrug-Induced Hemolytic Anemias (DIHA)\npositive DAT signals something (antibody/complement) attached red cells patient’s circulation\nHemolytic Transfusion Reactions (HTRs)Hemolytic Disease Fetus Newborn (HDFN)Autoimmune Hemolytic Anemias (AIHA)Drug-Induced Hemolytic Anemias (DIHA)\npositive DAT signals something (antibody/complement) attached red cells patient’s circulation","code":""},{"path":"blood-grouping.html","id":"blood-grouping","chapter":"Blood Grouping","heading":"Blood Grouping","text":"Routine blood grouping involves determining patient’s ABO group (using forward reverse typing) Rh(D) type (including Weak D testing appropriate). Accuracy paramount prevent potentially life-threatening transfusion reactions alloimmunization. Always ensure forward reverse ABO results match!, talking say “blood grouping”? Primarily, ’re determining patient’s ABO group Rh(D) typeLet’s break :","code":""},{"path":"blood-grouping.html","id":"the-abo-blood-group-system","chapter":"Blood Grouping","heading":"The ABO Blood Group System","text":"system arguably important transfusion medicine naturally occurring antibodies plasma ABO antigens lack red blood cells. known Landsteiner’s Rule. Messing can cause severe, potentially fatal, acute hemolytic transfusion reactionAntigens: specific carbohydrate structures found surface red blood cells. main ones B antigens. H antigen precursor structureAntibodies: proteins (immunoglobulins, mostly IgM ABO) found plasma/serum. “naturally occurring” “expected” develop early life, likely exposure environmental substances (like bacteria) similar structures B antigens\nantigen, anti-B antibodies\nB antigen, anti-antibodies\nB antigens (Group AB), neither anti-anti-B\nneither B antigens (Group O), anti-anti-B\nantigen, anti-B antibodiesIf B antigen, anti-antibodiesIf B antigens (Group AB), neither anti-anti-BIf neither B antigens (Group O), anti-anti-B","code":""},{"path":"blood-grouping.html","id":"how-do-we-test-for-abo","chapter":"Blood Grouping","heading":"How do we test for ABO?","text":"perform TWO tests concurrently, MUST match:Forward Grouping (Cell Typing)\ntests: Patient’s Red Blood Cells (RBCs) presence B antigens\n: mix patient’s RBCs known commercial reagent anti-sera (anti-anti-B)\nPrinciple: antigen present RBCs, corresponding antibody reagent bind , causing agglutination (clumping) sometimes hemolysis\nInterpretation\nAgglutination Anti-= Group \nAgglutination Anti-B = Group B\nAgglutination Anti-Anti-B = Group AB\nagglutination EITHER Anti-Anti-B = Group O\n\ntests: Patient’s Red Blood Cells (RBCs) presence B antigensHow: mix patient’s RBCs known commercial reagent anti-sera (anti-anti-B)Principle: antigen present RBCs, corresponding antibody reagent bind , causing agglutination (clumping) sometimes hemolysisInterpretation\nAgglutination Anti-= Group \nAgglutination Anti-B = Group B\nAgglutination Anti-Anti-B = Group AB\nagglutination EITHER Anti-Anti-B = Group O\nAgglutination Anti-= Group AAgglutination Anti-B = Group BAgglutination Anti-Anti-B = Group ABNO agglutination EITHER Anti-Anti-B = Group OReverse Grouping (Serum/Plasma Typing)\ntests: Patient’s Plasma Serum presence anti-anti-B antibodies\n: mix patient’s plasma/serum known commercial reagent RBCs (A1 cells B cells)\nPrinciple: antibody present plasma/serum, bind corresponding antigen reagent RBCs, causing agglutination\nInterpretation (Based Landsteiner’s Rule - confirm Forward Group)\nAgglutination B cells (means anti-B present) = Confirms Group \nAgglutination A1 cells (means anti-present) = Confirms Group B\nagglutination EITHER A1 B cells (neither antibody present) = Confirms Group AB\nAgglutination A1 B cells (antibodies present) = Confirms Group O\n\ntests: Patient’s Plasma Serum presence anti-anti-B antibodiesHow: mix patient’s plasma/serum known commercial reagent RBCs (A1 cells B cells)Principle: antibody present plasma/serum, bind corresponding antigen reagent RBCs, causing agglutinationInterpretation (Based Landsteiner’s Rule - confirm Forward Group)\nAgglutination B cells (means anti-B present) = Confirms Group \nAgglutination A1 cells (means anti-present) = Confirms Group B\nagglutination EITHER A1 B cells (neither antibody present) = Confirms Group AB\nAgglutination A1 B cells (antibodies present) = Confirms Group O\nAgglutination B cells (means anti-B present) = Confirms Group AAgglutination A1 cells (means anti-present) = Confirms Group BNO agglutination EITHER A1 B cells (neither antibody present) = Confirms Group ABAgglutination A1 B cells (antibodies present) = Confirms Group OThe Crucial Check: results forward reverse grouping MUST concordant (match). don’t match, ABO discrepancy, needs investigated resolved final blood type can reported blood components issued","code":""},{"path":"blood-grouping.html","id":"the-rh-blood-group-system-focus-on-rhd","chapter":"Blood Grouping","heading":"The Rh Blood Group System (Focus on Rh(D))","text":"Rh system much complex ABO (lots antigens!), clinically significant antigen far D antigen. ’s highly immunogenic, meaning exposure can easily stimulate antibody production (anti-D) individuals lack itAntigen: D antigen protein found RBC surfaceAntibodies: Unlike ABO, anti-D antibodies generally naturally occurring. typically “immune” antibodies, formed exposure D antigen pregnancy (Rh(D)-negative mother carrying Rh(D)-positive fetus) transfusion (Rh(D)-negative recipient receiving Rh(D)-positive blood). Anti-D usually IgG","code":""},{"path":"blood-grouping.html","id":"how-do-we-test-for-rhd","chapter":"Blood Grouping","heading":"How do we test for Rh(D)?","text":"Rh(D) Typing (Cell Typing)\ntests: Patient’s RBCs presence D antigen\n: mix patient’s RBCs known commercial reagent anti-D\nControl: control test run concurrently. ensures positive reaction anti-D isn’t due spontaneous agglutination factors. type control depends anti-D reagent used (e.g., Rh control reagent, using reagent diluent)\nPrinciple: D antigen present, anti-D bind, causing agglutination\nInterpretation\nAgglutination Anti-D (negative control) = Rh(D) Positive\nagglutination Anti-D (negative control) = Rh(D) Negative (least initially - see Weak D)\n\ntests: Patient’s RBCs presence D antigenHow: mix patient’s RBCs known commercial reagent anti-DControl: control test run concurrently. ensures positive reaction anti-D isn’t due spontaneous agglutination factors. type control depends anti-D reagent used (e.g., Rh control reagent, using reagent diluent)Principle: D antigen present, anti-D bind, causing agglutinationInterpretation\nAgglutination Anti-D (negative control) = Rh(D) Positive\nagglutination Anti-D (negative control) = Rh(D) Negative (least initially - see Weak D)\nAgglutination Anti-D (negative control) = Rh(D) PositiveNO agglutination Anti-D (negative control) = Rh(D) Negative (least initially - see Weak D)Weak D Testing\n: individuals weaker expression D antigen (fewer D antigen sites altered forms antigen). used called Du\ntest : ’s important individuals can sometimes make anti-D exposed “normal” D-positive cells, importantly, RBCs can immunize Rh(D)-negative recipient\ngets tested: Primarily blood donors initially type Rh(D) negative. ensures blood labeled correctly (Rh(D) Positive Weak D detected) prevent immunizing Rh(D)-negative recipients. Testing policies recipients vary, often Weak D testing isn’t routinely performed (usually transfused Rh(D) negative type negative initially). Weak D testing also often done newborns\n: initial Rh(D) test negative, test incubated 37°C converted Indirect Antiglobulin Test (IAT) adding Anti-Human Globulin (AHG)\nInterpretation\nAgglutination adding AHG = Weak D Positive (Reported Rh(D) Positive)\nagglutination adding AHG = Rh(D) Negative\n\n: individuals weaker expression D antigen (fewer D antigen sites altered forms antigen). used called DuWhy test : ’s important individuals can sometimes make anti-D exposed “normal” D-positive cells, importantly, RBCs can immunize Rh(D)-negative recipientWho gets tested: Primarily blood donors initially type Rh(D) negative. ensures blood labeled correctly (Rh(D) Positive Weak D detected) prevent immunizing Rh(D)-negative recipients. Testing policies recipients vary, often Weak D testing isn’t routinely performed (usually transfused Rh(D) negative type negative initially). Weak D testing also often done newbornsHow: initial Rh(D) test negative, test incubated 37°C converted Indirect Antiglobulin Test (IAT) adding Anti-Human Globulin (AHG)Interpretation\nAgglutination adding AHG = Weak D Positive (Reported Rh(D) Positive)\nagglutination adding AHG = Rh(D) Negative\nAgglutination adding AHG = Weak D Positive (Reported Rh(D) Positive)agglutination adding AHG = Rh(D) NegativeMethodologies traditional tube testing still common, many labs now use gel/column agglutination technology solid-phase methods, can semi-automated fully automated. Molecular genotyping can also determine ABO Rh types, especially complex cases, serology remains primary routine method","code":""},{"path":"blood-grouping.html","id":"key-terms-72","chapter":"Blood Grouping","heading":"Key Terms","text":"Antigen: molecule (usually protein carbohydrate) located surface red blood cells can elicit immune response. ABO grouping, B antigens; Rh, important D antigenAntibody: protein (immunoglobulin) found plasma serum produced immune system response antigen. ABO grouping, Anti-Anti-B; Anti-D key antibody Rh systemAgglutination: visible clumping red blood cells occurs antibodies bind corresponding antigens adjacent cells, forming lattice structure. endpoint reaction look many tube slide testsForward Grouping (Cell Typing): part ABO testing patient red blood cells tested known commercial Anti-Anti-B reagents determine ABO antigens presentReverse Grouping (Serum/Plasma Typing): part ABO testing patient plasma serum tested known commercial A1 B reagent red blood cells detect expected ABO antibodies (Anti-, Anti-B)Landsteiner’s Rule: fundamental principle ABO grouping stating healthy individuals possess ABO antibodies plasma directed ABO antigens lacking red blood cells. (e.g., Group person Anti-B)ABO Discrepancy: inconsistency disagreement results obtained forward grouping reverse grouping, requiring resolution blood type can finalizedRh(D) Positive: Indicates presence D antigen individual’s red blood cells, detected testing Anti-D reagentRh(D) Negative: Indicates absence D antigen individual’s red blood cells, detected testing Anti-D reagent (may require Weak D testing confirmation, especially donors)Weak D (formerly Du): phenotype D antigen expressed weakly fewer numbers red blood cell surface, often requiring indirect antiglobulin test (IAT) phase detection. Individuals Weak D phenotype typically considered Rh(D) positive, especially donation purposes","code":""},{"path":"compatibility.html","id":"compatibility","chapter":"Compatibility","heading":"Compatibility","text":"Two absolutely critical steps ensuring safe transfusions: Antibody Screen (Detection) Crossmatch. Think partners crime prevention – crime hemolytic transfusion reaction! work together distinct jobsThink like : antibody screen checks patient known “allergies” (antibodies) common blood ingredients (antigens). crossmatch checks specific bag blood contains ingredient patient allergic . essential safety checks!","code":""},{"path":"compatibility.html","id":"compatibility-testing-the-dynamic-duo","chapter":"Compatibility","heading":"Compatibility Testing: The Dynamic Duo","text":"overall goal ensure blood component give patient won’t cause harm. Antibody detection crossmatching key serologic tests use red blood cell transfusions establishing correct ABO/Rh type","code":""},{"path":"compatibility.html","id":"antibody-detection-the-antibody-screen","chapter":"Compatibility","heading":"Antibody Detection (The Antibody Screen)","text":"Goal: Reconnaissance Mission\ntest initial search party, sent scout patient’s plasma serum “unexpected” red blood cell antibodies\n’re looking clinically significant antibodies (usually IgG, reactive 37°C) common red cell antigens expected anti-anti-B. Examples include anti-D, anti-K, anti-Fya, anti-Jka, etc\n?: antibodies, present, destroy transfused red cells possessing corresponding antigen, causing transfusion reaction, cause Hemolytic Disease Fetus Newborn (HDFN) pregnancy\ntest initial search party, sent scout patient’s plasma serum “unexpected” red blood cell antibodiesWe’re looking clinically significant antibodies (usually IgG, reactive 37°C) common red cell antigens expected anti-anti-B. Examples include anti-D, anti-K, anti-Fya, anti-Jka, etcWhy?: antibodies, present, destroy transfused red cells possessing corresponding antigen, causing transfusion reaction, cause Hemolytic Disease Fetus Newborn (HDFN) pregnancyHow Works (Generally)\nuse Indirect Antiglobulin Test (IAT) principle\nPatient’s Plasma/Serum + Commercial Screening Cells (Group O cells known, wide range antigens) –> Incubate 37°C –> Wash –> Add Anti-Human Globulin (AHG) –> Centrifuge & Read\npositive result (agglutination/hemolysis) means ’ve detected something\nuse Indirect Antiglobulin Test (IAT) principlePatient’s Plasma/Serum + Commercial Screening Cells (Group O cells known, wide range antigens) –> Incubate 37°C –> Wash –> Add Anti-Human Globulin (AHG) –> Centrifuge & ReadA positive result (agglutination/hemolysis) means ’ve detected somethingSignificance\nNegative Screen: Great! suggests detectable common, clinically significant antibodies present. often allows streamlined crossmatch (like electronic)\nPositive Screen: Alert! unexpected antibody likely present. MUST perform Antibody Identification (using panel reagent cells) figure exactly antibody(ies) can select appropriate (antigen-negative) donor blood\nNegative Screen: Great! suggests detectable common, clinically significant antibodies present. often allows streamlined crossmatch (like electronic)Positive Screen: Alert! unexpected antibody likely present. MUST perform Antibody Identification (using panel reagent cells) figure exactly antibody(ies) can select appropriate (antigen-negative) donor blood","code":""},{"path":"compatibility.html","id":"the-crossmatch","chapter":"Compatibility","heading":"The Crossmatch","text":"Goal: Final Compatibility Checkpoint\ndirect test patient potential donor unit. ’s last chance catch incompatibility blood goes patient\nserves two main purposes:\nFinal ABO verification Catches potentially catastrophic ABO errors (e.g., wrong unit selected)\nDetects patient antibodies antigens specific donor cells crucial patient antibody (even one missed screen, like one low-frequency antigen) reacts chosen donor unit\n\ndirect test patient potential donor unit. ’s last chance catch incompatibility blood goes patientIt serves two main purposes:\nFinal ABO verification Catches potentially catastrophic ABO errors (e.g., wrong unit selected)\nDetects patient antibodies antigens specific donor cells crucial patient antibody (even one missed screen, like one low-frequency antigen) reacts chosen donor unit\nFinal ABO verification Catches potentially catastrophic ABO errors (e.g., wrong unit selected)Detects patient antibodies antigens specific donor cells crucial patient antibody (even one missed screen, like one low-frequency antigen) reacts chosen donor unitHow Works (Types)\nmix Patient’s Plasma/Serum + Red Cells specific Donor Unit segment.\nImmediate Spin () Crossmatch: Quick check primarily ABO incompatibility. Often sufficient antibody screen negative ’s history antibodies\nAntiglobulin (AHG) Crossmatch: Full IAT procedure (Incubate 37°C, Wash, AHG). Required patient clinically significant antibody (current historical) ensure selected antigen-negative unit truly compatible, crossmatch incompatible\nElectronic (Computer) Crossmatch: Uses validated computer system confirm ABO/Rh compatibility instead serologic testing. Strict criteria must met (negative screen, two concordant ABO/Rh types file, history antibodies, etc.). ’s fast efficient relies heavily accurate data system integrity\nmix Patient’s Plasma/Serum + Red Cells specific Donor Unit segment.Immediate Spin () Crossmatch: Quick check primarily ABO incompatibility. Often sufficient antibody screen negative ’s history antibodiesAntiglobulin (AHG) Crossmatch: Full IAT procedure (Incubate 37°C, Wash, AHG). Required patient clinically significant antibody (current historical) ensure selected antigen-negative unit truly compatible, crossmatch incompatibleElectronic (Computer) Crossmatch: Uses validated computer system confirm ABO/Rh compatibility instead serologic testing. Strict criteria must met (negative screen, two concordant ABO/Rh types file, history antibodies, etc.). ’s fast efficient relies heavily accurate data system integritySignificance\nCompatible Crossmatch: reaction observed (serologically) authorized (electronically). unit deemed safe transfuse immunologic perspective. Green light!\nIncompatible Crossmatch: Reaction observed (agglutination/hemolysis). STOP! Transfuse. unit safe patient. Investigate cause (ABO error? Antibody reacting donor antigen?). Red light!\nCompatible Crossmatch: reaction observed (serologically) authorized (electronically). unit deemed safe transfuse immunologic perspective. Green light!Incompatible Crossmatch: Reaction observed (agglutination/hemolysis). STOP! Transfuse. unit safe patient. Investigate cause (ABO error? Antibody reacting donor antigen?). Red light!","code":""},{"path":"compatibility.html","id":"the-relationship-screen-first-then-crossmatch","chapter":"Compatibility","heading":"The Relationship: Screen First, then Crossmatch","text":"Antibody Screen general search using representative cellsThe Crossmatch specific test actual unit intended transfusionThe results Antibody Screen heavily influence type Crossmatch performed. negative screen often allows electronic crossmatch, positive screen mandates finding antibody’s identity performing AHG crossmatch antigen-negative units","code":""},{"path":"antibody-detection.html","id":"antibody-detection","chapter":"Antibody Detection","heading":"Antibody Detection","text":"blood transfusion, ’s crucial look ‘unexpected’ trouble-makers patient’s plasma: red blood cell antibodies beyond naturally occurring anti-anti-B. Antibody Screen routine search, designed detect clinically significant antibodies potentially cause harmful transfusion reactions Hemolytic Disease Fetus Newborn. Identifying antibodies transfusion key safety step, allowing us select compatible, antigen-negative blood patient","code":""},{"path":"antibody-detection.html","id":"purpose-why-do-we-screen-for-antibodies","chapter":"Antibody Detection","heading":"Purpose: Why Do We Screen for Antibodies?","text":"primary goal antibody screen detect presence clinically significant, unexpected red blood cell antibodies patient’s plasma serumWhat “Unexpected” Antibodies?: antibodies naturally occurring anti-anti-B expect based ABO type. Examples include antibodies antigens Rh system (like anti-D, anti-E, anti-c), Kell system (anti-K), Duffy system (anti-Fya), Kidd system (anti-Jka), MNS system (anti-S, anti-s), etcWhy “Clinically Significant”?: ’re primarily looking antibodies (usually IgG) can:\nCause hemolytic transfusion reactions (HTRs) destroying transfused red blood cells possessing corresponding antigen\nCause Hemolytic Disease Fetus Newborn (HDFN) pregnant person antibody antigen fetus inherited father\nCause hemolytic transfusion reactions (HTRs) destroying transfused red blood cells possessing corresponding antigenCause Hemolytic Disease Fetus Newborn (HDFN) pregnant person antibody antigen fetus inherited fatherGoal: detect antibody, must identify select donor red blood cells LACK corresponding antigen transfusion prevent reaction","code":""},{"path":"antibody-detection.html","id":"when-is-antibody-detection-performed","chapter":"Antibody Detection","heading":"When is Antibody Detection Performed?","text":"Pretransfusion Testing: Essential patient might receive red blood cell transfusionPrenatal Testing: Routinely performed pregnant individuals identify antibodies potentially harm fetus (HDFN risk)Donor Blood Testing: always screening antibodies, donor centers perform tests ensure safetyTransfusion Reaction Workup: help determine unexpected antibody played role adverse reaction","code":""},{"path":"antibody-detection.html","id":"the-core-method-indirect-antiglobulin-test-iat","chapter":"Antibody Detection","heading":"The Core Method: Indirect Antiglobulin Test (IAT)","text":"antibody screen typically employs Indirect Antiglobulin Test (IAT). “indirect” part means ’re looking antibody vitro (test tube/system) seeing react reagent red cells","code":""},{"path":"antibody-detection.html","id":"components","chapter":"Antibody Detection","heading":"Components","text":"Patient Sample: Plasma Serum (potential antibody resides)Reagent Red Blood Cells (“Screening Cells”): commercially prepared Group O red blood cells\nGroup O?: avoid reactions patient’s naturally occurring anti-anti-B\nKnown Antigen Profile: cells come donors phenotyped wide array common, clinically significant antigens (D, C, E, c, e, K, k, Fya, Fyb, Jka, Jkb, Lea, Leb, M, N, S, s, P1, etc.)\nSets: Usually provided sets 2 3 different cell vials. Using multiple vials increases chances detecting antibodies combination cells covers antigen variations (e.g., homozygous vs. heterozygous expression)\nGroup O?: avoid reactions patient’s naturally occurring anti-anti-BKnown Antigen Profile: cells come donors phenotyped wide array common, clinically significant antigens (D, C, E, c, e, K, k, Fya, Fyb, Jka, Jkb, Lea, Leb, M, N, S, s, P1, etc.)Sets: Usually provided sets 2 3 different cell vials. Using multiple vials increases chances detecting antibodies combination cells covers antigen variations (e.g., homozygous vs. heterozygous expression)","code":""},{"path":"antibody-detection.html","id":"basic-iat-procedure-tube-method-example","chapter":"Antibody Detection","heading":"Basic IAT Procedure (Tube Method Example)","text":"Mix & Incubate Patient plasma/serum mixed screening cells\nEnhancement Media (Optional Common): Reagents like LISS (Low Ionic Strength Saline) PEG (Polyethylene Glycol) often added. reduce incubation time /enhance sensitivity promoting antibody uptake onto RBCs\nTemperature: Incubated 37°C (body temperature). optimal detecting clinically significant IgG antibodies\nSensitization: patient’s plasma contains antibody corresponding antigen screening cells, antibody bind cells incubation. coating invisible stage\nEnhancement Media (Optional Common): Reagents like LISS (Low Ionic Strength Saline) PEG (Polyethylene Glycol) often added. reduce incubation time /enhance sensitivity promoting antibody uptake onto RBCsTemperature: Incubated 37°C (body temperature). optimal detecting clinically significant IgG antibodiesSensitization: patient’s plasma contains antibody corresponding antigen screening cells, antibody bind cells incubation. coating invisible stageWashing CRITICAL step. cells washed thoroughly (usually 3-4 times) saline\nPurpose: remove unbound patient plasma proteins, especially unbound immunoglobulins. left behind, unbound antibodies neutralize AHG reagent added next step, leading false-negative result\nPurpose: remove unbound patient plasma proteins, especially unbound immunoglobulins. left behind, unbound antibodies neutralize AHG reagent added next step, leading false-negative resultAdd Anti-Human Globulin (AHG) AHG reagent (also called Coombs’ serum) added. reagent contains antibodies human immunoglobulins (anti-IgG) /complement components (anti-C3d)Centrifuge & Read tube centrifuged facilitate agglutination\nMechanism: screening cells coated IgG incubation (sensitization), anti-IgG AHG reagent bind Fc portion attached antibodies, forming bridges adjacent red blood cells\nObservation: bridging results visible agglutination (clumping) , less commonly, hemolysis (red cell lysis, often complement-mediated), either indicates positive reaction\nMechanism: screening cells coated IgG incubation (sensitization), anti-IgG AHG reagent bind Fc portion attached antibodies, forming bridges adjacent red blood cellsObservation: bridging results visible agglutination (clumping) , less commonly, hemolysis (red cell lysis, often complement-mediated), either indicates positive reactionAdd Check Cells (Coombs’ Control Cells) IgG-coated red blood cells. added negative AHG tests\nPurpose: validate negative result. check cells MUST agglutinate\nValidation: agglutinate, confirms active AHG reagent added washing step adequate (otherwise, AHG neutralized). check cells fail agglutinate, test invalid must repeated\nPurpose: validate negative result. check cells MUST agglutinateValidation: agglutinate, confirms active AHG reagent added washing step adequate (otherwise, AHG neutralized). check cells fail agglutinate, test invalid must repeated","code":""},{"path":"antibody-detection.html","id":"interpretation","chapter":"Antibody Detection","heading":"Interpretation","text":"Positive Screen: Agglutination hemolysis observed screening cells (phase testing, applicable, especially AHG phase)\nAction: Indicates presence one unexpected antibodies. next step Antibody Identification (using panel reagent RBCs detailed antigen profiles) determine specificity (e.g., anti-K? anti-Fya?)\nAction: Indicates presence one unexpected antibodies. next step Antibody Identification (using panel reagent RBCs detailed antigen profiles) determine specificity (e.g., anti-K? anti-Fya?)Negative Screen: agglutination hemolysis observed screening cell, check cells give appropriate positive reaction\nAction: Suggests detectable clinically significant antibodies present common antigens screening cells. patient needs blood, ABO/Rh compatible units can typically crossmatched (usually via immediate spin computer crossmatch)\nAction: Suggests detectable clinically significant antibodies present common antigens screening cells. patient needs blood, ABO/Rh compatible units can typically crossmatched (usually via immediate spin computer crossmatch)","code":""},{"path":"antibody-detection.html","id":"modern-methodologies","chapter":"Antibody Detection","heading":"Modern Methodologies","text":"tube testing classic method, many labs use:Column Agglutination Technology (Gel Test™): Uses microtubes containing gel beads pre-dispensed AHG. Patient plasma screening cells added. centrifugation, unagglutinated cells pass gel bottom, agglutinated cells trapped within gel matrix various levels depending reaction strength. Easy read standardizeSolid Phase Red Cell Adherence (SPRCA): Uses microtiter plates wells coated either reagent RBC membranes (capture antibodies patient plasma) anti-IgG (capture antibody-coated patient RBCs - DAT). Indicator cells added, adherence patterns centrifugation determine result. Highly automatable","code":""},{"path":"antibody-detection.html","id":"key-takeaways-clinical-significance","chapter":"Antibody Detection","heading":"Key Takeaways & Clinical Significance","text":"antibody screen safety net detect potentially harmful red cell antibodies transfusionIt primarily uses Indirect Antiglobulin Test (IAT) principle detect IgG antibodies reactive 37°CScreening cells carefully selected Group O cells known antigen profilesA positive screen necessitates antibody identification selection antigen-negative donor bloodA negative screen (valid controls) generally indicates ’s safe proceed ABO/Rh compatible crossmatchingProper technique (especially washing!) controls (check cells) crucial accurate results","code":""},{"path":"antibody-detection.html","id":"key-terms-73","chapter":"Antibody Detection","heading":"Key Terms","text":"Antibody Screen (Antibody Detection Test): routine laboratory test performed patient plasma serum detect presence unexpected, clinically significant red blood cell alloantibodiesUnexpected Antibody: red blood cell antibody present patient’s plasma/serum naturally occurring (“expected”) anti-/anti-B consistent ABO typeClinically Significant Antibody: red blood cell antibody capable causing adverse vivo events, decreased red cell survival (hemolytic transfusion reaction) Hemolytic Disease Fetus Newborn (HDFN). typically IgG antibodies reactive 37°CIndirect Antiglobulin Test (IAT): laboratory method used antibody screening (identification/crossmatching) detect vitro sensitization. involves incubating patient plasma/serum reagent red cells, washing away unbound antibodies, adding Anti-Human Globulin (AHG) detect bound IgG complementScreening Cells: Commercially prepared Group O reagent red blood cells known phenotypes wide array common, clinically significant antigens. used antibody screen test react potential antibodies patient’s plasma/serumAnti-Human Globulin (AHG) Reagent (Coombs’ Serum): reagent containing antibodies bind human immunoglobulins (anti-IgG) /complement components (anti-C3d) may coating red blood cells. acts bridge cause visible agglutination sensitized cellsSensitization: process antibodies (/complement) present plasma/serum bind corresponding antigens red blood cell surface. coating step occurs incubation vitro (IAT) vivo (DAT)Enhancement Media: Solutions (like LISS PEG) added incubation phase antibody detection tests promote speed sensitization process (antibody binding red cell antigens)Check Cells (Coombs’ Control Cells): IgG-coated reagent red blood cells added negative AHG tests. Agglutination check cells confirms AHG reagent active added correctly, validating negative test resultAlloantibody: antibody produced following exposure foreign red blood cell antigens (present individual’s cells), typically transfusion pregnancy. antibody screen designed primarily detect ","code":""},{"path":"crossmatch.html","id":"crossmatch","chapter":"Crossmatch","heading":"Crossmatch","text":"Think Crossmatch final, crucial compatibility checkpoint blood goes bag patient. Even ’ve determined ABO/Rh type screened unexpected antibodies, crossmatch provides extra layer safetyIts primary purpose simple vital: prevent transfusion reaction detecting potential incompatibilities patient’s plasma/serum specific donor red blood cells selected transfusion.","code":""},{"path":"crossmatch.html","id":"the-goal-what-are-we-trying-to-achieve","chapter":"Crossmatch","heading":"The Goal: What Are We Trying to Achieve?","text":"Final ABO Compatibility Check: ’s ultimate verification donor unit selected ABO compatible patient. incompatible crossmatch often points ABO error somewhere process (sample labeling, testing, unit selection)Detect Clinically Significant Antibodies: aims detect antibodies patient’s plasma/serum react antigens present donor’s red blood cells. especially important :\npatient antibody low-frequency antigen present screening cells used antibody screen\npatient’s antibody screen negative, ’s historical antibody weak antibody still cause issues\npatient antibody low-frequency antigen present screening cells used antibody screenThe patient’s antibody screen negative, ’s historical antibody weak antibody still cause issues","code":""},{"path":"crossmatch.html","id":"key-components","chapter":"Crossmatch","heading":"Key Components","text":"Patient Sample: Plasma Serum (containing potential antibodies). Requirements sample age vary institution patient history (e.g., must ≤3 days old recently transfused pregnant)Donor Red Blood Cells: Taken segment tubing attached actual donor unit selected transfusion. ensures ’re testing exact cells patient receive. cells usually washed prepared 2-5% suspension saline","code":""},{"path":"crossmatch.html","id":"types-of-crossmatches","chapter":"Crossmatch","heading":"Types of Crossmatches","text":"type crossmatch performed depends largely results patient’s antibody screen transfusion/antibody history","code":""},{"path":"crossmatch.html","id":"serologic-crossmatch-involves-physically-mixing-patient-plasmaserum-with-donor-rbcs","chapter":"Crossmatch","heading":"Serologic Crossmatch Involves physically mixing patient plasma/serum with donor RBCs","text":"Immediate Spin () Crossmatch\nUsed: Typically performed patient evidence clinically significant antibodies (current negative antibody screen) history antibodies\nProcedure: Patient plasma/serum mixed donor RBC suspension tube, centrifuged immediately room temperature, observed agglutination hemolysis\nDetects: Primarily detects ABO incompatibility (due naturally occurring IgM antibodies like anti-anti-B reacting room temp). generally detect clinically significant IgG antibodies react best 37°C\nInterpretation: agglutination/hemolysis = Compatible (). Agglutination/hemolysis = Incompatible; TRANSFUSE; investigate immediately\nUsed: Typically performed patient evidence clinically significant antibodies (current negative antibody screen) history antibodiesProcedure: Patient plasma/serum mixed donor RBC suspension tube, centrifuged immediately room temperature, observed agglutination hemolysisWhat Detects: Primarily detects ABO incompatibility (due naturally occurring IgM antibodies like anti-anti-B reacting room temp). generally detect clinically significant IgG antibodies react best 37°CInterpretation: agglutination/hemolysis = Compatible (). Agglutination/hemolysis = Incompatible; TRANSFUSE; investigate immediatelyAntiglobulin (AHG) Crossmatch (“Full” Crossmatch)\nUsed: Required patient current clinically significant antibody, history one, sometimes based institutional policy (e.g., specific patient populations like transplant recipients). Also used investigate incompatible crossmatch\nProcedure: follows steps Indirect Antiglobulin Test (IAT), uses donor RBCs instead screening cells:\n(Optional phase)\nMix patient plasma/serum + donor RBCs (+/- enhancement media like LISS/PEG)\nIncubate 37°C\nWash cells thoroughly (3-4 times)\nAdd Anti-Human Globulin (AHG) reagent\nCentrifuge read agglutination/hemolysis\nAdd Check Cells negative AHG tubes validate result\n\nDetects: Detects ABO incompatibility clinically significant IgG antibodies patient’s plasma react antigens donor cells 37°C/AHG phase\nInterpretation: agglutination/hemolysis = Compatible. Agglutination/hemolysis = Incompatible; TRANSFUSE; donor unit likely possesses antigen corresponding patient’s antibody\nUsed: Required patient current clinically significant antibody, history one, sometimes based institutional policy (e.g., specific patient populations like transplant recipients). Also used investigate incompatible crossmatchProcedure: follows steps Indirect Antiglobulin Test (IAT), uses donor RBCs instead screening cells:\n(Optional phase)\nMix patient plasma/serum + donor RBCs (+/- enhancement media like LISS/PEG)\nIncubate 37°C\nWash cells thoroughly (3-4 times)\nAdd Anti-Human Globulin (AHG) reagent\nCentrifuge read agglutination/hemolysis\nAdd Check Cells negative AHG tubes validate result\n(Optional phase)Mix patient plasma/serum + donor RBCs (+/- enhancement media like LISS/PEG)Incubate 37°CWash cells thoroughly (3-4 times)Add Anti-Human Globulin (AHG) reagentCentrifuge read agglutination/hemolysisAdd Check Cells negative AHG tubes validate resultWhat Detects: Detects ABO incompatibility clinically significant IgG antibodies patient’s plasma react antigens donor cells 37°C/AHG phaseInterpretation: agglutination/hemolysis = Compatible. Agglutination/hemolysis = Incompatible; TRANSFUSE; donor unit likely possesses antigen corresponding patient’s antibody","code":""},{"path":"crossmatch.html","id":"electronic-computer-crossmatch","chapter":"Crossmatch","heading":"Electronic (Computer) Crossmatch","text":"Used: safe alternative serologic crossmatching specific, strict conditions:\nfacility must validated computer system\nCritical patient/donor information must entered accurately (often via barcode scanners)\npatient must TWO identical ABO/Rh typing results file (one current sample, one historical second current sample)\npatient must current NEGATIVE antibody screen\npatient must history clinically significant antibodies\nfacility must validated computer systemCritical patient/donor information must entered accurately (often via barcode scanners)patient must TWO identical ABO/Rh typing results file (one current sample, one historical second current sample)patient must current NEGATIVE antibody screenThe patient must history clinically significant antibodiesProcedure: physical mixing occurs. computer system verifies ABO/Rh compatibility patient’s validated type donor unit’s confirmed type. checks pass, computer authorizes release ABO/Rh compatible unitAdvantages: Significantly faster, reduces reagent/supply usage, less hands-technologist timeLimitations: detect antibodies low-frequency antigens rare ABO incompatibilities missed routine typing. Relies heavily system validation accurate data entry","code":""},{"path":"crossmatch.html","id":"interpretation-summary","chapter":"Crossmatch","heading":"Interpretation Summary","text":"Compatible Crossmatch: agglutination hemolysis observed required phases testing (AHG, depending method) successful electronic crossmatch authorization. Indicates specific donor unit suitable transfusion patient immunologic perspectiveIncompatible Crossmatch: Agglutination hemolysis observed phase serologic testing\nSTOP! TRANSFUSE UNIT.\nInvestigate Cause: ABO incompatibility, alloantibody reacting donor antigen (expected patient known antibody antigen-negative unit wasn’t available/selected, unexpected antibody wasn’t previously detected), autoantibody interference, procedural issues\nSTOP! TRANSFUSE UNIT.Investigate Cause: ABO incompatibility, alloantibody reacting donor antigen (expected patient known antibody antigen-negative unit wasn’t available/selected, unexpected antibody wasn’t previously detected), autoantibody interference, procedural issues","code":""},{"path":"crossmatch.html","id":"important-considerations","chapter":"Crossmatch","heading":"Important Considerations","text":"crossmatch critical safety step doesn’t guarantee 100% prevention transfusion reactions (e.g., allergic reactions, febrile non-hemolytic reactions detected)doesn’t guarantee normal red cell survival patient (factors can affect )doesn’t prevent alloimmunization patient exposed antigen lack (unless antigen-negative units specifically selected based known antibodies)urgent, life-threatening situations, blood may need released crossmatch completion (e.g., Group O, Rh(D)-negative RBCs, type-specific uncrossmatched blood). Documentation completion testing afterward crucial","code":""},{"path":"crossmatch.html","id":"key-terms-74","chapter":"Crossmatch","heading":"Key Terms","text":"Crossmatch: compatibility test performed transfusion mixing recipient’s plasma/serum donor’s red blood cells detect potential immunologic incompatibilityCompatibility Test: series procedures including recipient identification, sample collection/labeling, ABO/Rh typing, antibody screening, crossmatching, designed ensure safest possible transfusionSerologic Crossmatch: crossmatch method involving physical mixing recipient plasma/serum donor red blood cells test tube platform (e.g., gel, solid phase) observe agglutination hemolysisImmediate Spin () Crossmatch: rapid serologic crossmatch phase performed room temperature designed primarily detect ABO incompatibilityAntiglobulin (AHG) Crossmatch (Full Crossmatch): serologic crossmatch includes incubation 37°C antiglobulin (AHG) phase detect clinically significant IgG antibodies reactive donor red blood cellsElectronic (Computer) Crossmatch: computer-assisted process uses validated software confirm ABO/Rh compatibility recipient donor unit, replacing need serologic crossmatch specific, controlled conditionsCompatible: result crossmatch indicating detectable serologic reactivity (agglutination/hemolysis) recipient plasma/serum donor red blood cells, suggesting unit safe transfusion immunologic standpointIncompatible: result crossmatch indicating presence agglutination hemolysis, signifying potential immunologic reaction; unit transfusedDonor Segment: sealed portion tubing attached blood collection bag containing red blood cells representative unit , used crossmatchingAlloimmunization: process individual develops antibodies (alloantibodies) foreign antigens (like transfused red blood cells fetal cells) lack","code":""},{"path":"ab-id-significance.html","id":"ab-id-significance","chapter":"Ab ID & Significance","heading":"Ab ID & Significance","text":"’ve detected unexpected antibody, now need figure exactly – ’s Antibody Identification. just importantly, need understand antibody actually capable causing problems – ’s assessing Clinical Significance. whole process detective work crucial patient safety!Think positive antibody screen alarm bell. Antibody identification figuring alarm went , assessing clinical significance tells us seriously need take alarm","code":""},{"path":"ab-id-significance.html","id":"antibody-identification-unmasking-the-culprit","chapter":"Ab ID & Significance","heading":"Antibody Identification: Unmasking the Culprit","text":"Goal: determine specific antigen(s) targeted unexpected antibody(ies) detected patient’s plasma/serum. anti-K? Anti-Fya? Anti-E? Anti-Jkb? maybe even multiple antibodies?’s Done\nCrucial Safe Transfusion: Knowing antibody specificity allows us select donor red blood cells LACK corresponding antigen. cornerstone preventing hemolytic transfusion reactions (HTRs)\nHDFN Prediction & Management: Identifying antibodies known cause Hemolytic Disease Fetus Newborn (e.g., anti-D, anti-K, anti-c) allows appropriate monitoring management pregnancy\nUnderstanding Incompatibilities: Explains unexpected incompatible crossmatches\nCrucial Safe Transfusion: Knowing antibody specificity allows us select donor red blood cells LACK corresponding antigen. cornerstone preventing hemolytic transfusion reactions (HTRs)HDFN Prediction & Management: Identifying antibodies known cause Hemolytic Disease Fetus Newborn (e.g., anti-D, anti-K, anti-c) allows appropriate monitoring management pregnancyUnderstanding Incompatibilities: Explains unexpected incompatible crossmatches","code":""},{"path":"ab-id-significance.html","id":"how-its-done-the-antibody-panel","chapter":"Ab ID & Significance","heading":"How It’s Done: The Antibody Panel","text":"Main Tool: Antibody Identification Panel: Similar screening cells, larger set (usually 11-20 vials) Group O reagent red blood cells. vial comes different donor unique extensively typed antigen profile, detailed accompanying sheet called antigramThe Method: Usually Indirect Antiglobulin Test (IAT)\nPatient plasma/serum mixed cells vial panel\nTesting often includes different phases enhancements (e.g., LISS PEG incubation 37°C, followed AHG phase). Reactions (agglutination hemolysis) strength (0 4+) recorded panel cell phase\nAutocontrol vital part panel testing patient’s plasma/serum red blood cells\nNegative Autocontrol: Usually points towards alloantibody (antibody formed foreign antigen transfusion pregnancy)\nPositive Autocontrol: Suggests autoantibody (reacting self-antigens) perhaps antibodies reacting recently transfused donor cells still circulating patient. complicates picture!\n\nPatient plasma/serum mixed cells vial panelTesting often includes different phases enhancements (e.g., LISS PEG incubation 37°C, followed AHG phase). Reactions (agglutination hemolysis) strength (0 4+) recorded panel cell phaseAutocontrol vital part panel testing patient’s plasma/serum red blood cells\nNegative Autocontrol: Usually points towards alloantibody (antibody formed foreign antigen transfusion pregnancy)\nPositive Autocontrol: Suggests autoantibody (reacting self-antigens) perhaps antibodies reacting recently transfused donor cells still circulating patient. complicates picture!\nNegative Autocontrol: Usually points towards alloantibody (antibody formed foreign antigen transfusion pregnancy)Positive Autocontrol: Suggests autoantibody (reacting self-antigens) perhaps antibodies reacting recently transfused donor cells still circulating patient. complicates picture!","code":""},{"path":"ab-id-significance.html","id":"interpreting-the-panel-pattern-recognition","chapter":"Ab ID & Significance","heading":"Interpreting the Panel: Pattern Recognition","text":"“Rule-” Method: key!\nLook panel cells react (result = 0) patient’s plasma\nnon-reactive cell, look antigens possesses. cell negative (0 reaction) positive certain antigen (especially homozygous, e.g., Fy(+b-)), patient’s antibody likely directed antigen. can “rule ” cross antigen specificity\nSystematically non-reactive cells across panel\nLook panel cells react (result = 0) patient’s plasmaFor non-reactive cell, look antigens possesses. cell negative (0 reaction) positive certain antigen (especially homozygous, e.g., Fy(+b-)), patient’s antibody likely directed antigen. can “rule ” cross antigen specificitySystematically non-reactive cells across panelMatching Pattern\nruling many specificities possible, look antigens remain\nExamine pattern positive reactions. patient’s plasma react () panel cells positive one remaining antigens?\npatient’s plasma react cells negative antigen?\npattern reactivity perfectly matches presence/absence single antigen across panel, likely identified antibody\nruling many specificities possible, look antigens remainExamine pattern positive reactions. patient’s plasma react () panel cells positive one remaining antigens?patient’s plasma react cells negative antigen?pattern reactivity perfectly matches presence/absence single antigen across panel, likely identified antibodyConfirmation: Need statistical confidence. Often requires seeing pattern hold true across enough informative cells (e.g., “rule three”: least 3 cells positive antigen react, least 3 cells negative antigen react). Sometimes selected cells (additional reagent cells specific antigen combinations) needed confirm separate multiple antibodiesConsidering Phase & Strength: IgG antibodies typically react 37°C/AHG phase. IgM often react stronger room temp/. Reaction strength can give clues (e.g., dosage – antibodies react stronger cells donors homozygous antigen, like Jk(+b-), versus heterozygous, like Jk(+b+))","code":""},{"path":"ab-id-significance.html","id":"dealing-with-complexities","chapter":"Ab ID & Significance","heading":"Dealing with Complexities","text":"Multiple Antibodies: plasma reacts pattern doesn’t fit single specificity. Requires careful rule-outs, potentially using techniques like enzyme treatment (destroys antigens like Fya, Fyb, M, N; enhances others like Rh, Kidd, Lewis) adsorption/elutionAutoantibodies: positive autocontrol muddies water. Techniques like adsorption (using patient cells cells pull autoantibody plasma) may needed see clinically significant alloantibodies hiding underneath. Elution (removing bound antibody patient’s red cells) can help identify autoantibody antibodies coating transfused cellsAntibodies High-Frequency Antigens (HFAs): Plasma reacts panel cells (often autocontrol negative). Requires testing rare cells lacking HFAsAntibodies Low-Frequency Antigens (LFAs): Antibody screen might negative, crossmatch specific unit incompatible. Identification can tricky","code":""},{"path":"ab-id-significance.html","id":"clinical-significance-does-this-antibody-matter","chapter":"Ab ID & Significance","heading":"Clinical Significance: Does This Antibody Matter?","text":"Just identified antibody doesn’t automatically mean cause harm. need assess potential cause problems vivoWhat Makes Antibody Clinically Significant?: ability cause:\nDecreased Red Cell Survival: Leading Hemolytic Transfusion Reactions (HTRs), can range mild delayed reactions life-threatening acute intravascular hemolysis\nHemolytic Disease Fetus Newborn (HDFN): maternal IgG antibodies cross placenta destroy fetal red blood cells\nDecreased Red Cell Survival: Leading Hemolytic Transfusion Reactions (HTRs), can range mild delayed reactions life-threatening acute intravascular hemolysisHemolytic Disease Fetus Newborn (HDFN): maternal IgG antibodies cross placenta destroy fetal red blood cellsFactors Determining Significance\nImmunoglobulin Class\nIgG: clinically significant antibodies IgG (especially subclasses IgG1 IgG3) react optimally body temperature (37°C), can cross placenta (causing HDFN), can effectively activate complement cleared macrophages\nIgM: Usually react best colder temperatures. considered clinically insignificant unless react strongly 37°C activate complement efficiently (e.g., ABO antibodies IgM highly significant!). Examples often considered insignificant include anti-M (unless reactive 37°C), anti-N, anti-P1, anti-Lea, anti-Leb\n\nThermal Amplitude: antibody react 37°C? Antibodies reactive 30°C generally significant transfusion unless high titer activate complement well (causing hemolysis vitro)\nProven Track Record: antibody specificity implicated causing HTRs HDFN ? notorious reputations!\nGenerally Significant: ABO, Rh (D, C, E, c, e), Kell (K, k), Duffy (Fya, Fyb), Kidd (Jka, Jkb), Ss\nGenerally Insignificant (usually): Lewis (Lea, Leb), P1, M (), N, Lua\nVariable: antibodies can hit miss\n\nImmunoglobulin Class\nIgG: clinically significant antibodies IgG (especially subclasses IgG1 IgG3) react optimally body temperature (37°C), can cross placenta (causing HDFN), can effectively activate complement cleared macrophages\nIgM: Usually react best colder temperatures. considered clinically insignificant unless react strongly 37°C activate complement efficiently (e.g., ABO antibodies IgM highly significant!). Examples often considered insignificant include anti-M (unless reactive 37°C), anti-N, anti-P1, anti-Lea, anti-Leb\nIgG: clinically significant antibodies IgG (especially subclasses IgG1 IgG3) react optimally body temperature (37°C), can cross placenta (causing HDFN), can effectively activate complement cleared macrophagesIgM: Usually react best colder temperatures. considered clinically insignificant unless react strongly 37°C activate complement efficiently (e.g., ABO antibodies IgM highly significant!). Examples often considered insignificant include anti-M (unless reactive 37°C), anti-N, anti-P1, anti-Lea, anti-LebThermal Amplitude: antibody react 37°C? Antibodies reactive 30°C generally significant transfusion unless high titer activate complement well (causing hemolysis vitro)Proven Track Record: antibody specificity implicated causing HTRs HDFN ? notorious reputations!\nGenerally Significant: ABO, Rh (D, C, E, c, e), Kell (K, k), Duffy (Fya, Fyb), Kidd (Jka, Jkb), Ss\nGenerally Insignificant (usually): Lewis (Lea, Leb), P1, M (), N, Lua\nVariable: antibodies can hit miss\nGenerally Significant: ABO, Rh (D, C, E, c, e), Kell (K, k), Duffy (Fya, Fyb), Kidd (Jka, Jkb), SsGenerally Insignificant (usually): Lewis (Lea, Leb), P1, M (), N, LuaVariable: antibodies can hit missAction Based Significance\nSignificant Antibody Identified: MUST provide antigen-negative red blood cell units transfusion. pregnant patients, requires careful monitoring HDFN\nInsignificant Antibody Identified: Usually, antigen-negative units required, though ’s good practice document antibody. Crossmatch compatible blood (electronic criteria met) typically sufficient. However, lab policies may vary\nSignificant Antibody Identified: MUST provide antigen-negative red blood cell units transfusion. pregnant patients, requires careful monitoring HDFNInsignificant Antibody Identified: Usually, antigen-negative units required, though ’s good practice document antibody. Crossmatch compatible blood (electronic criteria met) typically sufficient. However, lab policies may vary","code":""},{"path":"ab-id-significance.html","id":"key-terms-75","chapter":"Ab ID & Significance","heading":"Key Terms","text":"Antibody Identification: laboratory process determining specific red blood cell antigen(s) targeted unexpected antibody detected patient’s plasma/serumAntibody Panel: set 11-20 commercially prepared Group O reagent red blood cells, unique extensively documented antigen profile (antigram), used antibody identificationAntigram: chart accompanying antibody panel screening cell set, detailing specific antigen phenotype reagent red blood cell vialRule-Method: systematic process used antibody panel interpretation antigen specificities eliminated consideration based lack reactivity patient plasma panel cells possessing antigensMatching Pattern: process comparing pattern positive negative reactions observed patient plasma panel cells antigen profiles antigram pinpoint antibody specificityAutocontrol (AC): test performed concurrently antibody panel patient’s plasma/serum tested red blood cells. Helps differentiate alloantibodies autoantibodiesAlloantibody: antibody produced foreign red blood cell antigen encountered transfusion pregnancy. Usually associated negative autocontrolAutoantibody: antibody directed individual’s red blood cell antigens. Usually associated positive autocontrol may complicate alloantibody identificationDosage Effect: phenomenon antibody reacts strongly red blood cells expressing double dose (homozygous) antigen compared cells expressing single dose (heterozygous). Common Rh, Duffy, Kidd, MNS system antibodiesSelected Cells: Additional reagent red blood cells specific antigen combinations chosen help confirm antibody’s specificity differentiate multiple antibodiesClinical Significance: likelihood specific red blood cell antibody cause vivo harm, hemolytic transfusion reaction Hemolytic Disease Fetus Newborn. Determined factors like immunoglobulin class, thermal reactivity, historical evidenceAntigen-Negative Blood: Donor blood units lacking specific red blood cell antigen corresponding patient’s clinically significant alloantibody. Required safe transfusion casesEnzyme Treatment: Using proteolytic enzymes (e.g., ficin, papain) treat reagent red blood cells, enhances reactivity antibodies (Rh, Kidd, Lewis) destroying antigens targeted others (MNS, Duffy), aiding antibody identificationAdsorption: technique used remove antibodies plasma/serum incubating red blood cells possessing corresponding antigen(s). Often used remove autoantibodies detect underlying alloantibodiesElution: process used recover antibodies bound red blood cells (vivo vitro). recovered antibody solution (eluate) can tested determine specificity","code":""},{"path":"dat.html","id":"dat","chapter":"DAT","heading":"DAT","text":"Direct Antiglobulin Test often called DAT sometimes Direct Coombs test. fundamental test blood bank, understanding helps us figure something going wrong red blood cells inside patient’s bodyThink way: Antibody Screen Crossmatch (using Indirect Antiglobulin Test - IAT) look antibodies floating around plasma attach red cells. DAT, however, asks different question: “patient’s red blood cells already coated antibodies complement proteins right now, circulating bloodstream?”","code":""},{"path":"dat.html","id":"the-core-purpose-detecting-in-vivo-sensitization","chapter":"DAT","heading":"The Core Purpose: Detecting In Vivo Sensitization","text":"primary goal DAT detect red blood cells (RBCs) sensitized vivoIn Vivo: Means “within living body” – coating happened inside patient’s circulationSensitized: Means RBCs coated immunoglobulins (primarily IgG) /complement components (often C3d detect)","code":""},{"path":"dat.html","id":"why-would-we-perform-a-dat-clinical-indications","chapter":"DAT","heading":"Why Would We Perform a DAT? (Clinical Indications)","text":"usually run DAT suspect something causing red cell destruction interaction within patient. Key scenarios include:Transfusion Reaction Workup: Essential test patient shows signs/symptoms hemolytic transfusion reaction (HTR) receiving blood. positive DAT post-reaction sample (compared pre-reaction sample) suggests transfused cells coated recipient antibodiesHemolytic Disease Fetus Newborn (HDFN): Testing newborn’s cord blood peripheral blood cells. positive DAT suggests maternal IgG antibodies crossed placenta coated baby’s RBCs (baby corresponding antigen)Autoimmune Hemolytic Anemia (AIHA) Investigation: Patients may present unexplained anemia, jaundice, signs hemolysis. positive DAT hallmark finding AIHA, indicating patient making antibodies RBCs (Warm AIHA, Cold Agglutinin Disease, Mixed-Type AIHA)Drug-Induced Hemolytic Anemia (DIHA): Certain medications can cause antibodies form lead RBC sensitization destruction. DAT part investigationUnexplained Anemia/Hemolysis: Sometimes ordered investigate anemia cause isn’t clear","code":""},{"path":"dat.html","id":"how-the-dat-is-performed-the-basic-principle","chapter":"DAT","heading":"How the DAT is Performed (The Basic Principle)","text":"’s actually quite straightforward conceptually:Sample need patient’s Red Blood Cells. typically collected EDTA (lavender top) tube. EDTA chelates calcium, preventing vitro (tube) activation binding complement, otherwise cause false-positive results complementWASH, WASH, WASH! arguably CRITICAL STEP. patient’s RBCs must washed thoroughly (usually 3-4 times) saline\n?: remove traces unbound plasma proteins. unbound immunoglobulins (IgG) left behind plasma surrounding cells, neutralize AHG reagent added next, leading FALSE-NEGATIVE result. want AHG react antibodies/complement stuck cells\n?: remove traces unbound plasma proteins. unbound immunoglobulins (IgG) left behind plasma surrounding cells, neutralize AHG reagent added next, leading FALSE-NEGATIVE result. want AHG react antibodies/complement stuck cellsAdd Anti-Human Globulin (AHG) Reagent washing, AHG reagent (Coombs’ serum) added patient’s RBC button\nPolyspecific AHG: Often used first. Contains anti-IgG anti-C3d (sometimes anti-complement components). positive result tells something coating cells, specifically \nMonospecific AHG: polyspecific DAT positive, follow monospecific reagents:\nAnti-IgG: Contains antibodies human IgG\nAnti-C3d: Contains antibodies C3d component complement\n\nPolyspecific AHG: Often used first. Contains anti-IgG anti-C3d (sometimes anti-complement components). positive result tells something coating cells, specifically whatMonospecific AHG: polyspecific DAT positive, follow monospecific reagents:\nAnti-IgG: Contains antibodies human IgG\nAnti-C3d: Contains antibodies C3d component complement\nAnti-IgG: Contains antibodies human IgGAnti-C3d: Contains antibodies C3d component complementCentrifuge Read tube (gel card/microplate) centrifuged gently facilitate agglutination\nMechanism: patient’s RBCs coated vivo IgG C3d, corresponding antibodies AHG reagent bind molecules adjacent RBCs, forming bridges causing visible agglutination\nMechanism: patient’s RBCs coated vivo IgG C3d, corresponding antibodies AHG reagent bind molecules adjacent RBCs, forming bridges causing visible agglutinationInterpretation\nAgglutination = Positive DAT: Indicates vivo sensitization. pattern monospecific reagents helps determine coating cells (IgG, C3d, )\nAgglutination = Negative DAT: Indicates detectable coating IgG C3d. (Note: Check cells generally added DAT, positive reaction endpoint ’re looking . Controls usually involve ensuring cells don’t spontaneously agglutinate saline)\nAgglutination = Positive DAT: Indicates vivo sensitization. pattern monospecific reagents helps determine coating cells (IgG, C3d, )Agglutination = Negative DAT: Indicates detectable coating IgG C3d. (Note: Check cells generally added DAT, positive reaction endpoint ’re looking . Controls usually involve ensuring cells don’t spontaneously agglutinate saline)","code":""},{"path":"dat.html","id":"interpreting-dat-results-and-clinical-significance","chapter":"DAT","heading":"Interpreting DAT Results and Clinical Significance","text":"DAT result provides piece puzzle, MUST interpreted context patient’s clinical picture, history, lab findingsPositive Polyspecific DAT: Requires reflex testing monospecific Anti-IgG Anti-C3dMonospecific Results\nPositive IgG, Negative C3d: Common Warm AIHA, HDFN, DIHA, delayed HTRs\nNegative IgG, Positive C3d: Classic Cold Agglutinin Disease (CAD), Paroxysmal Cold Hemoglobinuria (PCH), complement-mediated HTRs, DIHA\nPositive IgG, Positive C3d: Seen Warm AIHA (especially severe cases associated conditions like lupus), DIHA, HTRs\nPositive IgG, Negative C3d: Common Warm AIHA, HDFN, DIHA, delayed HTRsNegative IgG, Positive C3d: Classic Cold Agglutinin Disease (CAD), Paroxysmal Cold Hemoglobinuria (PCH), complement-mediated HTRs, DIHAPositive IgG, Positive C3d: Seen Warm AIHA (especially severe cases associated conditions like lupus), DIHA, HTRsStrength Reaction: 4+ reaction generally concerning active hemolysis weak positive (w+) reaction, confirmed positive DAT right clinical setting significantA Positive DAT Doesn’t Always Mean Hemolysis: individuals, particularly elderly hospitalized patients, may positive DAT without clinical evidence increased red cell destruction. reason positive DAT still needs considerationImpact Testing: positive DAT (especially IgG) can interfere subsequent Rh typing (particularly Weak D testing) cells already coated antibody, potentially causing false positives. Special techniques might needed accurate typing required","code":""},{"path":"dat.html","id":"key-takeaways-1","chapter":"DAT","heading":"Key Takeaways","text":"DAT detects IgG /C3d coating RBCs vivo (inside patient)’s crucial investigating HTRs, HDFN, AIHA, DIHAWashing: patient’s RBCs thoroughly essential prevent false negativesTesting usually starts Polyspecific AHG, followed Monospecific Anti-IgG Anti-C3d positiveResults must correlated clinical context. positive DAT indicates sensitization, necessarily active hemolysis ","code":""},{"path":"dat.html","id":"key-terms-76","chapter":"DAT","heading":"Key Terms","text":"Direct Antiglobulin Test (DAT) (Direct Coombs Test): laboratory test used detect immunoglobulin (IgG) /complement components (C3d) bound red blood cells vivo (within patient’s bloodstream)Vivo Sensitization: coating red blood cells antibodies (primarily IgG) complement proteins circulating within bodyAnti-Human Globulin (AHG) Reagent (Coombs’ Serum): Reagent containing antibodies directed human IgG /complement components (like C3d). Used DAT IAT detect sensitization bridging antibody/complement-coated cells, causing agglutinationPolyspecific AHG: AHG reagent containing anti-IgG anti-C3d antibodies (potentially anti-complement antibodies). Used initial DAT screeningMonospecific AHG: AHG reagent containing antibodies one type molecule, typically either anti-IgG anti-C3d. Used determine specific nature coating polyspecific DAT positiveWashing (DAT/IAT): critical process repeatedly suspending red blood cells saline centrifuging remove unbound plasma/serum proteins, preventing neutralization AHG reagent ensuring test accuracyAgglutination: visible clumping red blood cells, endpoint reaction indicating positive result DAT (many blood bank tests)Hemolytic Transfusion Reaction (HTR): adverse reaction transfusion transfused red blood cells destroyed, often due antibody-antigen reaction. DAT key test workupHemolytic Disease Fetus Newborn (HDFN): condition maternal IgG antibodies cross placenta destroy fetal/newborn red blood cells possessing corresponding antigen. positive DAT infant’s cells characteristicAutoimmune Hemolytic Anemia (AIHA): group disorders immune system mistakenly produces autoantibodies attack individual’s red blood cells, often resulting positive DAT hemolysisDrug-Induced Hemolytic Anemia (DIHA): Hemolysis resulting immune response triggered medication, often involving red blood cell sensitization detectable DATEDTA (Ethylenediaminetetraacetic acid): anticoagulant commonly used collecting blood samples DAT testing chelates calcium, preventing vitro activation complement cascade interfere detection vivo complement binding","code":""},{"path":"reagents.html","id":"reagents","chapter":"Reagents","heading":"Reagents","text":"Think Reagents essential ingredients blood bank “recipes” – one specific job ensure get accurate results keep transfusions safe!use Blood Grouping Sera (known antibodies) find antigens Patient RBCsWe use Reagent RBCs (known antigens) find antibodies Patient PlasmaWe use Antiglobulin Sera (AHG) detect “invisible” binding IgG/Complement RBCs, either vitro (IAT) vivo (DAT)’s overview Big Three reagent categories:","code":""},{"path":"reagents.html","id":"blood-grouping-sera-the-detectors","chapter":"Reagents","heading":"Blood Grouping Sera (The “Detectors”)","text":": Reagents containing known antibodies (primarily Anti-, Anti-B, Anti-D)Job: detect corresponding antigens (, B, D) surface patient donor Red Blood Cells Forward TypingHow Work: antibody reagent specifically binds antigen RBCs, causing visible agglutination (clumping)Key Players\nAnti-(Blue): Detects antigen\nAnti-B (Yellow): Detects B antigen\nAnti-D (Clear/Colorless): Detects D antigen\nRh Control (Clear/Colorless): Crucial! Contains everything except Anti-D antibody; must negative validate Anti-D result\nAnti-(Blue): Detects antigenAnti-B (Yellow): Detects B antigenAnti-D (Clear/Colorless): Detects D antigenRh Control (Clear/Colorless): Crucial! Contains everything except Anti-D antibody; must negative validate Anti-D resultSource: Mostly highly specific monoclonal antibodies nowBottom Line: reagents establish fundamental ABO/Rh type – starting point compatibility testing","code":""},{"path":"reagents.html","id":"reagent-red-blood-cells-the-bait","chapter":"Reagents","heading":"Reagent Red Blood Cells (The “Bait”)","text":": Suspensions human Red Blood Cells known antigen profilesTheir Job: detect antibodies patient donor Plasma/SerumHow Work: patient’s plasma contains antibody, bind corresponding known antigen reagent RBCs, leading agglutination hemolysis (often requires AHG phase IgG antibodies)Key Players\nA1 Cells & B Cells: Used ABO Reverse Typing confirm presence expected anti-/anti-B\nScreening Cells (Set 2 3, Group O): Used Antibody Screen detect unexpected, clinically significant antibodies. MUST Group O avoid ABO interference. Come antigram detailing antigen profile\nPanel Cells (Set 11-20+, Group O): Used Antibody Identification screen positive. Provide variety antigen patterns (detailed antigram) help pinpoint antibody’s specificity\nA1 Cells & B Cells: Used ABO Reverse Typing confirm presence expected anti-/anti-BScreening Cells (Set 2 3, Group O): Used Antibody Screen detect unexpected, clinically significant antibodies. MUST Group O avoid ABO interference. Come antigram detailing antigen profilePanel Cells (Set 11-20+, Group O): Used Antibody Identification screen positive. Provide variety antigen patterns (detailed antigram) help pinpoint antibody’s specificitySource: Carefully selected human donorsBottom Line: cells allow us find identify antibodies patient’s plasma, critical selecting compatible blood. Watch expiration dates!","code":""},{"path":"reagents.html","id":"antiglobulin-sera-ahg-coombs-serum-the-bridge-builder","chapter":"Reagents","heading":"Antiglobulin Sera (AHG / Coombs’ Serum) (The “Bridge Builder”)","text":": Reagent containing antibodies directed human antibodies (Anti-IgG) /complement proteins (Anti-C3d)Job: detect red cells sensitized (coated) IgG complement, especially coating doesn’t cause direct agglutination ownHow Works: AHG antibodies bind IgG C3d already attached RBCs, forming “bridge” adjacent coated cells, causing visible agglutinationKey Players\nPolyspecific AHG: Contains Anti-IgG Anti-C3d. Used initial DAT screen\nMonospecific Anti-IgG: Contains Anti-IgG. Essential IAT procedures (Screen, ID, XM, Weak D) DAT follow-\nMonospecific Anti-C3d: Contains Anti-C3d. Used DAT follow-detect complement coating\nPolyspecific AHG: Contains Anti-IgG Anti-C3d. Used initial DAT screenMonospecific Anti-IgG: Contains Anti-IgG. Essential IAT procedures (Screen, ID, XM, Weak D) DAT follow-upMonospecific Anti-C3d: Contains Anti-C3d. Used DAT follow-detect complement coatingSource: Polyclonal (animal source) monoclonal (hybridoma) antibodies, often blendsBottom Line: AHG crucial detecting clinically significant IgG antibodies (IAT) investigating potential vivo red cell destruction (DAT). Remember: Washing cells adding AHG critical avoid false negatives! Check Cells validate negative results","code":""},{"path":"antiglobulin-sera.html","id":"antiglobulin-sera","chapter":"Antiglobulin Sera","heading":"Antiglobulin Sera","text":"Antiglobulin Sera, commonly known Anti-Human Globulin (AHG) sometimes historically called Coombs’ Serum, one crucial reagents blood bank. Honestly, without AHG, ’d miss huge number clinically significant antibodies! ’s key unlocks detection many IgG antibodies complement proteins bound red blood cellsThink like : antibodies (especially IgG) like tiny little hands can grab onto antigens red blood cells, ’re often small don’t bind way makes cells clump together (agglutinate) directly. coat cells invisibly! AHG like bigger molecule comes along says, “Hey, see little IgG hand stuck !” grabs onto , also grabs onto another one nearby cell, effectively linking cells together can see clumping","code":""},{"path":"antiglobulin-sera.html","id":"the-fundamental-purpose-detecting-invisible-sensitization","chapter":"Antiglobulin Sera","heading":"The Fundamental Purpose: Detecting Invisible Sensitization","text":"main job AHG detect red blood cells sensitized (coated) :IgG antibodies: Many clinically significant antibodies cause transfusion reactions HDFN IgG. bind body temperature (37°C) often don’t cause direct agglutinationComplement components: Sometimes, antibodies (IgG IgM) bind activate complement cascade. Fragments complement proteins (like C3b, C3d) can remain stuck red cell surfaceAHG allows us visualize otherwise invisible coating causing agglutination","code":""},{"path":"antiglobulin-sera.html","id":"how-is-ahg-made-the-basics","chapter":"Antiglobulin Sera","heading":"How is AHG Made? (The Basics)","text":"Historically, AHG made injecting human serum proteins (like IgG complement) animals (like rabbits). animals produce antibodies human proteins. animal antibodies harvested purified create reagent. produces polyclonal AHG (mix different antibodies recognizing different parts target human protein)Modern methods also include monoclonal antibody technology using hybridomas. creates highly specific antibodies recognize single epitope (part) target human protein (IgG C3d). Many current reagents blends monoclonal antibodies, sometimes mix monoclonal polyclonal","code":""},{"path":"antiglobulin-sera.html","id":"types-of-ahg-reagents-know-your-tools","chapter":"Antiglobulin Sera","heading":"Types of AHG Reagents: Know Your Tools!","text":"super important using right type tells different things:Polyspecific AHG\nContains: Anti-IgG Anti-C3d (often anti-complement components like anti-C3b)\nUse: Often used initial reagent Direct Antiglobulin Test (DAT). positive result tells something (IgG complement ) coating patient’s red cells vivo. Also sometimes used routine antibody screening (IAT), though many labs now prefer Anti-IgG screening\nThink : broad searchlight. tells anything \nContains: Anti-IgG Anti-C3d (often anti-complement components like anti-C3b)Use: Often used initial reagent Direct Antiglobulin Test (DAT). positive result tells something (IgG complement ) coating patient’s red cells vivo. Also sometimes used routine antibody screening (IAT), though many labs now prefer Anti-IgG screeningThink : broad searchlight. tells anything thereMonospecific AHG\nContains: Antibodies ONE specific component\nTypes & Use\nAnti-IgG: Contains antibodies Fc portion human IgG\nCrucial : Indirect Antiglobulin Test (IAT) – used antibody screening, antibody identification, Weak D testing, antigen typing, AHG crossmatch detect IgG antibodies bound vitro\nAlso used : DAT positive polyspecific result, determine specifically IgG coating cells\n\nAnti-C3d: Contains antibodies C3d fragment complement (C3d stable remains cell surface complement activation)\nUse: Primarily DAT positive polyspecific result, determine specifically complement coating cells (common Cold Agglutinin Disease, HTRs, drug-induced reactions). Rarely used routine IAT\n\n(Less common: Anti-C3b, Anti-C4, etc. - used specific reference lab investigations)\n\nThink : specific spotlights. tell exactly kind coating found (IgG? Complement?)\nContains: Antibodies ONE specific componentTypes & Use\nAnti-IgG: Contains antibodies Fc portion human IgG\nCrucial : Indirect Antiglobulin Test (IAT) – used antibody screening, antibody identification, Weak D testing, antigen typing, AHG crossmatch detect IgG antibodies bound vitro\nAlso used : DAT positive polyspecific result, determine specifically IgG coating cells\n\nAnti-C3d: Contains antibodies C3d fragment complement (C3d stable remains cell surface complement activation)\nUse: Primarily DAT positive polyspecific result, determine specifically complement coating cells (common Cold Agglutinin Disease, HTRs, drug-induced reactions). Rarely used routine IAT\n\n(Less common: Anti-C3b, Anti-C4, etc. - used specific reference lab investigations)\nAnti-IgG: Contains antibodies Fc portion human IgG\nCrucial : Indirect Antiglobulin Test (IAT) – used antibody screening, antibody identification, Weak D testing, antigen typing, AHG crossmatch detect IgG antibodies bound vitro\nAlso used : DAT positive polyspecific result, determine specifically IgG coating cells\nCrucial : Indirect Antiglobulin Test (IAT) – used antibody screening, antibody identification, Weak D testing, antigen typing, AHG crossmatch detect IgG antibodies bound vitroAlso used : DAT positive polyspecific result, determine specifically IgG coating cellsAnti-C3d: Contains antibodies C3d fragment complement (C3d stable remains cell surface complement activation)\nUse: Primarily DAT positive polyspecific result, determine specifically complement coating cells (common Cold Agglutinin Disease, HTRs, drug-induced reactions). Rarely used routine IAT\nUse: Primarily DAT positive polyspecific result, determine specifically complement coating cells (common Cold Agglutinin Disease, HTRs, drug-induced reactions). Rarely used routine IAT(Less common: Anti-C3b, Anti-C4, etc. - used specific reference lab investigations)Think : specific spotlights. tell exactly kind coating found (IgG? Complement?)","code":""},{"path":"antiglobulin-sera.html","id":"applications-where-we-rely-on-ahg","chapter":"Antiglobulin Sera","heading":"Applications: Where We Rely on AHG","text":"AHG cornerstone reagent :Indirect Antiglobulin Test (IAT): Detecting vitro sensitization (antibody plasma binding reagent cells test tube/system)\nAntibody Screening\nAntibody Identification\nWeak D Testing\nAntigen Typing (antigens requiring IAT)\nAHG Crossmatch\nAntibody ScreeningAntibody IdentificationWeak D TestingAntigen Typing (antigens requiring IAT)AHG CrossmatchDirect Antiglobulin Test (DAT): Detecting vivo sensitization (cells coated antibody/complement inside patient’s body)\nTransfusion Reaction Workups\nHDFN Investigations\nAutoimmune Hemolytic Anemia (AIHA) Workups\nDrug-Induced Hemolytic Anemia (DIHA) Workups\nTransfusion Reaction WorkupsHDFN InvestigationsAutoimmune Hemolytic Anemia (AIHA) WorkupsDrug-Induced Hemolytic Anemia (DIHA) Workups","code":""},{"path":"antiglobulin-sera.html","id":"mechanism-of-action-the-bridge","chapter":"Antiglobulin Sera","heading":"Mechanism of Action: The Bridge","text":"Whether ’s Anti-IgG binding Fc portion IgG molecules coating two adjacent red cells, Anti-C3d binding C3d molecules coating adjacent cells, AHG molecule acts bridge. bridging overcomes natural repulsive forces red cells, allowing formation stable lattice structure see agglutination","code":""},{"path":"antiglobulin-sera.html","id":"quality-control-critical-considerations","chapter":"Antiglobulin Sera","heading":"Quality Control & Critical Considerations","text":"Washing KING!: IAT DAT, inadequate washing red cells adding AHG #1 cause false-negative results. ? unbound human globulins (IgG) left surrounding fluid neutralize AHG reagent can bind globulins cellsCheck Cells (Coombs Control Cells): essential! IgG-coated red cells added negative AHG tests (IAT sometimes DAT depending policy/method). MUST agglutinate. don’t, means something wrong (AHG wasn’t added, inactive, washing poor), negative test result INVALIDProper Reaction Reading: Need correct technique (gentle resuspension) lightingReagent Storage & Handling: Follow manufacturer instructions preciselyMastering use interpretation AHG reagents fundamental safe effective blood banking. allows us detect hidden dangers – antibodies complement proteins can lead red cell destruction! Keep practicing DATs IATs!","code":""},{"path":"antiglobulin-sera.html","id":"key-terms-77","chapter":"Antiglobulin Sera","heading":"Key Terms","text":"Antiglobulin Sera (Anti-Human Globulin / AHG): Reagents containing antibodies directed human immunoglobulins (primarily IgG) /complement components (primarily C3d). Used detect red blood cells sensitized proteinsCoombs’ Test: historical name antiglobulin tests (Direct Indirect), named inventors (Coombs, Mourant, Race)Sensitization: coating red blood cells antibodies complement components, either vivo (inside body) vitro (test tube)Polyspecific AHG: AHG reagent containing anti-IgG anti-C3d activityMonospecific AHG: AHG reagent containing activity one specific component, typically either Anti-IgG Anti-C3dAnti-IgG: Monospecific AHG reagent detects IgG antibodies bound red blood cellsAnti-C3d: Monospecific AHG reagent detects C3d component complement bound red blood cellsIndirect Antiglobulin Test (IAT): Test procedure used detect vitro sensitization red blood cells (used antibody screening, ID, crossmatching, Weak D). Requires incubation plasma/serum cells, washing, addition AHGDirect Antiglobulin Test (DAT): Test procedure used detect vivo sensitization red blood cells (used HTR, HDFN, AIHA investigations). Involves washing patient red cells directly adding AHGAgglutination: Visible clumping red blood cells, indicating positive reaction antiglobulin testsNeutralization (AHG testing): Inactivation AHG reagent unbound human globulins remaining inadequate washing, leading false-negative resultsCheck Cells (Coombs Control Cells): IgG-coated red blood cells added negative AHG tests validate test system’s integrity (confirming active AHG present washing adequate)","code":""},{"path":"blood-grouping-sera.html","id":"blood-grouping-sera","chapter":"Blood Grouping Sera","heading":"Blood Grouping Sera","text":"Blood Grouping Sera essential tools use figuring ABO Rh(D) type patient donor. Think highly specific “detector” liquids latch onto antigens present red blood cells. Getting typing right reagents ground zero transfusion safety!","code":""},{"path":"blood-grouping-sera.html","id":"what-are-blood-grouping-sera","chapter":"Blood Grouping Sera","heading":"What Are Blood Grouping Sera?","text":"Blood grouping sera (antisera) laboratory reagents containing antibodies known specificity. use primarily Forward Typing determine antigens present individual’s red blood cellsPurpose: directly detect presence absence key red blood cell antigens, mainly , B, DMechanism: antibody reagent encounters corresponding antigen red blood cells, binds , causing red cells agglutinate (clump together). agglutination generally means antigen absent","code":""},{"path":"blood-grouping-sera.html","id":"the-main-players-abo-and-rhd-reagents","chapter":"Blood Grouping Sera","heading":"The Main Players: ABO and Rh(D) Reagents","text":"","code":""},{"path":"blood-grouping-sera.html","id":"abo-typing-reagents","chapter":"Blood Grouping Sera","heading":"ABO Typing Reagents","text":"Anti-Serum\nSpecificity: Contains antibodies specifically bind antigen\nSource: Almost exclusively monoclonal IgM antibodies produced using hybridoma technology\nAppearance: Traditionally colored BLUE easy identification (Think: Azure/Aqua)\nUse: Detects presence antigen RBCs. Agglutination indicates person antigen (Blood Group AB)\nSpecificity: Contains antibodies specifically bind antigenSource: Almost exclusively monoclonal IgM antibodies produced using hybridoma technologyAppearance: Traditionally colored BLUE easy identification (Think: Azure/Aqua)Use: Detects presence antigen RBCs. Agglutination indicates person antigen (Blood Group AB)Anti-B Serum\nSpecificity: Contains antibodies specifically bind B antigen\nSource: Almost exclusively monoclonal IgM antibodies\nAppearance: Traditionally colored YELLOW easy identification (Think: Banana/Butter)\nUse: Detects presence B antigen RBCs. Agglutination indicates person B antigen (Blood Group B AB)\nSpecificity: Contains antibodies specifically bind B antigenSource: Almost exclusively monoclonal IgM antibodiesAppearance: Traditionally colored YELLOW easy identification (Think: Banana/Butter)Use: Detects presence B antigen RBCs. Agglutination indicates person B antigen (Blood Group B AB)Anti-,B Serum (Less Common Routine Typing)\nSpecificity: Contains anti-anti-B antibodies. react cells possessing antigen, B antigen, \nSource: Can monoclonal blends historically derived Group O individuals (naturally anti-anti-B)\nAppearance: Usually clear/colorless\nUse: Primarily used historically check Group O individuals (non-reactive) sometimes testing newborns (whose ABO antigens/antibodies may weakly expressed). typically used routine /B/AB determination adults anymore\nSpecificity: Contains anti-anti-B antibodies. react cells possessing antigen, B antigen, bothSource: Can monoclonal blends historically derived Group O individuals (naturally anti-anti-B)Appearance: Usually clear/colorlessUse: Primarily used historically check Group O individuals (non-reactive) sometimes testing newborns (whose ABO antigens/antibodies may weakly expressed). typically used routine /B/AB determination adults anymore","code":""},{"path":"blood-grouping-sera.html","id":"rhd-typing-reagent","chapter":"Blood Grouping Sera","heading":"Rh(D) Typing Reagent","text":"Anti-D Serum\nSpecificity: Contains antibodies specifically bind Rh(D) antigen\nSource: Can complex! Modern reagents often blends monoclonal IgM IgG antibodies, chemically modified IgG, designed react reliably direct agglutination tests (like immediate spin) still suitable detecting Weak D variants (requires IAT procedure)\nAppearance: Usually clear/colorless (though packaging varies)\nUse: Detects presence D antigen. Agglutination (negative control) indicates person Rh(D) Positive. agglutination requires testing Weak D, especially donors\nSpecificity: Contains antibodies specifically bind Rh(D) antigenSource: Can complex! Modern reagents often blends monoclonal IgM IgG antibodies, chemically modified IgG, designed react reliably direct agglutination tests (like immediate spin) still suitable detecting Weak D variants (requires IAT procedure)Appearance: Usually clear/colorless (though packaging varies)Use: Detects presence D antigen. Agglutination (negative control) indicates person Rh(D) Positive. agglutination requires testing Weak D, especially donorsRh Control Reagent\nCRITICAL!: ’s technically “anti-serum” contains anti-D antibody\nComposition: Contains everything Anti-D reagent vial except actual anti-D antibody (e.g., protein concentration, diluent, additives)\nPurpose: Used concurrently Anti-D test. ensures agglutination seen Anti-D reagent due specific anti-D binding D antigen, due factors like high protein concentrations causing non-specific aggregation patient autoantibodies coating cells\nInterpretation: Rh control MUST NEGATIVE Anti-D test result (positive negative) considered valid\nCRITICAL!: ’s technically “anti-serum” contains anti-D antibodyComposition: Contains everything Anti-D reagent vial except actual anti-D antibody (e.g., protein concentration, diluent, additives)Purpose: Used concurrently Anti-D test. ensures agglutination seen Anti-D reagent due specific anti-D binding D antigen, due factors like high protein concentrations causing non-specific aggregation patient autoantibodies coating cellsInterpretation: Rh control MUST NEGATIVE Anti-D test result (positive negative) considered valid","code":""},{"path":"blood-grouping-sera.html","id":"other-rh-phenotyping-reagents-less-routine-for-initial-typing","chapter":"Blood Grouping Sera","heading":"Other Rh Phenotyping Reagents (Less Routine for Initial Typing)","text":"Reagents like Anti-C, Anti-c, Anti-E, Anti-e exist used extensive Rh phenotyping, often identifying antibodies selecting specialized units, aren’t part basic ABO/Rh grouping","code":""},{"path":"blood-grouping-sera.html","id":"production-monoclonal-dominance","chapter":"Blood Grouping Sera","heading":"Production: Monoclonal Dominance","text":"Polyclonal Era (Historical): Originally, antisera derived immunized human donors animals. contained mixture antibodies (polyclonal) sometimes lead variability cross-reactivity issuesMonoclonal Era (Current Standard): modern blood grouping reagents monoclonal. produced using hybridoma technology (fusing antibody-producing B-cell myeloma cell) create cell lines produce large quantities single, highly specific antibody clone\nAdvantages: High specificity, consistent potency, reduced lot--lot variation, fewer unwanted cross-reactions\nAdvantages: High specificity, consistent potency, reduced lot--lot variation, fewer unwanted cross-reactions","code":""},{"path":"blood-grouping-sera.html","id":"usage-and-methodologies","chapter":"Blood Grouping Sera","heading":"Usage and Methodologies","text":"reagents heart Forward Typing. basic principle involves mixing drop reagent drop patient/donor red blood cell suspension (usually 2-5% saline)Tube Testing: Classic method, reactions observed centrifugation (Immediate Spin ABO/Rh, potentially 37°C/AHG Weak D)Gel/Column Agglutination: Reagent often incorporated gel matrix microtube wellsSolid Phase: Reagent antibodies may bound surface microplate wells","code":""},{"path":"blood-grouping-sera.html","id":"quality-control-and-considerations","chapter":"Blood Grouping Sera","heading":"Quality Control and Considerations","text":"Ensuring reagents work correctly paramount!Daily QC: Must performed daily (per institutional policy) using known antigen-positive antigen-negative red cells confirm reactivity specificityManufacturer’s Instructions: Follow precisely storage conditions (usually refrigerated), expiration dates, testing proceduresPotency Specificity: Reagents must meet strict standards strongly react (potency) ensure react intended antigen (specificity)Avoiding Errors: Use correct reagent (check labels!), prevent contamination, interpret reactions accurately (know grade agglutination, recognize false positives like rouleaux), always ensure controls (Rh control, A1/B cells reverse type) give expected resultsBlood grouping sera fundamental diagnostic tools. Understanding specificity, work, importance controls absolutely key accurate blood typing patient safety. Keep colors straight (Blue=, Yellow=B)!","code":""},{"path":"blood-grouping-sera.html","id":"key-terms-78","chapter":"Blood Grouping Sera","heading":"Key Terms","text":"Blood Grouping Sera (Antisera): Laboratory reagents containing known antibodies used detect corresponding antigens red blood cells, primarily ABO Rh(D) typingForward Typing: process testing patient’s donor’s red blood cells known blood grouping sera (e.g., Anti-, Anti-B, Anti-D) determine antigens presentAntigen: molecule (usually protein carbohydrate) surface red blood cells can recognized antibodyAntibody: protein serum/plasma (reagent) binds specifically antigenAgglutination: visible clumping red blood cells caused antibodies binding antigens adjacent cells, forming lattice networkMonoclonal Antibodies: Antibodies produced single clone cells (hybridoma), resulting reagent highly specific single epitope target antigen. standard modern blood grouping seraPolyclonal Antibodies: Antibodies produced multiple different B-cell clones response antigen, resulting mixture antibodies may recognize different epitopes target antigen. Largely historical routine grouping seraAnti-: Reagent containing antibodies detect antigen (typically blue)Anti-B: Reagent containing antibodies detect B antigen (typically yellow)Anti-D: Reagent containing antibodies detect Rh(D) antigenRh Control: reagent used parallel Anti-D testing contains components Anti-D reagent except anti-D antibody. must negative ensure Anti-D result valid due non-specific factorsSpecificity: characteristic antibody (reagent) bind intended target antigen othersPotency: strength reactivity level antibody reagent","code":""},{"path":"reagent-rbcs.html","id":"reagent-rbcs","chapter":"Reagent RBCs","heading":"Reagent RBCs","text":"Just like need known antibodies (grouping sera) find unknown antigens patient cells, need known red cells (specific antigens) find unknown antibodies patient plasma! “bait” use catch antibodiesThink reference library red blood cells, carefully selected characterized","code":""},{"path":"reagent-rbcs.html","id":"what-are-reagent-red-blood-cells","chapter":"Reagent RBCs","heading":"What Are Reagent Red Blood Cells?","text":"suspensions human red blood cells known antigen profiles. commercially prepared used various tests detect identify red blood cell antibodies patient’s serum plasma, confirm ABO grouping","code":""},{"path":"reagent-rbcs.html","id":"main-types-of-reagent-rbcs-and-their-uses","chapter":"Reagent RBCs","heading":"Main Types of Reagent RBCs and Their Uses","text":"use different types reagent RBCs different jobs:","code":""},{"path":"reagent-rbcs.html","id":"abo-reverse-grouping-cells-a1-cells-and-b-cells","chapter":"Reagent RBCs","heading":"ABO Reverse Grouping Cells (A1 Cells and B Cells)","text":"Purpose: Used Reverse Typing detect expected naturally occurring ABO antibodies (anti-anti-B) patient plasma/serum, confirming forward typeComposition\nA1 Cells: Red cells obtained known Group A1 individuals. possess antigen (specifically A1 subtype, reacts strongly anti-)\nB Cells: Red cells obtained known Group B individuals. possess B antigen\nA1 Cells: Red cells obtained known Group A1 individuals. possess antigen (specifically A1 subtype, reacts strongly anti-)B Cells: Red cells obtained known Group B individuals. possess B antigenWhy Use ?: Landsteiner’s Rule! expect individuals antibodies ABO antigens lack. cells confirm presence (absence) expected antibodies\nGroup patient plasma react B cells (contains anti-B)\nGroup B patient plasma react A1 cells (contains anti-)\nGroup O patient plasma react A1 B cells (contains anti-anti-B)\nGroup AB patient plasma react NEITHER A1 B cells (contains neither antibody)\nGroup patient plasma react B cells (contains anti-B)Group B patient plasma react A1 cells (contains anti-)Group O patient plasma react A1 B cells (contains anti-anti-B)Group AB patient plasma react NEITHER A1 B cells (contains neither antibody)Source: Pooled single donor sources known A1 B phenotypes","code":""},{"path":"reagent-rbcs.html","id":"antibody-screening-cells","chapter":"Reagent RBCs","heading":"Antibody Screening Cells","text":"Purpose: Used Antibody Screen (Detection) Test detect presence unexpected, clinically significant antibodies patient plasma/serumComposition\nSets 2 3 different vials, containing red cells single Group O donor\nGroup O?: Crucial! prevents reactions patient’s expected anti-anti-B, interfere detecting unexpected antibodies ’re looking \nAntigen Profile: cells extensively phenotyped. 2 3 vials set, selected express (usually homozygous form possible, enhance reactivity via dosage) common clinically significant antigens various blood group systems (e.g., D, C, c, E, e, K, k, Fya, Fyb, Jka, Jkb, Lea, Leb, P1, M, N, S, s)\nAntigram: Comes detailed sheet (antigram) listing antigen profile cells vial\nSets 2 3 different vials, containing red cells single Group O donorWhy Group O?: Crucial! prevents reactions patient’s expected anti-anti-B, interfere detecting unexpected antibodies ’re looking forAntigen Profile: cells extensively phenotyped. 2 3 vials set, selected express (usually homozygous form possible, enhance reactivity via dosage) common clinically significant antigens various blood group systems (e.g., D, C, c, E, e, K, k, Fya, Fyb, Jka, Jkb, Lea, Leb, P1, M, N, S, s)Antigram: Comes detailed sheet (antigram) listing antigen profile cells vialHow Work: patient’s plasma contains antibody (like anti-K), one screening cells K antigen, reaction (agglutination/hemolysis) occur IAT procedure, indicating positive screen","code":""},{"path":"reagent-rbcs.html","id":"antibody-identification-panel-cells","chapter":"Reagent RBCs","heading":"Antibody Identification Panel Cells","text":"Purpose: Used determine specificity unexpected antibody detected antibody screenComposition\nLarger sets reagent RBCs, typically 11 20 different vials, single Group O donor\nGroup O?: reason screening cells – avoids ABO interference\nAntigen Profile: Like screening cells, extensively phenotyped, key difference VARIETY antigen patterns across vials. vial unique combination antigens present absent. variation essential “rule-” process used identification\nAntigram: Accompanied comprehensive antigram detailing phenotype cell vial. Often includes zygosity information (e.g., Jk(+b-) vs Jk(+b+)) helps identify antibodies showing dosage\nLarger sets reagent RBCs, typically 11 20 different vials, single Group O donorWhy Group O?: reason screening cells – avoids ABO interferenceAntigen Profile: Like screening cells, extensively phenotyped, key difference VARIETY antigen patterns across vials. vial unique combination antigens present absent. variation essential “rule-” process used identificationAntigram: Accompanied comprehensive antigram detailing phenotype cell vial. Often includes zygosity information (e.g., Jk(+b-) vs Jk(+b+)) helps identify antibodies showing dosageHow Work: testing patient’s plasma cells panel comparing pattern positive/negative reactions known antigen profiles antigram, can systematically rule specificities pinpoint identity antibody(ies)","code":""},{"path":"reagent-rbcs.html","id":"less-common-routine-qc-specific","chapter":"Reagent RBCs","heading":"Less Common Routine / QC Specific","text":"Known Typed Cells QC: Vials RBCs known ABO/Rh types (e.g., Pos, O Neg) used daily quality control blood grouping seraSpecialized Cells: Sometimes used reference labs, e.g., cord cells (lack antigen), enzyme-treated cells, cells lacking high-frequency antigens","code":""},{"path":"reagent-rbcs.html","id":"essential-characteristics-of-reagent-rbcs","chapter":"Reagent RBCs","heading":"Essential Characteristics of Reagent RBCs","text":"Source: Human donors (screened infectious diseases)Preservative Solution: Suspended special preservative solution designed maintain red cell viability antigen integrity duration shelf life. Contains buffers, nutrients, often antibiotics/antifungalsExpiration Date: Absolutely critical! Reagent RBCs limited shelf life (often 2-6 weeks) antigens degrade time. Using expired cells can lead false-negative results (especially weakly expressed labile antigens like P1, Lewis, M)Storage: Must stored strict refrigerated conditions (usually 1-6°C per manufacturer) maintain stability. NEVER FREEZE! Freezing lyses red cellsAppearance: inspected visually use signs hemolysis (red supernatant) bacterial contamination (clots, unusual turbidity), render unsuitable","code":""},{"path":"reagent-rbcs.html","id":"the-antigram-your-roadmap","chapter":"Reagent RBCs","heading":"The Antigram: Your Roadmap","text":"antigram information sheet provided manufacturer details antigen profile vial screening cells panel cells. ’s essential interpretation!Layout: Typically lists vial numbers across top antigens tested sideSymbols: Usually uses “+” indicate antigen present “0” “-” indicate ’s absentKey Information: Lot number, expiration date, detailed phenotype crucial pieces dataReagent RBCs indispensable antibody detection identification. Knowing type use test, understanding characteristics, respecting expiration dates, correctly interpreting results based antigram fundamental skills blood bank!","code":""},{"path":"reagent-rbcs.html","id":"key-terms-79","chapter":"Reagent RBCs","heading":"Key Terms","text":"Reagent Red Blood Cells (RBCs): Commercially prepared suspensions human red blood cells known antigen phenotypes, used various blood bank testsA1 Cells / B Cells: Reagent RBCs used ABO reverse grouping detect anti-anti-B patient plasma/serumScreening Cells: Sets 2 3 Group O reagent RBCs known phenotypes common, clinically significant antigens, used antibody detection (antibody screen)Panel Cells: Larger sets (11-20+) Group O reagent RBCs, unique pattern known antigens, used antibody identificationGroup O: Blood group lacking B antigens. Screening panel cells MUST Group O avoid interference patient anti-/anti-BAntigram: profile sheet accompanying screening panel cells details specific antigen makeup (+ 0) cells vialPhenotype: observable characteristics red blood cell, specifically profile antigens present surface determined testingDosage Effect: phenomenon antibodies react strongly red cells double dose (homozygous) antigen compared single dose (heterozygous). Screening/panel cells often include homozygous expressions aid detectionPreservative Solution: special medium reagent RBCs suspended maintain viability antigen integrity storageExpiration Date: date reagent RBCs used due potential degradation antigens, leading unreliable resultsHemolysis: rupture red blood cells, releasing hemoglobin. Visible hemolysis reagent RBCs indicates unsuitable use","code":""},{"path":"special-tests-reagents.html","id":"special-tests-reagents","chapter":"Special Tests & Reagents","heading":"Special Tests & Reagents","text":"“special forces” – specialized tests reagents tools call upon things get complex need deeper insights. tools help us solve puzzles routine testing might fully addressHere’s overview special tests reagents:","code":""},{"path":"special-tests-reagents.html","id":"enzymes-e.g.-ficin-papain","chapter":"Special Tests & Reagents","heading":"Enzymes (e.g., Ficin, Papain)","text":"Purpose: Modify red cell surface antigens enhance destroy antibody reactivityHow: Proteolytic enzymes cleave proteins/sialic acid residuesWhy Use : Helps separate mixtures antibodies (destroying antigens like MNS, Duffy) enhances others (like Rh, Kidd, Lewis), aiding identification. Crucial: Always run parallel non-enzyme methods!","code":""},{"path":"special-tests-reagents.html","id":"enhancement-media-liss-peg-albumin","chapter":"Special Tests & Reagents","heading":"Enhancement Media (LISS, PEG, Albumin)","text":"Purpose: Increase speed /sensitivity antibody-antigen reactions (IAT): Reduce zeta potential (Albumin), reduce ionic cloud (LISS), exclude water concentrate antibodies (PEG)Use : Allows shorter incubation times (LISS, PEG) detection weaker antibodies (especially PEG). Crucial: PEG can cause non-specific aggregation; don’t read macroscopically washing/AHG!","code":""},{"path":"special-tests-reagents.html","id":"lectins-e.g.-anti-a1---dolichos-anti-h---ulex","chapter":"Special Tests & Reagents","heading":"Lectins (e.g., Anti-A1 - Dolichos, Anti-H - Ulex)","text":"Purpose: Bind specifically certain carbohydrate antigensHow: Plant proteins act like highly specific antibodies sugarsWhy Use : Differentiating ABO subgroups (A1 vs. A2), identifying Bombay phenotype (Oh lacks H)","code":""},{"path":"special-tests-reagents.html","id":"adsorptions-auto--allo--rest","chapter":"Special Tests & Reagents","heading":"Adsorptions (Auto-, Allo-, RESt)","text":"Purpose: Remove specific antibodies (“sponges”) serum/plasmaHow: Incubate serum RBCs possessing target antigen(s)Use : Primarily remove interfering autoantibodies detect underlying clinically significant alloantibodies. Auto-adsorption uses patient cells (recently transfused); Allo-adsorption uses selected donor cells","code":""},{"path":"special-tests-reagents.html","id":"elutions-acid-heat-freeze-thaw","chapter":"Special Tests & Reagents","heading":"Elutions (Acid, Heat, Freeze-Thaw)","text":"Purpose: Recover antibodies bound RBCs vivo (positive DAT): Disrupt antigen-antibody bonds using pH changes, heat, freezingWhy Use : identify specificity antibody coating cells HDFN, HTRs, AIHA. Crucial: Thoroughly wash cells elution! Test eluate","code":""},{"path":"special-tests-reagents.html","id":"titrations","chapter":"Special Tests & Reagents","heading":"Titrations","text":"Purpose: Semi-quantify concentration (strength) known antibodyHow: Test serial dilutions serum antigen-positive cells (IAT)Use : Primarily monitor antibody levels pregnant patients risk HDFN. Also helps characterize HTLA antibodies. Crucial: Parallel testing previous sample essential monitoring","code":""},{"path":"special-tests-reagents.html","id":"cell-separations-differential-centrifugation","chapter":"Special Tests & Reagents","heading":"Cell Separations (Differential Centrifugation)","text":"Purpose: Isolate patient vs. donor RBCs mixed post-transfusion sampleHow: Centrifuge based RBC density differences (age-related)Use : Allows separate testing (DAT, phenotyping) patient-enriched vs. donor-enriched cell fractions, vital transfusion reaction workups","code":""},{"path":"special-tests-reagents.html","id":"elisa-enzyme-linked-immunosorbent-assay","chapter":"Special Tests & Reagents","heading":"ELISA (Enzyme-Linked Immunosorbent Assay)","text":"Purpose: Highly sensitive detection antigens antibodiesHow: Uses enzyme-linked antibodies substrate conversion produce measurable signal (color change) microplate wellsWhy Use : Primarily mandatory infectious disease screening donor blood (HIV, Hepatitis, etc.)","code":""},{"path":"special-tests-reagents.html","id":"molecular-techniques-genotyping","chapter":"Special Tests & Reagents","heading":"Molecular Techniques (Genotyping)","text":"Purpose: Predict RBC phenotype analyzing patient’s DNAHow: PCR amplification blood group genes followed various detection methods (probes, sequencing, microarrays)Use : Overcomes serology limitations (positive DAT, recent transfusion), fetal genotyping (non-invasive), high-throughput donor typing, resolving discrepancies","code":""},{"path":"special-tests-reagents.html","id":"neutralizationinhibition","chapter":"Special Tests & Reagents","heading":"Neutralization/Inhibition","text":"Purpose: Confirm antibody identity inhibiting reactivity soluble antigen “decoy.”: Add soluble antigen substance (e.g., Lewis substance, P1 substance, urine Sda) serumWhy Use : Confirms specificity antibodies like anti-Lewis, anti-P1, anti-Sda, anti-Ch/Rg","code":""},{"path":"special-tests-reagents.html","id":"use-of-thiol-reagents-dtt-2-me","chapter":"Special Tests & Reagents","heading":"Use of Thiol Reagents (DTT, 2-ME)","text":"Purpose: Differentiate IgM IgG antibodies; destroy Kell system antigensHow: Break disulfide bonds, dismantling IgM pentamers denaturing Kell antigensWhy Use : Determine antibody class (clinical significance), remove IgM interference, identify Kell system antibodies","code":""},{"path":"special-tests-reagents.html","id":"immunofluorescence-if","chapter":"Special Tests & Reagents","heading":"Immunofluorescence (IF)","text":"Purpose: Visualize antibody-antigen binding using fluorescent labelsHow: Fluorophore-labeled antibodies detected via fluorescence microscope flow cytometerWhy Use : Primarily platelet granulocyte antibody testing, flow cytometry crossmatching (highly sensitive). routine RBC serology","code":""},{"path":"special-tests-reagents.html","id":"solid-phase-red-cell-adherence-sprca","chapter":"Special Tests & Reagents","heading":"Solid Phase Red Cell Adherence (SPRCA)","text":"Purpose: Detect antibody-antigen reactions fixed surface (microplate well): Antigens antibodies coated wells; adherence pattern indicator cells determines result (diffuse layer = positive Ab screen/ID)Use : Alternative platform antibody screen/ID, DAT, crossmatch; sensitive automatable","code":""},{"path":"special-tests-reagents.html","id":"column-agglutination-test-cat-gel-test","chapter":"Special Tests & Reagents","heading":"Column Agglutination Test (CAT / Gel Test™)","text":"Purpose: Detect agglutination within gel/bead matrix microtubeHow: Agglutinates get trapped centrifugation; unagglutinated cells pellet bottomWhy Use : Alternative platform routine tests (ABO/Rh, Screen, ID, DAT, XM); standardized, stable results","code":""},{"path":"special-tests-reagents.html","id":"chloroquine-diphosphate-cdp","chapter":"Special Tests & Reagents","heading":"Chloroquine Diphosphate (CDP)","text":"Purpose: Gently remove IgG DAT-positive RBCs vitroHow: Dissociates IgG near neutral pHWhy Use : allow phenotyping DAT-positive cells preserving antigens (including Kell, Duffy, MNS)","code":""},{"path":"special-tests-reagents.html","id":"edta-glycine-acid-ega","chapter":"Special Tests & Reagents","heading":"EDTA-Glycine Acid (EGA)","text":"Purpose: Remove IgG DAT-positive RBCs vitro using low pHHow: Acidic environment dissociates IgGWhy Use : Alternative CDP phenotyping DAT-positive cells, often faster requires critical neutralization step prevent antigen damage","code":""},{"path":"enzymes.html","id":"enzymes","chapter":"Enzymes","heading":"Enzymes","text":"Enzymes aren’t everyday digestive enzymes; use specific proteolytic enzymes special reagents help us solve tricky antibody problems. powerful tools, like power tool, need know use safely!Think enzymes molecular scissors snip specific protein structures red blood cell surface. snipping action can either destroy certain blood group antigens enhance reactivity others. comparing patient’s plasma reacts enzyme-treated red cells versus untreated red cells, can get valuable clues antibodies present","code":""},{"path":"enzymes.html","id":"purpose-why-use-enzymes","chapter":"Enzymes","heading":"Purpose: Why Use Enzymes?","text":"Enzymes typically used adjunct technique antibody identification routine testing (like LISS PEG IAT) gives complex unclear results. main goals :Help Separate Multiple Antibodies patient , say, anti-Fya (destroyed enzymes) anti-E (enhanced), treating panel cells enzymes might make anti-Fya reactivity disappear, allowing anti-E reactivity seen clearlyTo Enhance Weak Reactions antibodies, particularly Rh Kidd systems, may react weakly standard testing. Enzyme treatment can often boost reactions, making easier detect identifyTo Confirm Antibody Specificity suspect anti-Fya, treating cells enzyme abolish reaction. suspect anti-Jka, reaction ideally become stronger. provides supporting evidence identification","code":""},{"path":"enzymes.html","id":"common-enzymes-used-in-blood-bank","chapter":"Enzymes","heading":"Common Enzymes Used in Blood Bank","text":"frequently encountered proteolytic enzymes :Ficin: Derived figs. Probably commonly usedPapain: Derived papayas. Also commonBromelin: Derived pineapples. Used less frequently ficin/papainTrypsin: Derived animal pancreas (porcine). Used even less commonly routine labsFicin papain generally workhorses enzyme techniques","code":""},{"path":"enzymes.html","id":"mechanism-of-action-molecular-snipping","chapter":"Enzymes","heading":"Mechanism of Action: Molecular Snipping","text":"enzymes work primarily cleaving protein molecules carry part blood group antigens RBC surface. also often cleave sialic acid residues. Sialic acid contributes significantly negative surface charge (zeta potential) keeps red cells naturally repelling otherReducing Zeta Potential: removing negatively charged sialic acid, enzymes allow red cells get closer together, can facilitate agglutination IgG antibodies (especially Rh antibodies) might bridge gap effectively otherwiseModifying Antigen Structure\nDestruction: antigen part protein structure enzyme cleaves, antigen determinant may destroyed removed entirely\nEnhancement: Sometimes, removing surrounding structures changing conformation membrane can make certain antigens accessible antibodies, thus enhancing reaction\nDestruction: antigen part protein structure enzyme cleaves, antigen determinant may destroyed removed entirelyEnhancement: Sometimes, removing surrounding structures changing conformation membrane can make certain antigens accessible antibodies, thus enhancing reaction","code":""},{"path":"enzymes.html","id":"the-critical-part-effects-on-blood-group-antigens","chapter":"Enzymes","heading":"The CRITICAL Part: Effects on Blood Group Antigens","text":"Knowing antigens affected enzymes non-negotiable! Using enzymes without knowledge like driving blindfolded. ’s general guide (Ficin/Papain):Memorize Destroyed (MNS, Duffy) Enhanced (Rh, Kidd, Lewis) groups! Kell unaffected also key.","code":""},{"path":"enzymes.html","id":"methodologies-one-stage-vs.-two-stage","chapter":"Enzymes","heading":"Methodologies: One-Stage vs. Two-Stage","text":"One-Stage Enzyme Technique: Patient serum, enzyme solution, reagent red cells incubated together. Faster, can sometimes enhance unwanted cold agglutinins, enzyme activity might reduced serum componentsTwo-Stage Enzyme Technique: Reagent red cells pre-treated enzyme solution, washed thoroughly remove enzyme, incubated patient serum. Generally provides “cleaner” results less interference cold antibodies, takes longer. often preferred complex workups","code":""},{"path":"enzymes.html","id":"advantages-of-using-enzymes","chapter":"Enzymes","heading":"Advantages of Using Enzymes","text":"Can enhance reactivity certain clinically significant antibodies (Rh, Kidd, Lewis), aiding detectionUseful tool separating mixtures antibodies (destroying antigens enhancing others)Can help confirm antibody specificities","code":""},{"path":"enzymes.html","id":"disadvantages-and-cautions-very-important","chapter":"Enzymes","heading":"Disadvantages and Cautions (VERY Important!)","text":"BIGGEST RISK: Missing Clinically Significant Antibodies!: enzymes destroy M, N, S, s, Fya, Fyb antigens, detect antibodies antigens using enzyme technique. Enzyme testing MUST always performed parallel method preserves antigens (like LISS PEG IAT).Enhancement “Nuisance” Antibodies: Enzymes can enhance clinically insignificant cold autoantibodies (like anti-), can mask presence significant underlying alloantibodiesRequires Careful Control: need run untreated panel alongside enzyme-treated panel proper comparison. autocontrol also essentialOver-treatment/-treatment: Enzyme activity can vary; incorrect incubation times concentrations can lead inconsistent results","code":""},{"path":"enzymes.html","id":"interpretation-1","chapter":"Enzymes","heading":"Interpretation","text":"Compare reaction patterns enzyme-treated panel versus untreated panel (e.g., LISS/PEG panel):Reactions disappear weaken significantly enzyme panel: Suggests antibodies enzyme-labile antigens (M, N, S, Fya, Fyb)Reactions become stronger enzyme panel: Suggests antibodies enzyme-enhanced antigens (Rh, Kidd, Lewis, P1, )Reactions remain essentially unchanged: Suggests antibodies enzyme-resistant antigens (like Kell) potentially mixture effects cancel outEnzymes valuable part advanced blood banker’s toolkit, excellent troubleshooting complex antibody problems. remember limitations, especially destruction important antigens, always use alongside standard IAT methods!","code":""},{"path":"enzymes.html","id":"key-terms-80","chapter":"Enzymes","heading":"Key Terms","text":"Proteolytic Enzymes: Enzymes break proteins (e.g., ficin, papain)Sialic Acid: Negatively charged sugar molecules RBC surface, contributing zeta potential. Removed many enzymesZeta Potential: electrostatic potential difference RBC surface surrounding fluid, creating repulsive force cells. Reduced enzymesAntigen Destruction: Enzyme treatment removes alters antigen determinant ’s longer recognized antibodyAntigen Enhancement: Enzyme treatment makes antigen accessible reactive antibodyOne-Stage Enzyme Technique: Serum, enzyme, cells incubated togetherTwo-Stage Enzyme Technique: Cells pre-treated enzyme, washed, incubated serumParallel Testing: Running enzyme-treated panel concurrently untreated panel (e.g., LISS PEG) comparison. Essential safe interpretation","code":""},{"path":"enhancement-media.html","id":"enhancement-media","chapter":"Enhancement Media","heading":"Enhancement Media","text":"Enhancement Media solutions add antibody testing (primarily Indirect Antiglobulin Test - IAT) give antibody-antigen reactions little “boost.” Think catalysts helpers make first stage agglutination – sensitization (antibody binds red cell antigen) – happen effectively quicklyTheir main goals typically :Increase speed: antibody uptake onto red cellsIncrease sensitivity: test, allowing us detect weaker antibodies antibodies present low concentrationsReduce incubation times, making testing efficientWe primarily use Indirect Antiglobulin Test (IAT) antibody screening, antibody identification, AHG-phase crossmatching. three common types ’ll encounter LISS, PEG, Albumin","code":""},{"path":"enhancement-media.html","id":"low-ionic-strength-saline-liss","chapter":"Enhancement Media","heading":"Low Ionic Strength Saline (LISS)","text":": solution containing saline (sodium chloride) lower concentration normal physiological saline (0.9%). often contains glycine components maintain osmolarityMechanism Action: Red blood cells net negative charge (due sialic acid), antibody molecules (extent). normal saline, positively charged sodium ions (Na+) cluster around negatively charged RBCs, forming “ionic cloud.” cloud partially shields antigens creates repulsive forces, making harder antibodies get close bind. LISS reduces concentration shielding ions. fewer Na+ ions around, ionic cloud shrinks, reducing repulsive forces allowing antibodies approach bind red cell antigens rapidlyAdvantages\nSignificantly reduces incubation time (typically 10-15 minutes compared 30-60 minutes saline incubation)\nIncreases sensitivity compared saline alone\nRelatively inexpensive widely used\nSignificantly reduces incubation time (typically 10-15 minutes compared 30-60 minutes saline incubation)Increases sensitivity compared saline aloneRelatively inexpensive widely usedDisadvantages/Cautions\nCan sometimes enhance reactivity cold, clinically insignificant antibodies\nsensitive ratio serum/plasma cells – usually requires equal volumes (e.g., 2 drops plasma: 1 drop 3-5% cells prepared washed LISS, per manufacturer). Deviating can alter final ionic strength, reducing effectiveness\nPotential false positives incubated long certain additives present (rare)\nCan sometimes enhance reactivity cold, clinically insignificant antibodiesVery sensitive ratio serum/plasma cells – usually requires equal volumes (e.g., 2 drops plasma: 1 drop 3-5% cells prepared washed LISS, per manufacturer). Deviating can alter final ionic strength, reducing effectivenessPotential false positives incubated long certain additives present (rare)Typical Use: common routine antibody screening, antibody identification, crossmatching. Reactions typically read 37°C incubation (optional) always washing adding AHG","code":""},{"path":"enhancement-media.html","id":"polyethylene-glycol-peg","chapter":"Enhancement Media","heading":"Polyethylene Glycol (PEG)","text":": water-soluble polymer added low ionic strength solutionMechanism Action: PEG works primarily steric exclusion water. large PEG molecules effectively “pull” water molecules away red blood cells. concentrates antibodies immediate vicinity cells, increasing likelihood rate antibody-antigen binding. works concert low ionic environmentAdvantages\nConsidered sensitive common enhancement medium, especially detecting weak IgG antibodies (particularly Kidd, Duffy, Rh antibodies)\nGenerally enhance cold agglutinins much LISS can\nAllows short incubation times (usually 10-15 minutes)\nConsidered sensitive common enhancement medium, especially detecting weak IgG antibodies (particularly Kidd, Duffy, Rh antibodies)Generally enhance cold agglutinins much LISS canAllows short incubation times (usually 10-15 minutes)Disadvantages/Cautions (CRITICAL!)\nPEG can cause non-specific red cell aggregation.: means read test agglutination macroscopically 37°C incubation step washing. often look clumpy, true agglutination. MUST proceed directly thorough washing AHG phase\nRequires meticulous washing (often 4 times) remove traces PEG adding AHG, residual PEG can interfere AHG reaction\nCan sometimes enhance warm autoantibodies, potentially masking underlying alloantibodies\nMay occasionally miss detecting certain IgM antibodies immediate spin/room temperature reading omitted (PEG procedures often skip )\nPEG can cause non-specific red cell aggregation.: means read test agglutination macroscopically 37°C incubation step washing. often look clumpy, true agglutination. MUST proceed directly thorough washing AHG phaseRequires meticulous washing (often 4 times) remove traces PEG adding AHG, residual PEG can interfere AHG reactionCan sometimes enhance warm autoantibodies, potentially masking underlying alloantibodiesMay occasionally miss detecting certain IgM antibodies immediate spin/room temperature reading omitted (PEG procedures often skip )Typical Use: Widely used antibody screening identification, especially maximum sensitivity desired. read reactions washing adding AHG.","code":""},{"path":"enhancement-media.html","id":"bovine-serum-albumin-bsa","chapter":"Enhancement Media","heading":"Bovine Serum Albumin (BSA)","text":": solution containing albumin (usually 22% 30%) derived cow serumMechanism Action: Albumin works primarily reducing zeta potential. Zeta potential force repulsion negatively charged red cells suspension. Albumin increases dielectric constant medium, effectively reduces repulsive forces, allowing red cells get closer together. makes easier IgG antibodies (smaller IgM) bridge gap sensitized cells cause agglutinationAdvantages\nCan enhance reactivity antibodies, particularly Rh system\nHistorically significant – one earliest enhancement media developed\nCan enhance reactivity antibodies, particularly Rh systemHistorically significant – one earliest enhancement media developedDisadvantages/Cautions\nLeast effective: common enhancement media terms increasing sensitivity reducing incubation time\nRequires longer incubation times (typically 30-60 minutes)\nCan occasionally cause non-specific aggregation rouleaux, requiring careful interpretation\nsensitive LISS PEG detecting many clinically significant antibodies\nLeast effective: common enhancement media terms increasing sensitivity reducing incubation timeRequires longer incubation times (typically 30-60 minutes)Can occasionally cause non-specific aggregation rouleaux, requiring careful interpretationNot sensitive LISS PEG detecting many clinically significant antibodiesTypical Use: Largely replaced LISS PEG routine antibody screening identification due lower sensitivity longer incubation time. May still encountered labs specific purposes (like certain Rh typing techniques) educational demonstrations. Reactions read 37°C incubation washing adding AHG","code":""},{"path":"enhancement-media.html","id":"summary-key-differences","chapter":"Enhancement Media","heading":"Summary & Key Differences","text":"Crucial Point Regardless enhancement medium used, MUST follow manufacturer’s instructions precisely regarding serum/plasma--cell ratios, incubation times, temperature, reading procedures. QC also essential ensure reagents performing expected!","code":""},{"path":"enhancement-media.html","id":"key-terms-81","chapter":"Enhancement Media","heading":"Key Terms","text":"Enhancement Media: Solutions added serum/plasma red cell mixtures increase speed /sensitivity antibody-antigen reactions, primarily IATSensitization: first stage agglutination; binding antibody (complement) antigens red blood cell surface. step often invisibleIndirect Antiglobulin Test (IAT): Laboratory test used detect vitro sensitization (antibodies plasma binding reagent cells). Involves incubation (often enhancement media), washing, adding AHGLISS (Low Ionic Strength Saline): Enhancement medium works reducing ionic strength around RBCs, promoting faster antibody uptakePEG (Polyethylene Glycol): Enhancement medium works excluding water, concentrating antibodies near RBC surface. Highly sensitive read 37°C incubation washingAlbumin (Bovine Serum Albumin / BSA): Enhancement medium works reducing zeta potential RBCs. Less sensitive requires longer incubation LISS PEGZeta Potential: electrostatic force repulsion adjacent, similarly charged particles (like RBCs) suspensionSteric Exclusion: principle PEG removes water around RBCs, promoting antibody binding","code":""},{"path":"lectins.html","id":"lectins","chapter":"Lectins","heading":"Lectins","text":"Lectins aren’t antibodies, act like highly specific antibodies certain situations. proteins, usually derived plants (like seeds) sometimes invertebrates, remarkable ability bind specifically certain carbohydrate (sugar) structures red blood cell surfaceThink picky eaters – bind one specific type sugar arrangement. blood group antigens often involve specific sugar structures, can use lectins specialized reagents help us identify differentiate certain blood types resolve discrepancies","code":""},{"path":"lectins.html","id":"purpose-why-use-lectins","chapter":"Lectins","heading":"Purpose: Why Use Lectins?","text":"Lectins aren’t used everyday ABO/Rh typing, become valuable tools specific situations:Resolving ABO Discrepancies: Especially useful differentiating ABO subgroups (like A1 vs A2)Identifying Rare Phenotypes: Critical identifying Bombay phenotype (Oh)Confirming Antigen Presence/Absence: Can used confirm presence certain antigens antisera might unavailable results unclear (though less common now monoclonal antisera)Investigating Polyagglutination: lectins react hidden “T” antigens exposed RBCs bacterial enzymes (reference lab investigation)","code":""},{"path":"lectins.html","id":"the-key-players-in-blood-bank","chapter":"Lectins","heading":"The Key Players in Blood Bank","text":"many lectins exist nature, routinely important blood bank setting:","code":""},{"path":"lectins.html","id":"anti-a1-lectin-from-dolichos-biflorus-seeds","chapter":"Lectins","heading":"Anti-A1 Lectin (from Dolichos biflorus seeds)","text":"Specificity: Binds strongly specifically A1 antigenMechanism: A1 antigen slightly different terminal carbohydrate structure compared subgroups (like A2). lectin recognizes specific A1 structurePrimary Use: Differentiating A1 A2 red blood cells. 80% Group (AB) individuals A1 subtype; remaining 20% A2 weaker subgroupsWhy Differentiate A1/A2?\nA2 (A2B) individuals can produce naturally occurring anti-A1 antibody plasma. causes discrepancy: Forward type looks Group , Reverse type shows reactivity A1 cells (patient’s anti-A1)\nTesting patient’s red cells Anti-A1 lectin helps resolve . lectin negative, patient likely A2 (weaker), explaining presence anti-A1 plasma\nA2 (A2B) individuals can produce naturally occurring anti-A1 antibody plasma. causes discrepancy: Forward type looks Group , Reverse type shows reactivity A1 cells (patient’s anti-A1)Testing patient’s red cells Anti-A1 lectin helps resolve . lectin negative, patient likely A2 (weaker), explaining presence anti-A1 plasmaInterpretation\nPatient RBCs + Anti-A1 Lectin = Agglutination –> A1 Positive\nPatient RBCs + Anti-A1 Lectin = Agglutination –> A1 Negative (likely A2 weaker subgroup forward typing indicates AB)\nPatient RBCs + Anti-A1 Lectin = Agglutination –> A1 PositivePatient RBCs + Anti-A1 Lectin = Agglutination –> A1 Negative (likely A2 weaker subgroup forward typing indicates AB)","code":""},{"path":"lectins.html","id":"anti-h-lectin-from-ulex-europaeus-seeds---gorse","chapter":"Lectins","heading":"Anti-H Lectin (from Ulex europaeus seeds - Gorse)","text":"Specificity: Binds specifically H antigenMechanism: H antigen carbohydrate precursor structure upon B antigens built. amount unconverted H antigen varies depending ABO group\nH: Group O\nIntermediate H: A2 > B > A2B\nLeast H: A1 > A1B\nH: Bombay phenotype (Oh)\nH: Group OIntermediate H: A2 > B > A2BLeast H: A1 > A1BNO H: Bombay phenotype (Oh)Primary Uses\nConfirming Group O status: Group O cells react strongly Anti-H lectin\nIdentifying weak B subgroups: often H antigen expected typical B types, might react strongly Anti-H\nIdentifying rare Bombay phenotype (Oh): critical! Bombay individuals genetically lack ability make H antigen. Therefore, red cells react Anti-H lectin, despite potentially genes B. also potent anti-, anti-B, anti-H plasma\nConfirming Group O status: Group O cells react strongly Anti-H lectinIdentifying weak B subgroups: often H antigen expected typical B types, might react strongly Anti-HIdentifying rare Bombay phenotype (Oh): critical! Bombay individuals genetically lack ability make H antigen. Therefore, red cells react Anti-H lectin, despite potentially genes B. also potent anti-, anti-B, anti-H plasmaInterpretation\nPatient RBCs + Anti-H Lectin = Agglutination –> H antigen present (strength varies ABO type)\nPatient RBCs + Anti-H Lectin = Agglutination –> H antigen absent severely deficient (Strongly suggests Bombay phenotype - requires confirmation!)\nPatient RBCs + Anti-H Lectin = Agglutination –> H antigen present (strength varies ABO type)Patient RBCs + Anti-H Lectin = Agglutination –> H antigen absent severely deficient (Strongly suggests Bombay phenotype - requires confirmation!)","code":""},{"path":"lectins.html","id":"others-less-commonly-used-in-routine-special-testing-now","chapter":"Lectins","heading":"Others (Less Commonly Used in Routine Special Testing Now)","text":"Anti-N Lectin (Vicia graminea): Specific N antigen. Largely replaced monoclonal Anti-N antiseraAnti-M Lectin (Iberis amara): Specific M antigen. Also largely replaced monoclonal Anti-MAnti-T Lectin (Arachis hypogaea - Peanut Agglutinin): Used polyagglutination workups detect exposure T antigen","code":""},{"path":"lectins.html","id":"how-lectins-are-used","chapter":"Lectins","heading":"How Lectins Are Used","text":"Methodology: Usually simple, direct agglutination tests performed tubes slides room temperatureProcedure: drop lectin reagent mixed suspension washed patient red blood cellsObservation: Checked agglutination brief incubation/centrifugation according manufacturer’s instructionsControls ESSENTIAL: Always run known positive known negative control cells concurrently ensure lectin reagent working correctly (e.g., A1 A2 cells Dolichos; O A1B cells Ulex)","code":""},{"path":"lectins.html","id":"advantages-3","chapter":"Lectins","heading":"Advantages","text":"Provide high specificity certain carbohydrate structuresReadily available stable reagentsInvaluable resolving specific ABO typing issues (subgroups, Bombay)","code":""},{"path":"lectins.html","id":"disadvantagescautions","chapter":"Lectins","heading":"Disadvantages/Cautions","text":"antibodies – don’t confuse mechanism interpretation entirely antibody-antigen reactionsTheir reactivity solely based carbohydrate structures, (rarely) might altered disease statesLimited range – useful specific structures recognizeRequire strict adherence QC proceduresLectins fantastic specialized tools! Knowing use Anti-A1 Anti-H lectins, particular, can help unravel perplexing ABO discrepancies identify rare, important phenotypes like Bombay","code":""},{"path":"lectins.html","id":"key-terms-82","chapter":"Lectins","heading":"Key Terms","text":"Lectins: Proteins (usually plant-derived) bind specifically carbohydrate structuresCarbohydrate: Sugar molecules; form basis many blood group antigens (like ABO, H, Lewis, P, )Anti-A1 Lectin (Dolichos biflorus): Reagent used differentiate A1 non-A1 (A2, etc.) red blood cells binding specifically A1 antigenAnti-H Lectin (Ulex europaeus): Reagent used detect presence relative strength H antigen. Crucial identifying Bombay phenotype (lacks H)A1/A2 Subgroups: Common subtypes blood group, differing slightly structure amount antigen expressed. A2 individuals can sometimes make anti-A1H Antigen: carbohydrate precursor structure required expression B blood group antigensBombay Phenotype (Oh): Rare phenotype individuals lack H antigen (genotype hh) therefore express B antigens, even B genes. red cells lack H, , B antigens, plasma contains anti-, anti-B, anti-HPolyagglutination: state red blood cells agglutinated normal adult human sera, often due exposure hidden antigens (like T) RBC surface","code":""},{"path":"adsorptions.html","id":"adsorptions","chapter":"Adsorptions","heading":"Adsorptions","text":"Adsorption techniques super important tool immunohematology reference lab (sometimes routine blood banks) ’re faced tricky antibody situations, especially autoantibodies interferingThink adsorption using red blood cells like specific sponges soak certain antibodies patient’s serum plasma, leaving antibodies behind us identify","code":""},{"path":"adsorptions.html","id":"the-core-purpose-removing-interfering-antibodies","chapter":"Adsorptions","heading":"The Core Purpose: Removing Interfering Antibodies","text":"primary goal adsorption usually remove unwanted antibodies (commonly autoantibodies) patient’s serum/plasma clinically significant alloantibodies (antibodies foreign red cell antigens) can detected identifiedOther uses include:Separating multiple alloantibodies present sampleConfirming specificity antibody showing can removed cells possessing corresponding antigenPreparing single-specificity antibody reagents (less common now monoclonals)","code":""},{"path":"adsorptions.html","id":"the-basic-principle","chapter":"Adsorptions","heading":"The Basic Principle","text":"Incubation Patient serum/plasma (containing antibody mixture) incubated red blood cells possess antigen(s) corresponding antibody(ies) want removeBinding incubation, target antibody(ies) bind antigens red blood cell surface (sensitization)Separation mixture centrifuged, packing red cells (now coated adsorbed antibody) bottomHarvesting supernatant plasma/serum (adsorbed serum) carefully removed. adsorbed serum now free (significantly reduced levels) antibody stuck red cellsTesting adsorbed serum tested antibody screening panel cells see antibodies remain","code":""},{"path":"adsorptions.html","id":"types-of-adsorption-techniques-choosing-your-sponge","chapter":"Adsorptions","heading":"Types of Adsorption Techniques: Choosing Your “Sponge”","text":"type red cells used adsorption critical defines technique:","code":""},{"path":"adsorptions.html","id":"autologous-adsorption-auto-adsorption","chapter":"Adsorptions","heading":"Autologous Adsorption (“Auto-adsorption”)","text":": Using patient’s red blood cells adsorb antibodies serum/plasmaWhen ’s Used: preferred method possible, especially removing warm autoantibodiesWhy ’s Preferred: Since patient’s cells lack foreign antigens (definition), adsorb autoantibodies. alloantibodies present serum bind patient’s cells remain adsorbed serum, ready detection identificationMajor Limitation: reliably performed patient recently transfused (typically within last 3 months). ? circulating donor red cells (foreign) mixed patient’s cells. donor cells potentially adsorb clinically significant alloantibodies patient’s serum, causing missed adsorbed serum (dangerous false-negative situation!)Challenge: Often, patients needing auto-adsorption positive Direct Antiglobulin Test (DAT), meaning cells already coated vivo autoantibody. coating can block antigen sites needed adsorption vitro. Therefore, patient cells often need pre-treatment adsorption:\nZZAP Treatment: reagent mixture containing proteolytic enzyme (papain ficin) thiol reagent (like DTT 2-). removes bound antibody (especially IgG) RBC surface also treats cells enzymatically. Caution: ZZAP destroys Kell system antigens M, N, S, Fya, Fyb antigens, wouldn’t able detect alloantibodies specificities also present adsorbed onto ZZAP-treated cells (though less concern auto-adsorption alloantibodies shouldn’t adsorb)\nChloroquine Diphosphate (CDP) Treatment: Gently dissociates IgG red cell surface, often without significantly damaging antigens (except possibly Bg antigens). Less harsh ZZAP might less effective removing strongly bound antibody\nZZAP Treatment: reagent mixture containing proteolytic enzyme (papain ficin) thiol reagent (like DTT 2-). removes bound antibody (especially IgG) RBC surface also treats cells enzymatically. Caution: ZZAP destroys Kell system antigens M, N, S, Fya, Fyb antigens, wouldn’t able detect alloantibodies specificities also present adsorbed onto ZZAP-treated cells (though less concern auto-adsorption alloantibodies shouldn’t adsorb)Chloroquine Diphosphate (CDP) Treatment: Gently dissociates IgG red cell surface, often without significantly damaging antigens (except possibly Bg antigens). Less harsh ZZAP might less effective removing strongly bound antibodyProcedure: Patient cells (potentially pre-treated) washed, packed, mixed patient serum/plasma, incubated (often 37°C warm autoantibodies, 4°C cold), centrifuged, adsorbed serum harvested. Often requires multiple rounds adsorption complete removal","code":""},{"path":"adsorptions.html","id":"allogeneic-adsorption-homologous-or-differential-adsorption","chapter":"Adsorptions","heading":"Allogeneic Adsorption (Homologous or Differential Adsorption)","text":": Using red blood cells individuals (donor cells) known antigen phenotypes adsorb antibodies patient’s serum/plasmaWhen ’s Used: Necessary autologous adsorption performed (e.g., recent transfusion, patient severely anemic insufficient RBCs)Big Challenge: Selecting donor cells carefully! goal remove interfering antibody (usually broadly reactive autoantibody) WITHOUT removing clinically significant alloantibodies patient might also haveHow ’s Done (Often Differential Adsorption): Requires careful planning. Typically uses three different donor cell samples specific Rh phenotypes maximize chance leaving common alloantibodies behind:\nR1R1 cells: (e.g., CDe/CDe) - Lack c E antigens\nR2R2 cells: (e.g., cDE/cDE) - Lack C e antigens\nrr cells: (e.g., cde/cde) - Lack C, D, E antigens\ncells also ideally cover common antigens like K, Fya, Fyb, Jka, Jkb, S, s\nR1R1 cells: (e.g., CDe/CDe) - Lack c E antigensR2R2 cells: (e.g., cDE/cDE) - Lack C e antigensrr cells: (e.g., cde/cde) - Lack C, D, E antigensThese cells also ideally cover common antigens like K, Fya, Fyb, Jka, Jkb, S, sProcedure: Patient serum adsorbed separately selected donor cell types. adsorbed serum aliquots tested panel cells. comparing results different aliquots untreated serum, underlying alloantibodies can often identified (e.g., anti-E present, remain serum adsorbed R1R1 rr cells, adsorbed R2R2 cells)Risk: ’s always risk, especially broadly reactive autoantibodies, co-existing alloantibody might react antigen present chosen donor cells inadvertently adsorbed ","code":""},{"path":"adsorptions.html","id":"rabbit-erythrocyte-stroma-rest-adsorption","chapter":"Adsorptions","heading":"Rabbit Erythrocyte Stroma (RESt) Adsorption","text":": Using rabbit red blood cell membranes (stroma) rich structures similar human , H, IH antigensWhen ’s Used: Primarily remove interfering cold autoantibodies (often anti-) causing problems room temperature immediate spin phases, potentially masking IgM alloantibodiesCaution: RESt can sometimes adsorb antibodies, including anti-B clinically significant antibodies like anti-Vel","code":""},{"path":"adsorptions.html","id":"interpretation-next-steps","chapter":"Adsorptions","heading":"Interpretation & Next Steps","text":"adsorption, adsorbed serum tested using standard antibody identification panel procedures (e.g., LISS PEG IAT)Compare results adsorbed serum panel results obtained unadsorbed serumAny clinically significant alloantibodies remain adsorbed serum (especially autoadsorption) specificity can now determined without interference removed antibodyIf reactivity disappears adsorption, suggests adsorbed antibody (e.g., autoantibody) presentAdsorption techniques powerful require careful planning, execution, interpretation. essential ensuring patient safety autoantibodies complicate serologic picture!","code":""},{"path":"adsorptions.html","id":"key-terms-83","chapter":"Adsorptions","heading":"Key Terms","text":"Adsorption: process removing antibodies serum/plasma allowing bind specific antigens red blood cells, followed separation serum antibody-coated cellsAdsorbed Serum: supernatant serum/plasma remaining adsorption procedure, ideally depleted targeted antibody(ies)Autologous Adsorption: Adsorption using patient’s red blood cells (preferred method removing autoantibodies recently transfused)Allogeneic Adsorption: Adsorption using red blood cells donor individuals known phenotypes (used autologous adsorption feasible)Differential Adsorption: type allogeneic adsorption using multiple cell samples carefully selected phenotypes (e.g., R1R1, R2R2, rr) help separate multiple antibodies remove autoantibodies preserving common alloantibodiesZZAP: reagent combining enzyme (ficin/papain) thiol reagent (DTT/2-), used remove bound IgG RBCs autoadsorption (destroys Kell, MNS, Duffy antigens)Chloroquine Diphosphate (CDP): chemical reagent used gently remove bound IgG RBCs autoadsorption, typically preserving RBC antigensRESt (Rabbit Erythrocyte Stroma): Used primarily adsorb cold autoantibodies (like anti-)Alloantibody: antibody directed red blood cell antigen foreign individual (usually stimulated transfusion pregnancy)Autoantibody: antibody directed individual’s red blood cell antigens","code":""},{"path":"elutions.html","id":"elutions","chapter":"Elutions","heading":"Elutions","text":"Elution technique use know red blood cells coated antibody vivo (Direct Antiglobulin Test - DAT - positive), want figure exactly antibody coatingThink gently prying antibody red blood cell can capture test separately. ’s detective work DAT alarm bell rung!","code":""},{"path":"elutions.html","id":"the-core-purpose-identifying-bound-antibody","chapter":"Elutions","heading":"The Core Purpose: Identifying Bound Antibody","text":"primary goal elution procedure recover intact antibodies bound red blood cells vivo, allowing identification specificityWe perform elutions almost exclusively patient positive Direct Antiglobulin Test (DAT), especially key scenarios:Hemolytic Disease Fetus Newborn (HDFN): identify maternal antibody (e.g., anti-D, anti-K) coating newborn’s red blood cellsTransfusion Reaction Investigation: identify recipient antibody coating transfused donor red blood cells (e.g., patient anti-Jka coating transfused Jk(+) cells)Autoimmune Hemolytic Anemia (AIHA): identify specificity autoantibody coating patient’s red blood cells (though often ’s broadly reactive common Rh specificity like anti-e)Drug-Induced Hemolytic Anemia (DIHA): help determine antibody coating cells drug-dependent","code":""},{"path":"elutions.html","id":"the-starting-material-antibody-coated-rbcs","chapter":"Elutions","heading":"The Starting Material: Antibody-Coated RBCs","text":"input elution thoroughly washed red blood cells individual positive DAT (patient sample, cord blood sample, post-reaction sample)WASHING PARAMOUNT!: stressed enough. cells must washed meticulously (often 6-8 times , using large volumes saline) remove traces unbound antibody surrounding plasma. plasma antibodies contaminate sample, end final eluate, leading false-positive misleading result. want recover antibody actually stuck cellsLast Wash Control: critical quality control step, supernatant fluid final wash saved tested parallel eluate. last wash control MUST NEGATIVE. shows reactivity, indicates insufficient washing, elution results invalid","code":""},{"path":"elutions.html","id":"the-basic-principle-disrupting-the-antigen-antibody-bond","chapter":"Elutions","heading":"The Basic Principle: Disrupting the Antigen-Antibody Bond","text":"Elution methods work manipulating physical conditions break chemical bonds holding antibody red cell antigen, without (ideally) destroying antibody . bond broken, antibody released surrounding fluid (eluting solution)","code":""},{"path":"elutions.html","id":"common-elution-methods","chapter":"Elutions","heading":"Common Elution Methods","text":"Different methods use different stresses break bonds:","code":""},{"path":"elutions.html","id":"acid-elution-e.g.-glycine-acid-citric-acid","chapter":"Elutions","heading":"Acid Elution (e.g., Glycine Acid, Citric Acid)","text":"Mechanism: Lowers pH environment (typically around 3.0). disrupts electrostatic hydrogen bonds antigen antibody, causing antibody dissociateProcedure: Washed packed RBCs mixed acid solution, incubated briefly, centrifuged immediately. supernatant fluid (containing released antibody) harvested immediately buffered back physiological pH (around 7.0) prevent denaturation antibody acidPros: Relatively fast, simple, generally effective recovering IgG antibodies, especially ABO antibodies cases HDFNCons: Requires rapid buffering maintain antibody activity. May effective antibody types","code":""},{"path":"elutions.html","id":"heat-elution","chapter":"Elutions","heading":"Heat Elution","text":"Mechanism: Uses increased temperature (typically 56°C) weaken antigen-antibody bondsProcedure: Washed packed RBCs suspended saline albumin, incubated 56°C 10 minutes, centrifuged still hot. supernatant eluate harvested immediatelyPros: Simple technique. Particularly good detecting ABO antibodies HDFN investigations involving cord blood cellsCons: Less sensitive acid solvent methods many non-ABO IgG antibodies. Heat can potentially denature antibodies","code":""},{"path":"elutions.html","id":"freeze-thaw-elution-lui-easy-freeze-method","chapter":"Elutions","heading":"Freeze-Thaw Elution (Lui Easy Freeze Method)","text":"Mechanism: Rapid freezing causes ice crystal formation, lyses red blood cells. process likely disrupts antigen-antibody interaction, releasing antibodyProcedure: Washed packed RBCs resuspended small volume saline ABO-compatible serum, frozen rapidly (e.g., alcohol/dry ice bath -70°C freezer), thawed quickly (e.g., 37°C water bath). mixture centrifuged, hemoglobin-stained supernatant (eluate) harvestedPros: simple fast. Effective detecting ABO antibodies HDFNCons: Generally less sensitive acid elution detecting IgG antibodies","code":""},{"path":"elutions.html","id":"organic-solvent-elution-e.g.-dichloromethane-xylene-ether---less-common-reference-lab","chapter":"Elutions","heading":"Organic Solvent Elution (e.g., Dichloromethane, Xylene, Ether - Less Common / Reference Lab)","text":"Mechanism: Organic solvents disrupt hydrophobic bonds involved antigen-antibody interactions also affect lipid bilayer red cell membrane, causing antibody releaseProcedure: Involves mixing washed RBCs solvent, agitation, centrifugation separate layers, careful harvesting aqueous eluate layerPros: Historically considered effective recovering various IgG antibodies, especially non-ABO typesCons: SIGNIFICANT SAFETY HAZARDS! solvents often flammable, volatile, toxic, requiring use specialized fume hoods careful disposal. Due safety concerns, largely replaced safer methods like acid elution routine clinical labs. Primarily used reference settings now","code":""},{"path":"elutions.html","id":"testing-the-eluate","chapter":"Elutions","heading":"Testing the Eluate","text":"harvested, eluate (fluid containing recovered antibody) tested like serum plasma panel reagent red blood cells (Group O panel cells) using Indirect Antiglobulin Test (IAT) method (often LISS PEG) determine antibody’s specificity","code":""},{"path":"elutions.html","id":"interpretation-2","chapter":"Elutions","heading":"Interpretation","text":"Specificity Identified: eluate reacts panel cells specific pattern (e.g., reacts D-positive cells), identifies antibody coating cells (e.g., anti-D)Panreactive Eluate: eluate reacts panel cells tested (last wash control negative), usually indicates warm autoantibody coating cells. testing patient’s serum (often adsorption) needed rule underlying alloantibodiesNegative Eluate: eluate non-reactive panel cells (last wash control negative), mean:\nDAT positive due complement coating (elution method used doesn’t recover complement)\nantibody weak detected elution\nantibody detached washing process (unlikely done correctly)\nelution procedure failed denatured antibody\ninitial DAT false positive\nDAT positive due complement coating (elution method used doesn’t recover complement)antibody weak detected elutionThe antibody detached washing process (unlikely done correctly)elution procedure failed denatured antibodyThe initial DAT false positive","code":""},{"path":"elutions.html","id":"key-terms-84","chapter":"Elutions","heading":"Key Terms","text":"Elution: process recovering antibodies bound red blood cells (usually vivo) disrupting antigen-antibody bondsEluate: fluid containing antibodies recovered elution procedureDirect Antiglobulin Test (DAT): Test used detect IgG complement coating red blood cells vivo. positive DAT primary indication performing elutionIn Vivo Sensitization: coating red blood cells antibody complement within patient’s bodyLast Wash Control: quality control step supernatant final wash red blood cells (adding eluting solution) tested parallel eluate. must non-reactive elution results validAcid Elution: Elution method using low pH dissociate antibodiesHeat Elution: Elution method using elevated temperature (e.g., 56°C) dissociate antibodiesFreeze-Thaw Elution: Elution method using rapid freezing thawing lyse cells release antibodiesOrganic Solvent Elution: Elution method using chemicals like dichloromethane ether dissociate antibodies (less common due safety)Specificity: particular antigen(s) antibody recognizes binds ","code":""},{"path":"titrations-1.html","id":"titrations-1","chapter":"Titrations","heading":"Titrations","text":"Antibody Titration technique might seem bit old-school compared molecular methods, remains incredibly valuable, especially monitoring pregnant patients. ’s less identifying antibody (usually know already) measuring much present, strongly reactsThink trying figure “concentration” “strength” antibody patient’s serum","code":""},{"path":"titrations-1.html","id":"the-core-purpose-quantifying-antibody-strength","chapter":"Titrations","heading":"The Core Purpose: Quantifying Antibody Strength","text":"primary goal titration provide semi-quantitative measure concentration specific antibody patient’s serum plasma. determining highest dilution serum still produces detectable reaction red blood cells possessing target antigenKey applications include:Monitoring Pregnant Patients Clinically Significant Antibodies: IMPORTANT use! Tracking titer IgG antibodies (like anti-D, anti-K, anti-c, etc.) known cause Hemolytic Disease Fetus Newborn (HDFN) helps assess potential risk fetus. significant rise titer pregnancy suggests increased antibody production may indicate worsening fetal jeopardyCharacterizing Antibodies: Helps differentiate certain types antibodies, like High Titer, Low Avidity (HTLA) antibodies. often show reactivity high dilutions reactions consistently weak, usually clinically insignificantSpecific Serologic Investigations: Occasionally used compare reactivity antibody different red cell samples (e.g., comparing reactivity cells homozygous vs. heterozygous antigen demonstrate dosage)Important Note Titration results generally used decide whether transfuse antigen-negative blood. patient clinically significant antibody, receive antigen-negative units regardless titer","code":""},{"path":"titrations-1.html","id":"the-basic-procedure-serial-dilution","chapter":"Titrations","heading":"The Basic Procedure: Serial Dilution","text":"Sample Patient serum plasma known contain antibody interestTarget Cells Washed red blood cells known positive antigen corresponding antibody titrated (e.g., use D-positive cells titrating anti-D). Ideally, use cells consistent antigen expression (e.g., R1r RzR1 anti-D, often homozygous cells like Jk(+b-) anti-Jka maximize reactivity)Serial Dilutions Prepare series doubling dilutions patient’s serum suitable diluent (usually saline). typically starts undiluted (neat) serum, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256, , often 1:1024 higher needed\nConsistency key: Use precise pipetting techniques ensure accurate dilutions!\nConsistency key: Use precise pipetting techniques ensure accurate dilutions!Incubation Add equal, consistent volume prepared target red cell suspension tube containing serum dilutionTest Method Incubate tubes using standard Indirect Antiglobulin Test (IAT) procedure (often using LISS saline medium, sometimes albumin, rarely PEG due reading difficulties). method chosen consistent subsequent titrations patientWashing & AHG incubation (usually 37°C), wash tubes thoroughly add Anti-Human Globulin (AHG)Reading & Grading Centrifuge gently, resuspend cell buttons, examine macroscopically agglutination. Crucially, grade reaction strength tube (e.g., 0, w+, 1+, 2+, 3+, 4+)","code":""},{"path":"titrations-1.html","id":"determining-the-titer-and-score","chapter":"Titrations","heading":"Determining the Titer and Score","text":"Titer Endpoint: titer reported reciprocal highest dilution serum shows 1+ macroscopic agglutination. example, 1:64 dilution shows 1+ agglutination, 1:128 dilution weaker (w+) negative (0), titer 64Scoring (Semi-Quantitative): endpoint can subjective small changes might missed, score often calculated provide sensitive measure, especially monitoring pregnant patients. grade agglutination assigned numerical value (scores vary slightly institution, common system ):\n4+ = 12\n3+ = 10\n2+ = 8\n1+ = 5\nw+ = 2 (3)\n0 = 0\n(Hemolysis, present antibody-mediated, might scored 10 12)\nscores reactive tubes (including w+ reactions 1+ endpoint) summed get total score\n4+ = 123+ = 102+ = 81+ = 5w+ = 2 (3)0 = 0(Hemolysis, present antibody-mediated, might scored 10 12)scores reactive tubes (including w+ reactions 1+ endpoint) summed get total score","code":""},{"path":"titrations-1.html","id":"interpretation-especially-in-hdfn-monitoring","chapter":"Titrations","heading":"Interpretation, Especially in HDFN Monitoring","text":"Baseline: initial titer established early pregnancy significant antibody foundMonitoring: Titrations repeated intervals (e.g., monthly, bi-weekly). Crucially, valid comparison, current sample MUST tested PARALLEL previously frozen sample patient, using target cells exact technique reader.Significant Change: clinically significant rise antibody level generally considered :\ntwo-dilution (four-fold) increase titer (e.g., 16 64)\n: increase score 10 (often sensitive titer endpoint alone)\ntwo-dilution (four-fold) increase titer (e.g., 16 64): increase score 10 (often sensitive titer endpoint alone)Critical Titer: predetermined titer level specific antibodies (e.g., often 16 32 anti-D, varies antibodies like anti-K level can concerning) risk severe HDFN high enough warrant intensive fetal monitoring (like Middle Cerebral Artery Doppler scans assess fetal anemia)","code":""},{"path":"titrations-1.html","id":"high-titer-low-avidity-htla-antibodies","chapter":"Titrations","heading":"High Titer, Low Avidity (HTLA) Antibodies","text":"Titration helps identify . typically show:\nhigh titers (e.g., ≥ 64, often much higher)\nWeak reaction strength (often ≤ 1+) persists even high dilutions\nNon-reactive weakly reactive PEG enzyme methods\nUsually clinically insignificant\nExamples: Anti-Ch, Anti-Rg, Anti-JMH, Anti-Sda\nhigh titers (e.g., ≥ 64, often much higher)Weak reaction strength (often ≤ 1+) persists even high dilutionsNon-reactive weakly reactive PEG enzyme methodsUsually clinically insignificantExamples: Anti-Ch, Anti-Rg, Anti-JMH, Anti-Sda","code":""},{"path":"titrations-1.html","id":"factors-affecting-reproducibility-critical","chapter":"Titrations","heading":"Factors Affecting Reproducibility (CRITICAL!)","text":"Titration results can highly variable performed meticulously! Consistency everythingPipetting Accuracy: Essential accurate serial dilutionsRed Cell Sample: Use cells donor phenotype parallel testing. Antigen strength can vary donorsCell Suspension Concentration: Must consistentReagents: Use method (LISS, saline), AHG lot# parallel testsIncubation: time temperatureReading/Grading: subjective! Ideally, technologist read parallel titrations. Consistent technique resuspension reading vitalTitrations labor-intensive require skill consistency, provide invaluable information managing pregnancies complicated red cell antibodies. Remember parallel testing gold standard monitoring changes time!","code":""},{"path":"titrations-1.html","id":"key-terms-85","chapter":"Titrations","heading":"Key Terms","text":"Titration: semi-quantitative method determine concentration strength antibody testing serial dilutions serum/plasma antigen-positive red cellsSerial Dilution: stepwise dilution substance (e.g., serum) quantity time (usually doubling dilutions like 1:2, 1:4, 1:8)Titer: reciprocal highest dilution serum/plasma showing defined positive reaction (typically 1+ macroscopic agglutination)Score: numerical value obtained summing scores assigned agglutination grades reactive tubes titration. Provides sensitive measure antibody strength titer endpoint aloneEndpoint: highest dilution producing minimal defined positive reaction (1+)Parallel Testing: Testing current patient sample simultaneously previously frozen sample patient, using identical reagents methods, accurately assess changes antibody level time. Essential HDFN monitoringCritical Titer: predefined antibody titer level , reached exceeded pregnancy, indicates high risk severe HDFN triggers closer fetal surveillanceHigh Titer, Low Avidity (HTLA): category antibodies characterized reactivity high dilutions weak reaction strength, typically clinically insignificant","code":""},{"path":"cell-separations.html","id":"cell-separations","chapter":"Cell Separations","heading":"Cell Separations","text":"Cell Separation techniques aren’t something ’ll every single day, patient mix red blood cells transfused donor red blood cells circulating, techniques become incredibly important, especially transfusion reaction investigations!Think like trying sort laundry someone mixed whites colors – need way separate different populations cells can examine individually","code":""},{"path":"cell-separations.html","id":"the-core-purpose-isolating-specific-rbc-populations","chapter":"Cell Separations","heading":"The Core Purpose: Isolating Specific RBC Populations","text":"main reason perform cell separations blood bank isolate patient’s autologous () red blood cells transfused allogeneic (donor) red blood cells present sampleWhy necessary?Transfusion Reaction Workups: #1 reason! patient might delayed hemolytic transfusion reaction, antibody might coating donor cells, . need separate populations :\nPerform Direct Antiglobulin Test (DAT) specifically donor cell population (detect antibody coating )\nPerform DAT specifically patient’s cell population (usually expected negative alloimmune reaction, positive ’s also autoantibody drug issue)\nAccurately phenotype patient’s cells, especially pre-transfusion type unknown needs confirmation\nPotentially phenotype donor cells needed (less common, usually rely unit tag)\nPerform Direct Antiglobulin Test (DAT) specifically donor cell population (detect antibody coating )Perform DAT specifically patient’s cell population (usually expected negative alloimmune reaction, positive ’s also autoantibody drug issue)Accurately phenotype patient’s cells, especially pre-transfusion type unknown needs confirmationPotentially phenotype donor cells needed (less common, usually rely unit tag)Monitoring Bone Marrow/Stem Cell Transplant Patients: patients can mixed chimerism (recipient donor cells present) engraftment. Cell separation might needed accurate phenotyping specialized testingInvestigating Mixed Field Agglutination routine typing shows mixed field reactions aren’t easily explained, separating cell populations might (rarely) help clarify situation","code":""},{"path":"cell-separations.html","id":"the-main-method-differential-centrifugation-based-on-cell-agedensity","chapter":"Cell Separations","heading":"The Main Method: Differential Centrifugation (Based on Cell Age/Density)","text":"common method relies fact red blood cells limited lifespan (120 days), density changes ageYounger RBCs (Neocytes/Reticulocytes): Less dense. includes newly produced patient reticulocytes often majority cells relatively fresh unit transfused bloodOlder RBCs (Gerocytes): dense. patient’s mature cells nearing end lifespanThe Principle spinning sample hard (microhematocrit centrifugation), can separate cells based density","code":""},{"path":"cell-separations.html","id":"the-procedure-simplified","chapter":"Cell Separations","heading":"The Procedure (Simplified)","text":"Wash Thoroughly wash patient’s post-transfusion EDTA sample remove plasmaCentrifuge Place washed red cells microhematocrit tubes centrifuge high speed set time (e.g., 5-10 minutes)Separate Layers Carefully score break microhematocrit tube separate layers:\nTop Layer: Contains least dense cells (enriched reticulocytes younger transfused cells - often considered “donor enriched” fraction post-transfusion)\nBottom Layer: Contains dense cells (enriched older patient cells - often considered “patient enriched” fraction)\nMiddle Layer: Contains mix cells intermediate age/density (often discarded tested cautiously)\nTop Layer: Contains least dense cells (enriched reticulocytes younger transfused cells - often considered “donor enriched” fraction post-transfusion)Bottom Layer: Contains dense cells (enriched older patient cells - often considered “patient enriched” fraction)Middle Layer: Contains mix cells intermediate age/density (often discarded tested cautiously)Harvest & Wash Suspend cells top bottom fractions separately saline wash againTesting Perform desired tests (DAT, phenotyping) top bottom fractions","code":""},{"path":"cell-separations.html","id":"validation-is-the-separation-good-enough","chapter":"Cell Separations","heading":"Validation (Is the Separation Good Enough?)","text":"Often, assess separation phenotyping top bottom fractions antigens known differ patient donor (pre-transfusion type known donor unit info available). example, patient K-negative received K-positive blood, top fraction enriched K-positive cells, bottom fraction predominantly K-negativeIt’s often perfect separation!: usually achieve enrichment rather pure populations. Interpretation requires acknowledging limitation","code":""},{"path":"cell-separations.html","id":"alternative-specialized-methods","chapter":"Cell Separations","heading":"Alternative / Specialized Methods","text":"Hypotonic Wash / Differential Lysis (Sickle Cell Patients): Normal donor red cells (HbA) resistant lysis low-salt solutions sickle cells (HbS). property can sometimes exploited preferentially lyse sickle cells, leaving donor cells relatively intact testing. Used specifically dealing sickle cell disease patientsImmunomagnetic Beads / Affinity Columns: sophisticated methods (usually research highly specialized labs) using antibodies attached beads columns bind separate cells based specific surface antigens. routine post-transfusion workups","code":""},{"path":"cell-separations.html","id":"post-separation-testing","chapter":"Cell Separations","heading":"Post-Separation Testing","text":"enriched fractions:DAT: Perform fractions using polyspecific monospecific AHG. positive DAT primarily top (donor-enriched) fraction strongly suggests alloantibody coating donor cells (transfusion reaction)Phenotyping: Type fractions confirm patient type (bottom fraction) potentially donor contribution (top fraction)","code":""},{"path":"cell-separations.html","id":"challenges-and-considerations","chapter":"Cell Separations","heading":"Challenges and Considerations","text":"Timing: Separation effective ’s significant age difference patient donor cells (e.g., patient hasn’t transfused recently old blood, patient high reticulocyte count)Patient Status: Conditions like hemolytic anemia (high reticulocytes) can affect density profile patient’s cellsDegree Separation: ’s rarely perfect. Results reflect enrichment, purityLabor Intensive: Requires careful technique timeCell separation valuable tool, primarily dissecting complex post-transfusion scenarios. Mastering differential centrifugation technique understanding interpret results enriched fractions key investigating potential hemolytic transfusion reactions!","code":""},{"path":"cell-separations.html","id":"key-terms-86","chapter":"Cell Separations","heading":"Key Terms","text":"Cell Separation: Techniques used isolate specific populations red blood cells mixed sampleAutologous Cells: patient’s red blood cellsAllogeneic Cells: Red blood cells donorDifferential Centrifugation: Separation method based differences red blood cell density (related cell age) using high-speed centrifugation (microhematocrit)Neocytes: Younger, less dense red blood cellsGerocytes: Older, dense red blood cellsReticulocytes: Immature red blood cells, less dense mature RBCsTop Fraction: Layer cells collected differential centrifugation containing least dense cells (often enriched reticulocytes/younger donor cells)Bottom Fraction: Layer cells collected differential centrifugation containing dense cells (often enriched older patient cells)Enrichment: Achieving higher concentration specific cell population fraction, necessarily completely pure separationMixed Field Agglutination: Agglutination pattern clumps agglutinated cells mixed unagglutinated cells, often indicating presence two cell populations reacting differentlyChimerism: presence individual two genetically distinct cell lines (e.g., post-transplant)","code":""},{"path":"elisa.html","id":"elisa","chapter":"ELISA","heading":"ELISA","text":"often associate blood bank agglutination tests (mixing cells serum), ELISA, stands Enzyme-Linked Immunosorbent Assay, powerhouse technique used extensively behind scenes, especially ensuring safety blood supplyThink ELISA highly sensitive detection method, often performed microtiter plates (plastic plates lots little wells), uses specificity antibody-antigen interactions coupled enzyme reaction generate measurable signal (usually color change)","code":""},{"path":"elisa.html","id":"the-core-purpose-detecting-specific-molecules","chapter":"ELISA","heading":"The Core Purpose: Detecting Specific Molecules","text":"context relevant blood banking transfusion medicine, ELISA primarily used :Infectious Disease Marker Screening: BIGGEST role far. Donor blood units mandatorily screened various transfusion-transmissible infections (TTIs) using highly sensitive methods, ELISA workhorse . look either:\nAntigens: produced infectious agent (e.g., Hepatitis B surface antigen - HBsAg; HIV p24 antigen)\nAntibodies: produced donor’s immune system response infection (e.g., antibodies HIV-1/2, Hepatitis C virus - HCV, Hepatitis B core antigen - HBc, HTLV-/II, Treponema pallidum - Syphilis, Trypanosoma cruzi - Chagas disease)\nAntigens: produced infectious agent (e.g., Hepatitis B surface antigen - HBsAg; HIV p24 antigen)Antibodies: produced donor’s immune system response infection (e.g., antibodies HIV-1/2, Hepatitis C virus - HCV, Hepatitis B core antigen - HBc, HTLV-/II, Treponema pallidum - Syphilis, Trypanosoma cruzi - Chagas disease)Detecting Certain Antigens Antibodies (Less Common Routine RBC Serology): primary method identifying red cell alloantibodies (use agglutination ), ELISA principles can adapted detecting specific protein antigens certain types antibodies (e.g., platelet antibodies, though flow cytometry often preferred )","code":""},{"path":"elisa.html","id":"the-basic-principle-illustrated-by-sandwich-elisa-for-antigen-detection","chapter":"ELISA","heading":"The Basic Principle (Illustrated by Sandwich ELISA for Antigen Detection)","text":"several variations, “Sandwich” ELISA detecting antigen (like HBsAg) great example:Coating wells microtiter plate coated specific “capture” antibody recognizes target antigen (HBsAg)Blocking remaining unbound sites plastic well surface blocked using irrelevant protein (like Bovine Serum Albumin - BSA casein). prevents non-specific binding later , cause false positivesSample Addition donor’s serum plasma sample added well. target antigen (HBsAg) present, binds capture antibody stuck wellWashing well washed thoroughly remove unbound components sample (everything except captured HBsAg)Detection Antibody second antibody, also recognizes target antigen (HBsAg) different site, added. detection antibody linked (conjugated) enzyme (e.g., Horseradish Peroxidase - HRP, Alkaline Phosphatase - AP)Washing well washed remove unbound enzyme-linked detection antibodySubstrate Addition chemical substrate specific enzyme added. enzyme acts substrate, converting detectable product – usually causing color changeReading intensity color measured using specialized spectrophotometer called microplate reader. amount color produced directly proportional amount target antigen (HBsAg) present original sample","code":""},{"path":"elisa.html","id":"other-common-elisa-formats","chapter":"ELISA","heading":"Other Common ELISA Formats","text":"Indirect ELISA: Used detect antibodies sample (like anti-HIV). , well coated target antigen. Patient serum added (patient antibodies bind). washing, enzyme-linked anti-human immunoglobulin antibody added, binds patient antibodies. Washing substrate addition follow aboveCompetitive ELISA: target molecule sample competes labeled version target binding sites limited amount capture antibody. target sample = less labeled target binds = weaker signal","code":""},{"path":"elisa.html","id":"why-elisa-is-so-important-in-blood-safety","chapter":"ELISA","heading":"Why ELISA is So Important in Blood Safety","text":"High Sensitivity: ELISAs can detect low concentrations antigens antibodies, crucial identifying potentially infectious units early infection processHigh Specificity: designed correctly, specific target molecule, minimizing (eliminating) reactions unrelated substancesHigh Throughput & Automation: microtiter plate format lends well automation, allowing donor centers screen thousands samples efficiently using robotic systemsQuantitative/Semi-Quantitative Potential: often used qualitatively (positive/negative) screening, ELISA results (signal intensity) can correlate amount target present","code":""},{"path":"elisa.html","id":"limitations-and-considerations","chapter":"ELISA","heading":"Limitations and Considerations","text":"Window Period: Even highly sensitive ELISAs can miss early infections antigens antibodies reach detectable levels (Nucleic Acid Testing - NAT - also used viruses like HIV HCV)False Positives: Non-specific binding cross-reactivity can occur, leading initially reactive results need investigation specific confirmatory tests (e.g., Western Blot, Immunoblot, NAT)False Negatives: Possible due low levels target, specific viral strains detected assay, technical errorRequires Specific Equipment: Microplate readers, washers, precision pipettes necessaryTurnaround Time: automatable, multiple incubation wash steps mean results typically take hours","code":""},{"path":"elisa.html","id":"quality-control-is-key","chapter":"ELISA","heading":"Quality Control is Key","text":"Every ELISA run includes multiple controls:Negative Controls: Ensure significant background signalPositive Controls: Ensure assay system working can detect targetCalibrators (Optional): Used establish cutoff value determining positivity quantificationKit Controls: Monitor specific steps reagent integrity","code":""},{"path":"elisa.html","id":"key-terms-87","chapter":"ELISA","heading":"Key Terms","text":"ELISA (Enzyme-Linked Immunosorbent Assay): immunoassay technique using enzyme linked antibody antigen detect specific substance, usually resulting color change measured microtiter plateImmunoassay: test uses antibody-antigen interactions detect substanceAntigen: molecule can bound antibodyAntibody: protein produced immune system binds specifically antigenMicrotiter Plate: flat plastic plate multiple small wells (commonly 96) used running assaysEnzyme Conjugate: antibody antigen chemically linked enzyme (like HRP AP)Substrate: molecule acted upon enzyme produce detectable signalCapture Antibody: antibody immobilized solid phase (well surface) bind target antigen sample (Sandwich ELISA)Detection Antibody: enzyme-linked antibody used detect captured antigen (Sandwich ELISA) primary antibody (Indirect ELISA)Sensitivity: ability test correctly identify individuals condition marker tested (low rate false negatives)Specificity: ability test correctly identify individuals condition marker tested (low rate false positives)Window Period: time infection test can reliably detect markers infectionConfirmatory Test: second, usually specific, test used verify initially reactive (positive) screening test result","code":""},{"path":"molecular-techniques.html","id":"molecular-techniques","chapter":"Molecular Techniques","heading":"Molecular Techniques","text":"Molecular Techniques relatively newer frontier compared century-old serology ’ve discussing, ’s becoming increasingly vital. ’s powerful addition toolkit, offering solutions traditional serology sometimes strugglesThink way: Serology looks finished product (antigens expressed cell surface antibodies plasma). Molecular techniques look genetic blueprint (DNA sequences code antigens)","code":""},{"path":"molecular-techniques.html","id":"the-core-purpose-analyzing-the-genes","chapter":"Molecular Techniques","heading":"The Core Purpose: Analyzing the Genes","text":"Molecular testing immunohematology focuses analyzing genes encode blood group antigens. Instead using antibodies detect antigen protein carbohydrate cell surface, look directly DNA sequence predict antigens expressedWhy useful? helps us overcome several limitations traditional serologic methods:Positive Direct Antiglobulin Test (DAT): patient’s cells coated antibody vivo, serologic typing can difficult impossible bound antibody blocks antigen sites causes spontaneous agglutination. Molecular testing isn’t affected antibody coating cellsRecent Transfusion: Patients recently transfused mixture cells donor cells, making accurate serologic phenotyping unreliable. Molecular testing uses DNA (usually white blood cells), reflects patient’s genetic makeup, regardless transfused red cellsLimited Antisera: blood group antigens available reliable serologic typing reagents (especially rare antigens). Molecular methods can identify alleles responsible antigensWeak Antigen Expression: individuals express antigens weakly (like certain Weak D types variants), making serologic detection challenging. Molecular testing can identify underlying gene variantHigh-Throughput Donor Typing: Molecular platforms allow rapid screening blood donors large number clinically significant antigens simultaneously, helping find rare antigen-negative units efficientlyFetal Genotyping: Determining fetus’s blood type antigens implicated HDFN (like D, K, C, c, E, e, Fya, Fyb, Jka, Jkb) using fetal DNA circulating mother’s plasma. non-invasive crucial risk assessment","code":""},{"path":"molecular-techniques.html","id":"key-applications-in-blood-banking","chapter":"Molecular Techniques","heading":"Key Applications in Blood Banking","text":"Predictive Phenotyping Patients\nPatients positive DATs\nRecently transfused patients\nPatients suspected antigen variants (e.g., Weak D, partial D)\nPatients requiring extensive antigen matching (e.g., sickle cell disease, thalassemia) multiple antibodies lack antisera complicate serology\nPatients positive DATsRecently transfused patientsPatients suspected antigen variants (e.g., Weak D, partial D)Patients requiring extensive antigen matching (e.g., sickle cell disease, thalassemia) multiple antibodies lack antisera complicate serologyPredictive Phenotyping Donors\nScreening donors multiple antigens simultaneously using high-throughput platforms\nIdentifying donors rare antigen profiles\nScreening donors multiple antigens simultaneously using high-throughput platformsIdentifying donors rare antigen profilesFetal Genotyping HDFN Risk Assessment\nTesting cell-free fetal DNA (cffDNA) maternal plasma predict fetal RhD type (common) significant antigens (K, RhCcEe, Duffy, Kidd)\nHelps guide management decisions pregnancy (e.g., need Rh Immune Globulin, intensity fetal monitoring)\nTesting cell-free fetal DNA (cffDNA) maternal plasma predict fetal RhD type (common) significant antigens (K, RhCcEe, Duffy, Kidd)Helps guide management decisions pregnancy (e.g., need Rh Immune Globulin, intensity fetal monitoring)Resolving Serologic Discrepancies: ABO Rh typing results unclear conflictingZygosity Determination: Determining person homozygous heterozygous certain alleles (e.g., father homozygous D/D heterozygous D/d?). Important predicting HDFN risk","code":""},{"path":"molecular-techniques.html","id":"common-molecular-techniques-used","chapter":"Molecular Techniques","heading":"Common Molecular Techniques Used","text":"underlying technologies can complex, basic approach involves obtaining DNA analyzing specific gene sequences:DNA Source: Usually extracted nucleated cells (WBCs) EDTA whole blood sample. fetal testing, cffDNA extracted maternal plasmaPCR (Polymerase Chain Reaction): cornerstone technique. Used amplify (make millions copies ) specific DNA region (gene part gene) interestDetection Methods (see result)\nSequence-Specific Primers (PCR-SSP): PCR primers designed bind amplify DNA specific allele sequence present. result often visualized running PCR product agarose gel – presence absence specific sized band indicates presence absence allele\nReal-Time PCR (qPCR) Allele-Specific Probes: Uses fluorescent probes bind preferentially one allele sequence another PCR process. Fluorescence monitored real-time. Often combined Melt Curve Analysis, temperature probe detaches DNA differs depending perfectly matches allele sequence\nBeadChip Technology / Microarrays: high-throughput method. Short DNA probes corresponding different blood group alleles attached microscopic beads fixed spots microarray chip. patient’s amplified DNA labeled (e.g., fluorescent tag) allowed hybridize (bind) probes array. Specialized readers detect binding occurred, revealing alleles present. Allows simultaneous testing dozens hundreds alleles\nDNA Sequencing (Sanger Next-Generation Sequencing - NGS): Determines exact nucleotide sequence amplified DNA region. Provides detailed information, essential identifying new alleles complex variants. NGS allows massive parallel sequencing many genes . often used reference labs research\nSequence-Specific Primers (PCR-SSP): PCR primers designed bind amplify DNA specific allele sequence present. result often visualized running PCR product agarose gel – presence absence specific sized band indicates presence absence alleleReal-Time PCR (qPCR) Allele-Specific Probes: Uses fluorescent probes bind preferentially one allele sequence another PCR process. Fluorescence monitored real-time. Often combined Melt Curve Analysis, temperature probe detaches DNA differs depending perfectly matches allele sequenceBeadChip Technology / Microarrays: high-throughput method. Short DNA probes corresponding different blood group alleles attached microscopic beads fixed spots microarray chip. patient’s amplified DNA labeled (e.g., fluorescent tag) allowed hybridize (bind) probes array. Specialized readers detect binding occurred, revealing alleles present. Allows simultaneous testing dozens hundreds allelesDNA Sequencing (Sanger Next-Generation Sequencing - NGS): Determines exact nucleotide sequence amplified DNA region. Provides detailed information, essential identifying new alleles complex variants. NGS allows massive parallel sequencing many genes . often used reference labs research","code":""},{"path":"molecular-techniques.html","id":"advantages-of-molecular-testing","chapter":"Molecular Techniques","heading":"Advantages of Molecular Testing","text":"Overcomes limitations serology (positive DAT, recent transfusion)Can predict phenotype antisera unavailable antigens weakly expressedProvides detailed information alleles variantsHigh-throughput capability donor screeningEnables non-invasive fetal genotyping","code":""},{"path":"molecular-techniques.html","id":"limitations-and-considerations-1","chapter":"Molecular Techniques","heading":"Limitations and Considerations","text":"Genotype vs. Phenotype Discrepancy: Molecular testing predicts phenotype based DNA sequence, gene expression can complex! Rare “silent” “null” alleles exist gene present doesn’t produce functional antigen cell surface. Serology detects actual antigen expression, two methods complementaryDoesn’t Detect Antibodies: Molecular testing tells patient’s antigens (potential antigens), antibodies may formed. Antibody screening/ID remains essential serologic workCost Expertise: Requires specialized equipment trained personnelTurnaround Time: Can sometimes longer routine serology, although high-throughput platforms fastDiscovery Variants Unknown Significance (VUS): Sequencing can sometimes identify new genetic variations whose effect antigen expression unknown","code":""},{"path":"molecular-techniques.html","id":"key-terms-88","chapter":"Molecular Techniques","heading":"Key Terms","text":"Molecular Techniques (Genotyping): Laboratory methods analyze DNA sequences predict blood group antigen phenotypesGene: segment DNA codes protein functional RNA moleculeAllele: specific variant form geneGenotype: specific combination alleles individual possesses particular genePhenotype: observable characteristics resulting genotype (e.g., antigens actually expressed red blood cell surface)PCR (Polymerase Chain Reaction): technique amplify specific DNA sequences exponentiallycffDNA (Cell-Free Fetal DNA): Small fragments fetal DNA circulating maternal bloodstream, used non-invasive prenatal testingPCR-SSP (Sequence-Specific Primers): PCR method using primers amplify specific allelesReal-Time PCR (qPCR): PCR method monitors DNA amplification using fluorescence reactionMelt Curve Analysis: Technique used qPCR identify specific DNA sequences based temperature double-stranded DNA dissociatesMicroarray / BeadChip: High-throughput platforms immobilized DNA probes used detect multiple alleles simultaneously via hybridizationHybridization: process complementary single strands DNA (DNA/RNA) bind togetherDNA Sequencing: Determining precise order nucleotides (, T, C, G) DNA segmentNull Allele / Silent Allele: gene variant present DNA fails produce functional protein product (antigen) cell surfaceZygosity: state identical (homozygous) different (heterozygous) alleles particular gene","code":""},{"path":"neutralization.html","id":"neutralization","chapter":"Neutralization","heading":"Neutralization","text":"Neutralization Inhibition techniques clever little tricks use blood bank, mostly antibody identification, suspect certain antibodies present want confirm identity get “way” can see antibodiesThink like adding specific “decoy” substance patient’s serum. antibody suspect present, bind decoy instead reagent red cells, effectively neutralizing inhibiting activity","code":""},{"path":"neutralization.html","id":"the-core-purpose-confirming-specificity-or-removing-interference","chapter":"Neutralization","heading":"The Core Purpose: Confirming Specificity or Removing Interference","text":"main goals neutralization/inhibition :Confirming Antibody Specificity: adding substance known contain soluble form specific blood group antigen causes antibody reactivity disappear, strongly confirms antibody directed antigenRemoving Interfering Antibodies: antibodies (especially high-frequency antigens substances present plasma) can mask presence , potentially significant, alloantibodies. Neutralizing interfering antibody can allow underlying antibodies detected","code":""},{"path":"neutralization.html","id":"the-basic-principle-1","chapter":"Neutralization","heading":"The Basic Principle","text":"Suspicion suspect particular antibody specificity based initial panel results (e.g., reactions consistent anti-Lea, anti-Leb, anti-P1, anti-Ch/Rg, anti-Sda)Neutralizing Substance Obtain substance known contain soluble form corresponding antigen (structurally similar substance)Incubation Mix patient’s serum/plasma neutralizing substance incubate (usually room temperature 37°C, depending antibody)Testing Test treated (neutralized) serum/plasma reagent red cells known positive suspected antigenControl Crucially, test control sample patient serum/plasma mixed inert substance (like saline) parallel reagent red cellsComparison Compare reactivity neutralized serum control serum","code":""},{"path":"neutralization.html","id":"interpretation-3","chapter":"Neutralization","heading":"Interpretation","text":"Neutralization Confirmed: reactivity antigen-positive cells significantly reduced completely abolished tube containing neutralized serum compared control tube (still show reactivity), neutralization occurred. confirms suspected antibody specificityNo Neutralization: reactivity remains neutralized serum tube control tube, antibody present likely one targeted neutralizing substance","code":""},{"path":"neutralization.html","id":"common-neutralizationinhibition-scenarios","chapter":"Neutralization","heading":"Common Neutralization/Inhibition Scenarios","text":"techniques useful antibodies directed antigens exist soluble form body fluids can obtained sources:","code":""},{"path":"neutralization.html","id":"lewis-system-antibodies-anti-lea-anti-leb","chapter":"Neutralization","heading":"Lewis System Antibodies (Anti-Lea, Anti-Leb)","text":"Neutralizing Substance: Commercial Lewis Substance (prepared pooled plasma saliva known contain soluble Lea Leb glycoproteins) sometimes saliva individuals secretor-tested Lewis phenotypeWhy Works: Lewis antigens primarily plasma antigens adsorb onto red blood cells. Soluble forms abundant plasma secretions (like saliva) individuals corresponding Lewis genesUse: Helps confirm anti-Lea anti-Leb specificity, especially might interfering detecting antibodies","code":""},{"path":"neutralization.html","id":"p1-antibody-anti-p1","chapter":"Neutralization","heading":"P1 Antibody (Anti-P1)","text":"Neutralizing Substance: Commercial P1 Substance (often derived hydatid cyst fluid, rich P1-like structures) pigeon egg whites (contain P1-like substance)Works: P1 antigen also present soluble formUse: Confirms anti-P1 specificity. Anti-P1 common, usually clinically insignificant cold antibody can sometimes interfere testing","code":""},{"path":"neutralization.html","id":"sda-antibody-anti-sda---sid","chapter":"Neutralization","heading":"Sda Antibody (Anti-Sda - Sid)","text":"Neutralizing Substance: Urine individuals (especially Sda-positive individuals). Guinea pig urine often used commercial sourceWhy Works: Sda antigen present high concentrations urineUse: Confirms anti-Sda specificity. Anti-Sda often causes characteristic small, refractile, mixed-field agglutinates can observed microscopically. Neutralization helps confirm often tricky--identify antibody","code":""},{"path":"neutralization.html","id":"chidorodgers-antibodies-anti-ch-anti-rg","chapter":"Neutralization","heading":"Chido/Rodgers Antibodies (Anti-Ch, Anti-Rg)","text":"Neutralizing Substance: Pooled normal human plasma/serum (plasma contains soluble C4 complement components, Ch Rg antigens located C4d)Works: Ch/Rg antigens determinants C4 component complement, circulates plasmaUse: Confirms anti-Ch anti-Rg specificity. common High Titer, Low Avidity (HTLA) antibodies, often weakly reactive panel cells. Neutralization helps distinguish weakly reactive antibodies","code":""},{"path":"neutralization.html","id":"important-considerations-controls","chapter":"Neutralization","heading":"Important Considerations & Controls","text":"Specificity Substance: Ensure neutralizing substance specific antigen questionDilution Control: addition neutralizing substance dilutes patient’s serum. saline control (patient serum + saline) essential ensure reduction reactivity isn’t simply due dilution effectPotency Substance: neutralizing substance must potent enough effectively inhibit antibodyNot Universally Applicable: works antibodies whose corresponding antigens exist soluble form can readily obtained safely used labInterpretation Caution: Complete neutralization ideal, significant inhibition (e.g., reduction reaction strength 2 grades ) often sufficient confirmation","code":""},{"path":"neutralization.html","id":"key-terms-89","chapter":"Neutralization","heading":"Key Terms","text":"Neutralization/Inhibition: technique used confirm antibody specificity adding soluble form corresponding antigen (similar substance) serum/plasma, binds antibody prevents reacting reagent red blood cellsSoluble Blood Group Substances: Blood group antigens exist soluble form body fluids like plasma, saliva, urine (e.g., Lewis, P1, Sda, Ch/Rg)Lewis Substance: Commercially prepared reagent containing soluble Lea Leb antigens, used neutralize anti-Lea anti-LebP1 Substance: Commercially prepared reagent (often hydatid cyst fluid) containing soluble P1 antigen, used neutralize anti-P1Urine (Sda): Used source soluble Sda antigen neutralize anti-SdaPooled Plasma/Serum (Ch/Rg): Used source soluble C4 (carrying Ch/Rg determinants) neutralize anti-Ch anti-RgDilution Control: control tube prepared mixing patient serum/plasma inert substance (like saline) volume neutralizing substance, account reduction antibody reactivity due solely dilution","code":""},{"path":"thiol-reagents.html","id":"thiol-reagents","chapter":"Thiol Reagents","heading":"Thiol Reagents","text":"Thiol Reagents chemicals sometimes use blood bank another specialized tool, primarily figure immunoglobulin class antibody (IgM IgG?) break certain antibody structuresThink chemicals specifically target break disulfide bonds. bonds like tiny molecular staples hold parts protein molecules together, particularly important structure IgM antibodies","code":""},{"path":"thiol-reagents.html","id":"the-core-purpose-differentiating-igm-from-igg","chapter":"Thiol Reagents","heading":"The Core Purpose: Differentiating IgM from IgG","text":"main reasons use thiol reagents :Determining Immunoglobulin Class (IgM vs. IgG): primary use. IgM antibodies large pentamers held together disulfide bonds “J chain” region. Thiol reagents break bonds, effectively dismantling pentamer smaller, often non-agglutinating, subunits. IgG antibodies, monomers, internal disulfide bonds lack J chain structure, making relatively resistant treatment\ndifferentiate?: Knowing Ig class helps assess clinical significance. clinically significant antibodies cause delayed HTRs HDFN IgG (reactive 37°C). Many IgM antibodies react best colder temperatures often clinically insignificant (notable exceptions like ABO antibodies!)\ndifferentiate?: Knowing Ig class helps assess clinical significance. clinically significant antibodies cause delayed HTRs HDFN IgG (reactive 37°C). Many IgM antibodies react best colder temperatures often clinically insignificant (notable exceptions like ABO antibodies!)Dispersing IgM-Mediated Agglutination: Sometimes strong IgM antibodies (like cold agglutinins) can interfere tests performed room temperature even 37°C, potentially masking underlying IgG antibodies. Treating serum cells thiol reagent can break IgM, eliminating reactivity allowing detection IgG antibodies presentDenaturing Kell System Antigens: Thiol reagents also destroy antigens within Kell blood group system (others like Kx, Cartwright (Yta), Dombrock (Doa, Dob), JMH). property can used:\npart complex antibody identification (similar enzyme treatment - reactivity disappears thiol treatment, Kell system antibodies suspected)\nprepare Kell-negative “control” cells certain procedures (less common)\npart complex antibody identification (similar enzyme treatment - reactivity disappears thiol treatment, Kell system antibodies suspected)prepare Kell-negative “control” cells certain procedures (less common)","code":""},{"path":"thiol-reagents.html","id":"common-thiol-reagents-used","chapter":"Thiol Reagents","heading":"Common Thiol Reagents Used","text":"Dithiothreitol (DTT): Probably commonly used thiol reagent blood banking procedures2-Mercaptoethanol (2-): Another effective thiol reagent, though often considered hazardous/odorous DTT","code":""},{"path":"thiol-reagents.html","id":"how-they-work-breaking-disulfide-bonds--s-s-","chapter":"Thiol Reagents","heading":"How They Work: Breaking Disulfide Bonds (-S-S-)","text":"Thiol reagents reducing agents. work breaking disulfide bonds (–S–S–) link cysteine amino acid residues within polypeptide chains. essentially add hydrogen across bond, converting two sulfhydryl groups (–SH HS–)Effect IgM: Breaks inter-subunit disulfide bonds holding five IgM monomers together via J chain. resulting IgM monomers often lose ability effectively agglutinate red cellsEffect IgG: Generally resistant. IgG monomers intra-chain disulfide bonds, less critical basic structure antigen-binding function context agglutination assays compared inter-subunit bonds IgMEffect Kell Antigens: Kell system antigens critical disulfide bonds required structural integrity. Breaking bonds denatures antigen, preventing antibody binding","code":""},{"path":"thiol-reagents.html","id":"common-applications-procedures","chapter":"Thiol Reagents","heading":"Common Applications & Procedures","text":"","code":""},{"path":"thiol-reagents.html","id":"treating-serumplasma-to-remove-igm-reactivity","chapter":"Thiol Reagents","heading":"Treating Serum/Plasma to Remove IgM Reactivity","text":"Mix patient serum/plasma solution DTT 2-specific concentrationIncubate (often 30-60 minutes 37°C)Test treated serum appropriate reagent red cells (e.g., panel cells) using IAT procedure (usually LISS PEG)Control Test untreated aliquot patient serum parallelInterpretation\nreactivity present untreated serum absent significantly reduced DTT/2-treated serum, antibody likely IgM\nreactivity persists treated serum (similar strength untreated), antibody likely IgG (possibly IgA)\nreactivity present untreated serum absent significantly reduced DTT/2-treated serum, antibody likely IgMIf reactivity persists treated serum (similar strength untreated), antibody likely IgG (possibly IgA)","code":""},{"path":"thiol-reagents.html","id":"treating-red-blood-cells-to-denature-kell-antigens","chapter":"Thiol Reagents","heading":"Treating Red Blood Cells to Denature Kell Antigens","text":"Wash red blood cells thoroughlyIncubate cells DTT solutionWash treated cells extensively remove DTTTest treated cells patient serum known antiseraInterpretation reactivity known Kell system antibodies disappears treatment, confirms Kell antigens successfully denatured. patient serum reactivity disappears treated cells present untreated cells, supports presence Kell system antibody patient serum","code":""},{"path":"thiol-reagents.html","id":"advantages-4","chapter":"Thiol Reagents","heading":"Advantages","text":"Relatively straightforward method differentiate IgM IgG antibodies based structural differencesUseful eliminating interference strong IgM antibodiesProvides alternative method (besides enzymes) modify red cell antigens (specifically destroying Kell) antibody identification purposes","code":""},{"path":"thiol-reagents.html","id":"disadvantages-and-cautions","chapter":"Thiol Reagents","heading":"Disadvantages and Cautions","text":"Safety: Thiol reagents like 2-strong, unpleasant odors can irritants. DTT generally preferred still requires careful handling according safety data sheetsDestruction Kell Antigens: treating serum, remember treated serum loses reactivity, due IgM antibody Kell system antigen (Kell-positive cells used testing, though less common serum treatment). treating cells, antigen destruction intended effectIncomplete Treatment: Insufficient concentration incubation time may fully inactivate strong IgM antibodiesEffect Antibodies/Antigens: Besides Kell, less common antigens affected (Yta, Dombrock, JMH, etc.). High concentrations might potentially affect IgG structure slightly, though usually enough abolish reactivity standard testsMust Use Controls: Comparing treated vs. untreated samples essential valid interpretation","code":""},{"path":"thiol-reagents.html","id":"key-terms-90","chapter":"Thiol Reagents","heading":"Key Terms","text":"Thiol Reagent: chemical reducing agent (like DTT 2-) breaks disulfide bonds (-S-S-) proteinsDisulfide Bond: covalent bond formed two sulfur atoms, typically cysteine amino acid residues, important protein structureIgM: class antibody exists pentamer (five monomer units linked J chain via disulfide bonds). Often reactive colder temperatures efficiently activates complementIgG: class antibody exists monomer. common type antibody plasma, reactive 37°C, can cross placenta, primary cause clinically significant delayed HTRs HDFN (excluding ABO)Dithiothreitol (DTT): common thiol reagent used blood banking2-Mercaptoethanol (2-): Another thiol reagent, known strong odorKell Blood Group System: major blood group system highly immunogenic antigens (like K) possess critical disulfide bonds, making susceptible denaturation thiol reagents","code":""},{"path":"immunofluorescence.html","id":"immunofluorescence","chapter":"Immunofluorescence","heading":"Immunofluorescence","text":"typically used day--day red blood cell antibody screens crossmatches (rely agglutination), Immunofluorescence () really valuable technique closely related areas, especially need visualize antibodies binding cell types like platelets, using advanced techniques like flow cytometryThink Immunofluorescence using tiny fluorescent “light bulbs” attached antibodies make specific targets glow special microscope instrument","code":""},{"path":"immunofluorescence.html","id":"the-core-purpose-visualizing-antibody-antigen-interactions","chapter":"Immunofluorescence","heading":"The Core Purpose: Visualizing Antibody-Antigen Interactions","text":"goal Immunofluorescence detect presence location specific antigens antibodies tissues cells using antibodies conjugated (linked) fluorescent dyes (fluorophores fluorochromes)context relevant us, helps answer questions like:antibody binding platelets? (Platelet Immunology)antibody binding granulocytes? (Granulocyte Immunology)Can detect antibody binding even doesn’t cause agglutination? (Flow Cytometry Applications)","code":""},{"path":"immunofluorescence.html","id":"the-basic-principle-making-targets-glow","chapter":"Immunofluorescence","heading":"The Basic Principle: Making Targets Glow","text":"Antibody Binding antibody (either directly labeled detected labeled secondary antibody) binds specifically target antigen cell tissueFluorophore Excitation sample illuminated light specific wavelength (excitation wavelength) fluorophore absorbsFluorescence Emission excited fluorophore quickly releases absorbed energy emitting light longer, specific wavelength (emission wavelength)Detection emitted fluorescent light detected using either:\nFluorescence Microscope: Allows visualization location pattern fluorescence cells tissue sections\nFlow Cytometer: Measures fluorescence intensity individual cells pass laser beam, allowing quantification analysis cell populations\nFluorescence Microscope: Allows visualization location pattern fluorescence cells tissue sectionsFlow Cytometer: Measures fluorescence intensity individual cells pass laser beam, allowing quantification analysis cell populations","code":""},{"path":"immunofluorescence.html","id":"key-components-1","chapter":"Immunofluorescence","heading":"Key Components","text":"Antibodies: Highly specific primary antibodies recognize target antigen, sometimes secondary antibodies recognize primary antibodyFluorophores (Fluorescent Dyes): Molecules chemically linked antibodies (e.g., FITC - green, PE - orange/red, APC - red). absorb light one wavelength emit anotherDetection System: Fluorescence microscope flow cytometer","code":""},{"path":"immunofluorescence.html","id":"types-of-immunofluorescence-techniques","chapter":"Immunofluorescence","heading":"Types of Immunofluorescence Techniques","text":"Direct Immunofluorescence (DIF)\nprimary antibody (one binds directly target antigen) already labeled fluorophore\nProcedure: Labeled antibody incubated cells/tissue, washed, viewed\nPros: Simpler, faster (fewer steps)\nCons: Requires specific labeled primary antibody target; signal intensity might lower (less amplification)\nprimary antibody (one binds directly target antigen) already labeled fluorophoreProcedure: Labeled antibody incubated cells/tissue, washed, viewedPros: Simpler, faster (fewer steps)Cons: Requires specific labeled primary antibody target; signal intensity might lower (less amplification)Indirect Immunofluorescence (IIF)\nunlabeled primary antibody binds target antigen\n, fluorophore-labeled secondary antibody (recognizes species type primary antibody, e.g., goat anti-human IgG-FITC) added\nProcedure: Incubate primary antibody, wash, incubate labeled secondary antibody, wash, view\nPros: Signal amplification (multiple secondary antibodies can bind one primary antibody); increased flexibility (one labeled secondary antibody can used many different unlabeled primary antibodies species); unlabeled primary antibodies often readily available\nCons: steps, longer procedure; potential non-specific binding secondary antibody\nunlabeled primary antibody binds target antigenThen, fluorophore-labeled secondary antibody (recognizes species type primary antibody, e.g., goat anti-human IgG-FITC) addedProcedure: Incubate primary antibody, wash, incubate labeled secondary antibody, wash, viewPros: Signal amplification (multiple secondary antibodies can bind one primary antibody); increased flexibility (one labeled secondary antibody can used many different unlabeled primary antibodies species); unlabeled primary antibodies often readily availableCons: steps, longer procedure; potential non-specific binding secondary antibody","code":""},{"path":"immunofluorescence.html","id":"applications-relevant-to-blood-bank-transfusion-medicine","chapter":"Immunofluorescence","heading":"Applications Relevant to Blood Bank & Transfusion Medicine","text":"routine RBC serology, critical :Platelet Immunology: major area!\nDetecting Platelet Antibodies: Used investigate conditions like:\nPost-Transfusion Purpura (PTP): Patient develops alloantibodies platelet antigens transfusion, causing severe thrombocytopenia\nNeonatal Alloimmune Thrombocytopenia (NAIT): Mother makes alloantibodies fetal platelet antigens inherited father; antibodies cross placenta destroy fetal/newborn platelets\nPlatelet Refractoriness: Patient fails achieve expected platelet count increments transfusion, often due HLA antibodies specific platelet antibodies\n\nPlatelet Crossmatching: techniques (especially flow cytometry-based) can used detect antibody binding donor platelets transfusion\nDetecting Platelet Antigens: Can used type platelets specific antigens (like HPA systems)\nDetecting Platelet Antibodies: Used investigate conditions like:\nPost-Transfusion Purpura (PTP): Patient develops alloantibodies platelet antigens transfusion, causing severe thrombocytopenia\nNeonatal Alloimmune Thrombocytopenia (NAIT): Mother makes alloantibodies fetal platelet antigens inherited father; antibodies cross placenta destroy fetal/newborn platelets\nPlatelet Refractoriness: Patient fails achieve expected platelet count increments transfusion, often due HLA antibodies specific platelet antibodies\nPost-Transfusion Purpura (PTP): Patient develops alloantibodies platelet antigens transfusion, causing severe thrombocytopeniaNeonatal Alloimmune Thrombocytopenia (NAIT): Mother makes alloantibodies fetal platelet antigens inherited father; antibodies cross placenta destroy fetal/newborn plateletsPlatelet Refractoriness: Patient fails achieve expected platelet count increments transfusion, often due HLA antibodies specific platelet antibodiesPlatelet Crossmatching: techniques (especially flow cytometry-based) can used detect antibody binding donor platelets transfusionDetecting Platelet Antigens: Can used type platelets specific antigens (like HPA systems)Flow Cytometry Crossmatching: uses principles . Patient serum incubated donor lymphocytes, platelets, granulocytes. fluorescently labeled anti-human globulin (AHG) added. flow cytometer detects patient antibody bound donor cells measuring increase fluorescence. sensitive traditional agglutination crossmatches detecting non-agglutinating antibodies, especially important platelets transplant settingsGranulocyte Immunology\nDetecting antibodies granulocyte antigens (HNA system)\nInvestigating Transfusion-Related Acute Lung Injury (TRALI), donor antibodies recipient granulocyte antigens often implicated\nDetecting antibodies granulocyte antigens (HNA system)Investigating Transfusion-Related Acute Lung Injury (TRALI), donor antibodies recipient granulocyte antigens often implicatedAutoimmune Investigations (Related Context): Tests like Antinuclear Antibody (ANA) test use IIF cell substrates (like HEp-2 cells). usually performed immunology rheumatology labs, positive ANA can sometimes seen patients autoimmune conditions (like Lupus) also associated hematologic issues like Autoimmune Hemolytic Anemia (AIHA) investigated blood bank","code":""},{"path":"immunofluorescence.html","id":"advantages-5","chapter":"Immunofluorescence","heading":"Advantages","text":"High Sensitivity: Can detect low levels antigen antibody bindingSpecificity: Relies high specificity antibody-antigen interactionsVisualization: Allows localization targets within cells tissues (microscopy)Quantification: Flow cytometry allows objective measurement fluorescence intensity large numbers individual cellsDetects Non-Agglutinating Antibodies: Crucial platelet granulocyte antibodies, useful flow crossmatching","code":""},{"path":"immunofluorescence.html","id":"disadvantageslimitations","chapter":"Immunofluorescence","heading":"Disadvantages/Limitations","text":"Requires Specialized Equipment: Fluorescence microscopes especially flow cytometers expensiveExpertise Needed: Interpretation (especially microscopy patterns) requires training experiencePhotobleaching: Fluorophores can fade upon prolonged exposure excitation lightAutofluorescence: Cells/tissues can sometimes natural background fluorescence can interfereNon-Specific Binding: Antibodies can sometimes stick non-specifically, requiring careful blocking steps controlsStandardization: Can challenging standardize intensity levels runs labs","code":""},{"path":"immunofluorescence.html","id":"key-terms-91","chapter":"Immunofluorescence","heading":"Key Terms","text":"Immunofluorescence (): Technique using fluorescently labeled antibodies detect specific antigens antibodiesFluorophore (Fluorochrome): fluorescent chemical compound can re-emit light upon light excitationFluorescence Microscope: Microscope equipped filters light sources excite fluorophores view emitted lightFlow Cytometer: Instrument measures physical chemical characteristics (including fluorescence) individual cells flow laser beamDirect Immunofluorescence (DIF): Uses fluorophore-labeled primary antibodyIndirect Immunofluorescence (IIF): Uses unlabeled primary antibody followed fluorophore-labeled secondary antibodyPlatelet Immunology: Study platelet antigens antibodies, important PTP, NAIT, platelet refractorinessFlow Cytometry Crossmatch: sensitive crossmatch method using fluorescence detect antibody binding donor cells (platelets, lymphocytes, etc.)Granulocyte Immunology: Study granulocyte antigens antibodies, relevant TRALI neutropeniaAutofluorescence: Natural fluorescence emitted biological structures can interfere signalsPhotobleaching: irreversible fading fluorophore due light exposure","code":""},{"path":"solid-phase.html","id":"solid-phase","chapter":"Solid Phase","heading":"Solid Phase","text":"Solid Phase Red Cell Adherence (SPRCA) really neat method ’ll see used quite bit, often automated semi-automated systems. Instead looking agglutination tube gel card, ’re looking whether red blood cells form layer across bottom tiny wellThink like : traditional tube testing, everything’s floating around see clump. solid phase, anchor either “bait” (antigen) “hook” (antibody) bottom well first, see sticks!","code":""},{"path":"solid-phase.html","id":"the-core-purpose-detecting-antibody-antigen-reactions-on-a-fixed-surface","chapter":"Solid Phase","heading":"The Core Purpose: Detecting Antibody-Antigen Reactions on a Fixed Surface","text":"Solid phase assays used many purposes tube gel testing, distinct advantages differences principle:Antibody Screening: Detecting unexpected antibodies patient plasma/serumAntibody Identification: Determining specificity antibodies using panel wellsCrossmatching: Assessing compatibility patient serum donor red cellsDirect Antiglobulin Test (DAT): Detecting IgG complement coating patient’s red cells vivoAntigen Typing: Determining presence specific antigens red cells (less commonly used RBCs way compared antibody detection)","code":""},{"path":"solid-phase.html","id":"the-basic-principle-immobilization-is-key","chapter":"Solid Phase","heading":"The Basic Principle: Immobilization is Key","text":"defining feature solid phase one component reaction (either antigen antibody) immobilized (bound) onto surface microplate wellThere two main ways set , depending ’re trying detect:","code":""},{"path":"solid-phase.html","id":"detecting-antibodies-in-plasmaserum-antibody-screen-id-crossmatch","chapter":"Solid Phase","heading":"Detecting Antibodies in Plasma/Serum (Antibody Screen, ID, Crossmatch)","text":"’s Stuck Well?: Red Blood Cell Antigens. Manufacturers lyse known reagent red blood cells (screening cells, panel cells, donor cells) bind membrane fragments (containing antigens) bottom microplate wellsThe Procedure (Simplified)\nAdd Patient Plasma/Serum Patient plasma/serum added antigen-coated well. LISS often added incorporated enhance reactivity\nIncubation (Sensitization) patient’s plasma contains antibody corresponding antigen coated well, antibody bind incubation (usually 37°C)\nWASHING (CRITICAL!) wells washed thoroughly remove unbound plasma proteins (including unbound antibodies). crucial!\nAdd Indicator Red Cells IgG-coated reagent red blood cells added well. key!\nCentrifugation microplate centrifuged\nAdd Patient Plasma/Serum Patient plasma/serum added antigen-coated well. LISS often added incorporated enhance reactivityIncubation (Sensitization) patient’s plasma contains antibody corresponding antigen coated well, antibody bind incubation (usually 37°C)WASHING (CRITICAL!) wells washed thoroughly remove unbound plasma proteins (including unbound antibodies). crucial!Add Indicator Red Cells IgG-coated reagent red blood cells added well. key!Centrifugation microplate centrifugedInterpretation (often opposite expect initially!)\nPOSITIVE Reaction: patient’s antibody bind coated antigens, forms layer covering bottom well. IgG-coated indicator cells added, bound patient antibody blocks reaching bottom (sometimes AHG coated well binds ). indicator cells form diffuse layer across bottom sides well. Diffuse Layer = Positive.\nNEGATIVE Reaction: patient’s plasma contain antibody coated antigens, nothing binds incubation. IgG-coated indicator cells added, free sink bottom centrifugation, forming tight pellet button center. Button = Negative.\nPOSITIVE Reaction: patient’s antibody bind coated antigens, forms layer covering bottom well. IgG-coated indicator cells added, bound patient antibody blocks reaching bottom (sometimes AHG coated well binds ). indicator cells form diffuse layer across bottom sides well. Diffuse Layer = Positive.NEGATIVE Reaction: patient’s plasma contain antibody coated antigens, nothing binds incubation. IgG-coated indicator cells added, free sink bottom centrifugation, forming tight pellet button center. Button = Negative.","code":""},{"path":"solid-phase.html","id":"detecting-antibodycomplement-coating-patient-cells-dat","chapter":"Solid Phase","heading":"Detecting Antibody/Complement Coating Patient Cells (DAT)","text":"’s Stuck Well?: Anti-Human Globulin (AHG) - specifically Anti-IgG /Anti-C3dThe Procedure (Simplified)\nAdd Patient Red Blood Cells patient’s washed red blood cells added AHG-coated wells\nCentrifugation microplate centrifuged\nAdd Patient Red Blood Cells patient’s washed red blood cells added AHG-coated wellsCentrifugation microplate centrifugedInterpretation (intuitive )\nPOSITIVE Reaction: patient’s red blood cells already coated vivo IgG C3d, bind Anti-IgG Anti-C3d coated well surface. binding causes cells form diffuse layer across well. Diffuse Layer = Positive.\nNEGATIVE Reaction: patient’s red blood cells coated IgG C3d, nothing bind well surface. centrifugation, slide form tight pellet button bottom. Button = Negative.\nPOSITIVE Reaction: patient’s red blood cells already coated vivo IgG C3d, bind Anti-IgG Anti-C3d coated well surface. binding causes cells form diffuse layer across well. Diffuse Layer = Positive.NEGATIVE Reaction: patient’s red blood cells coated IgG C3d, nothing bind well surface. centrifugation, slide form tight pellet button bottom. Button = Negative.","code":""},{"path":"solid-phase.html","id":"advantages-of-solid-phase-technology","chapter":"Solid Phase","heading":"Advantages of Solid Phase Technology","text":"Sensitivity: Often considered sensitive traditional tube testing (especially tube LISS), potentially detecting weaker antibodiesStandardization: Reading results (diffuse layer vs. button) generally less subjective grading agglutination tubes. Amenable automated reading cameras/plate readersAutomation Friendly: microplate format ideal high-throughput automated testing platformsStability: Reagent-coated plates often good shelf lifeReduced Sample Volume: Can sometimes require smaller volumes patient sample compared tube methods","code":""},{"path":"solid-phase.html","id":"disadvantages-and-considerations","chapter":"Solid Phase","heading":"Disadvantages and Considerations","text":"Cost: Requires specialized equipment (microplate centrifuges, potentially washers readers) reagent plates can expensive tubes/gel cardsInterpretation Nuances: Getting used “diffuse = positive” antibody screening/ID takes practice. Distinguishing weak positives negatives requires careProzone Potential: high concentrations antibody theoretically saturate sites interfere indicator cell binding, potentially causing false negative (less common well-designed modern assays)Interference: Fibrin strands particulate matter sample can sometimes interfere cell settling cause reading difficultiesWashing: Like tests using AHG, thorough washing critical prevent false results","code":""},{"path":"solid-phase.html","id":"key-terms-92","chapter":"Solid Phase","heading":"Key Terms","text":"Solid Phase Red Cell Adherence (SPRCA): Immunoassay technique used blood banking either antigens antibodies immobilized solid surface (microplate well)Microplate (Microtiter Plate): Plastic plate containing multiple small wells (commonly 96) used reaction vesselImmobilization: process attaching antigens antibodies surface microplate wellIndicator Red Cells: IgG-coated red blood cells used solid phase antibody detection methods. adherence pattern indicates test resultDiffuse Layer: pattern seen positive solid phase reaction, red cells spread across bottom well due bindingButton / Pellet: pattern seen negative solid phase reaction, red cells settle tight clump bottom wellCapture Antigen: Red cell membrane antigens bound well surface detect antibodies plasma/serumCapture Antibody: Anti-IgG Anti-C3d bound well surface detect sensitization patient red blood cells (DAT)","code":""},{"path":"column-agglutination.html","id":"column-agglutination","chapter":"Column Agglutination","heading":"Column Agglutination","text":"Column Agglutination Technology (CAT), often called Gel Test™ (actually specific brand name, frequently used generically) really popular visually elegant alternative traditional tube testing many routine special blood bank procedures!Think sophisticated sieve tiny tube. Instead looking clumps floating liquid, see clumps get trapped special gel bead matrix centrifugation","code":""},{"path":"column-agglutination.html","id":"the-core-purpose-detecting-agglutination-in-a-column","chapter":"Column Agglutination","heading":"The Core Purpose: Detecting Agglutination in a Column","text":"CAT provides standardized stable method performing many common immunohematology tests, including:ABO Forward Reverse GroupingRh(D) Typing (including Weak D testing)Antibody ScreeningAntibody IdentificationDirect Antiglobulin Test (DAT)Compatibility Testing (Crossmatching)Red Blood Cell Antigen Typing","code":""},{"path":"column-agglutination.html","id":"the-principle-sieving-through-gelbeads","chapter":"Column Agglutination","heading":"The Principle: Sieving Through Gel/Beads","text":"magic happens inside specially designed microtubes (“columns”) embedded plastic cards (often 6 microtubes per card)Microtube: top part reaction chamber. , microtube contains matrix either Sephadex gel glass beads suspended buffered solution. solution often contains pre-dispensed reagents depending test card type (e.g., Anti-, Anti-B, Anti-D, AHG)Process\nPatient/donor red cells /plasma/serum added reaction chamber top microtube, according specific test protocol\ncard incubated (required, e.g., IAT methods 37°C)\ncard centrifuged special centrifuge designed hold cards\nPatient/donor red cells /plasma/serum added reaction chamber top microtube, according specific test protocolThe card incubated (required, e.g., IAT methods 37°C)card centrifuged special centrifuge designed hold cardsThe Separation: centrifugation:\nUnagglutinated Red Blood Cells: small enough pass spaces gel/bead matrix form compact pellet bottom microtube\nAgglutinated Red Blood Cells: Form larger clumps big pass matrix. get trapped within gel/beads various levels depending size strength agglutinates\nUnagglutinated Red Blood Cells: small enough pass spaces gel/bead matrix form compact pellet bottom microtubeAgglutinated Red Blood Cells: Form larger clumps big pass matrix. get trapped within gel/beads various levels depending size strength agglutinates","code":""},{"path":"column-agglutination.html","id":"types-of-gel-cards","chapter":"Column Agglutination","heading":"Types of Gel Cards","text":"Different cards pre-filled specific tests:Neutral/Saline Cards: Contain buffered gel/bead matrix. Used ABO reverse grouping, autocontrols, situations specific reagent needed column itselfAntisera Cards: Contain specific blood grouping antisera (like Anti-, Anti-B, Anti-D) within gel/matrix. Used forward ABO/Rh typingAHG Cards (Anti-Human Globulin): Contain Anti-IgG (sometimes Anti-C3d polyspecific AHG) within gel/matrix. crucial :\nIndirect Antiglobulin Tests (IAT): Antibody screen, antibody ID, Weak D, crossmatch. Plasma/serum cells incubated added AHG card centrifugation\nDirect Antiglobulin Test (DAT): Patient’s washed red cells added directly AHG card centrifuged\nIndirect Antiglobulin Tests (IAT): Antibody screen, antibody ID, Weak D, crossmatch. Plasma/serum cells incubated added AHG card centrifugationDirect Antiglobulin Test (DAT): Patient’s washed red cells added directly AHG card centrifuged","code":""},{"path":"column-agglutination.html","id":"reading-and-interpreting-results","chapter":"Column Agglutination","heading":"Reading and Interpreting Results","text":"CAT really shines due clarity stability:Negative Reaction (0): red blood cells pass matrix form sharp, compact pellet bottom microtube. agglutinates trapped columnPositive Reaction (1+ 4+): Agglutinated cells trapped within gel/bead matrix. strength reaction correlates high cells trapped:\n4+: solid band agglutinated cells trapped top gel/bead column\n3+: Agglutinated cells primarily upper half column\n2+: Agglutinated cells dispersed throughout length column\n1+: Agglutinated cells mainly lower half column, cells possibly reaching bottom\n4+: solid band agglutinated cells trapped top gel/bead column3+: Agglutinated cells primarily upper half column2+: Agglutinated cells dispersed throughout length column1+: Agglutinated cells mainly lower half column, cells possibly reaching bottomMixed Field Reaction: Characterized layer agglutinated cells trapped top dispersed column pellet unagglutinated cells bottom. Often seen post-transfusion certain weak subgroupsHemolysis: Hemolysis (due complement activation, etc.) occurring centrifugation also considered positive result ’s antibody-mediated. supernatant gel/beads may appear pink red, may fewer intact cells pellet get trapped(Visualizing helps! Imagine clear tube filled gel/beads. Negative = red dot bottom. Positive = red line/smear trapped gel, higher = stronger reaction.)","code":""},{"path":"column-agglutination.html","id":"advantages-of-column-agglutination-technology","chapter":"Column Agglutination","heading":"Advantages of Column Agglutination Technology","text":"Standardization: Reduces variability associated tube testing techniques (e.g., inconsistent shaking/resuspension)Objectivity & Stability: Results stable hours (sometimes days), easy read, photograph, review. Grading generally consistent technologistsSensitivity: Often considered sensitive , slightly sensitive , traditional LISS tube testing detecting weak IgG antibodiesReduced Sample Volume: Can often use smaller amounts sample/reagentsAutomation: Easily incorporated semi-automated fully automated blood bank testing platformsSafety: Reduced aerosol production compared tube methods","code":""},{"path":"column-agglutination.html","id":"disadvantages-and-considerations-1","chapter":"Column Agglutination","heading":"Disadvantages and Considerations","text":"Cost: Cards specialized centrifuges/incubators can expensive basic tube testing suppliesSpecialized Equipment: Requires dedicated centrifuges sometimes incubators designed cardsHemolysis Detection: Detecting vitro hemolysis within opaque gel column can sometimes harder seeing supernatant tube, though hemolysis column visibleFibrin/Particulate Interference: Fibrin strands debris sample can sometimes get trapped nonspecifically top gel, potentially mimicking weak positive reaction. Clean samples importantTraining: Requires familiarity specific reading grading criteria","code":""},{"path":"column-agglutination.html","id":"key-terms-93","chapter":"Column Agglutination","heading":"Key Terms","text":"Column Agglutination Technology (CAT) / Gel Test™: Method using microtubes containing gel glass bead matrix trap agglutinated red blood cells centrifugationMicrotube/Column: individual reaction vessel within card containing gel/bead matrixGel Matrix / Glass Beads: sieving medium within microtube separates agglutinated unagglutinated cellsAgglutinates: Clumps red blood cells formed antibody bindingPellet: Compact button unagglutinated red blood cells bottom microtube (negative result)Trapped Cells: Agglutinated cells caught within gel/bead matrix (positive result)Mixed Field: Reaction pattern showing trapped agglutinates pellet free cells bottomAHG Card: Gel card containing Anti-Human Globulin (Anti-IgG +/- Anti-C3d) pre-dispensed matrix, used IAT DAT","code":""},{"path":"chloroquine-diphosphate.html","id":"chloroquine-diphosphate","chapter":"Chloroquine Diphosphate","heading":"Chloroquine Diphosphate","text":"Chloroquine Diphosphate (CDP) another one specialized reagents pull facing particular challenge, specifically need figure patient’s red cell phenotype cells coated IgG antibody (positive DAT)!Think CDP gentle chemical “key” tries unlock IgG antibodies red cell surface, hopefully without damaging red cell’s antigen “doors.”","code":""},{"path":"chloroquine-diphosphate.html","id":"the-core-purpose-removing-igg-to-allow-phenotyping","chapter":"Chloroquine Diphosphate","heading":"The Core Purpose: Removing IgG to Allow Phenotyping","text":"primary important use Chloroquine Diphosphate remove bound IgG antibodies red blood cells vitro, rendering cells DAT-negative (least significantly weaker IgG), can accurately phenotyped using standard serologic methodsWhy needed?Positive DAT Interference: patient IgG coating red cells (positive DAT), bound antibody can interfere antigen typing two main ways:\nFalse Positives bound IgG can cause spontaneous agglutination mixed high-protein reagents (like older Rh typing sera) AHG testing typing method requires \nBlocked Antigen Sites bound antibody might physically cover antigen sites ’re trying detect, potentially leading false-negative typing results\nFalse Positives bound IgG can cause spontaneous agglutination mixed high-protein reagents (like older Rh typing sera) AHG testing typing method requires itBlocked Antigen Sites bound antibody might physically cover antigen sites ’re trying detect, potentially leading false-negative typing resultsCDP Solution: removing interfering IgG, CDP treatment allows us test “naked” red cell actual antigens","code":""},{"path":"chloroquine-diphosphate.html","id":"mechanism-of-action-gently-dissociating-igg","chapter":"Chloroquine Diphosphate","heading":"Mechanism of Action: Gently Dissociating IgG","text":"exact mechanism isn’t perfectly understood, CDP believed work disrupting non-covalent bonds (like hydrogen bonds electrostatic interactions) hold IgG antibody red cell antigen. effectively weakens “grip” antibody, causing dissociate cell surfaceKey Advantage: CDP relatively gentle compared methods like ZZAP (uses enzymes + thiol reagents). removes IgG without significantly damaging common blood group antigens, including Rh, Kell, Duffy, Kidd, MNS systemsException: CDP can weaken denature Bg antigens (related HLA class antigens found red cells). , ’re specifically interested Bg typing, CDP treatment isn’t ideal","code":""},{"path":"chloroquine-diphosphate.html","id":"the-procedure-simplified-1","chapter":"Chloroquine Diphosphate","heading":"The Procedure (Simplified)","text":"Wash Patient Cells Thoroughly wash patient’s EDTA red blood cells saline remove unbound plasma proteins. critical!Incubation CDP Mix washed packed cells CDP reagent solution (typically specific concentration, like 0.2 M)Incubation Incubate mixture, often room temperature 37°C, period (e.g., 30 minutes 2 hours, depending protocol strength DAT)WASH Patient Cells (!) incubation, wash CDP-treated cells extensively saline (e.g., 4-6 times) remove CDP solution dissociated antibodyQuality Control (ESSENTIAL!) proceeding phenotyping:\nCheck DAT: Perform DAT (using Anti-IgG) treated cells. goal negative DAT. ’s still strongly positive, treatment may need repeated wasn’t effective. ’s weakly positive, typing might still possible requires caution\nCheck Antigen Integrity: Test treated cells known antisera antigens patient (known) common antigens, ensure CDP treatment didn’t inadvertently damage \nCheck DAT: Perform DAT (using Anti-IgG) treated cells. goal negative DAT. ’s still strongly positive, treatment may need repeated wasn’t effective. ’s weakly positive, typing might still possible requires cautionCheck Antigen Integrity: Test treated cells known antisera antigens patient (known) common antigens, ensure CDP treatment didn’t inadvertently damage themPhenotyping Use washed, DAT-negative (weakly positive), QC-passed treated cells antigen typing using standard serologic methods (usually low-protein reagents methods requiring AHG preferred DAT completely negative)","code":""},{"path":"chloroquine-diphosphate.html","id":"when-is-cdp-the-go-to-method","chapter":"Chloroquine Diphosphate","heading":"When is CDP the Go-To Method?","text":"need determine full RBC phenotype patient positive DAT due IgG (e.g., patient Warm Autoimmune Hemolytic Anemia - WAIHA)need preserve Kell, Duffy, MNS, Kidd, Rh antigens typing (unlike ZZAP destroys Kell, Duffy, MNS)","code":""},{"path":"chloroquine-diphosphate.html","id":"limitations-and-disadvantages","chapter":"Chloroquine Diphosphate","heading":"Limitations and Disadvantages","text":"Time-Consuming: incubation extensive washing steps take timeIncomplete Antibody Removal: May effectively remove strongly bound IgG antibodies. DAT might remain weakly positive, requiring careful selection typing reagents interpretationPotential Antigen Weakening: generally good preserving antigens, can weaken Bg antigens potentially others prolonged treatment certain specificitiesRequires Careful QC: Validating IgG removal antigen integrity crucial reporting phenotype resultsLess Effective Complement: Primarily targets IgG dissociation; less effective DAT positive due complement coating alone","code":""},{"path":"chloroquine-diphosphate.html","id":"comparison-to-zzap","chapter":"Chloroquine Diphosphate","heading":"Comparison to ZZAP","text":"CDP: Gentler, preserves antigens (except Bg), primarily removes IgGZZAP: Harsher (enzyme + thiol), removes IgG/Complement effectively, destroys Kell, MNS, Duffy antigens, making unsuitable need type systems","code":""},{"path":"chloroquine-diphosphate.html","id":"key-terms-94","chapter":"Chloroquine Diphosphate","heading":"Key Terms","text":"Chloroquine Diphosphate (CDP): chemical reagent used primarily dissociate IgG antibodies sensitized red blood cells vitroPositive Direct Antiglobulin Test (DAT): Indicates red blood cells coated vivo IgG /complementPhenotyping: Determining specific blood group antigens present individual’s red blood cells using known antiseraIgG Dissociation: process breaking bonds holding IgG antibodies red cell antigens, causing antibody detachAntigen Preservation: ability treatment (like CDP) leave red cell antigens intact detectable typing reagentsBg Antigens: Red blood cell antigens related HLA class antigens, known potentially weakened denatured CDP treatmentZZAP Reagent: combination proteolytic enzyme (papain/ficin) thiol reagent (DTT/2-) removes bound antibody/complement also destroys Kell, MNS, Duffy antigens","code":""},{"path":"edta-glycine-acid.html","id":"edta-glycine-acid","chapter":"EDTA-Glycine Acid","heading":"EDTA-Glycine Acid","text":"EDTA-Glycine Acid, often shortened EGA, another reagent special toolkit, quite similar purpose Chloroquine Diphosphate (CDP), using different approach achieve main goal: removing IgG antibodies stuck red blood cells can phenotype !Think EGA quick “acid wash” designed pop bound IgG antibodies without destroying underlying red cell antigens need identify","code":""},{"path":"edta-glycine-acid.html","id":"the-core-purpose-igg-removal-for-phenotyping-primarily","chapter":"EDTA-Glycine Acid","heading":"The Core Purpose: IgG Removal for Phenotyping (Primarily)","text":"Like CDP, main reason use EGA dissociate bound IgG antibodies red blood cells vitro. allows us perform accurate red blood cell phenotyping cells originally positive Direct Antiglobulin Test (DAT) due IgG coatingWhy? IgG coating interferes phenotyping, potentially causing false positives blocking antigen sites. EGA treatment aims create DAT-negative (least weaker) cells suitable testingA secondary, less common use, elution method . Since works lowering pH dissociate antibody, supernatant fluid treatment contains eluted antibody can potentially tested (neutralization) – essentially performing acid elution","code":""},{"path":"edta-glycine-acid.html","id":"mechanism-of-action-low-ph-dissociation-edta","chapter":"EDTA-Glycine Acid","heading":"Mechanism of Action: Low pH Dissociation + EDTA","text":"EGA leverages two components:Glycine-Acid: provides low pH environment (acidic). Similar acid elution techniques, low pH disrupts electrostatic hydrogen bonds holding IgG antibody red cell antigen, causing antibody detachEDTA (Ethylenediaminetetraacetic acid): component chelating agent, meaning binds calcium ions (Ca++). primary action low pH, EDTA’s presence helps prevent vitro complement activation procedure (though less critical sample collection, ’re usually starting already-coated cells) may contribute slightly destabilizing certain interactionsKey Difference CDP CDP works near neutral pH, EGA relies temporary drop acidic pH achieve dissociation","code":""},{"path":"edta-glycine-acid.html","id":"the-procedure-simplified-2","chapter":"EDTA-Glycine Acid","heading":"The Procedure (Simplified)","text":"Wash Patient Cells always techniques, start thoroughly washing patient’s EDTA red blood cells remove unbound plasma proteinsIncubation EGA Mix washed packed cells EGA reagent solutionIncubation Incubate mixture, usually short period (often just 1-2 minutes, sometimes longer depending protocol) room temperature. low pH works relatively quicklyNEUTRALIZATION (CRITICAL STEP!): Immediately short incubation, acidic reaction must stopped neutralized adding buffer solution (like Tris buffer specialized buffer). brings pH back physiological levels (~7.0) essential prevent damage red cell antigens prolonged acid exposureWASH Patient Cells (Extensively!): neutralization, wash EGA-treated cells thoroughly (e.g., 4-6 times) saline remove EGA reagent, buffer, dissociated antibodyQuality Control (ESSENTIAL!): phenotyping:\nCheck DAT: Perform DAT (using Anti-IgG) treated cells. Aim negative result. still positive, treatment may insufficient\nCheck Antigen Integrity: Test treated cells known antisera ensure common antigens weren’t damaged acid treatment inadequate neutralization\nCheck DAT: Perform DAT (using Anti-IgG) treated cells. Aim negative result. still positive, treatment may insufficientCheck Antigen Integrity: Test treated cells known antisera ensure common antigens weren’t damaged acid treatment inadequate neutralizationPhenotyping Use washed, neutralized, DAT-negative (weakly positive), QC-passed treated cells antigen typing","code":""},{"path":"edta-glycine-acid.html","id":"when-might-ega-be-chosen","chapter":"EDTA-Glycine Acid","heading":"When Might EGA Be Chosen?","text":"alternative CDP removing IgG phenotyping DAT-positive cellsSome labs find faster typical 2-hour incubation CDPMay sometimes effective CDP removing certain strongly bound IgG antibodiesWhen preservation Kell, Duffy, MNS, Kidd, Rh antigens needed (similar CDP, unlike ZZAP)","code":""},{"path":"edta-glycine-acid.html","id":"advantages-6","chapter":"EDTA-Glycine Acid","heading":"Advantages","text":"Rapid: Often requires shorter incubation times CDPEffective IgG Dissociation: Generally good removing bound IgGPreserves Antigens: Like CDP, avoids enzyme/thiol destruction seen ZZAP, preserving Kell, Duffy, MNS, etcCan Double Elution: supernatant can potentially used eluate","code":""},{"path":"edta-glycine-acid.html","id":"limitations-and-disadvantages-1","chapter":"EDTA-Glycine Acid","heading":"Limitations and Disadvantages","text":"Requires Rapid & Effective Neutralization: critical step unique EGA. Failure neutralize properly acid exposure damage red cell antigens, leading false-negative typing resultsPotential Antigen Damage: Even proper neutralization, brief exposure low pH might subtly affect antigens CDP treatment , although ’s generally considered safe common antigensIncomplete Antibody Removal: Like CDP, may remove IgG ’s strongly boundExtensive Washing Required: treatmentQC Paramount: Validating DAT negativity antigen integrity post-treatment non-negotiableLess Effective Complement: Primarily targets IgG dissociation","code":""},{"path":"edta-glycine-acid.html","id":"comparison-to-cdp-and-zzap","chapter":"EDTA-Glycine Acid","heading":"Comparison to CDP and ZZAP","text":"EGA vs. CDP: gently remove IgG, preserving antigens. EGA faster requires critical neutralization step due low pH. CDP slower avoids acid step. Choice often depends lab preference, protocols, sometimes one works better specific stubborn antibodyEGA vs. ZZAP: EGA preserves Kell, MNS, Duffy; ZZAP destroys . ZZAP better complete antibody/complement removal regardless antigen integrity; EGA used phenotyping specific antigen systems required DAT-positive cells","code":""},{"path":"edta-glycine-acid.html","id":"key-terms-95","chapter":"EDTA-Glycine Acid","heading":"Key Terms","text":"EDTA-Glycine Acid (EGA): reagent solution used dissociate IgG antibodies red blood cells vitro primarily temporary exposure low pHLow pH Dissociation: Using acidic environment break non-covalent bonds antibodies antigensNeutralization: critical step EGA treatment buffer added restore mixture physiological pH, preventing acid damage antigensPhenotyping DAT-positive Cells: main application EGA CDP – determining red cell antigen profile cells coated IgGAntigen Preservation: Maintaining integrity red cell antigens treatment can accurately typed afterwards","code":""},{"path":"quality-assurance.html","id":"quality-assurance","chapter":"Quality Assurance","heading":"Quality Assurance","text":"Quality Assurance (QA) Serologic Molecular testing isn’t just one thing – ’s comprehensive system ensuring accuracy safety start finish. Think three-legged stool: leg weak, whole thing wobbles! legs Blood Samples, Reagents, Test ProceduresHere’s overview QA applies :","code":""},{"path":"quality-assurance.html","id":"blood-samples-the-starting-material","chapter":"Quality Assurance","heading":"Blood Samples: The Starting Material","text":"Goal: Ensure sample unequivocally belongs correct patient suitable testing. Errors often critical!Key QA Checks\nPositive Patient Identification: Absolute cornerstone! Using least two unique identifiers (Name, DOB/MRN) verified directly patient’s ID band/information collection\nImpeccable Labeling: MUST done bedside/chairside immediately collection. Requires full patient name, second identifier, date/time collection, phlebotomist ID. Must legible secure. pre-labeling!\nCorrect Tube & Collection: Using right tube (usually EDTA), proper fill volume, appropriate collection technique avoid hemolysis clots, proper mixing\nTransport & Receipt: Prompt transport, avoiding temperature extremes. Lab verification label info vs. order, checking hemolysis/clots/QNS, documenting receipt time. Sample age limits must respected\nClear Acceptance/Rejection Criteria: Defined rules rejecting improperly identified, labeled, compromised samples\nPositive Patient Identification: Absolute cornerstone! Using least two unique identifiers (Name, DOB/MRN) verified directly patient’s ID band/information collectionImpeccable Labeling: MUST done bedside/chairside immediately collection. Requires full patient name, second identifier, date/time collection, phlebotomist ID. Must legible secure. pre-labeling!Correct Tube & Collection: Using right tube (usually EDTA), proper fill volume, appropriate collection technique avoid hemolysis clots, proper mixingTransport & Receipt: Prompt transport, avoiding temperature extremes. Lab verification label info vs. order, checking hemolysis/clots/QNS, documenting receipt time. Sample age limits must respectedClear Acceptance/Rejection Criteria: Defined rules rejecting improperly identified, labeled, compromised samples","code":""},{"path":"quality-assurance.html","id":"reagents-the-testing-tools","chapter":"Quality Assurance","heading":"Reagents: The Testing Tools","text":"Goal: Guarantee reagents (antisera, reagent cells, AHG, etc.) potent, specific, perform exactly expectedKey QA Checks\nReceipt & Validation: Checking shipment conditions, verifying order, inspecting vials, logging lot numbers/expiration dates. Crucially, validating new lots/shipments current lots use\nProper Storage: Maintaining required temperatures (usually 1-6°C) continuous monitoring alarms. Organized storage prevent mix-ups\nDaily Quality Control (QC): Testing day use known positive negative controls confirm expected reactivity specificity. Documenting QC results meticulously\nInventory Management: Rotating stock (FIFO - First-, First-), tracking usage, promptly discarding expired reagents\nTroubleshooting: clear procedures investigating documenting QC failures using reagent patient testing\nReceipt & Validation: Checking shipment conditions, verifying order, inspecting vials, logging lot numbers/expiration dates. Crucially, validating new lots/shipments current lots useProper Storage: Maintaining required temperatures (usually 1-6°C) continuous monitoring alarms. Organized storage prevent mix-upsDaily Quality Control (QC): Testing day use known positive negative controls confirm expected reactivity specificity. Documenting QC results meticulouslyInventory Management: Rotating stock (FIFO - First-, First-), tracking usage, promptly discarding expired reagentsTroubleshooting: clear procedures investigating documenting QC failures using reagent patient testing","code":""},{"path":"quality-assurance.html","id":"test-procedures-the-method","chapter":"Quality Assurance","heading":"Test Procedures: The Method","text":"Goal: Ensure every test performed consistently, accurately, precisely according validated instructions, regardless performs itKey QA Checks\nStandard Operating Procedures (SOPs): Detailed, --date written procedures every test, readily available followed exactly\nPersonnel Training & Competency: Ensuring staff initially trained regularly assessed (annually) ability perform test correctly\nEquipment Maintenance & Calibration: Regular checks, calibration, maintenance centrifuges, incubators, pipettes, automated systems, etc\nAdherence Critical Steps: Precisely following instructions incubation times/temps, washing, centrifugation speeds/times, reagent/sample volumes\nObjective Interpretation & Reporting: Using standardized criteria reading/grading results reporting accurately. Utilizing procedural controls (Rh control, Check Cells, etc.)\nProficiency Testing (PT): Participating external programs assess overall laboratory performance peers\nTroubleshooting & Corrective Action: Documenting investigation resolution errors discrepancies\nStandard Operating Procedures (SOPs): Detailed, --date written procedures every test, readily available followed exactlyPersonnel Training & Competency: Ensuring staff initially trained regularly assessed (annually) ability perform test correctlyEquipment Maintenance & Calibration: Regular checks, calibration, maintenance centrifuges, incubators, pipettes, automated systems, etcAdherence Critical Steps: Precisely following instructions incubation times/temps, washing, centrifugation speeds/times, reagent/sample volumesObjective Interpretation & Reporting: Using standardized criteria reading/grading results reporting accurately. Utilizing procedural controls (Rh control, Check Cells, etc.)Proficiency Testing (PT): Participating external programs assess overall laboratory performance peersTroubleshooting & Corrective Action: Documenting investigation resolution errors discrepancies","code":""},{"path":"blood-samples.html","id":"blood-samples","chapter":"Blood Samples","heading":"Blood Samples","text":"might seem basic, getting blood sample part right bedrock patient safety accurate results. Think way: sample isn’t good, isn’t properly identified, everything afterward meaningless, worse, dangerous!Quality Assurance (QA) blood samples covers entire journey, moment test ordered sample resulted stored discarded. Let’s break critical checkpoints:","code":""},{"path":"blood-samples.html","id":"pre-collection-getting-ready","chapter":"Blood Samples","heading":"Pre-Collection: Getting Ready","text":"Correct Test Order: Ensuring right tests ordered right patient Laboratory Information System (LIS) requisitionPatient Preparation: Usually minimal blood bank samples, ensuring patient hasn’t just received certain IV fluids interfere good practice applicable","code":""},{"path":"blood-samples.html","id":"collection-the-critical-interface","chapter":"Blood Samples","heading":"Collection: The CRITICAL Interface","text":"serious errors can occur, vigilance paramount!Patient Identification (IMPORTANT STEP!)\nPositive Patient Identification: stressed enough! Use least two unique patient identifiers (e.g., full name, date birth, medical record number)\nCompare, Compare, Compare: Actively compare information patient’s wristband (inpatient) directly requisition labels drawing blood. outpatients, confirm verbally check photo ID available/policy\nResolve Discrepancies: mismatch MUST resolved collecting sample. exceptions!\nPositive Patient Identification: stressed enough! Use least two unique patient identifiers (e.g., full name, date birth, medical record number)Compare, Compare, Compare: Actively compare information patient’s wristband (inpatient) directly requisition labels drawing blood. outpatients, confirm verbally check photo ID available/policyResolve Discrepancies: mismatch MUST resolved collecting sample. exceptions!Sample Labeling (Equally Critical!)\nLabel Bedside/Chairside: Tubes MUST labeled immediately collection, presence patient, leaving side. Never pre-label tubes!\nRequired Information: Labels must contain:\nPatient’s full name\nSecond unique identifier (DOB, MRN)\nDate collection\nTime collection\nPhlebotomist’s identification (initials, ID number)\n\nLegibility & Security: Labels must legible (barcodes ideal standard) securely affixed tube\nLabel Bedside/Chairside: Tubes MUST labeled immediately collection, presence patient, leaving side. Never pre-label tubes!Required Information: Labels must contain:\nPatient’s full name\nSecond unique identifier (DOB, MRN)\nDate collection\nTime collection\nPhlebotomist’s identification (initials, ID number)\nPatient’s full nameSecond unique identifier (DOB, MRN)Date collectionTime collectionPhlebotomist’s identification (initials, ID number)Legibility & Security: Labels must legible (barcodes ideal standard) securely affixed tubeTube Selection\nCorrect Anticoagulant: routine blood bank serologic testing (ABO/Rh, antibody screen, crossmatch) molecular testing, EDTA (lavender/pink top) preferred\nEDTA?: chelates calcium, preventing vitro complement activation (can interfere DATs cause confusing results) clotting, providing plasma intact red cells\n\nSerum (Red top/Gold top): Can used, plasma generally preferred stability preventing vitro complement issues. Required specific tests, less common routine pre-transfusion workups now\nCorrect Anticoagulant: routine blood bank serologic testing (ABO/Rh, antibody screen, crossmatch) molecular testing, EDTA (lavender/pink top) preferred\nEDTA?: chelates calcium, preventing vitro complement activation (can interfere DATs cause confusing results) clotting, providing plasma intact red cells\nEDTA?: chelates calcium, preventing vitro complement activation (can interfere DATs cause confusing results) clotting, providing plasma intact red cellsSerum (Red top/Gold top): Can used, plasma generally preferred stability preventing vitro complement issues. Required specific tests, less common routine pre-transfusion workups nowCollection Technique\nAseptic Technique: Standard precautions prevent infection sample contamination\nAvoiding Hemolysis: Hemolysis (rupture red blood cells) can significantly interfere interpretation (especially grading agglutination). Avoid:\nUsing small needle\nExcessive “probing”\nPulling plunger back forcefully (using syringe)\nVigorous shaking tubes (mix EDTA gently inversion)\nContamination alcohol (allow site dry)\nExtreme temperatures\n\nProper Fill Volume: Ensure vacuum tubes fill correctly\nMixing: Gently invert EDTA tubes 8-10 times immediately collection ensure proper anticoagulation prevent clots\nAseptic Technique: Standard precautions prevent infection sample contaminationAvoiding Hemolysis: Hemolysis (rupture red blood cells) can significantly interfere interpretation (especially grading agglutination). Avoid:\nUsing small needle\nExcessive “probing”\nPulling plunger back forcefully (using syringe)\nVigorous shaking tubes (mix EDTA gently inversion)\nContamination alcohol (allow site dry)\nExtreme temperatures\nUsing small needleExcessive “probing”Pulling plunger back forcefully (using syringe)Vigorous shaking tubes (mix EDTA gently inversion)Contamination alcohol (allow site dry)Extreme temperaturesProper Fill Volume: Ensure vacuum tubes fill correctlyMixing: Gently invert EDTA tubes 8-10 times immediately collection ensure proper anticoagulation prevent clots","code":""},{"path":"blood-samples.html","id":"post-collection-transport-receipt-and-storage","chapter":"Blood Samples","heading":"Post-Collection: Transport, Receipt, and Storage","text":"Transport: Samples transported lab promptly. Avoid extreme temperatures (don’t leave hot cars ice unless specifically required test like cold agglutinin studies). Ensure protected breakageLaboratory Receipt (Accessioning)\nVerification: Lab staff MUST verify label information matches requisition/LIS order required information present legible\nIntegrity Check: Inspect sample :\nHemolysis: Note degree hemolysis (may require redraw)\nClots: Clotted EDTA samples unacceptable\nQuantity Sufficient (QNS): Ensure adequate volume testing\nCorrect Tube Type: Verify ’s appropriate tube\nAge Sample: Note collection time. Samples pre-transfusion testing specific age limits (often 72 hours based institutional policy), especially critical patient recently transfused pregnant (within last 3 months)\n\nDocumentation: Record date time receipt\nVerification: Lab staff MUST verify label information matches requisition/LIS order required information present legibleIntegrity Check: Inspect sample :\nHemolysis: Note degree hemolysis (may require redraw)\nClots: Clotted EDTA samples unacceptable\nQuantity Sufficient (QNS): Ensure adequate volume testing\nCorrect Tube Type: Verify ’s appropriate tube\nAge Sample: Note collection time. Samples pre-transfusion testing specific age limits (often 72 hours based institutional policy), especially critical patient recently transfused pregnant (within last 3 months)\nHemolysis: Note degree hemolysis (may require redraw)Clots: Clotted EDTA samples unacceptableQuantity Sufficient (QNS): Ensure adequate volume testingCorrect Tube Type: Verify ’s appropriate tubeAge Sample: Note collection time. Samples pre-transfusion testing specific age limits (often 72 hours based institutional policy), especially critical patient recently transfused pregnant (within last 3 months)Documentation: Record date time receiptProcessing: Proper centrifugation techniques separate plasma/serum needed. Careful aliquoting required, ensuring aliquots also meticulously labeledStorage\nStore samples (whole blood, plasma, serum, cells) correct temperature (usually refrigerated 1-6°C processing/testing)\nStore manner prevents mix-ups allows easy retrieval\nAdhere sample retention policies (long samples must kept post-transfusion)\nStore samples (whole blood, plasma, serum, cells) correct temperature (usually refrigerated 1-6°C processing/testing)Store manner prevents mix-ups allows easy retrievalAdhere sample retention policies (long samples must kept post-transfusion)","code":""},{"path":"blood-samples.html","id":"sample-acceptance-and-rejection-criteria","chapter":"Blood Samples","heading":"Sample Acceptance and Rejection Criteria","text":"Clear criteria MUST place. Samples may rejected (requiring redraw) :Inadequate/Incorrect Patient Identification: Mismatched info, missing identifiersImproper Labeling: Missing info, illegible label, evidence tampering, tube labeled bedsideWrong Tube Type: Collected incorrect anticoagulant/additiveHemolysis: Moderate severe hemolysis often requires rejectionPresence Clots: anticoagulated tube (EDTA)Quantity Sufficient (QNS).Compromised Integrity: Broken tube, suspected contaminationAge Sample: Exceeds stability limits required testingDocumentation key throughout entire process! Every step, especially patient ID verification sample receipt/rejection, needs documented according lab policy","code":""},{"path":"blood-samples.html","id":"key-terms-96","chapter":"Blood Samples","heading":"Key Terms","text":"Positive Patient Identification: process correctly matching patient sample documentation using least two unique identifiersBedside Labeling: mandatory practice labeling blood tubes immediately collection, patient’s presence, leaving collection siteEDTA (Ethylenediaminetetraacetic acid): preferred anticoagulant blood bank testing, preventing clotting vitro complement activationHemolysis: rupture red blood cells, releasing hemoglobin, can interfere test interpretationAnticoagulant: substance prevents blood clottingSerum: liquid portion blood remaining clottingPlasma: liquid portion anticoagulated bloodAccessioning: process receiving sample laboratory, verifying identity integrity, assigning unique laboratory numberQNS (Quantity Sufficient): inadequate sample volume requested testingSample Integrity: state sample suitable testing (e.g., free hemolysis, clots, contamination)","code":""},{"path":"reagents-1.html","id":"reagents-1","chapter":"Reagents","heading":"Reagents","text":"Just like properly identified patient sample crucial, ensuring Reagents use test sample working perfectly absolutely fundamental. Faulty reagents lead faulty results, ’s something absolutely afford blood bank!Think reagents highly specialized tools – Anti-, Anti-D, Screening Cells, AHG, etc. QA ensures tools sharp, accurate, reliable every single time use . ’s continuous process governed strict standards (like AABB, CAP, FDA)’s breakdown key QA aspects blood bank reagents:","code":""},{"path":"reagents-1.html","id":"receiving-inspection-and-new-lot-validation","chapter":"Reagents","heading":"Receiving, Inspection, and New Lot Validation","text":"Verification Upon Arrival\nCheck shipping conditions. temperature-sensitive reagents shipped appropriately (e.g., refrigerated)?\nVerify shipment packing slip purchase order. get ordered? Correct reagent, correct number vials?\nInspect packaging damage, leakage, compromised seals\nCheck Lot Numbers Expiration Dates. Ensure adequate shelf life remains\nCheck shipping conditions. temperature-sensitive reagents shipped appropriately (e.g., refrigerated)?Verify shipment packing slip purchase order. get ordered? Correct reagent, correct number vials?Inspect packaging damage, leakage, compromised sealsCheck Lot Numbers Expiration Dates. Ensure adequate shelf life remainsDocumentation: Log date received, reagent name, manufacturer, lot number, expiration date, condition upon arrivalNew Lot / New Shipment Validation (CRITICAL!): new lot number (sometimes even new shipment existing lot) can put routine use, MUST tested parallel current, -use lot number\nPurpose: confirm new lot performs comparably old lot meets sensitivity/specificity requirements. Catches potential manufacturing issues damage shipping\n: Test new old lots known positive negative control cells/sera. Results consistent meet expected reactivity criteria. Document validation thoroughly\nPurpose: confirm new lot performs comparably old lot meets sensitivity/specificity requirements. Catches potential manufacturing issues damage shippingHow: Test new old lots known positive negative control cells/sera. Results consistent meet expected reactivity criteria. Document validation thoroughly","code":""},{"path":"reagents-1.html","id":"storage-maintaining-stability","chapter":"Reagents","heading":"Storage: Maintaining Stability","text":"Temperature Key: blood bank reagents require refrigeration (1-6°C). may need freezing room temperature storage\nMonitoring: Refrigerators/freezers MUST continuously monitored calibrated thermometers alarm systems. Temperatures must checked recorded daily (manually via electronic system)\nPlacement: Store reagents according manufacturer’s instructions (e.g., upright, protected light necessary). Don’t overcrowd shelves (allow air circulation). Don’t store doors temperatures fluctuate \nMonitoring: Refrigerators/freezers MUST continuously monitored calibrated thermometers alarm systems. Temperatures must checked recorded daily (manually via electronic system)Placement: Store reagents according manufacturer’s instructions (e.g., upright, protected light necessary). Don’t overcrowd shelves (allow air circulation). Don’t store doors temperatures fluctuate moreOrganization: Store reagents logically prevent mix-ups (e.g., separate different antisera clearly). mindful look-alike/sound-alike vialsPrevent Contamination: Use aseptic technique opening handling vials. Don’t interchange dropper caps","code":""},{"path":"reagents-1.html","id":"daily-quality-control-qc-the-routine-check-up","chapter":"Reagents","heading":"Daily Quality Control (QC): The Routine Check-Up","text":"cornerstone daily reagent QA – confirming reagents performing expected day usePurpose: Detects deterioration, contamination, loss potency may occurred since last use validationFrequency: Performed day use patient testing. methods might require QC per runMethod: Test reagent cells plasma known antigen/antibody profiles (positive negative controls)Specific QC Examples\nBlood Grouping Sera (Anti-, Anti-B, Anti-D, etc.): Test known , B, O, Rh(D)+, Rh(D)- cells. Must show expected positive reactions (appropriate strength) clear negative reactions. Specificity potency checked. Rh control reagent must always tested alongside Anti-D must negative\nReagent Red Blood Cells (Screening Cells, Panel Cells, A1/B Cells): Test known positive sera (e.g., weak anti-D screening cells) negative sera/saline. Must show expected reactivity lack spontaneous agglutination hemolysis. Visual inspection hemolysis vial also important\nAntiglobulin Sera (AHG - Polyspecific, Anti-IgG, Anti-C3d): Test known IgG-sensitized cells (like commercial Check Cells lab-prepared sensitized cells) unsensitized cells. Must agglutinate sensitized cells show reaction unsensitized cells. Check Cells also used validate negative IAT/DAT results\nLectins (Anti-A1, Anti-H): Test known positive (e.g., A1 cells Anti-A1) negative (e.g., A2 cells Anti-A1) cells\nBlood Grouping Sera (Anti-, Anti-B, Anti-D, etc.): Test known , B, O, Rh(D)+, Rh(D)- cells. Must show expected positive reactions (appropriate strength) clear negative reactions. Specificity potency checked. Rh control reagent must always tested alongside Anti-D must negativeReagent Red Blood Cells (Screening Cells, Panel Cells, A1/B Cells): Test known positive sera (e.g., weak anti-D screening cells) negative sera/saline. Must show expected reactivity lack spontaneous agglutination hemolysis. Visual inspection hemolysis vial also importantAntiglobulin Sera (AHG - Polyspecific, Anti-IgG, Anti-C3d): Test known IgG-sensitized cells (like commercial Check Cells lab-prepared sensitized cells) unsensitized cells. Must agglutinate sensitized cells show reaction unsensitized cells. Check Cells also used validate negative IAT/DAT resultsLectins (Anti-A1, Anti-H): Test known positive (e.g., A1 cells Anti-A1) negative (e.g., A2 cells Anti-A1) cellsInterpretation: Results MUST fall within laboratory’s established acceptance criteria (e.g., minimum reaction grade positives, clear negative negatives)Documentation: Record QC results, interpretations (Pass/Fail), date, time, technologist initials, reagent lot numbers/expiration dates","code":""},{"path":"reagents-1.html","id":"documentation-and-record-keeping","chapter":"Reagents","heading":"Documentation and Record Keeping","text":"Comprehensive Logs: Maintain detailed records everything: reagent receipt, validation, daily QC (including actual results, just Pass/Fail), temperature monitoring, corrective actions, disposalAccessibility & Retention: Records must organized, easily retrievable, kept duration required accrediting agencies (often years). Use standardized forms LIS modules","code":""},{"path":"reagents-1.html","id":"inventory-management","chapter":"Reagents","heading":"Inventory Management","text":"Track Usage: Monitor reagent usage ensure adequate stock levelsRotate Stock (FIFO): Use “First-, First-” principle. Place newer shipments behind older ones use reagents shorter expiration dates firstDiscard Expired Reagents: Regularly check expiration dates promptly discard expired reagents according safe disposal procedures. Never use expired reagents clinical testing!","code":""},{"path":"reagents-1.html","id":"troubleshooting-qc-failures","chapter":"Reagents","heading":"Troubleshooting QC Failures","text":"STOP!: QC result fails, reagent used patient testing issue resolvedInvestigate: Follow systematic approach:\nprocedural error? (Wrong sample, wrong reagent added?) Repeat QC\ncontrol cells/plasma suspect? Try different control materials\nequipment functioning correctly? (Centrifuge speed/timer, incubator temp?)\nTry new vial reagent lot. contamination/degradation specific vial\nstill failing, try vial different, validated lot number\nprocedural error? (Wrong sample, wrong reagent added?) Repeat QCAre control cells/plasma suspect? Try different control materialsIs equipment functioning correctly? (Centrifuge speed/timer, incubator temp?)Try new vial reagent lot. contamination/degradation specific vialIf still failing, try vial different, validated lot numberDocument: Record troubleshooting steps, findings, corrective actions takenNotify: Inform supervisor/QA coordinator","code":""},{"path":"reagents-1.html","id":"key-terms-97","chapter":"Reagents","heading":"Key Terms","text":"Quality Control (QC): Procedures performed routinely (e.g., daily) monitor performance reagents, equipment, methods, ensuring meet established criteriaLot Number: unique identifier assigned manufacturer specific batch reagent produced time conditionsExpiration Date: date reagent longer used, stability reactivity guaranteedValidation: process confirming new reagent lot, method, piece equipment performs expected put routine clinical usePotency: strength reactivity level reagent (e.g., strongly Anti-agglutinates cells)Specificity: ability reagent (e.g., antiserum) react intended target antigen othersPositive Control: material known contain substance tested , used confirm test system can detect positive resultNegative Control: material known lack substance tested , used confirm specificity test system rule false positivesParallel Testing: Testing new reagent lot method simultaneously current, established lot method using control materials comparisonFIFO (First-, First-): Inventory management principle ensuring older stock used newer stock minimize waste due expiration","code":""},{"path":"test-procedures.html","id":"test-procedures","chapter":"Test Procedures","heading":"Test Procedures","text":"’ve got good sample, reliable reagents – now need make sure way perform test accurate, consistent, follows rules every single time. standardization minimizing variables!Think like baking: even best ingredients (sample & reagents), don’t follow recipe (procedure) correctly – wrong oven temp, wrong mixing time – won’t get good cake. principle , stakes much higher!Quality Assurance test procedures ensures reliability reproducibility, whoever performing test whatever day. ’s ensure :","code":""},{"path":"test-procedures.html","id":"standard-operating-procedures-sops-the-recipe-book","chapter":"Test Procedures","heading":"Standard Operating Procedures (SOPs): The Recipe Book","text":"Foundation: Every test performed MUST detailed, written Standard Operating Procedure. ultimate guideContent Key: SOPs need comprehensive include:\nTest Principle: test work?\nSpecimen Requirements: Acceptable sample types, collection, handling, storage, rejection criteria\nReagents & Equipment: List necessary materials, including preparation instructions applicable\nQuality Control: Required frequency, materials, expected results, corrective actions failures\nStep--Step Instructions: Clear, concise, unambiguous directions performing entire test start finish\nResult Interpretation: Objective criteria reading results (e.g., grading agglutination, gel patterns, solid phase patterns)\nReporting: results documented reported (reference ranges, critical values, etc.)\nProcedural Limitations: can interfere test?\nReferences: Supporting literature manufacturer’s package inserts\nTest Principle: test work?Specimen Requirements: Acceptable sample types, collection, handling, storage, rejection criteriaReagents & Equipment: List necessary materials, including preparation instructions applicableQuality Control: Required frequency, materials, expected results, corrective actions failuresStep--Step Instructions: Clear, concise, unambiguous directions performing entire test start finishResult Interpretation: Objective criteria reading results (e.g., grading agglutination, gel patterns, solid phase patterns)Reporting: results documented reported (reference ranges, critical values, etc.)Procedural Limitations: can interfere test?References: Supporting literature manufacturer’s package insertsAccessibility & Updates: SOPs must readily available staff performing tests. need reviewed regularly (usually annually) updated whenever ’s change reagents, equipment, procedure. Version control essential!Following SOP: Staff must follow current SOP exactly written. shortcuts, “’ve always done .” Consistency crucial","code":""},{"path":"test-procedures.html","id":"personnel-training-and-competency-assessment-the-skilled-chef","chapter":"Test Procedures","heading":"Personnel Training and Competency Assessment: The Skilled Chef","text":"Initial Training: Staff must thoroughly trained procedure performing independently patient samples. includes understanding principle, reading SOP, hands-practice, demonstrating proficiencyCompetency Assessment: Regular assessment ensures staff maintain skills knowledge. isn’t just training; ’s proving can still right. Methods include:\nDirect Observation: Supervisor watches technologist perform test\nMonitoring QC Records: Reviewing daily performance\nReview Test Results: Checking accuracy interpretation time\nTesting Blind/Previously Tested Samples: Can reproduce results?\nProficiency Testing (PT): Successful performance external PT samples\nDirect Observation: Supervisor watches technologist perform testMonitoring QC Records: Reviewing daily performanceReview Test Results: Checking accuracy interpretation timeTesting Blind/Previously Tested Samples: Can reproduce results?Proficiency Testing (PT): Successful performance external PT samplesFrequency: Competency must assessed initial training, usually 6 months, annually thereafter test technologist performsDocumentation: training competency assessments must documented employee","code":""},{"path":"test-procedures.html","id":"equipment-and-environment-the-right-kitchen-tools","chapter":"Test Procedures","heading":"Equipment and Environment: The Right Kitchen Tools","text":"Equipment Function Checks & Calibration: Equipment used procedure must properly maintained monitored (covered partly Reagent/Sample QA):\nCentrifuges: Correct speed (RPM) time critical proper cell button formation resuspension. Calibrated regularly, timers checked\nIncubators/Water Baths/Heat Blocks: Accurate temperature vital antigen-antibody reactions (especially 37°C IgG). Monitored daily, calibrated regularly\nPipettes: Must deliver accurate volumes. Regularly calibrated maintained\nTimers: Must accurate\nAutomated Systems: Require validation, routine maintenance, built-QC checks per manufacturer\nCentrifuges: Correct speed (RPM) time critical proper cell button formation resuspension. Calibrated regularly, timers checkedIncubators/Water Baths/Heat Blocks: Accurate temperature vital antigen-antibody reactions (especially 37°C IgG). Monitored daily, calibrated regularlyPipettes: Must deliver accurate volumes. Regularly calibrated maintainedTimers: Must accurateAutomated Systems: Require validation, routine maintenance, built-QC checks per manufacturerWork Environment: Adequate lighting reading reactions, sufficient bench space, organized workflow prevent errors","code":""},{"path":"test-procedures.html","id":"test-performance---adherence-to-critical-steps","chapter":"Test Procedures","heading":"Test Performance - Adherence to Critical Steps","text":"Following SOP: Worth repeating!Correct Sample/Reagent Addition: Using right volumes, adding reagents correct sequenceProper Mixing: Ensuring adequate mixing samples/reagents without causing hemolysisIncubation Times & Temperatures: Adhering precisely times temperatures specified SOP critical allowing reactions reach completion avoiding unwanted reactionsWashing Steps (AHG tests): Performed correctly thoroughly remove unbound globulins – essential prevent false negatives. Correct saline volume, number washes, technique decantingCentrifugation: Using correct time speed specific procedure/equipment. much/little affects readingReading/Observation Technique: Using consistent, standardized technique resuspending cell buttons observing reactions gel/solid phase. Using appropriate optical aids needed. Good lighting essential","code":""},{"path":"test-procedures.html","id":"result-interpretation-and-reporting","chapter":"Test Procedures","heading":"Result Interpretation and Reporting","text":"Objective Criteria: Using grading system defined SOP consistently (e.g., 0-4+ agglutination, gel patterns). Avoiding subjective biasControls: Ensuring internal procedural controls (like Rh control, autocontrol, Check Cells negative AHG tests) give expected results accepting patient resultsCorrelation: Checking results make sense context tests (e.g., forward vs. reverse type, screen vs. crossmatch)Accurate Recording & Reporting: Transcribing results accurately, reporting using standard terminology, following procedures critical value reporting","code":""},{"path":"test-procedures.html","id":"troubleshooting-and-corrective-action","chapter":"Test Procedures","heading":"Troubleshooting and Corrective Action","text":"Recognizing Errors: Identifying unexpected discrepant results, QC failures, procedural deviationsFollowing Protocols: clear procedures investigating errors unexpected resultsCorrective Action: Implementing steps fix immediate problemPreventive Action: Analyzing root cause prevent recurrenceDocumentation: Recording troubleshooting corrective actions taken","code":""},{"path":"test-procedures.html","id":"proficiency-testing-pt-external-quality-assessment-eqa","chapter":"Test Procedures","heading":"Proficiency Testing (PT) / External Quality Assessment (EQA)","text":"External Check: Regularly testing “blind” samples external agency (like CAP)Purpose: Assesses laboratory’s overall performance specific test procedure compared peer labs. Confirms entire system (personnel, reagents, equipment, procedure) working correctlyProcess: PT samples must integrated routine workflow tested personnel normally perform test, using lab’s standard procedures","code":""},{"path":"test-procedures.html","id":"key-terms-98","chapter":"Test Procedures","heading":"Key Terms","text":"Standard Operating Procedure (SOP): Detailed, written instructions performing specific test task, ensuring consistency standardizationCompetency Assessment: evaluation individual’s ability perform test task correctly according procedure, conducted regular intervalsCalibration: process adjusting verifying accuracy measuring equipment (e.g., centrifuges, pipettes, thermometers) known standardsCritical Steps: Specific points within test procedure must performed precisely (e.g., incubation time/temp, washing, centrifugation) ensure accurate resultsResult Interpretation: process evaluating outcome test based objective criteria defined SOP (e.g., grading agglutination)Proficiency Testing (PT) / External Quality Assessment (EQA): program laboratories test unknown samples provided external agency assess performance peer laboratoriesCorrective Action: Steps taken resolve identified problem error (e.g., QC failure, procedural deviation)Preventive Action: Steps taken eliminate cause potential problems prevent occurringVersion Control: system managing changes documents like SOPs, ensuring current, approved version use","code":""},{"path":"indications.html","id":"indications","chapter":"Indications","heading":"Indications","text":"One practical important topics transfusion medicine: actually give blood components? ’s just replacing volume; ’s replacing specific functions patient lacking. Understanding Indications Transfusion absolutely key safe effective patient careRemember, transfusion essentially liquid tissue transplant! carries risks (infectious, immunologic, volume overload, etc.), decision transfuse always weigh potential benefits risks. aim treat patient symptoms, just number lab report, although lab values certainly guide decisions!’s breakdown indications major blood components:","code":""},{"path":"indications.html","id":"red-blood-cells-rbcs","chapter":"Indications","heading":"Red Blood Cells (RBCs)","text":": Carry oxygen lungs tissuesPrimary Goal Transfusion: improve oxygen-carrying capacity alleviate symptoms tissue hypoxia (oxygen deprivation)Key Indications\nAcute Blood Loss (Hemorrhage): Replacing lost red cell mass oxygen-carrying capacity actively bleeding patients (e.g., trauma, surgery, gastrointestinal bleeding). decision often based estimated volume blood loss, vital signs (hypotension, tachycardia), evidence poor tissue perfusion, just initial hemoglobin/hematocrit (may take time drop)\nSymptomatic Anemia: anemia (low hemoglobin/hematocrit) causes clinical signs symptoms like:\nShortness breath (dyspnea), especially rest minimal exertion\nChest pain (angina), particularly patients underlying coronary artery disease\nSignificant fatigue impacting daily function\nDizziness, fainting (syncope)\nTachycardia (rapid heart rate) heart failure symptoms\nImportant Note: specific hemoglobin “trigger” transfusion controversial highly patient-dependent. Historically, hemoglobin < 7 g/dL (hematocrit < 21%) often used general guideline stable, hospitalized patients. However, clinical judgment paramount. patient chronic, well-compensated anemia might tolerate hemoglobin 6.5 g/dL well, patient severe cardiac disease might become symptomatic 8.5 g/dL. treat symptoms related reduced oxygen delivery\n\nPerioperative Anemia: optimize oxygen delivery major surgery, especially patients tolerate lower hemoglobin levels due health issues. , focus preventing tissue hypoxia\nSpecific Conditions: Patients conditions like sickle cell disease thalassemia may require RBC transfusions (often specialized, like exchange transfusions) specific indications beyond just anemia (e.g., preventing stroke, managing acute chest syndrome)\nAcute Blood Loss (Hemorrhage): Replacing lost red cell mass oxygen-carrying capacity actively bleeding patients (e.g., trauma, surgery, gastrointestinal bleeding). decision often based estimated volume blood loss, vital signs (hypotension, tachycardia), evidence poor tissue perfusion, just initial hemoglobin/hematocrit (may take time drop)Symptomatic Anemia: anemia (low hemoglobin/hematocrit) causes clinical signs symptoms like:\nShortness breath (dyspnea), especially rest minimal exertion\nChest pain (angina), particularly patients underlying coronary artery disease\nSignificant fatigue impacting daily function\nDizziness, fainting (syncope)\nTachycardia (rapid heart rate) heart failure symptoms\nImportant Note: specific hemoglobin “trigger” transfusion controversial highly patient-dependent. Historically, hemoglobin < 7 g/dL (hematocrit < 21%) often used general guideline stable, hospitalized patients. However, clinical judgment paramount. patient chronic, well-compensated anemia might tolerate hemoglobin 6.5 g/dL well, patient severe cardiac disease might become symptomatic 8.5 g/dL. treat symptoms related reduced oxygen delivery\nShortness breath (dyspnea), especially rest minimal exertionChest pain (angina), particularly patients underlying coronary artery diseaseSignificant fatigue impacting daily functionDizziness, fainting (syncope)Tachycardia (rapid heart rate) heart failure symptomsImportant Note: specific hemoglobin “trigger” transfusion controversial highly patient-dependent. Historically, hemoglobin < 7 g/dL (hematocrit < 21%) often used general guideline stable, hospitalized patients. However, clinical judgment paramount. patient chronic, well-compensated anemia might tolerate hemoglobin 6.5 g/dL well, patient severe cardiac disease might become symptomatic 8.5 g/dL. treat symptoms related reduced oxygen deliveryPerioperative Anemia: optimize oxygen delivery major surgery, especially patients tolerate lower hemoglobin levels due health issues. , focus preventing tissue hypoxiaSpecific Conditions: Patients conditions like sickle cell disease thalassemia may require RBC transfusions (often specialized, like exchange transfusions) specific indications beyond just anemia (e.g., preventing stroke, managing acute chest syndrome)Typically Indicated : Volume expansion alone, nutritional supplement (iron, B12 deficiency – treat underlying cause!), “feeling tired” without significant symptomatic anemia, simply make lab number look better","code":""},{"path":"indications.html","id":"platelets-plts","chapter":"Indications","heading":"Platelets (PLTs)","text":": Form primary hemostatic plug stop bleeding injured blood vesselsPrimary Goal Transfusion: prevent treat bleeding due low platelet count (thrombocytopenia) platelet dysfunctionKey Indications\nTherapeutic Transfusion (Active Bleeding): Given patients actively bleeding thrombocytopenia suspected platelet dysfunction (e.g., massive hemorrhage, surgery, DIC bleeding)\nProphylactic Transfusion (Preventative): Given patients severe thrombocytopenia without active bleeding reduce risk spontaneous hemorrhage, particularly platelet counts low. Common scenarios include:\nPatients undergoing chemotherapy stem cell transplant leading bone marrow suppression (often transfused platelet count drops 10,000/µL)\nPatients needing invasive procedures (e.g., lumbar puncture, major surgery) may higher target threshold (e.g., < 50,000/µL higher depending procedure’s bleeding risk)\n\nPlatelet Dysfunction: Patients normal platelet counts whose platelets don’t function correctly (e.g., due certain medications like aspirin/clopidogrel bleeding, inherited platelet disorders, uremia) might receive platelets actively bleeding undergoing high-risk surgery\nTherapeutic Transfusion (Active Bleeding): Given patients actively bleeding thrombocytopenia suspected platelet dysfunction (e.g., massive hemorrhage, surgery, DIC bleeding)Prophylactic Transfusion (Preventative): Given patients severe thrombocytopenia without active bleeding reduce risk spontaneous hemorrhage, particularly platelet counts low. Common scenarios include:\nPatients undergoing chemotherapy stem cell transplant leading bone marrow suppression (often transfused platelet count drops 10,000/µL)\nPatients needing invasive procedures (e.g., lumbar puncture, major surgery) may higher target threshold (e.g., < 50,000/µL higher depending procedure’s bleeding risk)\nPatients undergoing chemotherapy stem cell transplant leading bone marrow suppression (often transfused platelet count drops 10,000/µL)Patients needing invasive procedures (e.g., lumbar puncture, major surgery) may higher target threshold (e.g., < 50,000/µL higher depending procedure’s bleeding risk)Platelet Dysfunction: Patients normal platelet counts whose platelets don’t function correctly (e.g., due certain medications like aspirin/clopidogrel bleeding, inherited platelet disorders, uremia) might receive platelets actively bleeding undergoing high-risk surgeryNOT Typically Indicated \nThrombotic Thrombocytopenic Purpura (TTP) Heparin-Induced Thrombocytopenia (HIT): Platelet transfusion generally contraindicated conditions can worsen thrombotic process (“add fuel fire”)\nImmune Thrombocytopenic Purpura (ITP): Transfused platelets rapidly destroyed autoantibodies; transfusion usually reserved life-threatening hemorrhage\nThrombotic Thrombocytopenic Purpura (TTP) Heparin-Induced Thrombocytopenia (HIT): Platelet transfusion generally contraindicated conditions can worsen thrombotic process (“add fuel fire”)Immune Thrombocytopenic Purpura (ITP): Transfused platelets rapidly destroyed autoantibodies; transfusion usually reserved life-threatening hemorrhage","code":""},{"path":"indications.html","id":"plasma-ffp-pf24-thawed-plasma","chapter":"Indications","heading":"Plasma (FFP, PF24, Thawed Plasma)","text":"contains: coagulation factors (stable labile), albumin, immunoglobulinsPrimary Goal Transfusion: replace multiple coagulation factors patients actively bleeding high risk bleeding invasive procedureKey Indications\nMultiple Coagulation Factor Deficiencies\nLiver Disease: Patients severe liver disease may synthesize factors adequately may need plasma bleeding prior procedures\nDisseminated Intravascular Coagulation (DIC): associated bleeding factor consumption\nMassive Transfusion: Replacing factors diluted consumed massive hemorrhage (often given ratio RBCs platelets)\n\nWarfarin Reversal: urgent reversal warfarin anticoagulation Vitamin K slow specific factor concentrates (like Prothrombin Complex Concentrates - PCCs) unavailable contraindicated\nPlasma Exchange Procedures: Used replacement fluid therapeutic plasma exchange (TPE) conditions like TTP\nRare Specific Factor Deficiencies: specific factor concentrates (like Factor XI concentrate) available\nMultiple Coagulation Factor Deficiencies\nLiver Disease: Patients severe liver disease may synthesize factors adequately may need plasma bleeding prior procedures\nDisseminated Intravascular Coagulation (DIC): associated bleeding factor consumption\nMassive Transfusion: Replacing factors diluted consumed massive hemorrhage (often given ratio RBCs platelets)\nLiver Disease: Patients severe liver disease may synthesize factors adequately may need plasma bleeding prior proceduresDisseminated Intravascular Coagulation (DIC): associated bleeding factor consumptionMassive Transfusion: Replacing factors diluted consumed massive hemorrhage (often given ratio RBCs platelets)Warfarin Reversal: urgent reversal warfarin anticoagulation Vitamin K slow specific factor concentrates (like Prothrombin Complex Concentrates - PCCs) unavailable contraindicatedPlasma Exchange Procedures: Used replacement fluid therapeutic plasma exchange (TPE) conditions like TTPRare Specific Factor Deficiencies: specific factor concentrates (like Factor XI concentrate) availableNOT Typically Indicated \nVolume Expansion: Use crystalloids (saline) colloids (albumin) instead\nNutritional Support: Plasma contains protein, enough nutritional purposes\nReversing Heparin: Protamine sulfate antidote heparin\nCorrecting mildly prolonged INR/PTT without bleeding planned procedure\nVolume Expansion: Use crystalloids (saline) colloids (albumin) insteadNutritional Support: Plasma contains protein, enough nutritional purposesReversing Heparin: Protamine sulfate antidote heparinCorrecting mildly prolonged INR/PTT without bleeding planned procedure","code":""},{"path":"indications.html","id":"cryoprecipitate-cryo","chapter":"Indications","heading":"Cryoprecipitate (Cryo)","text":": cold-insoluble precipitate forms FFP thawed slowly 1-6°C. ’s concentrated source specific plasma proteinsWhat contains (Concentrated): Fibrinogen (Factor ), Factor VIII, von Willebrand Factor (vWF), Factor XIII, FibronectinPrimary Goal Transfusion: provide concentrated source fibrinogen, Factor VIII, vWF, Factor XIIIKey Indications\nHypofibrinogenemia (Low Fibrinogen): common indication! Used treat bleeding associated low fibrinogen levels (<100-150 mg/dL, varies lab/situation) seen :\nDIC\nMassive Transfusion\nCongenital fibrinogen deficiency\nSevere liver disease\n\nFactor XIII Deficiency: Cryo good source\nHemophilia (Factor VIII Deficiency) von Willebrand Disease: specific factor concentrates (Factor VIII concentrate, vWF concentrate) unavailable. Concentrates preferred due viral safety standardization\nUremic Bleeding: Sometimes used empirically bleeding persists despite dialysis DDAVP treatment (mechanism less clear, possibly related vWF/Factor VIII)\nHypofibrinogenemia (Low Fibrinogen): common indication! Used treat bleeding associated low fibrinogen levels (<100-150 mg/dL, varies lab/situation) seen :\nDIC\nMassive Transfusion\nCongenital fibrinogen deficiency\nSevere liver disease\nDICMassive TransfusionCongenital fibrinogen deficiencySevere liver diseaseFactor XIII Deficiency: Cryo good sourceHemophilia (Factor VIII Deficiency) von Willebrand Disease: specific factor concentrates (Factor VIII concentrate, vWF concentrate) unavailable. Concentrates preferred due viral safety standardizationUremic Bleeding: Sometimes used empirically bleeding persists despite dialysis DDAVP treatment (mechanism less clear, possibly related vWF/Factor VIII)Typically Indicated : Conditions FFP suffice fibrinogen levels adequate","code":""},{"path":"indications.html","id":"general-principles","chapter":"Indications","heading":"General Principles","text":"Patient Blood Management (PBM): proactive, patient-centered approach minimize blood loss, optimize red cell mass, harness patient’s tolerance anemia, often reducing need transfusion. Consider alternatives first (iron, EPO, antifibrinolytics, cell salvage)Single Unit Transfusions: stable, non-bleeding anemic patients, transfusing one unit RBCs time followed reassessment symptoms hemoglobin often appropriate","code":""},{"path":"indications.html","id":"key-terms-99","chapter":"Indications","heading":"Key Terms","text":"Red Blood Cells (RBCs): blood component containing hemoglobin, responsible transporting oxygen lungs tissues. Transfusions indicated primarily increase oxygen-carrying capacity alleviate symptoms tissue hypoxia due anemia acute blood lossPlatelets (PLTs): Small blood cells essential primary hemostasis (forming initial plug sites injury). Transfusions indicated prevent treat bleeding caused low platelet counts (thrombocytopenia) platelet dysfunctionPlasma (e.g., FFP, PF24): liquid component blood containing water, proteins, coagulation factors. Transfusions indicated primarily replace multiple coagulation factors patients active bleeding needing invasive procedures, often due liver disease, DIC, massive transfusionCryoprecipitate (Cryo): plasma derivative prepared thawing FFP, providing concentrated source specific clotting factors including Fibrinogen (Factor ), Factor VIII, von Willebrand Factor, Factor XIII. Primarily indicated treat hypofibrinogenemiaSymptomatic Anemia: condition low red blood cell count (anemia) results clinical signs symptoms inadequate oxygen delivery (e.g., shortness breath, chest pain, severe fatigue, dizziness), serving key indication RBC transfusion rather relying solely specific hemoglobin levelHemoglobin Trigger: specific hemoglobin level (e.g., < 7 g/dL) often used guideline threshold consider red blood cell transfusion, although clinical symptoms patient context paramount final decisionThrombocytopenia: condition characterized abnormally low platelet count blood, increases risk bleeding primary indication platelet transfusion (either prophylactically therapeutically)Prophylactic Transfusion: transfusion given prevent potential complication, administering platelets severely thrombocytopenic patient without active bleeding reduce risk spontaneous hemorrhageHypofibrinogenemia: condition characterized abnormally low levels fibrinogen (Factor ) blood, impairing clot formation. common indication transfusing CryoprecipitatePatient Blood Management (PBM): patient-centered, systematic, evidence-based approach transfusion aims minimize blood loss, optimize patient red cell mass, manage anemia, rationalize transfusion decisions, often reducing need allogeneic blood transfusions","code":""},{"path":"component-therapy.html","id":"component-therapy","chapter":"Component Therapy","heading":"Component Therapy","text":"Component Therapy really cornerstone modern transfusion practice. Gone days (mostly!) just giving whole blood everything. Now, focus giving specific part blood patient actually needs. Understanding components, functions, storage requirements, indications fundamental providing safe effective transfusion support!Big Idea: Targeted ReplacementComponent therapy means separating donated whole blood constituent parts (Red Cells, Platelets, Plasma, Cryoprecipitate) transfusing component(s) required treat specific deficiency clinical problemWhy Component Therapy?Targeted Treatment: Addresses patient’s specific need (e.g., oxygen-carrying capacity, clotting factors, platelets) without giving unnecessary componentsReduced Volume: Avoids circulatory overload giving excess plasma cellsOptimal Storage: Different components require different storage conditions maximize shelf life functionEfficient Use Donations: One whole blood donation can potentially help multiple patientsHere’s comprehensive look major components:","code":""},{"path":"component-therapy.html","id":"red-blood-cells-rbcs-1","chapter":"Component Therapy","heading":"Red Blood Cells (RBCs)","text":": Primarily red cells remaining plasma platelets removed. Suspended anticoagulant-preservative solution (e.g., CPDA-1) often additive solution (e.g., -1, -3, -5) extend shelf life improve flow. Typically leukoreducedWhat : Increases oxygen-carrying capacity bloodStorage & Shelf Life\nTemperature: 1-6°C (Refrigerator)\nShelf Life: Varies solution (e.g., 21 days CPDA-1, 42 days additive solutions)\nTemperature: 1-6°C (Refrigerator)Shelf Life: Varies solution (e.g., 21 days CPDA-1, 42 days additive solutions)Typical Volume: ~300-350 mL per unitKey Indications: Symptomatic anemia (low hemoglobin/hematocrit causing symptoms like shortness breath, angina, severe fatigue), acute blood lossDosage & Expected Effect: One unit typically raises hemoglobin ~1 g/dL hematocrit ~3% average, non-bleeding adultCompatibility: MUST ABO compatible recipient’s plasma. Rh(D) type critical; Rh(D)-negative recipients receive Rh(D)-negative RBCs whenever possible, especially females childbearing potentialSpecial Modifications\nLeukoreduction: Standard practice now; removes white blood cells reduce febrile reactions, CMV transmission, HLA alloimmunization\nIrradiation: Prevents Transfusion-Associated Graft-vs-Host Disease (TA-GVHD) inactivating donor T-lymphocytes. Indicated immunocompromised patients, recipients directed donations relatives, etc. Reduces shelf life done near expiry\nWashing: Removes plasma proteins. Indicated patients history severe allergic reactions (anaphylaxis) IgA deficiency anti-IgA. Reduces shelf life significantly (use within 24 hours)\nVolume Reduction: Reduces volume neonatal/pediatric patients risk volume overload\nAntigen-Negative: Selected units lacking specific antigens patients corresponding clinically significant antibodies\nSickle Cell Negative: Units tested found negative Hemoglobin S, patients sickle cell disease\nCMV-Safe: Either CMV-seronegative units leukoreduced units (considered CMV-safe equivalent) -risk patients (e.g., CMV-negative transplant recipients, newborns)\nLeukoreduction: Standard practice now; removes white blood cells reduce febrile reactions, CMV transmission, HLA alloimmunizationIrradiation: Prevents Transfusion-Associated Graft-vs-Host Disease (TA-GVHD) inactivating donor T-lymphocytes. Indicated immunocompromised patients, recipients directed donations relatives, etc. Reduces shelf life done near expiryWashing: Removes plasma proteins. Indicated patients history severe allergic reactions (anaphylaxis) IgA deficiency anti-IgA. Reduces shelf life significantly (use within 24 hours)Volume Reduction: Reduces volume neonatal/pediatric patients risk volume overloadAntigen-Negative: Selected units lacking specific antigens patients corresponding clinically significant antibodiesSickle Cell Negative: Units tested found negative Hemoglobin S, patients sickle cell diseaseCMV-Safe: Either CMV-seronegative units leukoreduced units (considered CMV-safe equivalent) -risk patients (e.g., CMV-negative transplant recipients, newborns)","code":""},{"path":"component-therapy.html","id":"platelets-plts-1","chapter":"Component Therapy","heading":"Platelets (PLTs)","text":": Platelets suspended small amount plasma mixture plasma Platelet Additive Solution (PAS)Sources\nApheresis Platelets: Collected single donor using apheresis machine. Equivalent 4-6 units whole blood-derived platelets. Preferred product\nWhole Blood-Derived (WBD) Platelets: Prepared pooling platelet concentrates 4-6 different whole blood donations. Higher donor exposure\nApheresis Platelets: Collected single donor using apheresis machine. Equivalent 4-6 units whole blood-derived platelets. Preferred productWhole Blood-Derived (WBD) Platelets: Prepared pooling platelet concentrates 4-6 different whole blood donations. Higher donor exposureWhat : Essential primary hemostasis (forming platelet plugs)Storage & Shelf Life\nTemperature: 20-24°C (Room Temperature) - CRITICAL!\nAgitation: Requires continuous gentle agitation maintain viability prevent aggregation\nShelf Life: 5 days (sometimes 7 days bacterial detection testing performed). Short shelf life due risk bacterial growth room temp\nTemperature: 20-24°C (Room Temperature) - CRITICAL!Agitation: Requires continuous gentle agitation maintain viability prevent aggregationShelf Life: 5 days (sometimes 7 days bacterial detection testing performed). Short shelf life due risk bacterial growth room tempTypical Volume: Apheresis: ~200-400 mL; Pooled WBD: ~200-300 mLKey Indications: Prevent treat bleeding due thrombocytopenia (low count) platelet dysfunction. Prophylactic (e.g., count <10,000/µL) therapeutic (active bleeding)Dosage & Expected Effect: One unit (apheresis pool) typically raises platelet count 30,000-60,000/µL average adult without consumption factorsCompatibility: ABO compatibility preferred (especially plasma) strictly required unavailable. Platelets ABO antigens, incompatible plasma can cause mild hemolytic reactions poor platelet increments. Rh(D) type matters Rh(D)-negative females childbearing potential ideally receive Rh(D)-negative platelets prevent anti-D formation residual RBCs unit. Rh(D)-positive platelets must given, consider Rh Immune Globulin (RhIG)Special Modifications: Leukoreduction (standard), Irradiation (indications RBCs), Washing (rarely, significantly damages platelets)","code":""},{"path":"component-therapy.html","id":"plasma-ffp-pf24-thawed-plasma-1","chapter":"Component Therapy","heading":"Plasma (FFP, PF24, Thawed Plasma)","text":": Plasma separated whole blood frozen preserve coagulation factors\nFFP (Fresh Frozen Plasma): Frozen within 8 hours collection. Contains coagulation factors, including labile factors V VIII\nPF24 (Plasma Frozen within 24 hours): Frozen within 8-24 hours. May slightly reduced levels Factors V VIII compared FFP, generally clinically equivalent uses\nThawed Plasma: FFP PF24 thawed stored 1-6°C. Can used 5 days, labile factors (V, VIII) decrease time\nFFP (Fresh Frozen Plasma): Frozen within 8 hours collection. Contains coagulation factors, including labile factors V VIIIPF24 (Plasma Frozen within 24 hours): Frozen within 8-24 hours. May slightly reduced levels Factors V VIII compared FFP, generally clinically equivalent usesThawed Plasma: FFP PF24 thawed stored 1-6°C. Can used 5 days, labile factors (V, VIII) decrease timeWhat : Replaces multiple coagulation factorsStorage & Shelf Life\nFrozen: ≤ -18°C (colder) 1 year\nThawed: 1-6°C. Use within 24 hours (considered FFP/PF24) 5 days (relabeled Thawed Plasma)\nFrozen: ≤ -18°C (colder) 1 yearThawed: 1-6°C. Use within 24 hours (considered FFP/PF24) 5 days (relabeled Thawed Plasma)Typical Volume: ~200-250 mL per unitKey Indications: Correction multiple coagulation factor deficiencies (e.g., liver disease, DIC, massive transfusion, urgent warfarin reversal PCCs unavailable). Replacement fluid plasma exchange (e.g., TTP)Dosage & Expected Effect: Typically 10-15 mL/kg body weight. Aim increase factor levels ~20-30%. Monitor coagulation tests (PT/INR, PTT)Compatibility: MUST ABO compatible recipient’s RED CELLS (opposite RBCs!). Donor plasma antibodies must react recipient RBC antigens. Rh type generally disregarded unless transfusing large volumes Rh(D)-negative females childbearing potentialSpecial Modifications: Pathogen-Reduced Plasma (e.g., Solvent/Detergent treated) available regions","code":""},{"path":"component-therapy.html","id":"cryoprecipitate-cryo-1","chapter":"Component Therapy","heading":"Cryoprecipitate (Cryo)","text":": Cold-insoluble precipitate recovered FFP thawed slowly 1-6°C resuspended small amount residual plasmaWhat Contains (Concentrated): Fibrinogen (Factor ), Factor VIII, von Willebrand Factor (vWF), Factor XIII, FibronectinStorage & Shelf Life\nFrozen: ≤ -18°C 1 year\nThawed: 20-24°C (Room Temperature) - CRITICAL!\nShelf Life (Thawed): 6 hours single units. units pooled one bag (common), must used within 4 hours pooling due increased risk bacterial contamination (open system)\nFrozen: ≤ -18°C 1 yearThawed: 20-24°C (Room Temperature) - CRITICAL!Shelf Life (Thawed): 6 hours single units. units pooled one bag (common), must used within 4 hours pooling due increased risk bacterial contamination (open system)Typical Volume: small, ~10-15 mL per single unit. Often pooled (e.g., 5-10 units)Key Indications: Primarily hypofibrinogenemia (low fibrinogen levels) associated bleeding. Also used Factor XIII deficiency, historically Hemophilia /vWD factor concentrates unavailable (concentrates strongly preferred now)Dosage & Expected Effect: Typically given pool 5-10 units. Goal significantly raise fibrinogen levels (e.g., 100-150 mg/dL)Compatibility: ABO compatibility generally required due small volume, preferred readily available, especially neonates/infantsSpecial Modifications: Pooling common practice","code":""},{"path":"component-therapy.html","id":"key-terms-100","chapter":"Component Therapy","heading":"Key Terms","text":"Component Therapy: transfusion practice administering specific parts blood (e.g., RBCs, platelets, plasma) based patient’s specific needs, rather transfusing whole bloodLeukoreduction: process removing white blood cells blood component, primarily reduce risk febrile non-hemolytic reactions, CMV transmission, HLA alloimmunizationIrradiation: process exposing blood component gamma rays X-rays inactivate donor T-lymphocytes, preventing Transfusion-Associated Graft-versus-Host Disease (TA-GVHD)Washing: process removing plasma additive solutions cellular blood components (RBCs platelets) repeated suspension centrifugation saline. Used primarily patients severe allergic reactions IgA deficiencyApheresis: collection method whole blood drawn donor, specific component (e.g., platelets, plasma, RBCs) separated collected machine, remaining components returned donor. Allows collection larger dose single component one donorPooling: Combining multiple single units blood component (e.g., whole blood-derived platelets, cryoprecipitate) one container transfusion single dose. Increases donor exposurePlatelet Additive Solution (PAS): buffered salt solution designed replace portion plasma used platelet storage, potentially reducing allergic reactions related plasma proteinsCompatibility: Ensuring donor blood component cause harmful immune reaction recipient. Primarily involves ABO Rh(D) matching RBCs, ABO matching plasma","code":""},{"path":"adverse-effects.html","id":"adverse-effects","chapter":"Adverse Effects","heading":"Adverse Effects","text":"Vigilance patient ID, sample handling, compatibility testing, component selection, patient monitoring, prompt reaction investigation essential minimizing adverse effects. effects fall three broad categories: Immunologic reactions, Non-immunologic reactions, Transfusion-Transmitted DiseasesHere’s comprehensive overview:","code":""},{"path":"adverse-effects.html","id":"immunologic-reactions-the-immune-system-responds","chapter":"Adverse Effects","heading":"Immunologic Reactions: The Immune System Responds","text":"occur recipient’s immune system reacts donor blood components (vice-versa). Timing key (Acute: <24h; Delayed: >24h)Acute Reactions (<24h)\nAcute Hemolytic (AHTR): feared, often ABO incompatibility (clerical error!). Rapid intravascular hemolysis via complement. Symptoms: Fever, chills, back/flank pain, hemoglobinuria, hypotension, shock, DIC. Potentially fatal\nFebrile Non-Hemolytic (FNHTR): common. Due recipient antibodies vs. donor WBCs, cytokines stored unit. Symptoms: Fever (≥1°C rise), chills, malaise. hemolysis. Reduced leukoreduction\nAllergic (Urticarial): Common, mild. Reaction donor plasma proteins (histamine release). Symptoms: Hives, itching. fever\nAnaphylactic: Rare, severe. Often IgA-deficient patients anti-IgA. Symptoms: Rapid onset shock, respiratory distress, angioedema, fever. Requires washed components prevention\nTRALI (Transfusion-Related Acute Lung Injury): Leading cause transfusion death. Donor antibodies vs. recipient neutrophils -> lung capillary damage. Symptoms: Acute respiratory distress, hypoxia, bilateral pulmonary edema without circulatory overload, within 6 hours\nAcute Hemolytic (AHTR): feared, often ABO incompatibility (clerical error!). Rapid intravascular hemolysis via complement. Symptoms: Fever, chills, back/flank pain, hemoglobinuria, hypotension, shock, DIC. Potentially fatalFebrile Non-Hemolytic (FNHTR): common. Due recipient antibodies vs. donor WBCs, cytokines stored unit. Symptoms: Fever (≥1°C rise), chills, malaise. hemolysis. Reduced leukoreductionAllergic (Urticarial): Common, mild. Reaction donor plasma proteins (histamine release). Symptoms: Hives, itching. feverAnaphylactic: Rare, severe. Often IgA-deficient patients anti-IgA. Symptoms: Rapid onset shock, respiratory distress, angioedema, fever. Requires washed components preventionTRALI (Transfusion-Related Acute Lung Injury): Leading cause transfusion death. Donor antibodies vs. recipient neutrophils -> lung capillary damage. Symptoms: Acute respiratory distress, hypoxia, bilateral pulmonary edema without circulatory overload, within 6 hoursDelayed Reactions (>24h)\nDelayed Hemolytic (DHTR): Anamnestic response RBC antigens (Kidd, Duffy, Kell, Rh). Extravascular hemolysis days/weeks later. Symptoms: Falling Hgb, jaundice, fever, positive DAT. History check key!\nTA-GVHD (Transfusion-Associated Graft-vs-Host Disease): Rare, highly fatal. Donor T-cells attack recipient tissues (immunocompromised related donor). Symptoms: Rash, fever, diarrhea, liver dysfunction, pancytopenia (1-2 weeks post). Prevented irradiation\nPost-Transfusion Purpura (PTP): Rare. Abrupt severe thrombocytopenia (~1 week post) due platelet alloantibody destroying donor patient platelets\nAlloimmunization: Development antibodies RBC, platelet, HLA antigens. Risks future DHTR, HDFN, platelet refractoriness\nDelayed Hemolytic (DHTR): Anamnestic response RBC antigens (Kidd, Duffy, Kell, Rh). Extravascular hemolysis days/weeks later. Symptoms: Falling Hgb, jaundice, fever, positive DAT. History check key!TA-GVHD (Transfusion-Associated Graft-vs-Host Disease): Rare, highly fatal. Donor T-cells attack recipient tissues (immunocompromised related donor). Symptoms: Rash, fever, diarrhea, liver dysfunction, pancytopenia (1-2 weeks post). Prevented irradiationPost-Transfusion Purpura (PTP): Rare. Abrupt severe thrombocytopenia (~1 week post) due platelet alloantibody destroying donor patient plateletsAlloimmunization: Development antibodies RBC, platelet, HLA antigens. Risks future DHTR, HDFN, platelet refractoriness","code":""},{"path":"adverse-effects.html","id":"non-immunologic-reactions-physical-chemical-or-volume-issues","chapter":"Adverse Effects","heading":"Non-Immunologic Reactions: Physical, Chemical, or Volume Issues","text":"Caused component’s properties infusion process itselfTransfusion-Associated Circulatory Overload (TACO): Common, especially susceptible patients (elderly, cardiac/renal disease). Infused volume exceeds capacity. Symptoms: Respiratory distress, hypertension, tachycardia, jugular venous distension, pulmonary edema. Manage slower infusion, diureticsBacterial Contamination (Sepsis): common infectious risk now, esp. room-temp stored platelets. Rapid onset fever, chills, shock. Life-threatening. Requires immediate stop, cultures, antibioticsHypothermia: rapid infusion cold blood. Can worsen acidosis, coagulopathy. Prevent blood warmers massive/rapid infusionsCitrate Toxicity / Hypocalcemia: Citrate anticoagulant binds ionized calcium. Risk massive/rapid transfusion liver failure. Symptoms: Paresthesias, tetany, hypotension. Monitor ionized Ca++, give calcium PRNHyperkalemia: Potassium leaks RBCs storage. Risk rapid infusion older units, neonates, renal failure. Symptoms: Muscle weakness, cardiac arrhythmias. Use fresh/washed cells high-risk patientsPhysical Hemolysis: RBC damage improper storage (temp), handling (pressure), mixing non-isotonic IV fluids. Can mimic hemolytic reaction (DAT negative)Iron Overload (Hemosiderosis): Chronic complication long-term transfused patients. Iron deposition damages organs (heart, liver, endocrine). Requires iron chelation therapy","code":""},{"path":"adverse-effects.html","id":"transfusion-transmitted-diseases-ttds-infectious-agents","chapter":"Adverse Effects","heading":"Transfusion-Transmitted Diseases (TTDs): Infectious Agents","text":"Risk extremely low due rigorous donor screening testing, zero (“window period”)Viruses: HIV, HCV, HBV (risk minimized NAT), HTLV, CMV (risk immunocompromised; use CMV-neg leukoreduced), WNV, ZikaBacteria: See Sepsis aboveParasites: Malaria, Babesia, Chagas (risk depends geography/travel; screening/testing helps)Prions: vCJD (extremely rare; risk based geographic deferral)Prevention: Multi-layered approach: donor screening questionnaires, deferrals, lab testing (serology + NAT), bacterial detection (platelets), pathogen reduction (plasma/platelets)","code":""},{"path":"immunologic.html","id":"immunologic","chapter":"Immunologic","heading":"Immunologic","text":"Immunologic Adverse Effects Transfusion recipient’s immune system reacts inappropriately donor blood components. reactions range mild common severe life-threatening, recognizing promptly understanding underlying mechanisms absolutely critical!Remember, even careful testing, immune system can sometimes still recognize transfused cells proteins “foreign.”generally categorize reactions based timing: Acute (occurring within 24 hours transfusion) Delayed (occurring 24 hours transfusion)","code":""},{"path":"immunologic.html","id":"acute-immunologic-reactions-within-24-hours","chapter":"Immunologic","heading":"Acute Immunologic Reactions (Within 24 Hours)","text":"often require immediate attention!","code":""},{"path":"immunologic.html","id":"acute-hemolytic-transfusion-reaction-ahtr","chapter":"Immunologic","heading":"Acute Hemolytic Transfusion Reaction (AHTR)","text":"Big One: feared acute reaction, often due ABO incompatibility (e.g., giving Group blood Group O patient). ’s usually caused clerical error somewhere process!Immunologic Cause: Pre-formed recipient antibodies (typically IgM anti-, anti-B) bind donor RBC antigens -> activate complement cascade -> rapid intravascular hemolysis (destruction RBCs within blood vessels). Can also caused complement-fixing antibodies (less common acutely)Key Signs & Symptoms: Rapid onset (often within minutes starting transfusion). Fever, chills (often severe shaking), back flank pain, hemoglobinuria (red/brown urine), hypotension (low blood pressure), tachycardia, shortness breath, feeling impending doom, pain along infusion vein. Can rapidly progress shock, Disseminated Intravascular Coagulation (DIC), acute renal failureSeverity: Potentially life-threatening. Requires immediate cessation transfusion aggressive supportive care","code":""},{"path":"immunologic.html","id":"febrile-non-hemolytic-transfusion-reaction-fnhtr","chapter":"Immunologic","heading":"Febrile Non-Hemolytic Transfusion Reaction (FNHTR)","text":"Common: One frequently encountered reactions. Defined temperature rise ≥1°C (2°F) associated transfusion, without explanationImmunologic Cause: Two main proposed mechanisms:\nRecipient antibodies reacting antigens donor white blood cells (leukocytes) platelets\nRelease cytokines (inflammatory mediators) accumulated blood component storage (especially leukocytes)\nRecipient antibodies reacting antigens donor white blood cells (leukocytes) plateletsRelease cytokines (inflammatory mediators) accumulated blood component storage (especially leukocytes)Key Signs & Symptoms: Fever, chills, headache, malaise, sometimes mild shortness breath. Crucially, hemolysis.Severity: Generally mild self-limiting. Need rule serious causes (like AHTR sepsis). Leukoreduction blood components significantly reduces incidence FNHTR","code":""},{"path":"immunologic.html","id":"allergic-reaction-urticarial","chapter":"Immunologic","heading":"Allergic Reaction (Urticarial)","text":"Also Common: Usually mildImmunologic Cause: Recipient’s immune system (likely pre-existing IgE antibodies) reacts soluble donor plasma proteins. triggers mast cell degranulation, releasing histamineKey Signs & Symptoms: Hives (urticaria) itching (pruritus). Usually fever respiratory distressSeverity: Mild. Often, transfusion can paused, antihistamines administered, symptoms resolve, transfusion can cautiously restarted (per institutional policy)","code":""},{"path":"immunologic.html","id":"anaphylactic-reaction","chapter":"Immunologic","heading":"Anaphylactic Reaction","text":"Rare Severe: severe, systemic allergic reactionImmunologic Cause: Classic example involves IgA-deficient recipient developed anti-IgA antibodies. transfused plasma-containing components (RBCs, platelets, plasma), anti-IgA reacts donor IgA, leading massive mast cell basophil degranulation. Can also involve antigen-antibody systemsKey Signs & Symptoms: Rapid onset (often mLs transfused). Hypotension/shock, bronchospasm (wheezing, difficulty breathing), angioedema (swelling face, airways), urticaria, abdominal cramps, vomiting, loss consciousness. Usually fever.Severity: Life-threatening emergency. Requires immediate cessation transfusion administration epinephrine. Prevention involves using washed cellular components components IgA-deficient donors known susceptible patients","code":""},{"path":"immunologic.html","id":"transfusion-related-acute-lung-injury-trali","chapter":"Immunologic","heading":"Transfusion-Related Acute Lung Injury (TRALI)","text":"Serious Pulmonary Complication: leading cause transfusion-related mortality. Characterized acute respiratory distress non-cardiogenic pulmonary edemaImmunologic Cause: commonly attributed donor antibodies (anti-HLA class /II anti-HNA - human neutrophil antigens) reacting recipient leukocytes (especially neutrophils). activates neutrophils, causing sequester pulmonary vasculature, release damaging substances, increase capillary permeability -> fluid leaks alveoli. “two-hit” model (recipient predisposition + component factor) also proposedKey Signs & Symptoms: Occurs within 6 hours transfusion. Acute onset shortness breath (dyspnea), hypoxia (low blood oxygen), hypotension (sometimes hypertension initially), fever. Chest X-ray shows bilateral pulmonary infiltrates characteristic edema, without signs circulatory overload (like elevated central venous pressure)Severity: Ranges moderate severe respiratory failure; can fatal. Management primarily supportive respiratory care. Prevention strategies focus deferring donors implicated TRALI reactions potentially screening female donors (especially multiparous women) HLA antibodies","code":""},{"path":"immunologic.html","id":"delayed-immunologic-reactions-24-hours","chapter":"Immunologic","heading":"Delayed Immunologic Reactions (>24 Hours)","text":"can occur days, weeks, even months later","code":""},{"path":"immunologic.html","id":"delayed-hemolytic-transfusion-reaction-dhtr","chapter":"Immunologic","heading":"Delayed Hemolytic Transfusion Reaction (DHTR)","text":"Subtle Destruction: Occurs days weeks transfusionImmunologic Cause: Usually due anamnestic response recipient previously sensitized (via prior transfusion pregnancy) red cell antigen (e.g., Kidd (Jka/Jkb), Duffy (Fya/Fyb), Kell (K), Rh (E, c)). antibody level low detect pre-transfusion rises rapidly upon re-exposure antigen transfused RBCs. newly produced IgG antibody coats transfused cells, leading primarily extravascular hemolysis (RBC destruction macrophages spleen liver)Key Signs & Symptoms: Often milder AHTR. May include unexplained drop hemoglobin/hematocrit, fever, jaundice (due bilirubin RBC breakdown), sometimes hemoglobinuria (less common AHTR). positive Direct Antiglobulin Test (DAT) key finding post-transfusionSeverity: Usually less severe AHTR, can cause significant anemia morbidity. Emphasizes importance checking patient history antibodies!","code":""},{"path":"immunologic.html","id":"transfusion-associated-graft-versus-host-disease-ta-gvhd","chapter":"Immunologic","heading":"Transfusion-Associated Graft-versus-Host Disease (TA-GVHD)","text":"Rare Devastating: Occurs viable donor T-lymphocytes transfused component engraft susceptible recipient attack recipient’s tissues (skin, liver, gut, bone marrow)Immunologic Cause: Failure recipient’s immune system recognize destroy donor lymphocytes, donor lymphocytes recognize recipient tissues foreign. High risk :\nSeverely immunocompromised patients (e.g., congenital immunodeficiencies, stem cell transplant recipients)\nRecipients receiving blood blood relatives (donor may homozygous HLA haplotype shared recipient, recipient doesn’t see donor foreign, donor sees recipient foreign)\nSeverely immunocompromised patients (e.g., congenital immunodeficiencies, stem cell transplant recipients)Recipients receiving blood blood relatives (donor may homozygous HLA haplotype shared recipient, recipient doesn’t see donor foreign, donor sees recipient foreign)Key Signs & Symptoms: Typically develops 1-2 weeks post-transfusion. Fever, characteristic skin rash, diarrhea, liver dysfunction (elevated enzymes, jaundice), profound bone marrow failure (pancytopenia)Severity: Extremely high mortality rate (>90%). Prevention key Requires irradiation cellular blood components (RBCs, platelets, granulocytes) -risk patients inactivate donor T-lymphocytes","code":""},{"path":"immunologic.html","id":"post-transfusion-purpura-ptp","chapter":"Immunologic","heading":"Post-Transfusion Purpura (PTP)","text":"Platelet Destruction: rare complication characterized abrupt onset severe thrombocytopenia (low platelet count) typically 5-12 days transfusionImmunologic Cause: Usually occurs patients (often multiparous women) previously sensitized platelet-specific antigen lack (commonly HPA-1a). Upon re-exposure via transfusion, powerful anamnestic response occurs. resulting antibody destroys transfused antigen-positive platelets also, paradoxically, patient’s antigen-negative platelets complex mechanismsKey Signs & Symptoms: Severe thrombocytopenia, often <10,000/µL, leading purpura (bruising), bleeding (mucosal, gastrointestinal, rarely intracranial)Severity: Can cause life-threatening hemorrhage. Management often involves IVIG. Future transfusions require antigen-negative platelets possible","code":""},{"path":"immunologic.html","id":"alloimmunization","chapter":"Immunologic","heading":"Alloimmunization","text":"Antibody Development: truly “reaction” acute sense, immunologic consequence. recipient develops antibodies foreign antigens transfused RBCs, platelets, WBCs (HLA)Immunologic Cause: Exposure non-self antigens stimulates immune responseSignificance: Puts patient risk future DHTRs, HDFN (female becomes pregnant), platelet refractoriness (poor response platelet transfusions due anti-HLA anti-platelet antibodies)Prevention: Providing antigen-matched blood (beyond ABO/RhD) possible, especially chronically transfused patients (e.g., sickle cell disease). Leukoreduction reduces HLA alloimmunization","code":""},{"path":"immunologic.html","id":"general-principles-prevention","chapter":"Immunologic","heading":"General Principles & Prevention","text":"Vigilance: Meticulous patient identification sample labeling paramount prevent AHTRCompatibility Testing: Thorough ABO/Rh typing, antibody screening, crossmatchingComponent Modification: Using leukoreduced, irradiated, washed components indicatedPatient Monitoring: Closely monitor patients transfusionReporting & Investigation: Promptly report suspected reactions follow established investigation protocols","code":""},{"path":"immunologic.html","id":"key-terms-101","chapter":"Immunologic","heading":"Key Terms","text":"Hemolysis: destruction red blood cells. Can intravascular (within blood vessels, often complement-mediated, seen AHTR) extravascular (macrophages spleen/liver, seen DHTR)Complement Cascade: series plasma proteins , activated (e.g., IgM antibodies), leads inflammation, cell lysis, immune responsesCytokines: Small proteins released cells act signaling molecules immune system (e.g., interleukins, TNF-alpha), involved fever inflammation (FNHTR)Leukoreduction: process removing white blood cells (leukocytes) blood components. Reduces risk FNHTR, CMV transmission, HLA alloimmunizationUrticaria: Hives; raised, itchy welts skin, characteristic mild allergic reactionsAnaphylaxis: severe, potentially fatal systemic allergic reaction involving multiple organ systemsIgA Deficiency: condition individual lacks Immunoglobulin . individuals can develop anti-IgA antibodies, putting risk anaphylactic reactions transfused IgA-containing plasmaTRALI (Transfusion-Related Acute Lung Injury): Acute lung injury occurring within 6 hours transfusion, often caused donor antibodies recipient leukocytesAnamnestic Response: rapid heightened immune response following re-exposure antigen individual previously sensitized. Responsible DHTRsDAT (Direct Antiglobulin Test): Detects antibody complement coating red blood cells vivo. Positive AHTR (transiently), DHTR, AIHA, HDFNTA-GVHD (Transfusion-Associated Graft-versus-Host Disease): rare often fatal complication viable donor T-lymphocytes attack recipient tissues. Prevented irradiationIrradiation: Exposing cellular blood components radiation inactivate donor T-lymphocytesPTP (Post-Transfusion Purpura): Abrupt, severe thrombocytopenia occurring week transfusion, due platelet alloantibodiesAlloimmunization: development antibodies response foreign antigens encountered transfusion pregnancy","code":""},{"path":"nonimmunologic.html","id":"nonimmunologic","chapter":"Nonimmunologic","heading":"Nonimmunologic","text":"Non-Immunologic Adverse Effects problems caused physical, chemical, infectious properties blood component , process transfusion, rather antibody-antigen showdownThese reactions just important recognize manage! immediate, others develop time, require vigilance","code":""},{"path":"nonimmunologic.html","id":"infectious-complications","chapter":"Nonimmunologic","heading":"Infectious Complications","text":"Despite rigorous donor screening testing, risk transmitting infections, low developed countries, never zeroBacterial Contamination (Transfusion-Associated Sepsis)\nCause: Bacteria introduced blood component, usually donor phlebotomy (skin contaminants like Staphylococcus) , less commonly, processing. Platelets stored room temperature highest risk\nSigns & Symptoms: Rapid onset (often shortly transfusion) high fever, severe chills (rigors), profound hypotension (shock), nausea/vomiting, shortness breath, DIC\nSeverity: Life-threatening emergency! High mortality rate\nPrevention/Management: Strict aseptic technique collection, diversion first mLs collection, bacterial detection testing (culture surrogate markers) platelets. suspected: STOP transfusion immediately, draw blood cultures patient component bag, administer broad-spectrum antibiotics, provide aggressive supportive care\nCause: Bacteria introduced blood component, usually donor phlebotomy (skin contaminants like Staphylococcus) , less commonly, processing. Platelets stored room temperature highest riskSigns & Symptoms: Rapid onset (often shortly transfusion) high fever, severe chills (rigors), profound hypotension (shock), nausea/vomiting, shortness breath, DICSeverity: Life-threatening emergency! High mortality ratePrevention/Management: Strict aseptic technique collection, diversion first mLs collection, bacterial detection testing (culture surrogate markers) platelets. suspected: STOP transfusion immediately, draw blood cultures patient component bag, administer broad-spectrum antibiotics, provide aggressive supportive careViral Transmission\nCause: Transmission viruses present donor blood, often “window period” donor develops detectable antibodies viral load. Examples include HIV, Hepatitis B (HBV), Hepatitis C (HCV), West Nile Virus (WNV), Zika, CMV (Cytomegalovirus), HTLV-/II\nSigns & Symptoms: Highly variable depending virus. May asymptomatic initially cause flu-like illness, jaundice, specific disease manifestations weeks, months, even years later\nSeverity: Ranges asymptomatic/mild chronic illness fatal disease\nPrevention: Extensive donor screening questionnaires (risk factors), highly sensitive laboratory testing (serology - ELISA, Nucleic Acid Testing - NAT significantly shortens window period HIV, HCV, HBV, WNV). Pathogen reduction technologies also emerging plasma platelets\nCause: Transmission viruses present donor blood, often “window period” donor develops detectable antibodies viral load. Examples include HIV, Hepatitis B (HBV), Hepatitis C (HCV), West Nile Virus (WNV), Zika, CMV (Cytomegalovirus), HTLV-/IISigns & Symptoms: Highly variable depending virus. May asymptomatic initially cause flu-like illness, jaundice, specific disease manifestations weeks, months, even years laterSeverity: Ranges asymptomatic/mild chronic illness fatal diseasePrevention: Extensive donor screening questionnaires (risk factors), highly sensitive laboratory testing (serology - ELISA, Nucleic Acid Testing - NAT significantly shortens window period HIV, HCV, HBV, WNV). Pathogen reduction technologies also emerging plasma plateletsParasitic Transmission\nCause: Transmission parasites endemic certain regions. Examples include Plasmodium species (Malaria), Babesia microti (Babesiosis - tick-borne, northeastern US), Trypanosoma cruzi (Chagas disease - Central/South America)\nSigns & Symptoms: Variable; fever, chills, hemolysis (malaria, babesiosis), cardiac/gastrointestinal issues (Chagas)\nSeverity: Can significant, especially immunocompromised individuals\nPrevention: Donor screening questionnaires (travel history), specific laboratory testing endemic areas -risk donors (e.g., Chagas testing routine now US)\nCause: Transmission parasites endemic certain regions. Examples include Plasmodium species (Malaria), Babesia microti (Babesiosis - tick-borne, northeastern US), Trypanosoma cruzi (Chagas disease - Central/South America)Signs & Symptoms: Variable; fever, chills, hemolysis (malaria, babesiosis), cardiac/gastrointestinal issues (Chagas)Severity: Can significant, especially immunocompromised individualsPrevention: Donor screening questionnaires (travel history), specific laboratory testing endemic areas -risk donors (e.g., Chagas testing routine now US)","code":""},{"path":"nonimmunologic.html","id":"volumecirculatory-issues","chapter":"Nonimmunologic","heading":"Volume/Circulatory Issues","text":"Transfusion-Associated Circulatory Overload (TACO)\nCause: Transfusing fluid volume faster greater quantity patient’s circulatory system can handle, leading fluid overload hydrostatic pulmonary edema. Risk factors include elderly age, underlying cardiac renal disease, chronic anemia (plasma volume may already expanded), small body size\nSigns & Symptoms: Acute respiratory distress (shortness breath, difficulty breathing lying flat - orthopnea, cough), hypertension, tachycardia, headache, jugular venous distension (JVD), bilateral pulmonary edema chest X-ray, often positive fluid balance\nSeverity: Can range mild respiratory symptoms severe heart failure respiratory compromise\nPrevention/Management: Careful patient assessment pre-transfusion, slower infusion rates (especially RBCs), consider splitting units using smaller volume components, judicious use diuretics , , transfusion. suspected: STOP slow transfusion, sit patient upright, administer oxygen diuretics\nCause: Transfusing fluid volume faster greater quantity patient’s circulatory system can handle, leading fluid overload hydrostatic pulmonary edema. Risk factors include elderly age, underlying cardiac renal disease, chronic anemia (plasma volume may already expanded), small body sizeSigns & Symptoms: Acute respiratory distress (shortness breath, difficulty breathing lying flat - orthopnea, cough), hypertension, tachycardia, headache, jugular venous distension (JVD), bilateral pulmonary edema chest X-ray, often positive fluid balanceSeverity: Can range mild respiratory symptoms severe heart failure respiratory compromisePrevention/Management: Careful patient assessment pre-transfusion, slower infusion rates (especially RBCs), consider splitting units using smaller volume components, judicious use diuretics , , transfusion. suspected: STOP slow transfusion, sit patient upright, administer oxygen diuretics","code":""},{"path":"nonimmunologic.html","id":"metabolic-and-electrolyte-complications","chapter":"Nonimmunologic","heading":"Metabolic and Electrolyte Complications","text":"common rapid massive transfusionsHypothermia\nCause: Rapid infusion large volumes cold (1-6°C) blood components\nSigns & Symptoms: Shivering, decrease core body temperature\nSeverity: Can worsen acidosis, impair coagulation (enzyme function temperature-dependent), induce cardiac arrhythmias\nPrevention/Management: Use approved blood warmer rapid massive transfusions, especially RBCs\nCause: Rapid infusion large volumes cold (1-6°C) blood componentsSigns & Symptoms: Shivering, decrease core body temperatureSeverity: Can worsen acidosis, impair coagulation (enzyme function temperature-dependent), induce cardiac arrhythmiasPrevention/Management: Use approved blood warmer rapid massive transfusions, especially RBCsCitrate Toxicity (leading Hypocalcemia)\nCause: Citrate anticoagulant used blood components. binds (chelates) ionized calcium. Normally, liver rapidly metabolizes citrate. However, rapid/massive transfusion, patients severe liver dysfunction neonates (immature liver), citrate levels can rise faster can cleared. leads decrease physiologically active ionized calcium\nSigns & Symptoms: Paresthesias (tingling, especially around mouth fingertips), muscle tremors cramps, tetany, hypotension (calcium needed cardiac contractility), prolonged QT interval EKG, potential arrhythmias\nSeverity: Can cause significant cardiovascular compromise severe\nPrevention/Management: Slower infusion rates allow liver keep . Monitor ionized calcium levels massive transfusion. Administer calcium (e.g., calcium gluconate chloride) prophylactically therapeutically based levels clinical signs\nCause: Citrate anticoagulant used blood components. binds (chelates) ionized calcium. Normally, liver rapidly metabolizes citrate. However, rapid/massive transfusion, patients severe liver dysfunction neonates (immature liver), citrate levels can rise faster can cleared. leads decrease physiologically active ionized calciumSigns & Symptoms: Paresthesias (tingling, especially around mouth fingertips), muscle tremors cramps, tetany, hypotension (calcium needed cardiac contractility), prolonged QT interval EKG, potential arrhythmiasSeverity: Can cause significant cardiovascular compromise severePrevention/Management: Slower infusion rates allow liver keep . Monitor ionized calcium levels massive transfusion. Administer calcium (e.g., calcium gluconate chloride) prophylactically therapeutically based levels clinical signsHyperkalemia\nCause: Potassium gradually leaks red blood cells storage (longer storage, higher extracellular potassium unit). Rapid infusion older RBC units can deliver significant potassium load\nSigns & Symptoms: Muscle weakness, paresthesias, cardiac arrhythmias (peaked T waves EKG, bradycardia, ventricular fibrillation, asystole)\nSeverity: Can life-threatening, especially neonates, patients renal failure, receiving massive transfusions\nPrevention/Management: Use fresher RBC units (<7-14 days old) large-volume neonatal transfusions. Consider washing RBCs high-risk patients remove potassium-rich supernatant. Monitor potassium levels\nCause: Potassium gradually leaks red blood cells storage (longer storage, higher extracellular potassium unit). Rapid infusion older RBC units can deliver significant potassium loadSigns & Symptoms: Muscle weakness, paresthesias, cardiac arrhythmias (peaked T waves EKG, bradycardia, ventricular fibrillation, asystole)Severity: Can life-threatening, especially neonates, patients renal failure, receiving massive transfusionsPrevention/Management: Use fresher RBC units (<7-14 days old) large-volume neonatal transfusions. Consider washing RBCs high-risk patients remove potassium-rich supernatant. Monitor potassium levels","code":""},{"path":"nonimmunologic.html","id":"physicalstorage-related-complications","chapter":"Nonimmunologic","heading":"Physical/Storage-Related Complications","text":"Transfusion Physically Damaged/Hemolyzed Units\nCause: Non-immune hemolysis due improper handling storage: exposure extreme temperatures (freezing/overheating), mechanical trauma (e.g., pressure infusion small needle), mixing incompatible IV solutions (hypotonic solutions like D5W cause lysis; solutions calcium like Lactated Ringer’s can cause clotting citrated blood), bacterial contamination\nSigns & Symptoms: Can mimic mild hemolytic reaction (fever, chills, back pain), hemoglobinuria. DAT negative. Can potentially cause renal dysfunction free hemoglobin load high\nSeverity: Variable\nPrevention: Strict adherence storage temperatures, proper handling, visual inspection units discoloration/clots/hemolysis issue, never add medications non-isotonic IV fluids blood components, use appropriate infusion equipment\nCause: Non-immune hemolysis due improper handling storage: exposure extreme temperatures (freezing/overheating), mechanical trauma (e.g., pressure infusion small needle), mixing incompatible IV solutions (hypotonic solutions like D5W cause lysis; solutions calcium like Lactated Ringer’s can cause clotting citrated blood), bacterial contaminationSigns & Symptoms: Can mimic mild hemolytic reaction (fever, chills, back pain), hemoglobinuria. DAT negative. Can potentially cause renal dysfunction free hemoglobin load highSeverity: VariablePrevention: Strict adherence storage temperatures, proper handling, visual inspection units discoloration/clots/hemolysis issue, never add medications non-isotonic IV fluids blood components, use appropriate infusion equipment","code":""},{"path":"nonimmunologic.html","id":"iron-overload-transfusional-hemosiderosis","chapter":"Nonimmunologic","heading":"Iron Overload (Transfusional Hemosiderosis)","text":"Cause: chronic complication seen patients requiring long-term RBC transfusion support (e.g., thalassemia, sickle cell disease, myelodysplastic syndromes). unit RBCs contains approx. 200-250 mg iron. body lacks efficient mechanism excrete excess iron, leading accumulationSigns & Symptoms: Develops years. Iron deposition damages vital organs: liver (fibrosis, cirrhosis, hepatocellular carcinoma), heart (cardiomyopathy, arrhythmias, heart failure), endocrine glands (diabetes, hypothyroidism, hypogonadism), joints (arthritis)Severity: Significant cause morbidity mortality chronically transfused patientsPrevention/Management: Judicious use transfusions, exploring alternatives. Primary management involves iron chelation therapy (using drugs like deferoxamine, deferasirox, deferiprone) bind excess iron promote excretion","code":""},{"path":"nonimmunologic.html","id":"key-terms-102","chapter":"Nonimmunologic","heading":"Key Terms","text":"Transfusion-Associated Circulatory Overload (TACO): Pulmonary edema due inability circulatory system handle transfused volume, characterized respiratory distress, hypertension, signs fluid overloadCitrate Toxicity: Metabolic complication caused accumulation citrate anticoagulant rapid/massive transfusion, leading chelation ionized calcium (hypocalcemia)Hypocalcemia (Ionized): Abnormally low level physiologically active calcium blood, often resulting citrate toxicity transfusionHyperkalemia: Abnormally high level potassium blood, can occur rapid transfusion older stored red blood cells due potassium leakage storageBlood Warmer: medical device used warm blood components refrigerator temperature towards body temperature rapid massive infusion prevent hypothermiaIron Overload (Transfusional Hemosiderosis): Pathological accumulation excess iron body tissues due chronic red blood cell transfusionsIron Chelation Therapy: Treatment using medications bind excess iron, promoting excretion body, used manage iron overloadNucleic Acid Testing (NAT): Highly sensitive molecular tests used donor screening detect genetic material (RNA DNA) viruses like HIV, HCV, HBV, WNV, significantly reducing infectious window period compared antibody testsPathogen Reduction Technology (PRT): Methods applied plasma platelet components inactivate broad range viruses, bacteria, parasites, enhancing safety (universally available used RBCs yet)","code":""},{"path":"ttds.html","id":"ttds","chapter":"TTDs","heading":"TTDs","text":"modern blood banking practices made blood supply incredibly safe, especially developed countries, risk Transfusion-Transmitted Diseases (TTDs), although low, can never completely eliminated. Understanding risks crucial blood bankers clinicians","code":""},{"path":"ttds.html","id":"the-core-concept-infection-via-transfusion","chapter":"TTDs","heading":"The Core Concept: Infection via Transfusion","text":"TTD occurs infectious agent (virus, bacteria, parasite, prion) present donor’s blood transmitted recipient transfusion blood component","code":""},{"path":"ttds.html","id":"why-risk-still-exists-despite-rigorous-testing","chapter":"TTDs","heading":"Why Risk Still Exists (Despite Rigorous Testing)","text":"“Window Period”: critical time donor becomes infected laboratory tests can reliably detect infection (either organism’s genetic material donor’s antibody response). Modern tests, especially Nucleic Acid Testing (NAT), dramatically shortened window periods, haven’t eliminated entirelyTest Limitations: test 100% sensitive specificEmerging Pathogens: New infectious agents may arise testing yet availableDonor Honesty/Recall: Screening relies donors accurately reporting potential risk factorsBacterial Contamination: Can occur collection processing, especially components stored room temperature (platelets)Human Error: Although rare, errors testing processing occur","code":""},{"path":"ttds.html","id":"major-categories-of-transfusion-transmitted-agents","chapter":"TTDs","heading":"Major Categories of Transfusion-Transmitted Agents","text":"","code":""},{"path":"ttds.html","id":"viruses","chapter":"TTDs","heading":"Viruses","text":"group historically received attention driven many advances testingHuman Immunodeficiency Virus (HIV-1/2)\nCauses: Acquired Immunodeficiency Syndrome (AIDS)\nRisk: Extremely low now (<1 2 million US) due donor screening, antibody/antigen testing, mandatory NAT\nPrevention: Donor questionnaires, deferrals, serologic testing (anti-HIV 1/2 Ab p24 Ag), NAT\nCauses: Acquired Immunodeficiency Syndrome (AIDS)Risk: Extremely low now (<1 2 million US) due donor screening, antibody/antigen testing, mandatory NATPrevention: Donor questionnaires, deferrals, serologic testing (anti-HIV 1/2 Ab p24 Ag), NATHepatitis C Virus (HCV)\nCauses: Hepatitis C, leading chronic liver disease, cirrhosis, liver cancer\nRisk: Extremely low (<1 1.5-2 million)\nPrevention: Donor questionnaires, deferrals, serologic testing (anti-HCV Ab), NAT\nCauses: Hepatitis C, leading chronic liver disease, cirrhosis, liver cancerRisk: Extremely low (<1 1.5-2 million)Prevention: Donor questionnaires, deferrals, serologic testing (anti-HCV Ab), NATHepatitis B Virus (HBV)\nCauses: Hepatitis B, acute chronic liver disease, cirrhosis, liver cancer\nRisk: Remains slightly higher HIV/HCV (~1 1 million), partly due different infection dynamics (e.g., occult HBV)\nPrevention: Donor questionnaires, deferrals, serologic testing (HBsAg - surface antigen, anti-HBc - core antibody), NAT\nCauses: Hepatitis B, acute chronic liver disease, cirrhosis, liver cancerRisk: Remains slightly higher HIV/HCV (~1 1 million), partly due different infection dynamics (e.g., occult HBV)Prevention: Donor questionnaires, deferrals, serologic testing (HBsAg - surface antigen, anti-HBc - core antibody), NATHuman T-Lymphotropic Virus (HTLV-/II)\nCauses: HTLV-associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP), Adult T-cell Leukemia/Lymphoma (ATL). HTLV-II less clearly linked disease\nRisk: Low\nPrevention: Donor questionnaires, serologic testing (anti-HTLV-/II Ab)\nCauses: HTLV-associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP), Adult T-cell Leukemia/Lymphoma (ATL). HTLV-II less clearly linked diseaseRisk: LowPrevention: Donor questionnaires, serologic testing (anti-HTLV-/II Ab)Cytomegalovirus (CMV)\nCauses: Usually asymptomatic healthy individuals can cause severe disease (pneumonitis, hepatitis, retinitis) immunocompromised recipients (e.g., transplant patients, premature infants)\nRisk: High prevalence donors (~50-80% positive). Transmission occurs via leukocytes cellular components\nPrevention: Providing CMV-seronegative units leukoreduced components (considered CMV-safe equivalent) -risk recipients\nCauses: Usually asymptomatic healthy individuals can cause severe disease (pneumonitis, hepatitis, retinitis) immunocompromised recipients (e.g., transplant patients, premature infants)Risk: High prevalence donors (~50-80% positive). Transmission occurs via leukocytes cellular componentsPrevention: Providing CMV-seronegative units leukoreduced components (considered CMV-safe equivalent) -risk recipientsWest Nile Virus (WNV)\nCauses: Febrile illness, sometimes neuroinvasive disease (meningitis, encephalitis)\nRisk: Seasonal geographic variation (mosquito-borne)\nPrevention: NAT screening donations, especially peak season\nCauses: Febrile illness, sometimes neuroinvasive disease (meningitis, encephalitis)Risk: Seasonal geographic variation (mosquito-borne)Prevention: NAT screening donations, especially peak seasonZika Virus\nCauses: Usually mild illness, significant risk severe birth defects (microcephaly) transmitted pregnant women\nRisk: Geographic variation (mosquito-borne)\nPrevention: Donor questionnaires (travel), deferrals, NAT screening (investigational regional implementation based risk)\nCauses: Usually mild illness, significant risk severe birth defects (microcephaly) transmitted pregnant womenRisk: Geographic variation (mosquito-borne)Prevention: Donor questionnaires (travel), deferrals, NAT screening (investigational regional implementation based risk)Parvovirus B19\nCauses: Fifth disease children, transient aplastic crisis patients hemolytic anemias, potential fetal hydrops pregnancy\nRisk: common virus; high donor prevalence. routinely screened. Plasma derivatives undergo viral inactivation steps\nPrevention: specifically screened whole blood/RBCs. Risk mitigation via plasma derivative processing\nCauses: Fifth disease children, transient aplastic crisis patients hemolytic anemias, potential fetal hydrops pregnancyRisk: common virus; high donor prevalence. routinely screened. Plasma derivatives undergo viral inactivation stepsPrevention: specifically screened whole blood/RBCs. Risk mitigation via plasma derivative processing","code":""},{"path":"ttds.html","id":"bacteria","chapter":"TTDs","heading":"Bacteria","text":"Agent: Various bacteria, often skin contaminants (Staphylococcus epidermidis, Staphylococcus aureus) sometimes gut bacteria (Yersinia enterocolitica - associated RBCs, rare; Gram-negatives platelets)Disease: Transfusion-Associated SepsisRisk: common infectious risk transfusion today, primarily associated platelets stored room temperature (supports bacterial growth)Symptoms: Rapid onset fever, chills/rigors, hypotension/shock shortly transfusionPrevention: Meticulous arm scrub technique donation, diversion initial collection volume, visual inspection units, bacterial detection strategies platelets (culture, rapid tests)","code":""},{"path":"ttds.html","id":"parasites","chapter":"TTDs","heading":"Parasites","text":"Risk often geographically dependentPlasmodium species\nCauses: Malaria\nRisk: Low non-endemic areas like US/Canada\nPrevention: Donor screening questionnaires regarding travel residence malaria-endemic areas -> deferral\nCauses: MalariaRisk: Low non-endemic areas like US/CanadaPrevention: Donor screening questionnaires regarding travel residence malaria-endemic areas -> deferralBabesia microti\nCauses: Babesiosis (tick-borne illness)\nRisk: Increasing, particularly Northeastern Upper Midwestern US\nPrevention: Donor screening questions (history babesiosis). Laboratory testing (antibody /NAT) implemented endemic areas/states\nCauses: Babesiosis (tick-borne illness)Risk: Increasing, particularly Northeastern Upper Midwestern USPrevention: Donor screening questions (history babesiosis). Laboratory testing (antibody /NAT) implemented endemic areas/statesTrypanosoma cruzi\nCauses: Chagas disease (can lead chronic heart GI problems)\nRisk: Primarily donors lived endemic areas (Mexico, Central/South America)\nPrevention: Donor screening questions. Routine laboratory testing (antibody) first-time donors lived endemic areas risk factors standard US\nCauses: Chagas disease (can lead chronic heart GI problems)Risk: Primarily donors lived endemic areas (Mexico, Central/South America)Prevention: Donor screening questions. Routine laboratory testing (antibody) first-time donors lived endemic areas risk factors standard US","code":""},{"path":"ttds.html","id":"prions","chapter":"TTDs","heading":"Prions","text":"Agent: Abnormal prion proteinDisease: Variant Creutzfeldt-Jakob Disease (vCJD) - related Bovine Spongiform Encephalopathy (“Mad Cow Disease”)Risk: Extremely low, historically linked exposure UK/EuropePrevention: laboratory screening test. Prevention relies solely donor deferral based geographic risk factors (time spent specific countries defined periods)","code":""},{"path":"ttds.html","id":"multi-layered-safety-approach","chapter":"TTDs","heading":"Multi-Layered Safety Approach","text":"safety blood supply relies overlapping strategies:Strict Donor Eligibility Criteria: Based medical history, travel, risk behaviors (questionnaire)Donor Deferral Lists: Maintaining records ineligible donorsStringent Laboratory Testing: Using highly sensitive serologic NAT assays panel required infectious agentsBacterial Detection: Specific measures platelet componentsComponent Processing: Leukoreduction reduces CMV riskPathogen Reduction Technologies (PRT): Applied plasma platelet products inactivate broad range pathogens (yet feasible RBCs)Appropriate Clinical Use: Transfusing necessary","code":""},{"path":"ttds.html","id":"key-terms-103","chapter":"TTDs","heading":"Key Terms","text":"Transfusion-Transmitted Disease (TTD): infection transmitted donor recipient via blood component transfusionWindow Period: time initial infection donor laboratory tests can reliably detect infectionNucleic Acid Testing (NAT): Highly sensitive molecular tests detect genetic material (DNA RNA) viruses, significantly shortening window period compared antibody testsSerologic Testing: Laboratory tests detect antibodies produced donor response infection antigens produced infectious agent itselfBacterial Contamination / Sepsis: Presence bacteria blood component leading severe systemic infection recipient, commonly associated room-temperature stored plateletsPathogen Reduction Technology (PRT): Processes applied blood components (plasma, platelets) inactivate wide range viruses, bacteria, parasitesLeukoreduction: Removal white blood cells, primarily used reduce CMV transmission risk (among benefits)Donor Deferral: Temporarily permanently excluding individuals donating blood based risk factors identified screening questionnaires test results","code":""},{"path":"apheresis-extracorporeal-circulation.html","id":"apheresis-extracorporeal-circulation","chapter":"Apheresis & Extracorporeal Circulation","heading":"Apheresis & Extracorporeal Circulation","text":"Apheresis Extracorporeal Circulation (ECC) fascinating areas interact blood outside body specific therapeutic collection purposes. represent advanced applications within transfusion medicine critical careThink Extracorporeal Circulation broad umbrella term procedure blood taken body, circulated device purpose, returned patient. Apheresis specific type ECC focused separating selectively removing collecting certain blood components","code":""},{"path":"apheresis-extracorporeal-circulation.html","id":"apheresis-selective-separation-and-collectionremoval","chapter":"Apheresis & Extracorporeal Circulation","heading":"Apheresis: Selective Separation and Collection/Removal","text":"Apheresis (Greek word meaning “take away” “separate”) involves withdrawing whole blood individual (donor patient), passing medical device (apheresis machine) separates components, collecting desired component(s) removing undesired one(s), returning remaining elements individualBasic Principle apheresis machines use centrifugation separate blood components based differences density (RBCs heaviest, WBCs, platelets, plasma lightest). specialized procedures might use filtration based size","code":""},{"path":"apheresis-extracorporeal-circulation.html","id":"why-use-apheresis","chapter":"Apheresis & Extracorporeal Circulation","heading":"Why Use Apheresis?","text":"Component Collection (Donation) obtain larger quantity purer concentration specific blood component single, healthy donorTherapeutic Apheresis (Patient Treatment) remove harmful substance cellular element patient’s blood treat specific disease","code":""},{"path":"apheresis-extracorporeal-circulation.html","id":"apheresis-for-component-collection-donors","chapter":"Apheresis & Extracorporeal Circulation","heading":"Apheresis for Component Collection (Donors)","text":"Plateletpheresis: Collects large dose platelets (equivalent 4-6 whole blood-derived units) single donor. preferred source platelet transfusions, reducing recipient exposure multiple donorsPlasmapheresis: Collects plasma. Used obtaining Source Plasma (manufactured derivatives like albumin, IVIG, coagulation factors) collecting specific types like Convalescent Plasma ABO-compatible plasma transfusionErythrocytapheresis (Red Cell Apheresis): Collects two units RBCs (“double reds”) single qualifying donor. efficient RBC collectionLeukapheresis: Collects leukocytes, primarily granulocytes (Granulocytapheresis). Used infrequently provide granulocyte transfusions severely neutropenic patients specific infections unresponsive antibiotics. Requires donor stimulation (G-CSF, steroids)Hematopoietic Progenitor Cell (HPC) Collection (Stem Cell Collection): Collects peripheral blood stem cells (PBSCs) donor mobilized (usually G-CSF) release stem cells bone marrow circulation. Used stem cell transplantation","code":""},{"path":"apheresis-extracorporeal-circulation.html","id":"therapeutic-apheresis-patients","chapter":"Apheresis & Extracorporeal Circulation","heading":"Therapeutic Apheresis (Patients)","text":"Plasma Exchange (PEX) / Therapeutic Plasmapheresis (TPE)\nGoal: Remove harmful substances circulating patient’s plasma (e.g., autoantibodies, immune complexes, toxins, abnormal proteins)\nProcedure: Patient’s plasma separated removed; replacement fluid (usually Albumin 5%, sometimes FFP coagulation factors also needed, combination) returned patient’s cells\nIndications: Thrombotic Thrombocytopenic Purpura (TTP - life-saving!), Guillain-Barré Syndrome, Myasthenia Gravis crisis, Hyperviscosity Syndrome (e.g., Waldenström’s), certain autoimmune neurologic disorders\nGoal: Remove harmful substances circulating patient’s plasma (e.g., autoantibodies, immune complexes, toxins, abnormal proteins)Procedure: Patient’s plasma separated removed; replacement fluid (usually Albumin 5%, sometimes FFP coagulation factors also needed, combination) returned patient’s cellsIndications: Thrombotic Thrombocytopenic Purpura (TTP - life-saving!), Guillain-Barré Syndrome, Myasthenia Gravis crisis, Hyperviscosity Syndrome (e.g., Waldenström’s), certain autoimmune neurologic disordersCytapheresis (Selective Cell Removal)\nRed Cell Exchange: Remove large volume patient’s abnormal RBCs replace donor RBCs\nIndications: Sickle Cell Disease (acute stroke prevention/treatment, acute chest syndrome, preoperative preparation), severe Babesiosis Malaria infections\n\nLeukocytapheresis (Therapeutic): Remove excessively high numbers abnormal white blood cells (leukocytes)\nIndications: Hyperleukocytosis Acute Myeloid Leukemia (AML) prevent leukostasis (sludging blasts small vessels)\n\nThrombocytapheresis (Therapeutic): Remove excessively high numbers platelets\nIndications: Symptomatic extreme thrombocytosis (e.g., Essential Thrombocythemia) reduce risk thrombosis bleeding\n\nRed Cell Exchange: Remove large volume patient’s abnormal RBCs replace donor RBCs\nIndications: Sickle Cell Disease (acute stroke prevention/treatment, acute chest syndrome, preoperative preparation), severe Babesiosis Malaria infections\nIndications: Sickle Cell Disease (acute stroke prevention/treatment, acute chest syndrome, preoperative preparation), severe Babesiosis Malaria infectionsLeukocytapheresis (Therapeutic): Remove excessively high numbers abnormal white blood cells (leukocytes)\nIndications: Hyperleukocytosis Acute Myeloid Leukemia (AML) prevent leukostasis (sludging blasts small vessels)\nIndications: Hyperleukocytosis Acute Myeloid Leukemia (AML) prevent leukostasis (sludging blasts small vessels)Thrombocytapheresis (Therapeutic): Remove excessively high numbers platelets\nIndications: Symptomatic extreme thrombocytosis (e.g., Essential Thrombocythemia) reduce risk thrombosis bleeding\nIndications: Symptomatic extreme thrombocytosis (e.g., Essential Thrombocythemia) reduce risk thrombosis bleedingExtracorporeal Photopheresis (ECP)\nGoal: Treat certain T-cell mediated disorders\nProcedure: Leukocytes (primarily lymphocytes) collected via apheresis, treated ex vivo photosensitizing agent (8-methoxypsoralen), exposed UVA light, returned patient. induces apoptosis (cell death) treated T-cells modulates immune response\nIndications: Cutaneous T-Cell Lymphoma (CTCL), Graft-versus-Host Disease (GVHD) prophylaxis/treatment stem cell transplant, autoimmune disorders, organ transplant rejection\nGoal: Treat certain T-cell mediated disordersProcedure: Leukocytes (primarily lymphocytes) collected via apheresis, treated ex vivo photosensitizing agent (8-methoxypsoralen), exposed UVA light, returned patient. induces apoptosis (cell death) treated T-cells modulates immune responseIndications: Cutaneous T-Cell Lymphoma (CTCL), Graft-versus-Host Disease (GVHD) prophylaxis/treatment stem cell transplant, autoimmune disorders, organ transplant rejectionLDL Apheresis\nGoal: Remove Low-Density Lipoprotein (LDL) cholesterol\nProcedure: Uses specific adsorption columns filtration remove LDL plasma\nIndications: Severe Familial Hypercholesterolemia unresponsive medication\nGoal: Remove Low-Density Lipoprotein (LDL) cholesterolProcedure: Uses specific adsorption columns filtration remove LDL plasmaIndications: Severe Familial Hypercholesterolemia unresponsive medication","code":""},{"path":"apheresis-extracorporeal-circulation.html","id":"key-considerations-in-apheresis","chapter":"Apheresis & Extracorporeal Circulation","heading":"Key Considerations in Apheresis","text":"Anticoagulation: Citrate typically used; monitoring managing citrate toxicity (hypocalcemia) essentialVascular Access: Requires good venous access (often large-bore peripheral IVs central venous catheter)Fluid Shifts: Especially important therapeutic procedures; careful monitoring fluid balance neededCell Counts: Monitoring counts pre- post-procedureDonor Reactions: Vasovagal reactions, citrate toxicity symptoms","code":""},{"path":"apheresis-extracorporeal-circulation.html","id":"extracorporeal-circulation-ecc-beyond-apheresis","chapter":"Apheresis & Extracorporeal Circulation","heading":"Extracorporeal Circulation (ECC): Beyond Apheresis","text":"ECC refers procedure blood circulates outside body machine. Therapeutic apheresis form ECC, ECC also includes critical care techniques:Cardiopulmonary Bypass (CPB): “heart-lung machine” used open-heart surgery. Takes function heart (pumping) lungs (oxygenation/CO2 removal) allowing surgeon operate still, bloodless heart. Requires systemic anticoagulation (heparin), hemodilution (priming circuit), often significant blood product supportExtracorporeal Membrane Oxygenation (ECMO): Provides prolonged cardiac /respiratory support heart /lungs failing severely. Blood drained, oxygenated artificial lung, CO2 removed, returned. Can Veno-Venous (VV-ECMO, lung support ) Veno-Arterial (VA-ECMO, heart lung support). Also requires anticoagulation careful hematologic managementHemodialysis: Used patients kidney failure. Blood circulates dialyzer (artificial kidney) waste products excess fluid removed via diffusion ultrafiltration across semipermeable membraneContinuous Renal Replacement Therapy (CRRT): slower, continuous form dialysis used critically ill patients acute kidney injury may tolerate conventional hemodialysis","code":""},{"path":"apheresis-extracorporeal-circulation.html","id":"common-challenges-of-ecc-circuits-relevant-to-transfusion-practice","chapter":"Apheresis & Extracorporeal Circulation","heading":"Common Challenges of ECC Circuits (Relevant to Transfusion Practice)","text":"Hemodilution: circuit often primed crystalloid solution, diluting patient’s blood components (RBCs, platelets, factors)Coagulation Activation/Consumption: Contact blood artificial surfaces activates platelets coagulation cascade, necessitating anticoagulation (usually heparin) also leading potential consumption factors platelets (DIC-like picture)Hemolysis: Mechanical shear stress pumps tubing can damage RBCsInflammatory Response: Contact artificial surfaces triggers systemic inflammatory responseTemperature Changes: Blood cools passes circuit; warming often necessary","code":""},{"path":"apheresis-extracorporeal-circulation.html","id":"key-terms-104","chapter":"Apheresis & Extracorporeal Circulation","heading":"Key Terms","text":"Apheresis: Procedure separating whole blood components ex vivo, collecting desired components (donation) removing harmful ones (therapeutic)Extracorporeal Circulation (ECC): procedure blood circulates outside body device therapeutic purposesPlasmapheresis / Plasma Exchange (PEX/TPE): Apheresis procedure removing patient plasma replacing fluid (albumin/FFP) eliminate harmful plasma constituentsCytapheresis: Apheresis procedure removing specific cellular components (RBCs, WBCs, platelets)Red Cell Exchange: Cytapheresis removing patient RBCs replacing donor RBCs (common Sickle Cell Disease)Extracorporeal Photopheresis (ECP): Apheresis procedure collected leukocytes treated photosensitizer UVA light reinfusion modulate immune responsesCardiopulmonary Bypass (CPB): ECC circuit taking heart lung function cardiac surgeryECMO (Extracorporeal Membrane Oxygenation): ECC circuit providing prolonged cardiac /respiratory supportHemodialysis: ECC procedure filtering waste products blood patients kidney failureCitrate Toxicity: Hypocalcemia resulting anticoagulant citrate binding ionized calcium, risk apheresisLeukostasis: Sludging excessive white blood cells small blood vessels, complication hyperleukocytosis sometimes treated leukocytapheresis","code":""},{"path":"blood-administration-patient-blood-management.html","id":"blood-administration-patient-blood-management","chapter":"Blood Administration & Patient Blood Management","heading":"Blood Administration & Patient Blood Management","text":"section considers practical side things: actually giving blood components broader strategy Patient Blood Management (PBM). Getting blood administration process right critical immediate patient safety, PBM proactive, system-wide approach ensure transfusions truly necessary patient outcomes optimizedPBM Team Effort: Requires collaboration surgeons, anesthesiologists, hematologists, transfusion medicine specialists, nurses, pharmacists, hospital administration","code":""},{"path":"blood-administration-patient-blood-management.html","id":"blood-administration-the-hands-on-process","chapter":"Blood Administration & Patient Blood Management","heading":"Blood Administration: The Hands-On Process","text":"involves steps taken moment decision transfuse made transfusion complete. Accuracy vigilance step non-negotiable!","code":""},{"path":"blood-administration-patient-blood-management.html","id":"the-order-and-consent","chapter":"Blood Administration & Patient Blood Management","heading":"1. The Order and Consent","text":"Physician’s Order: clear, complete order required, specifying:\nPatient identifiers\nBlood component type (e.g., RBCs, Platelets, FFP)\nNumber units specific dose/volume\nRate infusion (duration)\nspecial requirements (e.g., irradiated, leukoreduced, CMV-safe, antigen-negative)\nPremedication, needed (e.g., antihistamines, antipyretics)\nPatient identifiersBlood component type (e.g., RBCs, Platelets, FFP)Number units specific dose/volumeRate infusion (duration)special requirements (e.g., irradiated, leukoreduced, CMV-safe, antigen-negative)Premedication, needed (e.g., antihistamines, antipyretics)Informed Consent: Except emergencies, patient (legal representative) must understand risks, benefits, alternatives transfusion provide consent. discussion documented","code":""},{"path":"blood-administration-patient-blood-management.html","id":"pre-transfusion-verification-safety-checks","chapter":"Blood Administration & Patient Blood Management","heading":"2. Pre-Transfusion Verification (Safety Checks!)","text":"Blood Bank (Issuing): Final check compatibility records, patient/unit identifiers, expiration date, special requirements met, visual inspection unit (leaks, clots, discoloration)Bedside (CRITICAL!): final important safety check prevent ABO incompatible transfusions. Performed two qualified individuals (e.g., two RNs, RN MD, per institutional policy):\nVerify Patient Identity: Match patient’s wristband information (least two unique identifiers like Name, DOB, MRN) directly blood component tag transfusion order/requisition. Actively involve patient possible (“Please state name date birth”)\nVerify Unit Information: Match information blood component tag exactly information unit requisition:\nPatient Name Identifiers\nUnit Number (unique donation identifier)\nABO/Rh type unit recipient (must compatible!)\nComponent Type\nExpiration Date Time\nSpecial Modifications (Irradiated, Leukoreduced, etc.)\n\nVisual Inspection: Re-check unit leaks, abnormal color, clots, particulate matter\nResolve Discrepancies: anything doesn’t match perfectly, TRANSFUSE. Return unit blood bank resolve issue\nVerify Patient Identity: Match patient’s wristband information (least two unique identifiers like Name, DOB, MRN) directly blood component tag transfusion order/requisition. Actively involve patient possible (“Please state name date birth”)Verify Unit Information: Match information blood component tag exactly information unit requisition:\nPatient Name Identifiers\nUnit Number (unique donation identifier)\nABO/Rh type unit recipient (must compatible!)\nComponent Type\nExpiration Date Time\nSpecial Modifications (Irradiated, Leukoreduced, etc.)\nPatient Name IdentifiersUnit Number (unique donation identifier)ABO/Rh type unit recipient (must compatible!)Component TypeExpiration Date TimeAny Special Modifications (Irradiated, Leukoreduced, etc.)Visual Inspection: Re-check unit leaks, abnormal color, clots, particulate matterResolve Discrepancies: anything doesn’t match perfectly, TRANSFUSE. Return unit blood bank resolve issue","code":""},{"path":"blood-administration-patient-blood-management.html","id":"obtaining-and-starting-the-transfusion","chapter":"Blood Administration & Patient Blood Management","heading":"3. Obtaining and Starting the Transfusion","text":"Timeliness: Blood components (especially RBCs) generally started within 30 minutes issued blood bank’s monitored storage prevent warming potential bacterial growthIV Access: Ensure patent venous access, preferably large-bore catheter (e.g., 18-20 gauge adults) RBCs prevent hemolysis, though smaller gauges can used careTubing Filter: Use sterile administration set standard blood filter (170-260 microns) designed remove clots debris. Use new filter set transfusion episode per manufacturer/policy (often good 2-4 units 4 hours)Compatible Fluids: IV fluid can run concurrently mixed blood components 0.9% Normal Saline (NaCl). Never add medications blood unit line. IV solutions can cause hemolysis (hypotonic solutions like D5W) clotting (calcium-containing solutions like Lactated Ringer’s)Baseline Vital Signs: Record temperature, pulse, respiration rate, blood pressure immediately starting. Assess patient’s baseline conditionInitiation: Start infusion slowly (e.g., 2 mL/min 75-100 mL/hr) first 15 minutes","code":""},{"path":"blood-administration-patient-blood-management.html","id":"monitoring-during-transfusion","chapter":"Blood Administration & Patient Blood Management","heading":"4. Monitoring During Transfusion","text":"Direct Observation: Stay patient monitor closely first 15 minutes. severe acute reactions (like AHTR, anaphylaxis) likely occurVital Signs: Recheck vital signs first 15 minutes. monitor periodically throughout transfusion according institutional policy (e.g., hourly, completion). Compare baselineObserve Reactions: Continuously assess patient signs symptoms adverse reaction (fever, chills, itching, hives, respiratory distress, back pain, anxiety, changes vital signs). Educate patient report unusual symptoms immediatelyInfusion Rate: initial 15 minutes (reaction), increase rate infuse component within prescribed timeTime Limit: Transfusion single unit generally completed within 4 hours time removed controlled storage minimize risk bacterial growth room temperature","code":""},{"path":"blood-administration-patient-blood-management.html","id":"completing-the-transfusion","chapter":"Blood Administration & Patient Blood Management","heading":"5. Completing the Transfusion","text":"Flush Line: component infused, flush IV line normal saline ensure patient receives full doseFinal Vital Signs: Record vital signs upon completionDisposal: Dispose used blood bag tubing according biohazard waste proceduresDocumentation: Complete required transfusion documentation meticulously","code":""},{"path":"blood-administration-patient-blood-management.html","id":"documentation-crucial-for-traceability-and-safety","chapter":"Blood Administration & Patient Blood Management","heading":"6. Documentation (Crucial for Traceability and Safety)","text":"Record everything: Physician’s order, patient consent, verification checks (including identifiers staff performing check), component information (unit number, type, ABO/Rh), start stop times, volume infused, baseline/intra-transfusion/post-transfusion vital signs, patient response, adverse reactions noted, actions taken","code":""},{"path":"blood-administration-patient-blood-management.html","id":"patient-blood-management-pbm-the-strategic-approach","chapter":"Blood Administration & Patient Blood Management","heading":"Patient Blood Management (PBM): The Strategic Approach","text":"PBM patient-centered, evidence-based, multidisciplinary strategy designed improve patient outcomes managing preserving patient’s blood, promoting patient safety, ensuring appropriate use blood components. goal simply avoid transfusion, ensure transfusion used truly indicated beneficial","code":""},{"path":"blood-administration-patient-blood-management.html","id":"the-three-pillars-of-pbm","chapter":"Blood Administration & Patient Blood Management","heading":"The Three Pillars of PBM","text":"","code":""},{"path":"blood-administration-patient-blood-management.html","id":"pillar-1-optimize-erythropoiesis-manage-anemia","chapter":"Blood Administration & Patient Blood Management","heading":"Pillar 1: Optimize Erythropoiesis / Manage Anemia","text":"Identify Treat Pre-existing Anemia: elective surgery anticipated need transfusion, diagnose cause anemia (iron deficiency common!) treat effectively (e.g., oral/IV iron, Vitamin B12, folate, Erythropoiesis-Stimulating Agents - ESAs like epoetin alfa). Don’t just wait transfuse!Stimulate Red Cell Production: Use ESAs appropriate (e.g., chronic kidney disease, chemotherapy-induced anemia, preoperative optimization)","code":""},{"path":"blood-administration-patient-blood-management.html","id":"pillar-2-minimize-blood-loss","chapter":"Blood Administration & Patient Blood Management","heading":"Pillar 2: Minimize Blood Loss","text":"Surgical/Procedural Techniques\nMeticulous surgical hemostasis\nUse minimally invasive techniques\nTopical hemostatic agents\nAntifibrinolytic medications (e.g., Tranexamic Acid - TXA, Epsilon-Aminocaproic Acid - EACA) reduce bleeding\nIntraoperative Cell Salvage (“Cell Saver”): Collecting, washing, reinfusing patient’s shed blood surgery\nAcute Normovolemic Hemodilution (ANH): Removing whole blood surgery, replacing volume crystalloid/colloid, reinfusing blood later (less common now)\nHypotensive anesthesia (appropriate safe)\nMeticulous surgical hemostasisUse minimally invasive techniquesTopical hemostatic agentsAntifibrinolytic medications (e.g., Tranexamic Acid - TXA, Epsilon-Aminocaproic Acid - EACA) reduce bleedingIntraoperative Cell Salvage (“Cell Saver”): Collecting, washing, reinfusing patient’s shed blood surgeryAcute Normovolemic Hemodilution (ANH): Removing whole blood surgery, replacing volume crystalloid/colloid, reinfusing blood later (less common now)Hypotensive anesthesia (appropriate safe)Reduce Diagnostic Blood Loss (Phlebotomy)\nMinimize routine lab draws\nUse pediatric-sized collection tubes\nConsider point--care testing\nMinimize routine lab drawsUse pediatric-sized collection tubesConsider point--care testing","code":""},{"path":"blood-administration-patient-blood-management.html","id":"pillar-3-harness-and-optimize-tolerance-to-anemia-optimize-coagulation","chapter":"Blood Administration & Patient Blood Management","heading":"Pillar 3: Harness and Optimize Tolerance to Anemia / Optimize Coagulation","text":"Evidence-Based Transfusion Thresholds: Adopt restrictive transfusion strategies. Transfuse based clinical signs/symptoms inadequate oxygenation, just hemoglobin number. many stable hospitalized patients, threshold Hgb < 7 g/dL evidence-based safe. Higher thresholds may needed patients active bleeding, acute coronary syndrome, etcOptimize Coagulation\nManage anticoagulants/antiplatelet agents appropriately pre-procedure\nUse point--care coagulation testing (e.g., TEG, ROTEM) active bleeding/massive transfusion guide targeted component therapy (FFP, cryo, platelets)\nPromptly reverse anticoagulation necessary (Vitamin K, PCCs, protamine)\nManage anticoagulants/antiplatelet agents appropriately pre-procedureUse point--care coagulation testing (e.g., TEG, ROTEM) active bleeding/massive transfusion guide targeted component therapy (FFP, cryo, platelets)Promptly reverse anticoagulation necessary (Vitamin K, PCCs, protamine)Single Unit Transfusions: stable, non-bleeding patients, transfuse one unit RBCs time reassess patient’s clinical status hemoglobin level ordering ","code":""},{"path":"blood-administration-patient-blood-management.html","id":"key-terms-105","chapter":"Blood Administration & Patient Blood Management","heading":"Key Terms","text":"Blood Administration: process infusing blood components patient’s circulationVerification (Bedside Check): critical final safety step performed patient’s side two qualified staff confirm patient identity component compatibility starting transfusionStandard Blood Filter: inline filter (typically 170-260 microns) required transfusing cellular plasma components remove clots debris0.9% Normal Saline (NaCl): intravenous fluid compatible concurrent administration mixing blood componentsPatient Blood Management (PBM): comprehensive, patient-centered approach focused managing anemia, minimizing blood loss, optimizing transfusion practices improve patient outcomesTransfusion Threshold (Trigger): guideline hemoglobin level (e.g., <7 g/dL) transfusion might considered, clinical assessment paramountRestrictive Transfusion Strategy: evidence-based approach advocating lower hemoglobin thresholds transfusion stable patients compared liberal strategiesErythropoiesis-Stimulating Agents (ESAs): Medications (e.g., epoetin alfa) stimulate bone marrow produce red blood cellsAntifibrinolytics: Medications (e.g., Tranexamic Acid - TXA) reduce bleeding inhibiting breakdown fibrin clotsCell Salvage (Intraoperative Autotransfusion): Collecting patient’s shed blood surgery, washing , reinfusing red blood cells","code":""}]
